Leading by Excellence Since 1983 - LuBioScience | Company · PDF fileDear Customers: Throughout its many years of service, the team at Peptides International has maintained a commitment

Leading by Excellence Since 1983Certified to ISO 9001:2008!

Dear Customers:

Throughout its many years of service, the team at Peptides International has maintained a commitment to offer a continuous stream of innovative products to facilitate ever-expanding areas of peptide research. In our current catalog you will find hundreds of new products re-flecting the increased expertise of our staff. These new offerings range from useful tools for making peptides (e.g. orthogonally protected amino acids and derivatives for Click chemistry) to a plethora of biologically active peptides such as disulfide rich mini proteins and activated KLH (Keyhole Limpet Hemocynanin) for peptide antigen conjugation. Since publication of a catalog captures just one point in time, we invite you to look for our latest product additions at PEPNET.COM under the “New Products” tab.Investment in additional state-of-the-art automated synthesis equipment now allows us to produce milligram to kilogram quantities of peptides even more efficiently. All of our produc-tion and distribution operations have also been certified to the ISO 9001:2008 International Quality System Standard, reflecting commitment to the quality of our products and the satis-faction of our customers. New additions to our peptide chemistry team include experts that can handle all of your discovery and development needs, whether your project involves com-plex organic chemistry or standard solid-phase techniques. Scale-up and smooth technol-ogy transfer into drug API products under full-cGMP is also available without any disruption from our cGMP partner, Peptisyntha. We thank you for your interest in our products and services and invite you to search for your peptide needs in our exciting new catalog. Should you require larger quantities than are listed, additional savings may be available by requesting a “bulk quotation”. We are confident that you will find all of our products competitively priced while giving you extraordinary value and quality that will lead to success in your research.

Sincerely,

Peptides International

Michael W. Pennington, Ph.D.President

Jackie B. SpatolaChair, Board of Directors

Bryce V. Johnson, Ph.D.Chief Executive Officer

Peptides International, Inc.Physical Address 11621 Electron Drive Louisville, Kentucky 40299

Mailing Address P. O. Box 99703 Louisville, Kentucky 40269-0703

Phone 1-502-266-8787 (Local and International Callers) 1-800-777-4779 (Toll-free USA and Canada only)

Fax 502-267-1329

Email [email protected]

Website

ii Order Hotline 1-800-777-4779 502-266-8787

Subsections in Bold

Introduction Peptide Institute ............................................................................................................................ vDistributors ................................................................................................................................... vicGMP............................................................................................................................................viiQuality .........................................................................................................................................viiiProduct Information ..................................................................................................................... ixProduct Packaging ...................................................................................................................... xvCommunication ...........................................................................................................................xviPurchasing ................................................................................................................................xviiiUsing the Catalog ....................................................................................................................... xx Ordering from PEPNET.COM ....................................................................................................xxi Terms and Conditions ...............................................................................................................xxiii Custom Peptide Synthesis ..................................................................................................... xxviii Addendum of New Products .................................................................................................... xxx Technology Platforms ...............................................................................................................xxxi

Biologically Active Peptides ......................................................................................1Adrenomedullins and Related Peptides.......................................................................................2 Amylins ..........................................................................................................................................9 Amyloid β-Protein Related Peptides ............................................................................................9 Angiotensin and Related Peptides .............................................................................................13 Arg-Gly-Asp "RGD" Peptides .....................................................................................................20 Bradykinin and Related Peptides ...............................................................................................27 Defensin Peptides .......................................................................................................................40 Endothelins..................................................................................................................................52 Enkephalins .................................................................................................................................56 Experimental Autoimmune Encephalomyelitis Products ...........................................................59 Galanins and Related Peptides..................................................................................................62 Ghrelin and Related Peptides ....................................................................................................64 Growth Hormone Releasing Factor (GRF, GH-RH) and Growth Hormone Related Peptides 70Guanylins and Uroguanylins .....................................................................................................71Hepcidin ......................................................................................................................................73 Kisspeptins/Metasins ..................................................................................................................77 Melanin-Concentrating Hormone and Related Peptides .........................................................81Neuroendocrine Regulatory Peptides ........................................................................................87Parathyroid Hormone (PTH) and Related Peptides ..................................................................99 Protease-Activated Receptor (PAR) Peptides .........................................................................108 RF Amide Related Peptides ..................................................................................................... 114 Stresscopins / Urocortin and Related Peptides ....................................................................... 118 Substance P and Related Peptides ......................................................................................... 119Toxins ........................................................................................................................................122Urotensin II and Related Peptides ...........................................................................................142Vasoactive Intestinal Peptide (VIP) ..........................................................................................143 Vasopressin, Vasotocin, and Related Peptides .......................................................................144

Table of Contents

Order Hotline 1-800-777-4779 502-266-8787 iii

Enzyme Inhibitors and SubstratesAssay Methods Substrates .....................................................................................................146

Enzyme Inhibitors .......................................................................................................................152Angiotensin I Converting Enzyme Inhibitors ............................................................................153 Caspase Inhibitors ....................................................................................................................156 Cathepsin and Thiol Protease Inhibitors ..................................................................................160 Chymotrypsin and Chymotrypsin-like Inhibitors ......................................................................163 Collagenase / MMP / Stromelysin Inhibitors ............................................................................164 Elastase Inhibitors .....................................................................................................................166 Ubiquitin Proteasome System Inhibitors ..................................................................................170 Examples of Proteolytic Enzymes and Their Inhibitors ...........................................................173

Enzyme Substrates & Related Compounds ............................................................................174ADAM-17 Substrates ................................................................................................................174 Aminopeptidases Substrates ....................................................................................................175 Calpain Substrates ...................................................................................................................179 Caspase Substrates .................................................................................................................180 Cathepsin and Thiol Protease Substrates ...............................................................................182 Chymotrypsin and Chymotrypsin-like Protease Substrates ....................................................185 Coagulation Factor Substrates .................................................................................................187 Collagenase / MMP / Stromelysin Substrates .........................................................................188 Elastase Substrates ..................................................................................................................191 Furin and Carboxyl Side of Paired Basic Residue Cleaving Enzyme Substrates .................193 Ubiquitin Proteasome System Substrates ...............................................................................206FRETs Peptides Library ............................................................................................................209Polypeptides ..............................................................................................................................215 Oligopeptides ............................................................................................................................215 Dipeptides .................................................................................................................................215 Tripeptides .................................................................................................................................216 Tetrapeptides .............................................................................................................................217

Specialty Products and Services Click Chemistry ...........................................................................................................................219 Specialty Biologically Active Peptides .....................................................................................221

Derivatizable Cell Penetrating Peptides (CCPs) .....................................................................221Other Specialty Peptides ..........................................................................................................221

Carbohydrates .............................................................................................................................223Glycosidase Inhibitors ...............................................................................................................225 Endotoxins(Synthetic) ...............................................................................................................226 Antiproliferative Factor ..............................................................................................................227

Maleimide activated-KLH ..............................................................................................................229 Specialty Tools for Peptide Synthesis .....................................................................................230

mini-PEG™ ...............................................................................................................................230 CLEAR-OXTM ............................................................................................................................232

Peptide Antisera ..........................................................................................................................236Antisera of Amyloid β-Protein Related Peptides......................................................................237Endothelin Antisera ...................................................................................................................241

Table of Contents (cont.)

iv Order Hotline 1-800-777-4779 502-266-8787

Tools for Peptide SynthesisAmino Acids .................................................................................................................................248

Click Chemistry Amino Acids ....................................................................................................248 l-Amino Acids ............................................................................................................................250 d-Amino Acids ...........................................................................................................................252 Amino Acid Esters .....................................................................................................................253 Side Chain Derivatives of Amino Acids ....................................................................................254 Boc-Protected l-Amino Acids ...................................................................................................255 Boc-Protected d-Amino Acids...................................................................................................258 Unusual Boc-Amino Acids ........................................................................................................260 Boc-N-Methyl Amino Acids .......................................................................................................266Boc-Amino Acid Esters .............................................................................................................266 Fmoc-Protected l-Amino Acids ................................................................................................267 Fmoc-Protected d-Amino Acids ................................................................................................271 Unusual Fmoc-Amino Acids .....................................................................................................272 Fmoc-N-Methyl Amino Acids ....................................................................................................278 Z-Protected l-Amino Acids .......................................................................................................279 Unusual Amino Acids ................................................................................................................281

Resins ...........................................................................................................................................282Unsubstituted Resins for Solid Phase Synthesis ....................................................................282 Chlorotrityl Resins .....................................................................................................................284 Boc-Amino Acid-Pam Resins ...................................................................................................287 Fmoc-Amino Acid-Wang Resins ..............................................................................................289 Fmoc-Amino Acid-Rink-Amide MBHA Resins .........................................................................292 TentaGel Resins ........................................................................................................................294

Reagents .......................................................................................................................................300Condensation Reagents, Additives, Linkers, and Other Reagents for Peptide Synthesis ....300 Boc-Amino Acid-Pam Linker Reagents ...................................................................................303 Protein Ligation Synthesis Reagents .......................................................................................304 PyClocK® ...................................................................................................................................305dPEG® .......................................................................................................................................306

Laboratory Equipment ................................................................................................................321Tubing and Connectors ............................................................................................................321 Specialty Glassware .................................................................................................................321 Replacement Screw Caps and Septa ......................................................................................322HF Apparatus and Parts ...........................................................................................................324

IndexBy Product Code .......................................................................................................................325By Product Name......................................................................................................................333

Table of Contents (cont.)

From its very inception, Peptides International has been proud to distribute the superb products manufactured by the Peptide Institute of Osaka, Japan. The biologically active peptides synthesized by the Peptide Institute are well known for their excellent quality. In addition to its historic link with the Peptide Institute, Peptides International works with other key suppliers around the world to supplement its own manufactured products to provide a complete portfolio of peptides and related products, as well as tools for peptide synthesis and research.

The Peptide Institute is a leading supplier of biologically active peptides, enzyme substrates and inhibitors, and peptide antisera. Customers in Japan may wish to contact this company directly.Peptide Institute, Inc.4-1-2 Ina Minoh-Shi Osaka 562 JapanPhone (0727) 29-4121Fax (0727) 29-4124 http://www.peptide.co.jp

Order Hotline 1-800-777-4779 502-266-8787 v

In Japan:

http://www.peptide.co.jp Osaka, Japan

Email: [email protected]://www.peptide.co.jp

In Switzerland:

Lucerne, SwitzerlandEmail: [email protected]://www.lubio.ch/

In Benelux:

Huissen, The Netherlands

Email: [email protected]://www.bio-connect.nl/

In Europe, Latin America, Australia, and New Zealand:

San Diego, CA USA

Email: [email protected]://www.axxora.com/index.php

vi Order Hotline 1-800-777-4779 502-266-8787

Distributors

Expertise & Reliability for YOUR cGMP Peptides

Order Hotline 1-800-777-4779 502-266-8787 vii

cGMP Partner

viii Order Hotline 1-800-777-4779 502-266-8787

Quality PolicyIt is Peptides International's goal is to achieve complete customer satisfaction by addressing customer needs and delivering what we promise. The company is committed to the Quality Management Sysyem and through review of quality objectives and metrics, is working towards its improvement and effectiveness.

Specifications and Purity AssaysEach product is accompanied by a detailed lot-specific analytical data sheet contain-ing all specifications. In addition to specification data, additional test results can be made available upon customer request. Product integrity is assured using techniques that include thin layer chromatography, high performance liquid chromatography, opti-cal rotation, nuclear magnetic resonance, IR spectroscopy, and mass spectrometry.

Peptide InstituteProducts from the Peptide Institute of Osaka, Japan are manufactured under strict quality control standards and are accompanied by analytical data sheets directly from the Institute. Peptide International products are designated by a -PI suffix to distinguish them from those produced by the Peptide Institute.

Now Certified to ISO 9001:2008

Quality

Order Hotline 1-800-777-4779 502-266-8787 ix

Product Information

Net Peptide WeightSome products from the Peptide Institute are distributed in premeasured vials. These are indicated by the suffix -s, or -v in their catalog number. The net peptide weight is precisely determined by amino acid analysis after acid hydrolysis, HPLC, and/or UV absorption, and the value is indicated clearly on the vial label. The indicated weight is only for the net peptide molecule, and the weights of any constituents (water or acetic acid) are excluded from the quantity. The amount of usable peptide meets and may exceed its advertised quantity.

Stability and StorageComplex peptides and antisera should generally be kept dry and frozen to prevent unnecessary deterioration, although they are stable at ambient temperature for sev-eral days. Almost all biologically active peptides are readily soluble in water or any suitable buffer solution. Stability of peptides in solution is relatively low even below -20 °C. Therefore a peptide solution, once prepared, should be used as soon as possible. If the solution must be stored overnight, it should be kept in a freezer at temperatures lower than -20 °C. When prolonged storage has occured, homogene-ity of the peptide in the solution should be reconfirmed prior to use. Please refer to the following table and to our website for additional information regarding stability and storage conditions.

x Order Hotline 1-800-777-4779 502-266-8787

Product Information

Product Storage ConditionsProduct Series Number Storage ConditionL- & D-Amino Acids 2700 & 2800 RTBoc-Amino Acids 2000 & 5000 4 °CFmoc-Amino Acids 1700, 1800, & 5000 4 °CUnusual Amino Acids 5000 4 °CReagents 1000 Varies:

RT, 4 °C,

or -20 °C

Unsubstituted Resins 1000 & 9000 RTSubstituted Resins 1000, 10000, 1100, 11000,

1200, 12000, 1300, 1400, & 9000

4 °C

All CLEAR Resins 1200, 12000 4 °CPeptides 3000 & 4000 -20 °CInhibitors 3000 & 4000 -20 °CSubstrates 3000 -20 °CAntisera 8000, 80000, & 14000 -20 °CCarbohydrates 24000 -20 °C

RT = Room Temperature4 4 °C = Refrigerator -20 °C = Freezer

All products (except RT) are stored in freezers for inventory purposes.

Order Hotline 1-800-777-4779 502-266-8787 xi

All of the products listed in this catalog are rigorously tested and the purity of the products is guaranteed according to the following criteria:

1000 SeriesThese reagent grade chemicals are of a quality confirmed by our chemists in Japan and the USA to be acceptable for peptide synthesis.

1100, 1200, 1300,1400, 10000, 11000 and 12000 SeriesThese substituted resins are manufactured in our Louisville, Kentucky facility. The parameters, described on the analytical data sheet included with each resin, are substitution, percent racemization (where appropriate), bead size, and percent cross-linking.

1700 SeriesFmoc-Amino Acids of the 1700 Series: No free amino acid is detectable by TLC when 100 micrograms is applied to the plate. Purity determined by HPLC analysis is higher than 98%.

2000 SeriesAmino acids of the 2000 Series: The homogeneity of the amino acids is moni-tored by thin layer chromatography (TLC) and is guaranteed to yield a single spot when 50 micrograms is applied to the plate. The optical purity of amino acids is higher than 99.9% except in the case of serine, which is frequently con-taminated by more than 1% enantiomeric serine; data are available on request. Optical purity is determined by Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) using chiral derivatizing reagents.

Product Information

Product Information

xii Order Hotline 1-800-777-4779 502-266-8787

Amino Acid Esters and Side Chain Derivatives of the 2000 Series: The following letters are used to designate the different grades:AA: A single spot is always detectable by two different TLC systems when

200 micrograms is applied to the plate. Homogeneity higher than 99% as determined by paper electrophoresis is guaranteed.

A: A trace of impurity might be detectable by TLC, but the maximum range is less than 2%.

B: Contamination of less than 3% might be detectable.

Boc- and Z-Amino Acids of the 2000 Series:The optical purity of the component amino acids is always higher than 99.9%, and contamination by the sec-butyl group is guaranteed to be less than 0.05%. The following letters are used to designate the different grades:AA: A single spot is detectable by TLC when 200 micrograms is applied to

the plate. The amount of contamination detectable by HPLC, if any, is less than 0.5%.

A: A trace of impurity might be detectable by TLC, but the maximum range determined by HPLC is less than 1%.

B: Contamination of less than 2% might be detectable by HPLC.AA-A: This compound is synthesized as material of grade AA, but may gradu-

ally decompose to grade A within one year, even under cold storage conditions.

A-B: This compound is synthesized as material of grade A, but may gradu-ally decompose to grade B within one year, even under cold storage conditions.

Product Information

Order Hotline 1-800-777-4779 502-266-8787 xiii

3000 SeriesAmino Acids and Peptide Derivatives of the 3000 Series: The following letters are used to designate the different grades:AA: A single spot is detectable by TLC when 100 micrograms is applied to

the plate. The amount of contamination detectable by HPLC is less than 1%.

A: A trace of impurity might be detectable by TLC when 100 micrograms is applied to the plate. The amount of contamination detectable by HPLC is less than 2%.

B: Contamination of less than 4% might be detectable by HPLC.A-B: This compound is synthesized as material of grade A, but may gradu-

ally decompose to grade B within one year, even under cold storage conditions.

4000 SeriesBiologically Active Peptides of the 4000 Series: All of these peptides are chemically synthesized using carefully selected amino acid derivatives from our products, and strictly purified to come up to our quality standards. Impurities detectable by ordinary gradient HPLC systems are less than 1% and a single TLC spot upon application of 50 micrograms is detected in almost all of our peptides, except Met-containing peptides. Some additional minor peaks on HPLC or minor spots on TLC are detectable with Met-containing peptides since they may be easily oxidized to Met-sulfoxide even during analysis. The peptides which are followed by the words “Purity Information” and letter symbols, such as “Purity Information: QP in this catalog”, can be explained as follows:

Product Information

xiv Order Hotline 1-800-777-4779 502-266-8787

QP: These compounds have some inherent instability. During storage, even under freezer conditions, a trace of impurity may become visible by TLC analysis. The amount of impurity determined by HPLC is less than 1%.

QE: These compounds have some inherent instability. Their purity is guar-anteed to be higher than 97% by HPLC.

QX: The purity of these compounds is guaranteed to be higher than 97% by HPLC.

QZ: The purity of these compounds is guaranteed to be higher than 95% by HPLC.

5000, 6000, and 53000 Series These unusual amino acids, amino acid derivatives, and other offerings rep-resent an expansion of quality products from Peptides International and are synthesized under appropriately high purity criteria.

14000 Series Peptide Antisera are sold in vials as amorphous powders which are obtained after lyophilization from 0.001 M Phosphate Buffer (pH 7.0). The specificity and sensitivity are determined by the enzyme immunoassay technique specified; the data for each vial are given on an attached sheet.

Bacterial Enzyme Inhibitors The microbial enzyme inhibitors (Microbial Products) listed in this catalog are isolated from cultured media of microorganisms. Many of these compounds are inherently unstable and thus difficult to categorize using our normal standards of purity. The homogeneity of these compounds cannot be guaranteed except for their specific inhibitory activities. Additional data for these series of compounds are available upon request.

Product Packaging

Order Hotline 1-800-777-4779 502-266-8787 xv

The biologically active peptides listed in this catalog are sold primarily as amorphous powders which have been lyophilized from aqueous or dilute acetic acid solutions. They are available in two package forms: screw-capped bottles (indicated as “Bulk”) and injection vials (indicated with a -v or –s suffix at the end of each catalog code number).

Screw-capped BottlesThe amorphous powder of each peptide is thoroughly dried over desiccant in vacuo and then weighed in a bottle. The weight indicated on the label represents the gross weight of the amorphous powder, which includes the peptide as well as the accompanying water and acetic acid, if any. The amount of water and acetic acid in each amorphous powder is precisely determined by elemental analysis, Karl Fischer titration or gas chromatography. In some cases, peptides contain hydrochloride or ammonia instead of acetic acid. The observed values of such accompanying constituents are given in the structural formula of the respective peptide described in this catalog. For example, code PBK-4002 Bradykinin is described as follows:

PBK-4002 Bradykinin Bulk 100 mgArg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg • 2AcOH • 3H2O(M.W. 1060.2 • 120.10 • 54.05)

The total molecular weight of this amorphous powder is calculated to be 1234.4, which consists of 1060.2 for the net bradykinin molecule, 120.10 for two mol-ecules of acetic acid and 54.05 for three molecules of water. This means that 100 mg of this powder contains a net weight of 85.9 mg of bradykinin molecules. Amounts of the accompanying water and acetic acid vary with the lot; the exact value in the purchased peptide is available on request.

Product Packaging

xvi Order Hotline 1-800-777-4779 502-266-8787

VialsPeptides with constant weights are lyophilized and sealed under nitrogen in indi-vidual vials. Net peptide weights are precisely determined by amino acid analy-sis after acid hydrolysis, HPLC analysis and/or UV absorption measurement, and is clearly indicated on the label of each vial. The indicated weight is only the net peptide molecule and does not include the weight of any additional con-stituents (water, acetic acid, etc.). For example, code PBK-4002-v Bradykinin is described as follows:

PBK-4002-v Bradykinin Vial 0.5 mgArg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1060.2)

This indicates that each vial contains ca. 0.5 mg of Bradykinin and the exact weight is indicated on the label (for example, 0.53 mg) and the analytical data sheet (for example, 0.53 mg, 0.50 micromol). The weight is precisely determined by quality control, insuring the quantity in each vial even if the content seems to be quite small. A peptide solution of a known concentration can be easily prepared by injecting a given volume of a suitable solvent into the vial using a calibrated syringe and dissolving the contents thoroughly. The peptide content in each vial is relatively small and accurately measured, and the peptide should not be taken out of the vial to prepare a solution with a guaranteed concentration.

Communication

Order Hotline 1-800-777-4779 502-266-8787 xvii

PEPNET NewsletterPeptide chemistry is constantly changing. The PEPNET newsletter will keep you abreast of many of the exciting new developments arising in the expanded field of peptide chemistry. PEPNET has been published regularly since 1987.

Our web site offers online ordering, new products, and other use-ful information. There are also scientific references, and links to industry organizations.

Other Media Just as peptide chemistry is ever-changing, Peptides International knows the way it conveys these changes will also vary over time. Look for us on Facebook, Google+, LinkedIn, Twitter, and other new outlets as they appear. If you wish to receive your own copy of this catalog or to be entered onto the subscription list for the newsletter, please place a request by contacting the company via telephone, fax, or email ([email protected]).

Custom services to stimulate inhibitor innovations

As a complement to these catalog offerings, Peptides

International also provides custom synthesis services to meet

structural requirements of specific enzyme or disease targets.

Peptides International has a wealth of chemical expertise and

know-how especially applicable to the design and synthesis

of complex enzyme inhibitors and substrates. These include

cyclic compounds (BQ-123), complex mimetics (BQ-788),

peptide aldehydes (Ac-LLN), hydroxamic acid derivatives

(TAPIs), alkylating moieties and others.

P.O. Box 24658Louisville, KY 40224 USAPhone: 502-266-8787Fax: 502-267-1329

A Newsletter from Peptides International

Volume 23, No. 1, 2010

Peptides International, Inc.

1-800-777-4779 E-mail: [email protected]

Enzymes Gone Wild! Inhibitors to the Rescue!

Enzyme inhibitors continue to generate strong research interest...

Product Quality and Value • Strict Confidentiality • Proactive Project Management • Friendly Service

Enzyme inhibitors and related products

Peptides International has long had a strong product focus

in the area of enzyme inhibitors that includes both syn-

thetic and microbial-derived materials. These include, for

example, popular matrix metalloprotease inhibitors (TAPI-0,

TAPI-1, TAPI-2), ubenimex, and actinonin. In addition, we

also offer other key products, such as chymostatin, elastati-

nal, leupeptin and epoxomicin, through our long-standing

distribution relationship with the Peptide Institute of Osaka.

These are available in multiple vials or in bulk quantities that

offer considerable savings.

Enzymes are essential in almost all biological processes and aberration of enzyme activity is implicated in many disease states. Therefore

modulation of enzyme function represents a well-researched route for drug development, a point underscored by the fact that enzyme

inhibitors represent almost half the drugs in clinical use today. Design, development and study of enzyme inhibitors continue to be a

major focus of pharmaceutical research. Therefore, this issue of PEPNET highlights this important area of research and includes key

articles devoted to proteasome and MMP inhibitors. We hope you will find our comprehensive collection of reagents for enzyme research

and custom synthesis services valuable for your innovations in this area.

Custom Synthesis ServicesPeptide aldehydes, ketones, hydroxy-isosteres

•

Cyclic compounds: termini / side chain / disulfide

•

Biotin, aminohexanoic acid, defined length PEGylations

•

Custom designed FRET substrates and libraries

•

Dabcyl, Dabsyl, Dansyl, EDANS, Farnesyl

•

Coumarin derivatives, Rhodamines, TAMRA

•

Glycosylated, Phosphorylated, Sulfated (Ser, Thr, Tyr)

•

Isotopically-labeled derivatives:

•

13C, 15N

Peptide International specializes in providing:

Exploratory compound sets and libraries

•

• Multi-gram to pilot-scale preparations for

development and diagnosticsPlease contact our technical experts to discuss your specific

needs and to learn about our cost effective and value added

services.

A comprehensive list of Peptides International enzyme

inhibitors (“The Enzyme Inhibitor Guide”), complementary

substrates (“The Enzyme Substrate Guide”) and related

literature are available from www.pepnet.com or by contacting

us via email [email protected] or by phone 800-777-4779.

Crystal structure of TACE (TNF-a Converting Enzyme) in complex with inhibitor

TAPI-2 (TNF-a Protease Inhibitor-2). TAPIs are proprietary TACE inhibitors sold by

Peptides International under license from US Patents: 5,387,610; 5,616,605; 5686,422.

Source: http://www.ebi.ac.uk/pdbe-srv/view/images/entry/2ddf600.png by J. Swaminathan &

MSD staff at the European Bioinformatics Institute http://www.ebi.ac.uk/

Pennington Joins PI Team as CTO

Peptides International proud-ly announces the addition of Dr. Michael Pennington to the company’s executive team as Chief Technical Officer effec-tive December 1st, 2010. Background Dr. Pennington has spent over

20 years in research and devel-opment management with the Bachem Group and was most

recently President and COO

of Bachem Bioscience Inc., the

company’s King of Prussia (Pennsylvania) facility.

He is the author of nearly 100 technical publications,

has served on the editorial boards of several industry

journals, and is on the Scientific Advisory Boards of a

number of drug development companies. He is also

a co-principal investigator on several NIH grants and

serves as an adjunct faculty member in the Department

of Chemistry at Villanova University. Mike and his

wife Michelle have recently moved to Kentucky and

are enjoying their new property in horse country.

ChangesDr. Pennington's addition has had an immediate

impact at PI. Along with a broadened custom peptide

emphasis, many new initiatives, products, and quality

procedures have been introduced or implemented. At

the same time, Dr. Channa Basava, who had been lead-

ing the company's technical and commercial organiza-

tions, has expanded his efforts in the areas of specialty

products and technologies, business development, and

sales and marketing management.


Volume 24, No. 1, 2011


The ‘custom’ peptide business has become com-

moditized in recent years as more and more low-cost,

quick turnaround sources appear around the world.

Yet researchers pursuing peptide-based drug devel-

opment projects increasingly seek more complex

structures and services that often exceed the capa-

bilities of many of these service providers. Peptides

International, with a long history of providing custom peptides, has

just completed a major commitment in personnel and equipment

that will allow it to satisfy the custom chemistry needs of the most

demanding researchers and their ever increasing challenges.

Addition of the new resources has resulted in the designation of

“complex custom peptides” as PI’s newest Technology Platform (see

PEPNET Vol. 22 No. 2). This designation provides an integrated,

company-wide effort that not only meets customers immediate

synthetic needs, but can offer additional services in areas such as

analytical testing, technology/process development, and scale-up.

Leading this effort is Dr. Michael Pennington, a well-known peptide

industry expert with over 20 years of experience meeting just such

challenges (see inset). Joining Dr. Pennington and PI’s existing

team of research, production, and QC scientists are Dr. Satendra

Chauhan and Dr. Rommel Talan (see page 2), who bring unique

breadth and experience to this team. PI laboratories, updated

and expanded in 2007, are now further enhanced with with state-

Growing AcCUSTOMed to New Challenges

PI Debuts New Technology Platform...

Dr. Michael PenningtonChief Technical Officer, Peptides International

Biotin

FITC

TMR

Linker

Not only is PI able to synthesize native ShK and custom analogs,but

our scientists can also attach labels such as fluorophores (TAMRA

and FITC) or Biotin with mini-PEGTM spacers, as shown.

Special

CUSTOM Issue

ShK - A 35 amino acid peptide isolated from

the Caribbean sea anemone, Stichodactyla helianthus

see PI Debuts..., page 3

Lys-22

ShK

Arg-1

PRESORTEDSTANDARD U.S. PostagePAIDPEPTIDES INTERNATIONAL

P.O. Box 99703 Louisville, KY 40224-0658USA

Address Service Requested

P.O. Box 99703Louisville, KY 40224-0658 USAPhone: 502-266-8787Fax: 502-267-1329



In This Issue

As in years past, we are including

a Kentucky Derby commemorative

glass with orders of $500 or more.

These glasses are highly collectable

and are often seen displayed during

visits to customers' labs and offices.

This year's edition will make a nice

addition (or start) to your collection. Order soon and don't

miss out! (No additional charge for shipping.)

By request and while quantities last. Limit one per laboratory,

please.

It's a Tradition: The 2011 Derby Glass

News and Notes

• Going Beyond Custom Synthesis

• Malemide-Activated KLH Carrier

Protein• New Products from the Peptide

Institute• Employee Spotlight(s)

This issue of PEPNET highlights Peptides International's recently

increased capabilities and offerings. We hope you enjoy perusing

this PEPNET edition. We look forward to hearing from you!

Coming Soon! Cell Penetrating Peptides, HDAC Products, New

Building Blocks/Synthetic Tools and much more….

The 22nd APS will be held June 25 - 30, 2011 in beautiful San

Diego, CA at the Sheraton Hotel and Marina in San Diego,

California.. Peptides International will be there and we hope you can stop by and say "hello"!

See You Soon...

20 th American Peptide Symposium On behalf of the American Peptide Society,

we are pleased to invite you to the 20th

jubilee of the American Peptide

Symposium, "Peptides for Youth" to be

held in Montreal, Canada from June 26 to

30, 2007. This symposium will serve to

remember the accomplishments of society

members since Professors Saul Lande and

Boris Weinstein organized the First

American Peptide Symposium at Yale

University in 1968. Moreover, "Peptides

for Youth" will strive to attract Young Investigators to participate in a meeting that

recognizes and highlights their achievements, and incites their interests with a stimulating

scientific program, featured in a vibrant city, Montreal. The night life and quality of

entertainment in Montreal are world renown and by holding the Meeting around the

time of the Montreal Grand Prix and Montreal Jazz Festival, participants can enjoy

mixing quality Science with fast motorcar racing, great music and fun. Bilingual, multi-

cultural and safe, Montreal offers outstanding facilities, hotels, restaurants and

entertainment centers for a memorable meeting.

Co-chairs: Emanuel Escher William D. Lubell

Université de Sherbrooke Université de Montréal

For More Information Please Contact

[email protected] Coordinator: Susan Seaman (514) 343-6111 ext 3907

Peptides International would like to acknowlege two former

employees with whom many customers and researchers

have had contact over the years: • Dr. DeAnna W. Long, who was Director of Business

Development, but during her tenure at PI wore many

hats, has moved on to a new role in academia.

• Lisa Civello, who was Product Manager, has taken a

position in the non-profit sector in marketing.

They will be missed and we wish both of them well in their

future endeavors!Lastly, please note our recent mailing address change:

P.O. Box 99703 Louisville, KY 40224-0658USA

Our physical location address remains the same.

PEPNET.COM → What's New → Look for Peptides International at the APS 2011

TM

Look who's citing us!Literature citations of PI products & services!1,200 and counting...

PRA=Propargyl-Gly) while using the other with a labeling

molecule (e.g. Azido-PEG). The possibilities employing this

type of strategy allow for almost limitless selective label

incorporation. Peptides International now offers a new

assortment of these types of building block tools to aid in

the application of Click chemistry to many different systems.

Clickable Cell-Penetrating PeptidesCell-penetrating peptides (CPP) have received considerable

interest for drug discovery applications because of their abili-ty to permeate the cell membrane and allow for payload or cargo molecules to be deliv-ered into the cytosol. These peptides were initially discovered from the venom of wasps and the TAT (Trans-Activator of Transcription) protein derived from HIV. They typically have a high content of argi-nine residues. CPPs can be functionalized with alkynes or azido groups which allow for the transport of cargo molecules such as cytotoxic drugs, siRNA molecules or kinase inhibitor sequences. Peptides International is pleased to offer a new CPP derived from

HIV, TAT (49-57) (TAT-3733-PI, TAT-3734-PI, and TAT-3735-PI).


Volume 24, No. 2, 2011


What is Click Chemistry?Selective orthogonal labeling of peptides has

been limited by the need to use thiol and

amine groups in the target peptide to interact

with maleimido, halo-acetyl and NHS-esters

of the desired labeling molecule. When more

than one thiol or amine is present in a specific

peptide, it is difficult to get selective incorporation without

using special protecting groups to minimize side reactions.

Click chemistry, the name popularized by Nobel Laureate

Dr. Barry Sharpless of the Scripps Research Institute, involves

the incorporation of groups that other-wise do not occur in biological molecules into both the peptide and labeling mol-ecules. These groups then react - or "click", achieving high selec-tivity under mild conditions.

Clickable Building Block Tools

The most popular use of Click chemistry for biological molecules involves a cyclo-addi-tion reaction using an azido-containing component and an alkyne-containing component that react in the presence of Cu(I) to form a 1,4 disubstituted 1,2,3 triazole (see figure). For peptide chemistry applications, the

number of possibilities can be increased by incorporating

one of the respective components within a peptide chain (e.g.

Meet "The Clickables"

CLICK Chemistry

Issue

see Meet..., page 3

PRESORTEDSTANDARD U.S. PostagePAIDPEPTIDES INTERNATIONAL

P.O. Box 99703 Louisville, KY 40269-0703Address Service Requested

P.O. Box 99703Louisville, KY 40269-0703 USAPhone: 502-266-8787Fax: 502-267-1329



In This Issue• Meet "The Clickables"• The Clickables: RGD Peptides

• NEW Feeding & Regulatory Peptides

• New Items from the Peptide Institute

• Advanced Equipment Installed

• Employee Spotlight(s)

This issue of PEPNET highlights Peptides International's entry

into the exciting area of Click Chemistry, as well as its use in cell

penetrating peptides, building blocks and RGD peptides. We hope

you enjoy perusing this PEPNET edition. We look forward to hear-

ing from you!Coming Soon! Toxins, Enzyme Inhibitors & Substrates and much

more….APS Wrap Up: Thanks to all those who

stopped by and took time to visit the Peptides

International booth in San Diego. Also, con-

gratulations to Dr. Aleksandr Rabinovich,

at right, who was the winner of our Kindle

giveaway there. It was , by all accounts, a very

successful meeting. See you at Number 23!

CA Representation: Speaking of San Diego, please be aware

that PI has a business consultant dedicated to California. Dr.

Smita Yadav, at left, conveniently located in the San Diego

area, has many years of experience in the

peptide, chemistry and biology fields.

She would love to discuss your current

(or future) peptide projects and needs.

She can be reached directly by email at

[email protected], or by phone at 858-

361-4175. If you are located in California,

please contact Dr. Yadav today to discuss

the ways Peptides International can create value for your

peptide projects.

Benefits of Being Social: The

Peptides International page is

an up-to-the-minute resource

where you'll find all the latest

announcements, offers, and events related to Peptides

International and the field of peptide chemistry.

News and Notes

Peptides International Introduces New Product Line

Peptide CO

CHNH

2

CH2CH2C CH

N N N

[Cu]+

O

RKKRRQRRR NH2

+Alkyne Component

Azido-TAT Peptide (TAT-3734-PI)

"Clicked" TAT

CLICK

O

RKKRRQRRR NH2

CH CH2CH

2

CO

NH2

Peptide

NN

N

AzidoComponent

Alkyne-Containing Labeling Molecule

PEPNET.COM → Stichodactyla Toxin (PSK-4287-s)

PEPNET.COM → Stichodactyla Toxin (PSK-4287-s)

NP2D.COM → Invited Speakers

Peptides International's Chief

Technical Officer, Dr. Michael

Pennington, is slated to be a keynote

speaker at the Natural Peptides To

Drugs 5th International Congress,

held from December 4 - 7, 2011, in

Zermatt, Switzerland. His topic,

Advancing ShK Peptide Into the Clinic for Treatment of Multiple

Sclerosis, has particular topicality for Peptides International:

ShK (Stichodactyla Toxin (PSK-4287-s)) is one of PI's extensive

toxins offerings. Following the conference, there will be

a "Conodays" event December 7 - 9. If you are attending,

please look up Peptides International while there! Look for

an in-depth review of peptide toxins in the next edition of the

PEPNET newsletter.

PI CTO @ NP2D (translation below)2D

NP

Scan here for a special offer!

Purchasing

xviii Order Hotline 1-800-777-4779 502-266-8787

Peptides International's customer service representatives are prepared to help process your orders, assist with product information, and answer technical questions. Orders can be placed by mail, telephone, fax, or email.

Address: Mailing Address Physical AddressPeptides International or Peptides InternationalP. O. Box 99703 11621 Electron DriveLouisville, Kentucky 40269-0703

Louisville, Kentucky 40299-3861

USA USA

Telephone: 1-502-266-8787 (Local and International Callers) 1-800-777-4779 Toll-free (USA and Canada) Customer service representatives are available during the following times to

assist you: Monday through Thursday - 8:30 AM - 6:00 PM (EST / EDT time) Friday - 8:30 AM - 5:00 PM (EST / EDT time)

Fax: 1-502-267-1329 Email: [email protected]

Web site:

Purchasing

Order Hotline 1-800-777-4779 502-266-8787 xix

OrdersWhen placing an order please specify: • Customer ID Number • Company or Institution • Billing Address • Shipping Address • Purchase Order Number or

Credit Card information • Catalog Code Number • Quantity and Product

Description • Quote Number, if applicable • Telephone Number • Fax Number • Email Address • Shipping Requirements • VAT, if applicable

Minimum OrdersPeptides International does not require a minimum order but encourages repeat customers to combine small orders, when possible, to minimize handling and shipping costs.

Confirming OrdersPlease mark all confirming orders clearly to avoid duplication.

Back OrdersShould an item be temporarily out of stock, this will be indicated in the “back order” column of the customer’s invoice. Most back order are shipped within two weeks.

Using the Catalog

xx Order Hotline 1-800-777-4779 502-266-8787

Catalog Key• This catalog has been designed to provide unique, concise information for

each product, with the intention of enabling easy navigation and ordering. • For further information or specific questions regarding a product, please

contact a Peptide International customer service representative.Biologically Active Peptides (All Are Acetate Form Unless Otherwise Indicated)

1. Major Product Section, designated as Biologically Active Peptides, Enzyme Inhibitors & Substrates, Specialty Products & Technologies, or Tools for Peptide Synthesis.2. Subsection Heading 3. Product Section (may include article and / or references)4. Product Name5. Product Code6. Unit Size

7. Alternate Name (when applicable)8. Storage Temperature (see page for key)9. Synthetic, Originally From... (when applicable) 10. Sequence (when applicable/available)11. Molecular Weight, Formula, and CAS Number (when available)12. Description (when applicable/available) 13. References (when available)

Peptides International strives to give accurate content, including product information, quantities, and pricing. Policies, pricing, and item availability are subject to change without notice. While Peptides International makes a good faith effort to ensure that the information displayed is accurate, we are not responsible for typographical errors or technical inac-curacies.

Toxinsw-AgatoxinsB.M. Olivera, G.P. Miljanich, J. Ramachandran, and M.E. Adams, Annu. Rev. Biochem., 63, 823 (1994). (Review) O.D. Uchitel, Toxicon, 35, 1161 (1997). (Review)

ω-Agatoxin IVA ω-Aga-IVA(Funnel Web Spider, Agelenopsis aperta)

PAG-4256-s-20 °C

0.1 mgvial

Lys-Lys-Lys-Cys-Ile-Ala-Lys-Asp-Tyr-Gly-Arg-Cys-Lys-Trp-Gly-Gly-Thr-Pro-Cys-Cys-Arg-Gly-Arg-Gly-Cys-Ile-Cys-Ser-Ile-Met-Gly-Thr-Asn-Cys-Glu-Cys-Lys-Pro-Arg-Leu-Ile-Met-Glu-Gly-Leu-Gly-Leu-Ala (Disulfide bonds between Cys4-Cys20, Cys12-Cys25, Cys19-Cys36 and Cys27-Cys34) (M.W. 5202.2) C217H360N68O60S10 P-type Ca2+ Channel Selective BlockerI.M. Mintz, V.J. Venema, K.M. Swiderek, T.D. Lee, B.P. Bean, and M.E. Adams, Nature, 355, 827 (1992). (Original) T.J. Turner, M.E. Adams, and K. Dunlap, Science, 258, 310 (1992). (Pharmacol.) H. Nishio, K.Y. Kumagaye, S. Kubo, Y.-N. Chen, A. Momiyama, T. Takahashi, T. Kimura, and S. Sakakibara, Biochem. Biophys. Res. Commun., 196, 1447 (1993). (Chem. Synthesis & Biological Activity) • This compound is distributed exclusively through Peptides International under license agreement with the University of Utah.

85

10

11

1312

12

3

479

6

Ordering from PEPNET.COM

Order Hotline 1-800-777-4779 502-266-8787 xxi

Visit our website for convenient, effecient, and secure ordering.

Search• Use the search function to locate your desired product(s).

Products may be located by seaching:• Product Code (e.g. MCA-3650-PI)• Product Name (e.g. l-Alanine)• Molecular Formula (e.g. C45H73N13O11)• Product Description (keywords, sequences)

A few search tips:• Searches are not case sensitive.• Greek characters are spelled out in text.• Words separated by dashes are considered as two words.• Product and category searches may designate any part of the name.• Keyword searches must match the first part of a word inside a product.• Searches by sequence may be partial if the order of the sequence is correct.

Ordering from PEPNET.COM

xxii Order Hotline 1-800-777-4779 502-266-8787

Registering Your Account and Checking OutAfter finding the desired product(s), and proceeding to checkout, you will be asked to create a new account. You will be provided with a unique and secure password upon completion and submittal of the form. Please keep the user name and password in a secure location. Additionally you may opt to have the website store your information for your convenience.

Peptides International values your privacy and the security of your information. Please note that we do not store credit card information within the website.

1. The Ordering link will take you to a menu allowing creation of a new or existing account.

2. Link to Create a New Account accessed via the Ordering link.3. Link to access existing account information.4. Form to submit creating a new account found on 25. The Contact Us link which Peptides International urges you to utilize should you have

any questions or concerns regarding the website, catalog, or products.

23

5

4

1

Order Hotline 1-800-777-4779 502-266-8787 xxiii

Applicable TermsThese Terms and Conditions of Sale shall become part of every order, sale, and purchase agreement between buyer and Peptides International.With the placement of an order, the buyer agrees to accept the Terms and Conditions of Sale. Peptides International shall not be bound by the purchasing conditions of the buyer, even if not explicitly stated. Orders containing addenda or statements that are worded differently or provide for further condi-tions will not be accepted unless spe-cifically agreed to in writing by Peptides International.The UN Convention on the International Sale of Goods shall not apply.

QuotationsQuotations must be requested for the following special situations:• Custom synthesis of materials not listed in Peptides International’s website or catalog (custom quotations)• Quantities of specific materials that exceed those listed in Peptides International’s website or catalog (bulk quotations)• Packaging alternatives, such as custom vialing, that are not offered in website or catalog listings• Large purchases of multiple items where a discount is requested (core quotations)Unless otherwise stated, quotations are valid for 30 days from date of issue.Quotation prices are valid only for indi-cated product(s) in the quantity, quality, salt form, and lead time specified in the quotation. Lead times for custom quotations are from date of receipt of an approved purchase order. Lead times for catalog products are subject to inventory status on date of receipt of an approved pur-chase order.Quotations are considered confidential

Terms and Conditions

xxiv Order Hotline 1-800-777-4779 502-266-8787

and are specific to the product(s) and customer. If appropriate, Non Disclosure Agreements may also be requested. Quotations are not transferable to other parties without express permission from Peptides International. Purchases based on accepted quota-tions remain subject to all other Terms and Conditions of Sale.

PricesAll prices are quoted in US Dollars and do not include value-added and/or sales tax, which may be invoiced separately as required. Prices include inner and outer packaging unless specifically noted oth-erwise. If the prices in Peptides International’s printed literature vary from the prices published on the Peptides International website (www.pepnet.com), then the prices on the website shall prevail.Shipping and handling charges apply to all shipments and Peptides International reserves the right to add a surcharge for any special shipment requirements (e.g. dry ice, inert gas).All product prices are subject to change without notice prior to confirmation of an order, but no product will be shipped at increased prices without prior notifica-tion. Peptides International reserves the right to charge a re-assaying and restocking fee on returned goods.

Order PlacementOrders may be placed by telephone, fax, email, letter or online using Peptides International’s website (www.pepnet.com).

Orders resulting from a prior quotation must reference the specific quotation number. Orders placed verbally or by electronic transmission shall become legally bind-ing only if they have been confirmed by receipt of an invoice number from Peptides International. Orders received by Peptides International are firm and binding upon the buyer and do not release the parties from their obligation(s) to deliver or to accept deliv-ery, nor release them from their financial obligations to Peptides International. Custom orders should be reviewed carefully for structures, sequences, and other particulars before placing orders. Peptides International may at its discre-tion accept change orders under condi-tions that provide for recovery of already incurred costs and any additional costs arising from the agreed upon changes.

Delivery and AcceptanceAgreed upon delivery deadlines refer to the shipment date of the goods. If the delivery deadline is extended by buyer, buyer shall specify an appropri-ate period for acceptable late delivery of the shipment. If the delivery deadline is extended by Peptides International, buyer will be notified of such extension prior to the original shipment deadline. Peptides International reserves the right to decline orders in the event the product can no longer be made or the customer is in arrears with any commitments or payments.Buyer is responsible for complying with national or international laws or regula-tions applicable to shipment, delivery, storage, processing or trading of any


Order Hotline 1-800-777-4779 502-266-8787 xxv

specifically designated products.Force majeure of any kind, unforesee-able operational disruptions, short-falls or failures in delivery by Peptides International’s suppliers, shortages of raw materials, power supplies and/or manpower, strikes, lockouts, problems in procuring means of transport, traffic obstructions, war, political unrest, acts of terrorism, natural disasters and order of higher authorities exempt the party concerned from the obligation to deliver or to accept delivery for the duration of the disruption and for any consequential damages arising therefrom, but shall not exempt such party from any financial obligations arising from any goods or services already supplied.

Warranty and Warranty DisclaimerAll Peptides International biochemicals are extensively tested for purity. Each shipment is accompanied by a detailed lot-specific “Analytical Data Sheet” (ADS). Peptides International warrants the purity, identity and content of its prod-ucts at the time of sale in accordance with the results listed in the ADS. The buyer shall visually inspect and test products immediately upon receipt to determine whether the condition and quantity of the goods conforms to the ADS and the applicable contractual agreement. All claims must be received in writing within 14 days from date of delivery of the product to the customer and failure to do so shall constitute a waiver by buyer for any and all such claims. Claims must include proof of non-compliance, specifically naming the product, the lot number, and the invoice number.

Peptides International shall ship replace-ment product for claims for which proof is submitted and which are received within the time period specified above. If the replacement delivery is also non-con-forming to the contractual agreement, then the buyer has the right to cancel the order or contract. Products that are the subject of com-plaint may be sent back only with Peptide International’s agreement and shipping arrangements for the return must be agreed upon by both parties in advance. Peptides International’s sole obligation is to replace material up to the extent of the purchase price, or provide a refund or credit. Peptides International makes no other warranties, express or implied, including, but not limited to, any implied warranty of merchantability or fitness for a particular purpose or implied warranty arising out of a course of dealing, cus-tom, or usage of trade.

Use and Limitation of LiabilityAll products sold by Peptides International are intended solely for laboratory and research use and should not be used in or on human subjects. Peptides International sup-plies such products only for the pur-poses of public research as conducted at experimental and teaching institutes, technical facilities and commercial enti-ties.It is the responsibility of the buyer to determine the adequacy of all materials for any intended or specific purpose or use. Peptides International makes no warranties as to use for an intended or specific purpose.


xxvi Order Hotline 1-800-777-4779 502-266-8787

Peptides International expressly forbids the distribution of dangerous substances to private individuals and draws atten-tion to the fact that the absence of a hazard warning sign does not indicate that the product concerned is harmless. Peptides International shall therefore not accept any liability for damage that could arise from the inappropriate handling or from any use in household applications or in humans and animals. Peptides International shall not be liable for any damage as a result of improper use or storage of its products. This limitation of liability also includes products that have been tampered with or altered by accident or negligence. Peptide International’s liability with respect to non-fulfillment or delay of delivery shall be limited to the invoice amount of the goods. All information contained in catalogs, brochures, publications and other printed or electronic media is compiled to the best of Peptide International’s knowl-edge. Peptides International hereby disclaims any liability for any possible errors or misprints. Peptides International shall not under any circumstances be liable to buyer for any direct, indirect, special, incidental, or consequential loss or damages (includ-ing, but not limited to, loss of profits, revenue, business, research, research results, opportunity or goodwill) aris-ing from or in any way related to the products or Peptides International’s sale of products, regardless of the legal or equitable theory under which such loss or damages are sought, including breach of warranty or contract, negligence, or strict liability.

Title and Proprietary RightsUntil full payment of the purchase price, including all secondary claims, the sup-plied products remain the property of Peptides International (reservation of title). If the buyer fails to pay for products despite receipt of late notices, Peptides International reserves the right to with-hold any further deliveries to the buyer and to require the return of the unpaid goods, unused and in original packag-ing, at the buyer’s expense.

Terms of PaymentTerms of payment are net 30 days for qualified buyers. A service charge of 1.5% per month (18% ANNUAL RATE) will be added to all balances which are 30 or more days past due. Discount deductions on invoices are not allowed. Reductions in Peptides International’s invoices may not be made without a credit invoice or note and if made without such, shall be considered a late or short payment. Peptides International reserves the right to change the terms of payment to payment in full or in part in advance of shipment. After an order is accepted or a sale com-mitment is made, any increase in, and all new taxes, excises, duties, or other governmental charges (except taxes on income) imposed on the production, sale, transportation, import or export of products sold to buyer which Peptides International is required to pay will be added to the price paid by customer for products.


Order Hotline 1-800-777-4779 502-266-8787 xxvii

Payment may be made by one of the following methods:• Check: Send a check, including

any clearing, processing, or other bank charges or fees to: Peptides International, Inc.P.O. Box 99703Louisville, KY 40269

• Wire Transfer: If not already in US dollars, arrange for conversion of the currency to US dollars, includ-ing shipping and handling charges (included on all invoices). Wire the total amount to the following account:Bank ABA # 083900680Account # 5183479840SWIFT # BRBTUS33BB&T401 West Main St.Louisville, KY 40202 USA Contact: Nell Prince Phone (502)-562-7902

• Credit Card: Peptides International accepts MasterCard, Visa, and American Express.

Important: After completing one of the steps above please email or fax a con-firming note to Peptides International indicating the date and amount of your payment. You should also include your invoice number or purchase order num-ber to insure proper credit.

Patent Claims, Protection Rights, Consultancy

With any purchase, the buyer acquires the product but no other rights asso-ciated with the product. Peptides International remains in possession of all intellectual property rights related to the manufacturing and composition of the product. The use of trademarks in offers does not provide for the use of such trademarks. Permission for such use must always be obtained from Peptides International in advance and in writing. Peptides International makes no guaran-tee that the use or resale of its products will not violate the protection or patent rights of third parties. Peptides International agrees to offer its customers technical support to the best of its knowledge. All comments or proposals for the use, application, or suitability of the products shall not be interpreted as an explicit guarantee of success.

Applicable Laws Any legal dispute involving these Terms and Conditions will be governed by the laws of the Commonwealth of Kentucky.If a provision in these conditions of sale or a provision in the context of other agreements are or become legally unenforceable, only that provision shall become null and void and all remaining provisions shall remain enforceable and in effect.


xxviii Order Hotline 1-800-777-4779 502-266-8787

Custom Products and ServicesIf peptides or other products you need are not listed in this catalog, we invite you to try our custom synthesis services. Peptides International has earned the reputation of providing exceptionally high quality custom peptide synthesis products to the research community. We specialize in 5 to 100 mg quantities (or greater) with purity levels of at least 95%. Amino acid analysis ratios, mass spectral data, and analytical HPLC chro-matograms are provided with custom peptides. Areas of expertise include: Multi-Disulfide PeptidesInterested in mini-proteins with multiple disulfide bonds? Peptides International researchers have extensive experience folding these highly complicated molecules to their biologically active forms. Examples include native molecules and analogs of conotoxins, defensins, hepcidins, chemokines, ion channel blockers (ShK, HwTX4, charybdotoxin, iberiotoxin, margatoxin, ProTx-II, mu-conotoxins, etc). They can also customize with labels such as TAMRA, FITC or Biotin using a mini-PEG™ spacer.Peptide-Protein ConjugatesPeptide-protein conjugates have a variety of applications, including the stimulation of antibodies for immunization. These conjugates can be customized as needed, includ-ing combinations with proteins such as Albumin, Ovalbumin, and Ferritin. Selective het-erobifunctional crosslinkers allow for selective attachment of a Cys-containing peptide to the protein of your choice. Using KLH-MCC will help streamline this reaction, and the product (KLH-6000-PI) is conveniently kept in stock at all times.Peptide DerivativesFluorescence resonance energy transfer (FRET) occurs when excitation energy is transferred from an excited fluorescent donor to a quenching acceptor in a distance-dependent manner. Cleavage of a scissile peptide bond within a fluorescence quenched substrate leads to separation of the intramolecular donor-acceptor pair, thus allowing an increase in fluorescence. The fluorescence increase is proportional to the amount of peptide hydrolyzed. To design a substrate for a newly discovered enzyme

Custom Peptide Synthesis

Order Hotline 1-800-777-4779 502-266-8787 xxix

or application, contact our specialists to begin a customized Substrates by Design™ project.Post Translation ModificationIncluding: Glycosylation, Phosphorylation, Fatty Acid Acylation, Pegylation, Cyclization, and Disulfide BondsPeptide SynthesisIncluding: Classical/Solution, Solid-Phase, Native Chemical Ligation, and Dendrimeric RGD PlatformsPeptidomimeticsIncluding: Hydroxyethylene Isostere, Reduced Peptide Bonds, Aldehydes, Chloro-methylketones, Depsipeptides, and PhosphonatesMulti-step Organic SynthesisIncluding: Novel Amino Acid Derivatives, Stereo Selective Synthesis, Special Protecting GroupsOther ServicesPeptides International is an excellent source for production of unusual amino acids and offers rapid, thorough, and cost effective hydrogen fluoride (HF) cleavage proce-dures. Please inquire for additional analytical services. ConfidentialityAll customer requests will be treated with strict confidentiality and non-disclosure agreements can easily be put in place. We offer molecular design consultations, project management and technology transfer for scale-up production.

Custom Peptide Synthesis

xxx Order Hotline 1-800-777-4779 502-266-8787

Addendum of New Products

H-Glu[cyclo (Arg-Ala-Asp-d-Phe-Lys)]2(Trifluoroacetate Form)Negative Control Peptide for PCI-3651-PI

PCI-3979-PI-20 °C

1 mg5 mg

25 mg

H-Glu{Glu[cyclo (Arg-Ala-Asp-d-Phe-Lys)]2}2(Trifluoroacetate Form)Negative Control Peptide for PCI-3975-PI

PCI-3978-PI-20 °C

1 mg5 mg

25 mg

H-Glu{Glu[cyclo (Arg-Gly-Asp-d-Phe-Lys)]2}2(Trifluoroacetate Form) H-E{E[cRGDfK]2}2(M.W. 2748.04) C123H179N39O34Tetrameric RGD Peptide

PCI-3975-PI-20 °C

1 mg5 mg

25 mg

S. Liu, Z.J. He, W.Y. Hsieh, Y.S. Kim, and Y. Jiang, Bioconjugate Chem., 17, 1499 (2006). S. Liu, W.Y. Hsieh, Y. Jiang, Y.S. Kim, S.G. Sreerama, X. Chen, B. Jia, and F. Wang, Bioconjugate Chem., 18, 438 (2007).

PRODUCT CODE QTY

The following products were released too late for inclusion in their respective section of this catalog. As always, you can access the latest product additions by refering to http://pepnet.com/ShoppingUsers/NewProducts.aspx

NEW!

NEW!

NEW!

Order Hotline 1-800-777-4779 502-266-8787 xxxi

Technology Platforms

As additional value, Peptides International has developed technology platforms that assure an intergrated company-wide effort that not only meets researcher's immedi-ate synthetic needs, but can offer additional services in such areas as analytical testing, technology/process development, and scale-up. Peptides International's RGD Technology Platform, is a natural outgrowth of its extensive catalog offerings, custom RGD experience, and technological expertise.

T e c h n o l o g y P l a t f o r m

RGDComplex Organic

Derivatives

MultimersConjugates

Industry Leading Catalog Portfolio

Defined-Length PEGylations

Process Scale-up Multi-gram Synthesis

Applications and Potential Benefits to Researchers:• Integrin related RGD research• NCEs and cancer drug development• Useful to prepare radiolabeled agents

• Tumor targeting, imaging and diagnostics• Novel biomaterial research & development• Tissue repair and wound healing studies

xxxii Order Hotline 1-800-777-4779 502-266-8787

Technology Platforms

The Custom Services Portfolio Platform spans a wide range of technologies rang-ing from traditional solution and solid phase synthesis to peptidomimetics as illus-trated by depsi-peptide bond formation and HET isostere incorporation. Expertise in multi-step organic synthesis and peptide modi-fication offer a virtually limitless range of custom options extending from glycosylation to fluorescent and isotopic labeling, cyclization, phosphorylation, and more.

Peptidomimetics

Post TranslationalModifications

Multi-disulfidePeptides

PeptideSynthesis

Multi-stepOrganic

SynthesisPeptide- Protein

Conjugates

Peptide Derivatives

PRODUCT CODE QTYPEPTIDES INTERNATIO

NALBIO

LOG

ICALLY ACTIVE PEPTIDES

Order Hotline 1-800-777-4779 502-266-8787 1

Biologically Active Peptides (All Are Acetate Form Unless Otherwise Indicated)

Ac-Asp-GluAc-Asp-Glu • H2O (Bulk)

(M.W. 304.26 • 18.02) C11H16N2O8 • H2O [3106-85-2]Endogenous Excitatory Neurotransmitter

PDE-4167-20 °C

25 mg100 mg

K.L. Reichert and F. Fonnum, J. Neurochem., 16, 1409 (1969). (Original) K.J. Koller and J.T. Coyle, Eur. J. Pharm., 98, 193 (1984). (Characterization of Receptor) K.J. Koller, R. Zaczek, and J.T. Coyle, J. Neurochem., 43, 1136 (1984). (Localization in Brain)J.H. Neale, T. Bzdega, and B. Wroblewska, J. Neurochem. 75, 443 (2000). (Review)

ACV (Delta-(l-Alpha aminoadipyl)-l-Cysteinyl-Bis-d-Valine)Bis-ACV

Delta-(l-a-aminoadipyl)-l-Cysteinyl-Bis-d-Valine (M.W. 724.86) C28H48N6O12S2Precursor for Biosynthesis of Penecillin

PAC-3860-PI-20 °C

25 mg

Adjuvant PeptideAdjuvant Peptide

N-Ac-Mur-Ala-d-Glu-NH2 (Mur: Muramic acid) (M.W. 492.48) C19H32N4O11 [53678-77-6]

PAD-4031-v-20 °C

0.5 mg vial

Adjuvant Peptide (Bulk) N-Ac-Mur-Ala-d-Glu-NH2 • 2H2O (Mur: Muramic acid) (M.W. 492.48 • 36.03 ) C19H32N4O11 • 2H2O [53678-77-6] Muramyl Dipeptide

PAD-4031-20 °C

25 mg

F. Ellouz, A. Adam, R. Ciorbaru, and E. Lederer, Biochem. Biophys. Res. Commun., 59, 1317 (1974). (Original) S. Kotani, Y. Watanabe, F. Kinoshita, T. Shimono, I. Morisaki, T. Shiba, S. Kusumoto, Y. Tarumi, and K. Ikenaka, Biken J., 18, 105 (1975). (Chem. Synthesis and Immun. Activity)

Adrenocorticotropic Hormone (ACTH)ACTH (Human, 1-24) Adrenocorticotropic Hormone (Human, 1-24)

Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val- Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro (M.W. 2933.4) C136H210N40O31S [16960-16-0]

PAC-4109-v-20 °C

0.5 mg vial

B. Riniker, P. Sieber, W. Rittel, and H. Zuber, Nature (New Biol.), 235, 114 (1972). (Original; Structure)

2 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Adrenomedullins and Related PeptidesK. Kitamura, K. Kangawa, H. Matsuo, and T. Eto, Drugs, 49, 485 (1995). (Review) D.A. Schell, R.C. Vari, and W.K. Samson, Trends Endocrinol. Metab., 7, 7 (1996). (Review)M. Julián, M. Cacho, M.A. Garcia, S. Martin-Santamaria, B. de Pascual-Teresa, A. Ramos, A. Martinez, and F. Cuttitta, Eur. J. Med. Chem., 40, 737 (2005). (Review)

Adrenomedullin (Human)*Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser-Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys-Leu-Ala- His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn- Val-Ala-Pro-Arg-Ser-Lys-lle-Ser-Pro-Gln-Gly-Tyr-NH2 (Disulfide bond between Cys16-Cys21) (M.W. 6028.7) C264H406N80O77S3 [148498-78-6] Hypotensive Peptide

PAD-4278-s-20 °C

0.1 mg vial

K. Kitamura, K. Kangawa, M. Kawamoto, Y. Ichiki, S. Nakamura, H. Matsuo, and T. Eto, Biochem. Biophys. Res. Commun., 192, 553 (1993). (Original) K. Kitamura, J. Sakata, K. Kangawa, M. Kojima, H. Matsuo, and T. Eto, Biochem. Biophys. Res. Commun., 194, 720 (1993). (Original; cDNA) • This product is distributed under the license of Shionogi & Co., Ltd. Its use for any purpose other than research is strictly prohibited.

* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.

Adrenomedullin (Human, 1-25)*Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser- Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys (Disulfide bond between Cys16-Cys21) (M.W. 2927.3) C125H192N40O36S3 Vasopressor Fragment of Human Adrenomedullin

PAD-4325-v-20 °C

0.5 mg vial

T.X. Watanabe, Y. Itahara, T. Inui, K. Yoshizawa-Kumagaye, K. Nakajima, and S. Sakakibara, Biochem. Biophys. Res. Commun., 219, 59 (1996). (Original)

Adrenomedullin (Human, 22-52)Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp- Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser- Pro-Gln-Gly-Tyr-NH2 (M.W. 3576.0) C159H252N46O48 [159899-65-7] Adrenomedullin Antagonist

PAD-4302-v-20 °C

0.5 mg vial

S. Eguchi, Y. Hirata, H. Iwasaki, K. Sato, T.X. Watanabe, T. Inui, K. Nakajima, S. Sakakibara, and F. Marumo, Endocrinology, 135, 2454 (1994). (Original)

Adrenomedullin (Rat)*Tyr-Arg-Gln-Ser-Met-Asn-Gln-Gly-Ser-Arg-Ser-Thr-Gly-Cys- Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln- Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met- Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 (Disulfide bond between Cys14-Cys19) (M.W. 5729.4) C242H381N77O75S5 Hypotensive Peptide

PAD-4281-s-20 °C

0.1 mg vial

J. Sakata, T. Shimokubo, K. Kitamura, S. Nakamura, K. Kangawa, H. Matsuo, and T. Eto, Biochem. Biophys. Res. Commun., 195, 921 (1993). (Original; cDNA and Biological Activity)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 3

Adrenomedullin 2 (Human)Intermedin (Human)

Thr-Gln-Ala-Gln-Leu-Leu-Arg-Val-Gly-Cys-Val-Leu-Gly- Thr-Cys-Gln-Val-Gln-Asn-Leu-Ser-His-Arg-Leu-Trp- Gln-Leu-Met-Gly-Pro-Ala-Gly-Arg-Gln-Asp-Ser-Ala- Pro-Val-Asp-Pro-Ser-Ser-Pro-His-Ser-Tyr-NH2 (Disulfide bond between Cys10 and Cys15) (M.W. 5100.7) C219H349N69O66S3

PAD-4421-s-20 °C

0.1 mgvial

Cardiovascular and Renal Regulator / Suppressor for Food Intake and Gastric Emptying M. Ogoshi, K. Inoue, and Y. Takei, Biochem. Biophys. Res. Commun., 311, 1072 (2003). (Takifugu rubripes Adrenomedullins) Y. Takei, K. Inoue, M. Ogoshi, T. Kawahara, H. Bannai, and S. Miyano, FEBS Lett., 556, 53 (2004). (Original; Adrenomedullin 2) J. Roh, C.L. Chang, A. Bhalla, C. Klein, and S.Y.T. Hsu, J. Biol. Chem., 279, 7264 (2004). (Original; Intermedin) Y. Fujisawa, Y. Nagai, A. Miyatake, Y. Takei, K. Miura, T. Shoukouji, A. Nishiyama, S. Kimura, and Y. Abe, Eur. J. Pharmacol., 497, 75 (2004). (Pharmacol.)M.M. Taylor, S.L. Bagley, and W.K. Samson, Am. J. Physiol. Regul. Integr. Comp. Physiol., 288, R919 (2005). (Pharmacol.)K. Takahashi, K. Kikuchi, Y. Maruyama, T. Urabe, K. Nakajima, H. Sasano, Y. Imai, O. Murakami, and K. Totsune, Peptides, 27, 1383 (2006). (Histochem.)D. Bell and B.J. McDermott, Br. J. Pharmacol., 153, S247 (2008). (Review)

Adrenomedullin 2 (Rat)Intermedin (Rat)

PAD-4422-s-20 °C

0.1 mg vial

Pro-His-Ala-Gln-Leu-Leu-Arg-Val-Gly-Cys-Val-Leu-Gly-Thr-Cys-Gln- Val-Gln-Asn-Leu-Ser-His-Arg-Leu-Trp-Gln-Leu-Val-Arg-Pro-Ser-Gly- Arg-Arg-Asp-Ser-Ala-Pro-Val-Asp-Pro-Ser-Ser-Pro-His-Ser-Tyr-NH2 (Disulfide bond between Cys10-Cys15) (M.W. 5216.9) C226H361N75O64S2 Potent Cardiovascular and Renal Regulator / Suppressor for Food Intake and Gastric Emptying M. Ogoshi, K. Inoue, and Y. Takei, Biochem. Biophys. Res. Commun., 311, 1072 (2003). (Takifugu rubripes Adrenomedullins) Y. Takei, K. Inoue, M. Ogoshi, T. Kawahara, H. Bannai, and S. Miyano, FEBS Lett., 556, 53 (2004). (Original; Adrenomedullin 2) J. Roh, C.L. Chang, A. Bhalla, C. Klein, and S.Y.T. Hsu, J. Biol. Chem., 279, 7264 (2004). (Original; Intermedin) Y. Fujisawa, Y. Nagai, A. Miyatake, Y. Takei, K. Miura, T. Shoukouji, A. Nishiyama, S. Kimura, and Y. Abe, Eur. J. Pharmacol., 497, 75 (2004). (Pharmacol.)M.M. Taylor, S.L. Bagley, and W.K. Samson, Am. J. Physiol. Regul. Integr. Comp. Physiol., 288, R919 (2005). (Pharmacol.)K. Takahashi, K. Kikuchi, Y. Maruyama, T. Urabe, K. Nakajima, H. Sasano, Y. Imai, O. Murakami, and K. Totsune, Peptides, 27, 1 383 (2006). (Histochem.)D. Bell and B.J. McDermott, Br. J. Pharmacol., 153, S247 (2008). (Review)

4 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES PAMP (Human) Proadrenomedullin N-terminal 20 Peptide (Human)

Ala-Arg-Leu-Asp-Val-Ala-Ser-Glu-Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-Arg-NH2 (M.W. 2460.8) C112H178N36O27 [150238-87-2] Hypotensive Peptide

PAM-4291-v-20 °C

0.5 mgvial

K. Kitamura, J. Sakata, K. Kangawa, M. Kojima, H. Matsuo, and T. Eto, Biochem. Biophys. Res. Commun., 194, 720 (1993). (Original; cDNA) H. Washimine, K. Kitamura, Y. Ichiki, Y. Yamamoto, K. Kangawa, H. Matsuo, and T. Eto, Biochem. Biophys. Res. Commun., 202, 1081 (1994). (Distribution in Human Tissue) K. Kitamura, K. Kangawa, Y. Ishiyama, H. Washimine, Y. Ichiki, M. Kawamoto, N. Minamino, H. Matsuo, and T. Eto, FEBS Lett., 351, 35 (1994). (Pharmacol.) F. Katoh, K. Kitamura, H. Niina, R. Yamamoto, H. Washimine, K. Kangawa, Y. Yamamato, H. Kobayashi, T. Eto, and A. Wada, J. Neurochemistry, 64, 459 (1995). (Pharmacol.) • This product is distributed under the license of Shionogi & Co., Ltd. Its use for any purpose other than research is strictly prohibited.

PAMP (Rat) Proadrenomedullin N-terminal 20 Peptide (Rat)

Ala-Arg-Leu-Asp-Thr-Ser-Ser-Gln-Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-Arg-NH2 (M.W. 2477.8) C111H177N37O28 Hypotensive Peptide

PAM-4292-v-20 °C

0.5 mgvial

J. Sakata, T. Shimokubo, K. Kitamura, S. Nakamura, K. Kangawa, H. Matsuo, and T. Eto, Biochem. Biophys. Res. Commun., 195, 921 (1993). (Original; cDNA)

PAMP-12 (Human) Proadrenomedullin N-terminal 20 Peptide (Human, 9-20)

Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-Arg-NH2 (M.W. 1618.9) C77H119N25O14 Hypotensive Peptide / Major Endogenous Form of PAMPK. Kuwasato, K. Kitamura, Y. Ishiyama, H. Washimine, J. Kato, K. Kangawa, and T. Eto, FEBS Lett., 414, 105 (1997). (Original)

PAM-4339-v-20 °C

0.5 mg


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 5

AdropinAdropin (Human, 34-76 ) (Rat, Mouse)

PAP-4456-s-20 °C

0.1 mgvial

Cys-His-Ser-Arg-Ser-Ala-Asp-Val-Asp-Ser-Leu-Ser-Glu-Ser-Ser- Pro-Asn-Ser-Ser-Pro-Gly-Pro-Cys-Pro-Glu-Lys-Ala-Pro-Pro- Pro-Gln-Lys-Pro-Ser-His-Glu-Gly-Ser-Tyr-Leu-Leu-Gln-Pro (Disulfide bond between Cys1-Cys23)(M.W. 4499.8) C190H293N55O68S2Synthetic ProductRegulatory Factor in Energy Homeostasis K.G. Kumar, J.L. Trevaskis, D.D. Lam, G.M. Sutton, R.A. Koza, V.N. Chouljenko, K.G. Kousoulas, P.M. Rogers, R.A. Kesterson, M. Thearle, A.W. Ferrante, Jr., R.L. Mynatt, T.P. Burris, J.Z. Dong, H.A. Halem, M.D. Culler, L.K. Heisler, and J.M. Stephens, Cell Metab., 8, 468 (2008). (Original: Primary Structure/Pharmacol.)

Peptides secreted from peripheral organs regulate lipid metabolism in key insulin-target tissues and are important for energy homeostasis and maintaining insulin sensitivity. Much attention has been given to adipokines secreted by adipocytes. While receiving less attention, liver-secreted factors are also critical for energy homeostasis.Adropin, initially identified during microarray analysis of liver gene expression in mouse models of obesity, is a 76-residue peptide encoded by the energy homeostasis associated gene Enho1). Bioinformatics analysis suggested adropin (34-76) being a secreted form of adropin with high probability. Thus disulfide-linked adropin (34-76) was chemically synthesized for biological tests; glucose homeostasis and hepatic lipid metabolism were improved in mouse with 90 or 900 nmol/kg/day through intra-peritoneal administration. These effects were independent of adiposity or food intake. Considering the alteration of adropin mRNA level associated with obesity, adropin (34-76) may be a powerful peptide in the study of obesity-associated hepatosteatosis and hyperinsulinemia.K.G. Kumar, J.L. Trevaskis, D.D. Lam, G.M. Sutton, R.A. Koza, V.N. Chouljenko, K.G. Kousoulas, P.M. Rogers, R.A. Kesterson, M. Thearle, A.W. Ferrante, Jr., R.L. Mynatt, T.P. Burris, J.Z. Dong, H.A. Halem, M.D. Culler, L.K. Heisler, J.M. Stephens, and A.A. Butler, Cell Metab., 8, 468 (2008). (Original: Primary Structure / Pharmacol.)

AgeleninAgelenin (Spider, Agelena opulenta)

Gly-Gly-Cys-Leu-Pro-His-Asn-Arg-Phe-Cys-Asn-Ala-Leu- Ser-Gly-Pro-Arg-Cys-Cys-Ser-Gly-Leu-Lys-Cys-Lys- Glu-Leu-Ser-Ile-Trp-Asp-Ser-Arg-Cys-Leu-NH2

PAG-4247-s-20 °C

0.1 mgvial

(Disulfide bonds between Cys3-Cys19, Cys10-Cys24 and Cys18-Cys34) (M.W. 3818.4) C160H254N52O45S6 Presynaptic Ca2+ Channel Antagonist K. Hagiwara, T. Sakai, A. Miwa, N. Kawai, and T. Nakajima, Biomedical Res., 11, 181 (1990). (Original) T. Inui, K. Hagiwara, K. Nakajima, T. Kimura, T. Nakajima, and S. Sakakibara, Pept. Res., 5, 140 (1992). (Chem. Synthesis, S-S Bond and Amide)N. Yamaji, K. Sugase, T. Nakajima, T. Miki, M. Wakamori, Y. Mori, and T. Iwashita, FEBS Lett., 581, 3789 (2007). (Solution Structure)

NEW!

6 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES AG30/5CPeptides with antimicrobial activity, in addition to angiogenic properties are good candidates for wound-healing drugs. One such peptide lead, AG30 (AG: Angiogenic Peptide) was identified in 2009 by the group of Drs. Nakagami and Kaneda of Osaka University.1 Actually, AG30 is predicted by in silico analysis of an angiogenic cDNA clone p3743.2 Through feasibility study and the subsequent clinical investigation of AG30, AG30/5C has just been discovered from the structure-activity relationship study of AG30. In AG30/5C the cationic residues of Arg and Lys replace five neutral amino acids.3 This modification in the primary structure revealed that i) the helical structure is maintained even in the lower extent than that of parental AG30, ii) the potencies are significantly improved in the migration and tube forming ability of human endothelial cells as well as in the antimicrobial activity against P. aeruginosa, Candida, and S. aureus, and iii) wound healing effects are observed in a diabetic mouse model and in a porcine model (100 μg/ml).In this study, AG30/5C is produced applying the conventional solution method compat-ible to Good Manufacturing Practice (GMP) guidelines. The structure and character-istics of AG30/5C are similar to those of LL-37, which is known as an antimicrobial peptide with angiogenic properties. AG30/5C, which may facilitate the discovery of novel therapeutic agents, is available now from Peptides International.

AG30: MLSLIFLHRLKSMRKRLDRKLRLWHRKNYPAG30/5C: MLKLIFLHRLKRMRKRLKRKLRLWHRKRYK

1. T. Nishikawa, H. Nakagami, A. Maeda, R. Morishita, N. Miyazaki, T. Ogawa, Y. Tabata, Y. Kikuchi, H. Hayashi, Y. Tatsu, N. Yumoto, K. Tamai, K. Tomono, and Y. Kaneda, J. Cell. Mol. Med., 13, 535 (2009). (Original; AG30 & Pharmacol.)2. T. Nishikawa, H. Nakagami, A. Matsuki, A. Maeda, C.Y. Yo, T. Harada, R. Morishita, K. Tamai, and Y. Kaneda, Hum. Gene Ther., 17, 470 (2006). (Angiogenic cDNA Clone p3743)3. H. Nakagami, T. Nishikawa, N. Tamura, A. Maeda, H. Hibino, M. Mochizuki, T. Shimosato, T. Moriya, R. Morishita, K. Tamai, K. Tomono, and Y. Kaneda, J. Cell. Mol. Med., doi: 10.1111/j.1582-4934.2011.01406.x (Original; AG30/5C & Pharmacol.)

AG30/5CMet-Leu-Lys-Leu-Ile-Phe-Leu-His-Arg-Leu-Lys- Arg-Met-Arg-Lys-Arg-Leu-Lys-Arg-Lys-Leu- Arg-Leu-Trp-His-Arg-Lys-Arg-Tyr-Lys(M.W. 4103.2) C189H330N66O32S2Antimicrobial Peptide with Angiogenic Properties

AGP-4469-s-20 °C

0.1 mgvial

• This product is distributed through Peptide Institute, Inc. under the license of AnGes MG, Inc. Its use for any purpose other than research is strictly prohibited.

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 7

Agouti-Related ProteinA gene encoding agouti-related protein (AGRP) was isolated in 1997 during a search of the proteins related to agouti protein which was known to affect pigmentation through the melanocortin receptor 1 (MC-1). AGRP shows some sequence similarity to agouti protein, including the distribution of the 10 cysteine residues in the C-terminal domain. However, AGRP and agouti protein bind to distinct types of melanocortin receptors. The receptors for AGRP are reported to be MC-3 and MC-4, which are known to participate in the regulation of feeding, whereby the binding of an antagonist like AGRP stimulates food intake. Some groups have attempted to identify the active domain of a 132 amino acid precursor protein, one of which is AGRP(86-132).1 IC50 values of this peptide in the competitive binding assay for MC-3 and MC-4, expressed in human embryonic kidney cells, were 2 nM and 19 nM, respectively. Competitive inhibition of α-MSH-stimulated cAMP production was also detected for MC-3 and MC-4, but not for MC-1 and MC-5, indicating the selective nature of the action of AGRP(86-132) with respect to melanocortin receptors.R.D. Rosenfeld, L. Zeni, A.A. Welcher, L.O. Narhi, C. Hale, J. Marasco, J. Delaney, T. Gleason, J.S. Philo, V. Katta, J. Hui, H. Baumgartner, M. Graham, K.L. Stark, and W. Karbon, Biochemistry, 37, 16041 (1998). (Original) E.J. Bures, J.O. Hui, Y. Young, D.T. Chow, V. Katta, M.F. Rohde, L. Zeni, R.D. Rosenfeld, K.L. Stark, and M. Haniu, Biochemistry, 37, 12172 (1998). (Structure; S-S Bond) J.R. Shutter, M. Graham, A.C. Kinsey, S. Scully, R. Lüthy, and K.L. Stark, Genes Dev., 11, 593 (1997). (Agouti-Related Transcript Sequence) D.M. Dinulescu and R.D. Cone, J. Biol. Chem., 275, 6695 (2000). (Review)A.M. Wilczynski, C.G. Joseph, and C. Haskell-Luevano, Med. Res. Rev., 25, 545 (2005). (Review)O. Ilnytska and G. Argyropoulos, Cell. Mol. Life Sci., 65, 2721 (2008). (Review)

Agouti-Related Protein (Human, 86-132) AGRP (Human, 86-132)

Arg-Cys-Val-Arg-Leu-His-Glu-Ser-Cys-Leu-Gly-Gln-Gln-Val-Pro-Cys-Cys-Asp-Pro-Cys-Ala-Thr-Cys-Tyr-Cys-Arg-Phe-Phe-Asn-Ala-Phe-Cys-Tyr-Cys-Arg-Lys-Leu-Gly-Thr-Ala-Met-Asn-Pro-Cys-Ser-Arg-Thr

PAR-4366-s-20 °C

0.1 mgvial

(Reported disulfide bonds between Cys87-Cys102, Cys94-Cys108, Cys101-Cys119, Cys105-Cys129, and Cys110-Cys117) (M.W. 5347.2) C223H339N69O63S11 Melanocortin Receptor-3/4 Antagonist, Appetite Boosting Peptide

AlarinAlarin (Human)

Ala-Pro-Ala-His-Arg-Ser-Ser-Thr-Phe-Pro-Lys-Trp-Val-Thr-Lys-Thr-Glu-Arg-Gly-Arg-Gln-Pro-Leu-Arg-SerAPAHRSSTFPKWVTKTERGRQPLRS(M.W. 2894.3) C127H205N43O35 [909409-86-5]Splice Variant of Galanin-Like Peptide Synthetic Product

PAL-4449-s-20 °C

0.1 mgvial

R. Lang, A.L. Gundlach, and B. Kofler, Pharmacol. Ther., 115, 177 (2007). (Review)R. Santic, K. Fenninger, K. Graf, R. Schneider, C. Hauser-Kronberger, F.H. Schilling, P. Kogner, M. Ratschek, N. Jones, W. Sperl, and B. Kofler, J. Mol. Neurosci., 29, 145 (2006). (Original)R. Santic, S.M. Schmidhuber, R. Lang, I. Rauch, E. Voglas, N. Eberhard, J.W. Bauer, S.D. Brain, and B. Kofler, Proc. Natl. Acad. Sci. U.S.A., 104, 10217 (2007). (Original)

NEW!

8 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES AMP-IBP5Dr. Minamino and his colleagues of the National Cerebral and Cardiovascular Center Research Institute have been performing the proteomics approach to unveil the endogenous peptides. His group has now identified a novel antimicrobial peptide, AMP-IBP5 [named after an antimicrobial peptide derived from insulin-like growth factor-binding protein 5 (IGFBP-5)] using human pancreatic neuroendocrine tumor cellQGP-1.1 AMP-IBP5 is actually a 22 amino acid residue peptide with dual post-transla-tional modifications: C-terminal amidation and intramolecular disulfide bond formation, the latter of which is a distinct finding because the disulfide linkage of IGFBP-5 has been differently predicted previously. The primary structure of AMP-IBP5 is conserved among many mammals including human, mouse, rat, pig, and cow. AMP-IBP5 is characterized to have a highly basic nature and exerts broad spectra of antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, and fungi (IC50 = μM range), the potency of which were comparable to LL-37 (Code 4445-s) and even higher than those of human β-defensin-2 (Code 4338-s). Interestingly, this function is missing in parental IGFBP-5. Major location sites of immunoreactive AMP-IBP5 in rats are clarified as being the pituitary gland, brain, and small intestine. This newly discovered AMP-IBP5 has the potential to become an essential peptide with antimicrobial activity, along with existing antimicrobial peptides such as defensins and LL-37.1. T. Osaki, K. Sasaki, and N. Minamino, J. Proteome Res., 10, 1870 (2011). (Original; Primary Structure & Pharmacol.)

AMP-IBP5 (Human) Insulin-Like Growth Factor-Binding Protein 5 (Human, 193-214 Amide)(Porcine, Rat, Mouse, Bovine)

AMP-4468-s-20 °C

0.1 mgvial

Ala-Val-Tyr-Leu-Pro-Asn-Cys-Asp-Arg-Lys-Gly-Phe-Tyr-Lys-Arg-Lys-Gln-Cys-Lys-Pro-Ser-Arg-NH2(Disulfide bond between Cys7-Cys18)(M.W. 2655.1) C117H188N38O29S2Antimicrobial Peptide


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 9

AmylinsG.J.S. Cooper, Endocrinol. Rev., 15, 163 (1994). (Review)J.W.M. Höppener, B. Ahrén, and C.J.M. Lips, N. Engl. J. Med., 343, 411 (2000). (Review)S.A. Jayasinghe and R. Langen, Biochim. Biophys. Acta, 1768, 2002 (2007). (Review)L. Haataja, T. Gurlo, C.J. Huang, and P.C. Butler, Endocr. Rev., 29, 303 (2008). (Review)

Amylin (Human) IAPP: Islet Amyloid Polypeptide DAP: Diabetes-Associated Peptide

(Trifluoroacetate Form)

PAM-4219-v-20 °C

0.5 mgvial

Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser- Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Disulfide bond between Cys2 and Cys7) (M.W. 3903.3) C165H261N51O55S2 [122384-88-7] Purity Information: Qx See page xivP. Westermark, C. Wernstedt, E. Wilander, D.W. Hayden, T.D. O’Brien, and K.H. Johnson, Proc. Natl. Acad. Sci. USA, 84, 3881 (1987). (Original; 36th A.A. Unknown) G.J.S. Cooper, A.C. Willis, A. Clark, R.C. Turner, R.B. Sim, and K.B.M. Reid, Proc. Natl. Acad. Sci. U.S.A., 84, 8628 (1987). (Original; Complete Sequence) A. Clark, G.J.S. Cooper, C.E. Lewis, J.F. Morris, A.C. Willis, K.B.M. Reid, and R.C. Turner, Lancet, 2, 231 (1987). (Pharmacol; May be Pathogenic) • U.S. Patent No. 5,367,052. This product is made under license from Amylin Pharmaceuticals, Inc. for sale for noncom-

mercial research use only. For other information and information about licenses for commercial research use may be obtained from Amylin Pharmaceuticals, Inc. at (858) 552-2200.

Amylin (Rat) IAPP: Islet Amyloid Polypeptide DAP: Diabetes-Associated Peptide

PAM-4220-v-20 °C

0.5 mgvial

Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser- Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Disulfide bond between Cys2 and Cys7) (M.W. 3920.4) C167H272N52O53S2 [124447-81-0]J.D. Leffert, C.B. Newgard, H. Okamoto, J.L. Milburn, and K.L. Luskey, Proc. Natl. Acad. Sci. USA, 86, 3127 (1989). (Original; cDNA) J. Asai, M. Nakazato, K. Kangawa, S. Matsukura, and H. Mastuo, Biochem. Biophys. Res. Commun., 164, 400 (1989). (Original; Isolation and Structure)

Amyloid b-Protein Related PeptidesAmyloid b-Protein (Human, 1-40)

(Trifluoroacetate Form) Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly- Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val (M.W. 4329.8) C194H295N53O58S [131438-79-4] Peptide Deposited in the Brain of Alzheimer’s Disease PatientPurity Information: Qz See page xiv

PAM-4307-v-20 °C

0.5 mgvial

B.A. Yankner, L.K. Duffy, and D.A. Kirschner, Science, 250, 279 (1990). (Original)

10 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Amyloid b-Protein (Human, 1-40) [HCI Form] Lyophilized from Dilute HCI Solution Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly- Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val (M.W. 4329.8) C194H295N53O58S [131438-79-4] Specific Form Easily Transferrable to β-Structure Purity Information: Qz See page xiv

PAB-4379-v-20 °C

0.5 mgvial

I. Kaneko, N. Yamada, Y. Sakuraba, M. Kamenosono, and S. Tutumi, J. Neurochem., 65, 2585 (1995). (Original) I. Kaneko, S. Tutumi, J. Neurochem., 68, 438 (1997). (Facile b-Structure Formation)

Amyloid b-Protein (Human, 1-42)(Trifluoroacetate Form) Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly- Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala (M.W. 4514.0) C203H311N55O60S [107761-42-2] Purity Information: Qz See page xiv

PAM-4349-v-20 °C

0.5 mg vial

D. Goldgaber, M.I. Lerman, O.W. McBride, U. Saffiotti, and D.C. Gajdusek, Science, 235, 877 (1987). (Original; cDNA) A.E. Roher, J.D. Lowenson, S. Clarke, A.S. Woods, R.J. Cotter, E. Gowing, and M.J. Ball, Proc. Natl. Acad. Sci. USA, 90, 10836 (1993). (Pathophysiology) N. Suzuki, T.T. Cheung, X.-D. Cai, A. Okada, L. Otvos, Jr., C. Eckman, T.E. Golde, and S.G. Younkin, Science, 264, 1336 (1994). (Pathophysiology) M. Citron, T.S. Diehl, G. Gordon, A.L. Biere, P. Seubert, and D.J. Selkoe, Proc. Natl. Acad. Sci. USA, 93, 13170 (1996). (Biosynthesis)

Amyloid b-Protein (Human, 1-43)(Trifluoroacetate Form) Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly- Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-Thr (M.W. 4615.1) C207H318N56O62S [134500-80-4] Major Plaque Component in Alzheimer’s Disease Purity Information: Qz See page xiv

PAB-4370-v-20 °C

0.5 mgvial

A. Tamaoka, T. Kondo, A. Odaka, N. Sahara, N. Sawamura, K. Ozawa, N. Suzuki, S. Shoji, and H. Mori, Biochem. Biophys. Res. Commun., 205, 834 (1994). (Pharmacol.) K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang, and G. Cole, Science, 274, 99 (1996). (Pharmacol.) K. Duff, C. Eckman, C. Zehr, X. Yu, C.-M. Prada, J. Perez-tur, M. Hutton, L. Buee, Y. Harigaya, D. Yager, D. Morgan, M.N. Gordon, L. Holcomb, L. Refolo, B. Zenk, J. Hardy, and S. Younkin, Nature, 383, 710 (1996). (Pharmacol.) T. Kawarabayashi, Y. Igeta, M. Sato, A. Sasaki, E. Matsubara, M. Kanai, Y. Tomidokoro, K. Ishiguro, K. Okamoto, S. Hirai, and M. Shoji, Brain. Res., 765, 343 (1997). (Pharmacol.)

Amyloid b-Protein (Human, 1-16)Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val- His-His-Gln-Lys (M.W. 1955.0) C84H119N27O28 [131580-10-4] Blocker for Plaque-Induced Microgliosis / Reducer for Brain Inflammation

PAB-4359-v-20 °C

0.5 mgvial

D. Giulian, L.J. Haverkamp, J. Yu, W. Karshin, D. Tom, J. Li, A. Kazanskaia, J. Kirkpatrick, and A.E. Roher, J. Biol. Chem., 273, 29719 (1998). (Original; Pharmacol.)M. Nakamura, N. Shishido, A. Nunomura, M.A. Smith, G. Perry, Y. Hayashi, K. Nakayama, and T. Hayashi, Biochemistry, 46, 12737 (2007). (Pharmacol.)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 11

Amyloid b-Protein (Human, 25-35)(Trifluoroacetate Form) Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met (M.W. 1060.3) C45H81N13O14S [131602-53-4] Neurotrophic / Neurodegenerative Peptide

PAM-4309-v-20 °C

0.5 mg vial

B.A. Yankner, L.K. Duffy, and D.A. Kirschner, Science, 250, 279 (1990). (Original) L. Meda, M.A. Cassatella, G.I. Szendrei, L. Otvos, Jr., P. Baron, M. Villalba, D. Ferrari, and F. Rossi, Nature, 374, 647 (1995). (Pharmacol.) L. Millucci, L. Ghezzi, G. Bernardini, and A. Santucci, Curr. Protein Pept. Sci., 11, 54 (2010). (Review)

[Pyr3]-Amyloid b-Protein (Human, 3-42)(Trifluoroacetate Form) Pyr-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala (M.W. 4309.9) C196H299N53O55S [183449-57-2] Major Neuritic Plaque Component in Alzheimer’s Disease Purity Information: Qz See page xiv

PAB-4367-v-20 °C

0.5 mgvial

T.C. Saido, T. Iwatsubo, D.M.A. Mann, H. Shimada, Y. Ihara, and S. Kawashima, Neuron, 14, 457 (1995). (Pharmacol.; Dominant Deposition in Senile Plaques) T. Iwatsubo, T.C. Saido, D.M.A. Mann, V.M.-Y. Lee, and J.Q. Trojanowski, Am. J. Pathol., 149, 1823 (1996). (Histochem.; Distribution in Brains of Patients) Y.-M. Kuo, M.R. Emmerling, A.S. Woods, R.J. Cotter, and A.E. Roher, Biochem. Biophys. Res. Commun., 237, 188 (1997). (Pharmacol.; Form in Neuritic Plaques and Vascular Amyloid Deposits)

Amyloid b-Protein (40-1)Peptide with Reversed Sequence of Amyloid b-Protein (Human, 1-40)


PAB-4413-s-20 °C

0.1 mgvial

Val-Val-Gly-Gly-Val-Met-Leu-Gly-Ile-Ile-Ala-Gly-Lys-Asn-Ser-Gly-Val-Asp-Glu-Ala-Phe- Phe-Val-Leu-Lys-Gln-His-His-Val-Glu-Tyr-Gly-Ser-Asp-His-Arg-Phe-Glu-Ala-Asp (M.W. 4329.8) C194H295N53O58S [144409-99-4] Negative Control Peptide for Amyloid β-Protein (Human, 1-40) Purity Information : QZ See page 3

Amyloid b-Protein (42-1)Peptide with Reversed Sequence of Amyloid b-Protein (Human, 1-42)


PAB-4420-s-20 °C

0.1 mgvial

Ala-Ile-Val-Val-Gly-Gly-Val-Met-Leu-Gly-Ile-Ile-Ala-Gly-Lys-Asn-Ser-Gly-Val-Asp-Glu-Ala- Phe-Phe-Val-Leu-Lys-Gln-His-His-Val-Glu-Tyr-Gly-Ser-Asp-His-Arg-Phe-Glu-Ala-Asp (M.W. 4514.0) C203H311N55O60S [317366-82-8] Negative Control Peptide for Amyloid β-Protein (Human, 1-42) Purity Information : QZ See page 3

Ac-Leu-Pro-N-Me-Phe-Phe-Asp-NH2b-Sheet Breaker Peptide iAb5p-A1

(M.W. 692.82) C36H48N6O8 Aβ (1-42) Fibrillogenesis Inhibitor, iAβ5p-A1

PAB-3637-PI-20 °C

5 mg

C. Adessi, M.J. Frossard, C. Boissard, S. Fraga, S. Bieler, T. Ruckle, F. Vilbois, S.M. Robinson,M. Mutter, W.A. Banks, and C. Soto, J. Biol. Chem., 278, 13905, (2003).

12 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Ac-Leu-Pro-Phe-Phe-Asp-NH2b-Sheet Breaker Peptide iAb5p

(M.W. 678.89) C35H46N6O8 Aβ (1-42) Fibrillogenesis Inhibitor, iAβ5p

PAB-3632-PI -20 °C

5 mg

C. Soto, E.M. Sigurdsson, L. Morelli, R.A. Kumar, E.M. Castaño, and B. Frangione, Nature Medicine, 4, 822 (1998). B. Permanne, C. Adessi, G.P. Saborio, S. Fraga, M.-J. Frossard, J.V. Dorpe, I. Dewachter, W.A. Banks, F. Van Leuven, and C. Soto, FASEB Journal, 16, 862, (2002).

Ac-Lys-N-Me-Leu-Val-N-Me-Phe-Phe-NH2(M.W. 721.95) C39H59N7O6 Membrane Permeable Inhibitor of Aβ (1-40) Fibrillogenesis

PAB-3631-PI-20 °C

1 mg5 mg

D.J. Gordon, K.L. Sciarretta, and S.C. Meredith, Biochemistry, 40, 8237 (2001). D.J. Gordon, R. Tappe, and S.C. Meredith, J. Pep. Res., 60(1), 37-55 (2002).

b-Sheet Breaker Peptide iAβ5Leu-Pro-Phe-Phe-Asp (M.W. 637.72) C33H43N5O8 [182912-74-9] Inhibitor of Amyloid Deposition

PAB-4358-v-20 °C

5 mgvial

C. Soto, E.M. Sigurdsson, L. Morelli, R.A. Kumar, E.M. Castano, and B. Frangione, Nat. Med., 4, 822 (1998). (Original, Pharmacol.)

b-Sheet Breaker Peptide iAβ5 (Bulk)Leu-Pro-Phe-Phe-Asp • AcOH • 4H2O (M.W. 637.74) C33H43N5O8 Inhibitor of Amyloid Deposition

PAB-3615-PI-20 °C

25 mg

C. Soto, E.M. Sigurdsson, L. Morelli, R.A. Kumar, E.M. Castano, and B. Frangione, Nat. Med., 4, 822 (1998). (Original)

Amphipathic Peptide AntibioticKKALLALALHHLAHLALHLALALKKA

H-Lys-Lys-Ala-Leu-Leu-Ala-Leu-Ala-Leu-His-His-Leu-Ala-His- Leu-Ala-Leu-His-Leu-Ala-Leu-Ala-Leu-Lys-Lys-Ala-OH (M.W. 2779.53) C132H228N38O27 Amphipathic Peptide Antibiotic, LAH4

PHR-3642-PI-20 °C

1 mg5 mg

A. Kichler, C. Leborgne, J. März, O. Danos, and B. Bechinger, Proc. Natl. Acad. Sci. USA, 100 (4), 1564 (2003).


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 13

Angiotensin and Related PeptidesI.H. Page and F.M. Bumpus (eds.), Angiotensin, Handbook of Experimental Pharmacology, Vol. 37, Springer-Verlag, Berlin, 1974. (Review) M.J. Peach, Physiol. Rev., 57, 313 (1997). (Review)

Ang II is part of the renin-angiotensin system which is responsible for the regulation of blood pressure and fluid balance. It is processed in a series of steps that begins with enzymatic activity of renin on angiotensinogen. Ang II produces many potent effects including vasoconstriction and release of aldosterone which increases reabsorption of electrolytes. Nagata et al. recently isolated a new angiotensinogen-derived peptide with an antibody that binds to the N-terminus of Ang II. The 12 amino acid peptide was named proangiotensin-12 (PAN-4439-v) and may be a precursor to Ang II.1 It was detected in significant concentrations in a number of rat tissues and demonstrated to have constrictive effects, though its activity was not as potent as Ang II. Its discovery suggests an alternative processing method for Ang II that may be independent of renin. 1. S. Nagata, J. Kato, K. Sasaki, N. Minamino, T. Eto, and K. Kitamura, Biochem. and Biophys. Res. Commun., 350, 1026 (2006). (Original; Primary Structure & Pharmacol.)

H-Ala-Arg-Val-Tyr-Ile-His-Pro-Phe-OHDes-Asp1-[Ala1]-Angiotensin II (Human)ARVYIHPF(M.W. 1002.19) C49H71N13O10 Vasoconstrictive Peptide / Angiotensin Peptide

PAN-3921-PI-20 °C

1 mg5 mg

V. Jankowski, R. Vanholder, M. van der Giet, M. Tölle, S. Karadogan, J. Gobom, J. Furkert, A. Oksche, E. Krause, T.N.A. Tran, M. Tepel, M. Schuchardt, H. Schlüter, A. Wiedon, M. Beyermann, M. Bader, M. Todiras, W. Zidek, and J. Jankowski, Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 297 ( 2007).

Angiotensin I (Human) (0.5 mg vial)(Porcine, Canine, Rat, Rabbit, Guinea pig) Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu(M.W. 1296.5) C62H89N17O14 [484-42-4]

PAN-4007-v-20 °C

0.5 mgvial

Angiotensin I (Human) (Bulk)(Porcine, Canine, Rat, Rabbit, Guinea pig) Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu(M.W. 1296.5) C62H89N17O14 [484-42-4]

PAN-4007-20 °C

25 mg

K. Arakawa, M. Nakatani, A. Minohara, and M. Nakamura, Biochem. J., 104, 900 (1967). (Original; Human)H. Akagi, T. Hayashi, T. Nakayama, T. Nakajima, T.X. Watanabe, and H. Sokabe, Chem. Pharm. Bull., 30, 2498 (1982). (Original; Porcine etc.)

Angiotensin II (Human)* (0.5 mg vial)Asp-Arg-Val-Tyr-Ile-His-Pro-Phe(M.W. 1046.2) C50H71N13O12 [4474-91-3]

PAN-4001-v-20 °C

0.5 mgvial

Angiotensin II (Human)* (Bulk)Asp-Arg-Val-Tyr-Ile-His-Pro-Phe • AcOH • 4H2O(M.W. 1046.2 • 60.05 • 72.06) C50H71N13O12 • CH3COOH • 4H2O

PAN-4001-20 °C

25 mg

K. Arakawa, M. Nakatani, A. Minohara, and M. Nakamura, Biochem. J., 104, 900 (1967). (Original)

[N-Me-Asp1]-Angiotensin IIH-N-Me-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OHVasoconstrictive Peptide / Angiotensin Peptide (M.W. 1060.23) C51H73N13O12

PAN-3949-PI-20 °C

1 mg5 mg

R.J. Kokje, W.L. Wilson, T.E. Brown, V.T. Karamyan, J.W. Wright, and R.C. Speth, Hypertension, 49, 1328 (2007).

NEW!

14 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Angiotensin III (Human)*Arg-Val-Tyr-Ile-His-Pro-Phe(M.W. 931.09) C46H66N12O9 [13602-53-4]

PAN-4028-v-20 °C

0.5 mg vial

Angiotensin III (Human)* (Bulk)Arg-Val-Tyr-lle-His-Pro-Phe • 2AcOH • 4H2O (M.W. 931.09 • 120.11 • 72.06) C46H66N12O9 • 2CH3COOH • 4H2O [100900-06-9]

PAN-4028-20 °C

25 mg

W.B Campbell, S.N. Brooks, and W.A. Pettinger, Science, 184, 994 (1974). (Original)

Angiotensin IV (Human)* Angiotensin (Human, 3-8)

Val-Tyr-Ile-His-Pro-Phe (M.W. 774.91) C40H54N8O8 [23025-68-5]

PAN-4331-v-20 °C

0.5 mgvial


Angiotensin IV (Human)* (Bulk)Angiotensin (Human, 3-8)

Val-Tyr-Ile-His-Pro-Phe • ½ AcOH • 3H2O (M.W. 774.91 • 30.03 • 54.05) C40H54N8O8 • ½ CH3COOH • 3H2O

PAN-4331-20 °C

25 mg

R.L. Haberl, P.J. Decker, and K.M. Einhäupl, Circ. Res., 68, 1621 (1991). (Biological Activity) J.W. Harding, V.I. Cook, A.V. Miller-Wing, J.M. Hanesworth, M.F. Sardinia, K.L. Hall, J.W. Stobb, G.N. Swanson, J.K.M. Coleman, J.W. Wright, and E.C. Harding, Brain Res., 583, 340 (1992). (Specific Binding Site in Brain) J.M. Hanesworth, M.F. Sardinia, L.T. Krebs, K.L. Hall, and J.W. Harding, J. Pharmacol. Exp. Ther., 266, 1036 (1993). (Specific Binding Site in Heart) M. de Gasparo, A. Husain, W. Alexander, K.J. Catt, A.T. Chiu, M. Drew, T. Goodfriend, J.W. Harding, T. Inagami, and P.B.M.W.M. Timmermans, Hypertension, 25, 924 (1995). (AT4 Receptor; Non AT½ Recognition, Nomenclature)


[Val5]-Angiotensin I (Bovine)*Asp-Arg-Val-Tyr-Val-His-Pro-Phe-His-Leu(M.W. 1282.4) C61H87N17O14 [484-43-5]

PAN-4069-v-20 °C

0.5 mgvial


[Val5]-Angiotensin I (Bovine)* (Bulk)Asp-Arg-Val-Tyr-Val-His-Pro-Phe-His-Leu • AcOH • 5H2O (M.W. 1282.4 • 60.05 • 90.08) C61H87N17O14 • CH3COOH • 5H2O

PAN-4069-20 °C

25 mg

D.F. Elliott and W.S. Peart, Biochem. J., 65, 246 (1957). (Original; Heterogenous Renin) H. Akagi, T. Hayashi, T. Nakayama, T. Nakajima, T.X. Watanabe, and H. Sokabe, Chem. Pharm. Bull., 30, 2498 (1982). (Original; Homologous Renin) M. Takai, Y. Kurano, T. Kimura, and S. Sakakibara, Peptide Chemistry, 1979, 187 (1980). (Chem. Synthesis)


[Asn1, Val5]-Angiotensin II*Asn-Arg-Val-Tyr-Val-His-Pro-Phe (M.W. 1031.2) C49H70N14O11 [53-73-6]

PAN-4036-v-20 °C

0.5 mgvial

[Asn1, Val5]-Angiotensin II* (Bulk)Asn-Arg-Val-Tyr-Val-His-Pro-Phe • AcOH • 4H2O (M.W. 1031.2 • 60.05 • 72.06) C49H70N14O11 • CH3COOH • 4H2O

PAN-4036-20 °C

25 mg



NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 15

Angiotensin (Human, 1-7)*(Canine, Rat)

Asp-Arg-Val-Tyr-Ile-His-Pro (M.W. 899.00) C41H62N12O11 [51833-78-4]

PAN-4332-v-20 °C

0.5 mg vial


[Sar1]-Angiotensin IIH-Sar-Arg-Val-Tyr-Ile-His-Pro-Phe-OH (M.W. 1002.19) C49H71N13O10 Vasoconstrictive Peptide / Angiotensin Peptide

PAN-3948-PI-20 °C

1 mg5 mg

R.J. Kokje, W.L. Wilson, T.E. Brown, V.T. Karamyan, J.W. Wright, and R.C. Speth, Hypertension, 49, 1328 (2007).

Angiotensin (Human, 1-7)* (Bulk)(Canine, Rat)

Asp-Arg-Val-Tyr-Ile-His-Pro • AcOH • 4H2O (M.W. 899.00 • 60.05 • 72.06) C41H62N12O11 • CH3COOH • 4H2O

PAN-4332-20 °C

25 mg

M.T. Schiavone, R.A.S. Santos, K.B. Brosnihan, M.C. Khosla, and C.M. Ferrario, Proc. Natl. Acad. Sci. U.S.A., 85, 4095 (1988). (Original) C.M. Ferrario, K.B. Brosnihan, D.I. Diz, N. Jaiswal, M.C. Khosla, A. Milsted, and E.A. Tallant, Hypertension, 18 (Suppl. III), III-126 (1991). (Review) R.A.S. Santos, K.B. Brosnihan, D.W. Jacobsen, P.E. DiCorleto, and C.M. Ferrario, Hypertension, 19 (Suppl. II), II-56 (1992). (Metabolic Pathway) A. DelliPizzi, S.D. Hilchey, and C.P. Bell-Quilley, Br. J. Pharmacol., 111, 1 (1994). (Pharmacol.)


[Sar1, Ala8]-Angiotensin IISar-Arg-Val-Tyr-Ile-His-Pro-Ala (M.W. 926.07) C43H67N13O10 [38027-95-11]

PAN-4035-v-20 °C

0.5 mg vial

[Sar1, Ala8]-Angiotensin II (Bulk)Sar-Arg-Val-Tyr-Ile-His-Pro-Ala • AcOH • 4H2O

PAN-4035-20 °C

25 mg

(M.W. 926.07 • 60.05 • 72.06) C43H67 N13O10 • CH3COOH • 4H2O Angiotensin II Selective Antagonist

D.T. Pals, F.D. Masucci, G.S. Denning, Jr., F. Sipos, and D.C. Fessler, Circ. Res., 29, 673 (1971). (Original) F.M. Bumpus, S. Sen, R.R. Smeby, C. Sweet, C.M. Ferrario, and M.C. Khosla, Circ. Res., 32 and 33 (Suppl. I), 1-150 (1973). (Pharmacol.)

[Sar1, Ile8]-Angiotensin IISar-Arg-Val-Tyr-Ile-His-Pro-Ile (M.W. 968.15) C46H73N13O10 [37827-06-8]

PAN-4016-v-20 °C

0.5 mg vial

[Sar1, Ile8]-Angiotensin II (Bulk)Sar-Arg-Val-Tyr-Ile-His-Pro-Ile • AcOH • 4H2O (M.W. 968.15 • 60.05 • 72.06) C46H73N13O10 • CH3COOH • 4H2O Angiotensin II Selective Antagonist

PAN-4016-20 °C

25 mg

F.M. Bumpus, S. Sen, R.R. Smeby, C. Sweet, C.M. Ferrario, and M.C. Khosla, Circ. Res., 32 and 33 (Suppl. I), 1-150 (1973). R.K. Türker, M.M. Hall, M. Yamamoto, C.S. Sweet, and F.M. Bumpus, Science, 177, 1203 (1972).

[Sar1, Thr8]-Angiotensin IISar-Arg-Val-Tyr-Ile-His-Pro-Thr (M.W. 956.10) C44H69N13O11 [53632-49-8]

PAN-4102-v-20 °C

0.5 mg vial

NEW!

16 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES [Sar1, Thr8]-Angiotensin II (Bulk) Sar-Arg-Val-Tyr-Ile-His-Pro-Thr • 2AcOH • 4H2O

PAN-4102-20 °C

25 mg

(M.W. 956.101 • 120.10 • 72.06) C44H69N13O11 • 2CH3COOH • 4H2O Angiotensin II Selective Antagonist

M.C. Khosla, M.M. Hall, R.B. Smeby, and F.M. Bumpus, J. Med. Chem., 17, 1156 (1974). (Original; Chem. Synthesis)

[Sar1, Val5, Ala8]-Angiotensin II*Sar-Arg-Val-Tyr-Val-His-Pro-Ala (M.W. 912.05) C42H65N13O10 [34273-10-4]

PAN-4071-v-20 °C

0.5 mgvial


[Sar1, Val5, Ala8]-Angiotensin II* (Bulk) Sar-Arg-Val-Tyr-Val-His-Pro-Ala • AcOH • 4H2O (M.W. 912.05 • 60.05 • 72.06) C42H65N13O10 • CH3COOH • 4H2O Angiotensin II Selective Antagonist

PAN-4071-20 °C

25 mg

D.T. Pals, F.D. Masucci, G.S. Denning, Jr., F. Sipos, and D.C. Fessler, Circ. Res., 29, 673 (1971). (Original)


[Val5]-Angiotensin II* Asp-Arg-Val-Tyr-Val-His-Pro-Phe (M.W. 1032.2) C49H69N13O12 [58-49-1]

PAN-4034-v-20 °C

0.5 mgvial


[Val5]-Angiotensin II* (Bulk)Asp-Arg-Val-Tyr-Val-His-Pro-Phe • AcOH • 4H2O (M.W. 1032.2 • 60.05 • 72.06) C49H69N13O12 • CH3COOH • 4H2O [5649-07-0]

PAN-4034-20 °C

25 mg

D.F. Elliot and W.S. Peart, Nature, 177, 527 (1956). (Original; Heterogenous Renin) H. Akagi, T. Hayashi, T. Nakayama, T. Nakajima, T.X. Watanabe, and H. Sokabe, Chem. Pharm. Bull., 30, 2498 (1982). (Original; Homologous Renin)


Des-Asp1-[Ile8]-Angiotensin IIArg-Val-Tyr-Ile-His-Pro-Ile (M.W. 897.08) C43H68N12O9 [52498-25-6]

PAN-4037-v-20 °C

0.5 mg vial

Des-Asp1-[Ile8]-Angiotensin II (Bulk)Arg-Val-Tyr-Ile-His-Pro-Ile • 2AcOH • 4H2O (M.W. 897.08 • 120.10 • 72.06) C43H68N12O9 • 2CH3COOH • 4H2O [102029-49-2] Angiotensin III Selective Antagonist

PAN-4037-20 °C

25 mg

T. Kono, F. Ikeda, F. Oseko, H. Imura, and J. Endo, J. Clin. Endocrinol. Metab., 52, 354 (1981). (Pharmacol.)

CGP 42112Nic-Tyr-Lys(Z-Arg)-His-Pro-Ile (Nic-Nicotinoyl, Z-: Benzyloxycarbonyl) (M.W. 1052.2) C52H69N13O11 [127060-75-7] Angiotensin AT2 Receptor Agonist

PAN-4296-v-20 °C

0.5 mg vial

S.E. Whitebread, V. Taylor, S.P. Bottari, B. Kamber, and M. de Gasparo, Biochem. Biophys. Res. Commun., 181, 1365 (1991). B. Buisson, S.P. Bottari, M. de Gasparo, N. Gallo-Payet, and M.D. Payet, FEBS Lett., 309, 161 (1992). (Pharmacol.) G. Koike, M. Horiuchi, T. Yamada, C. Szpirer, H.J. Jacob, and V.J. Dzau, Biochem. Biophys. Res. Commun., 203, 1842 (1994). (Pharmacol.)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 17

Proangiotensin-12 (Rat)Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Tyr(M.W. 1572.8) C77H109N19O17 [914910-73-9] New Member of Angiotensin Family

PAN-4439-v-20 °C

0.5 mgvial

S. Nagata, J. Kato, K. Sasaki, N. Minamino, T. Eto, and K. Kitamura, Biochem. and Biophys. Res. Commun., 350, 1026 (2006). (Original; Primary Structure & Pharmacol.)• This compound is distributed through Peptide Institute, Inc. under the license of University of Miyazaki.

A-Type (Atrial) Natriuretic Peptides (ANP) and Related PeptidesP. Needleman, E.H. Blaine, J.E. Greenwald, M.L. Michener, C.B. Saper, P.T. Stockmann, and H.E. Tolunay, Annu. Rev. Pharmacol. Toxicol., 29, 23 (1989). (Review) A. Rosenzweig and C.E. Seidman, Annu. Rev. Biochem., 60, 229 (1991). (Review)

ANP (Human, 1-28)* A-Type (Atrial) Natriuretic Peptide (Human, 1-28) (Porcine, Bovine, Canine)

PAF-4135-s-20 °C

0.1 mgvial

Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly- Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bond between Cys7-Cys23) (M.W. 3080.4) C127H203N45O39S3 [91917-63-4]


ANP (Human, 1-28)* A-Type (Atrial) Natriuretic Peptide (Human, 1-28) (Porcine, Bovine, Canine)

PAF-4135-v-20 °C

0.5 mgvial

K. Kangawa and H. Matsuo, Biochem. Biophys. Res. Commun., 118, 131 (1984). (Original) T.X. Watanabe, Y. Noda, N. Chino, Y. Nishiuchi, T. Kimura, S. Sakakibara, and M. Imai, Eur. J. Pharmacol., 147, 49 (1988). (Pharmacol.) • This compound is distributed under the license of Suntory Ltd. Its use or sale for diagnostics is strictly prohibited.


[Met(O)12]-ANP (Human, 1-28)* [Met(O)12]-A-Type (Atrial) Natriuretic Peptide (Human, 1-28)

PAF-4145-v-20 °C

0.5 mgvial

Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met(O)-Asp-Arg- Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bond between Cys7-Cys23) (M.W. 3096.4) C127H203N45O40S3

T.X. Watanabe, Y. Noda, N. Chino, Y. Nishiuchi, T. Kimura, S. Sakakibara, and M. Imai, Eur. J Pharmacol., 147, 49 (1988). (Pharmacol.)


ANP (Human, 3-28) A-Type (Atrial) Natriuretic Peptide (Human, 3-28) (Porcine, Bovine)

ANP-3755-PI-20 °C

1 mg5 mg

(Trifluoroacetate Form) H-Arg-Arg-Ser-Ser-[Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly- Ala-Gln-Ser-Gly-Leu-Gly-Cys]-Asn-Ser-Phe-Arg-Tyr-OH (Disulfide bond between Cys7-Cys23) (M.W. 2880.26) C118H187N43O36S3

J.J. Goy, et al., J. Cardiovasc Pharmacol, 12, 562 (1988). J. Bidiville, et al., Fundam Clin Pharmacol, 2, 413 (1988).

NEW!

NEW!

18 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES ANP (Human, 5-27)* A-Type (Atrial) Natriuretic Peptide (Human, 5-27)

Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly- Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg (Disulfide bond between Cys7-Cys23) (M.W. 2404.7) C97H154N34O32S3

PAF-4138-v-20 °C

0.5 mgvial

T.X. Watanabe, Y. Noda, N. Chino, Y. Nishiuchi, T. Kimura, S. Sakakibara, and M. Imai, Eur. J. Pharmacol., 147, 49 (1988). (Pharmacol.)


ANP (Human, 5-28)* A-Type (Atrial) Natriuretic Peptide (Human, 5-28)

Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala- Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bond between Cys7-Cys23) (M.W. 2567.8) C106H163N35O34S3

PAF-4137-v-20 °C

0.5 mgvial

S. Ueda, T. Sudoh, K. Fukuda, K. Kangawa, N. Minamino, and H. Matsuo, Biochem. Biophys. Res. Commun., 149, 1055, (1987). (Original) T.X. Watanabe, Y. Noda, N. Chino, Y. Nishiuchi, T. Kimura, S. Sakakibara, and M. Imai, Eur. J. Pharmacol., 147, 49 (1988). (Pharmacol.)


ANP (Human, 7-28)* A-Type (Atrial) Natriuretic Peptide (Human, 7-28)

Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln- Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bond between Cys7-Cys23)(M.W. 2393.7) C100H153N33O30S3

PAF-4139-v-20 °C

0.5 mgvial

T.X. Watanabe, Y. Noda, N. Chino, Y. Nishiuchi, T. Kimura, S. Sakakibara, and M. Imai, Eur. J. Pharmacol., 147, 49 (1988).


b-ANP (Human)* b-A-Type (Atrial) Natriuretic Peptide Antiparallel Dimer of ANP (Human, 1-28)

PAF-4168-s-20 °C

0.1 mgvial

Ser-Leu-Arg-Arg-Ser-Ser-Cys71-Phe-Gly-Gly-Arg-Met-Asp-Arg-lle-Gly-Ala-Gln-Ser-Gly-

Leu-Gly-Cys231-Asn-Ser-Phe-Arg-Tyr-Tyr-Arg-Phe-Ser-Asn-Cys231-Gly-Leu-Gly-Ser-

Gln-Ala-Gly-lle-Arg-Asp-Met-Arg-Gly-Gly-Phe-Cys71-Ser-Ser-Arg-Arg-Leu-Ser (Disulfide bonds betwen Cys7-Cys231

and Cys71-Cys231) (M.W. 6160.9) C254H406N90O78S6

K. Kangawa, A. Fukuda, and H. Matsuo, Nature, 313, 397 (1985). (Original) N. Chino, K. Yoshizawa-Kumagaye, Y. Noda, T.X. Watanabe, T. Kimura, and S. Sakakibara, Biochem. Biophys. Res. Commun., 141, 665 (1986). (Chem. Synthesis and Pharmacol.)


ANP (Rat, 1-28)* A-Type (Atrial) Natriuretic Peptide (Rat, 1-28) (Rabbit, Mouse)

PAF-4151-s-20 °C

0.1 mgvial

Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile- Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bond between Cys7-Cys23) (M.W. 3062.4) C128H205N45O39S2 [88898-17-3]



NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 19

ANP (Rat, 1-28)*A-Type (Atrial) Natriuretic Peptide (Rat, 1-28 (Rabbit, Mouse))

PAF-4151-v-20 °C

0.5 mgvial

T.G. Flynn, M.L. DeBold, and A.J. DeBold, Biochem. Biophys. Res. Commun., 117, 859 (1983). (Original) T.X. Watanabe, Y. Noda, N. Chino, Y. Nishiuchi, T. Kimura, S. Sakakibara, and M. Imai, Eur. J. Pharmacol., 147, 49 (1988). (Pharmacol.)


ANP (Rat, 3-28)* A-Type (Atrial) Natriuretic Peptide (Rat, 3-28)

Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly- Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bond between Cys7-Cys23) (M.W. 2862.2) C119H189N43O36S2 [90984-99-9]

PAF-4159-v-20 °C

0.5 mg vial

N.G. Seidah, C. Lazure, M. Chretien, G. Thibault, R. Garcia, M. Cantin, J. Genest, R.F. Nutt, S.F. Brady, T.A. Lyle, W.J. Paleveda, C.D. Colton, T.M. Ciccarone, and D.F. Veber, Proc. Natl. Acad. Sci. USA, 81, 2640 (1984). (Original)


Apamin Apamin (Honeybee, Apis mellifera)

Cys-Asn-Cys-Lys-Ala-Pro-Glu-Thr-Ala-Leu-Cys- Ala-Arg-Arg-Cys-Gln-Gln-His-NH2 (Disulfide bond between Cys1-Cys11 and Cys3-Cys15) (M.W. 2027.3) C79H131N31O24S4 [24345-16-2] Small Conductance Ca2+-Activated K+ Channel Blocker

PAP-4257-v-20 °C

0.5 mgvial

E. Haberman, Pharmacol. Ther., 25, 255 (1984). (Review) A.L. Blatz and K.L. Magleby, Nature, 323, 718 (1986). (Pharmacol.) M.L. Garcia, A. Galvez, M. Garcia-Calvo, V.F. King, J. Vazquez, and G.J. Kaczorowski, J. Bioenerg. Biomembr., 23, 615 (1991). (Review)

ApelinsS.C. Sorli, L. van den Berghe, B. Masri, B. Knibiehler, and Y. Audigier, Drug Discov. Today, 11, 1100 (2006). (Review)C. Carpene, C. Dray, C. Attane, P. Valet, M.P. Portillo, I. Churruca, F.I. Milagro, and I. Castan-Laure, J. Physiol. Biochem., 63, 359 (2007 (Review) I. Falcao-Pires, R. Ladeiras-Lopes, and A.F. Leite-Moreira, Expert Opin. Ther. Targets, 14, 633 (2010). (Review)

Apelin-36 (Human)Leu-Val-Gln-Pro-Arg-Gly-Ser-Arg-Asn-Gly-Pro-Gly-Pro- Trp-Gln-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg- Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe (M.W. 4195.8) C184H297N69O43S [252642-12-9] Ligand for APJ Receptor

PAP-4362-s-20 °C

0.1 mgvial

K. Tatemoto, M. Hosoya, Y. Habata, R. Fujii, T. Kakegawa, M.-X. Zou, Y. Kawamata, S. Fukusumi, S. Hinuma, C. Kitada, T. Kurokawa, H. Onda, and M. Fujino, Biochem. Biophys. Res. Commun., 251, 471 (1998). (Original; Human and Bovine) M.-X. Zou, H.-Y. Liu, Y. Haraguchi, Y. Soda, K. Tatemoto, and H. Hoshino, FEBS Lett., 473, 15 (2000). (Pharmacol.) M. Hosoya, Y. Kawamata, S. Fukusumi, R. Fujii, Y. Habata, S. Hinuma, C. Kitada, S. Honda, T. Kurokawa, H. Onda, O. Nishimura, and M. Fujino, J. Biol. Chem., 275, 21061 (2000). (Pharmacol.) • This compound is distributed through Peptide Institute, Inc. under license of Takeda Chemical Industries, Ltd.

20 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES [Pyr1]-Apelin-13 (Human, Bovine)(Rat)

Pyr-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe (M.W. 1533.8) C69H108N22O16S [217082-60-5] Ligand for APJ Receptor

PAP-4361-v-20 °C

0.5 mgvial

K. Tatemoto, M. Hosoya, Y. Habata, R. Fujii, T. Kakegawa, M.-X. Zou, Y. Kawamata, S. Fukusumi, S. Hinuma, C. Kitada, T. Kurokawa, H. Onda, and M. Fujino, Biochem. Biophys. Res. Commun., 251, 471 (1998). (Original; Human and Bovine) M.-X. Zou, H.-Y. Liu, Y. Haraguchi, Y. Soda, K. Tatemoto, and H. Hoshino, FEBS Lett., 473, 15 (2000). (Pharmacol.) M. Hosoya, Y. Kawamata, S. Fukusumi, R. Fujii, Y. Habata, S. Hinuma, C. Kitada, S. Honda, T. Kurokawa, H. Onda, O. Nishimura, and M. Fujino, J. Biol. Chem., 275, 21061 (2000). (Pharmacol.) D.K. Lee, R. Cheng, T. Nguyen, T. Fan, A.P. Kariyawasam, Y. Liu, D.H. Osmond, S.R. George, and B.F. O'Dowd, J. Neurochem., 74, 34 (2000). cDNA Seq.; Rat)N. De Mota, A.R.-L. Goazigo, S.E. Messari, N. Chartrel, D. Roesch, C. Dujardin, C. Kordon, H. Vaudry, F. Moos, and C. Llorens-Cortes, Proc. Natl. Acad. Sci. U.S.A., 101, 10464 (2004). (Endogenous Apelin 13 in Rat) • This compound is distributed through Peptide Institute, Inc. under license of Takeda Chemical Industries, Ltd.

Arg-Gly-Asp "RGD" Peptides.

The extracellular matrix (ECM) is central to cell recognition, adhesion and migration. ECM proteins have an arg-gly-asp (RGD) core that allows for receptor recognition. Synthetic peptides containing RGD can compete with ECM protein ligands for receptor binding. GRGDNP (PCI-3909-PI) binds to vitronectin and fibronectin receptors and block interaction to their perspective ligands, though it is a more active inhibitor of fibronectin receptor.1 GRGDNP was found to induce caspase 3 mediated apoptosis in cells and block tumor invasion, implicating fibronectin and vitronectin in tumor metastasis.2,3 In addition, these ECM proteins may influence cardiac function as well.4,5 1. M.D. Pierschbacher and E. Ruoslahti, J. Biol. Chem., 262, 17294 (1987). 2. C.D. Buckley, et al., Nature, 397, 534 (1999).

3. K.R. Gehlsen, et al., J. Cell Biol., 106, 925 (1988). 4. V. Sarin, et al., J. Physiol., 564.2, 603 (2005). 5. J.E. Mogford, et al., J. Clin. Invest., 100, 1647 (1997).

cyclo (Arg-Gly-Asp-d-Phe-Cys)c (RGDfC)

(M.W. 578.65) C24H34N8O7S RGD Tumor Targeting Peptide (linker additions via Cys) (Requires further derivatization before use)

PCI-3686-PI-20 °C

1 mg5 mg

25 mg

C. Pattillo, F. Sari-Sarraf, R. Nallamothu, B. Moore, G. Wood, and M. Kiani, Experim. Clin.Therapeutics, Radiation Research Society Meeting (2005)

cyclo (Arg-Ala-Asp-d-Phe-Cys)c(RADfC)

(M.W. 592.68) C25H36N8O7SNegative Control Peptide for PCI-3686-PI

PCI-3960-PI-20 °C

1 mg5 mg

25 mg

cyclo (Arg-Gly-Asp-d-Phe-Glu)c (RGDfE)

(M.W. 604.63) C26H36N8O9 RGD Peptide for Radiolabeling and Imaging (Requires further derivatization before use)

PCI-3687-PI-20 °C

1 mg5 mg

25 mg

G. Thumshirn, U. Hersel, S.L. Goodman, and H. Kessler, Chem. Eur. J., 9, 2717 (2003). T. Poethko, M. Schottelius, G. Thumshirn, U. Hersel, M. Herz, G. Henriksen, H. Kessler, M. Schwaiger, and H.J. Wester, J. Nucl. Med., 45, 892 (2004).

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 21

cyclo (Arg-Gly-Asp-d-Phe-Lys)c (RGDfK)

(M.W. 603.68) C27H41N9O7 αv β3 Integrin Binding RGD Peptide RGD Tumor Targeting Peptide (Requires further derivatization before use)

PCI-3661-PI-20 °C

1 mg5 mg

25 mg

M. Kantlehner, P. Schaffner, D. Finsinger, J. Meyer, A. Jonczyk, B. Diefenbach, B. Nies, G. Hozemann, S.L. Goodman, and H. Kessler. Chembiochem., 1, 107 (2000). R.J. Kok, A.J. Schraa, E.J. Bos, H.E. Moorlag, S.A. Ásgeirsdóttir, M. Everts, DK. Meijer, and G. Molema, Bioconjug. Chem., 13, 128 (2002).

cyclo (Arg-Gly-Asp-d-Phe-Lys)c(RGDfK)

(Trifluoroacetate Form) (M.W. 603.68) C27H41N9O7

PCI-3919-PI-20 °C

1 mg5 mg

25 mgM. Kantlehner, P. Schaffner, D. Finsinger, J. Meyer, A. Jonczyk, B. Diefenbach, B. Nies, G. Hozemann, S.L. Goodman, and H. Kessler, Chembiochem., 1, 107 (2000). R.J. Kok, A.J. Schraa, E.J. Bos, H.E. Moorlag, S.A. Ásgeirsdóttir, M. Everts, D.K. Meijer, and G. Molema, Bioconjug. Chem., 13, 128 (2002).

cyclo (Arg-Ala-Asp-d-Phe-Lys)c (RADfK)

(M.W. 617.71) C28H43N9O7 Negative Control RGD Peptide for PCI-3661-PI

PCI-3883-PI-20 °C

1 mg5 mg

25 mgP.K. Dubey, V. Mishra, S. Jain, S. Mahor, and S.P. Vyas, J. Drug Targeting, 12, 257 (2004).

cyclo [Arg-Gly-Asp-d-Phe-Lys (PEG-PEG-Azide)] one of The Clickables

(Trifluoroacetate Form) (M.W. 920.00) C39H61N13O13Clickable RGD for Dendrimer Constructs

PCI-3759-PI-20 °C

1 mg5 mg

cyclo [Arg-Gly-Asp-d-Phe-Lys (Azide)] one of The Clickables

(Trifluoroacetate Form) (M.W. 629.68) C27H39N11O7 Clickable RGD for Dendrimer Constructs

RGD-3749-PI-20 °C

1 mg5 mg

cyclo [Arg-Gly-Asp-d-Phe-Lys(PEG-PEG)]c (RGDfK(PEG-PEG))

where PEG = 8-Amino-3,6-Dioxaoctanoic Acid(M.W. 894.00) C39H63N11O13

PCI-3696-PI-20 °C

1 mg5 mg

25 mgRGD Peptide equipped with PEG spacers for more efficient binding to lipid surfaces (Requires further derivatization before use) P. Holig, M. Bach, T. Volkel, T. Nahde, S. Hoffmann, R. Muller, and R.E. Kontermann, Protein Engin. Design Selection, 17, 433 (2004).

cyclo [Arg-Ala-Asp-d-Phe-Lys(PEG-PEG)]c[RADfK(PEG-PEG)]

(M.W. 908.03) C40H65N11O13 Negative Control Peptide for PCI-3696-PI

PCI-3954-PI-20 °C

1 mg5 mg

25 mg

NEW!

NEW!

NEW!

NEW!

22 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES cyclo (Arg-Gly-Asp-d-Phe-Lys(Biotin-PEG-PEG))c (RGDfK(Biotin-PEG-PEG))

where PEG = 8-Amino-3,6-Dioxaoctanoic Acid (Trifluoroacetate Form) (M.W. 1120.30) C49H77N13O15S

PCI-3697-PI-20 °C

1 mg5 mg

RGD Peptide equipped with a biotin reporting tag and PEG spacers for more efficient binding to lipid surfaces (Requires further derivatization before use)C. Dolce, A. Vakani, L. Archer, J.A. Morris-Wiman, and L.S. Holliday, J. Dent. Res., 82, 682 (2003). P. Holig, M. Bach, T. Volkel, T. Nahde, S. Hoffmann, R. Muller, and R.E. Kontermann, Protein Engin. Design Selection, 17, 433 (2004).

cyclo [Arg-Gly-Asp-d-Phe-Lys(Ac-SCH2CO)] c [RGDfK (Ac-SCH2CO)]

(M.W. 719.82) C31H45N9O9S

PCI-3699-PI-20 °C

1 mg5 mg

25 mgRGD Peptide equipped with thioacetyl group for linking to liposomes (Requires further derivatization and deprotection before use) R.J. Kok, A.J. Schraa, E.J. Bos, H.E. Moorlag, S.A. Asgeirsdottir, M. Everts, D.K.F. Meijer, and G. Molema, Bioconjug. Chem., 13, 128 (2002). R.M. Schiffelers, G.A. Koning,, T.L.M. ten Hagen, M.H.A.M. Fens, A.J. Schraa, A.P.C.A. Janssen, R.J. Kok, G. Molema, and G. Storm, J. of Controlled Release, 91, 115 (2003). K. Darlak, R.B. Miller, M.S. Stack, A.F. Spatola, and R.D. Gray, J. Biol. Chem., 265, 5199 (1990).

cyclo (Arg-Ala-Asp-d-Phe-Lys(Ac-SCH2CO))c(RADfK(Ac-SCH2CO))

(M.W. 733.85) C32H47N9O9S Negative Control Peptide for PCI-3699-PI

PCI-3959-PI-20 °C

1 mg5 mg

25 mg

Galactosyl-cyclo (Arg-Gly-Asp-d-Phe-Lys) Cyclo(-Arg-Gly-Asp-d-Phe-Lys(SAA))

(M.W. 792.85) C34H52N10O12 [922175-70-0] Glycosylated RGD for radiolabellingHaubner, et al., Bioconjugate Chem., 15, 1, (2004).

RGD-3736-PI-20 °C

1 mg5 mg

H-Glu[cyclo (Arg-Gly-Asp-d-Phe-Lys)]2E-[c (RGDfK)2]

(M.W. 1318.47) C59H87N19O16 αv β3 Integrin Binding RGD Peptide RGD Tumor Targeting Peptide (Requires further derivatization before use)

PCI-3651-PI-20 °C

1 mg5 mg

25 mg

M.L. Janssen, W.J. Oyen, I. Dijkgraaf, L.F. Massuger, C. Frielink, D.S. Edwards, M. Rajopadhye, H. Boonstra, F.H. Corstens, and O.C. Boerman, Cancer. Res., 62, 6146 (2002). Y. Wu, X. Zhang, Z. Xiong, Z. Cheng, D.R. Fisher, S. Liu, S.S. Gambhir, and X. Chen, J. Nucl. Med., 46, 1707 (2005).

cyclo (Arg-Gly-Asp-d-Phe-Val)c(RGDfV)

(M.W. 574.63) C26H38N8O7 [137813-35-5] Angiogenesis Inhibitor

ICA-4304-v-20 °C

0.5 mgvial

P.C. Brooks, A.M.P. Montgomery, M. Rosenfeld, R.A. Reisfeld, T. Hu, G. Klier, and D.A. Cheresh, Cell, 79, 1157 (1994). (Original) M. Friedlander, C.L. Theesfeld, M. Sugita, M. Fruttiger, M.A. Thomas, S. Chang, and D.A. Cheresh, Proc. Natl. Acad. Sci. USA, 93, 9764 (1996). (Pharmacol.)

NEW!

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 23

cyclo (Arg-Gly-Asp-d-Phe-Val) • AcOH • 2H2O (Bulk)c(RGDfV)

ICA-4304-20 °C

25 mg

(M.W. 574.63 • 60.25 • 36.03) • C26H38N8O7 • CH3COOH • 2H2O Angiogenesis Inhibitor

cyclo (Arg-Ala-Asp-d-Phe-Val) c (RADfV)

(M.W. 588.67) C27H40N8O7 Negative Control Peptide for ICA-4304

PCA-3618-PI-20 °C

1 mg5 mg

25 mgM. Friedlander, C.L. Theesfeld, M. Sugita, M. Fruttiger, M.A. Thomas, S. Chang, and D.A. Cheresh, PNAS, 93, 9764 (1996).

cyclo (Arg-Gly-Asp-d-Tyr-Cys)c(RGDyC)

(M.W. 594.65) C24H34N8O8S

PCI-3912-PI-20 °C

1 mg

cyclo (Arg-Ala-Asp-d-Tyr-Cys)c(RADyC)

(M.W. 608.68) C25H36N8O8S Negative Control Peptide for PCI-3912-PI

PCI-3917-PI-20 °C

1 mg5 mg

cyclo (Arg-Gly-Asp-d-Tyr-Glu)c (RGDyE)

RGD Peptide for Radiolabeling (Requires further derivatization before use)(M.W. 620.62) C26H36N8O10

PCI-3688-PI-20 °C

1 mg5 mg

25 mg

cyclo (Arg-Gly-Asp-d-Tyr-Lys)c (RGDyK)

(M.W. 619.68) C27H41N9O7 αv β3 Integrin Binding RGD Peptide RGD Tumor Targeting and Tumor Imaging Peptide (Requires further derivatization before use)

PCI-3662-PI-20 °C

1 mg5 mg

25 mg

R. Haubner, H.J. Wester, F. Burkhart, R. Senekowitsch-Schmidtky, W. Weber, S.L. Goodman, H. Kessler, and M. Schwaiger, J. Nuclear Med., 42, 326 (2001). X. Chen, R. Park. A.H. Shahinian, M. Tohme, V. Khankaldyyan, M.H. Bozorgzdeh, J.R. Bading, R. Moats, W.E. Laug, and P.S. Conti, Nucl. Med. Biol., 31, 179 (2004). X. Chen, P.S. Conti, and R.A. Moats, Cancer Res., 641, 8009 (2004).


H-Glu[cyclo (Arg-Gly-Asp-d-Tyr-Lys)]2H-E[c (RGDyK)]2

(M.W. 1350.47) C59H87N19O18 RGD Tumor Targeting and Tumor Imaging Peptide (Requires further derivatization before use)

PCI-3899-PI-20 °C

1 mg5 mg

25 mg

Y. Wu, X. Zhang, Z. Xiong, Z. Cheng , D.R. Fisher, S. Liu, S.S. Gambhir, and X. Chen, J. Nucl. Med., 46, 1707 (2005). X. Chen, S. Liu, Y. Hou, M. Tohme, R. Park, J.R. Bading, and P.S. Conti, Mol. Imaging Biol., 6, 350 (2004). X. Chen, C. Plasencia, Y. Hou, and N. Neamati, J. Med. Chem., 48, 1098 (2005). X. Chen, M. Tohme, R. Park, Y. Hou, J.R. Bading, and P.S. Conti, Mol. Imaging, 3, 96 (2004).

NEW!

NEW!

24 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES H-AEEEA-Glu[cyclo (Arg-Gly-Asp-D-Tyr-Lys)]2PEG3-c(RGDyK)2

(Trifluoroacetate Form) (M.W. 1539.68) C67H102N20O22 Byclic RGD peptide for imaging

RGD-3766-PI-20 °C

1 mg5 mg

E. Chang, S. Liu, G. Gowrishankar, S. Yaghoubi, J.P. Wedgeworth, F. Chin, D. Berndorff, V. Gekeler, S.S. Gambhir and Z. Cheng, European Journal of Nuclear Medicine and Molecular Imaging, 38, 722 (2010). F.T. Chin, B. Shen, S. Liu, R.A. Berganos, E. Chang, E. Mittra, X. Chen and S.S. Gambhir, Molecular Imaging and Biology, 14, 88 (2011)..

cyclo (Arg-Gly-Glu-d-Phe-Lys)c(RGEfK)

(M.W. 617.71) C28H43N9O7

PCI-3953-PI-20 °C

1 mg5 mg

25 mg

Arg-Gly-Asp (RGD) for Cell Adhesion of BiomaterialsIntegrins, such as fibronectin, are involved in mediating cell to cell interactions and cell to extracellular matrix interactions. They play a central role in cell adhesion, chemotaxis, cell growth, tissue repair, and tumor development among others. A peptide containing the fibronectin active fragment or cell binding domain was first developed to increase cell attachment to biomaterial or plastic surfaces.1 Ac-GrGDSPASSKGGGGSrLLLLLLr-NH2 also contains a hydrophobic region, SPASSK which acts as a spacer between the cell attachment and biomaterial domains for improved cell attachment to nonbiological surfaces. Additional leucine residues were incorporated to obtain saturated binding. D-arginines were introduced and the N- and C- termini were protected to prevent degradation by endoproteases and exopeptidases respectively. Ac-GrGDSPASSKGGGGSrLLLLLLr-NH2 has been used as a research application for studying mechanochemical transduction and contractile forces by coating the peptide to magnetic microbeads. This has allowed for the study of contractile forces of airway smooth muscle cells and their role with asthma and mechanical study of the elasticity of alveolar epithelial cells.2,3 Besides its role in understanding cytoskeletal remodeling, the peptide has also been employed to block C. albicans adherence by binding to a fibronectin-like receptor on the yeast cells, reducing the number of pathogens in vitro and in vivo.4 This peptide could also prove useful in cell attachment to nonbiological surfaces for tissue regeneration and implantation associated with therapeutic applications.1. W.S. Craig, S. Cheng, D.G. Mullen, J. Blevitt, and M.D. Pierschbacher, Biopolymers Peptide Science, 37, 157 (1995). 2. S.S. An, B. Fabry, X. Trepat, N. Wang, and J.J. Fredberg, Am. J. Resp. Cell and Molec. Biol., 35, 55 (2006).3. X. Trepat, M. Grabulosa, F. Puig, G.N. Maksym, D. Navajas, and R. Farre, Am. J. Physiol. Lung Cell Mol. Physiol., 287, L1025 (2004). 4. S.A. Klotz, R.L. Smith, and B.W. Stewart, Antimicrob. Agents and Chemother., 36, 132 (1992).

Ac-Gly-D-Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-(Gly)4-Ser-d-Arg-(Leu)6-d-Arg-NH2

Ac-GrGDSPASSKGGGGSrLLLLLLr-Amide (Trifluoroacetate Form) (M.W. 2308.69) C98H174N34O30

PFA-3924-PI-20 °C

1 mg5 mg

NEW!

NEW!

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 25

H-Arg-Gly-Asp-Ser-Lys-OHRGDSK

(M.W. 561.60) C21H39N9O9RGD Tumor Targeting Peptide

PCI-3929-PI-20 °C

1 mg5 mg

S. Jasseron, C. Contino-Pepin, J.C. Maurizis, M. Rapp, B. Pucci, Bioorganic & Medicinal Chemistry Letters, 12, 7, (2002).S. Jasseron, C. Contino-Pepin, J.C. Maurizis, M. Rapp, B. Pucci, Eur J Med Chem, 38, 9, (2003).

H-Arg-Ala-Asp-Ser-Lys-OHRADSK

(M.W. 575.63) C22H41N9O9Negative Control Peptide for PLI-3929-PI

PCI-3930-PI-20 °C

1 mg5 mg

H-[Cys-Arg-Gly-Asp-Arg-Gly-Pro-Asp-Cys]-NH2H-[CRGDRGPDC]-NH2

(Trifluoroacetate Form) (M.W. 975.08) C35H58N16O13S2 (Disulfide bond between Cys1-Cys9) RGD Tumor Targeting PeptideK Sugahara, et al., Science, 328, 1031 (2010).Y. Ye, et al., Bioorg Med Chem Lett., 21, 1146 (2011).

RGD-3762-PI-20 °C

1 mg5 mg

H-[Cys-Arg-Gly-Asp-lys-Gly-Pro-Asp-Cys]-NH2H-[CRGDKGPDC]-NH2

(Trifluoroacetate Form) (M.W. 947.07) C35H58N14O13S2 (Disulfide bond between Cys1-Cys9) RGD Tumor Targeting PeptideK Sugahara, et al., Science, 328, 1031 (2010).Y. Ye, et al., Bioorg Med Chem Lett., 21, 1146 (2011).

RGD-3761-PI-20 °C

1 mg5 mg

Fibronectin Active Fragment (RGDS) Arg-Gly-Asp-Ser

(M.W. 433.42) C15H27N7O8 [91037-65-9]

PFA-4171-v-20 °C

0.5 mg vial

Fibronectin Active Fragment (RGDS) (Bulk)Arg-Gly-Asp-Ser • ½AcOH • 2H2O

PFA-4171-20 °C

25 mg 100 mg

(M.W. 433.42 • 30.03 • 36.03) C15H27N7O8 • ½CH3COOH • 2H2O Purity Information: Qp See page xiv M.D. Piershbacher and E. Ruoslahti, Nature, 309, 30 (1984). (Original) D.M. Haverstick, J.F. Cowan, K.M. Yamada, and S.A. Santoro, Blood, 66, 946 (1985). (Pharmacol.)

Fibronectin Active Fragment (GRGDS) Gly-Arg-Gly-Asp-Ser

(M.W. 490.47) C17H30N8O9 [96426-21-0]

PFA-4189-v-20 °C

0.5 mg vial

Fibronectin Active Fragment (GRGDS) (Bulk) Gly-Arg-Gly-Asp-Ser • ½AcOH • 2H2O

PFA-4189-20 °C

25 mg 100 mg

(M.W. 490.47 • 30.03 • 36.03) C17H30N8O9 • ½CH3COOH • 2H2O S.K. Akiyama and K.M. Yamada, J. Biol. Chem., 260, 10402 (1985). K. Olden, S. Mohia, S.A. Newton, S.L. White, and M.J. Humphries, Ann. N.Y. Acad. Sci., 551, 421 (1988).

NEW!

NEW!

NEW!

NEW!

26 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES H-Gly-Arg-Ala-Asp-Ser-Pro-OHGRADSP

(M.W. 601.62) C23H39N9O10 Negative Control Peptide for Fibronectin Inhibitors

PCI-3910-PI-20 °C

1 mg5 mg

D.G. Hoyt, J.M. Rusnak, R.J. Mannix, R.A. Modzelewski, C.S. Johnson, and J.S. Lazo, Cancer Res., 56, 4146 (1996).

H-Gly-Arg-Gly-Glu-Ser-OHGRGES

(M.W. 504.50) C18H32N8O9 Negative Control Peptide for PFA-4189-v

PFA-3907-PI-20 °C

5 mg25 mg

C.D. Buckley, D. Pilling, N.V. Henriquez, G. Parsonage, K. Threlfall, D. S-Toellner, D.L. Simmons, A.N. Akbar, J.M. Lord, and M. Salmon, Nature, 397, 534 (1999)

H-Gly-Arg-Gly-Asp-Asn-Pro-OHGRGDNP

(M.W. 614.62) C23H38N10O10 Inhibitor of Cell Adhesion to Fibronectin.

PCI-3909-PI-20 °C

5 mg25 mg

M.D. Pierschbacher and E. Ruoslahti, J. Biol. Chem., 262, 17294 (1987)

H-Gly-Gly-Gly-Gly-Arg-Gly-Asp-Ser-Pro-OHH-Gly-Gly-Gly-Gly-Arg-Gly-Asp-Ser-Pro-OHGGGGRGDSP (M.W. 758.75) C28H46N12O13

PCI-3965-PI-20 °C

5 mg25 mg

Fibronectin Adhesion-Promoting PeptideH-Trp-Gln-Pro-Pro-Arg-Ala-Arg-Ile-OH

(Trifluoroacetate Form)(M.W. 1023.22) C47H74N16O10 [125720-21-0]D.L.Mooradian, et al., Invest. Ophthalmol. Vis. Sci., 34, 153 (1993).A.Woods, et al., Mol. Biol. Cell, 4, 605 (1993).K.L.Hines, et al., Proc. Natl. Acad. Sci. USA, 91, 5187 (1994).

FAP-3758-PI-20 °C

1 mg5 mg

BivalirudinBivalirudin

(Trifluoroacetate Form) d-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH(M.W. 2180.33) C98H138N24O33Specific, Reversible, Direct Thrombin Inhibitor; Anti-coagulant

BIV-3767-PI-20 °C

1 mg5 mg

C. Michael, and G. Mckendall, Am. J. Health-System Pharma., 60, 18 (2003). T.E. Warkentin, Thromb. Haemost. 99, 830, 18 (2010).• This is a FDA-regulated product. It is the customer's responsibility to ensure complaince with Federal rules. Peptides International cannot be liable for any infringement of rights made by the user.

BQ-123, BQ-610, and BQ-788 See page 56 and Endothelin Antagonists on pages 166-167.

Bovine Adrenal Medulla Dodecapeptide (BAM-12P)BAM-12P Bovine Adrenal Medulla Dodecapeptide

Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu (M.W. 1424.6) C62H97N21O16S [75513-71-2]

PBM-4119-v-20 °C

0.5 mg vial

K. Mizuno, N. Minamino, K. Kangawa, and H. Matsuo, Biochem. Biophys. Res. Commun., 95, 1482 (1980). (Original)

NEW!

NEW!

NEW!

NEW!

NEW!

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 27

BombesinBombesin* (Frog, Bombina bombina)

Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 (M.W. 1619.8) C71H110N24O18S [31362-50-2]

PBM-4086-v-20 °C

0.5 mgvial

Bombesin* (Bulk) (Frog, Bombina bombina)

Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His- Leu-Met-NH2 • AcOH • 7H2O

PBM-4086-20 °C

25 mgvial

(M.W. 1619.8 • 60.05 • 126.11) C71H110N24O18S • CH3COOH • 7H2OA. Anastasi, V. Erspamer, and M. Bucci, Experientia, 27, 166 (1971). (Original) V. Erspamer and P. Melchiorri, Trends Pharmacol. Sci., 1, 391 (1980). (Review) J.G. McCoy and D.D. Avery, Peptides, 11, 595 (1990). (Review) L.K. Malendowicz, Horm. Metab Res., 30, 374 (1998). (Review)


Bradykinin and Related PeptidesE.G. Erdös (ed.) Bradykinin, Kallidin and Kallikrein, Handbook of Experimental Pharmacology, Vol. 25, Springer-Verlag, Berlin, 1970. (Review) E.G. Erdös (ed.) Bradykinin, Kallidin and Kallikrein, Handbook of Experimental Pharmacology, Vol. 25, Suppl., Springer-Verlag, Berlin, 1979. (Review)

Bradykinin* (Human, Bovine, Rat, Mouse)

Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1060.2) C50H73N15O11 [58-82-2]

PBK-4002-v-20 °C

0.5 mgvial

Bradykinin* (Bulk) (Human, Bovine, Rat, Mouse)

Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg • 2AcOH • 3H2O

PBK-4002-20 °C

25 mg100 mg

(M.W. 1060.2 • 120.10 • 54.05) C50H73N15O11 • 2CH3COOH • 3H2O

D.F. Elliott, G.P. Lewis, and E.W. Horton, Biochem. J., 76, 16P (1960). (Original; Bovine) E.D. Nicolaides and H.A. DeWald, J. Org. Chem., 26, 3872 (1961). (Chem. Synthesis) J.V. Pierce and M.E. Webster, Biochem. Biophys. Res. Commun., 5, 353 (1961). (Original; Human)

d-Arginyl-[Hyp3,Thi5,d-Tic7,Oic8]-Bradykinin Hoe 140, Icatibant

d-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-d-Tic-Oic-Arg

PKB-4293-v-20 °C

0.5 mgvial

(Thi: l-Thienylalanine, Tic: 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid, Oic: (3aS,7aS)-Octahydroindolyl-2-Carboxylic Acid) (M.W. 1304.5) C59H89N19O13S [130308-48-4]

28 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES d-Arginyl-[Hyp3,Thi5,d-Tic7,Oic8]-Bradykinin (Bulk) Hoe 140, Icatibant

PKB-4293-20 °C

25 mg

d-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-d-Tic-Oic-Arg • 2AcOH • 4H2O (Thi: l-Thienylalanine, Tic: 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid, Oic: (3aS,7aS)-Octahydroindolyl-2-Carboxylic Acid) (M.W. 1304.5 • 120.10 • 72.06) C59H89N19O13S • 2CH3COOH • 4H2O [138614-30-9] Bradykinin B2-Receptor Antagonist

F.J. Hock, K. Wirth, U. Albus, W. Linz, H.J. Gerhards, G. Wiemer, H.S. Henke, G. Breipohl, W. König, J. Knolle, and B.A. Schölkens, Br. J. Pharmacol., 102, 769 (1991). (Original; Pharmacol.; in vitro) K. Wirth, F.J. Hock, U. Albus, W. Linz, H.G. Alpermann, H. Anagnostopoulos, S. Henke, G. Breipohl, W. König, / J. Knolle, and B.A. Schölkens, Br. J. Pharmacol., 102, 774 (1991). (Original; Pharmacol.; in vivo) A.R. Baydon and B. Woodward, Br. J. Pharmacol., 103, 1829 (1991). (Pharmacol.) G. Wiener, R. Popp, B.A. Schölkens, and H. Gögelein, Brain Res., 638 261 (1994). (Pharmacol.; Icatibant)

d-Arginyl-[Hyp3, Thi5,8, d-Phe7]-Bradykinind-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-d-Phe-Thi-Arg (Thi: l-Thienylalanine) (M.W. 1294.5) C56H83N19O13S2 [103412-42-6]

PBK-4202-v-20 °C

0.5 mgvial

d-Arginyl-[Hyp3,Thi5,8,d-Phe7]-Bradykinin (Bulk)d-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-d-Phe-Thi-Arg • 2AcOH • 4H2O (Thi: l-Thienylalanine)

PBK-4202-20 °C

25 mg

(M.W. 1294.5 • 120.11 • 72.06) C56H83N19O13S2 • 2CH3COOH • 4H2O Bradykinin B2-Receptor AntagonistM. Schachter, Y. Uchida, D.J. Longridge, T. Labedz, E.T. Whalley, R.J. Vavrek, and J.M. Stewart, Br. J. Pharmacol., 92, 851 (1987). (Original) J.M. Stewart and R.J. Vavrek, Adv. Biosci., 65, 73 (1987). (Pharmacol.; pA2) D.C. Perry, Pharmacol. Biochem. Behav., 28, 15 (1987). (Pharmacol.; CNS)

Bradykinin-Potentiator B (Mamushi, Agkistrodon halys blomhoffii)

Pyr-Gly-Leu-Pro-Pro-Arg-Pro-Lys-Ile-Pro-Pro (M.W. 1182.4) C56H91N15O13 [30892-86-5]

IAB-4009-v-20 °C

0.5 mgvial

Inhibitor for Peptidyl-Dipeptidase A, Kininase II, and ACE (Angiotensin Converting Enzyme)H. Kato and T. Suzuki, Biochemistry, 10, 972 (1971). (Original)


Bradykinin-Potentiator C (Mamushi, Agkistrodon halys blomhoffii)

Pyr-Gly-Leu-Pro-Pro-Gly-Pro-Pro-Ile-Pro-Pro (M.W. 1052.2) C51H77N11O13 [30953-20-9]

IAC-4010-v-20 °C

0.5 mgvial

Inhibitor for Peptidyl-Dipeptidase A, Kininase II, and ACE (Angiotensin Converting Enzyme)H. Kato and T. Suzuki, Biochemistry, 10, 972 (1971). (Original)

Des-Arg9-BradykininArg-Pro-Pro-Gly-Phe-Ser-Pro-Phe (M.W. 904.02) C44H61N11O10 [15958-92-6]

PBK-4067-v-20 °C

0.5 mg

Des-Arg9-Bradykinin (Bulk)Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe • AcOH • 3H2O (M.W. 904.02 • 60.05 • 54.05) C44H61N11O10 • CH3COOH • 3H2O Bradykinin B1-Receptor Agonist

PBK-4067-20 °C

25 mg

D. Regoli, J. Barabe, and W.K. Park, Can. J. Physiol. Pharmacol., 55, 855 (1977). (Original)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 29

Des-Arg10-Kallidin Lysyl-Des-Arg9-Bradykinin

Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe (M.W. 1032.2) C50H73N13O11 [71800-36-7] Bradykinin B1-Receptor Agonist

PBK-4303-v-20 °C

0.5 mgvial

Des-Arg10-Kallidin (Bulk) Lysyl-Des-Arg9-Bradykinin

Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe • 2AcOH • 4H2O

PBK-4303-20 °C

25 mg

(M.W. 1032.2 • 120.10 • 72.06) C50H73N13O11 • 2CH3COOH • 4H2O Bradykinin B1-Receptor Agonist J.P. Galizzi, M.C. Bodinier, B. Chapelain, S.M. Ly, L. Coussy, S. Giraud, G. Neliat, and T. Jean, Br. J. Pharmacol., 113, 389 (1994). (Original) J.G. Menke, J.A. Borkowski, K.K. Bierilo, T. MacNeil, A.W. Derrick, K.A. Schneck, R.W. Ransom, C.D. Strader, D.L. Linemeyer, and J.F. Hess, J. Biol. Chem., 269, 21583 (1994). (Pharmacol.) J.S. Zuzack, M.R. Burkard, D.K. Curdrado, R.A. Greer, W.M. Selig, and E.T. Whalley, J. Pharmacol. Exp. Ther., 277, 1337 (1996). (Pharmacol.)

Des-Arg9-[Leu8]-BradykininArg-Pro-Pro-Gly-Phe-Ser-Pro-Leu (M.W. 870.01) C41H63N11O10 [64695-06-3]

PBK-4065-v-20 °C

0.5 mgvial

Des-Arg9-[Leu8]-Bradykinin (Bulk)Arg-Pro-Pro-Gly-Phe-Ser-Pro-Leu • AcOH • 3H2O (M.W. 870.01 • 60.05 • 54.05) C41H63N11O10 • CH3COOH • 3H2O [115035-45-5] Bradykinin B1-Receptor Antagonist

PBK-4065-20 °C

25 mg

D. Regoli, J. Barabe, and W.K. Park, Can. J. Physiol. Pharmacol., 55, 855 (1977). (Original; pA2 )

Des-Pro2-BradykininArg-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 963.09 ) C45H66N14O10 [80943-05-1]

IBK-4097-v-20 °C

0.5 mgvial

Des-Pro2-Bradykinin (Bulk) Arg-Pro-Gly-Phe-Ser-Pro-Phe-Arg • 2AcOH • 3H2O

IBK-4097-20 °C

25 mg

(M.W. 963.09 • 120.10 • 54.05) C45H66N14O10 • 2CH3COOH • 3H2O Inhibitor for Peptidyl-Dipeptidase A, Kininase II, and ACE (Angiotensin Converting Enzyme) Purity Information: Qp See page xiv M. Naruse, S. Tamanami, K. Shuto, S. Sakakibara, and T. Kimura, Chem. Pharm. Bull., 29, 3369 (1981).

[Hyp3]-Bradykinin (Human)*Arg-Pro-Hyp-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1076.2) C50H73N15O12 [37642-65-2]

PBK-4193-v-20 °C

0.5 mgvial

H. Kato, Y. Matsumura, and H. Maeda, FEBS Lett., 232, 252 (1988). (Original)


Isoleucyl-Seryl-Bradykinin* T-Kinin (Rat)

Ile-Ser-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1260.4) C59H89N17O14 [86030-63-9]

PBK-4130-v-20 °C

0.5 mgvial


30 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Isoleucyl-Seryl-Bradykinin* (Bulk) T-Kinin (Rat)

Ile-Ser-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg • 2AcOH • 5H2O

PBK-4130-20 °C

25 mg

(M.W. 1260.4 • 120.10 • 90.08) C59H89N17O14 • 2CH3COOH • 5H2OH. Okamoto and L.M. Greenbaum, Biochem. Biophys. Res. Commun., 112, 701 (1983). (Original)

Lysyl-Bradykinin* Kallidin (Human, Bovine)

Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1188.4) C56H85N17O12 [342-10-9]

PBK-4008-v-20 °C

0.5 mgvial


Lysyl-Bradykinin* (Bulk) Kallidin (Human, Bovine)

Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg • 3AcOH • 4H2O

PBK-4008-20 °C

25 mg

(M.W. 1188.4 • 180.16 • 72.06) C56H85N17O12 • 3CH3COOH • 4H2O [100900-38-7]

J.V. Pierce and M.E. Webster, Biochem. Biophys. Res. Commun., 5, 353 (1961). (Original; Human) D.F. Elliott and G.P. Lewis, Biochem. J., 95, 437 (1965). (Seq.; Bovine)


Lysyl-[Hyp3]-Bradykinin (Human)Lys-Arg-Pro-Hyp-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1204.4) C56H85N17O13

PBK-4191-v-20 °C

0.5 mgvial

M. Sasaguri, M. Ikeda, M. Ideishi, and K. Arakawa, Biochem. Biophys. Res. Commun., 150, 511 (1988). (Original)

Methionyl-Lysyl-Bradykinin (Human, Bovine)Met-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1319.6) C61H94N18O13S [550-19-6]

PBK-4012-v-20 °C

0.5 mgvial

Methionyl-Lysyl-Bradykinin (Human, Bovine) (Bulk)

PBK-4012-20 °C

25 mg

Met-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg • 3AcOH • 2H2O (M.W. 1319.6 • 180.16 • 36.03) C61H94N18O13S • 3CH3COOH • 2H2OD.F. Elliott and G.P. Lewis, Biochem. J., 95, 437 (1965). (Original; Bovine) I. Ohkubo, K. Kurachi, T. Takasawa, H. Shiokawa, and M. Sasaki, Biochemistry, 23, 5691 (1984). (cDNA Seq.; Human)

[Thi5,8, d-Phe7]-BradykininArg-Pro-Pro-Gly-Thi-Ser-d-Phe-Thi-Arg (Thi: l-Thienylalanine) (M.W. 1122.3) C50H71N15O11S2 [97825-07-5] Bradykinin B2-Receptor Antagonist

R.J. Vavrek and J.M. Stewart, Peptides, 6, 161 (1985). (Original)

PBK-4175-v-20 °C

0.5 mgvial

[Tyr8]-BradykininArg-Pro-Pro-Gly-Phe-Ser-Pro-Tyr-Arg (M.W. 1076.2) C50H73N15O12 [32222-00-7] For Radioimmunoassay

PBK-4075-v-20 °C

0.5 mgvial

M.D. Nielsen, F. Nielsen, A.M. Kappelgaard, and J. Giese, Clinica Chimica Acta, 125, 145 (1982). (Radioimmunoassay) M.J. Fredrick, F.C. Abel, W.A. Rightsel, E.E. Muirhead, and C.E. Odya, Life Sci., 37, 331 (1985). (Radioimmunoassay)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 31

Tyrosyl-Bradykinin Tyr-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1223.4) C59H82N16O13 [33289-76-8] For Radioimmunoassay

PBK-4056-v-20 °C

0.5 mgvial

R.E. Lewis, S.R. Childers, and M.I. Phillips, Brain Res., 346, 263 (1985). (Radioimmunoassay) M.J. Fredrick, F.C. Abel, W.A. Rightsel, E.E. Muirhead, and C.E. Odya, Life Sci., 37, 331 (1985). (Radioimmunoassay)

B-Type (Brain) Natriuretic Peptides (BNP)A. Rosenzweig and C.E. Seidman, Annu. Rev. Biochem., 60, 229 (1991). (Review)

BNP-32 (Human)* B-Type (Brain) Natriuretic Peptide-32 (Human)

PBN-4212-v-20 °C

0.5 mgvial

Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp- Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His (Disulfide bond between Cys10-Cys26) (M.W. 3464.0) C143H244N50O42S4 [124584-08-03] T. Sudoh, K. Maekawa, M. Kojima, N. Minamino, K. Kangawa, and H. Matsuo, Biochem. Biophys. Res. Commun., 159, 1427 (1989). (Original; cDNA) Y. Kambayashi, K. Nakao, M. Mukoyama, Y. Saito, Y. Ogawa, S. Shiono, K. Inouye, N. Yoshida, and H. Imura, FEBS Lett., 259, 341 (1990). (Original; Isolation and Structure)


Tyrosyl-BNP-32 (Human)* Tyrosyl-B-Type (Brain) Natriuretic Peptide-32 (Human)

PBN-4230-v-20 °C

0.5 mgvial

Tyr-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp- Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His (Disulfide bond between Cys10-Cys26) (M.W. 3627.2) C152H253N51O44S4 Purity Information: Qx See page xiv For Radioimmunoassay


BNP-26 (Porcine)* B-Type (Brain) Natriuretic Peptide-26 (Porcine)

Asp-Ser-Gly-Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-lle-Gly- Ser-Leu-Ser-Gly-Leu-Gly-Cys-Asn-Val-Leu-Arg-Arg-Tyr (Disulfide bond between Cys4-Cys20) (M.W. 2869.2) C120H198N42O36S2 [114547-28-3]

PBN-4200-v-20 °C

0.5 mgvial

T. Sudoh, K. Kangawa, N. Minamino, and H. Matsuo, Nature, 332, 78 (1988). (Original)


BNP-32 (Rat)* B-Type (Brain) Natriuretic Peptide-32 (Rat)

PBN-4213-v-20 °C

0.5 mgvial

Asn-Ser-Lys-Met-Ala-His-Ser-Ser-Ser-Cys-Phe-Gly-Gln-Lys-Ile-Asp- Arg-Ile-Gly-Ala-Val-Ser-Arg-Leu-Gly-Cys-Asp-Gly-Leu-Arg-Leu-Phe (Disulfide bond between Cys10-Cys26) (M.W. 3452.9) C146H239N47O44S3 [133448-20-1]M. Kojima, N. Minamino, K. Kangawa, and H. Matsuo, Biochem. Biophys. Res. Commun., 159, 1420 (1989). (Original; cDNA)


32 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES BNP-45 (Rat)* B-Type (Brain) Natriuretic Peptide-45 (Rat)

Ser-Gln-Asp-Ser-Ala-Phe-Arg-Ile-Gln-Glu-Arg-Leu-Arg-Asn-Ser-Lys-Met-Ala-His-Ser-Ser-Ser-Cys-Phe-Gly-Gln-Lys-Ile-Asp-Arg-Ile-Gly-Ala-Val-Ser-Arg-Leu-Gly-Cys-Asp-Gly-Leu-Arg-Leu-Phe (Disulfide bond between Cys23-Cys39) (M.W. 5040.7) C213H349N71O65S3 [123337-89-3]

PBN-4218-s-20 °C

0.1 mgvial

M. Aburaya, J. Hino, N. Minamino, K. Kangawa, and H. Matsuo, Biochem. Biophys. Res. Commun., 163, 226 (1989). (Original) Y. Kambayashi, K. Nakao, H. Itoh, K. Hosoda, Y. Saito, T. Yamada, M. Mukoyama, H. Arai, G. Shirakami, S. Suga, Y. Ogawa, M. Jougasaki, N. Minamino, K. Kangawa, H. Matsuo, K. Inouye, and H. Imura, Biochem. Biophys. Res. Commun., 163, 233 (1989). (Original)


C PeptideC-Peptide (Human) PCP-3725-PI

-20 °C

1 mg5 mg

H-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro- Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-OH(M.W. 3020.33) C129H211N35O48 [33017-11-7] Insulin Precursor (57-87) (Human)A.S.C.Ko and D.G.Smyth, Eur. J. Biochem., 20, 190 (1971).P.E.Oyer, et al., J. Biol. Chem., 246, 1375 (1971).K.Igano, et al., Bull. Chem. Soc. Jpn., 54, 3088 (1981).J.Wahren, et al., Exp. Diabesity Res., 5, 15 (2004).J.P.Palmer, et al., Diabetes, 53, 250 (2004).

[Tyr0]-C-Peptide (Human) tyrosyl human C-peptide

PCP-3724-PI-20 °C

1 mg 5 mg

H-Tyr-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro- Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-OH (M.W. 3183.50) C138H220N36O50 [57327-90-9] C-Peptide derivative for radioimmunoassay. V.K. Naithani, et al., Hoppe Seylers Z. Physiol. Chem., 356, 1305 (1975) N. Yanaihara, et al., Hoppe Seylers Z. Physiol. Chem., 362, 775 (1981) H. Sun, et al., Appl. Biochem. Biotechnol., 55, 167 (1995) V.K. Naithani, et al., Hoppe Seylers Z. Physiol. Chem., 356, 1305 (1975)

CalcitoninCalcitonin (Human)

Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr- Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe- Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH2 (Disulfide bond between Cys1-Cys7) (M.W. 3417.8) C151H226N40O45S3 [21215-62-3]

PCL-4051-s-20 °C

0.1 mg vial

Calcitonin (Human)R. Neher, B. Riniker, W. Rittel, and H. Zuber, Helv. Chim. Acta, 51, 1900 (1968). (Original) Y. Nakagawa, T. Morikawa, and S. Sakakibara, Peptide Chemistry 1977, 189 (1978). (Chem. Synthesis)

PCL-4051-v-20 °C

0.5 mgvial

NEW!

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 33

CART PeptidesP.J. Larsen and R.G. Hunter, Peptides, 27, 1981 (2006). (Review) A. Vicentic and D.C. Jones, J. Pharmacol. Exp. Ther., 320, 499 (2007). (Review)

CART (Human, 55-102) Cocaine-and Amphetamine-Regulated Transcript (Human, 55-102)

PCA-4350-s-20 °C

0.1 mgvial

Ile-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys- Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-Cys-Asp-Cys-Pro-Arg-Gly-Thr-Ser- Cys-Asn-Ser-Phe-Leu-Leu-Lys-Cys-Leu (Disulfide bonds between Cys68-Cys86, Cys74-Cys94, and Cys88-Cys101) (M.W. 5245.2) C225H365N65O65S7 [214050-22-3] Food-Intake InhibitorP. Kristensen, M.E. Judge, L. Thim, U. Ribel, K.N. Christjansen, B.S. Wulff, J.T. Clausen, P.B. Jensen, O.D. Madsen, N. Vrang, P.J. Larsen, and S. Hastrup, Nature, 393, 72 (1998). (Pharmacology; New Anorectic Peptide) J. Douglass and S. Daoud, Gene, 169, 241 (1996). (Original, cDNA) A.J. Kastin and V. Akerstrom, Am. J. Physiol., 277, E901 (1999). (Pharmacol.; across BBB) M.J. Kuhar, L.D. Adams, R.G. Hunter, S. Dall Vechia, and Y. Smith, Regul. Pept., 89, 1 (2000). (Review)

CART (Rat, 55-102) Cocaine-and Amphetamine-Regulated Transcript (Rat, 55-102)

PCA-4351-s-20 °C

0.1 mgvial

Ile-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly- Glu-Gln-Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-Cys-Asp- Cys-Pro-Arg-Gly-Thr-Ser-Cys-Asn-Ser-Phe-Leu-Leu-Lys-Cys-Leu (Disulfide bonds between Cys68-Cys86, Cys74-Cys94, and Cys88-Cys101) (M.W. 5259.2) C226H367N65O65S7 [209615-79-2] Food-Intake InhibitorP. Kristensen, M.E. Judge, L. Thim, U. Ribel, K.N. Christjansen, B.S. Wulff, J.T. Clausen, P.B. Jensen, O.D. Madsen, N. Vrang, P.J. Larsen, and S. Hastrup, Nature, 393, 72 (1998). (Pharmacology: New Anorectic Peptide) J. Douglass, A.A. McKinzie, and P. Couceyro, J. Neurosci., 15, 2471 (1995). (Original: cDNA) L. Thim, P.F. Nielsen, M.E. Judge, A.S. Andersen, I. Diers, M. Egel-Mitani, and S. Hastrup, FEBS Lett., 428, 263 (1998). (Biochem. & Pharmacol.) M.J. Kuhar, L.D. Adams, R.G. Hunter, S. Dall Vechia, and Y. Smith, Regul. Pept., 89, 1 (2000). (Review)

b-Casomorphinsb-Casomorphin-5 (Bovine)

Tyr-Pro-Phe-Pro-Gly (M.W. 579.64) C30H37N5O7 [72122-63-5]

PEK-4079-v -20 °C

0.5 mgvial

b-Casomorphin-5 (Bovine) (Bulk)Tyr-Pro-Phe-Pro-Gly • 2H2O (M.W. 579.64 • 36.03) C30H37N5O7 • 2H2O [72122-63-5]

PEK-4079-20 °C

25 mg100 mg

V. Brantl, H. Teschemacher, A. Henshen, and F. Lottespeich, Hoppe-Seyler’s Z. Physiol. Chem., 360, 1211 (1979). (Original; Isolation) A. Henschen, F. Lottspeich, V. Brantl, and H. Teschemacher, Hoppe-Seyler’s Z. Physiol. Chem., 360, 1217 (1979). (Original; Structure)

b-Casomorphin-7 (Bovine)Tyr-Pro-Phe-Pro-Gly-Pro-Ile (M.W. 789.92) C41H55N7O9 [72122-62-4]

PEK-4078-v-20 °C

0.5 mgvial

V. Brantl, H. Teschemacher, A. Henshen, and F. Lottespeich, Hoppe-Seyler’s Z. Physiol. Chem., 360, 1211 (1979). (Original; Isolation) A. Henschen, F. Lottspeich, V. Brantl, and H. Teschemacher, Hoppe-Seyler’s Z. Physiol. Chem., 360, 1217 (1979). (Original; Structure)

34 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES CCK See Cholecystokinin and Related Peptides on page 34.CGP 42112 See Code PAN-4296-v on page 22.

CGRPCGRP (Human)* Calcitonin Gene Related Peptide (Human) a-CGRP (Human)

PCG-4160-s-20 °C

0.1 mgvial

Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser- Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 (Disulfide bond between Cys2-Cys7) (M.W. 3789.3) C163H267N51O49S2 [90954-53-3]


CGRP (Human)* Calcitonin Gene Related Peptide (Human) a-CGRP (Human)

PCG-4160-v-20 °C

0.5 mgvial

H.R. Morris, M. Panico, T. Etienne, J. Tippins, S.l. Girgis, and I. Maclntyre, Nature, 308, 746 (1984). (Original) • This compound is distributed through Peptide Institute, Inc. under the license of The Salk Institute. However, it is no longer available in the United Kingdom due to patent rights held by Celltech. Ltd.


CGRP (Human, 8-37)* Calcitonin Gene Related Peptide (Human, 8-37) a-CGRP (Human, 8-37)

PCG-4232-v-20 °C

0.5 mgvial

Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys- Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 (M.W. 3125.6) C139H230N44O38 [119911-68-1] Calcitonin Gene Related Peptide (CGRP) AntagonistT. Chiba, A. Yamaguchi, T. Yamatani, A. Nakamura, T. Morishita, T. Inui, M. Fukase, T. Noda, and T. Fujita, Am. J. Physiol., 256, E331 (1989). (Original) S.-P. Han, L. Naes, and T.C. Westfall, Biochem. Biophys. Res. Commun., 168, 786 (1990). (Pharmacol.) T. Dennis, A. Fournier, A. Cadieux, F. Pomerleau, F.B. Jolicoeur, S. St. Pierre, and R. Quirion, J. Pharmacol. Exp. Ther., 254, 123 (1990). (Pharmacol.) S.M. Gardiner, A.M. Compton, P.A. Kemp, T. Bennett, C. Bose, R. Foulkes, and B. Hughes, Biochem. Biophys. Res. Commun., 171, 938 (1990). (Pharmacol.)


CGRP (Rat)* Calcitonin Gene Related Peptide (Rat) a-CGRP (Rat)

PCG-4163-s-20 °C

0.1 mgvial

Ser-Cys-Asn-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser- Gly-Gly-Val-Val-Lys-Asp-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Glu-Ala-Phe-NH2 (Disulfide bond between Cys2-Cys7) (M.W. 3806.2) C162H262N50O52S2 [83651-90-5]

• This compound is distributed through Peptide Institute, Inc. under the license of the Salk Institute.

CGRP (Rat)* Calcitonin Gene Related Peptide (Rat) a-CGRP (Rat)

PCG-4163-v-20 °C

0.5 mgvial

S.G. Amara, V. Jonas, M.G. Rosenfeld, E.S. Ong, and R.M. Evans, Nature, 298, 240 (1982). (Original) M.G. Rosenfeld, J.-J. Mermod, S.G. Amara, L.W. Swanson, P.E. Sawchenko, J. Rivier, W.W. Vale, and R.M. Evans, Nature, 304, 129 (1983). (Processing and Distribution in Neural Tissue)

• This compound is distributed through Peptide Institute, Inc. under the license of the Salk Institute.

Charybotoxin See Code PCB-4227-s in the Toxins section on page 124.


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 35

Chemotactic PeptideChemotactic PeptideFor-Met-Leu-Phe FMLP

(M.W. 437.55) C21H31N3O5S [59880-97-6]

PCT-4066-v-20 °C

0.5 mgvial

Chemotactic Peptide (Bulk)For-Met-Leu-Phe FMLP

(M.W. 437.55) C21H31N3O5S [59880-97-6]

PCT-4066-20 °C

25 mg100 mg

L.T. Williams, R. Snyderman, M.C. Pike, and R.J. Lefkowitz, Proc. Natl. Acad. Sci. USA, 74, 1204 (1977). (Receptor Site on Human Leukocyte)

Chlorotoxin See PCN-4282-v in the Toxins section on page 124.

Cholecystokinin (CCK) Related PeptidesJ.E. Jorpes and V. Mutt (eds.) Secretin, Cholecystokinin, Pancreozymin and Gastrin, Handbook of Experimental Pharmacology, Vol. 34, Springer-Verlag, Berlin, 1973. (Review)

CCK-Tetrapeptide (30-33)* CCK-4

(Hydrochloride Form) Trp-Met-Asp-Phe-NH2 (M.W. 596.70) C29H36N6O6S

PCK-4083-v-20 °C

0.5 mgvial


CCK-Tetrapeptide (30-33)* (Bulk) CCK-4

Trp-Met-Asp-Phe-NH2 • HCI • H2O

PCK-4083-20 °C

25 mg100 mg

(M.W. 596.70 • 36.46 • 18.02) C29H36N6O6S • HCI • H2O [5609-49-4]J.F. Rehfeld, L.l. Larsson, N.R. Goltermann, T.W. Schwartz, J.J. Holst, S.L. Jensen, and J.S. Morley, Nature, 284, 33 (1980). (Neural Pharmacol.)


CCK-Octapeptide (26-33) (Non-Sulfated Form)* CCK-8 (Non-Sulfated Form)

(Ammonium Form) Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH (M.W. 1063.2) C49H62N10O13S2 [25679-24-7]

PCK-4087-v

2

-20 °C

0.5 mgvial

M.A. Ondetti, J. Pluscec, E.F. Sabo, J.T. Sheehan, and N. Williams, J. Am. Chem. Soc., 92, 195 (1970). (Chem. Synthesis)


CCK-Octapeptide (26-33) (Sulfated Form)* CCK-8 (Sulfated Form)

(Ammonium Form) Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 (M.W. 1143.3) C49H62N10O16S3 [25126-32-3]

PCK-4100-v-20 °C

0.5 mgvial

M.A. Ondetti, J. Pluscec, E.F. Sabo, J.T. Sheehen, and N. Williams, J. Am. Chem. Soc., 92, 195 (1970). (Chem. Synthesis)


36 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES CCK-33 (Human)* Lys-Ala-Pro-Ser-Gly-Arg-Met-Ser-Ile-Val-Lys-Asn-Leu- Gln-Asn-Leu-Asp-Pro-Ser-His-Arg-Ile-Ser-Asp-Arg- Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 (M.W. 3945.4) C167H263N51O52S4 [96827-04-2]

PCK-4201-s-20 °C

0.1 mgvial

Y. Takahashi, K. Kato, Y. Hayashizaki, and K. Matsubara, Proc. Natl. Acad. Sci. U.S.A., 82, 1931 (1987). (Original; Nucleotide Seq.) Y. Kurano, T. Kimura, and S. Sakakibara, In, Peptides, Proceedings of the 10th American Peptide Symposium, (G.R. Marshall, ed.), ESCOM Science Publishers B.V. 1988, pp. 162-165. (Chem. Synthesis)


CCK-33 (Porcine)* Lys-Ala-Pro-Ser-Gly-Arg-Val-Ser-Met-Ile-Lys-Asn-Leu- Gln-Ser-Leu-Asp-Pro-Ser-His-Arg-Ile-Ser-Asp-Arg- Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 (M.W. 3918.4) C166H262N50O52S4 [67256-27-3]

PCK-4176-s-20 °C

0.1 mg vial

V. Mutt and J.E. Jorpes, Eur. J. Biochem., 6, 156 (1968). (Original; Partial Structure) V. Mutt and J.E. Jorpes, Biochem. J., 125, 57P (1971). (Original) Y. Kurano, T. Kimura, and S. Sakakibara, J. Chem. Soc. Chem. Commun., 5, 323 (1987). (Chem. Synthesis)


CD36 Binding PeptideH-Gly-Asp-Gly-Val-d-Ile-Thr-Arg-Ile-Arg-OH

(M.W. 986.15) C41H75N15O13CD36 Binding Peptide

PCI-3964-PI-20 °C

1 mg5 mg

J.S. Isenberg, Y. Jia, J. Fukuyama, C.H. Switzer, D.A. Wink, and D.D. Roberts, J. Biol. Chem., 282, 15404 (2007).

Chromagranin A (Human, 286-301 Amide) See Code PCR-4214-v on page 70.

CINC-1/groCINC-1/gro (Rat)Cytokine-Induced Neutrophil Chemoattractant-1/ growth-related oncogene (Rat)

PIL-4233-v-20 °C

20 µgvial

Ala-Pro-Val-Ala-Asn-Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Val-Ala-Gly-Ile-His-Phe-Lys-Asn-Ile-Gln-Ser-Leu-Lys-Val-Met-Pro-Pro-Gly-Pro-His-Cys-Thr-Gln-Thr-Glu-Val-Ile-Ala-Thr-Leu-Lys-Asn-Gly-Arg-Glu- Ala-Cys-Leu-Asp-Pro-Glu-Ala-Pro-Met-Val-Gln-Lys-Ile-Val-Gln-Lys-Met-Leu-Lys-Gly-Val-Pro-Lys (Disulfide bonds between Cys9-Cys35 and Cys11-Cys51) (M.W. 7845.3) C343H572N98O97S7

K. Watanabe, K. Konishi, M. Fujioka, S. Kinoshita, and H. Nakagawa, J. Biol. Chem., 264, 19559 (1989). (Original) Y. Nishiuchi, M. Tsunemi, S. Kumagaye, S. Kubo, H. Nishio, K. Watanabe, T. Kinoshita, and S. Sakaibara, In, (J.A. Smith and J.E Rivier eds.) Peptides: Chemistry and Biology (Proceeding of the 12th American Peptide Symposium), Escom, Lieden, 1992, pp. 911-913. (Chem. Synthesis) H. Nakagawa, N. Komorita, F. Shibata, A. Ikesue, K. Konishi, M. Fujioka, and H. Kato, Biochem. J., 301, 545 (1994). (CINC Family)

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 37

ColivelinColivelin

H-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Gly-Ala-Ser-Arg- Leu-Leu-Leu-Leu-Thr-gly-Glu-Ile-Asp-Leu-Pro-OH

PHN-3901-PI-20 °C

0.5 mg1.0 mg

SALLRSIPAPAGASRLLLLTGEIDLP (M.W. 2645.16) C119H206N32O35 Neuroprotective Peptide in Alzheimer’s Disease ResearchT. chiba, M. Yamada, Y. Hashimoto, M. Sato, J. Sasabe, Y. Kita, K. Terashita, S. Aiso, I. Nishimoto, and M. Matsuka, J. Neuroscience, 25 10252 (2005).

Corticotropin-Releasing Factor / Hormones (CRF/CRH)C.L. Rivier and P.M. Plotsky, Annu. Rev. Physiol., 48, 475 (1986). (Review) F.A. Antoni, Endocrinol. Rev., 7, 351 (1986). (Review) M.J. Owens and C.B. Nemeroff, Pharmacol. Rev., 43, 425 (1991). (Review) M. Schaefer, S.A. Mousa, and C. Stein, Eur. J. Pharmacol., 323, 1 (1997). (Review)

CRF (Human, Rat) Corticotropin-Releasing Factor (Human, Rat)

PCR-4136-s-20 °C

0.1 mgvial

Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met- Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Ile-NH2 (M.W. 4757.5) C208H344N60O63S2 [86784-80-7]

CRF (Human, Rat) Corticotropin-Releasing Factor (Human, Rat)

PCR-4136-v-20 °C

0.5 mgvial

J. Spiess, J. Rivier, and W. Vale, Biochemistry, 22, 4341 (1983). (Original; Rat) S. Shibahara, Y. Morimoto, Y. Furutani, M. Notake, H. Takahashi, S. Shimizu, S. Horikawa, and S. Numa, The EMBO Journal, 2, 775 (1983). (Original; Human) • This compound is distributed through Peptide Institute, Inc. under the license of The Salk Institute.

CRF (Ovine) Corticotropin-Releasing Factor (Ovine)

Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala- Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Leu-Asp-Ile-Ala-NH2 (M.W. 4670.3) C205H339N59O63S [79804-71-0]

PCR-4111-s-20 °C

0.1 mgvial

CRF (Ovine) Corticotropin-Releasing Factor (Ovine)

PCR-4111-v-20 °C

0.5 mgvial

W. Vale, J. Spiess, C. Rivier, and J. Rivier, Science, 213, 1394 (1981). (Original) • This compound is distributed through Peptide Institute, Inc. under the license of The Salk Institute.

Tyrosyl-CRF (Human, Rat) Tyrosyl-Corticotropin-Releasing Factor (Human, Rat)

PCR-4141-s-20 °C

0.1 mgvial

Tyr-Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His Leu-Leu- Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln- Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Ile-NH2 (M.W. 4920.6) C217H353N61O65S2 [100513-58-4] For Radioimmunoassay Purity Information: Qx: See page xivP.C. Wynn, G. Aguilera, J. Morell, and K.J. Catt, Biochem. Biophys. Res. Commun., 110, 602 (1983). (Biochem.) • This compound is distributed through Peptide Institute, Inc. under the license of The Salk Institute.

38 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES CortistatinCortistatin (Rat) CST-14 (Rat)

Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys (Disulfide bond between Cys2-Cys13) (M.W. 1721.0) C81H113N19O19S2 Neuronal Depressant and Sleep-Modulating Peptide

PCN-4329-v-20 °C

0.5 mgvial

L. De Lecea, J.R. Criado, O. Prospero-Garcia, K.M. Gautvik, P. Schweitzer, P.E. Danielson, C.L.M. Dunlop, G.R. Siggins, S.J. Henriksen, and J.G. Sutcliffe, Nature, 381, 242 (1996). (Original) L. De Lecea, J.A. Del Rio, J.R. Criado, S. Alcantara, M. Morales, P.E. Danielson, S.J. Henriksen, E. Soriano, and J.G. Sutcliffe, J. Neurosci., 17, 5868 (1997). (Biochem.) M. Connor, S.L. Ingram, and M.J. Christie, Br. J. Pharmacol., 122, 1567 (1997) (Pharmacol.) A.D. Spier and L. de Lecea, Brain Res. Rev., 33, 228 (2000). (Review)

C-Type Natriuretic Peptide (CNP)A. Rosenzweig and C.E. Seidman, Annu. Rev. Biochem., 60, 229 (1991). (Review)

CNP-22 (Human)* C-Type Natriuretic Peptide-22 (Human) (Porcine, Rat, Mouse)

PCT-4229-v-20 °C

0.5 mgvial

Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys (Disulfide bond between Cys6-Cys22) (M.W. 2197.6) C93H157N27O28S3 [127869-51-6]T. Sudoh, N. Minamino, K. Kangawa, and H. Matsuo, Biochem. Biophys. Res. Commun., 168, 863 (1990). (Original; Porcine) Y. Tawaragi, K. Fuchimura, S. Tanaka, N. Minamino, K. Kangawa, H. Matsuo, Biochem. Biophys. Res. Commun., 175, 645 (1991). (cDNA Seq.; Human) M. Kojima, N. Minamino, K. Kangawa, and H. Matsuo, FEBS Lett., 276, 209 (1990). (cDNA Seq.; Rat) Y. Ogawa, H. Itoh, Y. Yoshitake, M. Inoue, T. Yoshimasa, T. Serikawa, and K. Nakao, Genomics, 24, 383 (1994). (Nucleotide Seq.; Mouse)


CNP-53 (Human)*C-Type Natriuretic Peptide-53 (Human)

PCT-4241-s-20 °C

0.1 mgvial

Asp-Leu-Arg-Val-Asp-Thr-Lys-Ser-Arg-Ala-Ala-Trp-Ala-Arg-Leu- Leu-Gln-Glu-His-Pro-Asn-Ala-Arg-Lys-Tyr-Lys-Gly-Ala-Asn- Lys-Lys-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu- Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys (Disulfide bond between Cys37-Cys53) (M.W. 5801.7) C251H417N81O71S3 [141294-77-1]Y. Tawaragi, K. Fuchimura, S. Tanaka, N. Minamino, K. Kangawa, and H. Matsuo, Biochem. Biophys. Res. Commun., 175, 645 (1991). (Original)



NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 39

CNP-53 (Porcine, Rat)* C-Type Natriuretic Peptide-53 (Porcine, Rat)

Asp-Leu-Arg-Val-Asp-Thr-Lys-Ser-Arg-Ala-Ala-Trp-Ala-Arg-Leu-Leu-His-Glu-His-Pro-Asn-Ala-Arg-Lys-Tyr-Lys-Gly-Gly-Asn- Lys-Lys-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu- Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys (Disulfide bond between Cys37-Cys53) (M.W. 5796.7) C251H414N82O70S3

PCT-4240-s-20 °C

0.1 mgvial

N. Minamino, K. Kangawa, and H. Matsuo, Biochem. Biophys. Res. Commun., 170, 973 (1990). (Original; Porcine) Y. Tawaragi, K. Fuchimura, H. Nakazato, S. Tanaka, N. Minamino, K. Kangawa, and H. Matsuo, Biochem. Bipophys. Res. Commun., 172, 627 (1990). (Original; Porcine Nucleotide Seq.) M. Kojima, N. Minamino, K. Kangawa, and H. Matsuo, FEBS Lett., 276, 209 (1990). (Original; Rat cDNA)


Tyrosyl-CNP-22 (Human)* Tyrosyl-C-Type Natriuretic Peptide-22 (Human)

Tyr-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu- Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys (Disulfide bond between Cys6-Cys22) (M.W. 2360.8) C102H166N28O30S3 [142878-79-3] For Radioimmunoasay

PCT-4251-v-20 °C

0.5 mgvial

J. Brown and Z. Zuo, Am. J. Physiol., 266, R1383 (1994). (Pharmacol.) J. Zhao, N. Ardaillou, C.-Y. Lu, S. Placier, P. Pham, L. Badre, J. Cambar, and R. Ardaillou, Kidney Int., 46, 717 (1994). (Pharmacol.)


cyclo (Arg-Gly-Asp) Peptides See Arg-Gly-Asp Peptides on page 20.cyclo (d-Trp-d-Asp-Pro-d-Val-Leu) See Arg-Gly-Asp Peptides on page 20.BQ-123 Also see Endothelin peptides page 56.DAP (Diabetes-Associated Peptide) See Amylin on page 39.Decorsin See Arg-Gly-Asp-Peptides on page 20.

d-, l-Peptide with Antitumor ActivityKL-d-Leu-RLL-d-Lys-d-Lys-L-d-Leu-RL-d-Leu-LK-NH2

PDL-3643-PI-20 °C

1 mg5 mg

Lys-Leu-d-Leu-Arg-Leu-Leu-d-Lys-d-Lys-Leu-d-Leu-Arg-Leu-d-Leu-Leu-Lys-NH2 (M.W. 1860.56) C90H174N26O15 d-,l- Peptide with Antitumor ActivityN. Papo, M. Shahar, L. Eisenbach, and Y. Shai, J. Biol. Chem., 278, 21018 (2003).

Deamino-Dicarba-Arginine-Vasopressin See Code PVP-4026-v [Asu1,6, Arg8]-Vasopressin on page 144.Deamino-Dicarba-Arginine-Vasotocin See Code PVP-4027-v [Asu1,6, Arg8] Vasotocin on page 144.Deamino-Dicarba-Oxytocin See Code POX-4025-v [Asu1,6]-Oxytocin on page 98.

40 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES DecorsinDecorsin (Leech, Macrobdella decora)

PDC-4269-s-20 °C

0.1 mgvial

Ala-Pro-Arg-Leu-Pro-Gln-Cys-Gln-Gly-Asp-Asp-Gln-Glu-Lys-Cys-Leu-Cys-Asn-Lys-Asp- Glu-Cys-Pro-Pro-Gly-Gln-Cys-Arg-Phe-Pro-Arg-Gly-Asp-Ala-Asp-Pro-Tyr-Cys-Glu (Disulfide bonds between Cys7-Cys15, Cys17-Cys27, and Cys22-Cys38) (M.W. 4377.8) C179H271N55O62S6 Glycoprotein IIb / IIIa Antagonist, Platelet Aggregation InhibitorJ.L. Seymour, W.J. Henzel, B. Nevins, J.T. Stults, and R.A. Lazarus, J. Biol. Chem., 265, 10143 (1990). A.M. Krezel, G. Wagner, J. Seymour-Ulmer, and R.A. Lazarus, Science, 264, 1944 (1994). (S-S Bond)

Defensin PeptidesR.I. Lehrer and T. Ganz, Ann. N.Y. Acad. Sci., 797, 228 (1996). (Review) M. Zasloff, Nature, 415, 389 (2002). (Review)T. Hirsch, F. Jacobsen, H.-U. Steinau, and L. Steinstraesser, Protein Pept. Lett., 15, 238 (2008). (Review)M. Pazgier, X. Li, W. Lu, and J. Lubkowski, Curr. Pharm. Des., 13, 3096 (2007). (Review)Y.P. Lai and R.L. Gallo, Trends Immunol., 30, 131 (2009). (Review)

a-Defensin-1 (Human) HNP-1 (HNP: Human Neutrophil Peptide)

Ala-Cys-Tyr-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Tyr-Gly-Thr-Cys-Ile-Tyr-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys

PDF-4271-s-20 °C

0.1 mgvial

(Disulfide bonds are formed between Cys2-Cys30, Cys4-Cys19, and Cys9-Cys29) (M.W. 3442.0) C150H222N44O38S6 Antimicrobial Peptide / Chemoattractant for MonocytesT. Ganz, M.E. Selsted, D. Szklarek, S.S.L. Harwig, K. Daher, D.F. Bainton, and R.I. Lehrer, J. Clin. Invest., 76, 1427 (1985). (Original; Isolation) M.E. Selsted, S.S.L. Harwig, T. Ganz, J.W. Schilling, and R.I. Lehrer, J. Clin. Invest., 76, 1436 (1985). (Original; Structure)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 41

α-Defensin -2 (Human)HNP-2 (Human Neutrophil Peptide-2)

Cys-Tyr-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Tyr-Gly-Thr-Cys-Ile-Tyr-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys

PDF-4428-s-20 °C

0.1 mgvial

(Disulfide bonds between Cys1-Cys29, Cys3-Cys18, and Cys8-Cys28)(M.W. 3371.0) C147H217N43O37S6Antimicrobial Peptide

Human α-defensins are composed of 6 peptides: 4 human neutrophil peptides [HNP-1 (PDF-4271-s), HNP-2, HNP-3 (PDF-4416-s), and HNP-4 (PDF-4431-s)] and 2 human defensins [HD-5 (PDF-4415-s) and HD-6 (PDF-4458-s)]. Among them, the primary structures of HNP-1, HNP-2 and HNP-3 differ only at the amino-terminal residue, in which the first residue is Ala for HNP-1 and Asp for HNP-3, whereas HNP-2 lacks this position, resulting in the 29-residue peptide.1,2 Recent studies by mass spectroscopic analysis clarified that HNP-2 is the second major component in squamous cell carcinoma of human tongue3 and gingival crevicular fluid from periodontitis patients and healthy controls4, where HNP-1 is the most abundant and HNP-3 is the least. Taking this fact into account, it is speculated that HNP-2 is produced post-translationally from HNP-3. Concerning the activity, HNP-2 is revealed to be as active as HNP-1 in neutralizing anthrax lethal toxin5 and blocking papillomavirus infection6, although some differences were pointed out in the candidacidal activity among HNPs7.1. T. Ganz, M.E. Selsted, D. Szklarek, S.S.L. Harwig, K. Daher, D.F. Bainton, and R.I. Lehrer, J. Clin. Invest., 76, 1427 (1985). 2. M.E. Selsted, S.S.L. Harwig, T. Ganz, J.W. Schilling, and R.I. Lehrer, J. Clin. Invest., 76, 1436 (1985). 3. F.T. Lundy, D.F. Orr, J.R. Gallagher, P. Maxwell, C. Shaw, S.S. Napier, C.G. Cowan, P.-J. Lamey, and J.J. Marley, Am. J. Pathol., 160, 1311 (2002). 4. F.T. Lundy, D.F. Orr, C. Shaw, P.-J. Lamey, and G.J. Linden, Oral Oncol., 40, 139 (2004). 5. C. Kim, N. Gajendran, H.-W. Mittrüker, M. Weiwad, Y-H. Song, R. Hurwitz, M. Wilmanns, G. Fischer, and S.H.E. Kaufmann, Proc. Natl. Acad. Sci., U.S.A., 102, 4830 (2005). 6. C.B. Buck, P.M. Day, C.D. Thompson, J. Lubkowski, W. Lu, D.R. Lowy, and J.T. Schiller, Proc. Natl. Acad. Sci., U.S.A., 103, 1516 (2006).7. R.I. Lehler, T. Ganz, D. Szklarek, and M.E. Selsted, J. Clin. Invest., 81, 1829 (1988). (Pharmacol.; Activity difference in HNP)

NEW!

42 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES α−Defensin-3 (Human)HNP-3 (Human Neutrophil Peptide-3)

Asp-Cys-Tyr-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Tyr-Gly-Thr-Cys-Ile-Tyr-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys

PDF-4416-s-20 °C

0.1 mgvial

(Disulfide bonds between Cys2-Cys30, Cys4-Cys19, and Cys9-Cys29) (M.W. 3486.0) C151H222N44O40S6 Antimicrobial Peptide

HNP-1 to HNP-3 are the major components in azophilic granules of human neu-trophils.1, 2 The primary structures of HNP-1 to HNP-3 differ by only one amino acid residue at position 1; HNP-2 corresponds to positions 2 through 30 of HNP-1 (des-Ala1-HNP-1) while HNP-3 is Asp1-HNP-1. Interesting publications using HNP include: i) HNP-1 to HNP-3 may show anti-HIV-1 activity3, and ii) HNP-1 to HNP-3 are overexpressed in squamous cell carcinomas of the human tongue, representing a possible role in innate host defense against tumor invasion4. It has been reported that expression of HNP-1 to HNP-3 is not upregulated by lipopolysaccharide5, while they locate in intestinal epithelial cells in cases of inflammatory bowel disease6.1. T. Ganz, M.E. Selsted, D. Szklarek, S.S.L. Harwig, K. Daher, D.F. Bainton, and R.I. Lehrer, J. Clin. Invest., 76, 1427 (1985). (Original; Isolation of HNP 1-3)2. M.E. Selsted, S.S.L. Harwig, T. Ganz, J.W. Schilling, and R.I. Lehrer, J. Clin. Invest., 76, 1436 (1985). (Original; Structure of HNP 1-3)3. C.E. Mackewicz, J. Yuan, P. Tran, L. Diaz, E. Mack, M.E. Selsted, and J.A. Levy, AIDS, 17, F23 (2003). (Pharmacol.; Anti–HIV–1 Activity)4. F.T. Lundy, D.F. Orr, J.R. Gallagher, P. Maxwell, C. Shaw, S.S. Napier, C.G. Cowan, P.-J. Lamey, and J.J. Marley, Oral Oncol., 40, 139 (2004). (Pharmacol.; Role in Tumor Invasion)5. X.-M. Fang, Q. Shu, Q.-X. Chen, M. Book, H.-G. Sahl, A. Hoeft, and F. Stuber, Eur. J. Clin. Invest., 33, 82 (2003). (Histochem.; Regulation of Expression)6. R.N. Cunliffe, Mol. Immunol., 40, 463 (2003). (Histochem.; α-Defensin in Gastrointestinal Tract)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 43

α-Defensin-4 (Human) HNP-4 (Human Neutrophil Peptide-4)

PDF-4431-s-20 °C

0.1 mgvial

Val-Cys-Ser-Cys-Arg-Leu-Val-Phe-Cys-Arg-Arg-Thr-Glu-Leu-Arg-Val-Gly- Asn-Cys-Leu-Ile-Gly-Gly-Val-Ser-Phe-Thr-Tyr-Cys-Cys-Thr-Arg-Val (Disulfide bonds between Cys2-Cys30, Cys4-Cys19, and Cys9-Cys29)(M.W. 3709.40) C157H255N49O43S6Synthetic ProductAntimicrobial Peptide

Four α-defensins in neutrophils are called human neutrophil peptide-1 (HNP-1) to HNP-4, in which primary structures of HNP-1 to HNP-3 are similar; Ala and Asp are the first residue of HNP-1 (PDF-4271) and HNP-3 (PDF-4416), respectively, whereas HNP-2 (PDF-4428) lacks the corresponding amino acid residue at position 1. In contrast to these HNPs, α-defensin-4 (HNP-4) shows marked difference in its primary structure although all six Cys residues are conserved.1,2 Activities of HNP-4 reported so far include: i) inhibition of the ACTH action in rat adrenal cell suspension (ID50 = 7.0 X 10-7 M)1, ii) distinct antimicrobial activity3,4, iii) antiviral activity against X4 and R5 HIV-1 strains5, and iv) inhibition of Bacillus anthracis lethal factor (IC50 = 811 nM)6. In the HIV-1 inhibition, it is proposed that HNP-4 exerts the activity by the lectin-independent property with CD4 and/or gp120, which is different from that of HNP-1 to HNP-35). Although the research using HNP-4 seems to be proceeding relatively slowly at the moment, partly because HNP-4 is a minor component in the granulocytes HNPs, our synthetic HNP-4 will contribute significantly to clarify the total activity of HNPs in the body.1. A. Singh, A. Bateman, Q. Zhu, S. Shimasaki, F. Esch, and S. Solomon, Biochem. Biophys. Res. Commun., 155, 524 (1988). (Original; Primary Structure / Anti-ACTH Activity)2. C.G. Wilde, J.E. Griffith, M.N. Marra, J.L. Snable, and R.W. Scott, J. Biol. Chem., 264, 11200 (1989). (Original; Structure / HNP-4 / Antimicrobial Activity)3. Z. Wu, B. Ericksen, K. Tucker, J. Lubkowski, and W. Lu, J. Pept. Res., 64, 118 (2004). (Pharmacol; Antimicrobial Activity)4. B. Ericksen, Z. Wu, W. Lu, and R.I. Lehrer, Antimicrob. Agents Chemother., 49, 269 (2005). (Pharmacol; Antimicrobial Activity)5. Z. Wu, F. Cocchi, D. Gentles, B. Ericksen, J. Lubkowski, A. DeVico, R.I. Lehrer, and W. Lu, FEBS Lett., 579, 162 (2005). (Pharmacol.; HIV-1 Inhibitory Activity)6. G. Wei, E. de Leeuw, M. Pazgier, W. Yuan, G. Zou, J. Wang, B. Ericksen, W.-Y. Lu, R.I. Lehrer, and W. Lu, J. Biol. Chem., 284, 29180 (2009). (Pharmacol.;Iinhibition of Bacillus anthracis Lethal Factor)

NEW!

44 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES α-Defensin-5 (Human)HD-5 (Human Defensin-5)

PDF-4415-s-20 °C

0.1 mgvial

Ala-Thr-Cys-Tyr-Cys-Arg-Thr-Gly-Arg-Cys-Ala-Thr-Arg-Glu-Ser-Leu- Ser-Gly-Val-Cys-Glu-Ile-Ser-Gly-Arg-Leu-Tyr-Arg-Leu-Cys-Cys-Arg (Disulfide bonds between Cys3-Cys31, Cys5-Cys20, and Cys10-Cys30) (M.W. 3582.1) C144H238N50O45S6 Antimicrobial Peptide in Paneth Cells

HD-5 is expressed in Paneth cells in intestinal epithelium, thus, falls into a distinct subclass of human α-defensin.1, 2 The in vivo role of HD-5 was studied in transgenic mouse models injected by an HD-5 minigene, confirming that HD-5 expression was specific to Paneth cells and resulted in resistance to bacterial challenge.3 In patients with HIV-related cryptosporidiosis, HD-5 immunoreactivity was reduced in associa-tion with Paneth cell granule depletion.4 In inflammatory bowel disease, HD-5 was expressed in metaplastic Paneth cells in the colon.5 These evidences together point to HD-5 as being an essential factor in the defense against intestinal inflammation.1. D.E. Jones and C.L. Bevins, J. Biol. Chem., 267, 23216 (1992). (Original; Human Defensin-5)2. E.M. Porter, M.A. Poles, J.S. Lee, J. Naitoh, C.L. Bevins, amd T. Ganz, FEBS Lett., 434, 272 (1998). (Pharmacol.; Endogenous Form)3. N.H. Salzman, D. Ghosh, K.M. Huttner, Y. Paterson, and C.L. Bevins, Nature, 422, 522 (2003). (Pharmacol.)4. P. Kelly, R. Feakins, P. Domizio, J. Murphy, C. Bevins, J. Wilson, G. Mcphail, R. Poulsom, and W. Dhaliwal, Clin. Exp. Immunol., 135, 303 (2004). (Histochem.; Location in AIDS Patients)5. R.N. Cunliffe, Mol. Immunol., 40, 463 (2003). (Histochem.; α-Defensin in Gastrointestinal Tract)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 45

α-Defensin-6 (Human)[HD-6 (Human Defensin-6)]

PDF-4458-s-20 °C

0.1 mgvial

Ala-Phe-Thr-Cys-His-Cys-Arg-Arg-Ser-Cys-Tyr-Ser-Thr-Glu-Tyr-Ser- Tyr-Gly-Thr-Cys-Thr-Val-Met-Gly-Ile-Asn-His-Arg-Phe-Cys-Cys-Leu (Disulfide bonds between Cys4-Cys31, Cys6-Cys20, and Cys10-Cys30)(M.W. 3708.2) C156H228N46O46S7 Antimicrobial Peptide in Paneth Cells

Six α-defensins have been identified in the human; four of which are found in neutrophiles and thus named human neutrophil peptide-1, HNP-1 (PDF-4271-s), HNP-2 (PDF-4428-s), HNP-3 (PDF-4416-s) and HNP-4 (PDF-4431-s). The remaining two are called human defensin-5 (HD-5, PDF-4415-s) and human defensin-6 (HD-6)1, which are identified in intestinal Paneth cells. HD-6 was isolated from ileal neobladder urine as a 32-residue peptide.2 It appeared in the initial study that HD-6 was practically inactive against some bacteria and fungi.3 However, the experimental results proving HD-6 to be an antimicrobial peptide have been accumulating: i) Helicobacter pylori infection increases HD-6 expression in the fundus4, ii) HD-6 inhibits herpes simplex virus infection5, iii) HD-6 has influenza A virus neutralizing ability6, and iv) the HD-6 level is reduced in small intestinal Crohn’s disease7. In contrast to these positive effects in the host defense system, Neisseria gonorrhoeae-induced HD-6 enhances HIV infectivity, showing how complex HD-6 activity may be.8 Anyhow, these specific characteristics observed in HD-6 are attractive in the study of human innate immunity.1. D.E. Jones and C.L. Bevins, FEBS Lett., 315,187 (1993). (Original; mRNA Seq.)2. E.M. Porter, M.A. Poles, J.S. Lee, J. Naitoh, C.L. Bevins, and T. Ganz, FEBS Lett., 434, 272 (1998). (Endogenous Form)3. B. Ericksen, Z. Wu, W. Lu, and R.I. Lehrer, Antimicrob. Agents Chemother., 49, 269 (2005). (Pharmacol.; No Antibacterial Activity)4. J. Wehkamp, K. Schmidt, K.R. Herrlinger, S. Baxmann, S. Behling, C. Wohlschla ger, A.C. Feller, E.F. Stange, and K. Fellermann, J. Clin. Pathol., 56, 352 (2003). (Pharmacol.; Enhanced Expression in Helicobacter pylori Infection)5. E. Hazrati, B. Galen, W. Lu, W. Wang, Y. Ouyang, M.J. Keller, R.I. Lehrer, and B.C. Herold, J. Immunol., 177, 8658 (2006). (Pharmacol.; Inhibition of Herpes Simplex Virus Infection)6. M. Doss, M.R. White, T. Tecle, D. Gantz, E.C. Crouch, G. Jung, P. Ruchala, A.J. Waring, R.I. Lehrer, and K.L. Hartshorn, J. Immunol., 182, 7878 (2009). (Pharmacol.; Influenza A Virus Neutralizing Activity)7. M.J. Koslowski, J. Beisner, E.F. Stange, and J. Wehkamp, Int. J. Med. Microbiol., 300, 34 (2010). (Minireview; Antimicrobial Host Defense in Small Intestinal Crohn’s Disease)8. M.E. Klotman, A. Rapista, N. Teleshova, A. Micsenyi, G.A. Jarvis, W. Lu, E. Porter, and T.L. Chang, J. Immunol., 180, 6176 (2008). (Pharmacol.; Enhancement of HIV Infectivity)

β-Defensin-1 (Human) hBD-1

Asp-His-Tyr-Asn-Cys-Val-Ser-Ser-Gly-Gly-Gln-Cys-Leu- Tyr-Ser-Ala-Cys-Pro-Ile-Phe-Thr-Lys-Ile-Gln-Gly-Thr- Cys-Tyr-Arg-Gly-Lys-Ala-Lys-Cys-Cys-Lys

PDF-4337-s-20 °C

0.1 mgvial

(Disulfide bonds between Cys5-Cys34, Cys12-Cys27, and Cys17-Cys35) (M.W. 3928.5) C167H256N48O50S6 Antimicrobial PeptideK.W. Bensch, M. Raida, H-J. Mägert, P. Schulz-Knappe, and W.-G. Forssmann, FEBS Lett., 368, 331 (1995). (Original) M.J. Goldman, G.M. Anderson, E.D. Stolzenberg, U.P. Kari, M. Zasloff, and J.M. Wilson, Cell, 88, 553 (1997). (Pharmacol.; Inactivated in Cystic Fibrosis) T. Hiratsuka, M. Nakazato, T. Ihi, T. Minematsu, N. Chino, T. Nakanishi, A. Shimizu, K. Kangawa, and S. Matsukura, Nephron, 85, 34 (2000). (Pharmacol.)

NEW!

46 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES β-Defensin-2 (Human) hBD-2

PDF-4338-s-20 °C

0.1 mgvial

Gly-Ile-Gly-Asp-Pro-Val-Thr-Cys-Leu-Lys-Ser-Gly-Ala-Ile-Cys- His-Pro-Val-Phe-Cys-Pro-Arg-Arg-Tyr-Lys-Gln-Ile-Gly-Thr- Cys-Gly-Leu-Pro-Gly-Thr-Lys-Cys-Cys-Lys-Lys-Pro (Disulfide bonds between Cys8-Cys37, Cys15-Cys30, and Cys20-Cys38) (M.W. 4328.2) C188H305N55O50S6 Antibacterial Peptide Specific for Gram-Negative Bacteria / Also Effective for Candida albicansJ. Harder, J. Bartels, E. Christophers, and J.-M. Schroder, Nature, 387, 861 (1997). (Original) T. Hiratsuka, M. Nakazato, Y. Date, J. Ashitani, T. Minematsu, N. Chino, and S. Matsukura, Biochem. Biophys. Res. Commun., 249, 943 (1998). (Pharmacol.) D.M. Hoover, K.R. Rajashankar, R. Blumenthal, A. Puri, J.J. Oppenheim, O. Chertov, and J. Lubkowski, J. Biol. Chem., 275, 32911 (2000). (S-S Bond) T. Hiratsuka, H. Mukae, H. Iiboshi, J. Ashitani, K. Nabeshima, T. Minematsu, N. Chino, T. Ihi, S. Kohno, and M. Nakazato, Thorax, 58, 425 (2003). (Pharmacol.; Activity against Pseudomonas aeruginosa)S. Yanagi, J.-i. Ashitani, H. Ishimoto, Y. Date, H.Mukae, N. Chino, and M. Nakazato, Respiratory Res., 6, 130 (2005). (Pharmacol. & Immunohistochem.)

β-Defensin-3 (Human) hBD-3

PDF-4382-s-20 °C

0.1 mgvial

Gly-Ile-Ile-Asn-Thr-Leu-Gln-Lys-Tyr-Tyr-Cys-Arg-Val-Arg-Gly-Gly- Arg-Cys-Ala-Val-Leu-Ser-Cys-Leu-Pro-Lys-Glu-Glu-Gln-Ile-Gly- Lys-Cys-Ser-Thr-Arg-Gly-Arg-Lys-Cys-Cys-Arg-Arg-Lys-Lys (Disulfide bonds between Cys11-Cys40, Cys18-Cys33, and Cys23-Cys41) (M.W. 5155.1) C216H371N75O59S6 Antimicrobial Peptide / Staphylococcus aureus-Killing FactorThe human defensins represent an important family of antimicrobial peptides. They are composed of two subclasses: α-defensins and β-defensins (hBD), which are characterized by their distinct arrangement of three disulfide bonds. Following the dis-covery of hBD-1 (PDF-4337-s) and hBD-2 (PDF-4338-s) in 1995 and 1997, respectively, hBD-3 was included in 2001.1 hBD-3 was identified in lesional psoriatic scales, from which hBD-2 was also isolated. Peptide and DNA chemistry revealed hBD-3 to be a 45 amino acid residue peptide. The antimicrobial activity of hBD-3 is characterized by: i) a broad spectrum of antimicrobial activity against many pathogenic microbes such as multi-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus fae-cium without hemolytic activity, ii) salt-insensitivity up to 200 mM NaCl, iii) expression of activity through cell wall perforation, and iv) regulation by TNF-α and contact with bacteria.1 Later, although the data was obtained using the amino-terminally truncated peptide, hBD-3 (6-45), the following interesting findings were reported: i) hBD-3 is stimulated by interferon-γ, and ii) hBD-3 has monocyte activating function and elicits ion channel activity.2 It is also reported that unlike hBD-1 and hBD-2, hBD-3 mRNA expression is inhibited by corticosteroids.3 Significant amounts of these peptides are distributed in the following tissues: skin, tonsil, trachea, placenta, testis, thymus, and heart.1,2,4 With respect to the structural aspects of hBD-3, an amphipathic dimeric structure was proposed in solution, which is different from those of hBD-1 and hBD-2. This might be responsible for the bactericidal activity against Staphylococcus aureus.5 Thus, the hBD-3, as well as the other defensins, are useful tools for understanding their defense mechanisms against various microorganisms.1. J. Harder, J. Bartels, E. Christophers, and J.-M. Schröder, J. Biol. Chem., 276, 5707 (2001). (Original) 2. J.-R.C. García, et al., Cell Tissue Res., 306, 257 (2001). (Original; Amino-Terminally Truncated Peptide) 3. L.A. Duits, et al., Biochem. Biophys. Res. Commun., 280, 522 (2001). (Pharmacol.) 4. H.P. Jia, et al., Gene, 263, 211 (2001). (DNA Seq/Tissue Distribution) 5. D.J. Schibli, et al., J. Biol. Chem., 277, 8279 (2002). (Solution Structure) 6. S. Yanagi, et al., Respiratory Res., 6, 130 (2005). (Pharmacol. & Immunohistochem.)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 47

β-Defensin-4 (Human)hBD-4 Prepro hBD-4 (Human, 25-61)

PDF-4406-s-20 °C

0.1 mgvial

Glu-Leu-Asp-Arg-Ile-Cys-Gly-Tyr-Gly-Thr-Ala-Arg-Cys-Arg-Lys-Lys-Cys-Arg-Ser- Gln-Glu-Tyr-Arg-Ile-Gly-Arg-Cys-Pro-Asn-Thr-Tyr-Ala-Cys-Cys-Leu-Arg-Lys (Disulfide bonds between Cys6-Cys33, Cys13-Cys27, and Cys17-Cys34) (M.W. 4366.0) C180H295N63O52S6 Antimicrobial Peptide / Chemoattractant for Monocytes28 Human β-defensins were predicted in five gene clusters using a computational search approach.1 Among others, hBD-4, was proposed based on the cDNA sequence analysis, the precursor of which is composed of 72 amino acid residues. Although natural hBD-4, as far as we know, has not yet been isolated, hBD-4 was tentatively designed as the peptide corresponding to the positions between 25 and 61 in the precursor sequence [hereafter the term “hBD-4” is used for this peptide. Chemically synthesized hBD-4 was confirmed to share the conserved disulfide connectivity of the β-defensin family of peptides by the combination of enzymatic digestions and Edman degradation reaction2). Using this chemically synthesized hBD-4, the following obser-vations were reported2): i) hBD-4 elicits salt-sensitive antimicrobial activities against both Gram-positive and Gram-negative bacteria in human respiratory epithelial cells; ii) the most active antimicrobial activity is detected against Pseudomonas aeruginosa at 4.1 μg/ml; and iii) hBD-4 is a chemoattractant for human blood monocytes at 10 nM, but not for neutrophiles and eosinophiles. Interestingly, antimicrobial activities in the lungs were inducible by the infection and subsequent activation of protein kinase C, thus differing from the activation mechanism from hBD-2 and hBD-3, which are induced in response to the stimulation by TNF-α, IL-1α, IL-6 or interferon α. hBD-4 mRNA was expressed abundantly in testis and the stomach, and to a lesser extent but significantly in the uterus, neutrophiles thyroid, lungs, and kidney. hBD-4, which is regulated by specific stimulation that differs from those in hBD-2 and hBD-3, should be an essential component in clarifying the host defense mechanism in humans. Later, the existence of the immunoreactive hBD-4 in the body was reported3). Also, hBD-4 induces mast cell degranulation, prostaglandin D2 production, intracellular Ca2+ mobilization and chemotaxis4).1. B.C. Schutte, J.P. Mitros, J.A. Bartlett, J.D. Walters, H. Peng Jia, M.J. Welsh, T.L. Casavant, and P.B. McCray, Jr., Proc. Natl. Acad. Sci., USA, 99, 2129 (2002). (b-Defensin Family Peptides) 2. J.R.C. García, A. Krause, S. Schulz, F.-J. Rodríguez-Jiménez, E. Klüver, K. Adermann, U. Forssmann, A. Frimpong-Boateng, R. Bals, and W.-G. Forssmann, FASEB J., 15, 1819 (2001). (Original: hBD-4 & S-S Bond)3. S. Yanagi, J.-i. Ashitani, H. Ishimoto, Y. Date, H. Mukae, N. Chino, and M. Nakazato, Respiratory Res., 6, 130 (2005). (Pharmacol. & Immunohistochem.)4. X. Chen, F. Niyonsaba,H.Ushio,M.Hara, H. Yokoi, K. Matsumoto, H. Saito, I.Nagaoka, S. Ikeda, K.Okumura, and H. Ogawa, Eur. J. Immunol., 37, 434 (2007). (Pharmacol.)

48 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Delta Sleep-Inducing Peptide (DSIP)Delta Sleep-Inducing Peptide (DSIP)

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (M.W. 848.81) C35H48N10O15 [62568-57-4]

PDS-4054-v-20 °C

0.5 mgvial

Delta Sleep-Inducing Peptide (DSIP) (Bulk) Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu • 4H2O(M.W. 848.81 • 72.06) C35H48N10O15 • 4H2O [62568-57-4]

PDS-4054-20 °C

25 mg

G.A. Schoenenberger and M. Monnier, Proc. Natl. Acad. Sci., USA., 74, 1282 (1977). (Original) M. Monnier, L. Dudler, R. Gachter, P.F. Maier, H.J. Tobler, and G.A. Schoenenberger, Experientia, 33, 548 (1977). (Pharmacol.)

Dermcidin- 1L / DCDDermcidin- 1L (Human)DCD-1L (Human)

PDL-4454-s-20 °C

0.1 mgvial

Ser-Ser-Leu-Leu-Glu-Lys-Gly-Leu-Asp-Gly-Ala-Lys-Lys-Ala-Val-Gly-Gly- Leu-Gly-Lys-Leu-Gly-Lys-Asp-Ala-Val-Glu-Asp-Leu-Glu-Ser-Val-Gly- Lys-Gly-Ala-Val-His-Asp-Val-Lys-Asp-Val-Leu-Asp-Ser-Val-Leu(M.W. 4818.4) C210H359N57O71Synthetic ProductAntimicrobial Peptide in Sweat Glands

Dermcidin is a constitutively secreted antimicrobial peptide in human sweat.1 Dermcidin is revealed to be a 110-residue protein by cDNA analysis, which is proteolytically processed to several components with variable charges. Dermcidin-1L is one of such processed peptides with anionic property, which corresponds to the carboxyl-terminal 48-residues of the precursor protein.1,2 Studies using dermcidin-1L reported so far include: i) dermcidin-1L is active against Gram-positive and negative bacteria and fungus (1-100 μg/ml) 1, ii) in patients with atopic dermatitis the amounts of dermicidin-1L and other dermcidin-derived peptides are reduced3, and iii) dermcidin-1L activates human keratinocytes, inducing the generation of cytokines and chemokines (2.5-20 μg/ml).4 Dermcidin-1L does not show membrane permeability, thus, the mechanism exerting antimicrobial activity of dermcidin-1L is distinct from that of other antimicrobial peptide, LL-37 (PLL-4445-s).5 Dermcidin-1L in sweat may be essential for the battle with infectious pathogens on the human body surface, therefore it will be an important tool in the host defense research.1. B. Schittek, R. Hipfel, B. Sauer, J. Bauer, H. Kalbacher, S. Stevanovic, M. Schirle, K. Schroeder, N. Blin, F. Meier, G. Rassner, and C. Garbe, Nat. Immunol., 2, 1133 (2001). (Original; Antimicrobial Peptide)2. S. Rieg, H. Steffen, S. Seeber, A. Humeny, H. Kalbacher, K. Dietz, C. Garbe, and B. Schittek, J. Immunol., 174, 8003 (2005). (Endogenous Form)3. H. Steffen, S.Rieg, I. Wiedemann, H. Kalbacher, M. Deeg, H.-G. Sahl, A. Peschel, F. Götz, C. Garbe, and B. Schittek, Antimicrob. Agents Chemother., 50, 2608 (2006). (Pharmacol.)4. F. Niyonsaba, A. Suzuki, H. Ushio, I. Nagaoka, H. Ogawa, and K. Okumura,Br. J. Dermatol.,160,243 (2009). (Pharmacol.)5. I. Senyurek, M. Paulmann, T. Sinnberg, H. Kalbacher, M. Deeg, T. Gutsmann, M. Hermes, T. Kohler, F. Götz, C. Wolz, A. Peschel, and B. Schittek, Antimicrob. Agents Chemother., 53, 2499 (2009). (Pharmacol.)

Diabetes-Associated Peptide (DAP) See Code PAM-4219 Amylin (Human) and Code PAM-4220 Amylin (Rat) on page 9.

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 49

DynorphinsJ. Hughes, Br. Med. Bull., 39, 17 (1983). (Review) A.P. Smith and N.M. Lee, Annu. Rev. Pharmacol. Toxicol., 28, 123 (1988). (Review) M. Simonato and P. Romualdi, Prog. Neurobiol., 50, 557 (1996). (Review)

Dynorphin A (Human, 1-13) (Porcine, Rat, Bovine)

Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys (M.W. 1604.0) C75H126N24O15 [72957-38-1]

PDY-4080-v-20 °C

0.5 mgvial

A. Goldstein, S. Tachibana, L.I. Lowney, M. Hunkapiller, and L. Hood, Proc. Natl. Acad. Sci. U.S.A., 76, 6666 (1979). (Original; Porcine) S. Horikawa, T. Takai, M. Toyosato, H. Takahashi, M. Noda, H. Kakidani, T. Kubo, T. Hirose, S. Inayama, H. Hayashida, T. Miyata, and S. Numa, Nature, 306, 611 (1983). (Nucleotide Seq.; Human)

Dynorphin A (Human) (Porcine, Rat, Bovine)

PDY-4108-v-20 °C

0.5 mgvial

Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln (M.W. 2147.5) C99H155N31O23 [80448-90-4]S. Tachibana, K. Araki, S. Ohya, and S. Yoshida, The 1981 International Narcotic Research Conference, Kyoto, July 1981. (Original) A. Goldstein, W. Fischli, L.l. Lowney, M. Hunkapiller, and L. Hood, Proc. Natl. Acad. Sci. USA, 78, 7219 (1981). (Original; Porcine) S. Horikawa, T. Takai, M. Toyosato, H. Takahashi, M. Noda, H. Kakidani, T. Kubo, T. Hirose, S. Inayama, H. Hayashida, T. Miyata, and S. Numa, Nature, 306, 611 (1983). (Nucleotide Seq.; Human) O. Civelli, J. Douglass, A. Goldstein, and E. Herbert, Proc. Natl. Acad. Sci. U.S.A., 82, 4291 (1985). (Nucleotide Seq.; Rat)

Echistatin(Trifluoroacetate Form)H-Glu-Cys-Glu-Ser-Gly-Pro-Cys-Cys-Arg-Asn-Cys-Lys-Phe-Leu-Lys-Glu-Gly-Thr-Ile-Cys-Lys-Arg-Ala-Arg-Gly-Asp- Asp-Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Cys-Asp- Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH

ECT-3760-PI 1 mg 5 mg

(Disulfide bonds between Cys2-Cys11, Cys7-Cys32, Cys8-Cys37, and Cys20-Cys39)(M.W. 5417.14) C217H341N71O74S9 [154303-05-6] αVβ3 Integrin AntagonistJ. Musial, et al., Circulation, 82, 261 (1990). M. Sato, et al., J. Cell.Biol., 111, 1713 (1990). C.C. Kumar, et al., J. Pharmacol.Exp.Ther., 283, 843 (1997).V. Garsky, et al., Proc Nat Acad of Sciences, 86, 4022 (1989).

Echistatin See Code ECT-3760-PI in the Toxins section on page 129.

50 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES ElafinElafin (Human)

Ala-Gln-Glu-Pro-Val-Lys-Gly-Pro-Val-Ser-Thr-Lys-Pro-Gly-Ser-Cys-Pro-Ile-Ile-Leu-Ile-Arg-Cys-Ala-Met-Leu-Asn-Pro-Pro-Asn-Arg-Cys-Leu-Lys-Asp-Thr-Asp-Cys-Pro-Gly-Ile-Lys-Lys-Cys-Cys-Glu-Gly-Ser-Cys-Gly-Met-Ala-Cys-Phe-Val-Pro-Gln

PEL-4243-v-20 °C

20 mg vial

(Disulfide bonds between Cys16-Cys45, Cys23-Cys49, Cys32-Cys44, and Cys38-Cys53) (M.W. 5999.1) C254H416N72O75S10 Elastase-Specific Inhibitor from Human Skin / Innate Immune FactorO. Wiedow, J.-M. Schröder, H. Gregory, J.A. Young, and E. Christophers, J. Biol. Chem., 265, 14791 (1990). (Original) O. Wiedow, J.-M. Schröder, H. Gregory, J.A. Young, and E. Christophers, J. Biol. Chem., 266, 3356 (1991). (Correction of Sequence) M. Tsunemi, H. Kato, Y. Nishiuchi, S. Kumagaye, and S. Sakakibara, Biochem. Biophys. Res. Commun., 185, 967 (1992). (Chem. Synthesis & Biochem.) M. Tsunemi, H. Kato, Y. Nishiuchi, S. Kumagaye, and S. Sakakibara, Biochem. Biophys. Res. Commun., 185, 967 (1992). (Chem. Synthesis & Biochem.) M. Tsunemi, Y. Matsuura, S. Sakakibara, and Y. Katsube, Biochemistry, 35, 11570 (1996). (Biochem.; Crystal Structure of Elafin-Pancreatic Elastase Complex)L. Marischen, D. Wesch, J.-M. Schröder, O. Wiedow, and D. Kabelitz, Scand. J. Immunol., 70, 547 (2009). (Pharmacol.)S.M. Iqbal, T.B. Ball, P. Levinson, L. Maranan, W. Jaoko, C. Wachihi, B.J. Pak, V.N. Podust, K. Broliden, T. Hirbod,R. Kaul, and F.A. Plummer, AIDS, 23, 1669 (2009). (Pharmacol.)

Eledoisin Related PeptideEledoisin Related Peptide

Lys-Phe-Ile-Gly-Leu-Met-NH2 (M.W. 706.94) C34H58N8O6S [2990-43-4]

PEL-4003-v-20 °C

0.5 mg vial

Eledoisin Related Peptide (Bulk)Lys-Phe-Ile-Gly-Leu-Met-NH2 • 2AcOH • 3H2O (M.W. 706.94 • 120.10 • 54.05) C34H58N8O6S • 2CH3COOH • 3H2O

PEL-4003-20 °C

25 mg100 mg

S. Sakakibara and M. Fujino, Bull. Chem. Soc. Japan, 39, 947 (1966). (Chem. Synthesis)

EndokininsEndokinin C (Human)

Lys-Lys-Ala-Tyr-Gln-Leu-Glu-His-Thr-Phe-Gln-Gly-Leu-Leu-NH2 (M.W. 1674.9) C78H123N21O20 Peptide in α-Tachykinin Precursor 4

PND-4411-v-20 °C

0.5 mgvial

N.M. Page, N.J. Bell, S.M. Gardiner, I.T. Manyonda, K.J. Brayley, .G. Strange, and P.J. Lowry, Proc. Natl. Acad. Sci. USA, 100, 6245 (2003). (Original)J.N. Pennefather, A. Lecci, M.L. Candenas, E. Patak, F.M. Pinto, and C.A. Maggi, Life Sci., 74, 1445 (2004). (Review)N.M. Page, Cell. Mol. Life Sci.; 61, 1652 (2004). (Review)R. Naono, T. Nakayama, T. Ikeda, O. Matsushima, and T. Nishimori, Brain Res., 1165, 71 (2007). (Pharmacol.)Y. Yang and S. Dong, Peptides, 31, 94 (2010). (Pharmacol.)

Endokinin D (Human)Val-Gly-Ala-Tyr-Gln-Leu-Glu-His-Thr-Phe-Gln-Gly-Leu-Leu-NH2 (M.W. 1574.8) C73H111N19O20 Peptide in b-Tachykinin Precursor 4

PND-4412-v-20 °C

0.5 mg vial

N.M. Page, N.J. Bell, S.M. Gardiner, I.T. Manyonda, K.J. Brayley, P.G. Strange, and P.J. Lowry, Proc. Natl. Acad. Sci. USA, 100, 6245 (2003). (Original)J.N. Pennefather, A. Lecci, M.L. Candenas, E. Patak, F.M. Pinto, and C.A. Maggi, Life Sci., 74, 1445 (2004). (Review)N.M. Page, Cell. Mol. Life Sci.; 61, 1652 (2004). (Review)R. Naono, T. Nakayama, T. Ikeda, O. Matsushima, and T. Nishimori, Brain Res., 1165, 71 (2007). (Pharmacol.)Y. Yang and S. Dong, Peptides, 31, 94 (2010). (Pharmacol.)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 51

EndomorphinsJ. Fichna, A. Janecka, J. Costentin, and J.-C. do Rego, Pharmacol. Rev., 59, 88 (2007). (Review)

Endomorphin-1*(Human, Bovine)

Tyr-Pro-Trp-Phe-NH2(M.W. 610.70) C34H38N6O5 [189388-22-5]

PGX-4333-v-20 °C

0.5 mg vial



Tyr-Pro-Trp-Phe-NH2 • AcOH • H2O(M.W. 610.70 • 60.05 • 18.01) C34H38N6O5 • CH3COOH• H2OEndogenous μ-Opiate Receptor Selective Agonist

PGX-4333-20 °C

25 mg

J.E. Zadina, L. Hackler, L.-J. Ge, and A.J. Kastin, Nature, 386, 499 (1997). (Original; Bovine)H.C. Champion, J.E. Zadina, A.J. Kastin, L. Hackler, L.J. Ge, and P.J. Kadowitz, Biochem. Biophys. Res. Commun., 235, 567 (1997). (Pharmacol.)L.S. Stone, C.A. Fairbanks, T.M. Laughlin, H.O. Nguyen, T.M. Bushy, M.W. Wessendorf, and G.L. Wilcox, Neuroreport, 8, 3131 (1997). (Pharmacol.)L. Hackler, J.E. Zadina, L.J. Ge, and A.J. Kastin, Peptides, 18, 1635 (1997). (Isolation from Human Brain)



Tyr-Pro-Phe-Phe-NH2(M.W. 571.67) C32H37N5O5 [141801-26-5]

PLP-4334-v-20 °C

0.5 mgvial



Tyr-Pro-Phe-Phe-NH2 • AcOH • H2O(M.W. 571.67 • 60.05• 18.01) C32H37N5O5 • CH3COOH• H2OEndogenous μ-Opiate Receptor Selective Agonist

PLP-4334-20 °C

25 mg

J.E. Zadina, L. Hackler, L.-J. Ge, and A.J. Kastin, Nature, 386, 499 (1997). (Original; Bovine)H.C. Champion, J.E. Zadina, A.J. Kastin, L. Hackler, L.J. Ge, and P.J. Kadowitz, Biochem. Biophys. Res. Commun., 235, 567 (1997). (Pharmacol.)L.S. Stone, C.A. Fairbanks, T.M. Laughlin, H.O. Nguyen, T.M. Bushy, M.W. Wessendorf, and G.L. Wilcox, Neuroreport, 8, 3131 (1997). (Pharmacol.)L. Hackler, J.E. Zadina, L.J. Ge, and A.J. Kastin, Peptides, 18, 1635 (1997). (Isolation from Human Brain)


EndorphinsA. Goldstein, Ann. N.Y. Acad. Sci., 311, 49 (1978). (Review) F. Bloom, A. Bayon, E. Battenberg, E. French, L. Koda, G. Koob, M. Le Moal, J. Rossier, and W. Shoemaker, Adv. Biochem. Psychopharm., 22, 619 (1980). (Review) P.A. Berger, H. Akil, S.J. Watson, and J.D. Barchas, Annu. Rev. Med., 33, 397 (1982). (Review) F.E. Bloom, Annu. Rev. Pharmacol. Toxicol., 23, 151 (1983). (Review)

a-Endorphin b-Lipotropin (61-76)

PEN-4055-v-20 °C

0.5 mgvial

Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr (M.W. 1745.9) C77H120N18O26S [59004-96-5]

N. Ling, R. Burgus, and R. Guillemin, Proc. Natl. Acad. Sci. USA, 73, 3942 (1976). (Original; Porcine)

52 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES b-Endorphin (Equine)(Trifluoroacetate Form) H-Tyr-Gly-Gly-Phe-Met-Ser-Ser-Glu-Lys-Ser-Gln-Thr- Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys- Asn-Ala-His-Lys-Lys-Gly-Gln-OH

END-3756-PI-20 °C

1 mg5 mg

(M.W. 3424.01) C154H248N42O44S [79495-86-6]C.H.Li, et al., Int. J. Peptide Protein Res., 18, 242 (1981)

b-Endorphin (Human) b-Lipotropin (Human, 61-91)

PEN-4060-v-20 °C

0.5 mgvial

Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr- Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu (M.W. 3465.0) C158H251N39O46S [61214-51-5]

C.H. Li and D. Chung, Nature, 260, 622 (1976). (Original; Human) C.H. Li, D. Yamashiro, L.-F. Tseng, and H.H. Loh, J. Med. Chem., 20, 325 (1977). (Chem. Synthesis & Biological Activity)

g-Endorphin b-Lipotropin (61-77)

PEN-4089-v-20 °C

0.5 mgvial

Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu (M.W. 1859.1) C83H131N19O27S

N. Ling, R. Burgus, and R. Guillemin, Proc. Natl. Acad. Sci. USA, 73, 3942 (1976). (Original; Porcine)

EndothelinsM. Yanagisawa and T. Masaki, Trends Pharmacol. Sci., 10, 374 (1989). (Review) T. Sakurai, M. Yanagisawa, and T. Masaki, Trends Pharmacol. Sci., 13, (1992). (Review) A.F. James, Y. Urade, R.L. Webb, H. Karaki, I. Umemura, Y. Fujitani, K. Oda, T. Okada, R.W. Lappe, and M. Takai, Cardiovasc. Drug Rev., 11, 253 (1993). (Review)

Endothelin-1 (Human)* (Porcine, Canine, Rat, Mouse, Bovine)

Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys- Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 2491.9) C109H159N25O32S5 [117399-94-7]

PED-4198-s-20 °C

0.1 mgvial


Endothelin-1 (Human)* (Porcine, Canine, Rat, Mouse, Bovine)

PED-4198-v-20 °C

0.5 mgvial

M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, and M. Masaki, Nature, 332, 411 (1988). (Original) A. Inoue, M. Yanagisawa, S. Kimura, Y. Kasuya, T. Miyauchi, K. Goto, and T. Masaki, Proc. Natl. Acad. Sci. U.S.A., 86, 2863 (1989). (Naming) T.X. Wantanabe, Y. Itahara, K. Nakajima, S. Kumgaye, T. Kimura, and S. Sakakibara, J. Cardiovasc, Pharmocal., 17 (Suppl. 7), S5 (1991). (Pharmacol.) • This compound is distributed through Peptide Institute, Inc., under the license of Takeda Chemical Industries, Ltd. and the National Institute of Advanced Industrial Science and Technology (AIST).


NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 53

Endothelin-1 (1-31) (Human)*Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys- Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-Val- Asn-Thr-Pro-Glu-His-Val-Val-Pro-Tyr (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 3628.2) C162H236N38O47S5 [133972-52-8]

PED-4360-s-20 °C

0.1 mg vial

A. Nakao, F. Kishi, K. Minami, H. Wakabayashi, Y. Nakaya, and H. Kido, J. Immunol., 159, 1987 (1997). (Original; New Endogenous Form) F. Kishi, K. Minami, N. Okishima, M. Murakami, S. Mori, M. Yano, Y. Niwa, Y. Nakaya, and H. Kido, Biochem. Biophys. Res. Commun., 248, 387 (1998). (Pharmacol.) M. Yoshizumi, D. Inui, N. Okishima, H. Houchi, K. Tsuchiya, H. Wakabayashi, H. Kido, and T. Tamaki, Eur. J. Pharmacol., 348, 305 (1998). (Pharmacol.) M. Yoshizumi, S. Kim, S. Kagami, A. Hamaguchi, K. Tsuchiya, H. Houchi, H. Iwao, H. Kido, and T. Tamaki, Br. J. Pharmacol., 125, 1019 (1998). (Pharmacol.)


Endothelin-2 (Human)* (Canine)

Cys-Ser-Cys-Ser-Ser-Trp-Leu-Asp-Lys-Glu-Cys- Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 2546.9) C115H160N26O32S4 [123562-20-9]

PED-4209-s-20 °C

0.1 mgvial

A. Inoue, M. Yanagisawa, S. Kimura, Y. Kasuya, T. Miyauchi, K. Goto, and T. Masaki, Proc. Natl. Acad. Sci. U.S.A., 86, 2863 (1989). (Original; Human Nucleotide Seq.) Y. Itoh, C. Kimura, H. Odna, and H. Fujino, Nucleic Acids Res., 17, 5386 (1989). (Original; Canine cDNA) • This compound is distributed through Peptide Institute, Inc., under the license of Takeda Chemical Industries, Ltd. and the National Institute of Advanced Industrial Science and Technology (AIST).

Endothelin-3 (Human)* (Porcine, Rat, Rabbit, Mouse)

PED-4199-s-20 °C

0.1 mgvial

Cys-Thr-Cys-Phe-Thr-Tyr-Lys-Asp-Lys-Glu-Cys- Val-Tyr-Tyr-Cys-His-Leu-Asp-Ile-Ile-Trp (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 2643.0) C121H168N26O33S4 [117399-93-6]


Endothelin-3 (Human)* (Porcine, Rat, Rabbit, Mouse)

PED-4199-v-20 °C

0.5 mgvial

M. Yanagisawa, A. Inoue, T. Ishikawa, Y. Kasuya, S. Kimura, S. Kumagaye, K. Nakajima, T.X. Watanabe, S. Sakakibara, K. Goto, and T. Masaki, Proc. Natl. Acad. Sci., U.S.A., 85, 6964 (1988). (Original) A. Inoue, M. Yanagisawa, S. Kimura, Y. Kasuya, T. Miyauchi, K. Goto, and T. Masaki, Proc. Natl. Acad. Sci. U.S.A., 86, 2863 (1989). (Naming) K. Nakajima, S. Kumagaye, H. Nishio, H. Kuroda, T.X. Watanabe, Y. Kobayashi, H. Tamaoki, T. Kimura, and S. Sakakibara, J. Cardiovasc. Pharmacol., 13, (Suppl. 5), S8 (1989). (Chem. Synthesis and S-S Bond) K. Saida, N. Kometani, Y. Hirano, S. Oka, N. Tomizuka, and Y. Mitsui, Peptide Chemistry 1996, 133 (1997). (cDNA Seq.; Mouse)• This compound is distributed through Peptide Institute, Inc., under the license of Takeda Chemical Industries, Ltd. and the Agency of Industrial Science and Tech.


54 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Big-Endothelin-1 (Human, 1-38)*Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr- Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-Val-Asn-Thr-Pro-Glu- His-Val-Val-Pro-Tyr-Gly-Leu-Gly-Ser-Pro-Arg-Ser (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4282.9) C189H282N48O56S5 [120796-97-6]

PED-4208-s-20 °C

0.1 mgvial


Big Endothelin-1 (Human, 1-38)* Y. ltoh, M. Yanagisawa, S. Ohkubo, C. Kimura, T. Kosaka, A. Inoue, N. Ishida, Y. Mitsui, H. Onda, M. Fujino, and T. Masaki, FEBS Lett., 231, 440 (1988). (Original)T. Kashiwabara, Y. Inagaki, H. Ohta, A. Iwamatsu, M. Nomizu, A. Morita, and K. Nishikori, FEBS Lett., 247, 73 (1989). (Pharmacol.)

PED-4208-v-20 °C

0.5 mgvial


Big Endothelin-1 (Porcine, 1-39)*Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-Val-Asn-Thr-Pro-Glu-His-Ile- Val-Pro-Tyr-Gly-Leu-Gly-Ser-Pro-Ser-Arg-Ser (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4384.0) C193H289N49O58S5 [120796-99-8]

PED-4207-s-20 °C

0.1 mgvial

Y. Itoh, M. Yanagisawa, S. Ohkubo, C. Kimura, T. Kosaka, A. Inoue, N. Ishida, Y. Mitsui, H. Onda, M. Fujino, and T. Masaki, FEBS Letters, 231, 440 (1988). (Original) T. Kashiwabara, Y. Inagaki, H. Ohta, A. Iwamatsu, M. Nomizu, A. Morita, and K. Nishikori, FEBS Letters, 247, 73 (1989). (Pharmacol.) • This compound is distributed through Peptide Institute, Inc., under the license of Takeda Chemical Industries, Ltd.


Big Endothelin-1 (Porcine, 1-39)*M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, and T. Masaki, Nature, 332, 411 (1988).(Original)

PED-4207-v-20 °C

0.5 mgvial

T. Kashiwabara, Y. Inagaki, H. Ohta, A. Iwamatsu, M. Nomizu, A. Morita, and K. Nishikori, FEBS Letters, 247, 73 (1989). (Pharmacol.) • This compound is distributed through Peptide Institute, Inc., under the license of Takeda Chemical Industries, Ltd.


Big Endothelin-1 (Rat, 1-39)*Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-Val-Asn-Thr-Pro-Glu-Arg- Val-Val-Pro-Tyr-Gly-Leu-Gly-Ser-Pro-Ser-Arg-Ser (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4389.0) C192H292N50O58S5

PED-4266-s-20 °C

0.1 mgvial

T. Sakurai, M. Yanagisawa, A. Inoue, U.S. Ryan, S. Kimura, Y. Mitsui, K. Goto, and T. Masaki, Biochem. Biophys. Res. Commun., 175, 44 (1991). (Original; cDNA) • This compound is distributed through Peptide Institute, Inc., under the license of Takeda Chemical Industries, Ltd.



NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 55

Big-Endothelin-2 (Human, 1-37)*Cys-Ser-Cys-Ser-Ser-Trp-Leu-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-Val-Asn-Thr-Pro-Glu-Gln- Thr-Ala-Pro-Tyr-Gly-Leu-Gly-Asn-Pro-Pro (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4183.7) C188H269N45O56S4 [132699-72-0]

PED-4222-s-20 °C

0.1 mgvial

S. Ohkubo, K.Ogi, M. Hosoya, H. Matsumoto, N. Suzuki, C. Kimura, H. Onda, and M. Fujino, FEBS Lett., 274, 136 (1990). (Original; cDNA) • This compound is distributed through Peptide Institute, Inc., under the license of Takeda Chemical Industries, Ltd.


Big-Endothelin-2 (Human, 1-38)*Cys-Ser-Cys-Ser-Ser-Trp-Leu-Asp-Lys-Glu-Cys-Val-Tyr- Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-Val-Asn-Thr-Pro-Glu- Gln-Thr-Ala-Pro-Tyr-Gly-Leu-Gly-Asn-Pro-Pro-Arg (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4339.9) C194H281N49O57S4

PED-4253-s-20 °C

0.1 mg vial

T. Kosaka, N. Suzuki, Y. Ishibashi, H. Matsumato, Y. Itoh, S. Ohkubo, K. Ogi, C. Kitada, H. Onda, and M. Fujino, J. Biochem., 116, 443 (1994). (Biosynthesis.) S. Ohkubo, K. Ogi, M. Hosoya, H. Matsumoto, N. Suzuki, C. Kimura, H. Onda, and M. Fujino, FEBS Lett., 274, 136 (1990). (Original; cDNA) • This compound is distributed through Peptide Institute Inc., under the license of Takeda Chemical Industries, Ltd.

Big-Endothelin-3 (Human, 1-41 Amide)*Cys-Thr-Cys-Phe-Thr-Tyr-Lys-Asp-Lys-Glu-Cys-Val-Tyr-Tyr-Cys-His-Leu-Asp-Ile-Ile-Trp-Ile-Asn-Thr-Pro-Glu-Gln-Thr-Val-Pro-Tyr-Gly-Leu-Ser-Asn-Tyr-Arg-Gly-Ser-Phe-Arg-NH2 (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4923.5) C223H322N56O63S4

PED-4223-s-20 °C

0.1 mg vial

K.D. Bloch, R.L. Eddy, T.B. Shows, and T. Quertermous, J. Biol. Chem., 264, 18156 (1989). (Original; cDNA) T. Kosaka, N. Suzuki, Y. Ishibashi, H. Matsumato, Y. Itoh, S. Ohkubo, K. Ogi, C. Kitada, H. Onda, and M. Fujino, J. Biochem., 116, 443 (1994). (Original; Biosynthesis.) • This compound is distributed through Peptide Institute Inc., under the license of Takeda Chemical Industries, Ltd.


Big Endothelin-3 (Rat, 1-41 Amide)*Cys-Thr-Cys-Phe-Thr-Tyr-Lys-Asp-Lys-Glu-Cys-Val-Tyr-Tyr-Cys-His-Leu-Asp-Ile-Ile-Trp-Ile-Asn-Thr-Pro-Glu-Gln-Thr-Val-Pro-Tyr-Gly-Leu-Ser-Asn-His-Arg-Gly-Ser-Leu-Arg-NH2 (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4863.5) C217H322N58O62S4

PED-4267-s-20 °C

0.1 mg vial

R. Shiba, T. Sakural, G. Yamada, H. Morimoto, A. Salto, T. Masaki, and K. Goto, Biochem. Biophys. Res. Commun., 186, 588 (1992). (Original; cDNA) • This compound is distributed through Peptide Institute, Inc., under the license of Takeda Chemical Industries, Ltd.


56 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Suc-[Glu9, Ala11,15]-Endothelin-1 (8-21)* IRL 1620

Suc-Asp-Glu-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp (Suc: Succinyl) (M.W. 1820.9) C86H117N17O27 [142569-99-1] ETb Receptor Selective Agonist

PED-4285-v-20 °C

0.5 mg vial

M. Takai, I. Umemura, K. Yamasaki, T.Watakabe, Y. Fujitani, K. Oda, Y. Urade, T. Inui, T. Yamamura, and T. Okada, Biochem. Biophys. Res. Commun., 184, 953 (1992). (Original) S.S. Shetty, T. Okada, R.L. Webb, D. DelGrande, and R.W. Lappe, Biochem. Biophys. Res. Commun., 191, 459 (1993). (Pharmacol.) W.G. Haynes, A.P. Davenport, and D.J. Webb, Trends Pharmacol. Sci., 14, 225 (1993). (Report; 3rd Int. Conf. Endothelin) A.F. James, Y. Urade, R.L. Webb, H. Karaki, I. Umemura, Y. Fujitani, K. Oda, T. Okada, R.W. Lappe, and M. Takai, Cardiovasc. Drug Rev., 11, 253 (1993). (Review) • This product is distributed under the technical and scientific advices of International Research Laboratories of Novartis Pharma K.K.


VIC (Mouse)* Vasoactive Intestinal Contractor (Mouse)

Cys-Ser-Cys-Asn-Ser-Trp-Leu-Asp-Lys-Glu-Cys- Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 2573.9) C116H161N27O32S4

PED-4211-s-20 °C

0.1 mgvial

N. Ishida, K. Tsujioka, M. Tomoi K. Saida, and Y. Mitsui, FEBS Lett., 247, 337 (1989). (Original) K. Saida, Y. Mitsui, and N. Ishida, J. Biol. Chem., 264, 14613 (1989). (Original; Nucleotide Seq.) • This compound is distributed through Peptide Institute, Inc., under the license of Takeda Chemical Industries, Ltd. and the Agency of Industrial Science and Tech.


Endothelin Inhibitors Also see the Enzyme Inhibitors and Substrates section.

BQ-123 (Sodium Salt) cyclo (d-Trp-d-Asp-Pro-d-Val-Leu) Endothelin Antagonist (M.W. 610.72) C31H42N6O7

PED-3512-PI-20 °C

1 mg5 mg

BQ-610 (Sodium Salt) Homopiperdinyl-CO-Leu-d-Trp(CHO)-d-Trp-OH (M.W. 656.79) C36H44N6O6 ETA-Selective Antagonist

PED-3610-PI-20 °C

1 mg5 mg

BQ-788 (Sodium Salt) N-cis-2,6-Dimethylpiperidinocarbonyl-l-γ-Me-Leu-d-Trp(COOCH3)-d-Nle (M.W. 663.80) C34H50N5O7Na ETB-Selective Antagonist

PED-3788-PI-20 °C

1 mg5 mg

EnkephalinsLeucine-Enkephalin(Human, Porcine, Bovine, Rat, Mouse)

Tyr-Gly-Gly-Phe-Leu (M.W. 555.62) C28H37N5O7 [58822-25-6]

PEK-4043-v-20 °C

0.5 mg vial


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 57

Leucine-Enkephalin (Bulk) (Human, Porcine, Bovine, Rat, Mouse)

Tyr-Gly-Gly-Phe-Leu • H2O (M.W. 555.62 • 18.02) C28H37N5O7 • H2O [58822-25-6]

PEK-4043-20 °C

25 mg100 mg

J. Hughes, T.W. Smith, H.W. Kosterlitz, L.A. Fothergill, B.A. Morgan, and H.R. Morris, Nature, 258, 577 (1975). (Original; Porcine) M. Comb, P.H. Seeburg, J. Adelman, L. Eiden, and E. Herbert, Nature, 295, 663 (1982). (cDNA Seq.; Human) M. Noda, Y. Furutani, H. Takahashi, M. Toyosato, T. Hirose, S. Inayama, S. Nakanishi, and S. Numa, Nature, 295, 202 (1982). (cDNA Seq.; Bovine) K. Yoshikawa, C. Williams, and S.L. Sabol, J. Biol. Chem., 259, 14301 (1984). (cDNA Seq.; Rat)

Leucine-Enkephalin (Sulfated Form)Tyr(SO3H)-Gly-Gly-Phe-Leu (M.W. 635.69) C28H37N5O10S [80632-52-6]C.D. Unsworth and J. Hughes, Nature, 295, 519 (1982). (Original)

PEK-4118-v-20 °C

0.5 mgvial

Methionine-Enkephalin (Human, Porcine, Bovine, Rat, Mouse)

Tyr-Gly-Gly-Phe-Met (M.W. 573.66) C27H35N5O7S [58569-55-4]

PEK-4042-v-20 °C

0.5 mgvial

Methionine-Enkephalin (Bulk) (Human, Porcine, Bovine, Rat, Mouse)

Tyr-Gly-Gly-Phe-Met • H2O (M.W. 573.66 • 18.02) C27H35N5O7S • H2O [58569-55-4]

PEK-4042-20 °C

25 mg100 mg

J. Hughes, T.W. Smith, H.W. Kosterlitz, L.A. Fothergill, B.A. Morgan, and H.R. Morris, Nature, 258, 577 (1975). (Original; Porcine) M. Comb, P.H. Seeburg, J. Adelman, L. Eiden, and E. Herbert, Nature, 295, 663 (1982). (cDNA Seq.; Human) M. Noda, Y. Furutani, H. Takahashi, M. Toyosato, T. Hirose, S. Inayama, S. Nakanishi, and S. Numa, Nature, 295, 202 (1982). (cDNA Seq.; Bovine) K. Yoshikawa, C. Williams, and S.L. Sabol, J. Biol. Chem., 259, 14301 (1984). (cDNA Seq.; Rat)

[d-Ala2, d-Leu5]-EnkephalinTyr-d-Ala-Gly-Phe-d-Leu (M.W. 569.65) C29H39N5O7 [63631-40-3]

PEK-4115-v-20 °C

0.5 mgvial

[d-Ala2, d-Leu5]-Enkephalin (Bulk)Tyr-d-Ala-Gly-Phe-d-Leu • AcOH • H2O (M.W. 569.65 • 60.05 • 18.02) C29H39N5O7 • CH3COOH • H2O [94825-57-7]

PEK-4115-20 °C

25 mg100 mg

E.T. Wei, L.F. Tseng, H.H. Loh, and C.H. Li, Life Sci., 21, 321 (1977). (Original)

[d-Ala2, Met5]-EnkephalinTyr-d-Ala-Gly-Phe-Met (M.W. 587.69 ) C28H37N5O7S [61370-87-4]

PEK-4116-v-20 °C

0.5 mgvial

[d-Ala2, Met5]-Enkephalin (Bulk) Tyr-d-Ala-Gly-Phe-Met • AcOH • H2O (M.W. 587.69 • 60.05 • 18.02 ) C28H37N5O7S • CH3COOH • H2O [100929-62-6]

PEK-4116-20 °C

25 mg

D.H. Coy, A.J. Kastin, A.V. Schally, O. Morin, N.G. Caron, F. Labrie, J.M. Walker, R. Fertel, G.G. Berntson, and C.A. Sandman, Biochem. Biophys. Res. Commun., 73, 632 (1976). (Original; Chem. Synthesis)

58 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES [d-Ala2, Met5]-EnkephalinamideTyr-d-Ala-Gly-Phe-Met-NH2 (M.W. 586.70) C28H38N6O6S [61090-95-7]

PEK-4117-v-20 °C

0.5 mgvial

D.H. Coy, A.J. Kastin, A.V. Schally, O. Morin, N.G. Caron, F. Labrie, J.M. Walker, R. Fertel, G.G. Berntson, and C.A. Sandman, Biochem. Biophys. Res. Commun., 73, 632 (1976). (Original; Chem. Synthesis) C.B. Pert, A. Pert, J.-K. Chang, and B.T.W. Fong, Science, 194, 330 (1976). (Original)

Epitope Tag Peptide (Flag Peptide)H-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-OHDYKDDDDK

(M.W. 1012.99) C41H66N10O20Epitope Tag Peptide

PTG-3976-PI -20 °C

5 mg

Coussen, F. et al. J. Biol. Chem. 276, 27881 (2001). Zhao, M. et al. Mol. Cell. Biol. 23, 8982 (2003).Da Cruz, S. et al. J. Biol. Chem. 278, 4156 (2003). Carrillo, J. et al. J. Biol. Chem. 278, 42578 (2003). Hiromura, M. et al. J. Biol. Chem. 279, 53407 (2004).

ExendinExendin (5-39) (Lizard, Heloderma horridum)

Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu- Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly- Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (M.W. 3806.2) C169H262N44O54S GLP-1 Receptor Antagonist

PEX-4345-v-20 °C

0.5 mgvial

C. Montrose-Rafizadeh, H. Yang, B.D. Rodgers, A. Beday, L.A. Pritchette, and J. Eng, J. Biol. Chem., 272, 21201 (1997). (Original; Potent Antagonist)J.-I. Oka, E. Suzuki, and Y. Kondo, Brain Res., 878, 194 (2000). (Pharmacol.)

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 59

Experimental Autoimmune Encephalomyelitis ProductsExperimental autoimmune encephalomyelitis (EAE) has been used as a model for studying multiple sclerosis (MS) due to the clinical and histopathological similarities of the inflammatory diseases affecting the central nervous system. Both Myelin PLP (PLP-3602-PI) and MOG (PMG-3660-PI) are antigenic peptides that induce EAE by binding to MHC-II molecules on antigen presenting cells where they are recognized by class-II restricted T cells.PI expands its line of antigenic peptides to now include: MOG (40-54) (PMG-3962-PI) and vesicular stomatitis virus octopeptide (52-59) or VS-8 (PVS-3961-PI).1 This antigen binds to Kb MHC-1 where the antigen is presented to T cells. It has been used in the past to study vacuolar processing of exogenous Ag and the role of TAP (transporter associated with antigen processing) during this event.2 An understanding of events accompanying the processing and presentation of viral Ags can help assist in vaccine design and in the study of inflammatory-related diseases.Bulk quantities and other EAE peptides are available, please inquire.

1. G.M. van Bleek and S.G. Nathenson, Nature (Lond.), 348, 213 (1990).2. P.J. Chefalo and C.V. Harding, J. Immunol., 167, 1274 (2001).

Acetyl-Myelin Basic Protein (Mouse, 1-11)Ac-MBP (1-11)

Ac-Ala-Ser-Gln-Lys-Arg-Pro-Ser-Gln-Arg-Ser-Lys-OH (M.W. 1314.48) C53H95N21O18 Encephalitogenic Determinant

PMB-3657-PI-20 °C

1 mg5 mg

S.D. Wolf, B.N. Dittel, F. Hardardottir, and C.A. Janeway, J. Exp. Med., 184, 2271 (1996).

Acetyl-Myelin Basic Protein (Human, Rat, 1-11)Ac-MBP (Human, Porcine, Rat 1-11)

Ac-Ala-Ser-Gln-Lys-Arg-Pro-Ser-Gln-Arg-His-Gly-OH (M.W. 1293.42) C52H88N22O17 Encephalitogenic Determinant

PMB-3658-PI-20 °C

1 mg5 mg

J.E. Fenyk-Melody, A.E. Garrison, S.R. Brunnert, J.R. Weidner, F. Shen, B.A. Shelton, and J.S. Mudgett, J. Immunol., 160, 2940 (1998).

Myelin Basic Protein (1-20)MBP (1-20)ASQKRPSQRSKYLATASTMD

PMB-3972-PI-20 °C

1 mg5 mg

H-Ala-Ser-Gln-Lys-Arg-Pro-Ser-Gln-Arg-Ser-Lys-Tyr-Leu-Ala-Thr-Ala-Ser-Thr-Met-Asp-OH(M.W. 2226.51) C92H156N30O32SImmunogenic Peptide

Myelin Basic Protein (87-99)MBP (87-99)

VHFFKNIVTPRTPH-Val-His-Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro-OH(M.W. 1555.86) C74H114N20O17Encephalitogenic Determinant

PMB-3973-PI-20 °C

1 mg5 mg

NEW!

NEW!

60 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Myelin Basic Protein (111-129)MBP (111-129)

LSRFSWGAEGQRPGFGYGGH-Leu-Ser-Arg-Phe-Ser-Trp-Gly-Ala-Glu-Gly- Gln-Arg-Pro-Gly-Phe-Gly-Tyr-Gly-Gly-OH(M.W. 2029.22) C92H129N27O26Encephalitogenic Determinant

PMB-3974-PI-20 °C

1 mg5 mg

MOG (40-54)Myelin Oligodendrocyte Protein (40-54)

YRSPFSRVVHLYRNGH-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His- Leu-Tyr-Arg-Asn-Gly-OH(M.W. 1851.12) C84H127N27O21

D. Sun, et al., Int. Immunol., 15, 261 (2003)

PMG-3962-PI-20 °C

1 mg5 mg

MOG (92-106)Myelin Oligodendrocyte Protein (92-106)

DEGGYTCFFRDHSYQ

PMG-3968-PI-20 °C

1 mg5 mg

H-Asp-Glu-Gly-Gly-Tyr-Thr-Cys-Phe-Phe-Arg-Asp-His-Ser-Tyr-Gln-OH(M.W. 1823.91) C80H104N21O27S Encephalitogenic Determinant

MOG (Rat, Mouse, 35-55)Myelin Oligodendrocyte Protein (35-55)

PMG-3660-PI-20 °C

1 mg5 mg

H-Met-Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys-OH (M.W. 2582.01) C118H177N35O29S Encephalitogenic DeterminantM Ichikawa, T.G. Johns, J. Liu, and C.C. Bernard, J. Immunol. 157, 919-926 (1996). H.-C. von Büdingen, N. Tanuma, P. Villoslada, J.-C. Ouallet, S.L. Hauser, and C.P. Genain, J. Clin. Immunol., 21, 155 (2001).

Myelin PLP (57–70)Myelin Proteolipid Protein (57-70)

YEYLINVIHAFQYVH-Tyr-Glu-Tyr-Leu-Ile-Asn-Val-Ile-His-Ala-Phe-Gln-Tyr-Val-OH(M.W. 1772.05) C87H122N18O22Encephalitogenic Determinant

PLP-3970-PI-20 °C

1 mg5 mg

Myelin PLP (139-151)Myelin Proteolipid Protein (139-151)

H-His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe-OH (M.W. 1521.76) C72H104N20O17 Encephalitogenic DeterminantV.K. Kuchroo, J.M. Greer, D. Kaul, G. Ishioka, A. Franco, A. Sette, R.A. Sobel, and M.A. Lees, J. Immunol., 153, 3326 (1994).

PLP-3602-PI-20 °C

1 mg5 mg


NTWTTCQSIAFPSKH-Asn-Thr-Trp-Thr-Thr-Cys-Gln- Ser-Ile-Ala-Phe-Pro-Ser-Lys-OH(M.W. 1583.80) C70H106N18O22SEncephalitogenic Determinant

PLP-3967-PI-20 °C

1 mg5 mg

NEW!

NEW!

NEW!

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 61


WTTCQSIAFPSKTSASIGSL

PLP-3966-PI-20 °C

1 mg5 mg

H-Trp-Thr-Thr-Cys-Gln-Ser-Ile-Ala-Phe-Pro-Ser-Lys-Thr-Ser-Ala-Ser-Ile-Gly-Ser-Leu-OH(M.W. 2805.38) C92H145N23O30SEncephalitogenic Determinant

H-Arg-Gly-Tyr-Val-Tyr-Gln-Gly-Leu-OHRGYVYQGL

(M.W. 955.09) C44H66N12O12 Vesicular Stomatitis Virus (VSV)Nucleoprotein (52 - 59), VSV - 8

PVS-3961-PI-20 °C

1 mg5 mg

VP2 (70-86)Viral Protein 2 (70-86)

WTTSQEAFSHIRIPLPH

PVP-3971-PI-20 °C

1 mg5 mg

H-Trp-Thr-Thr-Ser-Gln-Glu-Ala-Phe-Ser-His-Ile-Arg-Ile-Pro-Leu-Pro-His-OH(M.W. 2020.30) C93H138N26O25Encephalitogenic DeterminantRichard K. Burt, Josette Padilla, Mauro C. Dal Canto, and Stephen D. Miller, Blood, 94, 2915 (1999).

FMRF-Amide See Code PFM-4142 Molluscan Cardioexitatory Neuropeptide on page 85.Fibronectin Active Fragment See Code PFA-4171 Arg-Gly-Asp-Ser on page 26 and Code PFA-4189 Gly-Arg-Gly-Asp-Ser on page 25.

Fibrinopeptide B[Glu1]-Fibrinopeptide B Glu-fibrinopeptide B

PFB-3742-PI-20 °C

1 mg5 mg

H-Glu-Gly-Val-Asn-Asp-Asn-Glu-Glu-Gly-Phe-Phe-Ser-Ala-Arg-OH (Trifluoroacetate Form) (M.W. 1570.60) C66H95N19O26 [103213-49-6]Mass Spec Standard for Proteomic ResearchC. Fu, C. Wu, T. Liu, T. Ago, P. Zhai, J. Sadoshima, H. Li, Mol. Cell. Proteomics, 8, 1674, (2009). J.B. Young and L Li, Anal Chem, 79, 5927 (2007). G.M. Janini, M. Zhou, L-R. Yu, J. Blonder, M. Gignac, T.P. Conrads, H.J. Issaq, and T.D. Veenstr, Anal Chem, 75, 1615 (2003).

NEW!

NEW!

NEW!

NEW!

62 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Galanins and Related PeptidesJ.N. Crawley and G.L. Wenk, Trends Neurosci., 12, 278 (1989). (Review) T. Bartfai, G. Fisone, and Ü. Langel, Trends Pharmacol. Sci., 13, 312 (1992). (Review)R. Lang, A.L. Gundlach, and B. Kofler, Pharmacol. Ther., 115, 177 (2007). (Review)I. Mechenthaler, Cell. Mol. Life Sci., 65, 1826 (2008). (Review)

Galanin [PGA-4245-v (human) and PGA-4244-v (rat)] is one of the brain-gut peptides having various biological activities including feeding regulation. This peptide is known to be a food intake stimulator which interacts with both of the galanin receptor sub-types 1 and 2 (GalR1 and GalR2, respectively) in a relatively non-selective manner. GalR1 is primarily expressed in the central nervous system (CNS), whereas GalR2 is expressed in both peripheral tissue and the CNS. In 1999, scientists at Takeda Pharmaceutical Company Limited discovered the GalR2-selective ligand in porcine hypothalamus. At the same time, they proposed the primary structures of the rat and human orthologues from the corresponding cDNA sequences.1 This newly identified peptide, known as galanin-like peptide (GALP), is composed of 60 amino acid resi-dues. GALP (9-21) is identical to galanin (1-13) and the sequence homology among the species is high. When 125I-labeled rat galanin is used as a ligand, porcine GALP interacts with GalR2 with an IC50 value of 0.24 nM, while the corresponding value for GalR1 is 4.3 nM, clearly indicating the receptor selectivity of GALP. Since then, additional data concerning the role of rat GALP in feeding have been reported dealing with: i) stimulation of food intake in rats2,3, ii) control of its expression by leptin4), and iii) crossing the blood brain barrier.5 Recently review articles concerning the function of GALP in relation to galanin and the galanin receptor have also been published.6-8

1. T. Ohtaki, S. Kumano, Y. Ishibashi, K. Ogi, H. Matsui, M. Harada, C. Kitada, T. Kurokawa, H. Onda, and M. Fujino, J. Biol. Chem., 274, 37041 (1999). (Original) 2. Y. Matsumoto, T. Watanabe, Y. Adachi, T. Itoh, T. Ohtaki, H. Onda, T. Kurokawa, O. Nishimura, and M. Fujino, Neurosci. Lett., 322, 67 (2002). (Stimulation of Food Intake) 3. H.-M. Tan, A.L. Gundlach, and M.J. Morris, Neuropeptides, 39, 333 (2005). (Pharmacol.; Exaggerated Feeding Response)4. A. Juréus, M.J. Cunningham, M.E. Mcclain, D.K. Clifton, and R.A. Steiner, Endocrinology, 141, 2703 (2000). (Pharmacol.) 5. A.J. Kastin, V. Akerstrom, and L. Hackler, Neuroendocrinology, 74, 423 (2001). (Brain Entry) 6. A.L. Gundlach, Eur. J. Pharmacol., 440, 255 (2002). (Review)7. P.S. Man and C.B. Lawrence, Neuropharmacology, 55, (2008). (Review)8. C.B. Lawrence, Physiol. Behav., 97, 515 (2009). (Review) • This compound is distributed through Peptide Institute, Inc. under the license of Takeda Chemical Industries, Ltd

Galanin (Human)*Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly- Pro-His-Ala-Val-Gly-Asn-His-Arg-Ser-Phe-Ser- Asp-Lys-Asn-Gly-Leu-Thr-Ser (M.W. 3157.4) C139H210N42O43 [119418-04-1]

PGA-4245-v-20 °C

0.5 mgvial

M. Bersani, A.H. Johnsen, P. Højrup, B.E. Dunning, J.J. Andreasen, and J.J. Holst, FEBS Lett., 283, 189 (1991). (Original)



NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 63

Galanin (Rat)*(Mouse)

Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Ile-Asp-Asn-His-Arg-Ser-Phe-Ser-Asp-Lys-His-Gly-Leu-Thr-NH2 (M.W. 3164.4) C141H211N43O41 [114547-31-8]

PGA-4244-v-20 °C

0.5 mg vial

M.E. Vrontakis, L.M. Peden, M.L. Duckworth, and H.G. Friesen, J. Biol. Chem., 262, 16755 (1987). (Original; cDNA-Pituitary Tumor) L.M. Kaplan, E.R. Spindel, K.J. Isselbacher, and W.W. Chin, Proc. Natl. Acad. Sci. USA, 85, 1065 (1988). (Original; cDNA-Hypothalamus)J. Lundkvist, T. Land, U. Kahl, K. Bedecs, and T. Bartfai, Neurosci. Lett., 200, 121 (1995). (Original; Mouse Hypothalamic cDNA)


Galanin-like Peptide (Human, 1-60)GALP (Human, 1-60)

PGL-4391-s-20 °C

0.1 mg vial

Ala-Pro-Ala-His-Arg-Gly-Arg-Gly-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly- Tyr-Leu-Leu-Gly-Pro-Val-Leu-His-Leu-Pro-Gln-Met-Gly-Asp-Gln- Asp-Gly-Lys-Arg-Glu-Thr-Ala-Leu-Glu-Ile-Leu-Asp-Leu-Trp-Lys- Ala-Ile-Asp-Gly-Leu-Pro-Tyr-Ser-His-Pro-Pro-Gln-Pro-Ser (M.W. 6500.3) C292H451N83O84S Ligand for Galanin Receptor 2 / Target Peptide for Feeding Regulation by Leptin

Gastrins and Related PeptidesJ.E. Jorpes and V. Mutt (eds.) Secretin, Cholecystokinin, Pancreozymin and Gastrin, Handbook of Experimental Pharmacology, Vol. 34, Springer-Verlag, Berlin, 1973. (Review)

Big Gastrin (Human)(Ammonium Form) Pyr-Leu-Gly-Pro-Gln-Gly-Pro-Pro-His-Leu-Val-Ala-Asp- Pro-Ser-Lys-Lys-Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu- Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 (M.W. 3849.2) C176H251N43O53S [60675-77-6]

PGR-4183-s-20 °C

0.1 mgvial

A.M. Choudhury, G.W. Kenner, S. Moore, K.L. Ramachandran, W.D. Thorpe, R. Ramage, G.J. Dockray, R.A. Gregory, L. Hood, and M. Hunkapillar, Hoppe-Seyler’s Z. Physiol. Chem., 361, 1719 (1980). (Original; Chem. Synthesis)

Gastrin I (Human)(Ammonium Form) Pyr-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu- Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 (M.W. 2098.2) C97H124N20O31S [10047-33-3]

PGR-4143-v-20 °C

0.5 mgvial

H. Gregory, P.M. Hardy, D.S. Jones, G.W. Kenner, and R.C. Sheppard, Nature, 204, 931 (1964). (Original) J.C. Anderson, M.A. Barton, R.A. Gregory, P.M. Hardy, G.W. Kenner, J.K. MacLeod, J. Preston, R.C. Sheppard, and J.S. Morley, Nature, 204, 933 (1964). (Chem. Synthesis)

Gastrin Related Peptide (Bulk)Aoc-Trp-Met-Asp-Phe-NH2 (Aoc: t-Amyloxycarbonyl) (M.W. 710.84) C35H46N6O8S

PGR-4004-20 °C

25 mg100 mg

Y. Ishii and H. Shinozaki, Japan J. Pharmacol., 18, 93 (1968). (Pharmacol.)


64 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES GIP (Human) Gastric Inhibitory Polypeptide (Human) Glucose-dependent Insulinotropia Polypeptide (Human)

PGR-4178-s-20 °C

0.1 mgvial

Tyr-Ala-Glu-Gly-Thr-Phe-lle-Ser-Asp-Tyr-Ser-lle-Ala-Met-Asp-Lys-lle-His-Gln-Gln-Asp-Phe- Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-lle-Thr-Gln (M.W. 4983.5) C226H338N60O66S [100040-31-1]

GIP (Human) Gastric Inhibitory Polypeptide (Human) Glucose-dependent Insulinotropia Polypeptide (Human)

PGR-4178-v-20 °C

0.5 mgvial

A.J. Moody, L. Thim, and I. Valverde, FEBS Lett.,172, 142 (1984). (Original) N. Fujii, M. Sakurai, K. Akaji, M. Nomizu, H. Yajima, K. Mizuta, M. Aono, M. Moriga, K. Inoue, R. Hosotani, and T. Tobe, Chem. Pharm. Bull., 34, 2397 (1986). (Glucose-dependent Insulinotropic Polypeptide)

GRP (Human) Gastrin Releasing Peptide (Human)

Val-Pro-Leu-Pro-Ala-Gly-Gly-Gly-Thr-Val-Leu-Thr-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 (M.W. 2859.4) C130H204N38O31S2 [93755-85-2]

PGR-4164-v-20 °C

0.5 mgvial

E.R. Spindel, W.W. Chin, J. Price, L.H. Rees, G.M. Besser, and J.F. Habener, Proc. Natl. Acad. Sci. USA, 81, 5699 (1984). (Original; cDNA)

GIF See Code PSI-4023 Somatostatin on page 116 and 117.

Ghrelin and Related Peptides Ghrelin was discovered in 1999 as the endogenous ligand of growth-hormone secretagogue receptor1: i) ghrelin is a 28 residue peptide with an n-octanoyl group on Ser3 and ii) the major ghrelin producing organ is the stomach. Since then, many researches have been carried out using synthetic ghrelin, clarifying that ghrelin is a multifunctional peptide. These functions include i) regulation of appetite, ii) cardiovascular functions, and more.3-12

1. M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa, Nature, 402, 656 (1999). (Original)2. P.L. Jeffery, R.P. Duncan, A.H. Yeh, R.A. Jaskolski, D.S. Hammond, A.C. Herington, and L.K. Chopin, Endocrinology, 146, 432 (2005). (Mouse RNA Seq.)3. C. Dieguez and F.F. Casanueva, Eur. J. Endocrinol., 142, 413 (2000). (Review)4. G.Muccioli,M. Tschöp,M. Papotti, R. Deghenghi,M. Heiman, and E. Ghigo, Eur. J. Pharmacol., 440, 235 (2002). (Review)5. G. Wang, H.-M. Lee, E. Englander, and G.H. Greeley, Jr., Regul. Pept., 105, 75 (2002). (Review)

Ghrelin (Human) (Trifluoro3618 Form)

PGH-4372-s-20 °C

0.1 mgvial

Gly-Ser-Ser(n-Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln- Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg (M.W. 3370.9) C149H249N47O42 [258279-04-8] Appetite Stimulating Peptide with Energy Homeostasis Regulation• This compound is distributed through Peptide Institute under license agreement with Dr. Kangawa.


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 65

Ghrelin (Rat)(Mouse)


PGH-4373-s-20 °C

0.1 mgvial

Gly-Ser-Ser(n-Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln- Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg (M.W. 3314.8) C147H245N45O42 [258338-12-4]Appetite Stimulating Peptide with Energy Homeostasis RegulationM. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa, Nature, 402, 656 (1999). (Original) C. Dieguez and F.F. Casanueva, Eur. J. Endocrinol., 142, 413 (2000). (Review) G. Muccioli, M. Tschöp, M. Papotti, R. Deghenghi, M. Heiman, and E. Ghigo, Eur. J. Pharmacol., 440, 235 (2002). (Review) G. Wang, H.-M. Lee, E. Englander, and G.H. Greeley, Jr., Regul. Pept., 105, 75 (2002). (Review) • This compound is distributed through Peptide Institute under license agreement with Dr. Kangawa.

Des-Acyl Ghrelin (Human)Des-n-Octanoyl Ghrelin (Human)

(Trifluoroacetate Form) Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg(M.W. 3244.7) C141H235N47O41Des-Octanoylated Ghrelin with Distinct Effect on Food Intake

PGH-4436-s-20 °C

0.1 mgvial

Des-Acyl Ghrelin (Rat)Des-n-Octanoyl Ghrelin (Rat)

(Trifluoroacetate Form) Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg(M.W. 3188.6) C139H231N45O41Des-Octanoylated Ghrelin with Distinct Effect on Food Intake

PGH-4437-s-20 °C

0.1 mgvial

Des-n-Octanoyl-[Ser3]-Ghrelin (Human)Non-Acylated Ghrelin (Human)

H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH (M.W. 3244.74) C141H235N47O41Counteracts Metabolic Effects of Acylated Ghrelin

PGH-3653-PI-20 °C

0.5 mgvial

F. Broglio, et al., J. Clin. Endoc. and Metabolism, 89, 3062 (2004). C. Gauna, et al.,, J. Clin. Endoc. and Metabolism, 89, 5035 (2004). A. Asakawa, A. Inui, M. Fujimiya, R. Sakamaki, N. Shinfuku, Y. Ueta, M.M. Meguid, and M. Kasuga, Gut, 54, 18 (2005).

Des-n-Octanoyl-[Ser3]-Ghrelin (Rat)Non-Acylated Ghrelin (Rat)

PGH-3654-PI-20 °C

0.5 mgvial

H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg- Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH (M.W. 3188.67) C139H231N45O41Counteracts Metabolic Effects of Acylated GhrelinH Hosoda, M Kojima, H Matsuo, and K Kangawa, Biochem. Biophys. Res. Commun., 279, 909 (2000). F. Broglio, C. Gottero, F. Prodam, C. Gauna, G. Muccioli, M. Papotti, T. Abribat, A.J. Van der Lely, and E. Ghigo, J. Clin. Endoc. and Metabolism, 89, 3062 (2004). C. Gauna, F.M. Meyler, J.A.M.J.L. Janssen, R.J.D. Delhanty, T. Abribat, P. van Koetsveld, L.J. Hofland, F. Broglio, E.Ghigo, and A.J. van der Lely, J. Clin. Endoc. and Metabolism, 89, 5035 (2004). A. Asakawa, A. Inui, M. Fujimiya, R. Sakamaki, N. Shinfuku, Y. Ueta, M.M. Meguid, and M. Kasuga, Gut, 54, 18 (2005).

66 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES H-His-d-Trp-d-Lys-Trp-d-Phe-Lys-NH2[D-Lys3]-Growth Hormone Releasing Peptide-6 (GHRP-6)

(M.W. 930.13) C49H63N13O6 Ghrelin Antagonist

PGH-3656-PI-20 °C

1 mg5 mg

K. Fujino, A. Inui, A. Asakawa, N. Kihara, M. Fujimura, and M. Fujimiya, J. Physiol., 550, 227 (2003).

H-His-d-Trp-Ala-Trp-d-Phe-Lys-NH2[His1,Lys6]-Growth Hormone Releasing Peptide (GHRP-6)

(M.W. 873.04) C46H56N12O6

PGH-3694-PI-20 °C

1 mg5 mg

C.Y. Bowers, F.A. Monamy, G.A. Renolds, and A. Hong, Endocrinol., 114, 1537 (1984).

Ghrelin (Human, 1-18) H-Gly-Ser-Ser(n-Octanoyl)-Phe-Leu-Ser-Pro-Glu- His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-NH2(M.W. 2225.51) C96H157N31O30

PGH-3625-PI-20 °C

1 mg5 mg

M.A. Bednarek, S.D. Feighner, S.-S. Pong, K.K. McKee, D.L. Hreniuk, M.V. Silva, V.A. Warren, A.D. Howard, L.H.Y. Van der Ploeg, and J.V. Heck, J. Med. Chem., 43, 4370 (2000).

Ghrelin (Human, 1-14) H-Gly-Ser-Ser(n-Octanoyl)-Phe-Leu-Ser- Pro-Glu-His-Gln-Arg-Val-Gln-Gln-OH (M.W. 1725.94) C76H121N22O24

PGH-3626-PI-20 °C

1 mg5 mg


Ghrelin (Human, Rat, 1-10) H-Gly-Ser-Ser(n-Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-NH2(M.W. 1213.37) C55H84N14O17

PGH-3627-PI-20 °C

1 mg5 mg


Ghrelin (Human, Rat, 1-5) H-Gly-Ser-Ser(n-Octanoyl)-Phe-Leu-NH2(M.W. 634.78) C31H50N6O8

PGH-3628-PI-20 °C

1 mg5 mg


Des-n-Octanoyl-[Ser3]-Ghrelin (Human, 1-18) H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val- Gln-Gln-Arg-Lys-Glu-Ser-NH2(M.W. 2099.31) C88H143N31O29 Non-acylated Analog of Ghrelin (Human, 1-18)

PGH-3645-PI-20 °C

1 mg5 mg

Des-n-Octanoyl-[Ser3]-Ghrelin (Human, 1-14)H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His- Gln-Arg-Val-Gln-Gln-OH (M.W. 1599.74) C68H106N22O23 Non-acylated Analog of Ghrelin (Human, 1-14)

PGH-3646-PI-20 °C

1 mg5 mg

Des-n-Octanoyl-[Ser3]-Ghrelin (Human, Rat, 1-10)

H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-NH2 (M.W. 1087.17) C47H70N14O16 Non-acylated Analog of Ghrelin (Human, 1-10)

PGH-3647-PI-20 °C

1 mg5 mg


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 67

Des-n-Octanoyl-[Ser3]-Ghrelin (Human, Rat, 1-5)H-Gly-Ser-Ser-Phe-Leu-NH2 (M.W. 508.58) C23H36N6O7 Non-acylated Analog of Ghrelin (Human, 1-5)

PGH-3648-PI-20 °C

1 mg5 mg

[Dap3]-Ghrelin (Human, Rat, 1-5)H-Gly-Ser-Dap(n-Octanoyl)-Phe-Leu-NH2 Dap = 2,3-diaminopropionic acid (M.W. 633.79) C31H51N7O7

PGH-3681-PI-20 °C

1 mg5 mg

Growth-Hormone Releasing Peptide Ghrelin Analog Active FragmentM.A. Bednarek, S.D. Feighner, S.-S. Pong, K.K. McKee, D.L. Hreniuk, M.V. Silva, V.A. Warren, A.D. Howard, L.H.Y. Van der Ploeg, and J.V. Heck, J. Med. Chem., 43, 4370-4376 (2000).

[Dap3]-Ghrelin (Rat)

PGH-3680-PI-20 °C

0.5 mgvial

H-Gly-Ser-Dap(n-Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln- Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH Dap = 2, 3-diaminopropionic acid(M.W. 3313.88) C147H246N46O41Growth-Hormone Releasing Peptide / Ghrelin AnalogM.A. Bednarek, S.D. Feighner, S.-S. Pong, K.K. McKee, D.L. Hreniuk, M.V. Silva, V.A. Warren, A.D. Howard, L.H.Y. Van der Ploeg, and J.V. Heck, J. Med. Chem., 43, 4370 (2000).

[Trp3, Arg5]-Ghrelin (1-5)H-Gly-Ser-Trp-Phe-Arg-OH M.W. 651.73) C31H41N9O7

PGH-3902-PI-20 °C

1 mg5 mg

Growth-Hormone Secretogue (GHS) Receptor Agonist / Stimulates Food-IntakeK. Ohinata, K. Kobayashi, M. Yoshikawa, Peptides, 27, 1632 (2006).

GlucagonGlucagon (Human)

His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr (M.W. 3482.7) C153H225N43O49S [16941-32-5]

PGL-4098-s-20 °C

0.1 mgvial

P.J. Lefebvre and R.H. Unger (eds.), Glucagon, Pergamon Press, Oxford, 1972. (Review)

Glucagon-Like PeptidesE. Blázquez, E. Alvarez, M. Navarro, I. Roncero, F. Rodríguez-Fonseca, J.A. Chowen, and J.A. Zueco, Mol. Neurobiol., 18, 157 (1998). (Review) G. van Dijk and T.E. Thiele, Neuropeptides, 33, 406 (1999). (Review) D.J. Drucker, Gut, 50, 428 (2002). (Review)

Glucagon-like Peptide 1 (Human, 7-36 Amide) GLP-1 (Human, 7-36 Amide)(Bovine, Canine, Rat, Guinea pig)

PGL-4344-v-20 °C

0.5 mgvial

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly- Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2 (M.W. 3297.6) C149H226N40O45 [107444-51-9]M.D. Turton, D. O’Shea, I. Gunn, S.A. Beak, C.M.B. Edwards, K. Meeran, S.J. Choi, G.M. Taylor, M.M. Heath, P.D. Lambert, J.P.H. Wilding, D.M. Smith, M.A. Ghatei,J. Herbert, and S.R. Bloom, Nature, 379, 69 (1996). (Orginial-CNS Effect on Feeding) M. Tang-Christensen, P.J. Larsen, R. Göke, A. Fink-Jensen, D.S. Jessop, M. Møller, and S.P. Sheikh, Am. J. Physiol., 271, R848 (1996). (Original, CNS Effect on Drinking) G. van Dijk, T.E. Thiele, R.J. Seeley, S.C. Woods, and I.L. Bernstein, Nature, 385, 214 (1997). (Correspondence)

68 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Glucagon-like Peptide 1 (Human, 7-37) GLP-1 (Human, 7-37)(Bovine, Canine, Rat, Guinea pig)

PGP-4280-v-20 °C

0.5 mgvial

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly- Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly (M.W. 3355.7) C151H228N40O47 [106612-94-6]G.G. Holz IV, W.M. Kühtreiber, and J.F. Habener, Nature, 361, 362 (1993). (Original)G.S. Meneilly, C.H.S. McIntosh, R.A. Pederson, J.F. Habener, R. Gingerich, J.M. Egan, and D. Elahi, Diabetes Care, 24, 964 (2001). (Pharmacol.)

Glucagon-like Peptide 1 (Human, 7-36)-Lys(Biotinyl)-AmideGLP-1 (7-36)-Lys(Biotin)-amide

PGL-3723-PI-20 °C

1 mg 5 mg

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln- Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Lys(biotinyl)-NH2 (M.W. 3652.18) C165H252N44O48SH. John, E. Maronde, W.G. Forssmann, M. Meyer, K. Adermann, Eur. J. Med Res., 13, 73 (2008). B. Ahrén, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, P.-A. Jansson, M. Sandqvist, P. Båvenholm, S. Efendic, J.W. Eriksson, S. Dickinson, and D. Holmes, Diabetes Care, 25, 869 (2002). C.F. Deacon, A. Plamboeck, S. Møller, J.J. Holst, Am. J. Physiol. Endocrinol. Metab., 282, E873 (2002). B. Rolin, C.F. Deacon, R.D. Carr, B.Ahrén, Eur. J. Pharmacol., 494, 283 (2004). D. Elahi, J.M. Egan, R.P. Shannon, G.S. Meneilly, A. Khatri, J.F. Habener, and D.K. Andersen, Obesity, 16, 1501 (2008).

Glucagon-like Peptide 1 (Human, 9-36 Amide)GLP-1 metabolite; GLP-1 (Human, 9-36 amide)

H-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2 (M.W. 3089.48) C140H214N36O43 [161748-29-4]

PGL-3722-PI-20 °C

1 mg5 mg

NEW!

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 69

Glucagon-like Peptide 2 (Human) GLP-2 (Human)

PGL-4376-v-20 °C

0.5 mgvial

His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn- Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp (M.W. 3766.1) C165H254N44O55S [223460-79-5] D.J. Drucker, Gut, 50, 4289 (2002). (Review) B. Hartmann, A.H. Johnsen, C. Ørskov, K. Adelhorst, L. Thim, and J.J. Holst, Peptides, 21, 73 (2000). (Pharmacol.) M. Tang-Christensen, P.J. Larsen, J. Thulesen, J. Rømer, and N. Vrang, Nat. Med., 6, 802 (2000). (Pharmacol.)

The proglucagon gene encodes glucagon, glucagon-like peptide 1 (GLP-1) and GLP-2 tandemly. Among these, the location and function of GLP-1 have long been studied, showing that GLP-1 is one of the typical brain-gut peptides and has pleiotro-pic functions, including stimulation of insulin gene expression, regulation of food and water intake, etc. The chemical structure of GLP-2 in human ileum was reported to be identical to the 33 amino acid residue peptide corresponding to proglucagon (126-158).1 GLP-2 is present in human plasma, the concentration of which was shown to be elevated 3- to 4-fold after ingestion of a meal.1 Further studies revealed that GLP-2’s immunoreactivity was distributed in rat brain, especially in the ventral part of the dorsomedial hypothalamic nucleus (DMH) (and also found in the paraventricular and arcuate nuclei). Central administration of GLP-2 decreases food intake in ad libitum-fed rats at concentrations above 5 μg.2 This inhibition is effective for a short-duration. Surprisingly the GLP-1 receptor antagonist, exendin (9-39), reverses the GLP-2 induced anorexia, although the GLP-2 receptor is expressed in the compact part of the DMH. In addition, GLP-2 decreases NPY-induced food intake by 40%, but this peptide does not affect angiotensin II-induced drinking behavior.21. B. Hartmann, A.H. Johnsen, C.Ørskov, K. Adelhorst, L. Thim, and J.J. Holst, Peptides, 21, 73 (2000). (Pharmacol.)2. M. Tang-Christensen, P.J. Larsen, J. Thulesen, J. Rømer, and N. Vrang, Nat. Med., 6, 802 (2000). (Pharmacol.)3. D.J. Drucker, Gut, 50, 428 (2002). (Review)4. K. Wallis, J.R.F. Walters, and A. Forbes, Aliment. Pharmacol. Ther., 25, 365 (2007). (Review)5. P.E. Dube ´and P.L. Brubaker, Am. J. Physiol. Endocrinol, Metab., 293, E460 (2007). (Review)6. K.J. Rowland and P.L. Brubaker, Mol. Cell. Endocrinol., 288, 63 (2008). (Review)7. R. Yazbeck, G.S. Howarth, and C.A. Abbott, Cytokine Growth Factor Rev., 20, 175 (2009). (Review)8. R. Yazbeck, C.A. Abbott, and G.S. Howarth, Curr. Opin. Investig. Drugs, 11, 440 (2010). (Review)

70 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Growth Hormone Releasing Factor (GRF, GH-RH) and Growth Hormone Related Peptides

Growth hormone releasing peptide-2 or H-d-Ala-d-Nal(2’)-Ala-Trp-d-Phe-Lys-NH2 (GHRP-2) (PGH-3911-PI) is part of the growth hormone secretagogue (GHS) family first identified nearly 20 years ago. Ghrelin was later isolated and like GHRPs, were found to stimulate release of growth hormone.1,2 Ghrelin and GHRPs act on growth hormone secretagogue receptor type 1a (GSR1a) in a synergistic manner, and both can stimulate increase of food intake in humans.3-6 Besides its role in energy balance, GHRP-2 has been implicated to have anti inflammatory effects in arthritic rats due to its ability to decrease IL-6 in serum, a major mediator of tissue destruction in this disease.7 Cardio protective functions have been observed as well.8

GSR1a was found to exhibit high basal activity independent of ghrelin activation.9 Constitutive, ligand independent activation of GSR1a is physiologically important, and inverse agonists would be helpful in studies focused on such activity. [d-Arg1,d-Phe5,d-Trp7,9,Leu11]-substance P (PGH-3652-PI) is a selective inverse agonist for GSR1a with low antagonist activity.10 The pentapeptide core required for inverse agonist activity was determined to be wFwLL.11 Addition of a positive charged amino acid led to a novel peptide KwFwLL (PGH-3908-PI); the most potent and shortest inverse agonist for GSR1a.http://pepnet.com/products/ghrelin_obestatin.pdf

1. Arvat, et al., J. Clin. Endocrinol. Metab., 86,1169 (2001). 2. F. Broglio, et al., J. Clin. Endocrinol. Metab., 88, 1537 (2003). 3. Cunha et al., Endocrinology, 83, 1186 (2002). 4. Hataya, et al., J. Clin. Endocrinol. Metab., 86, 4552 (2001). 5. Wren, et al., J. Clin. Endocrinol. Metab., 89, 2832 (2001).

6. Laferrere, et al., J. Clin. Endocrinol. Metab., 90, 611 (2005).7. Granando, et al., Am. J.Physiol. Endocrinol. Metab., 288, E486 (2005).8. Weekers, et al., Endocinol., 141, 3993 (2000). 9. Asakawa, et al., Gastroenterology, 120, 337 (2001). 10. Pantel, et al., J. Clin. Investig., 116, 760 (2006). 11. Holst, et al., Mol. Pharmacol., 70, 936 (2006).

GRF (Human) Growth Hormone Releasing Factor (Human)

Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-lle-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 (M.W. 5039.7) C215H358N72O66S [83930-13-6]

PGR-4127-s-20 °C

0.1 mgvial

• This product is distributed through Peptide Institute, Inc. under license of The Salk Institute.

GRF (Human) Growth Hormone Releasing Factor (Human)

PGR-4127-v-20 °C

0.5 mgvial

R. Guillemin, P. Brazeau, P. Böhlen, F. Esch, N. Ling, and W.B. Wehrenberg, Science, 218, 585 (1982). (Original; Pancreatic Tumor) N. Ling, F. Esch, P. Böhlen, P. Brazeau, W.B. Wehrenberg, and R. Guillemin, Proc. Natl. Acad. Sci. USA, 81, 4302 (1984). (Original; Hypothalamus) • This product is distributed through Peptide Institute, Inc. under the license of The Salk Institute.

H-d-Ala-d-Nal(2’)-Ala-Trp-d-Phe-Lys-NHGHRP-2

(M.W. 818) C45H55N9O6Growth Hormone Releasing Peptide / Food Intake Stimulator

PGH-3911-PI -20 °C

1 mg5 mg

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 71

H-Lys-d-Trp-Phe-d-Trp-Leu-Leu-NH2KwFwLL

(M.W. 891.14) C49H66N10O6 Potent Full Inverse Agonist for Ghrelin Receptor

PGH-3908-PI -20 °C

1 mg5 mg

Guanylins and UroguanylinsL.R. Forte and M.G. Currie, FASEB J., 9, 643 (1995). (Review) L.R. Forte, X.H. Fan, and F.K. Hamra, Am. J. Kidney Dis., 28, 296 (1996). (Review)L.R. Forte, Jr., Pharmacol. Ther., 104, 137 (2004). (Review)

Guanylin (Human)Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys (Disulfide bonds between Cys4-Cys12 and Cys7-Cys15) (M.W. 1458.7) C58H87N15O21S4 [183200-12-6] Guanylate Cyclase C Activator

PGN-4274-s-20 °C

0.1 mgvial

R.C. Wiegand, J. Kato, M.D. Huang, K.F. Foc, J.F. Kachur, and M.G. Currie, FEBS Lett., 311, 150 (1992). (Original; cDNA) F.J. de Sauvage, S. Keshav, W.-J. Kuang, N. Gillett, W. Henzel, and D.V. Goeddel, Proc. Natl. Acad. Sci. USA, 89, 9089 (1992). (Original; cDNA) M. Kuhn, M. Raida, K. Adermann, P. Schulz-Knappe, R. Gerzer, J.-M. Heim, and W.-G. Forssmann, FEBS Lett., 318, 205 (1993). (Circulating Form) O. Hill, M. Kuhn, H.-D. Zucht, Y. Cetin, H. Kulaksiz, K. Adermann, G. Klock, G. Rechkemmer, W.-G. Forssmann, and H.-J. Maegert, Proc. Natl. Acad. Sci. U.S.A., 92, 2046 (1995). (Immunohistochem.)

Guanylin (Rat, Mouse)Pro-Asn-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys (Disulfide bonds between Cys4-Cys12 and Cys7-Cys15) (M.W. 1515.7) C60H90N16O22S4 Guanylate Cyclase C Activator

PGN-4275-s-20 °C

0.1 mgvial

M.G. Currie, K.F. Fok, J. Kato, R.J. Moore, F.K. Hamra, K.L. Duffin, and C.E. Smith, Proc. Natl. Acad. Sci. USA, 89, 947 (1992). (Original; Rat) R.C. Wiegand, J. Kato, and M.G. Currie, Biochem. Biophys. Res. Commun., 185, 812 (1992). (Original; Rat cDNA) S. Schults, T.D. Chrisman, and D.L. Garbers, J. Biol. Chem. 267, 16019 (1992). (Tissue distribution) F.J. de Sauvage, S. Keshav, W.-J. Kuang, N. Gillett, W. Henzel, and D.V. Goeddel, Proc. Natl. Acad. Sci. USA, 89, 9089 (1992). (Original; Mouse cDNA)

Uroguanylin (Rat)Thr-Asp-Glu-Cys-Glu-Leu-Cys-Ile-Asn-Val-Ala-Cys-Thr-Gly-Cys (Disulfide bonds between Cys4-Cys12 and Cys7-Cys15) (M.W. 1569.8) C60H96N16O25S4 Guanylate Cyclase C Activator / Natriuretic Factor

PUG-4354-s-20 °C

0.1 mgvial

M. Nakazato, H. Yamaguchi, Y. Date, M. Miyazato, K. Kangawa, M.F. Goy, N. Chino, and S. Matsukura, Endocrinology, 139, 5247 (1998). (Original) H. Ieda, S. Naruse, M. Kitagawa, H. Ishiguro, and T. Hayakawa, Regul. Pept., 79, 165 (1999). (Pharmacol.) M. Kikuchi, S. Fujimoto, H. Fukae, H. Kinoshita, T. Kita, M. Nakazato, and T. Eto, J. Am. Soc. Nephrol., 16, 392 (2005). (Pharmacol.; Natriuretic Activity)

NEW!

72 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Uroguanylin Isomer A (Human)(Trifluoroacetate Form) Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn- Val-Ala-Cys-Thr-Gly-Cys-Leu (Disulfide bonds between Cys4-Cys12 and Cys7-Cys15) (M.W. 1667.9) C64H102N18O26S4 [154525-25-4]Guanylate Cyclase C Activator Purity Information: Qz See page xiv

PUG-4295-s-20 °C

0.1 mgvial

T. Kita, C.E. Smith, K.F. Fok, K.L. Duffin, W.M. Moore, P.J. Karabatsos, J.F. Kachur, F.K. Hamra, N.V. Pidhorodeckyj, L.R. Forte, and M.G. Currie, Am. J. Physiol., 266, F342 (1994). (Original) M. Nakazato, H. Yamaguchi, H. Kinoshita, K. Kangawa, H. Matsuo, N. Chino, and S. Matsukura, Biochem. Biophys. Res. Commun., 220, 586 (1996). (Biologically Active/Inactive Isomer) H. Kinoshita, S. Fujimoto, M. Nakazato, N. Yokota, Y. Date, H. Yamaguchi, S. Hisanaga, and T. Eto , Kidney Int., 52, 1028 (1997). (Urine/Plasma Level; Renal Disease) N. Chino, S. Kubo, T. Kitani, T. Yoshida, R. Tanabe, Y. Kobayashi, M. Nakazato, K. Kangawa, and T. Kimura, FEBS Lett., 421, 27 (1998). (Biochem.; Topological Isomers)N.G. Moss, D.A. Riguera, R.M. Solinga,M.M. Kessler, D.P. Zimmer, W.J. Arendshorst, M.G. Currie, and M.F. Goy, Hypertension, 53, 867 (2009). (Natriuretic Activity of Topological Isomers)

Uroguanylin Isomer B (Human)(Trifluoroacetate Form)

PUG-4463-s-20 °C

0.1 mgvial

Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu(Disulfide bonds between Cys4-Cys12 and Cys7-Cys15)(M.W. 1667.9) C64H102N18O26S4Natriuretic FactorUroguanylin is a well-known activator of guanylyl cyclase-C (GC-C) in the intestine. Regulation of natriuresis in the kidney postprandial is another important function of this peptide.1 In the case of human uroguanylin,2 the so-called topological isomers (iso-mer A and isomer B in this catalog) are generated because of the carboxyl-terminal extension of Leu residue from the core structure formed by two disulfide bonds in a 1-3/2-4 pattern resulting in the stabilization of two topological stereoisomers. Isomer A (PUG-4295-s) stimulates GC-C, whilst isomer B is a weak agonist in this assay.3 What is the biological role of isomer B? The answer was obtained that isomer B possesses natriuretic activity4 with a sigmoidal dose-response curve (ED50 = 20 nmol/kg in rats). It is of interest that isomer A also shows natriuretic activity at 25 nmol/kg, however, a distinct bell-shaped dose-response curve was observed. Furthermore, co-administration of isomer A (100 nmol/kg) and isomer B (35 nmol/kg) induced almost as efficient natriuretic response as that of a mere administration of isomer A, indicat-ing that a large amount of coexisting isomer A antagonize, even in part, the natriuretic activity of isomer B. Considering the report that uroguanylin and guanlylin exert natri-uretic activity in mice even lacking the GC-C receptor,5 the natriuresis of uroguanylin might be mediated by a novel receptor other than GC-C. The availability of synthetic human uroguanylin isomer A and isomer B should allow for more precise research to help clarify the complicated biological response of the individual topological isomers. Please note: It has been reported that isomer A and isomer B of human uroguanylin are interconvertible in solution.6 Keeping the prepared solution at low temperature (below 4 °C) should help avoid this possible interconversion.1. L.R. Forte, J. Clin. Invest., 112. 1138 (2003). (Review: Natriuretic Factor)2. T. Kita, et al., Am. J. Physiol., 266, F342 (1994). (Original)3. M. Nakazato, et al., Biochem. Biophys. Res. Commun., 220, 586 (1996). (GC-C Stimulating Activity of Topological Isomers)4. N.G. Moss, et al., Hypertension, 53, 867 (2009). (Natriuretic Activity of Topological Isomers)5. S.L. Carrithers, et al., Kidney Int., 65, 40 (2004). (GC-C-Independent Natriuretic Activity)6. N. Chino, et al., FEBS Lett., 421, 27 (1998). (Interconversion of Topological Isomers)

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 73

HepcidinHepcidin is an antimicrobial peptide and negative regulator of iron homeostasis.1 Both iron loading and inflammation can stimulate hepcidin production in the liver.2,3 Humans have one copy of the hepcidin gene while mice contain 2 copies; hepcidin 1 and 2. Overexpression of hepcidin 1 but not 2 in mice led to anemia, suggesting the former is the predominant regulator of iron metabolism.4 In addition, disruption of hepcidin 1 in mice caused severe multivisceral iron overload and hemochromatosis.5 1. C.H. Park, E.V. Valore, A.J. Waring, and T. Ganz, J. Biol. Chem., 276, 7806 (2001). 2. C. Pigeon, et al., J. Biol. Chem., 276, 7811 (2001).3. G. Nicholas, et al., J. Clin. Invest., 110, 1037 (2002).4. D.-Q. Lou, et al., Blood, 103, 2816 (2004). 5. J.-C. Lesbordes-Brion, et al., Blood, 108, 1402 (2006).

[13C18,15N3]-Hepcidin (Human) See Code 3405-v on page 44. Hepcidin (Baboon)

(Trifluoroacetate Form) Liver-Expressed Antimicrobial Peptide (Baboon)H-Asp-Thr-His-Phe-Pro-Ile-Cys-Ile-Phe-Cys-Cys-Gly-Cys-Cys-His-Arg-Ser-Lys-Cys-Gly-Met-Cys-Cys-Arg-Thr-OH

PLP-3745-PI -20 °C

1 mg5 mg

(Disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22) (M.W. 2817.41) C113H170N36O31S9

G.M. Morrison, et al., Mol Biol Evol., 20, 460 (2003).

Hepcidin 1 (Mouse) Liver-Expressed Antimicrobial Peptide 1 (Mouse)Asp-Thr-Asn-Phe-Pro-Ile-Cys-Ile-Phe-Cys-Cys-Lys-Cys- Cys-Asn-Asn-Ser-Gln-Cys-Gly-Ile-Cys-Cys-Lys-Thr(Disulfide bonds undetermined) (M.W. 2754.2) C111H169N31O35S8Iron-Regulatory Hormone-

PLP-4434-s -20 °C

0.1 mgvial

Hepcidin (Rat) (50 µg vial) Liver-Expressed Antimicrobial Peptide (Rat)H-Asp-Thr-Asn-Phe-Pro-Ile-Cys-Leu-Phe-Cys-Cys Lys-Cys- Cys-Lys-Asn-Ser-Ser-Cys-Gly-Leu-Cys-Cys-Ile-Thr(Disulfide bonds undetermined) (M.W. 2712.2) C111H169N31O35S8Synthetic Product Iron-Regulatory Hormone

PLP-4467-v -20 °C

0.05 mgvial

C. Pigeon, G. Ilyin, B. Courselaud, P. Leroyer, B. Turlin, P. Brissot, and O. Loréal, J. Biol. Chem., 276, 7811 (2001). (Primary structure: GenBank accession No. AF344185)

Hepcidin (Rat) (Bulk)(Trifluoroacetate Form) Liver-Expressed Antimicrobial Peptide (Rat)H-Asp-Thr-Asn-Phe-Pro-Ile-Cys-Leu-Phe-Cys-Cys Lys-Cys- Cys-Lys-Asn-Ser-Ser-Cys-Gly-Leu-Cys-Cys-Ile-Thr

PLP-3769-PI -20 °C

1 mg5 mg

(Disulfide between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22) (M.W. 2712.2) C111H169N31O35S8Synthetic Product Iron-Regulatory Hormone

NEW!

NEW!

NEW!

74 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Biotinyl-PEG3-Hepcidin (Rat) Biotin-PEG3-Asp-Thr-Asn-Phe-Pro-Ile-Cys-Leu-Phe-Cys-Cys-Lys-Cys-Cys-Lys-Asn-Ser-Ser-Cys-Gly-Leu-Cys-Cys-Ile-Thr-OH

PLP-3768-PI -20 °C

0.5 mg1 mg

(Disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14- Cys22) (M.W. 3127.80) C129H200N32O40S9

Important Information: In order to avoid confusion caused by the two components of LEAP peptides and by the previous product name, the Peptide Institute has changed the names for PLP-4392-s and PLP-4405-s.

Product Code PLP-4392-sPLP-4405-s

New product name Hepcidin / LEAP-1 (Human) LEAP-2 (Human)

Previous product name Liver-Expressed Antimicrobial Peptide 1 (Human) Liver-Expressed Atimicrobial Peptide 2 (Human)

Hepcidin/LEAP-1 (Human) contains 8 Cys residues, disulfide connectivity of which was first determined to be Cys7-Cys23, Cys10-Cys22, Cys11-Cys19, and Cys13-Cys14 based on the results from NMR analysis of the synthetic peptide. Recently, this connectivity has been revised to be Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22 using the natural peptide from urine, two recombinant peptides expressed in CHO cells or E. coli, and the chemically synthesized peptide.5 Methods applied to determine this newly reported connectivity include: NMR, X-ray crystallography of the anti-hepcidin/LEAP-1 antibody Fab complex, and disulfide mapping by partial reduc-tion/alkylation procedure. Based on these experimental facts, we have now changed the disulfide connectivity of our hepcidin/LEAP-1 (Human) to the newly reported one, that is, (Reported disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22). 1. A. Krause, S. Neitz, H.-J. Mägert, A. Schulz, W.-G. Forssmann, P. Schulz-Knappe, and K. Adermann, FEBS Lett., 480, 147 (2000). (Original; LEAP-1)2. C.H. Park, E.V. Valore, A.J. Waring, and T. Ganz, J. Biol. Chem., 276, 7806 (2001). (Original; Hepcidin)3. T. Ganz and E. Nemeth, Am. J. Physiol., 290, G199 (2006). (Review)4. H.N. Hunter, D.B. Fulton, T. Ganz, and H.J. Vogel, J. Biol. Chem., 277, 37597 (2002). (Previously published S-S Bond Connectivity)5. J.B. Jordan, L. Poppe, M. Haniu, T. Arvedson, R. Syed, V. Li, H. Kohno, H. Kim, P.D. Schnier, T.S. Harvey, L.P. Miranda, J. Cheetham, and B.J. Sasu, J. Biol. Chem., 284, 24155 (2009). (Newly published S-S Bond Connectivity)

Hepcidin/LEAP-1 (Human)Liver-Expressed Antimicrobial Peptide

Asp-Thr-His-Phe-Pro-Ile-Cys-Ile-Phe-Cys-Cys-Gly-Cys- Cys-His-Arg-Ser-Lys-Cys-Gly-Met-Cys-Cys-Lys-Thr

PLP-4392-s-20 °C

0.1 mg vial

(Disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14- Cys22) (M.W. 2789.4) C113H170N34O31S9 Liver-Specific Antimicrobial Peptide / Iron-Regulatory Hormone M. Zasloff, Nature, 475, 389 (2002). (Review) A. Krause, S. Neitz, H.-J. Mägert, A. Schulz, W.-G. Forssmann, P. Schulz-Knappe, and K. Adermann, FEBS Lett., 480, 147 (2000). (Original; LEAP-1) C.H. Park, E.V. Valore, A.J. Waring, and T. Ganz, J. Biol. Chem., 276, 7806 (2001). (Original; Hepcidin) H.N. Hunter, D.B. Fulton, T. Ganz, and H.J. Vogel, J. Biol. Chem., 277, 37597 (2002). (S-S Bond) R.E. Fleming and W.S. Sly, Proc. Natl. Acad. Sci. USA, 98, 8160 (2001). (Regulation of Iron Homeostasis)

NEW!

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 75

LEAP-2 (Human)Liver-Expressed Antimicrobial Peptide 2 (Human) Prepro-LEAP-2 (Human, 38-77)

PLP-4405-s-20 °C

0.1 mg vial

Met-Thr-Pro-Phe-Trp-Arg-Gly-Val-Ser-Leu-Arg-Pro-Ile-Gly-Ala-Ser-Cys-Arg-Asp-Asp- Ser-Glu-Cys-Ile-Thr-Arg-Leu-Cys-Arg-Lys-Arg-Arg-Cys-Ser-Leu-Ser-Val-Ala-Gln-Glu (Disulfide bonds between Cys17-Cys28 and Cys23-Cys33) (M.W. 4581.3) C191H316N64O57S5 Antimicrobial PeptideA. Krause, R. Sillard, B. Kleemeier, E. Klüver, E. Maronde, J.R. Conejo-García, W.G. Forssmann, P. Schulz-Knappe, M.C. Nehls, F. Wattler, S. Wattler, and K. Adermann, Protein Sci., 12, 143 (2003). (Original & S-S Bond).

HistatinHistatin 5 (Human)

Asp-Ser-His-Ala-Lys-Arg-His-His-Gly-Tyr-Lys-Arg-Lys- Phe-His-Glu-Lys-His-His-Ser-His-Arg-Gly-Tyr (M.W. 3036.3) C133H195N51O33 [104339-66-4] Parotid Histidine-rich Protein / Salivary Antimicrobial Peptide

PHS-4270-s-20 °C

0.1 mgvial

F.G. Oppenheim, T. Xu, F.M. McMillian, S.M. Levitz, R.D. Diamond, G.D. Offner, and R.F. Troxier, J. Biol. Chem., 263, 7472 (1988). (Original) P.A. Raj, M. Edgerton, and M.J. Levine, J. Biol. Chem., 265, 3898 (1990). (Pharmacol.) Y. Murakami, T. Takeshita, S. Shizukuishi, A. Tsunemitsu, and S. Aimoto, Arch. Oral Biol., 35, 775 (1990). (Pharmacol.) M. Nishikata, T. Kanehira, H. Oh, H. Tani, M. Tazaki, and Y. Kuboki, Biochem. Biophys. Res. Commun., 174, 625 (1991). (Pharmacol.)

HumaninI. Nishimoto, M. Matsuoka, and T. Niikura, Trends Mol. Med., 10, 102 (2004). (Review) T. Arakawa, Y. Kita, and T. Niikura, Curr. Med. Chem., 15, 2086 (2008). (Review)

Humanin (Trifluoroacetate Form) Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala (M.W. 2687.2) C119H204N34O32S2 [330936-69-1]Endogenous Rescue Factor Abolishing Neuronal Cell Death Purity Information: Qz See page xiv

PHN-4384-v-20 °C

0.5 mgvial

[Gly14]-Humanin (Trifluoroacetate Form) Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala (M.W. 2657.2) C118H202N34O31S2 [330936-70-4]Potent Rescue Factor Abolishing Neuronal Cell Death Purity Information: Qz See page xiv

PHN-4385-v-20 °C

0.5 mgvial

Y. Hashimoto, T. Niikura, H. Tajima, T. Yasukawa, H. Sudo, Y. Ito, Y. Kita, M. Kawasumi, K. Kouyama, M. Doyu, G. Sobue, T. Koide, S. Tsuji, J. Lang, K. Kurokawa, and I. Nishimoto, Proc. Natl. Acad. Sci. USA, 98, 6336 (2001). (Original) Y. Hashimoto, Y. Ito, T. Niikura, Z. Shao, M. Hata, F. Oyama, and I. Nishimoto, Biochem. and Biophys. Res. Comm., 283, 460 (2001). (Pharmacol.) T. Mamiya and M. Ukai, Br. J. Pharmacol., 134, 1597 (2001). (Pharmacol.) S. Kariya, N. Takahashi, N. Ooba, M. Kawahara, H. Nakayama, and S. Ueno, Neurochemistry, 13, 903 (2002). (Pharmacol.) S.S. Jung and W.E. Van Nostrand, J. Neurochem., 84, 266 (2003). (Pharmacol.)

76 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES InsulinE. Dorzbach (ed.), Insulin I, Handbook of Experimental Pharmacology, Vol. 32 (1), Springer-Verlag, Berlin, 1971. (Review) A. Hasselblatt and F.V. Bruchhausen (eds.), Insulin II, Handbook of Experimental Pharmacology, Vol. 32 (2), Springer-Verlag, Berlin, 1975. (Review)

4-[D10]Leu-Insulin (Human) See Code 3404-s on page 44.

Insulin (Human) Enzymatically Derived from Porcine Insulin

PlN-4088-s-20 °C

0.1 mgvial

A-chain: Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn B-chain: Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr (Disulfide bonds between CysA6-CysA11,CysA7-CysB7, and CysA20-CysB19) (M.W. 5807.6) C257H383N65O77S6 [11061-68-0]

Insulin (Human) Enzymatically Derived from Porcine Insulin Purity Information: QE See page xiv

PlN-4088-v-20 °C

0.5 mgvial

K. Morihara, T. Oka, and H. Tsuzuki, Nature, 280, 412 (1979). (Semi-Synthesis) K. Morihara, T. Oka, H. Tsuzuki, Y. Tochino, and T. Kanaya, Biochem. Biophys. Res. Commun., 92, 396 (1980). (Semi-Synthesis)

Joining PeptidesJoining Peptide (Rat)

Ala-Glu-Glu-Glu-Thr-Ala-Gly-Gly-Asp-Gly-Arg- Pro-Glu-Pro-Ser-Pro-Arg-Glu-NH2 (M.W. 1882.9) C75H119N25O32 Pivotal Neuropeptide in Cardiovascular Regulation

PJP-4288-v-20 °C

0.5 mgvial

T. Hamakubo, M. Yoshida, K. Nakajima, T.X. Watanabe, R. Mosqueda-Garcia, and T. Inagami, Am. J. Physiol., 265, R1184 (1993). (Original) M. Yoshida, T. Hamakubo, and T. Inagami, Am. J. Physiol., 266, R802 (1994). (Pharmacol.)

Kallidin See Code PBK-4008 Lysyl-Bradykinin on page 29.


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 77

Kisspeptins/MetasinsMetastasis suppressor gene KiSS-1 encodes a peptide with multiple biological functions such as inhibition of cancer metastasis, vasoconstriction, reproduction, and so on. In human and rat, the encoded mature peptide is composed of 54 and 52 amino acid residues, respectively, which is named metastin or kisspeptin.1,2,3 Kisspeptin-10 (Human) / Metastin (Human, 45-54) is an active segment of the human peptide from the C-terminal portion and is already available from our catalog (PMT-4389-v). Very recently, in collaboration with Dr. Tsukamura and her colleagues in Nagoya University, Ihe Peptide Institute has successfully clarified that the corresponding rat 10-residue peptide, Kisspeptin-10 (Rat) / Metastin (Rat, 43-52), exerts the luteinizing hormone (LH) releasing activity in male rats4). Actually, intracerebroventricular or intravenously administration at a dose of 1 nmol/kg or 10 nmol/kg stimulates LH release and significantly increases plasma LH level in male rats. Now the precise experiment using Kisspeptin-10 (Rat) / Metastin (Rat, 43-52) is possible in rat studies. T. Ohtaki, et al., Nature, 411, 613 (2001). (Metastin)M. Kotani, et al., J. Biol. Chem., 276, 34631 (2001). (Kisspeptin)Y. Terao, et al., Biochim. Biophys. Acta, 1678, 102 (2004). (Original; Rat Metastin)V. Pheng, et al., J. Reprod. Dev., 55, 378 (2009). (Pharmacol.)M.L. Gottsch, et al., Peptides, 30, 4 (2009). (Review)

Note: Based on the nomenclature recommendation5), we hereafter use the product name of "Kisspeptin / Metastin" for peptides derived from KiSS-1 gene, including Code PMT-4389-v (see below).

Kisspeptin-10 (Human) / Metastin (Human, 45-54) Former Name Metastin (Human, 45-54)Kp-10 (Human) / KiSS-1 Gene Product (Human, 112-121 Amide)

Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2(M.W. 1302.4) C63H83N17O14 [374675-21-5]Ligand for hOT7T175 / GPR54

PMT-4389-v-20 °C

0.5 mgvial

T. Ohtaki, Y. Shintani, S. Honda, H. Matsumoto, A. Hori, K. Kanehashi, Y. Terao, S. Kumano, Y. Takatsu, Y. Masuda, Y. Ishibashi, T. Watanabe, M. Asada, T. Yamada, M. Suenaga, C. Kitada, S. Usuki, T. Kurokawa, H. Onda, O. Nishimura, and M. Fujino, Nature, 411, 613 (2001). (Original; Metastin)A.I. Muir, L. Chamberlain, N.A. Elshourbagy, D. Michalovich, D.J. Moore, A. Calamari, P.G. Szekeres, H.M. Sarau, J.K. Chambers, P. Murdock, K. Steplewski, U. Shabon, J.E. Miller, S.E. Middleton, J.G. Darker, C.G.C. Larminie, S. Wilson, D.J. Bergsma, J. Biol. Chem., 276, 28969 (2001). (Original; Kisspeptin)M. Kotani, M. Detheux, A. Vandenbogaerde, D. Communi, J.-M. Vanderwinden, E. Le Poul, S. Brezillon, R. Tyldesley, N. Suarez-Huerta, F. Vandeput, C. Blanpain, S. N. Schiffmann, G. Vassart, and M. Parmentier, J. Biol. Chem., 276, 34631 (2001). (Original; Kisspeptin)A. Hori, S. Honda, M. Asada, T. Ohtaki, K. Oda, T. Watanabe, Y. Shintani, T. Yamada, M. Suenaga, C. Kitada, H. Onda, T. Kurokawa, O. Nishimura, and M. Fujino, Biochem. Biophys. Res. Commun., 286, 958 (2001). (Pharmacol.)M. Kinoshita, H. Tsukamura, S. Adachi, H. Matsui, Y. Uenoyama, K. Iwata, S. Yamada, K. Inoue, T. Ohtaki, H. Matsumoto, and K.-I. Maeda, Endocrinology, 146, 4431 (2005). (Pharmacol.)S. Ramaswamy, S.B. Seminara, C.R. Pohl, M.J. DiPietro,W.F. Crowley, Jr. and T.M. Plant, Endocrinology, 148, 3364 (2007). (Pharmacol.)S.B. Seminara and U.B. Kaiser, Endocrinology, 146, 1686 (2005). (Minireview)K.I. Maeda, S. Adachi, K. Inoue, S. Ohkura, and H. Tsukamura, Rev. Endocrinol. Metab. Disord., 8, 21 (2007). (Review)• This compound is distributed through Peptide Institute, Inc. under the license of Takeda Pharmaceutical Company Limited.

NEW!

78 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Kisspeptin-54 (Human) / Metastin (Human, 1-54) [Kp-54 (Human) / KiSS-1 Gene Product (Human, 68-121 Amide)]

PMT-4446-v-20 °C

0.5 mgvial

Gly-Thr-Ser-Leu-Ser-Pro-Pro-Pro-Glu-Ser-Ser-Gly-Ser-Arg-Gln-Gln-Pro-Gly-Leu-Ser-Ala-Pro-His-Ser-Arg-Gln-Ile-Pro-Ala-Pro-Gln-Gly-Ala-Val-Leu-Val-Gln-Arg-Glu-Lys-Asp-Leu-Pro-Asn-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2(M.W. 5857.4) C258H401N79O78 Stimulator of Hypothalamic-Pituitary Gonadal Axis

Kisspeptin-52 (Human) / Metastin (Human, 1-52) Kp-52 (Rat) / KiSS-1 Gene Product (Rat, 68-119 Amide)

PMT-4447-s-20 °C

0.1 mgvial

Thr-Ser-Pro-Cys-Pro-Pro-Val-Glu-Asn-Pro-Thr-Gly-His-Gln-Arg-Pro-Pro-Cys- Ala-Thr-Arg-Ser-Arg-Leu-Ile-Pro-Ala-Pro-Arg-Gly-Ser-Val-Leu-Val-Gln-Arg- Glu-Lys-Asp-Met-Ser-Ala-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Tyr-NH2(Disulfide bond between Cys4-Cys18)(M.W. 5836.6) C254H398N80O73S3Stimulator of Hypothalamic-Pituitary Gonadal AxisY. Terao, S. Kumano, Y. Takatsu, M. Hattori, A. Nishimura, T. Ohtaki, and Y. Shintani, Biochim. Biophys. Acta.,1678,102 (2004). (Original; Rat Metastin)

Kisspeptin-10 (Rat) / Metastin (Rat, 43-52) Kp-10 (Rat) / KiSS-1 Gene Product (Rat, 110-119 Amide)

Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Tyr-NH2(M.W. 1318.4) C63H83N17O15Ligand for hOT7T175 / GPR54

PKS-4453-v-20 °C

0.5 mgvial

Laminin Laminin Pentapeptide YIGSR-NH2

Tyr-lle-Gly-Ser-Arg-NH2 (M.W. 593.68) C26H43N9O7 [110590-65-3]

PLP-4194-v-20 °C

0.5 mgvial

Laminin Pentapeptide YIGSR-NH2 (Bulk)Tyr-lle-Gly-Ser-Arg-NH2 • 2AcOH • 2H2O (M.W. 593.68 • 120.10 • 36.03) C26H43N9O7 • 2CH3COOH • 2H2O

PLP-4194-20 °C

25 mg100 mg

Y. Iwamoto, F.A. Robey, J. Graf, M. Sasaki, H.K. Kleinman, Y. Yamada, and G.R. Martin, Science, 238, 1132 (1987). (Original)

Leu-Pro-Leu-Arg-Phe-NH2 • 2AcOH • 2H2O*(M.W. 643.82 • 120.11 • 36.03) C32H53N9O5 • 2CH3COOH • 2H2O Chicken Brain Peptide

PBC-4144-20 °C

25 mg100 mg

G.J. Dockray, J.R. Reeve Jr., J. Shively, R.J. Gayton, and C.S. Barnard, Nature, 305, 328 (1983). (Original)

Liver-Cell Growth Factor* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.

Liver-Cell Growth Factor (Bulk)Gly-His-Lys • AcOH • H2O (M.W. 340.38 • 60.05 • 18.02) C14H24N6O4 • CH3COOH • H2O [72957-37-0]

PLC-4022-20 °C

25 mg100 mg

L. Pickart, L. Thayer, and M.M. Thaler, Biochem. Biophys. Res. Commun., 54, 562 (1973). (Original)

NEW!

NEW!

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 79

LL-37 Cathelicidin Antimicrobial PeptideLL-37 (Human)

Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile- Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp- Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser(M.W. 4493.30) C205H340N60O53 Cathelicidin Antimicrobial Peptide

PLL-4445-s-20 °C

0.1 mgvial

Antimicrobial peptides (often abbreviated as AMPs) play essential roles in self-defense systems. Defensins are potential protecting factors against microbial infection and members of AMPs in human: we have been offering α-defensin-1 (PDF-4271), -2 (PDF-4428), -3 (PDF-4416), -4 (PDF-4431), -5 (PDF-4415), and -6 (PDF-4458), as well as β-defensin-1 (PDF-4337), -2 (PDF-4338), -3 (PDF-4382), and -4 (PDF-4406) as our catalog items. Another member of AMP in human is LL-37, the so-called cathelicidin AMP.1,2 Cathelicidins are one family of multifunctional AMPs, characterized by con-served pro-peptide sequences that have been identified in several mammalian spe-cies. On the contrary to disulfide cross-linked defensins, LL-37 is a linear, amphipathic peptide with α-helical structure. LL-37 is reported to exert not only antimicrobial activ-ity but also immunomodulatory activity.2,3 Recent papers describe the involvement of LL-37 in toll-like receptor (TLR) activation: i) vitamin D receptor-mediated induction of LL-37 through TLR2/1L activation was observed in human monocyte4 and ii) LL-37 interacts to self-DNA in psoriasis, after which the complex formed triggers TLR9, resulting in the induction of interferon-α production.5 In the latter special case, LL-37 might be the pathogenic factor of psoriasis, one of the autoimmune diseases, although LL-37, together with β-defensin-2, is reported to be highly expressed in psoriasis to protect the infection with Staphylococcus aureus.6 Thus, LL-37 should be valuable in the research of human defense systems, especially to clarify the mechanism of innate immunity and LL-37’s role in autoimmunity and cancer.71. G.H. Gudmundsson, B. Agerberth, J. Odeberg, T. Bergman, B. Olsson, and R. Salcedo, Eur. J. Biochem., 238, 325 (1996). (Original)2. R. Bals and J.M. Wilson, Cell. Mol. Life Sci., 60, 711 (2003). (Review)3. M. Zanetti, J. Leukoc. Biol., 75, 39 (2004). (Review)4. P.T. Liu, S. Stenger, H. Li, L.Wenzel, B.H. Tan, S.R. Krutzik, M.T. Ochoa, J. Schauber, K. Wu, C. Meinken, D.L. Kamen, M. Wagner, R. Bals, A. Steinmeyer, U. Zügel, R.L. Gallo, D. Eisenberg, M. Hewison, B.W. Hollis, J.S. Adams, B.R. Bloom, and R.L. Modlin, Science, 311, 770 (2006). (Pharmacol.)5. R. Lande, J. Gregorio, V. Facchinetti, B. Chatterjee, Y.-H.Wang, B. Homey, W. Cao, Y.-H.Wang, B. Su, F.O.Nestle, T. Zal, I. Mellman, J.-M. Schröder, Y.-J. Liu, and M. Gilliet, Nature, 449, 564 (2007). (Pharmacol.)6. P.Y. Ong, T. Ohtake, C. Brandt, I. Strickland, M. Boguniewicz, T. Ganz, R.L. Gallo, and, D.Y.M. Leung, New Engl. J. Med., 347, 1151 (2002). (Pharmacol.)7. D.W. Hoskin and A. Ramamoorthy, Biochim. Biophys. Acta, 1778, 357 (2008). (Review)8. Y.P. Lai and R.L. Gallo, Trends Immunol., 30, 131 (2009). (Review)9. M.F. Burton and P.G. Steel, Nat. Prod. Rep., 26, 1572 (2009). (Review)

Luteinizing Hormone-Releasing Hormone (LH-RH) LH-RH (Human) Luteinizing Hormone Releasing Hormone (Human) (GnRH (Gonadotropin-Releasing Hormone) (Human) (Porcine, Rat)

Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (M.W. 1182.3) C55H75N17O13 [33515-09-2]

PLR-4013-v-20 °C

0.5 mgvial

NEW!

80 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES LH-RH (Human) (Bulk) Luteinizing Hormone Releasing Hormone (Human) (GnRH (Gonadotropin-Releasing Hormone) (Human) (Porcine, Rat)

PLR-4013-20 °C

25 mg

Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 • 2AcOH • 4H2O (M.W. 1182.3 • 120.10 • 72.06) C55H75N17O13 • 2CH3COOH • 4H2O [71447-49-9]H. Matsuo, Y. Baba, R.M.G. Nair, A. Arimura, and A.V. Schally, Biochem. Biophys. Res. Commun, 43, 1334 (1971). (Original)

b-Lipotropin (61-76) See Code PEN-4055-v a-Endorphin on page 51.b-Lipotropin (61-77) See Code PEN-4089-v g-Endorphin on page 52.b-Lipotropin (Human, 61-91) See Code PEN-4060-v b-Endorphin (Human) on page 52.

MagaininMagainin 1 (Frog, Xenopus laevis)

Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Gly-Lys-Phe- Gly-Lys-Ala-Phe-Val-Gly-Glu-Ile-Met-Lys-Ser (M.W. 2409.8) C112H177N29O28S [108433-99-4] Antimicrobial PeptideM. Zasloff, Proc. Natl. Acad. Sci. USA, 84, 5449 (1987). (Original)

PMG-4196-v-20 °C

0.5 mgvial

MastoparanMastoparan (Wasp, Vespula lewisii)

Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2 (M.W. 1478.9) C70H131N19O15 [72093-21-1]

PMS-4107-v-20 °C

0.5 mgvial

Mastoparan (Bulk) (Wasp, Vespula lewisii)

PMS-4107-20 °C

25 mg

Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2 • 4AcOH • 6H2O (M.W. 1478.9 • 240.21 • 108.09) C70H131N19O15 • 4CH3COOH • 6H2O

Y. Hirai, T. Yasuhara, H. Yoshida, T. Nakajima, M. Fujino, and C. Kitada, Chem. Pharm. Bull., 27, 1942 (1979). (Original; Chem. Synthesis)

a-Mating Factora-Mating Factor (Yeast, Saccharomyces cerevisiae)

Trp-His-Trp-Leu-Gln-Leu-Lys-Pro-Gly-Gln-Pro-Met-Tyr (M.W. 1684.0) C82H114N20O17S [59401-28-4]

PMF-4076-v-20 °C

0.5 mgvial

D. Stöetzler, H.-H. Kilts, and W. Duntze, Eur. J. Biochem., 69, 397 (1976). (Original) T. Tanaka, H. Kita, T. Murakami, and K. Narita, J. Biochem., 82, 1681 (1977). (Original) Y. Masui, N. Chino, S. Sakakibara, T. Tanaka, T. Murakami, and H. Kita, Biochem. Biophys. Res. Commun., 78, 534 (1977). (Chem. Synthesis) • This compound is distributed through Peptide Institute Inc., under the license of Suntory Limited.


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 81

Mast Cell Degranulating Peptide (MCD)MCD-Peptide* Mast Cell Degranulating Peptide (Honeybee, Apis mellifera)

PMC-4258-v-20 °C

0.5 mgvial

Ile-Lys-Cys-Asn-Cys-Lys-Arg-His-Val-Ile-Lys-Pro-His-Ile-Cys-Arg-Lys-Ile-Cys-Gly-Lys-Asn-NH2 (Disulfide bonds between Cys3-Cys15 and Cys5-Cys19) (M.W. 2587.2) C110H192N40O24S4 [32908-73-9] Voltage-Dependent K+ Channel BlockerE. Haberman, Science, 177, 314 (1972). (Review) M.R. Ziai, S. Russek, H.-C. Wang, B. Beer, and A.J. Blume, J. Pharm. Pharmacol., 42, 457 (1990). (Review) • This compound is distributed through Peptide Institute, Inc. under the license of The Salk Institute.


Melanin-Concentrating Hormone and Related PeptidesMelanin-Concentrating Hormone (Human) MCH (Human) (Rat, Mouse)

PMC-4369-v-20 °C

0.5 mgvial

Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Gln-Val (Disulfide bond between Cys7-Cys16) (M.W. 2386.8) C105H160N30O26S4 [128315-56-0] Appetite Boosting Peptide• This compound is distributed through Peptide Institute, Inc. under the license of The Salk Institute.

Melanin-Concentrating Hormone (MCH) was isolated from salmon pituitary and was found to induce aggregation of melanin granules in melanophores. Later, a mammalian homolog was identified in rat hypothalamus as a 19 amino acid peptide with a single disulfide bond [Endocrinology, 125, 1660 (1989)]. Subsequently, the human MCH sequence was found to be the same as that of the rat peptide.1 Interestingly, the MCH of hypothalamus was reported in 1996 to be involved in the regulation of body weight.2 Actually, the injection of MCH into the lateral ventricles increased food consumption in rats. Further evidence in the literature indicates that MCH-deficient mice are lean due to hypophagia.31 K.M. Knigge, D. Baxter-Grillo, J. Speciale, and J. Wagner, Peptides, 17, 1063 (1996). (Review) 2. D. Qu, D.S. Ludwig, S. Gammeltoft, M. Piper, M.A. Pelleymounter, M.J. Cullen, W.F. Mathes, J. Przypek, R. Kanarek, and E. Maratos-Flier, Nature, 380, 243 (1996). (Pharmacol.) 3. M. Shimada, N.A. Tritos, B.B. Lowell, J.S. Flier, and E. Maratos-Flier, Nature, 396, 670 (1998). (Pharmacol.)4. J. Chambers, R.S. Ames, D. Bergsma, A. Muir, L.R. Fitzgerald, G. Hervieu, G.M. Dytko, J.J. Foley, J.Martin,W.-S. Liu, J. Park, C. Ellis, S. Ganguly, S. Konchar, J. Cluderay, R. Leslie, S. Wilson, and H.M. Sarau, Nature, 400, 261 (1999). (Pharmacol.; Ligand for Orphan SLC-1 Receptor)5. Y, Saito, H.-P. Nothacker, Z. Wang, S.H.S. Lin, F. Leslie, and O. Civelli, Nature, 400, 265 (1999). (Pharmacol.; Ligand for Orphan SLC-1 Receptor)• This compound is distributed through Peptide Institute, Inc. under the license of The Salk Institute.

Ac-Arg-[Cys-Met-Ava-Arg-Val-Tyr-Ava-Cys]-NH2 Disulfide bond between Cys2 and Cys9

(M.W. 1167.49) C49H82N16O11S3 Ava = Aminovaleric acid Melanin Concentrating Hormone Receptor 1 Antagonist.

PMC-3881-PI-20 °C

1 mg5 mg

M.A. Bednarek, D.L. Hreniuk, C. Tan, O.C. Palyha, D.J. MacNeil, L.H. Y. Van der Ploeg, A.D. Howard, and S.D. Feighner, Biochemistry, 41, 6383 (2002)

82 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Ac-d-Arg-[Cys-Met-Leu-Asn-Arg-Val-Tyr-Arg-Pro-Cys]-NH2

Disulfide bond between Cys2 and Cys11

(M.W. 1449.80) C60H100N22O14S3 Melanin Concentrating Hormone Receptor 1 Agonist

PMC-3886-PI-20 °C

1 mg5 mg

M.A. Bednarek, C. Tan, D.L. Hreniuk, O.C. Palyha, D.J. MacNeil, L.H.Y. Van der Ploeg, A.D. Howard, and S.D. Feighner, J. Biol. Chem., 277, 13821 (2002).

Melanocyte Stimulating Hormone (MSH) and Related Peptidesa-MSH a-Melanocyte Stimulating Hormone (Human, Porcine, Bovine, Rat, Mouse)

Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (M.W. 1664.9) C77H109N21O19S [581-05-5]

PMR-4057-v-20 °C

0.5 mgvial

T.H. Lee and A.B. Lerner, J. Biol. Chem., 221, 943 (1956). (Original; Porcine) R.A. Boissonnas, St. Guttmann, R.L. Huguenin, P.-A. Jaquenoud, and E. Sandrin, Helv. Chim. Acta, 41, 1867 (1958). (Chem. Synthesis) R. Schwyzer, A. Costpanagiotis, and P. Sieber, Helv. Chim. Acta, 46, 870 (1963). (Chem. Synthesis) A.C.Y. Chang, M. Cochet, S.N. Cohen, Proc. Natl. Acad. Sci. U.S.A., 77, 4890 (1980). (Nucleotide Seq.; Human)

MSH-Release Inhibiting Factor (Bulk)(MIF)

Pro-Leu-Gly-NH2 • ½H2O (M.W. 284.35 • 9.01) C13H24N4O3 • ½ H2O [2002-44-0]A. Vivas and M.E. Celis, J. Endocrinol., 78, 1 (1978). (Pharmacol.)

PMI-4024-20 °C

25 mg100 mg


[Nle4, d-Phe7]-b-MSH-AmideAc-Ser-Tyr-Ser-Nle-Glu-His-d-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (M.W. 1646.88) C78H111N21O19

PMC-3669-PI-20 °C

1 mg5 mg

Melanocyte Stimulating Hormone Agonist / Melanocortin 1, 3, 4, and 5 Receptor AgonistT.K. Sawyer, P.J. Sanfilippo, V.J. Hruby, M.H. Engel, ClB. Heward, J.B. Burnett, and M.E. Hadley, Proc. Natl. Acad. Sci., 77, 5754 (1980).

Ac-His-d-Phe(p-Iodo)-Arg-Trp-NH2(M.W. 811.69) C34H42N11O5IMelanocortin Receptor 1/4/5 Agonist / Receptor 3 Antagonist

PMC-3684-PI-20 °C

1 mg5 mg

J.R. Holder, R.M. Bauzo, Z. Xiang, and C. Haskell-Luevano, J. Med. Chem., 45, 3073-3081 (2002).

Ac-Nle-cyclo [Asp-His-d-Phe-Arg-Trp-Lys]-NH2Melanotan II, MT-II

(M.W. 1024.2) C50H69N15O9Potent Melanocortin 1, 3, 4 and 5 Receptor Agonist

PMC-3683-PI-20 °C

1 mg5 mg

F. Al-Obeidi,V.J. Hruby, A.M. Castrucci, and M.E. Hadley, J. Med. Chem., 32, 174 (1989).

Ac-Tyr-Val-Nle-Gly-His-d-Phe-Arg-Trp-Asp-Arg-Phe-Gly-NH2

(M.W. 1593.83) C77H104N22O16Melanocortin 1, 3, 4 and 5 Receptor Agonist

PMC-3685-PI-20 °C

1 mg5 mg

M. Cai, A.V. Mayorov, C. Cabello, KM. Stankova, D. Trivedi, and V.J. Hruby, J. Med. Chem., 48, 1839 (2005).


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 83

cyclo [CO-(CH2)2-CO-d-Nal(2’)-Arg-Trp-Lys]-NH2(M.W. 766.88) C40H48N9O7Melanocortin 4 Receptor Antagonist

PMC-3887-PI-20 °C

1 mg5 mg

M.A. Bednarek, T. MacNeil, R.N. Kalyani, R. Tang, L.H.Y. Van der Ploeg, and D.H. Weinberg, J. Med. Chem., 44, 3665 (2001).

Metastin See Kisspeptin on page 77.

MHC-class I-restricted epitope in hgp100Cytotoxic T cells or CD8+ T cells play an important role in the immune defense and destruction of tumor and infected cells. They are capable of recognizing antigen (Ag) associated with major histo compatibility complex (MHC) class I molecules on these target cells. Following Ag stimulation, T cells are selected to undergo clonal selection and proliferation in the thymus if they have low autoreactivity to self antigens, leading to an appropriate immune response. Recognition of tumor antigens by T cells has prompted interest and research in antigen-based cancer vaccines. Progress was initially hampered by the lack of responsiveness to tumor antigens in clinical trials by T cells, probably because these Ags are expressed on normal as well as tumor cells; therefore the level of autoreactivity is too high to lead to clonal selection of specific T cells. One of these candidate Ags is gp100; an antigen expressed on normal melanocytes as well as malignant melanomas. Later studies observed that xenogeneic immuniza-tion of mice with human gp100 (hgp100) could activate gp100 specific T cells, while mouse gp100 (mgp100) could not.1 In addition, in vivo studies found that reactive gp100 specific T cells followed by recombinant IL-2 treatment dramatically reduced pulmonary metastases.1 Further investigation determined Db to be the MHC class I molecule restricting gp100 recognition and its epitope to be hgp100 (25-33).1 The peptide epitope hgp100 (25-33) was observed to have stronger binding affinity to Db than mgp100 (25-33) and could be used to activate T cells for adoptive therapy in the syngeneic mouse melanoma model.1,2 The peptide epitope can be referred to as a heteroclitic epitope or an altered peptide that is more efficient at inducing T cell activa-tion. Immunization of mice with a minigene encoding the heteroclitic epitope produced specific T cells that protected mice challenged with B16 melanoma, just as effectively as mice immunized with full length hgp100 DNA.1. W.W. Overwijk, A. Tsung, K.R. Irvine, M.R. FParkhust, T.J. Goletz, K. Tsung, M.W. Carroll, C. Liu, B. Moss, S.A. Rosenber, and N.P. Restifo, J. Exper. Med., 188, 277 (1998).2. J.S. Gold, C.R. Ferrone, Jj.A. G.-Patino, W.G. Hawkins, R. Dyall, M.E. Engelhorn, J.D. Wolchok, J.J. Lewis, and A.N. Houghton, J. Immunol., 170, 5188 (2003).

H-Lys-Val-Pro-Arg-Asn-Gln-Asp-Trp-Leu-OHKVPRNQDWLHuman GP 100 (25–33)(M.W. 1155.33) C52H82N16O14MHC-class I-restricted epitope in hgp100Heteroclitic MHC class I epitope in hgp100.

PCP-3922-PI-20 °C

1 mg5 mg

W.W. Overwijk, A. Tsung, K.R. Irvine, M.R. Parkhurst, T.J. Goletz, K. Tsung, M.W. Carroll, C. Liu, B. Moss, S.A. Rosenberg, and N.P. Restifo, J. Exp. Med., 188, 277 (1998).J.S. Gold, C.R. Ferrone, J.A.G.-Patino, W.G. Hawkins, R. Dyall, M.E. Engelhorn, J.D. Wolchok, J.J. Lewis, and A.N. Houghton, J. Immunol., 170, 5188 (2003)

NEW!

84 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES MidkinesMidkine (Human)

Lys-Lys-Lys-Asp-Lys-Val-Lys-Lys-Gly-Gly-Pro-Gly-Ser-Glu-Cys-Ala-Glu-Trp-Ala-Trp-Gly-Pro-Cys-Thr-Pro-Ser-Ser-Lys-Asp-

PMK-4298-v-20 °C

50 µgvial

Cys-Gly-Val-Gly-Phe-Arg-Glu-Gly-Thr-Cys-Gly-Ala-Gln-Thr- Gln-Arg-Ile-Arg-Cys-Arg-Val-Pro-Cys-Asn-Trp-Lys-Lys-Glu- Phe-Gly-Ala-Asp-Cys-Lys-Lys-Phe-Glu-Asn-Trp-Gly-Ala- Cys-Asp-Gly-Gly-Thr-Gly-Thr-Lys-Val-Arg-Gln-Gly-Tyr- Thr-Leu-Lys-Lys-Ala-Arg-Tyr-Asn-Ala-Gln-Cys-Gln-Glu- Thr-Ile-Arg-Val-Thr-Lys-Pro-Cys-Thr-Pro-Lys-Thr-Lys- Ala-Lys-Ala-Lys-Ala-Lys-Lys-Gly-Lys-Gly-Lys-Asp (Disulfide bonds between Cys15-Cys39,Cys23-Cys48, Cys30-Cys52,Cys62-Cys94, and Cys72-Cys104) (M.W. 13240.1) C570H915N177O167S10 [170138-17-7] Heparin-Binding Growth/Differentiation Factor (Neurotrophic Factor, Neurite Outgrowth-Promoting Factor) Plasminogen Activator Activity EnhancerJ.-I. Tsutsui, K. Uehara, K. Kadomatsu, S. Matsubara, and T. Muramatsu, Biochem. Biophys. Res. Commun., 176, 792 (1991). H. Muramatsu, T. Inui, T. Kimura, S. Sakakibara, X.-j. Song, H. Maruta, and T. Muramatsu, Biochem. Biophys. Res. Commun., 203, 1131 (1994). T. Inui, J. Bódi, S. Kubo, H. Nishio, T. Kimura, S. Kojima, H. Maruta, T. Muramatsu, and S. Sakakibara, J. Peptide Sci., 2, 28 (1996). (Chem. Synthesis) G.S.P. Yu, J.Hu, and H. Nakagawa, Neurosci. Lett., 254, 128 (1998). (Pharmacol.; Inhibition of b-amyloid cytotoxicity) • This product is distributed under the license of Prof. Takashi Muramatsu. Its use for any purpose other than research is strictly prohibited.


Midkine (Human, 60-121)Ala-Asp-Cys-Lys-Tyr-Lys-Phe-Glu-Asn-Trp-Gly-Ala-Cys-Asp-Gly-Gly-Thr-Gly-Thr-Lys-Val-Arg-Gln-Gly-Thr-Leu-Lys-Lys- Ala-Arg-Tyr-Asn-Ala-Gln-Cys-Gln-Glu-Thr-Ile-Arg-Val- Thr-Lys-Pro-Cys-Thr-Pro-Lys-Thr-Lys-Ala-Lys-Ala- Lys-Ala-Lys-Lys-Gly-Lys-Gly-Lys-Asp (Disulfide bonds between Cys62-Cys94 and Cys72-Cys104) (M.W. 6788.8) C292H483N91O87S4 Heparin-Binding Growth/Differentiation Factor Active-Domain (Neurite Outgrowth-Promoting Factor) Plasminogen Activator Activity Enhancer

PMK-4299-s-20 °C

0.1 mgvial

J.-i. Tsutsui, K. Uehara, K. Kadomatsu, S. Matsubara, and T. Muramatsu, Biochem. Biophys. Res. Commun., 176, 792 (1991). (Original)H. Muramatsu, T. Inui, T. Kimura, S. Sakakibara, X.-J. Song, H. Maruta, and T. Muramamtsu, Biochem. Biophys. Res. Commun., 203, 1131 (1994). T. Inui, J. Bódi, S. Kubo, H. Nishio, T. Kimura, S. Kojima, H. Maruta, T. Muramatsu, and S. Sakakibara, J. Peptide Sci., 2, 28 (1996). (Chem. Synthesis)G.S.P. Yu, J. Hu, and H. Nakagawa, Neurosci. Lett., 254, 128 (1998). (Pharmacol.; Inhibition of b-amyloid cytotoxicity)• This product is distributed under the license of Prof. Takashi Muramatsu. Its use for any purpose other than research is strictly prohibited.


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 85

Molluscan Cardioexcitatory NeuropeptideFMRF-Amide* Molluscan Cardioexcitatory Neuropeptide

Phe-Met-Arg-Phe-NH2 (M.W. 598.76) C29H42N8O4S [64190-70-1]

PFM-4142-v-20 °C

0.5 mgvial


FMRF-Amide* (Bulk) Molluscan Cardioexcitatory Neuropeptide

PFM-4142-20 °C

25 mg100 mg

Phe-Met-Arg-Phe-NH2 • 1½ AcOH • 2H2O (M.W. 598.76 • 90.08 • 36.03) C29H42N8O4S • 11⁄2CH3COOH • 2H2OD.A. Price and M.J. Greenberg, Science, 197, 670 (1977). (Original)


Morphine Tolerance PeptideMorphine Tolerance Peptide (Bulk)

cyclo (Leu-Gly) (M.W. 170.21 ) C8H14N2O2 [5845-67-0]

PMT-4070-20 °C

25 mg100 mg

R. Walter, R. Ritzmann, H.N. Bhargava, and L.B. Flexner, Proc. Natl. Acad. Sci. USA, 76, 518 (1979). (Original)

MotilinMotilin (Human, Porcine)

Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg- Met-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln (M.W. 2699.0) C120H188N34O35S [52906-92-0]

PML-4147-v-20 °C

0.5 mgvial

J.C. Brown, M.A. Cook, and J.R. Dryburgh, Can. J. Biochem., 51, 533 (1973). (Original; Porcine) H. Schubert and J.C. Brown, Can. J. Biochem., 52, 7 (1974). (Correction of Sequence; Gln14) Y. Seino, K. Tanaka, H. Takahashi, T. Mitani, M. Kurono, T. Kayano, G. Koh, H. Fukumoto, H. Yano, J. Fujita, N. Inagaki, Y. Yamada, and H. Imura, FEBS Lett., 223, 74 (1987). (Original; Human-cDNA) C.H.S. McIntosh and J.C. Brown, Adv. Metab. Dis., 11, 439 (1988). (Review)

MSH See Code PMI-4024 MSH-Release Inhibiting Factor on page 82Muramyl Dipeptide See Code PAD-4031 Adjuvant Peptide on page 1.

86 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Neuroendocrine Regulatory Peptides“Peptidome”, one of the principle research fields in the post-genome era, is a power-ful method to discover novel peptides. One such study has been reported recently from the collaboration of several groups including National Cardiovascular Center Research Institute and University of Miyazaki. The peptides disclosed are neuroendo-crine regulatory peptide-1 and -2 (abbreviated as NERP-1 and NERP-2, respectively). Both peptides were isolated either from medullary thyroid carcinoma TT cells or rat brain applying modern techniques of peptide chemistry / biochemistry. Human and rat NERP-1 are composed of 26 and 25 amino acid residues, respectively, and NERP-2 of both species are composed of 38 amino acid residues, all contain the carboxyl-terminal amide functionality. Interestingly, these peptides were the segments of the neurosecretory protein VGF, suggesting a unique processing signal for NERP-2.

NERP-1 (Human): RPESALLGGSEAGERLLQQGLAQVEA-NH2

NERP-1 (Rat): LEGSFLGGSEAGERLLQQGLAQVEA-NH2

NERP-2 (Human): <EAEATRQAAAQEERLADLASDLLLQYLLQGGARQRGLG-NH2

NERP-2 (Rat): <EAEATRQAAAQEERLADLASDLLLQYLLQGGARQRDLG-NH2

Biological activity reported is: i) suppression of vasopressin release induced by intracerebroventricular administration of angiotensin II in rat and ii) suppression of basal and angiotensin II-induced vasopressin secretion from the paraventricular and supraoptic nuclei of rat hypothalamus in vitro. Considering the fact that NERPs coexist with vasopressin in the hypothalamus, these newly identified peptides may be “potent endogenous suppressor of vasopressin release”, thus implying an essential role in body fluid homeostasis. 1. H. Yamaguchi, K. Sasaki, Y. Satomi, T. Shimbara, H. Kageyama, M.S. Mondal, K. Toshinai, Y. Date, L.J. Gonz´alez, S. Shioda, T. Takao, M. Nakazato, and N. Minamino, J. Biol., Chem., 282, 26354 (2007). (Original)2. E. Mishiro-Sato, K. Sasaki, T. Matsuo, H. Kageyama, H. Yamaguchi, Y. Date, M. Matsubara, T. Ishizu, K. Yoshizawa-Kumagaye, Y. Satomi, T. Takao, S. Shioda, M. Nakazato, and N. Minamino, J. Neurochem., 114, 1097 (2010). (Processing & Histochem.)• These compounds are distributed through Peptide Institute, Inc. under the license of Takeda Pharmaceutical Company Limited.

Neuroendocrine Regulatory Peptide-1 (Human) NERP-1 (Human)

RPESALLGGSEAGERLLQQGLAQVEA-NH2H-Arg-Pro-Glu-Ser-Ala-Leu-Leu-Gly-Gly-Ser-Glu-Ala-Gly-Glu-Arg-Leu-Leu-Gln-Gln-Gly-Leu-Ala-Gln-Val-Glu-Ala-NH2(M.W. 2679.0) C113H192N36O39 [954420-50-9]Endogenous Suppressor of Vasopressin Release

PNR-4441-s-20 °C

0.1 mgvial

H. Yamaguchi, K. Sasaki, Y. Satomi, T. Shimbara, H. Kageyama, M.S. Mondal, K. Toshinai, Y. Date, L.J. Gonzalez, S. Shioda, T. Takao, M. Nakazato, and N. Minamino, J. Biol. Chem., 282, 26354 (2007). (Original)

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 87

Neuroendocrine Regulatory Peptide-1 (Rat) NERP-1 (Rat)

LEGSFLGGSEAGERLLQQGLAQVEA-NH2H-Leu-Glu-Gly-Ser-Phe-Leu-Gly-Gly-Ser-Glu-Ala-Gly-Glu-Arg-Leu-Leu-Gln-Gln-Gly-Leu-Ala-Gln-Val-Glu-Ala-NH2(M.W. 2558.8) C110H180N32O38Endogenous Suppressor of Vasopressin Release

PNR-4442-s-20 °C

0.1 mgvial


Neuroendocrine Regulatory Peptide-2 (Human) NERP-2 (Human)

EAEATRQAAAQEERLADLASDLLLQYLLQGGARQRGLG-NH2Pyr-Ala-Glu-Ala-Thr-Arg-Gln-Ala-Ala-Ala-Gln-Glu-Glu-Arg-Leu-Ala-Asp-Leu-Ala-Ser-Asp-Leu-Leu-Leu-Gln-Tyr-Leu- Leu-Gln-Gly-Gly-Ala-Arg-Gln-Arg-Gly-Leu-Gly-NH2

(M.W. 4064.5) C173H288N56O57 Endogenous Suppressor of Vasopressin Release

PNR-4443-s-20 °C

0.1 mgvial


Neuroendocrine Regulatory Peptide-2 (Rat) NERP-2 (Rat)

EAEATRQAAAQEERLADLASDLLLQYLLQGGARQRDLG-NH2Pyr-Ala-Glu-Ala-Thr-Arg-Gln-Ala-Ala-Ala-Gln-Glu-Glu-Arg-Leu-Ala-Asp-Leu-Ala-Ser-Asp-Leu-Leu-Leu-Gln-Tyr-Leu- Leu-Gln-Gly-Gly-Ala-Arg-Gln-Arg-Asp-Leu-Gly-NH2 (M.W. 4122.5) C175H290N56O59Endogenous Suppressor of Vasopressin Release

PNR-4444-s-20 °C

0.1 mgvial


Neo-Endorphinsa-Neo-Endorphin (Porcine)

Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys (M.W. 1228.4) C60H89N15O13

K. Kangawa, N. Minamino, N. Chino, S. Sakakibara, and H. Matsuo, Biochem. Biophys. Res. Commun., 99, 871 (1981). (Original)

PEN-4090-v-20 °C

0.5 mgvial

b-Neo-Endorphin (Porcine)Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro (M.W. 1100.3) C54H77N13O12 [77739-21-0] N. Minamino, K. Kangawa, N. Chino, S. Sakakibara, and H. Matsuo, Biochem. Biophys. Res. Commun., 99, 864 (1981). (Original)

PEN-4091-v -20 °C

0.5 mg vial

NeurokininsNeurokinin A* Neuromedin L, Substance K (Human, Porcine, Rat, Mouse)

His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2 (M.W. 1133.3) C50H80N14O14S [86933-74-6]

PNK-4154-v-20 °C

0.5 mgvial


NEW!

NEW!

NEW!

88 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Neurokinin A* (Bulk) Neuromedin L, Substance K (Human, Porcine, Rat, Mouse)

His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2 • 2AcOH • 5H2O (M.W. 1133.3 • 120.10 • 90.08) C50H80N14O14S • 2CH3COOH • 5H2O NK2 Receptor Selective Agonist

PNK-4154-20 °C

25 mg

S. Kimura, M. Okada, Y. Sugita, I. Kanazawa, and E. Munekata, Proc. Jpn. Acad., 59 (B), 101 (1983). (Original; Porcine Neurokinin A) K. Kangawa, N. Minamino, A. Fukuda, and H. Matsuo, Peptide Chemistry 1983, 309 (1984). (Original; Porcine Neuromedin L) H. Nawa, T. Hirose, H. Takashima, S. Inayama, and S. Nakanishi, Nature, 306, 32 (1983). (Original; Porcine Substance K) A.J. Harmar, A. Armstrong, J.C. Pascall, K. Chapman, R. Rosie, A. Curtis, J. Going, C.R.W. Edwards, and G. Fink, FEBS Lett., 208, 67 (1986). (cDNA Seq.; Human)

Neurokinin B (Neuromedin K)Neurokinin B Neuromedin K (Human, Porcine, Bovine, Rat, Mouse)

Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2 (M.W. 1210.4) C55H79N13O14S2 [86933-75-7]

PNP-4317-v-20 °C

0.5 mgvial

Neurokinin B (Bulk) Neuromedin K (Human, Porcine, Bovine, Rat, Mouse)

PNP-4317-20 °C

25 mg

Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2 • 1/2AcOH • 4H2O (M.W. 1210.4 • 30.03 • 72.06) C55H79N13O14S2 • 1/2CH3COOH • 4H2O NK3 Receptor Selective AgonistS. Kimura, M. Okada, Y. Sugita, I. Kanazawa, and E. Munekata, Proc. Jpn. Acad., 59 (B), 101 (1983). (Original; Porcine Neurokinin B) K. Kangawa, N. Minamino, A. Fukuda, and H. Matsuo, Biochem. Biophys. Res. Commun., 114, 533 (1983). (Original; Porcine Neuromedin K) M.K. Chawla, G.M. Gutierrez, W.S. Young III, N.T. McMullen, and N.E. Rance, J. Comp. Neurol., 384, 429 (1997). (Neurokinin B Nucleotide Seq.; Human) T.I. Bonner., H.-U. Affolter, A.C. Young, and W.S. Young III, Mol. Brain Res., 2, 243 (1987). (cDNA Seq.; Rat)

NeuromedinsNeuromedin B* (Human, Porcine, Rat)

Gly-Asn-Leu-Trp-Ala-Thr-Gly-His-Phe-Met-NH2 (M.W. 1132.3) C52H73N15O12S [87096-84-2]

PNM-4152-v-20 °C

0.5 mgvial


Neuromedin B* (Bulk) (Human, Porcine, Rat)

Gly-Asn-Leu-Trp-Ala-Thr-Gly-His-Phe-Met-NH2 • AcOH • 5H2O

PNM-4152-20 °C

25 mg

(M.W. 1132.3 • 60.05 • 90.08) C52H73N15O12S • CH3COOH • 5H2ON. Minamino, K. Kangawa, and H. Matsuo, Biochem. Biophys. Res. Commun., 114, 541 (1983). (Original; Porcine) I.M. Krane, S.L. Naylor, D. Helin-Davis, W.W. Chin, and E.R. Spindel, J. Biol. Chem., 263, 13317 (1988). (cDNA Seq.; Human) E. Wada, J. Way, A.M. Lebacq-Verheyden, and J.F. Battey, J. Neurosci., 10, 2917 (1990). (cDNA Seq.; Rat)



NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 89

Neuromedin C* Gastrin Releasing Peptide (Human, 18-27) GRP (18-27)(Human, Porcine, Canine)

Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 (M.W. 1120.3) C50H73N17O11S [81608-30-2]

PNM-4153-v-20 °C

0.5 mgvial


Neuromedin C* (Bulk) Gastrin Releasing Peptide (Human, 18-27) GRP (18-27) (Human, Porcine, Canine)

Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 • 2AcOH • 5H2O

PNM-4153-20 °C

25 mg

(M.W. 1120.3 • 120.11 • 90.08) C50H73N17O11S • 2CH3COOH • 5H2OK.A. Roth, C.J. Evans, R.G. Lorenz, E. Weber, J.D. Barchas, and J.K. Chang, Biochem. Biophys. Res. Commun., 112, 528 (1983). (Original; GRP (18-27)) N. Minamino, K. Kangawa, and H. Matsuo, Biochem. Biophys. Res. Commun., 119, 14 (1984). (Original; Porcine Neuromedin C) M.S. Orloff, J.R. Reeve, Jr., C.M. Ben-Avram, J.E. Shively, and J.H. Walsh, Peptides, 5, 865 (1984). (Seq.; Human) J.R. Reeve, Jr., H. Walsh, P. Chew, B. Clark, D. Hawke, and J.E. Shively, J. Biol. Chem., 258, 5582 (1983). (Isolation & Seq.; Canine Bombesin-like Peptide)


Neuromedin S (Human)NMS (Human)

Ile-Leu-Gln-Arg-Gly-Ser-Gly-Thr-Ala-Ala-Val-Asp-Phe- Thr-Lys-Lys-Asp-His-Thr-Ala-Thr-Trp-Gly-Arg-Pro- Phe-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2(M.W. 3791.3) C173H265N53O44Food Intake Suppressor / Regulator of Circadian Rhythm

PNM-4426-s-20 °C

0.1 mgvial

• This compound is distributed through Peptide Institute, Inc. under the license of National Cardiovascular Center and Takeda Pharmaceutical Company Limited.

Neuromedin S (Rat)NMS (Rat)

Leu-Pro-Arg-Leu-Leu-His-Thr-Asp-Ser-Arg-Met-Ala-Thr-Ile- Asp-Phe-Pro-Lys-Lys-Asp-Pro-Thr-Thr-Ser-Leu-Gly-Arg- Pro-Phe-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2(M.W. 4241.9) C193H307N57O49SFood Intake Suppressor / Regulator of Circadian Rhythm

PNM-4427-s-20 °C

0.1 mgvial

• This compound is distributed through Peptide Institute, Inc. under the license of National Cardiovascular Center and Takeda Pharmaceutical Company Limited

90 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Neuromedin U (Rat) NMU-23 (Rat)

Tyr-Lys-Val-Asn-Glu-Tyr-Gln-Gly-Pro-Val-Ala-Pro-Ser- Gly-Gly-Phe-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 (M.W. 2643.0) C124H180N34O31 [117505-80-3] Food Intake Suppressor

PNM-4377-v-20 °C

0.5 mgvial

J.M. Conlon, J. Domin, L. Thim, V. DiMarzo, H.R. Morris, and S.R. Bloom, J. Neurochem., 51, 988 (1988). (Original; Primary Structure) N. Minamino, K. Kangawa, M. Honzawa, and H. Matsuo, Biochem. Biophys. Res. Commun., 156, 355 (1988). (Original; Primary Structure) A.D. Howard, R. Wang, S.-S. Pong, T.N. Mellin, A. Strack, X.-M. Guan, Z. Zeng, D.L. Williams, Jr., S.D. Feighner, C.N. Nunes, B. Murphy, J.N. Stair, H. Yu, Q. Jiang, M.K. Clements, C.P. Tan, K.K. McKee, D.L. Hreniuk, T.P. McDonald, K.R. Lynch, J.F. Evans, C.P. Austin, C.T. Caskey, L.H.T. Van der Ploeg, and Q. Liu, Nature, 406, 70 (2000). (Pharmacol.) M. Nakazato, R. Hanada, N. Murakami, Y. Date, M.S. Mondal, M. Kojima, H. Yoshimatsu, K. Kangawa, and S. Matsukura, Biochem. Biophys. Res. Commun., 277, 191 (2000). (Pharmacol.)

H-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2Neuromedin U8 PorcineYFLFRPRN-Amide

(M.W. 1111.32) C54H78N16O10 Neuropeptide

PNM-3698-PI -20 °C

1 mg5 mg

N. Minamino, K. Kangawa, and H. Matsuo, Biochem. Biophys. Res. Commun., 130, 1078 (1985).

NeuronostatinNeuronostatin-13 (Human) Neuronostatin-13 (Human)(Chimpanzee, Porcine, Canine, Ovine, Bovine, Chicken)

Leu-Arg-Gln-Phe-Leu-Gln-Lys-Ser-Leu-Ala-Ala-Ala-Ala-NH2(M.W. 1415.7) C64H110N20O16

PNS-4452-v-20 °C

0.5 mgvial

Brain/Gut Hormone in Pro-Somatostatin with Neuronal/Neuroendocrine/Cardiovascular Activity

In the post-genome era, a novel peptide called neuronostatin-13 has been predicted in pro-somatostatin gene sequence based on bioinformatics method. Neuronostatin-13 was purified from porcine tissue by immuno-affinity procedure and then confirmed to be an endogenous peptide. Actually, neuronostatin-13 is a 13 amino acid residue peptide with carboxyl-terminal amidation, the primary structure of which is conserved in human, chimpanzee and some other mammals.The biological functions of neuronostatin-13 reported so far include: i) intracerebroventricular administration of neuronostatin-13 in rats increased blood pressure but suppressed food intake and water drinking (0.3 nmol per rat)1), ii) in both brain and gastric cells, neuronostatin-13 stimulates c-Fos expression and cell proliferation/migration1, and iii) this peptide depresses cardiac contractile function.2 Thus, neuronostatin-13 might be a new member of brain/gut hormones. In addition, the function of neuronostatin-13 is not mediated by somatostatin receptors. Neuronostatin-13 with "diverse neuronal, neuroendocrine, and cardiovascular actions" could be of interest in the research field of hormonal regulation of the body.1. W.K. Samson, J.V. Zhang, O. Avsian-Kretchmer, K. Cui, G.L.C. Yosten, C. Klein, R.-M. Lyu, Y.X. Wang, X.Q. Chen, J. Yang, C.J. Price, T.D. Hoyda, A.V. Ferguson, X.-bin Yuan, J.K. Chang, and A.J.W. Hsueh, J. Biol. Chem., 283, 31949 (2008). (Original; Structure & Pharmacol.)2. Y. Hua, H. Ma, W.K. Samson, and J. Ren, Am. J. Physiol. Regul. Integr. Comp. Physiol., 297, 682 (2009). (Pharmacol.)

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 91

NeuropeptidesNeuropeptide B-29 (Rat) (Non-Brominated Form)NPB-29 (Rat) (Non-brominated)

Trp-Tyr-Lys-Pro-Ala-Ala-Gly-Ser-His-His-Tyr-Ser-Val-Gly-Arg-Ala-Ala-Gly-Leu-Leu-Ser-Ser-Phe-His-Arg-Phe-Pro-Ser-Thr(M.W. 3188.5) C147H211N43O38Synthetic Product Ligand of NPBWR1 (GPR7)

PNP-4459-v-20 °C

0.5 mgvial

R. Fujii, H. Yoshida, S. Fukusumi, Y. Habata, M. Hosoya, Y. Kawamata, T. Yano, S. Hinuma, C. Kitada, T. Asami, M. Mori, Y. Fujisawa, and M. Fujino, J. Biol. Chem., 277, 34010 (2002). (Original; cDNA Sequence)H. Tanaka, T. Yoshida, N. Miyamoto, T. Motoike, H. Kurosu, K. Shibata, A. Yamanaka, S.C. Williams, J.A. Richardson, N. Tsujino, M.G. Garry, M.R. Lerner, D.S. King, B.F. O’Dowd, T. Sakurai, and M. Yanagisawa, Proc. Natl. Acad. Sci. U.S.A., 100, 6251 (2003). (Pharmacol.)S. Aikawa, M. Ishii, M. Yanagisawa, Y. Sakakibara, and T. Sakurai, Regul. Pept.,151,147 (2008). (Pharmacol.; Food Intake Regulatory Activity)N. Hirashima, T. Tsunematsu, K. Ichiki, H. Tanaka, T.S. Kilduff, and A. Yamanaka, Sleep, 1, 31 (2011). (Pharmacol.; Slow Wave Sleep Induction Activity)

Neuropeptide S (Human)NPS (Human)

Ser-Phe-Arg-Asn-Gly-Val-Gly-Thr-Gly-Met-Lys- Lys-Thr-Ser-Phe-Gln-Arg-Ala-Lys-Ser (M.W. 2187.5) C93H155N31O28S [412938-67-1]

PNP-4425-v-20 °C

0.5 mgvial

Novel Modulator of Arousal and Anxiety / Food Intake Suppressor

Y.L. Xu, R.K. Reinscheid, S. Huitron-Resendiz, S.D. Clark, Z. Wang, S.H. Lin, F.A. Brucher, J. Zeng, N.K. Ly, S.J. Henriksen, L. de Lecea, and O. Civelli, Neuron, 43, 487 (2004). (Original)R.K. Reinscheid and Y.-L. Xu, FEBS J., 272, 5689 (2005). (Minireview)B. Beck, B. Fernette, and A. Stricker-Krongrad, Biochem. Biophys. Res. Commun., 332, 859 (2005). (Pharmacol.)K.L. Smith, M. Patterson, W.S. Dhillo, S.R. Patel, N.M. Semjonous, J.V. Gardiner, M.A. Ghatei, and S.R. Bloom, Endocrinology, 147, 3510 (2006). (Pharmacol.)A. Fedeli, S. Braconi, D. Economidou, N. Cannella, M. Kallupi, R. Guerrini, G. Calo, C. Cifani, M. Massi, and R. Ciccocioppo, Eur. J. Neurosci., 30, 1594 (2009). (Pharmacol.)

Neuropeptide W-30 (Human)NPW30 (Human) hL8C

Trp-Tyr-Lys-His-Val-Ala-Ser-Pro-Arg-Tyr-His-Thr- Val-Gly-Arg-Ala-Ala-Gly-Leu-Leu-Met-Gly- Leu-Arg-Arg-Ser-Pro-Tyr-Leu-Trp (M.W. 3543.1) C165H249N49O37S [383415-80-3] Food Intake-Regulating Peptide / GPR7 / GPR8 Ligand

PNP-4403-v-20 °C

0.5 mgvial

NEW!

92 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Neuropeptide W-30 (Rat)NPW30 (Rat), rL8C

Trp-Tyr-Lys-His-Val-Ala-Ser-Pro-Arg-Tyr-His-Thr- Val-Gly-Arg-Ala-Ser-Gly-Leu-Leu-Met-Gly- Leu-Arg-Arg-Ser-Pro-Tyr-Leu-Trp (M.W. 3559.1) C165H249N49O38S [383415-90-5] Food Intake-Regulating Peptide / GPR7 / GPR8 Ligand

PNP-4404-v-20 °C

0.5 mgvial

Y. Shimomura, M. Harada, M. Goto, T. Sugo, Y. Matsumoto, M. Abe, T. Watanabe, T. Asami, C. Kitada, M. Mori, H. Onda, and M. Fujino, J. Biol. Chem., 277, 35826 (2002). (Original; NPW) S. Brezillon, V. Lannoy, J.-D. Franssen, E. Le Poul, V. Dupriez, J. Lucchetti, M. Detheux, and M. Parmentier, J. Biol. Chem., 278, 776 (2003). (Original; hL8C) H. Tanaka, T. Yoshida, N. Miyamoto, T. Motoike, H. Kurosu, K. Shibata, A. Yamanaka, S.C. Williams, J.A. Richardson, N. Tsujino, M.G. Garry, M.R. Lerner, D.S. King, B.F. O’Dowd, T. Sakurai, and M. Yanagisawa, Proc. Natl. Acad. Sci. USA, 100, 6251 (2003). (cDNA) M.S. Mondal, H. Yamaguchi, Y. Date, T. Shimbara, K. Toshinai, Y. Shimomura, M. Mori, and M. Nakazato, Endocrinology, 144, 4729 (2003). (Pharmacol.) F. Takenoya, S. Kitamura,, H. Kageyama, N. Nonaka, M. Seki, K. Itabashi, Y. Date, M. Nakazato, and S. Shioda, Regul. Pept., 145, 159 (2008) (Pharmacol.)•This compound is distributed through Peptide Institute, Inc. under license of Takeda Chemical Industries, Ltd.


Neuropeptide Y (NPY) and Related PeptidesY. Dumont, J.-C. Martel, A. Fournier, S. St-Pierre, and R. Quirion, Progr. Neurobiol., 38, 125 (1992). (Review). C. Wahlestedt and D.J. Reis, Annu. Rev. Pharmacol. Toxicol., 32, 309 (1993). (Review)

NPY (Human, Rat)* Neuropeptide Y (Human, Rat)

Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro- Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His- Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 (M.W. 4271.7) C189H285N55O57S [90880-35-6]

PNP-4158-s-20 °C

0.1 mgvial

NPY (Human, Rat)*Neuropeptide Y (Human, Rat)

Purity Information: Qp See page xiv

PNP-4158-v-20 °C

0.5 mgvial

C.D. Minth, S.R. Bloom, J.M. Polka, and J.E. Dixon, Proc. Natl. Acad. Sci. U.S.A., 81, 4577 (1984). (Original; Human cDNA) D. Larhammer, A. Ericsson, and H. Persson, Proc. Natl. Acad. Sci. U.S.A., 84, 2068 (1987). (Original; Rat Nucleotide Seq.)

NPY (Porcine, Bovine)* Neuropeptide Y (Porcine, Bovine)

Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala- Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr- Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 (M.W. 4253.6) C190H287N55O57 [83589-17-7]

PNP-4162-s-20 °C

0.1 mg


NPY (Porcine, Bovine)* Neuropeptide Y (Porcine, Bovine)

Purity Information: Qp See page xivK. Tatemoto, Proc. Natl. Acad. Sci. USA, 79, 5485 (1982). (Original)

PNP-4162-v-20 °C

0.5 mgvial



NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 93

[Leu31,Pro34]-NPY (Porcine) [Leu31,Pro34]-Neuropeptide Y (Porcine) (Bovine)

Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala- Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr- Ile-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 (M.W. 4222.6) C190H286N54O56 [125580-28-1] NPY Y1-Receptor Selective Agonist Purity Information: Qp See page xiv

PNP-4314-s-20 °C

0.1 mg vial

J. Fuhlendorff, U. Gether, L. Aakerlund, N. Langeland-Johansen, H. Thøgersen, S.G. Melberg, U.B. Olsen, O. Thastrup, and T.W. Schwartz, Proc. Natl. Acad. Sci. USA, 87, 182 (1990). (Original) S.P. Sheikh, Am. J. Physiol., 261, G701 (1991). (Pharmacol.)

NPY (Porcine, 13-36) Neuropeptide Y (Porcine, 13-36) (Bovine)

Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg- His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 (M.W. 2982.4) C135H209N41O36 [113662-54-7] NPY Y2-Receptor Selective Agonist

PNP-4315-s-20 °C

0.1 mg vial

M.W. Walker and R.J. Miller, Mol. Pharmacol., 34, 779 (1988). (Pharmacol.) J. Fuhlendorff, U. Gether, L. Aakerlund, N. Langeland-Johansen, H.Thøgersen, S.G. Melberg, U.B. Olsen, O. Thastrup, and T.W. Schwartz, Proc. Natl. Acad. Sci. USA, 87, 182 (1900). (Pharmacol.) S.P. Sheikh, Am. J. Physiol., 261, G701 (1991). (Pharmacol.)

NeurotensinNeurotensin (Human, Bovine, Canine, Mouse)

Pyr-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu (M.W. 1672.9) C78H121N21O20 [55508-42-4]

PNT-4029-v-20 °C

0.5 mgvial

Neurotensin (Bulk) (Human, Bovine, Canine, Mouse)

PNT-4029-20 °C

25 mg

Pyr-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu • 2AcOH • 6H2O (M.W. 1672.9 • 120.10 • 108.09) C78H121N21O20 • 2CH3COOH • 6H2OR. Carraway and S.E. Leeman, J. Biol. Chem., 248, 6854 (1973). (Original; Bovine) R.A. Hammer, S.E. Leeman, R. Carraway, and R.H. Williams, J. Biol. Chem., 255, 2476 (1980). (Original; Human) P.R. Dobner, D.L. Barber, L. Villa-Komaroff, and C. McKiernan, Proc. Natl. Acad. Sci. U.S.A., 84, 3516 (1987). (cDNA Seq.; Canine) P.R. Dobner, J. Fadel, N. Deitemeyer, R.E. Carraway, and A.Y. Deutch, Proc. Natl. Acad. Sci. U.S.A., 98, 8048 (2001). (cDNA Seq.; Mouse)

94 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES NociceptinNociceptin (Human) Orphanin FQ (Human) (Rat, Mouse, Bovine, Porcine)

PNO-4318-v-20 °C

0.5 mg vial

Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln (M.W. 1809.0) C79H129N27O22 [170713-75-4] Agonist of Opioid Receptor-Like-1 (ORL1) ReceptorJ.-C. Meunier, C. Mollereau, L. Toll, C. Suaudeau, C. Moisand, P. Alvinerie, J.-L. Butour, J.-C. Guillemot, P. Ferrara, B. Monsarrat, H. Mazarguil, G. Vassart, M. Parmentier, and J. Costentin, Nature, 377, 532 (1995). (Original; Nociceptin-ORL1 Receptor Agonist) R.K. Reinscheid, H.-P. Nothacker, A. Bourson, A. Ardati, R.A. Henningsen, J.R. Bunzow, D.K. Grandy, H. Langen, F.J. Monsma, Jr., and O. Civelli, Science, 270, 792 (1995). (Original; Orphanin FQ) C. Mollereau, M.-J. Simons, P. Soularue, F. Liners, G. Vassart, J.-C. Meunier, and M. Parmentier, Proc. Natl. Acad.Sci. U.S.A., 93, 8666 (1996). (Original; Human, Rat, & Mouse Nociceptin-Nucleotide Seq.) J.C. Meunier, Eur. J. Pharmacol., 340, 1 (1997). (Review)G. Csaba and K. Tekes, Brain Dev., 27, 465 (2005). (Review)Z.S. Zadori, N. Shujaa, L. Koeles, K.P. Kiraly, K. Tekes, and K. Gyires, Peptides, 29, 2257 (2008). (Pharmacol.)

NocistatinsNocistatin (Human)

Met-Pro-Arg-Val-Arg-Ser-Leu-Phe-Gln-Glu-Gln- Glu-Glu-Pro-Glu-Pro-Gly-Met-Glu-Glu-Ala- Gly-Glu-Met-Glu-Gln-Lys-Gln-Leu-Gln (M.W. 3561.9) C149H238N42O53S3

PNO-4355-v-20 °C

0.5 mgvial

Endogenous Allodynia / Hyperalgesia-Blocking Peptide Nociceptin Action Blocking PeptideT. Minami, E. Okuda-Ashitaka, Y. Nishiuchi, T. Kimura, S. Tachibana, H. Mori, and S. Ito, Br. J. Pharmacol., 124, 1016 (1998). (Original; Pharmacol.) C. Mollereau, M.-J. Simons, P. Soularue, F. Liners, G. Vassart, J.-C. Meunier, and M. Parmentier, Proc. Natl. Acad. Sci. U.S.A., 93, 8666 (1996). (Original; Prepronociceptin Nucleotide Seq.) T.-L. Lee, F.M.Y. Fung, F.-G. Chen, N. Chou, E. Okuda-Ashitaka, S. Ito, Y. Nishiuchi, T. Kimura, and S. Tachibana, NeuroReport, 10,1537 (1999). (Original; Identification in Human) Z.S. Zadori, N. Shujaa, L. Koeles, K.P. Kiraly, K. Tekes, and K. Gyires, Peptides, 29, 2257 (2008). (Pharmacol.)

Nocistatin (Bovine)(Ammonium Form) Thr-Glu-Pro-Gly-Leu-Glu-Glu-Val-Gly-Glu-Ile- Glu-Gln-Lys-Gln-Leu-Gln (M.W. 1927.1) C82H135N21O32 Endogenous Allodynia / Hyperalgesia-Blocking Peptide Nociceptin Action Blocking Peptide

PNO-4336-v-20 °C

0.5 mgvial

E. Okuda-Ashitaka, T. Minami, S. Tachibana, Y. Yoshihara, Y. Nishiuchi, T. Kimura, and S. Ito, Nature, 392, 286 (1998). (Original) B. Nicol, D.J. Lambert, D.J. Rowbothan, E. Okuda-Ashitaka, S. Ito, D. Smart, and A.T. McKnight, Eur. J. Pharmacol., 356, R1 (1998). (Pharmacol.) T. Nakagawa, M. Kaneko, S. Inamura, and M. Satoh, Neurosci. Lett., 265, 64 (1999). (Pharmacol.) H. Nakano, T. Minami, K. Abe, T. Arai, M. Tokumura, N. Ibii, E. Okuda-Ashitaka, H. Mori , and S. Ito, J. Pharmacol. Exp. Ther., 292, 331 (2000). (Pharmacol.) M. Fantin, C. Fischetti, C. Trapella, and M. Morari, Br. J. Pharmacol., 152, 549 (2007). (Pharmacol.)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 95

Obestatin and Related AnalogsObestatin (Human)(Human, Monkey)

PGH-3890-PI-20 °C

1 mg5 mg

H-Phe-Asn-Ala-Pro-Phe-Asp-Val-Gly-Ile-Lys-Leu-Ser-Gly-Val-Gln-Tyr-Gln-Gln-His-Ser-Gln-Ala-Leu-NH2 FNAPFDVGIKLSGVQYQQHSQAL-NH2 (M.W. 2546.89) C116H176N32O33 Suppressor of Food Intake and Gastric EmptyingJ.V. Zhang, P. Ren, O. Avsian-Kretchmer, C. Luo, R. Rauch, C. Klein, and A.J.W. Hsueh, Science, 310, 996 (2005). M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa, Nature, 402, 656 (1999).

Obestatin (Rat, Mouse) H-Phe-Asn-Ala-Pro-Phe-Asp-Val-Gly-Ile-Lys-Leu-Ser- Gly-Ala-Gln-Tyr-Gln-Gln-His-Gly-Arg-Ala-Leu-NH2FNAPFDVGIKLSGAQYQQHGRAL-NH2 (M.W. 2516.87) C114H174N34O31 Suppressor of Food Intake and Gastric Emptying

PGH-3891-PI-20 °C

1 mg5 mg

J.V. Zhang, P. Ren, O. Avsian-Kretchmer, C. Luo, R. Rauch, C. Klein, and A.J.W. Hsueh, Science, 310, 996 (2005). M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa, Nature, 402, 656 (1999).

Des 1-10 Obestatin (Human)Obestatin (Human, 11-23)

H-Leu-Ser-Gly-Val-Gln-Tyr-Gln-Gln-His-Ser-Gln-Ala-Leu-NH2H-LSGVQYQQHSQAL-NH2(M.W. 1457.62) C63H100N20O20Truncated Analog of Obestatin

PGH-3892-PI-20 °C

1 mg5 mg


Des 1-10 Obestatin (Rat, Mouse) Obestatin (Rat, Mouse, 11-23)

H-Leu-Ser-Gly-Ala-Gln-Tyr-Gln-Gln-His-Gly-Arg-Ala-Leu-NH2H-LSGAQYQQHGRAL-NH2(M.W. 1427.60) C61H98N22O18Truncated Analog of Obestatin

PGH-3893-PI-20 °C

1 mg5 mg


96 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES OrexinsT. Sakurai, Regul. Pept., 85, 25 (1999). (Review) J.M. Siegel, Cell, 98, 409 (1999). (Review) L. De Lecea and J.G. Sutcliffe, Cell. Mol. Life Sci., 56, 473 (1999). (Review) R.J. Rodgers, Y. Ishii, J.C.G. Halford, and J.E. Blundell, Neuropeptides, 36, 303 (2002). (Review)N. Tsujino and T. Sakurai, Pharmacol. Rev., 61, 162 (2009). (Review)M. Mieda and T. Sakurai, CNS Neurol. Disord. Drug Targets, 8, 281 (2009). (Review)B.C. Baccari, Curr. Protein Pept. Sci., 11, 148 (2010). (Review)

Orexin-A (Human) (Rat, Mouse, Bovine)

POR-4346-s-20 °C

0.1 mgvial

Pyr-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr- Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2 (Disulfide bonds between Cys6-Cys12 and Cys7-Cys14) (M.W. 3561.1) C152H243N47O44S4 [205640-90-0] Appetite-Boosting Peptide / Sleep-Wakefulness State RegulatorT. Sakurai, A. Amemiya, M. Ishii, I. Matsuzaki, R.M. Chemelli, H. Tanaka, S.C. Williams, J.A. Richardson, G.P. Kozlowski, S. Wilson, J.R.S. Arch, R.E. Buckingham, A.C. Haynes, S.A. Carr, R.S. Annan, D.E. McNulty, W.-S. Liu, J.A. Terrett, N.A. Elshourbagy, D.J. Bergsma, and M. Yanagisawa, Cell, 92, 573 (1998). (Original) L. de Lecea, T.S. Kilduff, C. Peyron, X.-B. Gao, P.E. Foye, P.E. Danielson, C. Fukuhara, E.L.F. Battenberg, V.T. Gautvik, F.S. Bartlett II, W.N. Frankel, A.N. van den Pol, F.E. Bloom, K.M. Gautvik, and J.G. Sutcliffe, Proc. Natl. Acad. Sci. U.S.A., 95, 322 (1998). (cDNA; Same Sequence [Hypocretin]) N. Takahashi, T. Okumura, H. Yamada, and Y. Kohgo, Biochem. Biophys. Res. Commun., 254, 623 (1999). (Pharmacol.) T. Ida, K. Nakahara, T. Murakami, R. Hanada, M. Nakazato, and N. Murakami, Biochem. Biophys. Res. Commun., 270, 318 (2000). (Pharmacol.)

Orexin-B (Human)Arg-Ser-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Leu- Gln-Arg-Leu-Leu-Gln-Ala-Ser-Gly-Asn- His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH2 (M.W. 2899.3) C123H212N44O35S [205640-91-1] Appetite-Boosting Peptide / Sleep-Wakefulness State Regulator

POR-4348-s-20 °C

0.1 mgvial

T. Sakurai, A. Amemiya, M. Ishii, I. Matsuzaki, R.M. Chemelli, H. Tanaka, S.C. Williams, J.A. Richardson, G.P. Kozlowski, S. Wilson, J.R.S. Arch, R.E. Buckingham, A.C. Haynes, S.A. Carr, R.S. Annan, D.E. McNulty, W.-S. Liu, J.A. Terrett, N.A. Elshourbagy, D.J. Bergsma, and M. Yanagisawa, Cell, 92, 573 (1998). (Original) L. de Lecea, T.S. Kilduff, C. Peyron, X.-B. Gao, P.E. Foye, P.E. Danielson, C. Fukuhara, E.L.F. Battenberg, V.T. Gautvik, F.S. Bartlett II, W.N. Frankel, A.N. van den Pol, F.E. Bloom, K.M. Gautvik, and J.G. Sutcliffe, Proc. Natl. Acad. Sci. U.S.A., 95, 322 (1998). (cDNA; Same Sequence [Hypocretin]) N. Takahashi, T. Okumura, H. Yamada, and Y. Kohgo, Biochem. Biophys. Res. Commun., 254, 623 (1999). (Pharmacol.)

Orexin-B (Rat, Mouse)Hypocretin 2 (Rat, Mouse)

Arg-Pro-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Ala-Asn-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH2 (M.W. 2936.4) C126H215N45O34S [202801-92-1] Appetite-Boosting Peptide / Sleep-Wakefulness State Regulator Purity Information: Qp See page xiv

POR-4347-s-20 °C

0.1 mgvial

T. Sakurai, A. Amemiya, M. Ishii, I. Matsuzaki, R.M. Chemelli, H. Tanaka, S.C. Williams, J.A. Richardson, G.P. Kozlowski, S. Wilson, J.R.S. Arch, R.E. Buckingham, A.C. Haynes, S.A. Carr, R.S. Annan, D.E. McNulty, W.-S. Liu, J.A. Terrett, N.A. Elshourbagy, D.J. Bergsma, and M. Yanagisawa, Cell, 92, 573 (1998). (Original) L. de Lecea, T.S. Kilduff, C. Peyron, X.-B. Gao, P.E. Foye, P.E. Danielson, C. Fukuhara, E.L.F. Battenberg, V.T. Gautvik, F.S. Bartlett II, W.N. Frankel, A.N. van den Pol, F.E. Bloom, K.M. Gautvik, and J.G. Sutcliffe, Proc. Natl. Acad. Sci. U.S.A., 95, 322 (1998). (cDNA; Same Sequence [Hypocretin]) N. Takahashi, T. Okumura, H. Yamada, and Y. Kohgo, Biochem. Biophys. Res. Commun., 254, 623 (1999). (Pharmacol.) M.S. Mondal, M. Nakazato, Y. Date, N. Murakami, M. Yanagisawa, and S. Matsukura, Biochem. Biophys. Res. Commun., 256, 495 (1999). (Distribution)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 97

OsteocalcinsGla17,21,24-Osteocalcin (Human) Osteocalcin (Human, Gla17,21,24)

(Ammonium Form)

POS-4262-s-20 °C

0.1 mgvial

Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-Gla-Pro-Arg-Arg-Gla-Val-Cys-Gla-Leu-Asn-Pro-Asp-Cys-Asp-Glu-Leu-Ala-Asp-His-Ile-Gly-Phe-Gln-Glu-Ala-Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val (Gla: l-g-Carboxyglutamic acid) (Disulfide bond between Cys23-Cys29) (M.W. 5929.4) C269H381N67O82S2 [136461-80-8] Bone Gla Protein Purity Information: Qx See page xiv

J.W. Poser, F.S. Esch, N.C. Ling, and P.A. Price, J. Biol. Chem., 255, 8685 (1980). (Original) M. Nakao, Y. Nishiuchi, M. Nakata, T. Kimura, and S. Sakakibara, Pept. Res., 7, 171 (1994). (Chem. Synthesis) P.V. Hauschka, J.B. Lian, D.E.C. Cole, and C.M. Gundberg, Physiol. Rev., 69, 990 (1989). (Review) • This compound is produced by Peptide Institute, Inc., under the license of Mitsubishi Chemical Corporation and is

distributed exclusively through Mitsubishi Chemical Corporation.

Glu17,Gla21,24-Osteocalcin (Human) Osteocalcin (Human, Glu17,Gla21,24)

(Ammonium Form)

POS-4261-s-20 °C

0.1 mgvial

Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-Glu-Pro-Arg-Arg-Gla-Val-Cys-Gla-Leu-Asn-Pro-Asp-Cys-Asp-Glu-Leu-Ala-Asp-His-Ile-Gly-Phe-Gln-Glu-Ala-Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val (Gla: l-g-Carboxyglutamic acid) (Disulfide bond between Cys23-Cys29) (M.W. 5885.4) C268H381N67O80S2 Bone Gla Protein Purity Information: Qx See page xivJ.W. Poser, F.S. Esch, N.C. Ling, and P.A. Price, J. Biol. Chem., 255, 8685 (1980). (Original) M. Nakao, Y. Nishiuchi, M. Nakata, T. Kimura, and S. Sakakibara, Pept. Res., 7, 171 (1994). (Chem. Synthesis) P.V. Hauschka, J.B. Lian, D.E.C. Cole, and C.M. Gundberg, Physiol. Rev., 69, 990 (1989). (Review) • This compound is produced by Peptide Institute, Inc. under the license of Mitsubishi Chemical Corporation and is

distributed exclusively through Mitsubishi Chemical Corporation.

OVA Peptide Fragment Also see MOG and Ac-MBP Fragments on page 59.

OVA Peptide (257-264)Chicken ovalbumin fragment (257-264)

H-Ser-Ile-Ile-Asn-Phe-Glu-Lys-Leu-OH (M.W. 963.15) C45H74N10O13 T-cell Activating Peptide

POV-3659-PI-20 °C

1 mg5 mg

F.R. Carbone, S.J. Sherry, J. Butler, S. Rodda, and M.W. Moore, Int. Immunol. 4, 861 (1992).

OVA Peptide (323-339)Chicken ovalbumin fragment (323-339)

POV-3636-PI-20 °C

1 mg5 mg

H-Ile-Ser-Gln-Ala-Val-His-Ala-Ala-His-Ala-Glu-Ile-Asn-Glu-Ala-Gly-Arg-OH (M.W. 1773.94) C74H120N26O25 T-cell Activating Peptide

F. De Mattia, S. Chomez, F. Van Laethem, V. Moulin, J. Urbain, M. Moser, O. Leo, and F. Andris, J. Immunol., 163, 5929, (1999). S.-J. Sung, C.E. Rose, and S.M. Fu, J. Immunol., 166, 1261, (2001).


98 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES OxytocinsB. Berde (ed.), Neurohypophysial Hormones and Similar Polypeptides, Handbook of Experimental Pharmacology, Vol. 23, Springer-Verlag, Berlin, 1968. (Review)

Oxytocin* (Human, Porcine, Bovine, Rat, Ovine)

Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (Disulfide bond between Cys1-Cys6) (M.W. 1007.2) C43H66N12O12S2 [50-56-6]

POX-4084-v-20 °C

0.5 mgvial

V. Du Vigneaud, C. Ressler, and S. Trippett, J. Biol. Chem., 205, 949 (1953). (Original) R.A. Boissonnas, St. Guttmann, P.-A. Jaquenoud, and J.-P. Waller, Helv. Chim. Acta, 38, 1491 (1955). (Chem. Synthesis) M. Zaoral and J. Rudinger, Collection Czech. Chem. Commun., 20, 1183 (1955). (Chem. Synthesis) A. Light and V. Du Vigneaud, Proc. Soc. Exp. Biol. Med., 98, 692 (1958). (Original; Human)


[Asu1,6]-Oxytocin* (Deamino-Dicarba-Oxytocin)

cyclo (Tyr-lle-Gln-Asn-Asu)-Pro-Leu-Gly-NH2 (cyclic form between Asu w-Carboxyl group and Tyr a-amino group) (Asu: l-a-Aminosuberic acid) (M.W. 956.10) C45H69N11O12 [14317-68-1]

POX-4025-v-20 °C

0.5 mgvial

T. Yamanaka, S. Hase, S. Sakakibara, I.L. Schwartz, B.M. Dubois, and R. Walter, Mol. Pharmacol., 6, 474 (1970). (Original)


PancreastatinsChromogranin A (Human, 286-301 Amide)

(Hydrochloride Form) Glu-Glu-Glu-Glu-Glu-Met-Ala-Val-Val-Pro-Gln-Gly-Leu-Phe-Arg-Gly-NH2 (M.W. 1819.0) C78H123N21O27S [133605-57-9] Purity Information: QE See page xiv

PCR-4214-v-20 °C

0.5 mgvial

D.S. Konecki, U.M. Benedum, H.H. Gerdes, and W.B. Huttner, J. Biol. Chem., 262, 17026 (1987). (Original; cDNA)

[Pyr33]-Pancreastatin (Porcine, 33-49)Pyr-Glu-Glu-Glu-Glu-Glu-Thr-Ala-Gly-Ala-Pro- Gln-Gly-Leu-Phe-Arg-Gly-NH2 (M.W. 1829.9) C77H116N22O30

PPP-4186-v -20 °C

0.5 mgvial

K. Tatemoto, S. Efendic, V. Mutt, G. Makk, G.J. Feistner, and J.D. Barchas, Nature, 324, 476 (1986). (Original)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 99

Parathyroid Hormone (PTH) and Related PeptidesParathyroid Hormone (Human, 1-84) PTH (Human, 1-84)

PTH-4134-v-20 °C

20 µgvial

Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn- Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val- His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Pro-Leu-Ala-Pro-Arg-Asp- Ala-Gly-Ser-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn- Val-Leu-Val-Glu-Ser-His-Glu-Lys-Ser-Leu-Gly- Glu-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val- Leu-Thr-Lys-Ala-Lys-Ser-Gln (M.W. 9424.6) C408H674N126O126S2 [68893-82-3]G.N. Hendy, H.M. Kronenberg, J.T. Potts, Jr., and A. Rich, Proc. Natl. Acad. Sci. U.S.A., 78, 7365 (1981). (Original; cDNA Sequence) T. Kimura, M. Takai, K. Yoshizawa, and S. Sakakibara, Biochem. Biophys. Res. Commun., 114, 493 (1983). (Chem. Synthesis) H. Takasu, H. Baba, N. Inomata, Y. Uchiyama, N. Kubota, K. Kumaki, A. Matsumoto, K. Nakajima, T. Kimura, S. Sakakibara, T. Fujita, K. Chihara, and I. Nagai, Endocrinology, 137, 5537 (1996). (Pharmacol.)

Parathyroid Hormone (Human, 1-37) PTH (Human, 1-37)

PTH-3753-PI-20 °C

1 mg5 mg

(Trifluoroacetate Form) H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His- Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys- Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-OH (M.W. 4401.18) C195H316N58O54S2 [136799-54-7]C.P. Schmitt, et al., Kidney Int., 57, 1484 (2000).


Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys- His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg- Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe (M.W. 4117.7) C181H291N55O51S2 [52232-67-4]

PTH-4068-s-20 °C

0.1 mgvial


PTH-4068-v-20 °C

0.5 mgvial

M. Takai, Y. Kurano, T. Kimura, and S. Sakakibara, Peptide Chemistry 1979, 187 (1980). (Chem. Synthesis)

Parathyroid Hormone (Human, 1-31 Amide) PTH (Human, 1-31 Amide)

Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys- His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg- Lys-Lys-Leu-Gln-Asp-Val-NH2 (M.W. 3718.3) C162H270N50O46S2 Adenylate Cyclase- / Bone Growth Stimulating Peptide

PTH-4324-v-20 °C

0.5 mgvial

R.H. Rixon, J.F. Whitfield, L. Gagnon, R.J. Isaacs, S. Maclean, B. Chakravarthy, J.P. Durkin, W. Neugebauer, V. Ross, W. Sung, and G.E. Willick, J. Bone Miner. Res., 9, 1179 (1994) (Original) W. Neugebauer, J.-R. Barbier, W.L. Sung, J.F. Whitfield, and G.E. Willick, Biochemistry, 34, 8835 (1995). (Biochem.) J.F. Whitfield, and P. Morley, Trends Pharmacol. Sci., 16, 382 (1995). (Review) J.F. Whitfield, P. Morley, G.E. Willick, V. Ross, J.-R. Barbier, R.J. Isaacs, and L. Ohannessian-Barry, Calcif. Tissue Int., 58, 81 (1996). (Pharmacol.)

NEW!

100 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Parathyroid Hormone (Human, 1-44) PTH (Human, 1-44)

Ser-Val-Ser-Glu-lle-Gln-Leu-Met-His-Asn-Leu-Gly-Lys- His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu- Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe- Val-Ala-Leu-Gly-Ala-Pro-Leu-Ala-Pro-Arg (M.W. 5063.9) C225H366N68O61S2 [85568-24-7] Purity Information: Qx See page xiv

PTH-4094-v-20 °C

0.5 mgvial

T. Kimura, M. Takai, Y. Masui, T. Morikawa, and S. Sakakibara, Biopolymers, 20, 1823 (1981). (Chem. Synthesis)


Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu- Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe (M.W. 2808.2) C125H199N39O33S [81306-64-1]

PTH-4106-v-20 °C

0.5 mgvial

R. Nakamura, H. Sokabe, T. Kimura, and S. Sakakibara, Endocrinol. Jpn., 28, 547 (1981). (Pharmacol.; Hypotension) K. Sakaguchi, M. Fukase, I. Kobayashi, T. Kimura, S. Sakakibara, S. Katsuragi, K. Morita, T. Noda, and T. Fujita, J. Bone Miner. Res., 2, 83 (1987). (Pharmacol.)


(Hydrochloride Form) Ala-Pro-Leu-Ala-Pro-Arg-Asp-Ala-Gly-Ser-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Glu-Lys-Ser-Leu-Gly (M.W. 3285.6) C139H234N46O46 Purity Information: Qx See page xiv

PTH-4124-v-20 °C

0.5 mgvial

P. D’Amour, F. Labelle, R. Wolde-Giorghis, and L. Hamel, J. Immunoass., 10, 191 (1989). (Radioimmunoassay) T. Yamaguchi, M. Arao, and M. Fukase, Acta Endocrinol., 127, 267 (1992). (Biochem.; PTH Degradation) T. Yamaguchi, M. Fukase, H. Kido, T. Sugimoto, N. Katunuma, and K. Chihara, Life Sci., 54, 381 (1994). (Biochem.; PTH Degradation)


Ala-Pro-Leu-Ala-Pro-Arg-Asp-Ala-Gly-Ser-Gln-Arg-Pro-Arg- Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Glu-Lys- Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val- Leu-Thr-Lys-Ala-Lys-Ser-Gln (M.W. 4984.5) C211H357N67O72 [90880-43-6

PTH-4169-v-20 °C

0.5 mgvial

P. D’Amour, F. Labelle, R. Wolde-Giorghis, and L. Hamel, J. Immunoass., 10, 191 (1989). (Biochem.; Presence in Circuration) T. Yamaguchi, M. Arao, and M. Fukase, Acta Endocrinol., 127, 267 (1992). (Biochem.; PTH Degradation) T. Yamaguchi, M. Fukase, H. Kido, T. Sugimoto, N. Katunuma, and K. Chihara, Life Sci., 54, 381 (1994). (Biochem.; PTH Degradation)


(Hydrochloride Form) Glu-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val- Leu-Thr-Lys-Ala-Lys-Ser-Gln (M.W. 1716.9) C72H125 N21O27Purity Information: QE See page xiv

PTH-4170-v-20 °C

0.5 mgvial

P. D’Amour, F. Labelle, R. Wolde-Giorghis, and L. Hamel, J. Immunoass., 10, 191 (1989). (Radioimmunoassay) H. Takasu, H. Baba, N. Inomata, Y. Uchiyama, N. Kubota, K. Kumaki, A. Matsumoto, K. Nakajima, T. Kimura, S. Sakakibara, T. Fujita, K. Chihara, and I. Nagai, Endocrinology, 137, 5537 (1996). (Pharmacol.)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 101

[Nle8,18,Tyr34]-Parathyroid Hormone (Human, 1-34) [Nle8,18,Tyr34]-PTH (Human, 1-34)

PTH-4129-v-20 °C

0.5 mgvial

Ser-Val-Ser-Glu-Ile-Gln-Leu-Nle-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser- Nle-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Tyr (Nle: l-Norleucine) (M.W. 4097.6) C183H295N55O52

T. Noda, S. Katsuragi, and S. Watanabe, The 41st Annual Meeting of Chemical Society of Japan, Osaka, April 1980, Abstr. No 4S12. (Original)

[Nle8,18,Tyr34]-Parathyroid Hormone (Human, 18 1-34 Amide) [Nle8,18,Tyr34]-PTH (Human, 1-34 Amide)

PTH-4180-v-20 °C

0.5 mgvial

Ser-Val-Ser-Glu-Ile-Gln-Leu-Nle-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Nle- Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Tyr-NH2 (Nle: l-Norleucine) (M.W. 4096.7) C183H296N56O51

M. Rosenblatt, D. Goltzman, H.T. Keutmann, G.W. Tregear, and J.T. Potts, Jr., J. Biol. Chem., 251, 159 (1976). (Chem. Synthesis & Biological Activity) M.L. Thomas and L.R. Forte, Comp. Biochem. Physiol., 73A, 691 (1982). (Biological Activity) I. Yamamoto, C. Shigeno, J.T. Potts, Jr., and G.V. Segre, Endocrinology, 122, 1208 (1988). (Radioimmunoassay)

[Nle8,18,Tyr34]-Parathyroid Hormone (Human, 3-34 Amide) [Nle8,18,Tyr34]-PTH (Human, 3-34 amide)

PTH-4181-v-20 °C

0.5 mgvial

Ser-Glu-Ile-Gln-Leu-Nle-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Nle-Glu- Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Tyr-NH2 (Nle: l-Norleucine) (M.W. 3910.4) C175H282N54O48

S.R. Goldring, J.E. Mahaffey, M. Rosenblatt, J.-M. Dayer, J.T. Potts, Jr., and S.M. Krane, J. Endocrinol. Metab., 48, 655 (1979). (Pharmacol.) T.C. Chen, M. Rosenblatt, and J.B. Puschett, Biochem. Biophys. Res. Commun., 94, 1227 (1980). (Pharmacol.) D.A. Gray, J.A. Parsons, J.T. Potts, Jr., M. Rosenblatt, and R.W. Stevenson, Br. J. Pharmacol., 76, 259 (1982). (Pharmacol.)

[Tyr34]-Parathyroid Hormone (Bovine, 1-34 Amide) [Tyr34]-PTH (Bovine, 1-34 Amide)

PTH-4179-v-20 °C

0.5 mgvial

Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-Met- Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Tyr-NH2 (M.W. 4123.7) C183H289N55O50S2

M. Rosenblatt, Pathobiol. Annu., 11, 53 (1981). (Review)

[Tyr34]-Parathyroid Hormone (Bovine, 7-34 Amide) [Tyr34]-PTH (Bovine, 7-34 Amide)

PTH-4185-v-20 °C

0.5 mgvial

Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val- Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Tyr-NH2 (M.W. 3496.0) C156H244N48O40S2 [86292-93-5] PTH AntagonistN. Horiuchi, M.F. Holick, J.T. Potts, Jr., and M. Rosenblatt, Science, 220, 1053 (1987). (Original)

102 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES PTH-rP(Human, 1-34 Amide) Parathyroid Hormone Related Protein (Human, 1-34 Amide) (Rat, Mouse)

PTH-4205-v-20 °C

0.5 mgvial

Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu- Arg-Arg-Arg-Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-NH2 (M.W. 4016.6) C180H288N58O47 [112955-31-4]L.J. Suva, G.A. Winslow, R.E.H. Wettenhall, R.G. Hammonds, J.M. Moseley, H. Diefenbach-Jagger, C.P. Rodda, B.E. Kemp, H. Rodriguez, E.Y. Chen, P.J. Hudson, T.J. Martin, and W.I. Wood, Science, 237, 893 (1987). (Original; cDNA) N. Horiuchi, M.P. Caulfield, J.E. Fisher, M.E. Goldman, R.L. McKee, J.E. Reagan, J.J. Levy, R.F. Nutt, S.B. Rodan, T.L. Schofield, T.L. Clemens, and M. Rosenblatt, Science, 238, 1566 (1987). (Pharmacol.; Synthetic PTH-rP Amide) B.E. Kemp, J.M. Moseley, C.P. Rodda, P.R. Ebeling, R.E.H. Wettenhall, D. Stapleton, H. Diefenbach-Jagger, F. Ure, V.P. Michelangeli, H.A. Simmons, L.G. Raisz, and T.J. Martin, Science, 238, 1568 (1987). (Pharmacol.; Synthetic PTH-rP Amide)

PTH-rP(Human, 7-34 Amide) Parathyroid Hormone Related Protein (Human, 7-34 Amide)

Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-NH2 (M.W. 3364.9) C153H247N49O37 [115695-30-2] PTH-rP Antagonist

PTH-4215-v-20 °C

0.5 mgvial

K. Nagasaki, K. Yamaguchi, Y. Miyake, C. Hayashi, S. Honda, K. Urakami, K. Miki, S. Kimura, T. Watanabe, and K. Abe, Biochem. Biophys. Res. Comun., 158, 1036 (1989). (Original) L.J. Suva, G.A. Winslow, R.E.H. Wettenhall, R.G. Hammonds, J.M. Moseley, H. Diffenbach-Jagger, C.P. Rodda, B.E. Kemp, H. Rodriguez, E.Y. Chen, P.J. Hudson,T.J. Martin, and W.l. Wood, Science, 237, 893 (1987). (Original; cDNA)

Peptide 234Ac-D-Ala-Asn-Trp-Asn-Gly-Phe-Gly-D-Trp-Arg-Phe-NH2 (M.W. 1295.4) C63H78N18O13Synthetic Kisspeptin Antagonist

PPT-4460-v-20 °C

0.5 mgvial

A.K. Roseweir, A.S. Kauffman, J.T. Smith, K.A. Guerriero, K. Morgan, J. Pielecka-Fortuna, R. Pineda, M.L. Gottsch, M. Tena-Sempere, S.M. Moenter, E. Terasawa, I.J. Clarke, R.A. Steiner, and R.P. Millar, J. Neurosci., 29, 3920 (2009). (Pharmacol.)X.-F. Li, J.S. Kinsey-Jones, Y. Cheng, A.M.I. Knox, Y. Lin, N.A. Petrou, A. Roseweir, S.L. Lightman, S.R. Milligan, R.P. Millar, and K.T. O’Byrne, PLoS One., 4, e8334 (2009). (Pharmacol.) R. Pineda, D. Garcia-Galiano, A. Roseweir, M. Romero, M.A. Sanchez-Garrido, F. Ruiz-Pino, K. Morgan, L. Pinilla, R.P. Millar, and M. Tena-Sempere, Endocrinology, 151, 722 (2010). (Pharmacol.)

Peptide Histidine-Methionine (PHM)PHM-27(Human) Peptide Histidine-Methionine

His-Ala-Asp-Gly-Val-Phe-Thr-Ser-Asp-Phe-Ser-Lys-Leu-Leu-Gly-Gln-Leu-Ser-Ala-Lys-Lys-Tyr-Leu-Glu-Ser-Leu-Met-NH2 (M.W. 2985.4) C135H214N34O40S [87403-73-4]

PPM-4177-v-20 °C

0.5 mgvial

N. Itoh, K. Obata, N. Yanaihara, and H. Okamoto, Nature, 304, 547 (1983). (Original)

Peptide TPeptide T

Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr (M.W. 857.86) C35H55N9O16

PPT-4188-v-20 °C

0.5 mgvial

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 103

Peptide T (Bulk)Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr • 4H2O (M.W. 857.86 • 72.06) C35H55N9O16 • 4H2O

PPT-4188-20 °C

25 mg

M.R. Ruff, B.M. Martin, E.l. Ginns, W.L. Farrar, and C.B. Pert, FEBS Lett., 211, 17 (1987). (Pharmacol.) C.B. Pert, J.M. Hill, M.R. Ruff, R.M. Berman, W.G. Robey, L.O. Arthur, F.W. Ruscetti, and W.L. Farrar, Proc. Natl. Acad. Sci. USA, 83, 9254 (1986). (Original)

Peptide YYPeptide YY (Dog, Mouse, Porcine, Rat, 3-36) PYY (Dog, Mouse, Porcine, Rat, 3-36)

PYY-3726-PI-20 °C

1 mg5 mg

H-Ala-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Ser-Arg-Tyr- Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2(M.W. 3980.45) C176H272N52O54 [126339-09-1] Physiological inhibitor for food intake/ Y2-receptor agonist D.Grandt, M. Schimiczek, F. Feth, O. Ahrens, W. Rascher, H. Layer, J.E. Goegell, J.E. Shively, J.R. Reeve Jr, and V.E. Eysselein, Regul. Peptides, 40, 161 (1992). R.L.Batterham, M. A. Cowley, C. J. Small, H. Herzog, M. A. Cohen, C. L. Dakin, A. M. Wren, A. E. Brynes, M. J. Low, M. A. Ghatei, R. D. Cone and S. R. Bloom, Nature, 418, 650 (2002). R.L.Batterham, MA. Cohen, S.M. Ellis, C.W. Le Roux, D.J. Withers, G.S. Frost, M. A. Ghatei, and S.R. Bloom, N. Engl. J. Med., 349, 941 (2003). Y. Shechter, H. Tsubery, M. Mironchik, M. Rubinstein, M. Fridkin, FEBS Lett., 579, 2439 (2005). I.G.Halatchev and R.D.Cone, Cell Metab., 1, 159 (2005). C.Acuna-Goycolea and A.N.van den Pol, J. Neurosci., 25, 10510 (2005). G.H.Ballantyne, Obes. Surg., 16, 651 (2006) P.K. Chelikani, A.C. Haver , and R.D. Reidelberger, Am. J Phyiol Regul Integr Comp Physiol, 293, R39 (2007).

Peptide YY (Human, 3-36) PYY (Human, 3-36)

PYY-4400-v-20 °C

0.5 mgvial

Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu- Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr- Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 (M.W. 4049.5) C180H279N53O54 Physiological Inhibitor for Food Intake / NPY Y2-Receptor AgonistR.L. Batterham, M.A. Cowley, C.J. Small, H. Herzog, M.A. Cohen, C.L. Dakin, A.M. Wren, A.E. Brynes, M.J. Low, M.A. Ghatei, R.D. Cone, and S.R. Bloom, Nature, 418, 650 (2002). (Original; Inhibition of Food Intake) G.A. Eberlein, V.E. Eysselein, M. Schaeffer, P. Layer, D. Grandt, H. Goebell, W. Niebel, M. Davis, T.D. Lee, J.E. Shively, and J.R. Reeve, Jr., Peptides, 10, 797 (1989). (Original; Endogenous Form) D.A. Keire, P. Mannon, M. Kobayashi, J.H. Walsh, T.E. Solomon, and J.R. Reeve, Jr., Am. J. Physiol., 279, G126 (2000). (Original; NPY Y2 Receptor Selectivity) S. Chamorro, O. Della-Zuana, J.-L. Fauchère, M. Félétou, J.-P. Galizzi, and N. Levens, Int. J. Obesity., 26, 281 (2002). (Review; Y2 R Selectivity) A. Sainsbury, C. Schwarzer, M. Couzens, S. Fetissov, S. Furtinger, A. Jenkins, H.M. Cox, G. Sperk, T Hökfelt, and H. Herzog, Proc. Natl. Acad. Sci. USA, 99, 8938 (2002). (Pharmacol.; Food intake Regulation through Y2R)

PhysalaeminPhysalaemin* (Frog, Physalaemus fuscumaculatus)

Pyr-Ala-Asp-Pro-Asn-Lys-Phe-Tyr-Gly-Leu-Met-NH2 (M.W. 1265.4) C58H84N14O16S [2507-24-6]

PPY-4030-v-20 °C

0.5 mgvial


NEW!

104 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Physalaemin* (Bulk) (Frog, Physalaemus fuscumaculatus)

PPY-4030-20 °C

25 mg

Pyr-Ala-Asp-Pro-Asn-Lys-Phe-Tyr-Gly-Leu-Met-NH2 • AcOH • 3H2O (M.W. 1265.4 • 60.05 • 54.06) C58H84N14O16S • CH3COOH • 3H2OV. Erspamer, A. Anastasi, G. Bertaccini, and J.M. Cei, Experientia, 20, 489 (1964). (Original) L. Bernardi, G. Bosisio, O. Goffredo, and R. de Castiglione, Experientia, 20, 490 (1964). (Chem. Synthesis)


Pituitary Adenylate Cyclase Activating Polypeptide (PACAP)A. Arimura, Peptides, 28, 1617 (2007). (Review)J. Watanabe, T. Nakamachi, R. Matsuno, D. Hayashi, M. Nakamura, S. Kikuyama, S. Nakajo, and S. Shioda, Peptides, 28, 1713 (2007). (Review)M. Nakata and T. Yada, Curr. Pharm. Des., 13, 1105 (2007). (Review)D. Vaudry, A. Falluel-Morel, S. Bourgault, M. Basille, D. Burel, O. Wurtz, A. Fournier, B.K. Chow, H. Hashimoto, L. Galas, and H. Vaudry, Pharmacol. Rev., 61, 283 (2009). (Review)

PACAP38 (Human)* Pituitary Adenylate Cyclase Activating Polypeptide 38 (Human)(Ovine, Rat)

PPA-4221-v-20 °C

0.5 mgvial

His-Ser-Asp-Gly-lle-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys- Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 (M.W. 4534.3) C203H331N63O53SA. Miyata, A. Arimura, R.R. Dahl, N. Minamino, A. Uehara, L. Jiang, M.D. Culler, and D.H. Coy, Biochem Biophys. Res. Commun., 164, 567 (1989). (Original) • This compound is distributed through Peptide Institute, Inc. under the license of Tulane University.


PACAP27 (Human, 1-27 Amide)* Pituitary Adenylate Cyclase Activating Polypeptide 27 (Human, 1-27 Amide) (Ovine, Rat)

His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-NH2 (M.W. 3147.6) C142H224N40O39S [127317-03-7]

PPA-4231-v-20 °C

0.5 mgvial

A. Miyata, L. Jiang, R.D. Dahl, C. Kitada, K. Kubo, M. Fujino, N. Minamino, and A. Arimura, Biochem. Biophys. Res. Commun., 170, 643 (1990). (Original) C. Kimura, S. Ohkubo, K. Ogi, M. Hosoya, Y. Itoh, H. Onda, A. Miyata, L. Jiang, R.R. Dahl, H.H. Stibbs, A. Arimura, and M. Fujino, Biochem. Biophys. Res. Commun., 166, 81 (1990). (Original; Human and Bovine cDNA) K. Ogi, C. Kimura, H. Onda, A. Arimura, and M. Fujino, Biochem. Biophys. Res. Commun., 173, 1271 (1990). (Original: Rat cDNA) • This compound is distributed through Peptide Institute, Inc. under the license of Tulane University.


PACAP (Human, 6-38) Pituitary Adenylate Cyclase Activating Polypeptide (Human, 6-38) (Ovine, Rat)

PPA-4286-v-20 °C

0.5 mgvial

Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu- Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 (M.W. 4024.7) C182H300N56O45S [143748-18-9] PACAP Selective AntagonistP. Robberecht, P. Gourlet, P. De Neef, M-C. Woussen-Colle, M-C. Vandermeers-Piret, A. Vandermeers, and J. Christophe, Eur. J. Biochem., 207, 239 (1992). (Original) A. Vandermeers, S. Vandenborre, X. Hou, P. De Neef, P. Robberecht, M-C. Vandermeers-Piret, and J. Christophe, Eur. J. Biochem., 208, 815 (1992). (Pharmacol.)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 105

Platelet Factor-4 Related PeptidePlatelet Factor-4 (Human, 58-70)

Pro-Leu-Tyr-Lys-Lys-Ile-Ile-Lys-Lys-Leu-Leu-Glu-Ser (M.W. 1573.0) C76H133N17O18 [82989-21-7] Angiogenesis InhibitorT.E. Maione, G.S. Gray, J. Petro, A.J. Hunt, A.L. Donner, S.I. Bauer, H.F. Carson, and R.J. Sharpe, Science, 247, 77 (1990). (Original)

IPF-4305-v-20 °C

0.5 mgvial

PlectasinPlectasin (PDF-4432-s) is a newly discovered defensin and the first to be isolated from a fungus, Pseudoplectania nigrella.1 This peptide was shown to cure mice of S. pneumoniae induced, experimental peritonitis and pneumonia just as well as antibi-otic treatment. The same concentration of plectasin that alters microbial growth also effectively kills the bacteria, suggesting the process is irreversible. Plectasin is also effective against antibiotic resistant strains of S. pneumoniae and exhibits low toxic-ity in mice models. This peptide should prove to be an exciting new addition to our growing number of antimicrobial products.1. Mygind, et al., Nature, 437, 975 (2005). (Original ; Structure & Antimicrobial Activity)

Plectasin(Fungus, Pseudoplectania nigrella)

PDF-4432-s-20 °C

0.1 mg vial

Gly-Phe-Gly-Cys-Asn-Gly-Pro-Trp-Asp-Glu-Asp-Asp-Met-Gln- Cys-His-Asn-His-Cys-Lys-Ser-Ile-Lys-Gly-Tyr-Lys-Gly-Gly- Tyr-Cys-Ala-Lys-Gly-Gly-Phe-Val-Cys-Lys-Cys-Tyr(M.W. 4401.9) C189H267N53O56S7 Antimicrobial PeptideP.H. Mygind, R.L. Fischer, K.M. Schnorr, M.T. Hansen, C.P. Sönksen, S. Ludvigsen, D. Ravento ´s, S. Buskov, B. Christensen, L. De Maria, O. Taboureau, D. Yaver, S.G. Elvig-Jürgensen, M.V. Sörensen, B.E. Christensen, S. Kjaerulff, N. Frimodt-Moller, R.I. Lehrer, M. Zasloff, and H.-H. Kristensen, Nature, 437, 975 (2005). (Original; Structure & Antimicrobial Activity)S. Hara, H. Mukae, N. Sakamoto, H. Ishimoto, M. Amenomori, H. Fujita, Y. Ishimatsu, K. Yanagihara, S. Kohno, Biochem. Biophys. Res. Commun., 374, 709 (2008). (Pharmacol.)K. Mandal, B.L. Pentelute, V. Tereshko, V. Thammavongsa, O. Schneewind, A.A. Kossiakoff, and S.B.H. Kent, Protein Sci., 18, 1146 (2009). (X-ray Structure)T. Schneider, T. Kruse, R. Wimmer, I. Wiedemann, V. Sass, U. Pag, A. Jansen, A.K. Nielsen, P.H. Mygind, D.S. Raventos, S. Neve, B. Ravn, A.M. Bonvin, L. De Maria, A.S. Andersen, L.K. Gammelgaard, H.G. Sahl, and H.H. Kristensen, Science, 328, 1168 (2010). (Pharmacol.)

NEW!

106 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES PleiotrophinPleiotrophin (Human) PTN (Human)

PTN-4335-v-20 °C

50 µgvial

Gly-Lys-Lys-Glu-Lys-Pro-Glu-Lys-Lys-Val-Lys-Lys-Ser-Asp-Cys-Gly-Glu- Trp-Gln-Trp-Ser-Val-Cys-Val-Pro-Thr-Ser-Gly-Asp-Cys-Gly-Leu-Gly-Thr- Arg-Glu-Gly-Thr-Arg-Thr-Gly-Ala-Glu-Cys-Lys-Gln-Thr-Met-Lys-Thr-Gln- Arg-Cys-Lys-Ile-Pro-Cys-Asn-Trp-Lys-Lys-Gln-Phe-Gly-Ala-Glu-Cys-Lys- Tyr-Gln-Phe-Gln-Ala-Trp-Gly-Glu-Cys-Asp-Leu-Asn-Thr-Ala-Leu-Lys-Thr- Arg-Thr-Gly-Ser-Leu-Lys-Arg-Ala-Leu-His-Asn-Ala-Glu-Cys-Gln-Lys-Thr- Val-Thr-Ile-Ser-Lys-Pro-Cys-Gly-Lys-Leu-Thr-Lys-Pro-Lys-Pro-Gln-Ala- Glu-Ser-Lys-Lys-Lys-Lys-Lys-Glu-Gly-Lys-Lys-Gln-Glu-Lys-Met-Leu-Asp (Disulfide bonds between Cys15-Cys44, Cys23-Cys53, Cys30-Cys57, Cys67-Cys99, and Cys77-Cys109) (M.W. 15302.6) C658H1079N197O198S12 Heparin-Binding Growth Factor (Neurite Outgrowth-Promoting Factor)Y.-S. Li, P.G. Milner, A.K. Chauhan, M.A. Watson, R.M. Hoffman, C.M. Kodner, J. Milbrandt, and T.F. Deuel, Science, 250, 1690 (1990). (Primary Structure) P.G. Milner, D. Shah, R. Veile, H. Donis-Keller, and B.V. Kumar, Biochemistry, 31, 12023 (1992). (Nucleotide Seq.; Human) F. Czubayko, A.M. Schulte, G.J. Berchem, and A. Wellstein, Proc. Natl. Acad. Sci. U.S.A., 93, 14753 (1996). (Pharmacol.) T. Inui, M. Nakao, H. Nishio, Y. Nishiuchi, S. Kojima, T. Muramatsu, T. Kimura, and S. Sakakibara, J. Pept. Res., 55, 384 (2000). (Chem. Synthesis & S-S Bond)

PLTX-II See Code PPL-4300-s in the Toxins section on page 136.

Prolactin-Releasing PeptidesB. Sun, K. Fujiwara, S. Adachi, and K. Inoue, Regul. Pept., 126, 27 (2005). (Review)S. Fukusumi, R. Fujii, and S. Hinuma, Peptides, 27, 1073 (2006). (Review)D.A. Bechtold and S.M. Luckman, J. Endocrinol., 192, 3 (2007). (Review)

Prolactin-Releasing Peptide (Human) PrRP31 (Human)

PPR-4352-v-20 °C

0.5 mgvial

Ser-Arg-Thr-His-Arg-His-Ser-Met-Glu-Ile-Arg-Thr-Pro-Asp-Ile-Asn- Pro-Ala-Trp-Tyr-Ala-Ser-Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH2 (M.W. 3664.1) C160H252N56O42S Multifunctional Peptide in Neuroendocrinology S. Hinuma, Y. Habata, R. Fujii, Y. Kawamata, M. Hosoya, S. Fukusumi, C. Kitada, Y. Masuo, T. Asano, H. Matsumoto, M. Sekiguchi, T. Kurokawa, O. Nishimura, H. Onda, and M. Fujino, Nature, 393, 272 (1998). (Original, cDNA) F. Satoh, D.M. Smith, J.V. Gardiner, M. Mahmoodi, K.G. Murphy, M.A. Ghatei, and S.R. Bloom, Br. J. Pharmacol., 129, 1787 (2000). (Pharmacol.) • This compound is distributed through Peptide Institute, Inc. under the license of Takeda Chemical Industries, Ltd.


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 107

Prolactin-Releasing Peptide (Rat) PrRP31 (Rat)

Ser-Arg-Ala-His-Gln-His-Ser-Met-Glu-Thr-Arg- Thr-Pro-Asp-Ile-Asn-Pro-Ala-Trp-Tyr-Thr-Gly- Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH2 (M.W. 3594.0) C156H242N54O43S Multifunctional Peptide in Neuroendocrinology

PPR-4353-v-20 °C

0.5 mgvial

S. Hinuma, Y. Habata, R. Fujii, Y. Kawamata, M. Hosoya, S. Fukusumi, C. Kitada, Y. Masuo, T. Asano, H. Matsumoto, M. Sekiguchi, T. Kurokawa, O. Nishimura, H. Onda, and M. Fujino, Nature, 393, 272 (1998). (Original; cDNA) M. Maruyama, H. Matsumoto, K. Fujiwara, J. Noguchi, C. Kitada, S. Hinuma, H. Onda, O. Nishimura, M. Fujino, T. Higuchi, and K. Inoue, Neurosci. Lett., 276, 193 (1999). (Pharmacol.) F. Satoh, D.M. Smith, J.V. Gardiner, M. Mahmoodi, K.G. Murphy, M.A. Ghatei, and S.R. Bloom, Br. J. Pharmacol., 129, 1787 (2000). (Pharmacol.) H. Matsumoto, M. Maruyama, J. Noguchi, Y. Horikoshi, K. Fujiwara, C. Kitada, S. Hinuma, H. Onda, O. Nishimura, K. Inoue, and M. Fujino, Neurosci. Lett., 285, 234 (2000). (Pharmacol.) • This compound is distributed through Peptide Institute, Inc. under the license of Takeda Chemical Industries, Ltd.

Prolactin Releasing Hormone See Code PTR-4011 TRH on page 121 znd 122.Renin Substrate See Code MRP-3110 Suc-Arg-Pro-Phe-His-Leu-Leu-Val-Tyr-MCA in the Enzyme Inhibitors and Substrates section.Renin Substrate See Code SDH-4133 Asp-Arg-Val-Tyr-lle-His-Pro-Phe-His-Leu-Val-Ile-His in the Enzyme Inhibitors and Substrates section.

108 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Protease-Activated Receptor (PAR) Peptides N. Vergnolle, Br. J. Pharmacol., 141, 1264 (2004). (Review)

Proteinase-activated receptor (PAR) is a unique member of the G protein-coupled receptor (GPCR) family that is activated primarily by proteases. PAR2 is activated by trypsin cleavage which can lead to a diverse number of physiological responses. For example, PARs have been reported to relax tracheal and bronchial smooth muscle cells and participate in hypotension, arterial vasodilation in diabetes, and gastric secretions.1-4 PAR participation in tissue repair, cell survival, and inflammation following injury indicates that it may play an important role in controlling inflammatory-mediated diseases as well. In addition, PAR2 is expressed by a wide number of tumor cells including breast and colon cancers, suggesting a role in angiogenesis.5,6 1. A. Kawabata, S. Kubo, T. Ishiki, N. Kawao, F. Sekiguchi, R. Kuroda, M.D. Hollenberg, T. Kanke, and N. Saito, J. Pharmacol. Exp. Ther., 311,402 (2004).. 2. Cicala, et al., THE FASEB J., 10, 1996 (2001). 3. F. Roviezzo, M. Bucci, V. Brancaleone, A. Di Lorenzo, P. Geppetti, S. Farneti, L. Parente, G. Jungarella, S. Fiorucci, and G. Cirino, Arteriosclerosis, Thrombosis, and Vasc. Biol., 25, 2349 (2005). 4. Kawao, et al., British J. of Pharm., 135, 1292 (2002). 5. D. Darmoul, V. Gratio, H. Devaud, T. Lehy, and M. Laburthe, Am. J. Patho., 162, 1503 (2003). 6. S. Even-Ram, B. Uziely , P. Cohen , S. Grisaru-Granovsky , M. Maoz , Y. Ginzburg , R. Reich R, I. Vlodavsky I, and R. Bar-Shavit, Nat. Med., 4, 909 (1998).

Protease-Activated Receptor 1 (PAR1) H-Ala-Phe(para-Fluoro)-Arg-Cha-Cit-Tyr-NH2H-Ala-Phe(4-F)-Arg-Cha-Cit-Tyr-Amide

(M.W. 883.04) C42H63N12O8F Protease-Activated Receptor 1 (PAR1) Agonist

PAR-3931-PI -20 °C

1 mg5 mg

A. Kawabata, M. Saifeedine, B. A-Ani, L. Leblond, and M.D. Hollenberg, J. of Pharm. and Exper. Therap., 288, 358 (1999)

H-Phe-Leu-Leu-Arg-Asn-OHFLLRN

(M.W. 661.81) C31H51N9O7 Protease-Activated Receptor 1 (PAR1) Antagonist

PAR-3944-PI -20 °C

1 mg5 mg

R.R. Vassallo, Jr, T. Kieber-Emmons, K. Cichowski, and L.F Brass, J. Biol. Chem., 267, 6081 (1992)

H-Ser-Phe-Leu-Leu-Arg-NH2SFLLR-Amide

(M.W. 633.80) C30H51N9O6 Protease-Activated Receptor 1 (PAR1) Antagonist

PAR-3942-PI -20 °C

1 mg5 mg

MD. Hollenberg, S.G. Yang, A.A. Laniyonu, C.J. Moore, and M. Saifeddine, Mol. Pharmacol., 42, 186 (1992).

H-Ser-Phe-Leu-Leu-Arg-OHSFLLR

(M.W. 634.78) C30H50N8O7 Acid Form of PAR-3942-PI

PAR-3936-PI -20 °C

1 mg5 mg

H.-S. Ahn, C. Foster, G. Boykow, L. Arik, A.S.-Torhan, D. Hesk, and M. Chatterjee, Mol. Pharmacol., 51, 350 (1997). M.D. Hollenberg, S.G. Yang, A.A. Laniyonu, C.J. Moore, and M. Saifeddine, Mol. Pharmacol., 42, 186 (1992).

NEW!

NEW!

NEW!

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 109

H-Phe-Thr-Leu-Leu-Arg-Asn-Pro- Asn-Asp-Lys-NH2FTLLRNPNDK-Amide

(M.W. 1216.42) C54H89N17O15

PAR-3926-PI -20 °C

1 mg5 mg

Protease-Activated Receptor 1 (PAR1) Negative Control Peptide for PAR1 Agonist PAR-3925-PIB.D. Blackhart, K. Emilsson, D. Nguyen, W. Teng, A.J. Martelli, S. Nystedt, J. Sundelin, and R.M. Scarborough, J. Biol. Chem., 271, 16466 (1996).

H-Ser-Phe-Leu-Leu-Arg-Asn-OHSFLLRN


PAR-3943-PI -20 °C

1 mg5 mg

H.-S. Ahn, C.Foster, G. Boykow, L. Arik, A.S.-Torhan, D. Hesk, and M. Chatterjee, Mol. Pharmacol., 51, 350 (1997). R.R. Vassallo, Jr, T. Kieber-Emmons, K. Cichowski, and L.F. Brass, J. Biol. Chem., 267, 6081 (1992).

H-Ser-Phe-Leu-Leu-Arg-Asn-Pro-OHSFLLRNP

(M.W. 846.00) C39H63N11O10 Protease-Activated Receptor 1 (PAR1) Agonist

PAR-3945-PI -20 °C

1 mg5 mg

M.L. Webb, D.S. Taylor, and C.J. Molloy, Biochem. Pharmacol., 45, 1577 (1993).

H-Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe-NH2SFLLRNPNDKYEPF-Amide

(M.W. 1738.98) C81H119N21O22

PAR-3935-PI -20 °C

1 mg5 mg

J.R. Ngaiza and E.A. Jaffe, Biochem. Biophys. Res. Commun., 179, 1656 (1991).D.M. Feng, D.F. Veber, T.M. Connolly, C. Condra, M.J. Tang, and R.F. Nutt, J. Med. Chem.,38,4125 (1995).

H-Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe-OHSFLLRNPNDKYEPF

(M.W. 1739.96) C81H118N20O23Acid Form of PAR-3935-PI

PAR-3934-PI -20 °C

1 mg5 mg

H.-S. Ahn, C. Foster, G. Boykow, L. Arik, A.S.-Torhan, D. Hesk, and M. Chatterjee, Mol. Pharmacol., 51, 350 (1997).J.R. Ngaiza and E.A. Jaffe, Biochem. Biophys. Res. Commun., 179, 1656 (1991).D.M. Feng, D.F. Veber, T.M. Connolly, C. Condra, M.J. Tang,and R.F. Nutt, J. Med. Chem.,38, 4125 (1995).

H-Ser-Phe-Leu-Leu-Cit-OHSFLLcit

(M.W. 635.77) C30H49N7O8 Protease-Activated Receptor 1 (PAR1) AgonistT. Sabo, et al., Biochem. Biophys. Res. Commun., 188, 604 (1992).

PAR-3941-PI -20 °C

1 mg5 mg

H-Thr-Phe-Leu-Leu-Arg-Asn- Pro-Asn-Asp-Lys-NH2TFLLRNPNDK-Amide

(M.W. 1216.42) C54H89N17O15 Protease-Activated Receptor 1 (PAR1) Agonist.

PAR-3925-PI -20 °C

1 mg5 mg

B.D. Blackhart, K. Emilsson, D. Nguyen, W. Teng, A.J. Martelli, S. Nystedt, J. Sundelin, and R.M. Scarborough, J. Biol. Chem., 271, 16466 (1996)

NEW!

NEW!

NEW!

NEW!

NEW!

NEW!

NEW!

110 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES H-Ser-Phe-Leu-Leu-Arg-Asn-NH2SFLLRN-Amide

(M.W. 747.90) C34H57N11O8 Selective Protease-Activated Receptor 1 (PAR1) Agonist

PAR-3676-PI-20 °C

1 mg5 mg

R.R. Vassallo, Jr., T. Kieber-Emmons, K. Cichowski, and L.F. Brass, J. Biol. Chem., 267, 6081 (1992).

H-Thr-Phe-Leu-Leu-Arg-NH2TFLLR-Amide


PAR-3665-PI-20 °C

1 mg5 mg

M.D. Hollenberg, M. Saifeddine, B. al-Ani, and A. Kawabata, Can. J. Physiol. Pharmacol., 75, 832 (1997).

H-Arg-Leu-Leu-Phe-Thr-NH2RLLFT-Amide

(M.W. 647.82) C31H53N9O6 Protease-Activated Receptor 1 (PAR1) Negative Control Peptide

PAR-3695-PI-20 °C

1 mg5 mg

S. Asfaha, V. Brusse, K. Chapman, D.W. Zochodne, and N. Vergnolle, Br. J. Pharmacol., 135, 1101 (2002). M. Fang, J. K.J. Kovacs, L.L. Fisher, and A.A. Larson, Physiol., 549, 903 (2003).

Protease-Activated Receptor 2 (PAR2) 2-Furoyl-Orn-Leu-Arg-Gly-Ile-Leu-NH22-Furoyl-OrnLRGIL-Amide

(M.W. 777.97) C36H63N11O8

PAR-3951-PI -20 °C

1 mg5 mg

Protease-Activated Receptor 2 (PAR2 ) Negative Control Peptide for PAR-3663-PI J.J. McGuire, M. Saifeddine, C.R. Triggle, K. Sun, and M.D. Hollenberg, J. of Pharm. Exp. Ther., 309, 1124 (2004).

2-Furoyl-Leu-Ile-Gly-Arg-Leu-Orn-NH22-Furoyl-LIGRLO-Amide

(M.W. 777.97) C36H63N11O8

PAR-3663-PI-20 °C

1 mg5 mg

Potent and Selective Protease-Activated Receptor 2 (PAR2) AgonistJ.J. McGuire, M. Saifeddine, C.R. Triggle, K. Sun, and M.D. Hollenberg, J Pharmacol. Exp. Ther., 309, 1124 (2004).

3-Mercaptopropionyl-Phe-Cha-Cha-Arg-Lys-Pro-Asn-Asp-Lys-NH23-Mercaptopropionyl-F-Cha-Cha-RKNDK-Amide

(M.W. 1297.64) C61H100N16O13S.

PAR-3677-PI-20 °C

1 mg5 mg

Protease-Activated Receptor 1 (PAR1) Antagonist / Protease-Activated Receptor 2 (PAR2) AgonistA. Kawabata, M. Saifeddine, B. Al-Ani, L. Leblond and M.D. Hollenberg, J. Pharmacol. and Experim. Therapeutics, 88, 358 (1999). S.M. Seiler, M. Peluso, I.M. Michel, H. Goldenberg, J.W. Fenton 2nd, D. Riexinger, and S. Natarajan, Biochem. Pharmacol., 49, 519 (1995)

H-Ser-Leu-Ile-Gly-Arg-Leu-NH2 SLIGRL-Amide


PAR-3664-PI-20 °C

1 mg5 mg

B. Al-Ani, M. Saifeddine, and M.D. Hollenberg, Can. J. of Physiol. Pharmacol., 73, 1203 (1995).

H-Leu-Ser-Ile-Gly-Arg-Leu-NH2LSIGRL-Amide

(M.W. 656.83) C29H56N10O7

PAR-3913-PI -20 °C

1 mg5 mg

Protease-Activated Receptor 2 (PAR2) Negative Control for PAR-3664-PIH. Nishikawa, K. Kawai, M. Tanaka, H. Ohtani, S. Tanaka, C. Kitagawa, M. Nishida, T. Abe, H. Araki, and A. Kawabata, J. Pharm. and Experim. Therap., 312, 324 (2005).

NEW!

NEW!

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 111

H-Ser-Leu-Ile-Gly-Arg-Leu-OH SLIGRL


PAR-3940-PI -20 °C

1 mg5 mg

A. Bhattacharya, G.F. Smith, and M.L. Cohen, J. Pharmacol. Exp. Ther., 297, 573 (2001). B. Al-Ani, M. Saifeddine, and M.D. Hollenberg, Can. J. of Physiol. Pharmacol., 73, 1203 (1995).

H-Ser-Leu-Ile-Gly-Arg-NH2 SLIGR-Amide

(Trifluoroacetate Form)(M.W. 543.67) C23H45N9O6 PAR2 Agonist

PAR-3743-PI-20 °C

1 mg5 mg

R.M. Scarborough, Curr. Med. Chem., 1, 73 (2003). B. Al-Ani, M. Saifeddine , A.Kawabata , B. Renaux , S. Mokashi , M.D. Hollenberg , J. Pharmacol. And Experim Therapm., 290, 753 (1999).

H-Phe-Ser-Leu-Leu-Arg-Tyr-NH2FSLLRY-Amide

(M.W. 796.98) C39H60N10O8

PAR-3888-PI -20 °C

1 mg5 mg

Selective Antagonist for Protease-Activated Receptor 2 (PAR2) Agonist FSLLRY-NH2 blocks trypsin but not SLIGRL-NH2 activation of PAR2 in receptor-expressing KNRK cells.B. Al-Ani, M. Saifeddine, S.J. Wijesuriya, and M.D. Hollenberg, J. Pharmacol. Exp. Ther., 300, 702 (2002).S.Wilson, B. Greer, J. Hooper, A. Zijlstra, B. Walker, J. Quigley, and S. Hawthorne, Biochem. J., 388, 967 (2005).

H-Ser-Leu-Ile-Gly-Lys-Val-NH2SLIGKV-Amide

(M.W. 614.79) C25H54N8O7

PAR-3889-PI-20 °C

1 mg5 mg

PAR2 Tethered Ligand (Human) / Protease-Activated Receptor 2 (PAR2) AgonistS.K. Bohm, W. Kong, D. Bromme, S.P. Smeekens, D.C. Anderson, A. Connolly, M. Kahn, H.A. Nelken, S.R. Coughlin, D.G. Payan, and N.W. Bunnett, Biochem. J., 314, 1009 (1996).

H-Leu-Ser-Ile-Gly-Lys-Val-NH2LSIGKV-Amide

(M.W. 614.79) C28H54N8O7

PAR-3920-PI -20 °C

1 mg5 mg

Protease-Activated Receptor 2 (PAR2) Negative Control Peptide for PAR-3889-PII.A. Akers, M. Parsons, M.R. Hill, M.D. Hollenberg, S. Sanjar, G.J. Laurent, and R.J. McAnulty, Am. J. Physiol. Lung Cell. Mol. Physiol., 278, L193 (2000). S. Miyata, N. Koshikawa, H. Yasumitsu, and K. Miyazaki, J. Biol. Chem., 275, 4592 (2000). S. Miike, A.S. McWilliam, and H. Kita, J. Immunol., 167, 6615 (2001).

H-Ser-Leu-Ile-Gly-Lys-Val-OHSLIGKV


PAR-3938-PI -20 °C

1 mg5 mg

S.K. Bohm, W. Kong, D. Bromme, S.P. Smeekens, D.C. Anderson, A. Connolly, M. Kahn, H.A. Nelken, S.R. Coughlin, D.G. Payan, and N.W. Bunnett, Biochem. J., 314, 1009 (1996).W.R. Ferrell, J.C. Lockhart, E.B. Kelso, L. Dunning, R. Plevin, S.E. Meek, Andrew J.H. Smith, G.D. Hunter, J.S. McLean, F. McGarry, R. Ramage, L. Jiang, T. Kanke, and J. Kawagoe, J. Clin. Invest., 111, 35 (2003)..

Protease-Activated Receptor 3 PAR3

H-Thr-Phe-Arg-Gly-Ala-Pro-NH2TFRGAP-Amide

(M.W. 646.75) C29H46N10O7PAR3 Tethered Ligand (Human) / Activates PAR1 and PAR2

PAR-3689-PI -20 °C

1 mg5 mg

K.K. Hansen, M. Saifeddine, and M.D. Hollenberg, Immunology, 112, 183 (2004).

NEW!

NEW!

NEW!

NEW!

112 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES H-Ser-Phe-Asn-Gly-Gly-Pro-NH2SFNGGP-Amide

(M.W. 576.61) C25H36N8O8PAR3 Tethered Ligand (Murine) / Activates PAR1 and PAR2

PAR-3691-PI-20 °C

1 mg5 mg

K.K. Hansen, M. Saifeddine, and M.D. Hollenberg, Immunology, 112, 183 (2004).

Protease-Activated Receptor 4 (PAR4) H-Gly-Tyr-Pro-Gly-Lys-Phe-NH2GYPGKF-Amide

(M.W. 666.78) C33H46N8O7

PAR-3672-PI-20 °C

1 mg5 mg

PAR4 Tethered Ligand (Murine) / Protease-Activated Receptor 4 (PAR4) AgonistM.L. Kahn, Y.W. Zheng, W. Huang, V. Bigornia, D. Zeng, S. Moff, R. Farese, C. Tam, and S.R. Coughlin, Nature, 394, 690 (1998). M.L. Kahn, M. Nakanishi-Matsui, M. J. Shapiro, H. Ishihara, and S.R. Coughlin, J. Clin. Invest., 103, 879 (1999). M.D. Hollenberg, M Saifeddine, B Al-Ani, and Y. Gui, Can. J. Physiol. Pharmacol., 77, 458 (1999).

H-Gly-Tyr-Pro-Gly-Gln-Val-NH2GYPGQV-Amide

(M.W. 618.70) C28H42N8O8

PAR-3673-PI-20 °C

1 mg5 mg

PAR4 Tethered Ligand (Human) / Protease-Activated Receptor 4 (PAR4) AgonistW. Xu, H. Andersen, T.E. Whitmore, S.R. Presnell, D.P. Yee, A. Ching, T. Gilbert, E.W. Davie, and D.C. Foster, Proc. Nat’l. Acad. Sci. U.S.A., 95, 6642 (1998). M.D. Hollenberg, M. Saifeddine, B. Al-Ani, and Y. Gui, Can. J. Physiol. Pharmacol., 77, 458 (1999).

H-Ala-Tyr-Pro-Gly-Lys-Phe-OHAYPGKF

(M.W. 681.80) C34H47N7O8 Acid form of PAR-3674-PI

PAR-3939-PI -20 °C

1 mg5 mg

E.A. Lidington, R. Steinberg, A.R. Kinderlerer, R.C. Landis, M. Ohba, A. Samarel, D.O. Haskard, and J.C. Mason, Am J Physiol Cell Physiol, 289, C1437 (2005).M.D. Hollenberg, M. Saifeddine, S. Sandhu, S. Houle, and N. Vergnolle, Br. J. Pharmacol., 143, 443 (2004)

H-Ala-Phe(para-Fluoro)-Arg-Cha-homo Arg-Tyr-NH2H-Ala-Phe(4-F)-Arg-Cha-homoArg-Tyr-Amide

Thrombin Receptor Activating Peptide

PAR-3932-PI -20 °C

1 mg5 mg

D.M. Feng, D.F. Veber, T.M. Connolly, C. Condra, M.J. Tang, and R.F. Nutt, J. Med. Chem.,38 4125 (1995).H.-S. Ahn, C.Foster, G. Boykow, L. Arik, A. S.-Torhan, D. Hesk, and M. Chatterjee, Mol. Pharmacol., 51, 350 (1997).

H-Ala-Tyr-Pro-Gly-Lys-Phe-NH2AYPGKF-Amide

(M.W. 680.81) C34H48N8O7 Selective Protease-Activated Receptor 4 (PAR4) Agonist.

PAR-3674-PI-20 °C

1 mg5 mg

M.D. Hollenberg, M. Saifeddine, B. Al-Ani, and Y. Gui, Can. J. Physiol. Pharmacol., 77, 458 (1999). T.R. Faruqi, E.J. Weiss, M.J. Shapiro, W. Huang, and S.R. Coughlin, J. Biol. Chem., 275, 19728 (2000). M.D. Hollenberg, M. Saifeddine, S. Sandhu, S. Houle, and N. Vergnolle, Br. J. Pharmacol., 143, 443 (2004)

H-Tyr-Ala-Pro-Gly-Lys-Phe-NH2YAPGKF-Amide

(M.W. 680.81) C34H48N8O7

PAR-3933-PI -20 °C

1 mg5 mg

Protease-Activated Receptor 4 (PAR4) Negative Control Peptide for PAR-3674-PIM.D. Hollenberg, M. Saifeddine, S. Sandhu, S. Houle, and N. Vergnolle, Br. J. Pharmacol., 143, 443 (2004).

NEW!

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 113

trans-Cinnamoyl-Tyr-Pro-Gly-Lys-Phe-NH2trans-Cinnamoyl-YPGKF-Amide

(M.W. 739.88) C40H49N7O7 Selective Protease-Activated Receptor 4 (PAR4) Agonist

PAR-3675-PI-20 °C

1 mg5 mg

L. Ma, M.D. Hollenberg, and J.L. Wallace, Br. J. Pharmacol., 134, 701 (2001). M.D. Hollenberg and M. Saifeddine, Can. J. Physiol. Pharmacol., 79, 439 (2001).

Pyroglutamylated RFamide PeptideThe group of Takeda Pharmaceutical Company Limited has long been involved in discovering orphan receptor ligands and identified a novel peptide in human utiliz-ing the recently established gene database. Actually, they searched the database to detect peptides with the carboxyl-terminal Arg-Phe-NH2 (RFamide) moiety in the mature peptide. As a result, the peptide termed Pyroglutamylated RFamide pep-tide (QRFP) was identified by analyzing the expressed peptide in Chinese hamster ovary cells as a 43 amino acid residue peptide.1 The peptide corresponding to the carboxyl-terminal 26 amino acid residues of QRFP was also predicted by another group using a similar approach and then termed P518.2 Both of these peptides were found to interact with an orphan receptor (AQ27/SP9155/GPR103; all of these denote the same orphan receptor of interest). Human 26RFa was proposed by another group based on the primary structure of their determined frog peptide in which 26RFa is identical to P518.3 The biological activities of QRFP and 26RFa reported are: i) upon intravenous administration in rats at doses between 40 and 400 nmol/kg, QRFP induced aldosterone secretion in a dose-dependent manner, ii) intracerebroventricular administration of 26RFa in mice (after partial food deprivation for 18 h) stimulated food intake at doses of 100 and 1000 ng/mouse, iii) central QRFP (rat QRFP is used in this report) administration evoked feeding, behavioral arousal, and elevation of blood pressure in mice4, and iv) intracerebroventricular infusion of QRFP increased fat mass and decreased rectal temperature in mice.5 QRFP might have variable activities other than those identified, thus, it should serve as an essential member of the RFamide family peptides in humans.1. S. Fukusumi, H. Yoshida, R. Fujii, M. Maruyama, H. Komatsu, Y. Habata, Y. Shintani, S. Hinuma, and M. Fujino, J. Biol. Chem., 278, 46387 (2003). (Original: QRFP)2. Y. Jiang, L. Luo, E.L. Gustafson, D. Yadav, M. Laverty, N. Murgolo, G. Vassileva, M. Zeng, T.M. Laz, J. Behan, P. Qiu, L.Wang, S.Wang, M. Bayne, J. Greene, F. Monsma, Jr., and F.L. Zhang, J. Biol. Chem., 278, 27652 (2003). (Orphan Receptor Ligand / 26-Residue Peptide, P518)3. N. Chartrel, C. Dujardin, Y. Anouar, J. Leprince, A. Decker, S. Clerens, J.-C. Do-Régo, F. Vandesande, C. Llorens-Cortes, J. Costentin, J.-C. Beauvillain, and H. Vaudry, Proc. Natl. Acad. Sci. U.S.A., 100, 15247 (2003). (26-Residue Peptide, 26RFa)4. S. Takayasu, T. Sakurai, S. Iwasaki, H. Teranishi, A. Yamanaka, S.C. Williams, H. Iguchi, Y.I. Kawasawa, Y. Ikeda, I. Sakakibara, K. Ohno, R.X. Ioka, S. Murakami, N. Dohmae, J. Xie, T. Suda, T. Motoike, T. Ohuchi, M. Yanagisawa, and J. Sakai, Proc. Natl. Acad, Sci. U.S.A., 103, 7438 (2006). (Pharmacol.)5. R. Moriya, H. Sano, T. Umeda, M. Ito, Y. Takahashi, M. Matsuda, A. Ishihara, A. Kanatani, and H. Iwaasa, Endocrinology, 147, 2916 (2006). (Pharmacol.)6. S. Fukusumi, R. Fujii, and S. Hinuma, Peptides, 27, 1073 (2006). (Review)7. D.A. Bechtold and S.M. Luckman, J. Endocrinol., 192, 3 (2007). (Review)

Pyroglutamylated RFamide Peptide (Human)QRFP (Human)

PRF-4419-s-20 °C

0.1 mgvial

Pyr-Asp-Glu-Gly-Ser-Glu-Ala-Thr-Gly-Phe-Leu-Pro-Ala-Ala-Gly-Glu- Lys-Thr-Ser-Gly-Pro-Leu-Gly-Asn-Leu-Ala-Glu-Glu-Leu-Asn-Gly- Tyr-Ser-Arg-Lys-Lys-Gly-Gly-Phe-Ser-Phe-Arg-Phe-NH2 (M.W. 4503.8) C199H301N55O65 Endogenous Ligand for AQ27 / SP9155 / GPR103

114 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Pyr-Lys-Arg-Pro-Ser-Gln-Arg-Ser-Lys-Tyr-Leu See Code SKL-4237-v.QRFP (Human) See Code PRF-4419-s Pyroglutamylated RFamide Peptide (Human) page 113.Renin Substrate See Code MRP-3110 Suc-Arg-Pro-Phe-His-Leu-Leu-Val-Tyr-MCA and Code SDH-4133 Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His.

RF Amide Related PeptidesRFamide-Related Peptide-1 (Human)RFRP-1 (Human)

Ser-Leu-Asn-Phe-Glu-Glu-Leu-Lys-Asp-Trp-Gly-Pro-Lys- Asn-Val-Ile-Lys-Met-Ser-Thr-Pro-Ala-Val-Asn-Lys-Met- Pro-His-Ser-Phe-Ala-Asn-Leu-Pro-Leu-Arg-Phe-NH2 (M.W. 4256.9) C195H304N52O51S2 Endogenous Ligand for OT7T022 / FF1

PRF-4380-s-20 °C

0.1 mgvial

D.A. Price and M.J. Greenberg, Science, 197, 670 (1977). (Original: FMRF-Amide) S. Fukusumi, Y. Habata, H. Yoshida, N. Iijima, Y. Kawamata, M. Hosoya, R. Fujii, S. Hinuma, C. Kitada, Y. Shintani, M. Suenaga, H. Onda, O. Nishimura, M. Tanaka, Y. Ibata, and M. Fujino, Biochim. Biophys. Acta, 1540, 221 (2001). (Endogenous Form) S. Hinuma, Y. Shintani, S. Fukusumi, N. Iijima, Y. Matsumoto, M. Hosoya, R. Fujii, T. Watanabe, K. Kikuchi, Y. Terao, T. Yano, T. Yamamoto, Y. Kawamata, Y. Habata, M. Asada, C. Kitada, T. Kurokawa, H. Onda, O. Nishimura, M. Tanaka, Y. Ibata, and M. Fujino, Nat. Cell Biol., 2, 703 (2000). (Original: cDNA & Pharmacol. of RFRP-1) Q. Liu, X.-M. Guan, W.J. Martin, T.P. McDonald, M.K. Clements, Q. Jiang, Z. Zeng, M. Jacobson, D.L. Williams, Jr., H. Yu, D. Bomford, D. Figueroa, J. Mallee, R. Wang, J. Evans, R. Gould, and C.P. Austin, . Biol. Chem., 276, 36961 (2001). (Original: NPSF) T. Yano, N. Iijima, K. Kakihara, S. Hinuma, M. Tanaka, and Y. Ibata, Brain Res., 982, 156 (2003). (Histochem.)A. Pertovaara, M. Östergård, M.-L. Änkö, S. Lehti-Koivunen, A. Brandt, B.W. Hong, E.R. Korpi, and P. Panula, Neuroscience, 134, 1023 (2005). (Pharmacol.)S. Fukusumi, R. Fujii, and S. Hinuma, Peptides, 27, 1073 (2006). (Review)D.A. Bechtold and S.M. Luckman, J. Endocrinol., 192, 3 (2007). (Review) • This compound is distributed through Peptide Institute, Inc. under the license of Takeda Chemical Industries, Ltd.

RFamide-Related Peptide-3 (RFRP-3) RFamide-Related Peptide-3 (RFRP-3) was discovered from the cDNA sequences, in which two other family peptides, RFRP-1 (Code 4380-s for one of the endogenous forms) and RFRP-2 are encoded.1,2 Endogenous forms of human and rat RFRP-3 were determined to be an 8- and 18-residue peptide, respectively.3,4 Biological activities of RFRP-3 include:

• function as gonadotropin inhibitory hormone (GnIH), resulting in the reduction in LH secretion • increase in food intake and growth hormone secretion• no effect on Kiss-1 mRNA expression.5,6

RFRP-3 should be especially valuable research tools in reproduction and puberty studies. 1. S. Hinuma, et al., Nat.Cell Biol., 2, 703 (2000). (Original: Human & Rat cDNA)2. I.J. Clarke, et al., Endocrinology, 149, 5811 (2008). (Original: Ovine cDNA)3. T. Ubuka, et al., PLoS One., 4, e8400 (2009). (Endogenous Form: Human RFRP-3)

4. K. Ukena, et al.,, FEBS Lett., 512, 255 (2002). (Endogenous Form: Rat RFRP-3)5. I.J. Clarke, et al., Front.Neuroendocrinol., 30, 371 (2009). (Review: Pharmacol.)6. M.A. Johnson and G.S. Fraley, Neuroendocrinology, 88, 305 (2008). (Pharmacol.)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 115

RFamide-Related Peptide-3 (Human)RFRP-3 (Human) (Ovine)

Val-Pro-Asn-Leu-Pro-Gln-Arg-Phe-NH2(M.W. 969.14) C45H72N14O10Gonadotropin-Inhibitory Hormone

PRF-4461-v -20 °C

0.5 mgvial

RFamide-Related Peptide-3 (Rat)RFRP-3 (Rat)

Ala-Asn-Met-Glu-Ala-Gly-Thr-Met-Ser-His- Phe-Pro-Ser-Leu-Pro-Gln-Arg-Phe-NH2(M.W. 2020.30) C88H134N26O25S2Gonadotropin-Inhibitory Hormone

PRF-4462-v-20 °C

0.5 mgvial

S. Hinuma, Y. Shintani, S. Fukusumi, N. Iijima, Y. Matsumoto, M. Hosoya, R. Fujii, T. Watanabe, K. Kikuchi, Y. Terao, T. Yano, I.J. Clarke, I.P. Sari, Y. Qi, J.T. Smith, H.C. Parkington, T. Ubuka, J. Iqbal, Q. Li, A. Tilbrook, K. Morgan, A.J. Pawson,K. Tsutsui, R.P. Millar, and G.E. Bentley, Endocrinology, 149, 5811 (2008). (Original: Ovine cDNA) T. Yamamoto, Y. Kawamata, Y. Habata, M. Asada, C. Kitada, T. Kurokawa, H. Onda, O. Nishimura, M. Tanaka, Y. Ibata, and M. Fujino, Nat. Cell Biol., 2, 703 (2000). (Original: cDNA)K. Ukena, E. Iwakoshi, H. Minakata, and K. Tsutsui, FEBS Lett., 512, 255 (2002). (Identification of RERP-3 in Rat Hypothalamus)M.A. Johnson, K. Tsutsui, and G.S. Fraley, Horm. Behav., 51,171 (2007). (Pharmacol.)M.A. Johnson and G.S. Fraley, Neuroendocrinology, 88,305 (2008). (Pharmacol.)E. Ducret, G.M. Anderson, and A.E. Herbison,Endocrinology, 150, 2799 (2009). (Pharmacol.)

SalusinsSalusin-a (Human)

Ser-Gly-Ala-Leu-Pro-Pro-Ala-Pro-Ala-Ala-Pro-Arg-Pro-Ala-Leu-Arg-Ala-Gln-Arg-Ala-Gly-Pro-Ala-Gly-Pro-Gly-Ala-Lys-NH2 (M.W. 2603.0 ) C114H192N40O30 Hypotensive / Mitogenic Peptide

PSL-4417-s-20 °C

0.1 mgvial

Salusin-b (Human)Ala-Ile-Phe-Ile-Phe-Ile-Arg-Trp-Leu-Leu-Lys-Leu-Gly-His-His-Gly-Arg-Ala-Pro-Pro (M.W. 2342.8 ) C115H176N32O21 Hypotensive / Mitogenic Peptide

PSL-4418-s-20 °C

0.1 mg vial

M. Shichiri, S. Ishimaru, T. Ota, T. Nishikawa, T. Isogai, and Y. Hirata, Nat. Med., 9, 1166 (2003). (Original)

Schizophrenia Related PeptideSchizophrenia Related Peptide (Bulk)

Thr-Val-Leu (M.W. 331.41) C15H29N3O5

C.E. Frohman, Chem. Eng. News, 1977, 35. (Original)

PSC-4061-20 °C

25 mg100 mg


NEW!

NEW!

116 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES SecretinJ.E. Jorpes and V. Mutt (eds.) Secretin, Cholecystokinin, Pancreozymin and Gastrin, Handbook of Experimental Pharmacology, Vol. 34, Springer-Verlag, Berlin, 1973. (Review)

Secretin (Human)His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Glu-Gly-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2 (M.W. 3039.4) C130H220N44O40 [108753-74-8]

PSE-4165-v-20 °C

0.5 mgvial

M. Carlquist, H. Jörnvall, W.G. Forssmann, L. Thulin, C. Johansson, and V. Mutt, IRCS Med. Sci., 13, 217 (1985). (Original) K. Iguchi, T. Mochizuki, T. Inoue, C. Yanaihara, S. Naruse, K. Nokihara, W.G. Forssmann, V. Mutt, T. Kanno, and N. Yanaihara, Peptide Chemistry 1985, 191 (1986). (Chem. Synthesis and Biological Activity)

Secretin (Porcine) His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Asp-Ser-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2 (M.W. 3055.4) C130H220N44O41 [17034-35-4]

PSE-4112-v-20 °C

0.5 mgvial

Serum Thymic FactorSerum Thymic Factor

Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (M.W. 858.85) C332H54N12O15 [63958-90-7]

PST-4058-v-20 °C

0.5 mgvial

Serum Thymic Factor (Bulk)Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn • AcOH • 2H2O (M.W. 858.85 • 60.05 • 36.03) C33H54N12O15 • CH3COOH • 2H2O

PST-4058-20 °C

25 mg

J.F. Bach, M. Dardenne, J.M. Pleau, and J. Rosa, Nature, 266, 55 (1977). (Original)

SNX-482 See Code PCB-4363-s in the Toxins section on page 140.

Sodium Potassium ATPase Inhibitor-1 (SPAI-1)SPAI-1 (Porcine) Sodium Potassium ATPase Inhibitor-1 (Porcine) Na+, K+-ATPase Inhibitor-1 (Porcine)

PSP-4216-s-20 °C

0.1 mgvial

Leu-Leu-Ser-Lys-Arg-Gly-His-Cys-Pro-Arg-Ile-Leu-Phe-Arg-Cys-Pro-Leu-Ser- Asn-Pro-Ser-Asn-Lys-Cys-Trp-Arg-Asp-Tyr-Asp-Cys-Pro-Gly-Val-Lys- Lys-Cys-Cys-Glu-Gly-Phe-Cys-Gly-Lys-Asp-Cys-Leu-Tyr-Pro-Lys (Disulfide bonds are between Cys8-Cys37, Cys15-Cys41, Cys24-Cys36, and Cys30-Cys45) (M.W. 5628.6) C245H378N72O65S8

K. Araki, J. Kuroki, O. Ito, M. Kuwada, and S. Tachibana, Biochem. Biophys. Res. Commun., 164, 496 (1989). (Original) K. Araki, M. Kuwada, O. Ito, J. Kuroki, and S. Tachibana, Biochem. Biophys. Res. Commun., 172, 42 (1990). (S-S Bond) H. Nishio, S. Kumagaye, H. Kuroda, N. Chino, J. Emura, T. Kimura, and S. Sakakibara, Pept. Res., 5, 227 (1992). (Chem. Synthesis)


Somatostatin (SRIF) and Related PeptidesSomatostatin SRIF: (Somatotropin Release Inhibiting Factor) GIF: (Growth Hormone Release Inhibiting Factor) (Human, Ovine, Porcine, Rat, Mouse)

Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys (Disulfide bond between Cys3-Cys14) (M.W. 1637.9) C76H104N18O19S2 [38916-34-6]

PSI-4023-v-20 °C

0.5 mgvial


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 117

Somatostatin (Bulk) SRIF: (Somatotropin Release Inhibiting Factor) GIF: (Growth Hormone Release Inhibiting Factor) (Human, Ovine, Porcine, Rat, Mouse)

PSI-4023-20 °C

25 mg

Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys • 2AcOH • 6H2O (Disulfide bond between Cys3-Cys14) (M.W. 1637.9 • 120.10 • 108.09) C76H104N18O19S2 • 2CH3COOH • 6H2OP. Brazeau, W. Vale, R. Burgus, N. Ling, M. Butcher, J. Rivier, and R. Guillemin, Science, 179, 77 (1973). (Original; Ovine) D.J. Koerker, W. Ruch, E. Chideckel, J. Palmer, C.J. Goodner, . Ensinck, and C.C. Gale, Science, 184, 482 (1974). (Pharmacol.) A. Arimura, H. Sato, A. Dupont, N. Nishi, and A.V. Schally, Science, 189, 1007 (1975). (Pharmacol.) L.-P. Shen, R.L. Pictet, and W.J. Rutter, Proc. Natl. Acad. Sci. U.S.A., 79, 4575 (1982). (cDNA Seq.; Human)

Somatostatin-28(Trifluoroacetate Form) H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg- Glu-Arg-Lys-Ala-Gly-Cys-Lys-Asn-Phe-Phe- Trp-Lys-Thr-Phe-Thr-Ser-Cys

PSI-3747-PI-20 °C

1 mg5 mg

(Disulfide bond Cys17-Cys 28) (M.W. 3148.62) C137H207N41O39S3 [73032-94-7]

[d-Trp8]-SomatostatinAla-Gly-Cys-Lys-Asn-Phe-Phe-d-Trp-Lys-Thr-Phe-Thr-Ser-Cys (Disulfide bonds between Cys3-Cys14) (M.W. 1637.9) C76H104N18O19S2 [58976-46-8]

PSI-4101-v-20 °C

0.5 mgvial

J. Rivier, H. Brown, and W. Vale, Biochem. Biophys. Res. Commmun., 65, 746 (1975). (Original)

[Tyr1]-SomatostatinTyr-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys (Disulfide bonds between Cys3-Cys14) (M.W. 1730.0) C82H108N18O20S2 For Radioimmunoassay Purity Information: Qx See page xiv

PSI-4038-v-20 °C

0.5 mgvial

A. Arimura, H. Sato, D.H. Coy, and A.V. Schally, Proc. Soc. Exp. Biol. Med., 148, 784 (1975). (Original)

Spantide See Code PSP-4173 (d-Arg1,d-Trp7,9, Leu11)-Substance P on page 120.

Src Homology 2 Domain LigandSrc Homology 2 Domain Ligand (Biotinylated)

Biotinyl-ε-aminocaproyl-Glu-Pro-Gln-Tyr(PO3H2)-Glu-Glu-Ile-Pro-Ile-Tyr-Leu- (M.W. 1813.01) C82H122N15O27SP [215876-01-0] Src Homology 2 Domain Ligand

SRC-3737-PI-20 °C

1 mg 5 mg

L.M.Sonatore, D. Wisniewski, L.J. Frank, P.M. Cameron, J.D. Hermes, A. Marcy, S.P. Salowe, Anal Biochem, 240, 289 (1996). R-H Yeh, T.R. Lee, and D.S. Lawrence, J. Biol Chem, 276, 12235 (2001). X. Liu, et al., Bull Korean Chem Soc, 27, 1353 (2006). S.-H. Park, J. Wona, and K.-H. Lee, J. Med. Chem., 43, 1173 (2000).

Substance K See Code PNK-4154 Neurokinin A on page 87.

NEW!

NEW!

118 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Stresscopins / Urocortin and Related PeptidesStresscopin (Human)

Thr-Lys-Phe-Thr-Leu-Ser-Leu-Asp-Val-Pro-Thr-Asn-Ile-Met-Asn-Leu-Leu-Phe-Asn-Ile-Ala-Lys-Ala-Lys-Asn-Leu-Arg-Ala-Gln-Ala-Ala-Ala-Asn-Ala-His-Leu-Met-Ala-Gln-Ile-NH2 (M.W. 4367.1) C195H326N56O53S2 Selective Ligand for Type 2 CRF Receptors

PST-4387-s-20 °C

0.1 mgvial

S.Y. Hsu and A.J.W. Hsueh, Nat. Med., 7, 605 (2001). (Original) F.M. Dautzenberg and R.L. Hauger, Trends Pharmacol. Sci., 23, 71 (2002). (Review) V. Martínez, L. Wang, J.E. Rivier, W. Vale, and Y. Taché, J. Pharmacol. Exp. Ther., 301, 611 (2002). (Pharmacol.) A. Chanalaris, K.M. Lawrence, A. Stephanou, R.D. Knight, S.Y. Hsu, A.J.W. Hsueh, and D.S. Latchman, J. Mol. Cell. Cardiol., 35, 1295 (2003). (Pharmacol.)

Stresscopin-Related Peptide (Human) (Hydrochloride Form) His-Pro-Gly-Ser-Arg-Ile-Val-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Leu-Gln-Ile-Leu-Leu-Glu-Gln-Ala-Arg-Ala-Arg-Ala-Ala-Arg-Glu-Gln-Ala-Thr-Thr-Asn-Ala-Arg-Ile-Leu-Ala-Arg-Val-NH2 (M.W. 4687.5) C205H358N68O57 Selective Ligand for Type 2 CRF Receptors

PST-4388-s-20 °C

0.1 mgvial

S.Y. Hsu and A.J.W. Hsueh, Nat. Med., 7, 605 (2001). (Original) F.M. Dautzenberg and R.L. Hauger, Trends Pharmacol. Sci., 23, 71 (2002). (Review) V. Martínez, L. Wang, J.E. Rivier, W. Vale, and Y. Taché, J. Pharmacol. Exp. Ther., 301, 611 (2002). (Pharmacol.) A. Chanalaris, K.M. Lawrence, A. Stephanou, R.D. Knight, S.Y. Hsu, A.J.W. Hsueh, and D.S. Latchman, J. Mol. Cell. Cardiol., 35, 1295 (2003). (Pharmacol.)

Urocortin (Human)Asp-Asn-Pro-Ser-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu- Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH2 (M.W. 4696.2) C204H337N63O64 [176591-49-4] Ligand for Type 1 / Type-2 CRF Receptors

PUC-4328-s-20 °C

0.1 mgvial

C.J. Donaldson, S.W. Sutton, M.H. Perrin, A.Z. Corrigan, K.A. Lewis, J.E. Rivier, J.M. Vaughan, and W.W. Vale, Endocrinology, 137, 2167 (1996). (Original; cDNA & Pharmacol.) D.P. Behan, O. Khongsaly, N. Ling, and E.B. De Souza, Brain Res., 725, 263 (1996). (Biochem.) Y. Murakami, T. Mori, K. Koshimura, M. Kurosaki, T. Hori, N. Yanaihara, and Y. Kato, Endocr. J., 44, 627 (1997). (Pharmacol.) K. Takahashi, K. Totsune, M. Sone, O. Murakami, F. Satoh, Z. Arihara, H. Sasano, K. Lino, and T. Mouri, Peptides, 19, 643 (1998). (Immunohistochem.)

Urocortin (Rat) (Mouse)

Asp-Asp-Pro-Pro-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu- Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH2 (M.W. 4707.3) C206H338N62O64 [171543-83-2] Ligand for Type 1 / Type-2 CRF Receptors

PUC-4327-s-20 °C

0.1 mgvial

J. Vaughan, C. Donaldson, J. Bittencourt, M.H. Perrin, K. Lewis, S. Sutton, R. Chan, A.V. Turnbull, D. Lovejoy, C. Rivier, J. Rivier, P.E. Sawchenko, and W. Vale, Nature, 378, 278 (1995). (Original, cDNA & Pharmacol.) A.V. Turnbull, W. Vale, and C. Rivier, Eur. J. Pharmacol., 03, 213 (1996). (Pharmacol.; Inhibition of Edema) M. Spina, E. Merlo-Rich, R.K.W. Chan, A.M. Basso, J. Rivier, W. Vale and G.F. Koob, Science, 273, 1561 (1996). (Pharmacol.; Suppresion of Appetite) L.Y. Zhao, C.J. Donaldson, G.W. Smith, and W.W. Vale, Genomics, 50, 23 (1998). (Nucleotide Seq.; Mouse)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 119

Urocortin II (Mouse)Val-Ile-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Leu-Arg-Ile-Leu-Leu-Glu-Gln-Ala-Arg-Tyr-Lys-Ala-Ala-Arg-Asn-Gln-Ala- Ala-Thr-Asn-Ala-Gln-Ile-Leu-Ala-His-Val-NH2 (M.W. 4152.9) C187H320N56O50 Selective Ligand for Type 2 CRF Receptors

PUC-4383-s-20 °C

0.1 mg vial

C.J. Donaldson, S.W. Sutton, M.H. Perrin, A.Z. Corrigan, K.A. Lewis, J.E. Rivier, J.M. Vaughan, and W.W. Vale, Endocrinology, 137, 2167 (1996). (Original; Human Urocortin) T.M. Reyes, K. Lewis, M.H. Perrin, K.S. Kunitake, J. Vaughan, C.A. Arias, J.B. Hogenesch, J. Gulyas, J. Rivier, W.W. Vale, and P.E. Sawchenko, Proc. Natl. Acad. Sci. USA, 98, 2834 (2001). (Original; Urocortin II) K. Lewis, C. Li, M.H. Perrin, A. Blount, K. Kunitake, C. Donaldson, J. Vaughan, T.M. Reyes, J. Gulyas, W. Fischer, L. Bilezikjian, J. Rivier, P.E. Sawchenko, and W.W. Vale, Proc. Natl. Acad. Sci. USA, 98, 7570 (2001). (Original; Urocortin II) S.Y. Hsu and A.J.W. Hsueh, Nat. Med., 7, 605 (2001). (Original; Stresscopin & Stresscopin Related Peptides) F.M. Dautzenberg and R.L. Hauger, Trends Pharmacol. Sci., 23, 71 (2002). (Review) M. Million, C. Maillot, P. Saunders, J. Rivier, W. Vale, and Y. Taché, Am. J. Physiol., 282, G34 (2002). (Pharmacol.) C. Li, J. Vaughan, P.E. Sawchenko, and W.W. Vale, J. Neurosci., 22, 991 (2002). (Histochem.) V. Martínez, L. Wang, J.E. Rivier, W. Vale, and Y. Taché, J. Pharmacol. Exp. Ther., 301, 611 (2002). (Pharmacol.)

Substance P and Related PeptidesD. Regoli, A. Boudon, and J.-L. Fauchere, Pharmacol. Rev., 46, 551 (1994). (Review)

Substance P* (Human, Bovine, Rat, Mouse)

Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 (M.W. 1347.6) C63H98N18O13S [33507-63-0]

PSP-4014-v-20 °C

0.5 mgvial

Substance P* (Bulk) (Human, Bovine, Rat, Mouse)

PSP-4014-20 °C

25 mg

Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 • 3AcOH • 5H2O (M.W. 1347.6 • 180.16 • 90.08) C63H98N18O13S • 3CH3COOH • 5H2O Purity Information: Qp See page xiv U.S. von Euler and J.H. Gaddum, J. Physiol., 72, 74 (1931). (Naming) M.M. Chang, S.E. Leeman, and H.D. Niall, Nature New Biol., 232, 86, (1971). (Original; Bovine) A.J. Harmar, A. Armstrong, J.C. Pascall, K. Chapman, R.Rosie, A. Curtis, J. Going, C.R.W. Edwards, and G. Fink, FEBS Lett., 208, 67 (1986). (cDNA Seq.; Human)

[d-Arg1,d-Pro2,d-Trp7,9,Leu11]-Substance P(Hydrochloride Form) d-Arg-d-Pro-Lys-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Leu-NH2 (M.W. 1497.8) C75H108N20O13 [84676-91-5]

PSP-4172-v-20 °C

0.5 mgvial

[d-Arg1,d-Phe5,d-Trp7,9,Leu11]-Substance P d-Arg-Pro-Lys-Pro-d-Phe-Gln-d-Trp-Phe-d-Trp-Leu-Leu-NH2 (M.W. 1516.87) C79H109N19O12

PGH-3652-PI-20 °C

1 mg5 mg

Ghrelin Antagonist / Potent Ghrelin Inverse Agonist Bombesin AntagonistP.J. Woll and E. Rozengurt, Proc. Natl. Acad. Sci. USA, 85, 1859 (1988). (Original: Bombesin Antagonist) B. Holst, A. Cygnakiewicz, T.H. Jensen, M. Ankersen, and T.W. Schwartz, Mol. Endocrin. In Press. (2003). (Original: Ghrelin Antagonist)

[d-Arg1,d-Pro2,d-Trp7,9,Leu11]-Substance P (Bulk)d-Arg-d-Pro-Lys-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Leu-NH2 • 3HCl • 8H2O (M.W. 1497.8 • 109.38 • 144.12) C75H108N20O13 • 3HCI • 8H2O Bombesin Receptor Antagonist Purity Information: Qp See page xiv

PSP-4172-20 °C

25 mg

R.T. Jensen, S.W. Jones, K. Folkers, and J.D. Gardner, Nature, 309, 61 (1984). (Original; Bombesin Antagonist)

120 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES [d-Arg1,d-Trp7,9,Leu11]-Substance P Spantide

(Hydrochloride Form) d-Arg-Pro-Lys-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Leu-NH2 (M.W. 1497.8) C75H108N20O13 [91224-37-2]

PSP-4173-v-20 °C

0.5 mgvial

[d-Arg1,d-Trp7,9,Leu11]-Substance P (Bulk) Spantide

PSP-4173-20 °C

25 mg

d-Arg-Pro-Lys-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Leu-NH2 • 3HCl • 8H2O (M.W. 1497.8 • 109.38 • 144.12) C75H108N20O13 • 3HCI • 8H2O Substance P Antagonist Purity Information: Qp See page xiv K. Folkers, R. Hákanson, J. Hörig, X. Jie-Cheng, and S. Leander, Br. J. Pharmacol., 83, 449 (1984). (Original)

[d-Pro2,d-Trp7,9]-Substance P (Hydrochloride Form) Arg-d-Pro-Lys-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Met-NH2 (M.W. 1515.8) C74H106N20O13S [80434-86-2]

PSP-4113-v-20 °C

0.5 mgvial

[d-Pro2,d-Trp7,9]-Substance P (Bulk)Arg-d-Pro-Lys-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Met-NH2 • 3HCI • 6H2O (M.W. 1515.8 • 109.38 • 108.12) C74H106N20O13S • 3HCI • 6H2O Substance P Antagonist Purity Information: Qp See page xiv

PSP-4113-20 °C

25 mg

G. Engberg, T.H. Svensson, S. Rosell, and K. Folkers, Nature, 293, 222 (1981). (Original)


[d-Pro4,d-Trp7,9]-Substance P (4-11)d-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Met-NH2l (M.W. 1134.4) C57H75N13O10S [81039-85-2] Substance P Antagonist

PSP-4114-v-20 °C

0.5 mgvia

S. Caranikas, J. Mizrahi, P. D’Orleans-Juste, and D. Regoli, Eur. J. Pharmacol., 77, 205 (1982). (Original)

[Tyr8]-Substance P*Arg-Pro-Lys-Pro-Gln-Gln-Phe-Tyr-Gly-Leu-Met-NH2 (M.W. 1363.6) C63H98N18O14S [55614-10-3] For Radioimmunoassay Purity Information: Qx See page xiv

PSP-4059-v-20 °C

0.5 mgvial


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 121

[D-Leu7]-(-)-TernatinProfessor Uemura of Nagoya University isolated (-)-ternatin from the mushroom Coriolus versicolor and determined its structure by the combination of NMR analysis and total chemical synthesis.1 The inhibitory effects of this highly N-methylated cyclic 7-peptide, (-)-ternatin, in both adipogenesis and lipid metabolism, have been clarified in vitro as well as in vivo.2,3 These include: i) a fat accumulation inhibitory effect and cell viability in 3T3-L1 murine adipocytes (IC50 = 0.027 μM and 0.28 μM, respectively) and ii) suppression of body weight gain and fat accumulation in C57BL/6J mice at a dose of 5 mg/kg/day, together with iii) mechanism for exerting these inhibitory activity.Later, his group found [D-Leu7]-(-)-ternatin as a useful derivative of (-)-ternatin during a structure-activity relationship study. Actually, this peptide, a deletion analog of β-OH group from the 7th amino acid, β-OHD-Leu, maintains not only fat accumulation inhibi-tory activity with only an 8-fold-lower potency, but also the structural integrity of the parent molecule.4,5 This specific analog, [D-Leu7]-(-)-ternatin, may be an alternative to (-)-ternatin in the study to combat metabolic diseases in the modern world. [D-Leu7]-(-)-Ternatin is now available from Peptides International, Inc. under an agreement with Professor Uemura.1. K. Shimokawa, I. Mashima, A. Asai, K. Yamada, M. Kita, and D. Uemura, Tetrahedron Lett., 47, 4445 (2006). ((-)-Ternatin; Structure Determination / Biological Activity in vitro)2. K. Shimokawa, K. Yamada, M. Kita, and D. Uemura, Bioorg. Med. Chem. Lett., 17, 4447 (2007). ((-)-Ternatin; Biological Activity in vivo)3. M. Ito, J. Ito, H. Kitazawa, K. Shimamura, T. Fukami, S. Tokita, K. Shimokawa, K. Yamada, A. Kanatani, and D. Uemura, Peptides, 30, 1074 (2009). ((-)-Ternatin; Mechanism of Inhibitory Activity)4. K. Shimokawa, Y. Iwase, K. Yamada, and D. Uemura, Org. Biomol. Chem., 6, 58 (2008). (D-Leu7-(-)-Ternatin; Biological Activity in vivo)5. K. Shimokawa, R. Miwa, K. Yamada, and D. Uemura, Org. Biomol. Chem., 7, 777 (2009). (D-Leu7-(-)-Ternatin; Conformation-Biological Activity Relationship)• This compound is distributed through Peptide Institute, Inc. under the license of Nagoya University

[D-Leu7]-(-)-Ternatincyclo(-d-aIle-MeAla-MeLeu-Leu-MeAla-D-MeAla-d-Leu-)(M.W. 721.97)) C37H67N7O7Fat Accumulation Inhibitor against 3T3-L1 Adipocytes

TNN-4464-v-20 °C

1 mgvial

T-Kinin See Code PBK-4130 Isoleucyl-Seryl-Bradykinin on page 29.Thrombin Receptor Activating Peptide See Code PAR-3932-PI H-Ala-Tyr-Pro-Gly-Lys-Phe-OH on page 112.

Thyrotropin Releasing Hormone (TRH)TRH Thyrotropin Releasing Hormone (Human, Ovine, Porcine, Rat)

Pyr-His-Pro-NH2 (M.W. 362.38) C16H22N6O4 [24305-27-9]

PTR-4011-v-20 °C

0.5 mgvial

122 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES TRH (Bulk) Thyrotropin Releasing Hormone (Human, Ovine, Porcine, Rat)

Pyr-His-Pro-NH2 • H2O (M.W. 362.38 • 18.02) C16H22N6O4 • H2O

PTR-4011-20 °C

25 mg 100 mg

R. Burgus, T.F. Dunn, D. Desiderio, and R. Guillemin, C.R. Acad. Sci. Paris, 269, 1870 (1969). (Original; Ovine) J. Bøler, F. Enzman, K. Folkers, C.Y. Bowers, and A.V. Schally, Biochem. Biophys. Res. Commun., 37, 705 (1969). (Original; Porcine) M. Yamada, S. Radovick, F.E. Wondisford, Y. Nakayama, B.D. Weintraub, and J.F. Wilber, Mol. Endocrinol., 4, 551 (1990). (cDNA Seq.; Human)


TMRIA-K4TMRIA-K4

S-[2-({4-[3,6-Bis(dimethylamino)xanthylium-9-yl]-3-carboxyphe-nyl}amino)-2-oxoethyl]-Cys-(Lys-Ile-Ala-Ala-Leu-Lys-Glu)4 (Trifluoroacetate Form) (M.W. 3578.40) C169H282N40O42S Fluorophore Peptide in Coiled-Coil Tag-Probe Labeling System

PTM-3401-v-20 °C

0.5 mgvial

Y. Yano, A. Yano, S. Oishi, Y. Sugimoto, G. Tsujimoto, N. Fujii, and K. Matsuzaki, ACS Chem. Biol., 3, 341 (2008). (TMR-K4; Reference Paper to TMRIA-K4)

Toxinsw-Agatoxins

B.M. Olivera, G.P. Miljanich, J. Ramachandran, and M.E. Adams, Annu. Rev. Biochem., 63, 823 (1994). (Review) O.D. Uchitel, Toxicon, 35, 1161 (1997). (Review)

w-Agatoxin IVA w-Aga-IVA(Funnel Web Spider, Agelenopsis aperta)

PAG-4256-s-20 °C

0.1 mgvial

Lys-Lys-Lys-Cys-Ile-Ala-Lys-Asp-Tyr-Gly-Arg-Cys-Lys-Trp-Gly-Gly-Thr-Pro-Cys-Cys-Arg-Gly-Arg-Gly-Cys-Ile-Cys-Ser-Ile-Met-Gly-Thr-Asn-Cys-Glu-Cys-Lys-Pro-Arg-Leu-Ile-Met-Glu-Gly-Leu-Gly-Leu-Ala (Disulfide bonds between Cys4-Cys20, Cys12-Cys25, Cys19-Cys36 and Cys27-Cys34) (M.W. 5202.2) C217H360N68O60S10 P-type Ca2+ Channel Selective BlockerI.M. Mintz, V.J. Venema, K.M. Swiderek, T.D. Lee, B.P. Bean, and M.E. Adams, Nature, 355, 827 (1992). (Original) T.J. Turner, M.E. Adams, and K. Dunlap, Science, 258, 310 (1992). (Pharmacol.) H. Nishio, K.Y. Kumagaye, S. Kubo, Y.-N. Chen, A. Momiyama, T. Takahashi, T. Kimura, and S. Sakakibara, Biochem. Biophys. Res. Commun., 196, 1447 (1993). (Chem. Synthesis & Biological Activity) • This compound is distributed exclusively through Peptides International under license agreement with the University of Utah.

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 123

w-Agatoxin TK w-Aga-TK, w-Aga-IVB (Funnel Web Spider, Agelenopsis aperta)

PAG-4294-s-20 °C

0.1 mgvial

Glu-Asp-Asn-Cys-Ile-Ala-Glu-Asp-Tyr-Gly-Lys-Cys-Thr-Trp-Gly-Gly-Thr-Lys-Cys-Cys-Arg-Gly-Arg-Pro-Cys-Arg-Cys-Ser-Met-Ile-Gly-Thr-Asn-Cys-Glu-Cys-Thr-Pro-Arg-Leu-Ile-Met-Glu-Gly-Leu-d-Ser-Phe-Ala (Disulfide bonds between Cys4-Cys20, Cys12-Cys25,Cys19-Cys36 and Cys27-Cys34) (M.W. 5273.0) C215H337N65O70S10 [145017-83-0] P-type Ca2+ Channel Selective Blocker Purity Information: QE See page xivM. Kuwada, T. Teramoto, K.Y. Kumagaye, K. Nakajima, T.Watanabe, T. Kawai, Y. Kawakami, T. Niidome, K. Sawada, Y. Nishizawa, and K. Katayama, Mol. Pharmacol., 46, 587 (1994). (Original) Y. Shikata, T. Watanabe, T. Teramoto, A. Inoue, Y. Kawakami, Y. Nishizawa, K. Katayama, and M. Kuwada, J. Biol. Chem., 270, 16719 (1995). (l-Ser to d-Ser Isomerase) M.E. Adams, I.M. Mintz, M.D. Reily, V. Thanabal, and B.P. Bean, Mol. Pharmacol., 38, 681 (1990). (Original; ω-Aga-IVB)S.D. Heck, P.R. Kelbaugh, M.E. Kelly, P.F. Thadeio, N.A. Saccomano, J.G Stroh. and R.A. Volkmann, J. Am. Chem. Soc., 116, 10426 (1994). (S-S Bond; ω-Aga-IVB) T. Teramoto, T. Niidome, M. Kimura, M. Ohgoh, Y. Nishizawa, K. Katayama, T. Mayumi, and K. Sawada, Brain Res., 756, 225 (1997). (Pharmacol.) S.P. Lieske and J.-M. Ramirez, J. Neurophysiol., 95, 1323 (2006). (Pharmacol.) • This product is distributed under the license of Eisai Co., Ltd. Its use for any purpose other than research is strictly prohibited.

Biotinyl-ω-Agatoxin IVABiotinyl-ω-Aga-IVA


PAG-3402-s-20 °C

0.1 mgvial

Biotinyl-Lys-Lys-Lys-Cys-Ile-Ala-Lys-Asp-Tyr-Gly-Arg-Cys-Lys-Trp-Gly-Gly-Thr-Pro-Cys-Cys-Arg-Gly-Arg-Gly-Cys-Ile-Cys-Ser-Ile-Met-Gly-Thr-Asn-Cys-Glu-Cys-Lys-Pro-Arg-Leu-Ile-Met-Glu-Gly-Leu-Gly-Leu-Ala(Disulfide bonds between Cys4-Cys20, Cys12-Cys25, Cys19-Cys36 and Cys27-Cys34)(M.W. 5428.5) C227H374N70O62S11Reagent for Localization Study of ω-Agatoxin IVA Binding SiteH. Nishio, K. Y. Kumagaye, S. Kubo, Y.-N. Chen, A. Momiyama, T. Takahashi, T. Kimura, and S. Sakakibara, Biochem. Biophys. Res. Commun., 196, 1447 (1993). (Chem. Synthesis & Biological Activity)S. Nakanishi, A. Fujii, T. Kimura, S. Sakakibara, and K. Mikoshiba, J. Neurosci. Res., 41, 532 (1995). (Biochem.: Distribution of Binding Sites)

Calcicludine (CaC)* (Green Mamba, Dendroaspis angusticeps)

PCC-4310-s-20 °C

0.1 mgvial

Trp-Gln-Pro-Pro-Trp-Tyr-Cys-Lys-Glu-Pro-Val-Arg-Ile-Gly-Ser-Cys-Lys- Lys-Gln-Phe-Ser-Ser-Phe-Tyr-Phe-Lys-Trp-Thr-Ala-Lys-Lys-Cys-Leu- Pro-Phe-Leu-Phe-Ser-Gly-Cys-Gly-Gly-Asn-Ala-Asn-Arg-Phe-Gln- Thr-Ile-Gly-Glu-Cys-Arg-Lys-Lys-Cys-Leu-Gly-Lys (Disulfide bonds between Cys7-Cys57, Cys16-Cys40, and Cys32-Cys53) (M.W. 6980.1) C321H476N86O78S6 Neuronal L-type Ca2+ Channel BlockerH. Schweitz, C. Heurteaux, P. Bois, D. Moinier, G. Romey, and M. Lazdunski, Proc. Natl. Acad. Sci. USA, 91, 878 (1994). (Original) H. Nishio, Y. Nishiuchi, T. Inui, M. Nakao, T.X. Watanabe, T. Kimura, and S. Sakakibara, Peptide Chemistry 1995, 113 (1996). (Chem. Synthesis & Pharmacol.) O.D. Uchitel, Toxicon, 35, 1161 (1997). (Review)J. Santos-Torres, A. Fuente, J.M. Criado, A.S. Riolobos, M. Heredia, and J. Yajeya, J. Neurosci. Res., 85, 634 (2007). (Pharmacol.)


NEW!

124 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Calciseptine* (Black mamba, Dendroaspis polylepis polylepis)

PCL-4255-s-20 °C

0.1 mg vial

Arg-Ile-Cys-Tyr-Ile-His-Lys-Ala-Ser-Leu-Pro-Arg-Ala-Thr-Lys-Thr-Cys- Val-Glu-Asn-Thr-Cys-Tyr-Lys-Met-Phe-Ile-Arg-Thr-Gln-Arg-Glu-Tyr-Ile- Ser-Glu-Arg-Gly-Cys-Gly-Cys-Pro-Thr-Ala-Met-Trp-Pro-Tyr-Gln-Thr- Glu-Cys-Cys-Lys-Gly-Asp-Arg-Cys-Asn-Lys (Disulfide bonds are between Cys3-Cys22, Cys17-Cys39, Cys41-Cys52, and Cys53-Cys58) (M.W. 7036.1) C299H468N90O87S10 [134710-25-1] L-type Ca2+ Channel BlockerJ.R. De Weille, H. Schweitz, P. Maes, A. Tartar, and M. Lazdunski, Proc. Natl. Acad. Sci. USA, 88, 2437 (1991). (Original) H. Kuroda, Y.-N. Chen, T.X. Watanabe, T. Kimura, and S. Sakakibara, Pept. Res., 5, 265 (1992). (Chem. Synthesis) T.X. Watanabe, Y. Itahara, H. Kuroda, Y.-N. Chen, T. Kimura, and S. Sakakibara, Jpn. J. Pharmacol., 68, 305 (1995). (Pharmacol.) N. Teramoto, R. Ogata, K. Okabe, A. Kameyama, M. Kameyama, T.X. Watanabe, H. Kuriyama, and K. Kitamura, Pflügers Arch., 432 (1996). (Pharmacol.)


CharybdotoxinM.L. Garcia, H.-G. Knaus, P. Munujos, R.S. Slaughter, and G.J. Kaczorowski, Am. J. Physiol., 269, C1 (1995). (Review)

Charybdotoxin (ChTX)* (Scorpion, Leiurus quinquestriatus hebraeus)

PCB-4227-s-20 °C

0.1 mgvial

Pyr-Phe-Thr-Asn-Val-Ser-Cys-Thr-Thr-Ser-Lys-Glu-Cys- Trp-Ser-Val-Cys-Gln-Arg-Leu-His-Asn-Thr-Ser-Arg-Gly- Lys-Cys-Met-Asn-Lys-Lys-Cys-Arg-Cys-Tyr-Ser (Disulfide bonds between Cys7-Cys28, Cys13-Cys33, and Cys17-Cys35) (M.W. 4295.9) C176H277N57O55S7 [95751-30-7] Ca2+-Activated K+ Channel BlockerG. Gimenez-Gallego, M.A. Navia, J.P. Reuben, G.M. Katz, G.J. Kaczorowski, and M.L. Garcia, Proc. Natl. Acad. Sci. USA, 85, 3329 (1988). (Original) P. Lambert, H. Kuroda, N. Chino, T.X. Watanabe, T. Kimura, and S. Sakakibara, Biochem. Biophys. Res. Commun., 170, 684 (1990). (Chem. Synthesis & Pharmacol.)


Chlorotoxin (Scorpion, Leiurus quinquestriatus)

Met-Cys-Met-Pro-Cys-Phe-Thr-Thr-Asp-His-Gln-Met-Ala-Arg-Lys-Cys-Asp-Asp-Cys-Cys-Gly-Gly-Lys-Gly-Arg-Gly-Lys-Cys-Tyr-Gly-Pro-Gln-Cys-Leu-Cys-Arg-NH2

PCN-4282-v-20 °C

0.5 mgvial

(Reported Disulfide bonds between Cys2-Cys19,Cys5-Cys28,Cys16-Cys33 and Cys20-Cys35) (M.W. 3995.7) C158H249N53O47S11 [163515-35-3] Small-Conductance Cl - Channel BlockerJ.A. DeBin, J.E. Maggio, and G.R. Strichartz, Am. J. Physiol., 264, C361 (1993). (Original) J. Najib, P. Sautiere, J.C. Gesquiere, and A. Tartar, In, Innovation and Perspective in Solid Phase Synthesis, (R. Epton, ed.), Mayflower Worldwide, Birmingham, 1994, pp. 615-618. (Original; Amide) G. Lippens, J. Najib, S.J. Wodak, and A. Tartar, Biochemistry, 34, 13 (1995). (NMR Structure) L. Soroceanu, Y. Gillespie, M.B. Khazaeli, and H. Sontheimer, Cancer Res., 58, 4871 (1998). (Pharmacol.) D.B. Jacoby, E. Dyskin, M. Yalcin, K. Kesavan, W. Dahlberg, J. Ratliff, E.W. Johnson, and S.A. Mousa, Anticancer Res., 30, 39 (2010). (Review)K. Kesavan, J. Ratliff, E.W. Johnson, W. Dahlberg, J.M. Asara, P. Misra, J.V. Frangioni, and D.B. Jacoby, J. Biol. Chem., 285, 4366 (2010). (Review)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 125

ConantokinsW.R. Gray and B.M. Olivera, Annu. Rev. Biochem., 57, 665 (1998). (Review)

Conantokin G (Marine Snail, Conus geographus)

Gly-Glu-Gla-Gla-Leu-Gln-Gla-Asn-Gln- Gla-Leu-Ile-Arg-Gla-Lys-Ser-Asn-NH2 (Gla: l-g-Carboxyglutamic acid) (M.W. 2264.2) C88H138N26O44 [93438-65-4]

PCO-4265-v-20 °C

0.5 mgvial

Sleeper Peptide, N-Methyl-d-Aspartate (NMDA) Receptor Antagonist Purity Information: Qx See page xivJ.M. McIntosh, B.M. Olivera, L.J. Cruz, and W.R. Gray, J. Biol. Chem., 259, 14343 (1984). (Original) L.G. Hammerland, B.M. Olivera, and D. Yoshikami, Eur. J. Pharmacol., 226, 239 (1992). (Pharmacol.) Y. Nishiuchi, M. Nakao, M. Nakata, T. Kimura, and S. Sakakibara, Int. J. Pept. Protein Res, 42, 533 (1993). (Chem. Synthesis)

Conantokin T (Marine Snail, Conus tulipa)

Gly-Glu-Gla-Gla-Tyr-Gln-Lys-Met-Leu-Gla-Asn-Leu- Arg-Gla-Ala-Glu-Val-Lys-Lys-Asn-Ala-NH2 (Gla: l-g-Carboxyglutamic acid) (M.W. 2683.8) C110H175N31O45S

PCO-4264-v-20 °C

0.5 mgvial

Sleeper Peptide, N-Methyl-d-Aspartate (NMDA) Receptor Antagonist Purity Information: Qx See page xivJ.A. Haack, J. Rivier, T.N. Parks, E.E. Mena, L.J. Cruz, and B.M. Olivera, J. Biol. Chem., 265, 6025 (1990). (Original) Y. Nishiuchi, M. Nakao, M. Nakata, T. Kimura, and S. Sakakibara, Int. J. Pept. Protein Res., 42, 533 (1993). (Chem. Synthesis)


Conotoxins ‡B.M. Olivera, W.R. Gray, R. Zeikus, J.M. McIntosh, J. Varga, J. Rivier, V. De Santos, and L.J. Cruz, Science, 230, 1338 (1985). (Review) W.R. Gray, B.M. Olivera, and L.J. Cruz, Annu. Rev. Biochem., 57, 665 (1988). (Review) R.A. Myers, L.J. Cruz, J.E. Rivier, and B.M. Olivera, Chem. Rev., 93, 1923 (1993). (Review) B.M. Olivera, G.P. Miljanich, J. Ramachandran, and M.E. Adams, Annu. Rev. Biochem., 63, 823 (1994). (Review)

a-Conotoxin GI*‡ (Marine Snail, Conus geographus)

(Hydrochloride Form) Glu-Cys-Cys-Asn-Pro-Ala-Cys-Gly-Arg-His-Tyr-Ser-Cys-NH2 (Disulfide bonds between Cys2-Cys7 and Cys3-Cys13) (M.W. 1437.6) C55H80N20O18S4 [76862-65-2] Blocker for Nicotinic Acetylcholine Receptor Purity Information: QE See page xiv

PCN-4126-v-20 °C

0.5 mgvial

W.R. Gray, A. Luque, B.M. Olivera, J. Barrett, and L.J. Cruz, J. Biol. Chem., 256, 4734 (1981). (Original) Y. Nishiuchi and S. Sakakibara, FEBS Lett., 148, 260 (1982). (Chem. Synthesis)


‡ PLEASE NOTE: For shipping within the United States, please contact Peptides International for important information regard-ing the CDC Select Agent Transfer Program and additional requirements for placing orders. Conotoxin peptides are not avail-able for export without a license from the US Department of Commerce.

126 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES a-Conotoxin ImI‡ (Marine Snail, Conus imperialis)

Gly-Cys-Cys-Ser-Asp-Pro-Arg-Cys-Ala-Trp-Arg-Cys-NH2 (Disulfide bonds between Cys2-Cys8 and Cys3-Cys12) (M.W. 1351.6) C52H78N20O15S4 [156467-85-5]

PCN-4311-v-20 °C

0.5 mgvial

Blocker for Nicotinic Acetylcholine Receptor in Central Nervous SystemJ.M. McIntosh, D. Yoshikami, E. Mahe, D.B. Nielsen, J.E. Rivier, W.R. Gray, and B.M. Olivera, J. Biol. Chem., 269, 16733 (1994). (Original) D.S. Johnson, J. Martinez, A.V. Elgoyhen, S.F. Heinemann, and J.M. McIntosh, Mol. Pharmacol., 48, 194 (1995). (Pharmacol.) E.F.R. Pereira, M. Alkondon, J.M. McIntosh, and E.X. Albuquerque, J. Pharmacol. Exp. Ther., 278, 1472 (1996). (Pharmacol.; Competitive Antagonist)

a-Conotoxin MI*‡ (Marine Snail, Conus magus)

PCN-4140-v-20 °C

0.5 mgvial

Gly-Arg-Cys-Cys-His-Pro-Ala-Cys-Gly-Lys-Asn-Tyr-Ser-Cys-NH2 (Disulfide bonds between Cys3-Cys8 and Cys4-Cys14) (M.W. 1493.7) C58H88N22O17S4 Blocker for Nicotinic Acetylcholine ReceptorM. Mclntosh, L.J. Cruz, M.W. Hunkapiller, W.R. Gray, and B.M. Olivera, Arch. Biochem. Biophys., 218, 329 (1982). (Original) Y. Nishiuchi and S. Sakakibara, Peptide Chemistry 1983, 191, (1984). (Chem. Synthesis)


a-Conotoxin SI*‡ (Marine Snail, Conus striatus)

Ile-Cys-Cys-Asn-Pro-Ala-Cys-Gly-Pro-Lys-Tyr-Ser-Cys-NH2 (Disulfide bonds between Cys2-Cys7 and Cys3-Cys13) (M.W. 1353.6) C55H84N16O16S4 Blocker for Nicotinic Acetylcholine Receptor

PCN-4228-v-20 °C

0.5 mgvial

G.C. Zafaralla, C. Ramilo, W.R. Gray, R. Karlstrom, B.M. Olivera, and L.J. Cruz, Biochemistry, 27, 7102 (1988). (Original)


m-Conotoxin GIIIB*‡ (Marine Snail, Conus geographus)

Arg-Asp-Cys-Cys-Thr-Hyp-Hyp-Arg-Lys-Cys-Lys-Asp- Arg-Arg-Cys-Lys-Hyp-Met-Lys-Cys-Cys-Ala-NH2

PCN-4217-v-20 °C

0.5 mgvial

(Disulfide bonds between Cys3-Cys15, Cys4-Cys20, and Cys10-Cys21) (M.W. 2640.2) C101H175N39O30S7 [140678-12-2] Na+ Channel Blocker: Specific for Skeletal MuscleS. Sato, H. Nakamura, Y. Ohizumi, J. Kobayashi, and Y. Hirata, FEBS Lett., 155, 277 (1983). (Original) L.J. Cruz, W.R. Gray, B.M. Olivera, R.D. Zeikus, L. Kerr, D. Yoshikami, and E. Mocyzydlowski, J. Biol. Chem., 260, 9280 (1985). (Naming) Y. Ohizumi, H. Nakamura, J. Kobayashi, and W.A. Catterall, J. Biol. Chem., 261, 6149 (1986). (Pharmacol.) S. Kubo, N. Chino, T.X. Watanabe, T. Kimura, and S. Sakakibara, Pept. Res., 6, 66 (1993). (Chem. Synthesis and Pharmacol.)




NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 127

m-Conotoxin GS‡ (Marine snail, Conus geographus)

Ala-Cys-Ser-Gly-Arg-Gly-Ser-Arg-Cys-Hyp-Hyp-Gln-Cys-Cys-Met-Gly-Leu-Arg-Cys-Gly-Arg-Gly-Asn-Pro-Gln-Lys-Cys-Ile-Gly-Ala-His-Gla-Asp-Val (Gla: l-g-Carboxyglutamic acid)

PCN-4263-v-20 °C

0.5 mgvial

(Disulfide bonds between Cys2-Cys14, Cys9-Cys19, and Cys13-Cys27) (M.W. 3618.1) C139H226N52O48S7 Na+ Channel BlockerY. Yanagawa, T. Abe, M. Satake, S. Odani, J. Suzuki, and K. Ishikawa, Biochemistry, 27, 6256 (1988). (Original) M. Nakao, Y. Nishiuchi, M. Nakata, T. Kimura, and S. Sakakibara, Lett. Pept. Sci., 2, 17 (1995). (Chem. Synthesis and S-S Bond)

μ-Conotoxin SIIIA‡(Marine Snail, Conus striatus)

Pyr-Asn-Cys-Cys-Asn-Gly-Gly-Cys-Ser-Ser-Lys- Trp-Cys-Arg-Asp-His-Ala-Arg-Cys-Cys-NH2

PCN-4440-v-20 °C

0.5 mgvial

(Reported disulfide bonds between Cys3-Cys13, Cys4-Cys19, and Cys8-Cys20)(M.W. 2207.5) C83H123N33O27S6Tetrodotoxin-Resistant Na+ Channel Blocker with Analgesic ActivityG. Bulaj, P.J. West, J.E. Garrett, M. Marsh, M.-M. Zhang, R.S. Norton, B.J. Smith, D. Yoshikami, and B.M. Olivera, Biochemistry, 44, 7259 (2005). (Original; Primary Structure & Pharmacol.)S. Yao, M.-M. Zhang, D. Yoshikami, L. Azam, B.M. Olivera, G. Bulaj, and R.S. Norton, Biochemistry, 47, 10940 (2008). (Solution Structure & Pharmacol.)C.-Z. Wang, H. Zhang, H. Jiang,W. Lu, Z.-Q. Zhao, and C.-W. Chi, Toxicon, 47, 122 (2006). (Pharmacol.)B.R. Green, P. Catlin, M.-M. Zhang, B. Fiedler, W. Bayudan, A. Morrison, R.S. Norton, B.J. Smith, D. Yoshikami, B.M. Olivera, and G. Bulaj, Chem. Biol., 14, 399 (2007). (Pharmacol.)

w-Conotoxin GVIA*‡ (Marine Snail, Conus geographus)

Cys-Lys-Ser-Hyp-Gly-Ser-Ser-Cys-Ser-Hyp-Thr-Ser-Tyr-Asn-Cys-Cys-Arg-Ser-Cys-Asn-Hyp-Tyr-Thr-Lys-Arg-Cys-Tyr-NH2

PCN-4161-v-20 °C

0.5 mgvial

(Disulfide bonds between Cys1-Cys16, Cys8-Cys19, and Cys15-Cys26) (M.W. 3037.3) C120H182N38O43S6 [106375-28-4] N-type Ca2+ Channel BlockerB.M. Olivera, J.M. Mclntosh, L.J. Cruz, F.A. Luque, and W.R. Gray, Biochemistry, 23, 5087 (1984). (Original) Y. Nishiuchi, K. Kumagaye, Y. Noda, T.X. Watanabe, and S. Sakakibara, Biopolymers, 25, S61 (1986). (Chem. Synthesis and S-S Bond)


w-Conotoxin MVIIA*‡ (Marine Snail, Conus magus)

Cys-Lys-Gly-Lys-Gly-Ala-Lys-Cys-Ser-Arg-Leu-Met-Tyr-Asp-Cys-Cys-Thr-Gly-Ser-Cys-Arg-Ser-Gly-Lys-Cys-NH2

PCN-4289-v-20 °C

0.5 mgvial

(Disulfide bonds between Cys1-Cys16,Cys8-Cys20,and Cys15-Cys25) (M.W. 2639.1) C102H172N36O32S7 [107452-89-1] Reversible N-type Ca2+ Channel BlockerB.M. Olivera, L.J. Cruz, V. de Santos, G.W. Le Cheminant, D. Griffin, R. Zeikus, J.M. McIntosh, R. Galyean, J. Varga, W.R. Gray, and J. Rivier, Biochemistry, 26, 2086 (1987). (Original) K. Valentino, R. Newcomb, T. Gadbois, T. Singh, S. Bowersox, S. Binter, A. Justice, D. Yamashiro, B.B. Hoffman, R. Ciaranello, G. Miljanich, and J. Ramachandran, Proc. Natl. Acad. Sci. USA, 90, 7894 (1993). (Pharmacol.) J.A. Fox, Pflügers Arch., 429, 873 (1995). (Pharmacol.)



NEW!

128 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES w-Conotoxin MVIIC‡ (Marine Snail, Conus magus)

Cys-Lys-Gly-Lys-Gly-Ala-Pro-Cys-Arg-Lys-Thr-Met-Tyr-Asp-Cys-Cys-Ser-Gly-Ser-Cys-Gly-Arg-Arg-Gly-Lys-Cys-NH2 (Disulfide bonds between Cys1-Cys16,Cys8-Cys20, and Cys15-Cys26) (M.W. 2749.3) C106H178N40O32S7 [147794-23-8]

PCN-4283-s-20 °C

0.1 mgvial

w-Conotoxin MVIIC‡ (Marine Snail, Conus magus)

P/Q-type Ca2+ Channel Blocker

PCN-4283-v-20 °C

0.5 mgvial

D.R. Hillyard, V.D. Monje, I.M. Mintz, B.P. Bean, L. Nadasdi, J. Ramachandran, G. Miljanich, A. Azimi-Zoonooz, J.M. McIntosh, L.J. Crutz, J.S. Imperial, and B.M. Olivera, Neuron, 9, 69 (1992). (Original; cDNA and Pharmacol.) M.E. Adams, R.A. Myers, J.S. Imperial, and B.M. Olivera, Biochemistry, 32, 12566 (1993). (Pharmacol.) W.A. Sather, T. Tanabe, J.-F. Zhang, Y. Mori, M.E. Adams, and R.W. Tsien, Neuron, 11, 291 (1993). (Pharmacol.) D.B. Wheeler, A. Randall, and R.W. Tsien, Science, 264, 107 (1994). (Pharmacol.)

w-Conotoxin SVIB*‡ (Marine Snail, Conus striatus)

Cys-Lys-Leu-Lys-Gly-Gln-Ser-Cys-Arg-Lys-Thr-Ser-Tyr-Asp-Cys-Cys-Ser-Gly-Ser-Cys-Gly-Arg-Ser-Gly-Lys-Cys-NH2

PCN-4284-v-20 °C

0.5 mgvial

(Reported disulfide bonds between Cys1-Cys16,Cys8-Cys20, and Cys15-Cys26) (M.W. 2739.1) C105H176N38O36S6 [150433-82-2] N-type Ca2+ Channel BlockerC.A. Ramilo, G.C. Zafaralla, L. Nadasdi, L.G. Hammerland, D.Yoshikami, W.R. Gray, R. Kristipati, J. Ramachandran, G. Miljanich, B.M. Olivera, and L.J. Cruz, Biochemistry, 31, 9919 (1992). (Original.)


Dendrotoxin I (Black mamba, Dendroaspis polylepis polylepis)

PDN-4330-s-20 °C

0.1 mgvial

Pyr-Pro-Leu-Arg-Lys-Leu-Cys-Ile-Leu-His-Arg-Asp-Pro-Gly-Arg-Cys- Tyr-Gln-Lys-Ile-Pro-Ala-Phe-Tyr-Tyr-Asn-Gln-Lys-Lys-Lys-Gln-Cys- Glu-Gly-Phe-Thr-Trp-Ser-Gly-Cys-Gly-Gly-Asn-Ser-Asn-Arg-Phe- Lys-Thr-Ile-Glu-Glu-Cys-Arg-Arg-Thr-Cys-Ile-Arg-Lys (Disulfide bonds between Cys7-Cys57, Cys16-Cys40, and Cys32-Cys53) (M.W. 7133.2) C312H487N97O84S6 [107950-33-4] Voltage-Dependant K+ Channel BlockerD.J. Strydom, Nature New Biol., 243, 88 (1973). (Original) J.-N. Bidard, C. Mourre, and M. Lazdunski, Biochem. Biophys. Res. Commun., 143, 383 (1987). (Pharmacol.) A.L. Harvey, D.L. Marshall, F.A. De-Allie, and P.N. Strong, Biochem. Biophys. Res. Commun., 163, 394 (1989). (Pharmacol.) H. Nishio, T. Inui, Y. Nishiuchi, C.L.C. De Medeiros, E.G. Rowan, A.L. Harvey, E. Katoh, T. Yamazaki, T. Kimura, and S. Sakakibara, J. Pept. Res., 51, 355 (1998). (Chem. Synthesis & Correction of Sequence; Asp12)



NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 129

EchistatinEchistatin

(Trifluoroacetate Form)H-Glu-Cys-Glu-Ser-Gly-Pro-Cys-Cys-Arg-Asn-Cys-Lys-Phe-Leu-Lys-Glu-Gly-Thr-Ile-Cys-Lys-Arg-Ala-Arg-Gly-Asp- Asp-Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Cys-Asp- Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH

ECT-3760-PI-20 °C

1 mg 5 mg

(Disulfide bonds between Cys2-Cys11, Cys7-Cys32, Cys8-Cys37, and Cys20-Cys39)(M.W. 5417.14) C217H341N71O74S9 [154303-05-6] αVβ3 Integrin AntagonistJ. Musial, et al., Circulation, 82, 261 (1990). M. Sato, et al., J. Cell.Biol., 111, 1713 (1990). C.C. Kumar, et al., J. Pharmacol.Exp.Ther., 283, 843 (1997).V. Garsky, et al., Proc Nat Acad of Sciences, 86, 4022 (1989).

EnterotoxinEnterotoxigenic E.coli are able to produce several toxic peptides which may cause acute diarrhea in humans and domestic animals. The E.coli heat-stable Enterotoxin STp is syntheszied in vivo as a 72 amino acid precursor consisting of pre-, pro-, and mature region. Mature STp is composed of 18 amino acids containing three intramolecular disulfide bonds, which seem to be important for the correct conformation of the biologically active structure. K.Okamoto, et al., Infect. Immun., 55, 2121 (1987).K.Okamoto and M.Takahara, J. Bacteriol., 172, 5260 (1990).

H.Ozaki, et al., J. Biol. Chem., 266, 5934 (1991).H.Yamanaka, et al., Microbiol. Immunol., 37, 195 (1993). H.Yamanaka, et al., J. Bacteriol., 176, 2906 (1994).

Enterotoxin STp(Trifluoroacetate Form) H-Asn-Thr-Phe-Tyr-Cys-Cys-Glu-Leu-Cys-Cys-Asn- Pro-Ala-Cys-Ala-Gly-Cys-Tyr-OH

ENT-3744-PI-20 °C

1 mg5 mg

(Disulfide bonds between Cys5-Cys10, Cys6-Cys14, and Cys9-Cys17)(M.W. 1972.28) C81H110N20O26S6 [115474-04-9] Mature Heat-stable EnterotoxinK.Okamoto, et al., Infect. Immun., 55, 2121 (1987). K.Okamoto and M.Takahara, J. Bacteriol., 172, 5260 (1990). H.Ozaki, et al., J. Biol. Chem., 266, 5934 (1991). H.Yamanaka, et al., Microbiol. Immunol., 37, 195 (1993). H.Yamanaka, et al., J. Bacteriol., 176, 2906 (1994).

GsMTx-4(Chilean Rose Tarantula, Grammostola spatulata)

Gly-Cys-Leu-Glu-Phe-Trp-Trp-Lys-Cys-Asn-Pro-Asn-Asp- Asp-Lys-Cys-Cys-Arg-Pro-Lys-Leu-Lys-Cys-Ser-Lys- Leu-Phe-Lys-Leu-Cys-Asn-Phe-Ser-Phe-NH2

PCB-4393-s-20 °C

0.1 mgvial

(Reported disulfide bonds between Cys2-Cys17, Cys9-Cys23, and Cys16-Cys30)(M.W. 4095.8) C185H273N49O45S6Inhibitor for Cation-Selective Stretch-Activated Channels / Atrial Fibrillation Inhibiting Peptide

NEW!

130 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES GuangxitoxinRecent efforts for identifying new drugs for Type II Diabetes have focused on inhibitors that target the delayed-rectifier K+ current (IDR), found in insulin secreting β-cells and believed to aide in repolarizing action potentials.1 Such inhibitors may increase cytosolic calcium levels and insulin secretion.2,3 A novel peptide toxin, guangxitoxin (GxTX)-1E (PGX-4433-s), was found to inhibit mouse IDR by 90%, selectively block Kv2.1/Kv2.2 channels (IC50 ~1 nmol/l), and shift the voltage-dependence for channel activation to more positive potentials, acting as a gating modifier peptide.4 Furthermore, GxTX-1E was able to increase the duration of action potentials (30% ± 6%), calcium oscillations, and insulin secretion (3.5 fold) in a glucose dependent manner in β-cell IDR.2,3,4,5 This novel peptide may help determine the mechanism and role of β-cell IDR in insulin secretion and lead to better glucose-dependent methods for treatment of Type II Diabetes.1. P.A. Smith, K. Bokvist, P. Arkhammar, P.O. Berggren, and P. Rorsman, J. Gen. Physiol., 95, 1041 (1990).2. P.E. MacDonald, S. Sewing, J. Wang, J.W. Joseph, S.R. Smukler, G. Sakellaropoulos, M.C. Saleh, C.B. Chan, R.G. Tsushima, A.M. Salapatek, and M.B.Wheeler, J. Biol. Chem., 277, 44938 (2002).3. P.E. MacDonald, X.F. Ha, J. Wang, S.R. Smukler, A.M. Sun, H.Y. Gaisano, A.M. Salapatek, P.H. Backx, and M.B.Wheeler, Mol. Endocrinol., 15, 1423 (2001).4. J. Herrington, Y.-P. Zhou, R.M. Bugianesi, P.M. Dulski, Y. Feng, V.A. Warren, M.M. Smith, M.G. Kohler, V.M. Garsky, M. Sanchez, M. Wagner, K. Raphaelli, P. Banerjee, C. Ahaghotu, D. Wunderler, B.T. Priest, J.T. Mehl, M.L. Garcia, O.B. McManus, G.J. Kaczorowski, and R.S. Slaughter, Diabetes, 55,1034 (2006).5. L. Yan, D.J. Figueroa, C.P. Austin, Y. Liu, R.M. Bugianesi, R.S. Slaughter, G.J. Kaczorowski, and M.G. Kohler, Diabetes, 53, 597 (2004).

Guangxitoxin-1EGxTX-1E(Tarantula, Pleisiophrictus guangxiensis sp. nov.)

PGX-4433-s -20 °C

0.1 mgvial

(Trifluoroacetate Form)Glu-Gly-Glu-Cys-Gly-Gly-Phe-Trp-Trp-Lys-Cys-Gly-Ser-Gly-Lys-Pro-Ala-Cys-Cys- Pro-Lys-Tyr-Val-Cys-Ser-Pro-Lys-Trp-Gly-Leu-Cys-Asn-Phe-Pro-Met-Pro(Reported disulfide bonds between Cys4-Cys19, Cys11-Cys24 and Cys18-Cys31)(M.W. 3948.6) C178H248N44O45S7Kv2.1/Kv2.2 Channel Blocker / Enhancer of Glucose-Dependent Insulin Secretion Purity Information: QE See page xivJ. Herrington, et al.,, 55, 1034-1042 (2006). P.E. MacDonald, S. Sewing, J. Wang, J.W. Joseph, P.E. MacDonald, S. Sewing, J. Wang, J.W. Joseph, S.R. Smukler, G. Sakellaropoulos, J.Wang, M.C. Saleh, C.B. Chan,R.G. Tsushima, A.M.F. Salapatek, and M.B. Wheeler, J. Biol. Chem., 277, 44938 (2002). (Pharmacol.; Role of Kv2.1 in Glucose-Dependent Insulin Secretion) N.A. Tamarina, A. Kuznetsov, L.E. Fridlyand, and L.H. Philipson, Am. J. Physiol. Endocrinol. Metab., 289,E578 (2005). (Pharmacol.; Role of Kv2.1 in Glucose-Dependent Ca2+ response) J. Herrington,Toxicon, 49, 231 (2007). (Review)S. Lee, M. Milescu, H.H. Jung, J.Y. Lee, C.H. Bae, C.W. Lee, H.H. Kim, K.J. Swartz, and J.I. Kim, Biochemistry, 49, 5134 (2010). (Solution Structure & S-S Bond)

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 131

Huwentoxin- IV HWTX-IVChinese Bird Spider, (Ornithoctonus huwena)

PLL-4455-s-20 °C

0.1 mgvial

(Trifluoroacetate Form)Glu-Cys-Leu-Glu-Ile-Phe-Lys-Ala-Cys-Asn-Pro-Ser-Asn-Asp-Gln-Cys-Cys-Lys-Ser-Ser-Lys-Leu-Val-Cys-Ser-Arg-Lys-Thr-Arg-Trp-Cys-Lys-Tyr-Gln-Ile-NH2 (Disulfide bonds between Cys2-Cys17, Cys9-Cys24, and Cys16-Cys31)(M.W. 4106.8) C174H278N52O51S6Neuronal Tetrodotoxin-Sensitive Na+- Channel BlockerK. Peng, Q. Shu, Z. Liu, and S. Liang, J. Biol. Chem., 277, 47564 (2002). (Original)J. Diao, Y. Lin, J. Tang, and S. Liang, Toxicon, 42, 715 (2003). (cDNA Seq)Y. Xiao, J.-P. Bingham, W. Zhu, E. Moczydlowski, S. Liang, and T.R. Cummins, J. Biol. Chem., 283, 27300 (2008). (Pharmacol.) Y. Xiao, X. Luo, F. Kuang, M. Deng, M. Wang, X. Zeng, and S. Liang, Toxicon, 51, 230 (2008). (Pharmacol.)

Huwentoxin-IV was isolated from the venom of the Chinese bird spider Ornithoctonus huwena. Its structure was elucidated to be a 35-residue peptide with three disulfide linkages which are arranged to form the inhibitor cystine knot.1,2 Huwentoxin-IV is a potent inhibitor of neuronal tetrodotoxin-sensitive Na+ channels with IC50 = 30 nM.1 Further studies clarified that i) among neuronal voltage-gated Na+ channels, human Nav1.7 is most sensitive to huwentoxin-IV where site 4 of the channel is the interacting site (IC50 = 26 nM)3), and ii) huwentoxin-IV interacts with central Na+ channel isoforms from rat hippocampus neurons, while the affinity is low (IC50 = ~ 0.4 μM).4 Interestingly, huwentoxin-IV fails to partition into the artificial membrane bilayers, indicating that the mechanism for blocking Na+ channels by huwentoxin-IV is distinct from that of ProTx-II (4450-s), another Na+ channel blocker isolated from the tarantula. 4

1. K. Peng, Q. Shu, Z. Liu, and S. Liang, J. Biol. Chem., 277, 47564 (2002). (Original)2. J. Diao, Y. Lin, J. Tang, and S. Liang, Toxicon, 42, 715 (2003). (cDNA Seq.)3. Y. Xiao, J.-P. Bingham, W. Zhu, E. Moczydlowski, S. Liang, and T.R. Cummins, J. Biol. Chem., 283, 27300 (2008). (Pharmacol.)4. Y. Xiao, X. Luo, F. Kuang, M. Deng, M. Wang, X. Zeng, and S. Liang, Toxicon, 51, 230 (2008). (Pharmacol.)

Iberiotoxin* IbTX (Scorpion, Buthus tamulus)

PIB-4235-s-20 °C

0.1 mgvial

Pyr-Phe-Thr-Asp-Val-Asp-Cys-Ser-Val-Ser-Lys-Glu-Cys-Trp-Ser-Val-Cys-Lys-Asp- Leu-Phe-Gly-Val-Asp-Arg-Gly-Lys-Cys-Met-Gly-Lys-Lys-Cys-Arg-Cys-Tyr-Gln (Disufide bonds between Cys7-Cys28, Cys13-Cys33, and Cys17-Cys35). (M.W. 4230.8) C179H274N50O55S7 [129203-60-7] Ca2+-Activated K+ Channel Blocker (Maxi-K+ Channel Blocker)A. Galvez, G. Gimenez-Gallego, J.P. Reuben, L. Roy-Contancin, P. Feigenbaum, G.J. Kaczorowski, and M.L. Garcia, J. Biol. Chem., 265, 11083 (1990). (Original) M.L. Garcia, A. Galvez, M. Garcia-Calvo, V.F. King, J. Vazquez, and G.J. Kaczorowski, J. Bioenerg. Biomembr., 23, 615 (1991). (Review) K.M. Giangiacomo, M.L. Garcia, and O.B. McManus, Biochemistry, 31, 6719 (1992). (Pharmacol.) G.J. Kaczorowski, H.-G. Kaus, R.J. Leonard, O.B. McManus, and M.L. Garcia, J. Bioenerg. Biomembr., 28, 255 (1996). (Review)


NEW!

132 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Imperatoxin A IpTXa (Scorpion, Pandinus imperator)

PIM-4343-s-20 °C

0.1 mgvial

Gly-Asp-Cys-Leu-Pro-His-Leu-Lys-Arg-Cys-Lys-Ala-Asp-Asn-Asp-Cys-Cys- Gly-Lys-Lys-Cys-Lys-Arg-Arg-Gly-Thr-Asn-Ala-Glu-Lys-Arg-Cys-Arg (Disulfide bonds between Cys3-Cys17, Cys10-Cys21, and Cys16-Cys32) (M.W. 3758.4) C148H254N58O45S6 [172451-37-5] Purity: greater than 94% by HPLC Activator of Ca2+ Release Channels/Ryanodine ReceptorsH.H. Valdivia, M.S. Kirby, W.J. Lederer, and R.Coronado, Proc. Natl. Acad. Sci. U.S.A., 89, 12185 (1992). (Pharmacol.) R. El-Hayek, A.J. Lokuta, C. Arévalo, and H.H. Valdivia, J. Biol. Chem., 270, 28696 (1995). (Pharmacol.) F.Z. Zamudio, G.B. Gurrola, C. Arévalo, R. Sreekumar, J.W. Walker, H.H. Valdivia, and L.D. Possani, FEBS Lett., 405, 385 (1997). (Original; Structure) K. Takeuchi, J.I. Kim, H. Takahashi, K. Sato, and I. Shimada, Peptide Science, 1999, 307 (2000). (S-S Bond)

Kaliotoxin (1-37)* (Scorpion, Androctonus mauretanicus mauretanicus)

PKL-4259-s-20 °C

0.1 mgvial

Gly-Val-Glu-Ile-Asn-Val-Lys-Cys-Ser-Gly-Ser-Pro-Gln-Cys-Leu-Lys- Pro-Cys-Lys-Asp-Ala-Gly-Met-Arg-Phe-Gly-Lys-Cys- Met-Asn-Arg-Lys-Cys-His-Cys-Thr-Pro (Reported disulfide bonds between Cys8-Cys28, Cys14-Cys33, and Cys18-Cys35) (M.W. 4021.8) C165H271N53O48S8 High Conductance Ca2+-Activated K+ Channel BlockerM. Crest, G. Jacquet, M. Gola, H. Zerrouk, A. Benslimane, H. Rochat, P. Mansuelle, and M.-F. Martin-Eauclaire, J. Biol. Chem., 267, 1640 (1992). (Original) R. Romi, M. Crest, M. Gola, F. Sampieri, G. Jacquet, H. Zerrouk, P. Mansuelle, O. Sorokine, A.V. Dorsselaer, H. Rochat, M.-F. Martin-Eauclaire, and J.V. Rietschoten, J. Biol. Chem., 268, 26302 (1993). (Chem. Synthesis & Pharmacol.) F.R. Romi, S. Szendeffy, M.F. Martin-Eauclaire, H. Rochat, J.V. Rietschoten, M. Pons, and E. Giralt, Biochemistry, 33, 14256 (1994). (Unique Structure) A.L. Harvey, H. Vatanpour, E.G. Rowan, S. Pinkasfeld, C. Vita, A. Menez, and M.-F. Martin-Eauclaire, Toxicon, 33, 425 (1995). (Pharmacol.)


Kurtoxin (Scorpion, Parabuthus transvaalicus)

Lys-Ile-Asp-Gly-Tyr-Pro-Val-Asp-Tyr-Trp-Asn-Cys-Lys-Arg-Ile-Cys-Trp-Tyr-Asn-Asn-Lys-Tyr-Cys-Asn-Asp-Leu-Cys-Lys-Gly-Leu-Lys-Ala-Asp-Ser-Gly-Tyr-Cys-Trp-Gly-Trp-Thr-Leu-Ser- Cys-Tyr-Cys-Gln-Gly-Leu-Pro-Asp-Asn-Ala-Arg-Ile-Lys-Arg- Ser-Gly-Arg-Cys-Arg-Ala

PKT-4375-s-20 °C

0.1 mgvial

(Disulfide bonds between Cys12-Cys61Cys16-Cys37, Cys23-Cys44, and Cys27-Cys46) (M.W. 7386.4) C324H478N94O90S8 T-type Ca2+ Channel Blocker Purity Information: Qp See page xivR.S-I. Chuang, H. Jaffe, L. Cribbs, E. Perez-Reyes, and K.J. Swartz, Nat. Neurosci., 1, 668 (1998). (Original) S.S. Sidach and I.M. Mintz, J. Neurosci., 22, 2023 (2002). (Pharmacol.; Specificity for Ca2+ Channel Blocking Activity) T. Olamendi-Portugal, B.I. Garcá, I. López-González, J. Van Der Walt, K. Dyason, C. Ulens, J. Tytgat, R. Felix, A. Darszon, and L.D. Possani, Biochem. Biophys. Res. Commun., 299, 562 (2002). (Pharmacol.) I. López-González, T. Olamendi-Portugal, J.L. De La Vega-Beltrán, J. Van der Walt, K. Dyason, L.D. Possani, R. Felix, and A. Darszon, Biochem. Biophys. Res. Commun., 300, 408 (2003). (Pharmacol.) H. Nishio, Y. Nishiuchi, M. Ishimaru, and T. Kimura, Lett. Pept. Sci., in press. (Chem. Synthesis & S-S Bond)

Leiurotoxin I See Code PSC-4260 Scyllatoxin on page 140.


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 133

Margatoxin (MgTX) (Scorpion, Centruroides margaritatus)

Thr-Ile-Ile-Asn-Val-Lys-Cys-Thr-Ser-Pro-Lys-Gln-Cys-Leu-Pro-Pro-Cys-Lys-Ala-Gln-Phe-Gly-Gln-Ser-Ala-Gly-Ala-Lys- Cys-Met-Asn-Gly-Lys-Cys-Lys-Cys-Tyr-Pro-His

PAR-4290-s-20 °C

0.1 mgvial

(Reported disulfide bonds between Cys7-Cys29,Cys13-Cys34, and Cys17-Cys36) (M.W. 4178.9) C178H286N52O50S7 [145808-47-5] Volgate-Dependent K+ Channel Blocker (Specific for Kv1.3 Channel)R.J. Leonard, M.L. Garcia, R.S. Slaughter, and J.P. Reuben, Proc. Natl. Acad. Sci. U.S.A., 89, 10094 (1992). (Pharmacol.) M. Garcia-Calvo, R.J. Leonard, J. Novick, S.P. Stevens, W. Schmalhofer, G.J. Kaczorowski, and M.L. Garcia, J. Biol. Chem., 268, 18866 (1993). (Original) M.A. Bednarek, R.M. Bugianesti, R.J. Leonard, and J.P. Felix, Biochem. Biophys. Res. Commun., 198, 619 (1994). (Chem. Synthesis & S-S Bond) H.G. Knaus, R.O.A. Koch, A. Eberhart, G.J. Kaczorowski, M.L. Garcia, and R.S. Slaughter, Biochemistry, 34,13627 (1995). (Pharmacol.)

Muscarinic ToxinsK.N. Bradley, Pharmacol. Ther., 85, 87 (2000). (Review) L.T. Potter, Life Sci., 68, 2541 (2001). (Review)D. Servent and C. Fruchart-Gaillard, J. Neurochem., 109, 1193 (2009). (Review)E. Karlsson, M. Jolkkonen, E. Mulugeta, P. Onali, and A. Adem, `, 82, 793 (2000). (Review)

List of Muscarinic ToxinsCode Compound Specificity Quantity Page

PMT-4341-s Muscarinic Toxin 1 (MT1, MTX1)

M1/4 0.1 mg vial below

PMT-4410-s Muscarinic Toxin 3 (MT3, MTX3, m4-toxin)

M4 0.1 mg vial 134

PMT-4340-s Muscarinic Toxin 7 (MT7, MTX7, m1-toxin1)

M1 0.1 mg vial 134

PMT-4424-s Muscarinic Toxin α (MTα) M3/4/5 0.1 mg vial 134

Muscarinic Toxin 1 MTX1, MT1 (Green Mamba, Dendroaspis angusticeps)

PMT-4341-s-20 °C

0.1 mgtvial

Leu-Thr-Cys-Val-Thr-Ser-Lys-Ser-Ile-Phe-Gly-Ile-Thr-Thr-Glu-Asn-Cys-Pro-Asp-Gly-Gln-Asn-Leu- Cys-Phe-Lys-Lys-Trp-Tyr-Tyr-Ile-Val-Pro-Arg-Tyr-Ser-Asp-Ile-Thr-Trp-Gly-Cys-Ala-Ala-Thr-Cys- Pro-Lys-Pro-Thr-Asn-Val-Arg-Glu-Thr-Ile-Arg-Cys-Cys-Glu-Thr-Asp-Lys-Cys-Asn-Glu (Disulfide bonds between Cys3-Cys24, Cys17-Cys42, Cys46-Cys58, and Cys59-Cys64) (M.W. 7509.5) C326H499N87O101S8 Agonist for Muscarinic Acetylcholine Receptor-1 (M1 / M4 ) (Non-Specific Ligand)Purity Information: Qp See page xivM. Jolkkonen, A. Adem, U. Hellman, C. Wernstedt, and E. Karlsson, Toxicon, 33, 399 (1995). (Original-Structure) D. Jerusalinsky and A.L. Harvey, Trends Pharmacol. Sci., 15, 424 (1994). (Review; Toxin for Muscarinic Receptor) A. Adem and E. Karlsson, Life Sci., 60, 1069 (1997). (Pharmacol.) H.Nishio, Y. Nishiuchi, T. Inui, K.N. Bradley, A.L. Harvey, and T. Kimura, Peptide Science, 1999, 125 (2000). (S-S Bond )

134 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Muscarinic Toxin 3MT3, MTX3, m4-toxin(Green Mamba, Dendroaspis angusticeps)

PMT-4410-s-20 °C

0.1 mgvial

Leu-Thr-Cys-Val-Thr-Lys-Asn-Thr-Ile-Phe-Gly-Ile-Thr-Thr-Glu-Asn-Cys-Pro-Ala-Gly-Gln-Asn-Leu- Cys-Phe-Lys-Arg-Trp-His-Tyr-Val-Ile-Pro-Arg-Tyr-Thr-Glu-Ile-Thr-Arg-Gly-Cys-Ala-Ala-Thr- Cys-Pro-Ile-Pro-Glu-Asn-Tyr-Asp-Ser-Ile-His-Cys-Cys-Lys-Thr-Asp-Lys-Cys-Asn-Glu(Disulfide bonds between Cys3- Cys24, Cys17- Cys42, Cys46- Cys57, and Cys58- Cys63)(M.W. 7379.4) C319H489N89O97S8 Specific Ligand for Muscarinic Acetylcholine Receptor-4 (M4)M. Jolkkonen, P.L.M. van Giersbergen, U. Hellman, C. Wernstedt, and E. Karlsson, FEBS Lett., 352, 91 (1994). (Original; MT3) J.-S. Liang, J. Carsi-Gabrenas, J.L. Krajewski, J.M. McCafferty, S.L. Purkerson, M.P. Santiago, W.L. Strauss, H.H. Valentine, and L.T. Potter, Toxicon, 34, 1257 (1996). (Original; m4-toxin) A. Adem and E. Karlsson, Life Sci., 60, 1069 (1997). (Pharmacol.; Muscarinic Receptor Subtype Specificity)S. Katayama, M. Ishimaru, H. Nishio, Y. Nishiuchi, and T. Kimura, Peptide Science 2004, 161 (2005). (S-S Bond)

Muscarinic Toxin 7 MTX7, MT7, m1-toxin 1 (Green Mamba, Dendroaspis angusticeps)

PMT-4340-s-20 °C

0.1 mgvial

Leu-Thr-Cys-Val-Lys-Ser-Asn-Ser-Ile-Trp-Phe-Pro-Thr-Ser-Glu-Asp-Cys-Pro-Asp-Gly-Gln-Asn-Leu- Cys-Phe-Lys-Arg-Trp-Gln-Tyr-Ile-Ser-Pro-Arg-Met-Tyr-Asp-Phe-Thr-Arg-Gly-Cys-Ala-Ala-Thr- Cys-Pro-Lys-Ala-Glu-Tyr-Arg-Asp-Val-Ile-Asn-Cys-Cys-Gly-Thr-Asp-Lys-Cys-Asn-Lys (Disulfide bonds between Cys3-Cys24, Cys17-Cys42, Cys46-Cys57, and Cys58-Cys63) (M.W. 7472.4) C322H484N90O98S9 Specific Ligand for Muscarinic Acetylcholine Receptor-1 (M1)A. Adem and E. Karlsson, Life Sci., 60, 1069 (1997). (Original) H. Nishio, Y. Nishiuchi, T. Inui, K.N. Bradley, A.L. Harvey, and T. Kimura, Peptide Science, 1999, 125 (2000). (S-S Bond) J.M. Carsi and L.T. Potter, Toxicon, 38, 187 (2000). (Original; m1-toxin1) Z. Gu, P. Zhong, and Z. Yan, J. Biol. Chem., 278, 17546 (2003). (Pharmacol; Inhibition of b-Amyloid signaling)

Muscarinic Toxin α MTα(Black Mamba, Dendroaspis polylepis)

PMT-4424-s-20 °C

0.1 mgvial

Leu-Thr-Cys-Val-Thr-Ser-Lys-Ser-Ile-Phe-Gly-Ile-Thr-Thr-Glu-Asn-Cys-Pro-Asp-Gly-Gln-Asn-Leu- Cys-Phe-Lys-Lys-Trp-Tyr-Tyr-Leu-Asn-His-Arg-Tyr-Ser-Asp-Ile-Thr-Trp-Gly-Cys-Ala-Ala-Thr- Cys-Pro-Lys-Pro-Thr-Asn-Val-Arg-Glu-Thr-Ile-His-Cys-Cys-Glu-Thr-Asp-Lys-Cys-Asn-Glu(Disulfide bonds between Cys3-Cys24, Cys17-Cys42, Cys46-Cys58, and Cys59-Cys64)(M.W. 7545.4) C326H491N89O102S8Ligand for Muscarinic Acetylcholine Receptor-3/4/5 (M3/M4/M5) (Non-specific Ligand)

Muscarinic acetylcholine receptors have been classified into five subtypes (M1 to M5). These receptors are involved in various biological functions, which can be studied using specific ligands to each receptor subtype, including the peptidic "muscarinic toxin" (abbreviated as MT in this short description). Muscarinic toxins are isolated from the venom of the mamba species and are composed of 65 to 66 amino acid residues with four intramolecular disulfide linkages.1 It is indicated that the activation of muscarinic acetylcholine receptors can regulate the metabolism of amyloid precursor protein, and that muscarinic agonists led to a reduction of amyloid β-protein production2,3,. For example, synthetic MT7 (PMT-4340-s) has been used to study M1 receptor's role in amyloid β-protein-induced signaling.4 (continued next page)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 135

We offer two muscarinic toxins bearing different receptor subtype selectivity. These are muscarinic toxin 3 (MT3) and muscarinic toxin α (MTα). We determined the disulfide arrangement of synthetic MT35 and MTα, although the experimental details have not yet published for MTα. MT3 was isolated from the green mamba Dendroaspis angusticeps and is composed of 65 amino acid residues. This peptide shows selectivity for the M4 receptor with low affinity to M1 receptor, and no binding to M2, M3, andM5 receptors.6-9 Another 66-residue peptide toxin, MTα is reported to be a component of the venomous toxins of the black mamba Dendroaspis polylepis. This peptide possesses high affinity to all five subtypes; inhibition constants for M1 through M5 are 23 nM, 44 nM, 3 nM, 5 nM, and 8 nM, respectively.8, 10, 11 As far as we know, a specific ligand to M3 and M5 does not exist, thus, MTα is attractive for this reason although the subtype selectivity is rather low. Combined utilization with already commercially available MT1 (PMT-4341-s) and MT7, the research concerning biological functions elicited through muscarinic acetylcholine receptors should advance significantly, using these chemically synthesized MT3 and MTα. 1. K.N. Bradley, Pharmacol. Ther., 85, 87 (2000). (Review)2. T.G. Beach, D.G. Walker, P.E. Potter, L.I. Sue, and A. Fisher, Brain Res., 905, 220 (2001). (Pharmacol.)3. C. Hock, A. Maddalena, A. Raschig, F. Müller-Spahn, G. Eschweiler, K. Hager, I. Heuser, H. Hampel, T. Müller-Thomsen, W. Oertel M. Wienrich, A. Signorell, C. Gonzalez-Agosti, and R.M. Nitsch, J. Protein Folding Disord., 10, 1 (2003). (Pharmacol.)4. Z. Gu, P. Zhong, and Z. Yan, J. Biol. Chem., 278, 17546 (2003). (Pharmacol.; Role in Aβ -Induced Signaling)5. S. Katayama, M. Ishimaru, H. Nishio, Y. Nishiuchi, and T. Kimura, Peptide Science 2004, 161 (2005). (S-S Bond of MT3)6. M. Jolkkonen, P.L.M. van Giersbergen, U. Hellman, C. Wernstedt, and E. Karlsson, FEBS Lett., 352, 91 (1994). (Original; MT3)7. J.-S. Liang, J. Carsi-Gabrenas, J.L. Krajewski, J.M. McCafferty, S.L. Purkerson, M.P. Santiago, W.L. Strauss, H.H. Valentine, and L.T. Potter, Toxicon, 34, 1257 (1996). (Original; m4-toxin)8. A. Adem and E. Karlsson, Life Sci., 60, 1069 (1997). (Pharmacol.; Muscarinic Receptor Subtype Specificity) 9. M. C. Olianas, A. Adem, E. Karlsson, and P. Onali, Eur. J. Pharmacol., 357, 235 (1998). (Pharmacol.; cAMP-Coupled M4 Receptor)10. M. Jolkkonen, P.L.M. van Giersbergen, U. Hellman, C.Wernstedt, A. Oras, N. Satyapan, A. Adem, and E. Karlsson, Eur. J. Biochem., 234, 579 (1995). (Original; MTα)11. M. Jolkkonen, A. Oras, T. Toomela, E. Karlsson, J. Järv, and K.E.O. Åkerman, Toxicon, 39, 377 (2001). (Pharmacol.; Mechanism of Receptor Binding)

Neurotoxin NSTX-3 (Papua New Guinean Spider, Nephila maculata)

2,4-Dihydroxyphenylacetyl-l-Asparaginyl-N1- (l-Arginyl-Putreanyl)-Cadaverine (M.W. 664.80) C30H52N10O7

PNT-4195-s-20 °C

0.1 mgvial

Y. Aramaki, T. Yasuhara, T. Higashijima, M. Yoshioka, A. Miwa, N. Kawai, and T. Nakajima, Proc. Japan Acad., 62 (B), 359 (1986). (Original) T. Teshima, T. Wakamiya, Y. Aramaki, T. Nakajima, N. Kawai, and T. Shiba, Tetrahedron Letters, 28, 3509 (1987). (Chem. Synthesis, Preliminary) T. Teshima, T. Matsumoto, T. Wakamiya, T. Shiba, Y. Aramaki, T. Nakajima, and N. Kawai, Tetrahedron, 47, 3305 (1991). (Chem. Synthesis; Total Synthesis) • This compound is distributed through Peptide Institute, Inc. under the license of Takeda, Chemical Industries, Ltd. and the Tokyo Metropolitan Institute for Neurosciences.

NEW!

136 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES PLTX-II (spider, Plectreurys tristes)

Ala-Asp-Cys-Ser-Ala-Thr-Gly-Asp-Thr-Cys-Asp-His-Thr-Lys-Lys-Cys-Cys-Asp-Asp-Cys-Tyr-Thr-Cys-Arg-Cys-Gly- Thr-Pro-Trp-Gly-Ala-Asn-Cys-Arg-Cys-Asp-Tyr-Tyr- Lys-Ala-Arg-Cys-Asp-Thr(Palmitoyl)-NH2 (Disulfide bonds undetermined) (M.W. 5108.7) C208H313N61O70S10 Presynaptic Ca2+ Channel Blocker

PPL-4300-s-20 °C

0.1 mgvial

W.D. Branton, L. Kolton, Y.N. Jan, and L.Y. Jan, J. Neurosci., 7, 4195 (1987). (Original) H.-T. Leung, W.D. Branton, H.S. Phillips, L. Jan, and L. Byerly, Neuron, 3, 767 (1989). (Pharmacol.) W.D. Branton, M.S. Rudnick, Y. Zhou, E.D. Eccleston, G.B. Fields, and L.D. Bowers, Nature, 365, 496 (1993). (Thr(Pal)amide) J. Bódi, H. Nishio, Y. Zhou, W.D. Branton, T. Kimura, and S. Sakakibara, Pept. Res., 8, 228 (1995). (Chem. Synthesis & Biological Activity) G.F. King, Toxicon, 49, 513 (2007). (Review)

ProTx-I and ProTx-IIProTx-I and ProTx-II were first isolated and characterized from the venom of taran-tula Thrixopelma pruriens.1-3 These peptide toxins belong to the inhibitory cystine knot (ICK) family, which is known to interact with voltage-gated ion channels. They are unique because they alter the rate of activation rather than inactivation of chan-nels. Otherwise, there is no sequence homology between ProTx-I and Pro-Tx-II. ProTx-II is the newest toxin currently offered by Peptides International and produced by the Peptide Institute in Japan. It was shown to be at least 100-fold selective for Nav1.7 channel with an IC50 of 0.3 nM.4 Sodium channel subtype Nav1.7 has a role in modulating neuronal signaling for pain, and recent studies indicate loss-of-function mutations in Nav1.7 cause insensitivity to pain.5 Others have identified gain-of-function mutations in Nav1.7 as the cause of certain pain disorders.6-8 Thus Nav1.7 is a poten-tial target for the development of analgesics.The highly sensitive nature of ProTx-II for Nav1.7 is believed to be due to the presence of a unique phenylalanine residue (F813) present in the C-terminal domain II S3 of the channel, which makes it different than the other sodium channel subtypes. Indeed, mutation of the F813 residue to glycine or serine reduced the sensitivity of ProTx-II significantly.4 Evidence indicates ProTx-II may not be able to cross the blood-nerve barrier since intravenous administration in rats did not significantly block acute pain response. In addition, the toxin can block C-fiber action potential propagation in desheathed but not intact nerves.4 While this may limit the use of ProTx-II, the toxin should still act as an important tool for locating novel inhibitors for Nav1.7.1. R.E. Middleton, et al., Biochemistry, 41, 14734 (2002). (Original) 2. B.T. Priest, et al., Toxicon, 49, 194 (2007). (Review) 3. J.J. Smith, et al., J. Biol. Chem.,282, 12687 (2007). (Pharmacol.; Novel Toxin Binding Site Coupled to Nav Activation)4. W.A. Schmalhofer, et al., Mol. Pharmacol., 74,1476 (2008).

5. S.D. Dib-Hajj, et al., Trends Neurosci, 30, 555 (2007).6. C.R. Fertleman, et al., Neuron, 52, 767 (2006).

7. C. Han, et al., Ann Neurol., 59, 553 (2006). 8. Y. Yang,et al., Journal of Med. Genetics, 41171 (2004).


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 137

ProTx-I(Tarantula, Thrixopelma pruriens)

Glu-Cys-Arg-Tyr-Trp-Leu-Gly-Gly-Cys-Ser-Ala-Gly-Gln- Thr-Cys-Cys-Lys-His-Leu-Val-Cys-Ser-Arg-Arg-His- Gly-Trp-Cys-Val-Trp-Asp-Gly-Thr-Phe-Ser

PTX-4409-s-20 °C

0.1 mgvial

(Disulfide bonds between Cys2-Cys16, Cys9-Cys21, and Cys15- Cys28)(M.W. 3987.5) C171H245N53O47S6T-Type Ca2+ Channel / Na+ Channel / K+ Channel Blocker (Gating Modifier)R.E. Middleton, V.A. Warren, R.L. Kraus, J.C. Hwang, C.J. Liu, G. Dai, R.M. Brochu, M.G. Kohler, Y.D. Gao, V.M. Garsky, M.J. Bogusky, J.T. Mehl, C.J. Cohen, and M.M. Smith, Biochemistry, 41, 14734 (2002). (Original)T. Ohkubo, J. Yamazaki, and K. Kitamura, J. Pharmacol. Sci., 112, 452 (2010). (Pharmacol.)B.T. Priest, K.M. Blumenthal, J.J. Smith, V.A. Warren, and M.M. Smith, Toxicon, 49, 194 (2007). (Review)

ProTx-II(Tarantula, Thrixopelma pruriens)

YCQKWMWTCDSERKCCEGMVCRLWCKKKLW

PTX-4450-s -20 °C

0.1 mgvial

Tyr-Cys-Gln-Lys-Trp-Met-Trp-Thr-Cys-Asp-Ser-Glu-Arg-Lys-Cys-Cys- Glu-Gly-Met-Val-Cys-Arg-Leu-Trp-Cys-Lys-Lys-Lys-Leu-Trp(Disulfide bonds between Cys2-Cys16, Cys9- Cys21, and Cys15-Cys25) (M.W. 3826.60) C168H250N46O41S8 Na+ Channel (Especially Nav1.7) / Ca2

+ Channel Blocker (Gating Modifier)R.E. Middleton, V.A. Warren, R.L. Kraus, J.C. Hwang, C.J. Liu, G. Dai, R.M. Brochu, M.G. Kohler, Y.-D. Gao, V.M. Garsky, M.J. Bogusky, J.T. Mehl, C.J. Cohen, and M.M. Smith, Biochemistry, 41, 14734 (2002). (Original)J.J. Smith, T.R. Cummins, S. Alphy, and K.M. Blumenthal, J. Biol. Chem., 282, 12687 (2007). (Pharmacol.; Novel Toxin Binding Site Coupled to Nav Activation)W.A. Schmalhofer, J. Calhoun, R. Burrows, T. Bailey, M.G. Kohler, A.B. Weinglass, G.J. Kaczorowski, M.L. Garcia, M. Koltzenburg, and B.T. Priest, Mol. Pharmacol, 74, 1476 (2008). (Pharmacol.; Inhibition of Nav1.7 Channels)S.D. Dib-Hajj, T.R. Cummins, J.A. Black, and S.G. Waxman, Trends Neurosci., 30, 555 (2007). (Review)B.T. Priest, K.M. Blumenthal, J.J. Smith, V.A. Warren, and M.M. Smith, Toxicon, 49, 194 (2007). (Review) S. Sokolov, R.L. Kraus, T. Scheuer, and W.A. Catterall, Mol. Pharmacol., 73, 1020 (2008). (Pharmacol.)

NEW!

138 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES PsalmotoxinThe acid-sensing ion channel (ASIC) family is involved with pain perception, learning, and memory. In addition, the ion channels may contribute to brain injury and neuronal death. ASIC is stimulated by H+ ligand, and activation is calcium dependent.1,2 Peptide toxins have been invaluable tools for inhibition of ion conductance pathways and in functional/structural studies of channels. Psalmotoxin 1 (PTX-4435-s), isolated from the venom of tarantula Psalmopoeus cambridgei, is the first potent peptide blocker shown to inhibit ASIC1a by increasing affinity of the channel for H+, leading to receptor desensitization.4,5,6 This toxin showed promise as a neuroprotective agent for ASIC1a mediated ischemic brain injury (100 ng/ml) and could selectively inhibit malignant glioma (IC50 = 36 pM) Na+ channels (both inward and outward).7,8 Further studies of Psalmotoxin ASIC1a interaction could lead to potential diagnosis and therapy of these and other ASIC1a-related diseases.1. E.L. Bässler, et. al., J. Biol. Chem., 276, 33782 (2001). 2. E. Babini, et. al., J.Biol. Chem., 277, 41597 (2002). 3. V.I. Pidoplichko and J.A. Dani, PNAS, 203, 11376 (2006). 4. P. Escoubas, et. al., J. Biol. Chem., 275, 25116 (2000).

5. M. Salinas, et. al., J. Physiol., 570, 339 (2005). 6. X. Chen, et. al., J. Gen. Physiol., 126, 71 (2005). 7. G. Pignataro, et. al., Brain, 10, 1093 (2006). 8. J.K. Bubien, et. al., Am. J. Physiol. Cell Physiol., 287, C1282 (2004).

Psalmotoxin 1PcTX1(South American Tarantula, Psalmopoeus cambridgei)


PTX-4435-s-20 °C

0.1 mgvial

Glu-Asp-Cys-Ile-Pro-Lys-Trp-Lys-Gly-Cys-Val-Asn-Arg-His-Gly-Asp-Cys-Cys-Glu-Gly- Leu-Glu-Cys-Trp-Lys-Arg-Arg-Arg-Ser-Phe-Glu-Val-Cys-Val-Pro-Lys-Thr-Pro-Lys-Thr(Disulfide bonds between Cys3-Cys18, Cys10-Cys23, and Cys17-Cys33)(M.W. 4689.40) C200H312N62O57S6Selective Blocker for Acid-Sensitive Ion Channel, ASIC1a Purity Information: QE See page xivP. Escoubas, J.R. De Weille, A. Lecoq, S. Diochot, R. Waldmann, G. Champigny, D. Moinier, A. Menez, and M. Lazdunski, J. Biol. Chem., 275, 25116 (2000). (Original; Primary Structure & ASIC Blocking Selectivity)P. Escoubas, C. Bernard, G. Lambeau, M. Lazdunski, and H. Darbon, Protein Sci., 12, 1332 (2003). (Three-dimensional Solution Structure)X. Chen, H. Kalbacher, S. Grunder, J. Gen. Physiol., 127, 267 (2006). (Pharmacol.; State-Dependent Function) X. Chen, H. Kalbacher, and S. Gründer, J. Gen. Physiol., 126, 71 (2005). (Pharmacol.; Mechanism of Channel Inhibition)J.K. Bubien, H.-L. Ji, G. Yancey Gillespie, C.M. Fuller, J.M. Markert, T.B. Mapstone, and D.J. Benos, Am. J. Physiol. Cell Physiol., 287, C1282 (2004). (Pharmacol.; Inhibition of Malignant Glioma Na+ Channels)Z.-G. Xiong, X.-M. Zhu, X.-P. Chu, M. Minami, J. Hey, W.-L. Wei, J.F. MacDonald, J.A. Wemmie, M.P. Price, M.J. Welsh, and R.P. Simon, Cell, 118, 687 (2004). (Pharmacol.; Neuroprotection in Ischemia)S. Diochot, M. Salinas, A. Baron, P. Escoubas, and M. Lazdunski, Toxicon, 49, 271 (2007). (Review)Y.J. Qadri, B.K. Berdiev, Y. Song, H.L. Lippton, C.M. Fuller, and D.J. Benos, J. Biol. Chem., 284, 17625 (2009). (Pharmacol.)

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 139

Purotoxin-1(Wolf Spider, Geolycosa sp.)

PPT-4457-v -20 °C

0.1 mg vial

Gly-Tyr-Cys-Ala-Glu-Lys-Gly-Ile-Arg-Cys-Asp-Asp-Ile- His-Cys-Cys-Thr-Gly-Leu-Lys-Cys-Lys-Cys-Asn- Ala-Ser-Gly-Tyr-Asn-Cys-Val-Cys-Arg-Lys-Lys (Reported disulfide bonds between Cys3-Cys16, Cys10-Cys21, Cys15-Cys32, and Cys23-Cys30)(M.W. 3836.50) C155H248N50O48S8Inhibitor of P2X3 PurinoreceptorsE.V. Grishin, G.A. Savchenko, A.A. Vassilevski, Y.V. Korolkova, Y.A. Boychuk, V.Y. Viatchenko-Karpinski, K.D. Nadezhdin, A.S. Arseniev, K.A. Pluzhnikov, V.B. Kulyk, N.V. Voitenko, and O.O. Krishtal, Ann. Neurol., 67, 680 (2010). (Original; Structure & Pharmacol.)

SarafotoxinsE. Kochva, A. Bdolah, and Z. Wollberg, Toxicon, 31, 541 (1993). (Review)F. Ducancel, Toxicon, 40, 1541 (2002). (Review)F. Ducancel, Cell. Mol. Life Sci., 62, 2828 (2005). (Review)

Sarafotoxin S6b* (Snake, Atractaspis engaddensis)

Cys-Ser-Cys-Lys-Asp-Met-Thr-Asp-Lys-Glu-Cys- Leu-Tyr-Phe-Cys-His-Gln-Asp-Val-Ile-Trp (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 2563.9) C110H159N27O34S5 [120972-53-4] Endothelin Related Peptide

PSF-4206-s-20 °C

0.1 mgvial

C. Takasaki, N. Tamiya, A. Bdolah, Z. Wollberg, and E. Kochva, Toxicon, 26, 543 (1988). (Original; Chem. Structure) Y. Kloog, I. Ambar, M. Sokolovsky, E. Kochva, Z. Wollberg, and A. Bdolah, Science, 242, 268 (1988). (Original; Biochem.) K. Nakajima, S. Kumagaye, H. Nishio, H. Kuroda, T.X. Watanabe, Y. Kobayashi, H. Tamaoki, T. Kimura, and S. Sakakibara, J. Cardiovasc. Pharmacol., 13 (Suppl. 5), 58 (1989). (Chem. Synthesis and Biological Activity) T.X. Watanabe, Y. Itahara, K. Nakajima, S. Kumagaya, T. Kimura, and S. Sakakibara, J. Cardiovasc. Pharmacol., 17, S5 (1991). (Pharmacol.)


Sarafotoxin S6c* (Snake, Atractaspis engaddensis)

Cys-Thr-Cys-Asn-Asp-Met-Thr-Asp-Glu-Glu-Cys- Leu-Asn-Phe-Cys-His-Gln-Asp-Val-Ile-Trp (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 2515.8) C103H147N27O37S5 [121695-87-2] Selective ETB Receptor Agonist

PSF-4246-s-20 °C

0.1 mgvial

C. Takasaki, N. Tamiya, A. Bdolah, Z. Wolberg, and E. Kochva, Toxicon, 26, 543 (1988). (Original; Chem. Structure) W.G. Nayler, X.H. Gu, and D.J. Casley, Biochem. Biophys. Res. Commun., 161, 89 (1989). (Pharmacol.) D.L. Williams, Jr., K.L. Jones, D.J. Pettibone, E.V. Lis, and B.V. Clineschmidt, Biochem. Biophys. Res. Commun., 175, 556 (1991). (Pharmacol.)


NEW!

140 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Scyllatoxin Leiurotoxin I (Scorpion, Leiurus quinquestriatus hebraeus)

PSC-4260-s-20 °C

0.1 mgvial

Ala-Phe-Cys-Asn-Leu-Arg-Met-Cys-Gln-Leu-Ser-Cys-Arg-Ser-Leu-Gly- Leu-Leu-Gly-Lys-Cys-Ile-Gly-Asp-Lys-Cys-Glu-Cys-Val-Lys-His-NH2 (Reported disulfide bonds betwen Cys3-Cys21, Cys8-Cys26, and Cys12-Cys28) (M.W. 3423.1) C142H237N45O39S7 [142948-19-4] Small Conductance Ca2+-Activated K+ Channel BlockerG.G. Chicchi, G. Gimenez-Gallego, E. Ber, M.L. Garcia, R. Winquist, and M.A. Cascieri, J. Biol. Chem., 263, 10192 (1988). (Original) P. Auguste, M. Hugues, C. Mourre, D. Moinier, A. Tartar, and M. Lazdunski, Biochemistry, 31, 648 (1992). (Pharmacol.) J.C. Martins, F.J.M. Van de Ven, and F.A.M. Borremans, J. Mol. Biol., 253, 590 (1995). (S-S Bond)

SNX-482 (Tarantula, Hysterocrates gigas)

PCB-4363-s-20 °C

0.1 mgvial

Gly-Val-Asp-Lys-Ala-Gly-Cys-Arg-Tyr-Met-Phe-Gly-Gly-Cys-Ser-Val- Asn-Asp-Asp-Cys-Cys-Pro-Arg-Leu-Gly-Cys-His-Ser-Leu-Phe-Ser- Tyr-Cys-Ala-Trp-Asp-Leu-Thr-Phe-Ser-Asp (Reported disulfide bonds between Cys7-Cys21, Cys14-Cys26, and Cys20-Cys33) (M.W. 4495.0 ) C192H274N52O60S7 [203460-30-4] Class-E (R-Type) Ca2+ Channel BlockerR. Newcomb, B. Szoke, A. Palma, G. Wang, X.-h. Chen, W. Hopkins, R. Cong, J. Miller, L. Urge, K. Tarczy-Hornoch, J.A. Loo, D.J. Dooley, L. Nadasdi, R.W. Tsien, J. Lemos, and G. Miljanich, Biochemistry, 37, 15353 (1998). (Original) L. Ürge, B. Szöke, D. Silva, P. Tran-Tau, D. Hom, K. Tarczy-Hornoch, and L. Nádasdi, In, Peptides 1998, Proceedings of 25th European Peptide Symposium (S. Bajusz and F. Hudecz, eds.), Akadémiai Kiadó Butapest, 1998, 748-749 (1998). (S-S Bond) A. Tottene, S. Volsen, and D. Pietrobon, J. Neurosci., 20, 171 (2000). (Pharmacol.) G. Wang, G. Dayanithi, R. Newcomb, and J.R. Lemos, J. Neurosci., 19, 9235 (1999). (Pharmacol.) D. Sochivko, A. Pereverzev, N. Smyth, C. Gissel, T. Schneider, and H. Beck, J. Physiol., 542, 699 (2002). (Pharmacol.)X. Jing, D.-Q. Li, C.S. Olofsson, A. Salehi, V.V. Surve, J. Caballero, R. Ivarsson, I. Lundquist, A. Pereverzev, T. Schneider, P. Rorsman, and E. Renstroem, J. Clin. Invest., 115, 146 (2005). (Pharmacol.)

Stichodactyla Toxin (ShK) (Sea Anemone, Stichodactyla helianthus)

Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala- Phe-Gln-Cys-Lys-His-Ser-Met-Lys-Tyr-Arg-Leu-Ser- Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys

PSK-4287-s-20 °C

0.1 mgvial

(Disulfide bonds between Cys3-Cys35, Cys12-Cys28, and Cys17-Cys32) (M.W. 4054.8) C169H274N54O48S7 Voltage Dependent K+ Channel (A Channel) BlockerE. Karlsson, A.L. Harvey, A. Aneiros, and O. Castaneda, Toxicon, 31, 504 (1993). (Original; in Abstract)J. Pohl, F. Hubalek, M.E. Byrnes, K.R. Nielsen, A. Woods, and M.W. Pennington, Lett. Pept. Sci., 1, 291 (1994). (S-S Bond) O. Castañeda, V. Sotolongo, A.M. Amor, R. Stöcklin, A.J. Anderson, A.L. Harvey, Å. Engström, C. Wernstedt, and E. Karlsson, Toxicon, 33, 603 (1995). (Pharmacol.)

5-Fam-ShK(Sea Anemone, Stichodactyla helianthus)

(Trifluoroacetate Form) Fluorescein-5-carbonyl-AEEAc-Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Met-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys-NH2

SHK-3746-PI-20 °C

1 mg

(Disulfide bonds between Cys3-Cys35, Cys12-Cys28, and Cys17-Cys32)(M.W. 4557.33) C196H296N56O56S7

C. Beeton, et al., J. Biol. Chem., 278, 9928 (2003)R.S. Norton, et al., Curr. Med. Chem., 11, 3141 (2004)

NEW!


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 141

Tertiapin (Honey Bee, Apis mellifera)

Ala-Leu-Cys-Asn-Cys-Asn-Arg-Ile-Ile-Ile-Pro-His- Met-Cys-Trp-Lys-Lys-Cys-Gly-Lys-Lys-NH2 (Disulfide bonds between Cys3-Cys14 and Cys5-Cys18) (M.W. 2455.1) C106H176N34O23S5 Inward Rectifier K+ Channel Blocker

PTK-4364-s-20 °C

0.1 mgvial

W. Jin and Z. Lu, Biochemistry, 37, 13291 (1998). (Original; Pharmacol.) X. Xu and J.W. Nelson, Proteins Struct. Funct. Genet., 17, 124 (1993). (Structure; S-S Bond) H. Kitamura, M. Yokoyama, H. Akita, K. Matsushita, Y. Kurachi, and M. Yamada, J. Pharmacol. Exp.Ther., 293, 196 (2000). (Pharmacol.) M.-D. Drici, S. Diochot, C. Terrenoire, G. Romey, and M.L. Lazdunski, Br. J. Pharmacol., 131, 569 (2000). (Pharmacol.)

Tityustoxin Kα (TsTX-Kα) (Scorpion, Tityus serrulatus)

PTT-4313-s-20 °C

0.1 mgvial

Val-Phe-Ile-Asn-Ala-Lys-Cys-Arg-Gly-Ser-Pro-Glu-Cys-Leu-Pro-Lys-Cys-Lys-Glu- Ala-Ile-Gly-Lys-Ala-Ala-Gly-Lys-Cys-Met-Asn-Gly-Lys-Cys-Lys-Cys-Tyr-Pro (Reported disulfide bonds between Cys7-Cys28, Cys13-Cys33, and Cys17-Cys35) (M.W. 3941.7) C168H275N49O46S7 Voltage-Dependent K+ Channel (A Channel) BlockerT.R.Werkman, T.A. Gustafson, R.S. Rogowski, M.P. Blaustein, and M.A. Rogawski, Mol. Pharmacol., 44, 430 (1993). (Original) R.S. Rogowski, B.K. Krueger, J.H. Collins, and M.P. Blaustein, Proc. Natl. Acad. Sci. U.S.A., 91, 1475 (1994). (Pharmacol.) W.F. Hopkins, J. Pharmacol. Exp. Ther., 285, 1051 (1998). (Pharmacol.) K.C. Ellis, T.C. Tenenholz, H. Jerng, M. Hayhurst, C.S. Dudlak, W.F. Gilly, M.P. Blaustein, and D.J. Weber, Biochemistry, 40, 5942 (2001). (S-S Bond)

TuftsinTuftsin

Thr-Lys-Pro-Arg (M.W. 500.59) C21H40N8O6 [9063-57-4]

PTF-4020-v-20 °C

0.5 mgvial

Tuftsin (Bulk)Thr-Lys-Pro-Arg • 2AcOH • 4H2O (M.W. 500.59 • 120.10 • 72.06) C21H40N8O6 • 2CH3COOH • 4H2O [72103-53-8] Phagocytosis-Stimulating PeptideK. Nishioka, A. Constantpoulos , P.S. Satoh, and V.A. Najjar, Biochem. Biophys. Res. Commun., 47, 172 (1972). (Original) K. Nishioka, P.S. Satoh, A. Constantpoulos, and V.A. Najjar, Biochim. Biophys. Acta, 310, 230 (1973). (Chem. Synthesis & Pharmacol.)

PTF-4020-20 °C

25 mg100 mg

Urantide™ See Code PUT-3639-PI Urotensin Related Products on page 88.Urocortin See Stresscopins / Urocortin and Related Peptides on page 88.

142 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Urotensin II and Related PeptidesUrotensin II is one of the most potent vasoconstrictors known, and Urantide has been reported to be the most potent antagonist of urotensin II - until now.1,2 Recent stud-ies replacing the Asp amino acid in Urantide led to the discovery of a new urotensin II antagonist, H-Tic-[Pen-Phe-d-Trp-Orn-Tyr-Cys]-Val-OH. It was found to be more potent than Urantide at inducing contractions in isolated rat thoracic aorta, with a pA2 value of 9.0 compared to a pA2 value of 8.3 for Urantide.31. R.S. Ames, et al., Nature, 401, 282 (1999).2. R. Patacchini, et al., Br. J. Pharmacol., 140, 1155 (2003). 3. Patent N. FI2007A000032. Patent N. FI2006A000340

Urotensin II (Human)(Hydrochloride Form) Glu-Thr-Pro-Asp-Cys-Phe-Trp-Lys-Tyr-Cys-Val (Disulfide bonds between Cys5-Cys10) (M.W. 1388.6) C64H85N13O18S2 [251293-28-4] Potent Vasoconstrictor Purity Information: QE See page xiv

PUT-4365-v-20 °C

0.5 mgvial

Y. Coulouarn, I. Lihrmann, S. Jegou, Y. Anouar, H. Tostivint, J.C. Beauvillain, J.M. Conlon, H.A. Bern, and H. Vaudry, Proc. Natl. Acad. Sci. U.S.A., 95, 15803 (1998). (Original) R.S. Ames, H.M. Sarau, J.K. Chambers, R.N. Willette, N.V. Aiyar, A.M. Romanic, C.S. Louden, J.J. Foley, C.F. Sauermelch, R.W. Coatney, Z. Ao, J. Disa, S.D. Holmes, J.M. Stadel, J.D. Martin, W.-S. Liu, G.I. Glover, S. Wilson, D.E. McNulty, C.E. Ellis, N.A. Elshourbagy, U. Shabon, J.J. Trill, D.W.P. Hay, E.H. Ohlstein, D.J. Bergsma, and S.A. Douglas, Nature, 401, 282 (1999). (Pharmacol.) M.R. MacLean, D. Alexander, A. Stirrat, M. Gallagher, S.A. Douglas, E.H. Ohlstein, I. Morecroft, and K. Polland, Br. J. Pharmacol., 130, 201 (2000). (Pharmacol.)

Urotensin II (Rat) [Pyr110]-Prepro-Urotensin II (Rat, 110-123)

Pyr-His-Gly-Thr-Ala-Pro-Glu-Cys-Phe-Trp-Lys-Tyr-Cys-Ile (Disulfide bonds between Cys8-Cys13) (M.W. 1663.9) C77H102N18O20S2 Vasoconstrictor

PUT-4371-v-20 °C

0.5 mgvial

Y. Coulouarn, S. Jégou, H. Tostivint, H. Vaudry, and I. Lihrmann, FEBS Lett., 457, 28 (1999). (Original) S.M. Gardiner, J.E. March, P.A. Kemp, A.P. Davenport, and T. Bannett, Br. J. Pharmacol., 132, 1625 (2001). (Pharmacol.)

Urotensin II-Related Peptide (Human, Rat, Mouse)

Ala-Cys-Phe-Trp-Lys-Tyr-Cys-Val (Disulfide bond between Cys2 - Cys7) (M.W. 1017.2) C49H64N10O10S2 [342878-90-4] Endogenous Hypotensive Peptide

PUT-4408-v-20 °C

0.5 mgvial

Y. Coulouarn, S. Jégou, H. Tostivint, H. Vaudry, and I. Lihrmann, FEBS Lett., 457, 28 (1999). (Original; Rat Urotensin Precursor Sequence) T. Sugo, Y. Murakami, Y. Shimomura, M. Harada, M. Abe, Y. Ishibashi, C. Kitada, N. Miyajima, N. Suzuki, M. Mori, and M. Fujino, Biochem. Biophys. Res. Commun., 310, 860 (2003). (Original: Urotensin II-Related Peptide)


NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 143

Urantide™ H-Asp-[Pen-Phe-d-Trp-Orn-Tyr-Cys]-Val-OH

(Trifluoroacetate Form) [Pen5, D-Trp7, Orn8]-Urotensin II (Human, 4-11) (Disulfide bond between Pen2-Cys7) (M.W. 1075.28) C51H66N10O12S2 Potent Urotensin II AntagonistR. Patacchini, P. Santicioli, S. Giuliani, P. Grieco, E. Novellino, P. Rovero, and C.A. Maggi, Br. J. Pharmacol., 140, 1155 (2003). (Urantide™) • This product is sold under exclusive license.

PUT-3639-PI-20 °C

1 mg

H-Asp-[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-OH(Disulfide bond between Pen2-Cys7) (M.W. 1089.31) C52H68N10O12S2 Potent Urotensin II AgonistP. Grieco, A. Carotenuto, P. Campiglia, E. Zampelli, R. Patacchini, C.A. Maggi, E. Novellino, and P. Rovero, J. Med. Chem., 45, 4391 (2002). (Urotensin Agonist)

PUT-3640-PI-20 °C

1 mg

H-Tic-[Pen-Phe-d-Trp-Orn-Try-Cys]-Val-OH(M.W. 1119.38) C57H70N10O10S2Potent Urotensin II AntagonistM. Sala, L. Auriemma, T. Campiglia, I. Gomez-Monterrey, P. Santiciolli, C.A. Maggi, P. Rovero, A. Carotenuto, E. Novellino, and P. Grieco, Poster Presentation at the 20th American Peptide Symposium, Montreal, Canada (2007). Patent N. FI2007A000032. Patent N. FI2006A000340

PUT-3928-PI -20 °C

1 mg

Vasoactive Intestinal Peptide (VIP)VIP (Human, Porcine)* Vasoactive Intestinal Peptide (Human, Porcine) (Bovine, Rat, Canine)

His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 (M.W. 3325.8) C147H238N44O42S [40077-57-4]

PVA-4110-s-20 °C

0.1 mgvial

VIP (Human, Porcine)* Vasoactive Intestinal Peptide (Human, Porcine) (Bovine, Rat, Canine)

[40077-57-4]

PVA-4110-v-20 °C

0.5 mgvial

V. Mutt and S.I. Said, Eur. J. Biochem., 42, 581 (1974). (Original; Porcine) N. Itoh, K. Obata, N. Yanaihara, and H. Okamoto, Nature, 304, 547 (1983). (cDNA Seq.; Human) R. Dimaline, J.R. Reeve, Jr., J.E. Shively, and D. Hawke, Peptides, 5, 183 (1984). (Original; Rat) S.C. Wang, B.H. Du, J. Eng, M. Chang, J.D. Hulmes, Y.-C.E. Pan, and R.S. Yalow, Life Sci., 37, 979 (1985). (Original; Canine)

VIP Antagonist(Trifluoroacetate Form) H-Lys-Pro-Arg-Arg-Pro-Tyr-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 (M.W. 3467.13) C154H257N49O40S [125093-93-8]

PVA-3757-PI-20 °C

1 mg5 mg

II. Gozes, et al., Endocrinology, 125, 2945 (1989.)T.W. Moody, et al., Proc. Natl. Acad. Sci. USA, 90, 4345 (1993).

NEW!

NEW!

144 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

BIO

LOG

ICAL

LY A

CTIV

E PE

PTID

ES Vasopressin, Vasotocin, and Related PeptidesB. Berde (ed.), Neurohypophysial Hormones and Similar Polypeptides, Handbook of Experimental Pharmacology, Vol. 23, Springer-Verlag, Berlin, 1968. (Review)

[Arg8]-Vasopressin* (Human, Bovine, Ovine, Rat, Mouse)

Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bond between Cys1-Cys6) (M.W. 1084.2) C46H65N15O12S2 [113-79-1]

PVP-4085-v-20 °C

0.5 mgvial

E.A. Popenoe and V. Du Vigneaud, J. Biol. Chem., 205, 133 (1953). (Original; Bovine) A. Light and V. Du Vigneaud, Proc. Soc. Exp. Biol. Med., 98, 692 (1958). (Original; Human) H. Schmale, S. Heinsohn, and D. Richter, EMBO J., 2, 763 (1983). (Nucleotide Seq.; Rat)


[Asu1,6,Arg8]-Vasopressin* Deamino-Dicarba-Arginine-Vasopressin

cyclo (Tyr-Phe-Gln-Asn-Asu)-Pro-Arg-Gly-NH2 (Asu: l-a-Aminosuberic Acid)

PVP-4026-v-20 °C

0.5 mgvial

(Cyclic form between Asu w-carboxl group and Tyr a-amino group) (M.W. 1033.1) C48H68N14O12 [40944-53-4] Purity Information: Qx See page xivS. Hase, S. Sakakibara, et al., J. Amer. Chem. Soc., 94, 3590 (1972). (Original)


[Pmp1,Tyr(Me)2]-Arg8-Vasopressin*Pmp-Tyr(Me)-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Pmp: b-Mercapto-b,b-Cyclopentamethylene Propionic Acid) (Tyr(Me): O-Methyl-l-Tyrosine) (Disulfide bond between Cys1-Cys6) (M.W. 1151.4) C52H74N14O12S2 [73168-24-8] Potent Arginine Vasopressin V1 Antagonist

PVP-4203-v-20 °C

0.5 mgvial

M. Kruszynski, B. Lammerk, M. Manning, J. Seto, J. Halder, and W.H. Sawyer, J. Med. Chem., 23, 364 (1980). (Original)


[Arg8]-Vasotocin* (Frog, Chicken)

Cys-Tyr-lle-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bond between Cys1-Cys6) (M.W. 1050.2) C43H67N15O12S2 [74927-14-3]

PVP-4192-v-20 °C

0.5 mgvial

R. Acher, J. Chauvet, M.T. Lenci, F. Morel, and J. Maetz, Biochim. Biophys. Acta, 42, 379 (1960). (Original; Frog) J. Chauvet, M.T. Lenci, and R. Acher, Biochim. Biophys. Acta, 38, 571 (1960). (Original; Chicken)


[Asu1,6,Arg8]-Vasotocin* Deamino-Dicarba-Arginine-Vasotocin

cyclo (Tyr-lle-Gln-Asn-Asu)-Pro-Arg-Gly-NH2 (Asu: l-a-Aminosuberic Acid)

PVP-4027-v-20 °C

0.5 mgvial

(Cyclic form between Asu w-carboxl group and Tyr a-amino group) (M.W. 999.12) C45H70N14O12 [35375-13-4]S. Hase, S. Sakakibara, et al., J. Am. Chem. Soc., 94, 3590 (1972). (Original)



NALBIO

LOG


Order Hotline 1-800-777-4779 502-266-8787 145

Virus Replication Inhibiting PeptideVirus Replication Inhibiting Peptide (Bulk)

Z-d-Phe-Phe-Gly (Z: Benzyloxcarbonyl) (M.W. 503.55) C28H29N3O6 [75539-79-6]

PVI-4092-20 °C

25 mg100 mg

C.D. Richardson, A. Scheid, and P.W. Choppin, Virology, 105, 205 (1980). (Original)

XeninXenin 25 (Human)

Met-Leu-Thr-Lys-Phe-Glu-Thr-Lys-Ser-Ala-Arg-Val-Lys- Gly-Leu-Ser-Phe-His-Pro-Lys-Arg-Pro-Trp-Ile-Leu (M.W. 2971.6) C139H224N38O32S Xenopsin Related Peptide

PXN-4279-v-20 °C

0.5 mgvial

G.E. Feurle, G. Hamscher, R. Kusiek, H.E. Meyer, and J.W. Metzger, J. Biol. Chem., 267, 22305 (1992). (Original)

PEPT

IDES

INTE

RNAT

IONA

LEN

ZYM

E IN

HIBI

TORS

AND

SUB

STRA

TES

PEPT

IDES

INTE

RNAT

IONA

L

146 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LEN

ZYM

E IN

HIBI

TORS

AND

SUB

STRA

TES

Peptidyl-NH O

CH3

O + H2O Peptide + N2H OO

CH3

Enzyme

Reagents 1) Substrate stock solution: Vial, in DMSO at 10 mM 2) AMC stock solution: Content of vial (Code MCA-3099-v AMC), in DMSO at 1 mM 3) Buffer 4) Enzyme solution

Procedure Choose the proper conditions for the measurement, such as substrate concentration and sensitivity setting, depending on the purpose of the experiment and the instrument available. Described here is one of the recommended procedures for the fluorometric method (initial-rate method).

1) Set a fluorescence spectrophotometer at λex = 380 nm and λem = 460 nm at 25 °C (1.0 Relative fluorescence unit at 10-6 M of AMC)

2) Pipette 2940 µL of buffer and 30 µL of substrate stock solution into the cuvette 3) Incubate in the fluorescence spectrophotometer for 3-4 min (for temperature equilibration) 4) Add 30 µL of enzyme solution 5) Record the increase of the fluorescence intensity for 3-4 min 6) Calculate the amount of AMC released using the following equation

The initial rate of increase in the AMC concentration can be monitored 1) fluorometrically at λex = 380 nm and λem = 460 nm (Fig. 1a) or 2) photometrically at 370 nm (Fig. 1b).

Assay Methods Using Peptidyl-MCA Substrates (1)Principle

* Photometric measurement can be carried out by the same procedure as that of the fluorometric method using a UV spectrophotometer. Set the wavelength at 370 nm (ε 7700).

Peptidyl-MCA AMC

PEPTIDES INTERNATIONAL

Order Hotline 1-800-777-4779 502-266-8787 147

ENZYME INHIBITO

RS AND SUBSTRATES

Wavelength (nm)

400 450 500 550

Ex = 350 nmEx = 380 nm

Flu

ores

cenc

e

Fig. 2 b Fluorescence Spectra of AMC (Product)

Wavelength (nm)

350 400 450 500 550

Ex = 330 nmEx = 340 nmEx= 350 nmEx = 360 nmEx= 370 nmEx = 380 nm

F ig. 2 a F luorescence Spectra of Peptidyl-MC A (Substrate)

Flu

ores

cenc

e

Assay Methods Using Peptidyl-MCA Substrates (2) (Measurement on an Auto-Fluorescence Spectrophotometer for Multiplate) Reagents 1) Substrate stock solution: Content of vial, in DMSO at 10 mM 2) AMC standard solution: Content of vial (Code MCA-3099-v AMC), in DMSO at 1 mM 3) Buffer 4) Enzyme solution

Instrument: Auto-fluorescence spectrophotometer Selection of filter: 380 nm, 390 nm or 355 nm filter will be recommended for measurement. In using 355 nm filter, observe caution for overlapping of fluorescence of the substrate itself.

Procedure

Choose the proper conditions for the measurement, such as substrate, enzyme concentration and other reaction conditions, depending on the purpose of the experiment.

1) Set the auto-fluorescence spectrophotometer at λex = 380 nm, λem = 460 nm at 25 °C (1.0 Relative fluorescence unit at 10-6 M of AMC)

2) Pipette 160 µL of buffer and 20 µL of substrate solution in well for final concentration of 100 µM 3) Incubate the plate in the fluorescence spectrophotometer for 3-4 min (for temperature equilibration) 4) Take the multiplate out and add 20 µL of enzyme solution in each well5) Mount the plate in the fluorescence spectrophotometer6) Record the increase in fluorescence intensity for 30 min with a premixing time of 3 sec7) Calculate the amount of released AMC

PEPT

IDES

INTE

RNAT

IONA

LEN

ZYM

E IN

HIBI

TORS

AND

SUB

STRA

TES

PEPT

IDES

INTE

RNAT

IONA

L

148 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LEN

ZYM

E IN

HIBI

TORS

AND

SUB

STRA

TES Assay Methods Using Peptidyl-MCA Substrates (3)

(Example for Caspase-7 using an Auto-fluorescence Spectrophotometer for Multiplate) Reagents 1) Substrate stock solution: Content of vial (Code SAP-3171-v Ac-DEVD-MCA), in DMSO at

10 mM 2) AMC standard solution: Content of vial (Code MCA-3099-v AMC), in DMSO at 1 mM 3) Buffer: ICE standard buffer (100 mM HEPES-KOH, pH 7.5, 10% sucrose (w/v), 0.1%

CHAPS (w/v) ,10 mM DTT, 0.1 mg/ml ovalbumin) 4) Enzyme solution: reconstitute Caspase-7 in buffer

Instrument: Fluoroskan Ascent (Labsystems) This instrument can be used for both initial rate assay and end point assay

Procedure a) Initial rate assay for 30 min at lex = 390 nm, lem = 460 nm b) End-point (30 min) assay at 5 different substrate

concentrations at lex = 355 nm or 380 nm, lem = 460 nm 1) Set a fluorescence spectrophotometer at lex =

390 nm ( or 380 nm, 355 nm), lem = 460 nm. Relative fluorescence is determined with 10-6 M of AMC at each condition

2) Substrate: Dilute the stock solution with the buffer (×10, ×20, ×40, ×80, ×160)

3) Caspase-7: Dissolve in buffer 4) Pipette 160 μl of buffer and 20 μl of substrate

solutions (1, 1/2, 1/4, 1/8, 1/16 mM) in each well 5) Incubate in the fluorescence spectrophotometer

for 3-4 min for temperature equilibration 6) Take the multiplate out and add 20 μl of enzyme

solution to each well 7) Mount the plate in the fluorescence spectrophotometer 8) Calculate the amount of released AMC

Results

Reaction Time

Substrate conc. (µM)

0 min

30 min

50

0

250

0 20 40 60 80 100 120

Fluo

resc

ence

(Em

460

nm

)

0

1000

1500

2000

0

3000

4000

3500

b2) End-point assay(Ex 355 nm)

XXX XX

Reaction Time (min)

Substrate conc. ( M)

X100

50

25

12.5

6.25

100

50

0

150

200

300

250

0 5 10 15 20 25 30 35

Flu

ores

cenc

e (E

m 4

60 n

m)

µ

a) Initial rate assay(Ex 390 nm)

Reaction Time

Substrate conc. (µM)

0 min

30 min

100

50

0

150

250

200

0 20 40 60 80 100 120

Flu

ores

cenc

e (E

m 4

60 n

m)

b1) End-point assay(Ex 380 nm)


Order Hotline 1-800-777-4779 502-266-8787 149

ENZYME INHIBITO

RS AND SUBSTRATES

Flu

ores

cenc

e

Wavelength (nm)

Fig. Fluorescence Spectra of MOCAc-Pro-Leu-Gly-OH

300 350 400 450

Ex SpectrumEm=393 nm

Em SpectrumEx=328 nm

Enzyme

100

50

0

60 sec

dF

Amount (pmol) of the reference compound released/min

=

= 3 X dF pmol/min

100 pmol X dF % X 3 ml1 ml X 100 % X 1 min

Time

Ref

eren

ce C

ompo

und

100

nM =

100

pm

ol/m

l

Reagents 1) Substrate stock solution: Code MOC-3163-v in DMSO at 2 • 10-4 M 2) MOCAc-Pro-Leu-Gly (reference compound) stock solution: Code MOC-3164-s in 10 ml of DMSO (2 • 10-5 M) 3) Buffer: 0.1 M-Tris • HCl, pH 7.5 containing 0.1 M NaCl, 10 mM CaCl2 and 0.05% Brij-35 4) Enzyme solution

Procedure Choose the proper conditions for the measurement, such as substrate concentration and sensitivity setting, depending on the purpose of the experiment and the instrument available. Described here is one of the recommended procedures for the fluorometric method (initial-rate method).

1) Set a fluorescence spectrophotometer at λex = 328 nm and λem = 393 nm at 25 °C (1.0 Relative fluorescence unit at 10-7 M of the reference compound) 2) Pipette 2900 µl of buffer and 50 µl of substrate stock solution into the cuvette 3) Incubate in the fluorescence spectrophotometer for 3-4 min (for temperature equilibration) 4) Add 50 µl of enzyme solution 5) Record the increase of the fluorescence intensity for 3-4 min 6) Calculate the amount of reference compound released using the following equation

Assay Method Using MOCAc/Dnp type Fluorescence-Quenching Substrates(Example using MOC-3163-v MOCAc-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2)

Principle The highly fluorescent (7-methoxycoumarin-4-yl)acetyl (MOCAc) group in the substrate such as Code MOC-3163-v is efficiently quenched by the 2,4-dinitrophenyl (Dnp) group. When metalloenzyme cleaves to the Gly-Leu bond, the fluorescence at λex = 328 nm and λem = 393 nm increases 190-fold.1

1) C.G. Knight, F. Willenbrock, and G. Murphy, FEBS Lett., 296, 263 (1992).

PEPT

IDES

INTE

RNAT

IONA

LEN

ZYM

E IN

HIBI

TORS

AND

SUB

STRA

TES

PEPT

IDES

INTE

RNAT

IONA

L

150 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LEN

ZYM

E IN

HIBI

TORS

AND

SUB

STRA

TES

Enzyme

100

50

0

60 sec

dF

Amount (pmol) of the cleaved substrate/min

=

= 2 X dF pmol/min

1000 pmol X dF % X 0.2 ml1 ml X 100 % X 1 min

Time

Ref

eren

ce C

ompo

und

1 µM

= 1

nm

ol/m

lR

elat

ive

Fluo

resc

ence

(%)

1) D.M. Bickett, M.D. Green, J. Berman, M. Dezube, A.S. Howe, P.J. Brown, J.T. Roth, and G.M. McGeehan, Anal. Biochem., 212, 58 (1993). 2) S. Tanskul, K. Oda, H. Oyama, N. Noparatnaraporn, M. Tsunemi, and K. Takada, Biochem. Biophys. Res. Commun., 309, 547 (2003).

Reagents1) Substrate stock solution: 100 μM-10 μM in an appropriate solvent2) Reference compounds stock solution: a 1:1 mixture of two solutions of Code STD-3720-v and

STD-3721-v, each of which is reconstituted by dissolving peptides in 0.5 ml of DMSO at the concentration of 2 mM (1 mM, each reference compound)

3) Enzyme solution: an enzyme of interest in an appropriate buffer4) BufferProcedure Choose the proper conditions for the measurement, such as substrate concentration and sensitivity setting, depending on the purpose of the experiment and the instrument available. Described here is one of the recommended procedures for the fluorometric method (initial-rate method).

1) Set a fluorescence spectrometer at λex = 340 nm and λem = 440 nm (1.0 Relative fluorescence unit at 1 µM of the reference compound) 2) Pipette 160 µl of buffer and 2-20 µl of substrate solution in well for final concentration of 1 µM. 3) Incubate in the fluorescence spectrophotometer for 3-4 min for temperature equilibration 4) Add 20 µl of enzyme solution prepared at an appropriate concentration 5) Record the increase of the fluorescence intensity 6) Calculate the amount of the cleaved substrate using the following equation

Assay Method Using Nma/Dnp type Fluorescence-Quenching SubstratesPrincipleThe highly fluorescent 2-(N-methylamino)benzoyl (Nma) group in the substrates such as Code SFQ-3217-v and SFR-3224-v is efficiently quenched by the 2,4-dinitrophenyl (Dnp) group. When an enzyme of interest cleaves any peptide bond between Nma- and Dnp-containing amino acid residues in the substrate, the fluorescence at λex = 340 nm and λem = 440 nm increases in proportion to the release of the Nma fluorophore from the internal Dnp quencher.1,2

Flu

ores

cenc

e

Wavelength (nm)

Fig. Fluorescence Spectra of a 1:1 mixture of D-A2pr(Nma)-Gly and Ala-Phe-Pro-Lys(Dnp)-D-Arg-D-Arg

300 350 400 450 500

Ex SpectrumEm=440 nm

Em SpectrumEx=340 nm


Order Hotline 1-800-777-4779 502-266-8787 151

ENZYME INHIBITO

RS AND SUBSTRATES

Amount (mmol) of pNA released/min = 1 mmol X dA X 3 ml 1 ml X 9.992 x 1 min

= 0.32 X dA mmol/minEnzyme dA

60 secpNA

1/992

0 M=0

.101 m

mol/m

l

Time0

0.5

1.0OD 405 nm

Assay Method Using Peptidyl-pNA SubstratesPrinciple A protease with limited specificity hydrolyzes a peptidyl-pNA substrate, releasing p-nitroaniline (pNA) as follows:

Peptidyl-pNA pNA

Fig. UV-Aborption Spectra

5

10

15

300 400 500Wavelength (nm)

405 nm

e X 103

Peptidyl-N- -NO2 Peptide + H2N - - NO2

Peptidyl-pNA pNA

H

The initial rate of increase in the pNA concentration can be monitored photometrically at 405 nm.

Reagents 1) Substrate stock solution: 10 mM (DMSO or distilled water) 2) Buffer 3) Enzyme solution

Procedure Choose the proper conditions for the measurement, such as substrate concentration and sensitivity setting, depending on the purpose of the experiment and the instrument available. Described here is one of the recommended procedures for the photometric method (initial-rate method).

1) Set a spectrophotometer at λ= 405 nm at 25˚ C (ε405 nm=9920)* 2) Pipette 2940 µl of buffer and 30 µl of substrate stock solution into the cuvette 3) Incubate in the spectrophotometer for 3-4 min (for temperature equilibration) 4) Add 30 µl of enzyme solution 5) Record the increase of the absorption intensity for 3-4 min 6) Calculate the amount of pNA released using the following equation

*R. Lottenberg, U. Christensen, C.M. Jackson, and P.L. Coleman, In, Proteolytic Enzymes Part C, Methods in Enzymolology, Vol. 80, (L. Lorand, ed.) Academic Press, New York, 1981, pp. 341-361.

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

152 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

152 Order Hotline 1-800-777-4779 502-266-8787

Enzyme Inhibitors

AminopeptidaseActinonin

3-[[1-[[2-(hydroxymethyl)-1-pyrrolidinyl]-carbonyl]-2-methylpropyl]-carbamoyl]-octanohydroxamic acid (M.W. 385.51) C19H35N3O5 [13434-13-4] Synthetic Product Inhibitor for Aminopeptidase M and Leucyl Aminopeptidase

IAC-4157-PI-20 °C

25 mg100 mg

CH3

O NHCH3

CH3 O

N

OH

O

NH

OH

IAC-4157-PI

Amastatin[(2S,3R)-3-Amino-2-hydroxy-5-methylhexanoyl]-l-valyl-l-valyl-l-aspartic acid(M.W. 474.55) C21H38N4O8 [67655-94-1] Synthetic Product

IAM-4095-v-20 °C

0.5 mg vial

O

NH

NH

NH

O

OH O

NH2

O

OH

O

OH

4095-v

Amastatin (Bulk)[(2S,3R)-3-Amino-2-hydroxy-5-methylhexanoyl]-l-valyl-l-valyl-l-aspartic acid(M.W. 474.55) C21H38N4O8 Synthetic Product Inhibitor for Aminopeptidase A/PS and Leucyl Aminopeptidase

IAM-4095-20 °C

25 mg

Arphamenine A(Sulfate Form)

IAR-4148-v-20 °C

0.5 mg vial4148

NH

NH2NH

NH2

O

O

OH(2R,5S)-5-Amino-8-guanidino-4-oxo-2-phenylmethyloctanoic acid (M.W. 320.39) C16H24N4O3 [96551-81-4] Microbial Product

H. Umezawa, T. Aoyagi, S. Ohuchi, A. Okuyama, H. Suda, T. Takita, M. Hamada, and T. Takeuchi, J. Antibiotics, 36, 1572 (1983). (Original with IC50) S. Ohuchi, H. Suda, H. Naganawa, T. Takita, T. Aoyagi, H. Umezawa, H. Nakamura, and Y. Iitaka, J. Antibiotics, 36, 1576 (1983). (Original; Chem. Structure) • This compound is distributed through Peptide Institute, Inc. under the technical and scientific advices of the Microbial Chemistry Research Foundation.

Arphamenine B(Sulfate Form)(2R, 5S)-5-Amino-8-Guanidino-4-Oxo-2-p-hydroxyphenylmethyloctanoic Acid (M.W. 336.39) C16H24N4O4 [103900-19-2] Microbial Product

IAR-4149-v-20 °C

0.5 mg vial

4149-v

NH

NH2NH

NH2

O

O

OH

OH

Arphamenine B (Bulk)(2R, 5S)-5-Amino-8-Guanidino-4-Oxo-2-p-hydroxyphenylmethyloctanoic Acid • hemisulfate monohydrate

IAR-4149-20 °C

25 mg100 mg

(M.W. 336.39 • 49.04 • 18.02) C16H24N4O4 • ½H2SO4 • H2O [144110-38-3] Microbial Product Inhibitor for Aminopeptidase B

H. Umezawa, T. Aoyagi, S. Ohuchi, A. Okuyama, H. Suda, T. Takita, M. Hamada, and T. Takeuchi, J. Antibiotics, 36, 1572, (1983). (Original with IC50) S. Ohuchi, H. Suda, H. Naganawa, T. Takita, T. Aoyagi, H. Umezawa, H. Nakamura, and Y. Iitaka, J. Antibiotics, 36, 1576 (1983). (Original; Chem. Structure) • This compound is distributed through Peptide Institute, Inc. under the technical and scientific advices of the Microbial Chemistry Research Foundation.


NAL

Order Hotline 1-800-777-4779 502-266-8787 153

ENZYME INHIBITO

RS AND SUBSTRATES

Ebelactone A (Bulk)3,11-Dihydroxy-2,4,6,8,10,12-hexamethyl- 9-oxo-(E)-6-tetra-decen-3-olide (M.W. 338.48) C20H34O4 [76808-16-7] Microbial Product Inhibitor for Esterase, Lipase, and N-Formylmethionine Aminopeptidase

IEB-4155-20 °C

25 mg

4155

OO O OH

H. Umezawa, T. Aoyagi, K. Uotani, M. Hamada, T. Takeuchi, and S. Takahashi, J. Antibiotics, 33, 1594 (1980). K. Uotani, H. Naganawa, S. Kondo, T. Aoyagi, and H. Umezawa, J. Antibiotics, 35, 1495 (1982). K. Uotani, H. Naganawa, T. Aoyagi, and H. Umezawa, J. Antibiotics., 35, 1670 (1982). • This compound is distributed exclusively through Peptide Institute, Inc. under the license of the Microbial Chemistry Research Foundation.

Leuhistin(2R,3S)-3-Amino-2-hydroxy-2-(1H-imidazol-4-ylmethyl)-5-methylhexanoic acid(M.W. 241.29) C11H19N3O3 [129085-76-3] Microbial Product Inhibitor for Aminopeptidase M

ILH-4249-v-20 °C

0.5 mg vial

4249-v

NH

N

NH2OH OH

O

T. Aoyagi, S. Yoshida, N. Matsuda, T. Ikeda, N. Hamada, and T. Takeuchi, J. Antibiotics, 44, 573 (1991). (Original; IC50) S. Yoshida, H. Nagasawa, T. Aoyagi, T. Takeuchi, Y. Takeuchi, Y. Kodama, J. Antibiotics, 44, 579 (1991). (Original; Chem. Structure) S. Yoshida, T. Aoyagi, and T. Takeuchi, J. Antibiotics, 44, 683 (1991). (Original; Biosynthesis) • This compound is distributed exclusively through Peptide Institute, Inc. under the license of the Microbial Chemistry Research Foundation.

Phebestin (2S,3R)-3-Amino-2-hydroxy-4-phenylbutanoyl-l-valyl-l-phenylalanine (M.W. 441.53) C24H31N3O5 Synthetic Product Inhibitor for Aminopeptidase N

IPH-4342-v-20 °C

5 mg vial

4342-v

NH2

OHNH

O

O

NH

O

OH

M. Nagai, F. Kojima, H. Naganawa, M. Hamada, T. Aoyagi, and T. Takeuchi, J. Antibiotics, 50, 82 (1997). (Original) • This compound is distributed exclusively through Peptide Institute, Inc. under the license of the Microbial Chemistry Research Foundation.

Ubenimex (Bestatin) (Bulk)[(2S,3R)-3-Amino-2-hydroxy-4-Phenyl-Butanoyl]-l-Leu (M.W. 308.38) C16H24N2O4 [58970-76-6]H. Umezawa, T. Aoyagi, H. Suda, M. Hamada, and T. Takeuchi, J. Antibiotics, 29, 97 (1976).

IBS-4093-PI-20 °C

25 mg100 mg

O

NH

CH3

CH3

COOHNH

OH

IBS-4093-PI

Angiotensin I Converting Enzyme InhibitorsBradykinin-Potentiator B

Pyr-Gly-Leu-Pro-Pro-Arg-Pro-Lys-lle-Pro-Pro (M.W. 1182.4) C56H91N15O13 [30892-86-5] Synthetic Product

IAB-4009-v-20 °C

0.5 mg vial

Bradykinin-Potentiator B (Bulk)Pyr-Gly-Leu-Pro-Pro-Arg-Pro-Lys-Ile-Pro-Pro • AcOH • 4H2O (M.W. 1182.4 • 60.05 • 72.06) C56H91N15O13 • CH3COOH • 4H2O Synthetic Product

IAB-4009-20 °C

25 mg

Inhibitor for Peptidyl-Dipeptidase A, Kininase II, and ACE (Angiotensin I Converting Enzyme)H. Kato and T. Sazuki, Biochemistry, 10, 972 (1971). (Original)

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

154 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYBradykinin-Potentiator C

Pyr-Gly-Leu-Pro-Pro-Gly-Pro-Pro-Ile-Pro-Pro (M.W. 1052.2) C51H77N11O13 [30953-20-9] Synthetic Product

IAC-4010-v-20 °C

0.5 mg vial

Bradykinin-Potentiator C (Bulk)Pyr-Gly-Leu-Pro-Pro-Gly-Pro-Pro-Ile-Pro-Pro • 3H2O (M.W. 1052.2 • 54.05) C51H77N11O13 • 3H2O Synthetic Product

IAC-4010-20 °C

25 mg

Inhibitor for Peptidyl-Dipeptidase A, Kininase II, and ACE (Angiotensin I Converting Enzyme)H. Kato and T. Sazuki, Biochemistry, 10, 972, (1971). (Original)

Cpp-AAF-pAbN-[(RS)-1-Carboxy-3-phenyl-propyl]-Ala-Ala-Phe-4-Abz-OH (M.W. 89.67) C32H37N4O7 Inhibitor of ACEM.Orlowski, et al., Biochemistry, 27, 597 (1988)D.T.O.Martins, et al., Br. J. Pharmacol., 103, 1851 (1991)C.H.Williams, et al.., Biochem. J., 294, 681 (1993)R.Yamin, et al., J. Biol. Chem., 274, 18777 (1999)

IAP-3754-PI-20 °C

1 mg5 mg

Des-Pro2-BradykininArg-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 963.09) C45H66N14O10 [80943-05-1] Synthetic Product

IBK-4097-v-20 °C

0.5 mg vial

Des-Pro2-Bradykinin (Bulk)Arg-Pro-Gly-Phe-Ser-Pro-Phe-Arg • 2AcOH • 3H2O(M.W. 963.09 • 120.10 • 54.05) C45H66N14O10 • 2CH3COOH • 3H2O Synthetic Product

IBK-4097-20 °C

25 mg

Inhibitor for Peptidyl-Dipeptidase A, Kininase II, and ACE (Angiotensin I Converting Enzyme)M. Naruse, S. Tamanami, K. Shuto, S. Sakakibara, and T. Kimura, Chem. Pharm. Bull., 29, 3369 (1981). (Original)

Foroxymithine(3S,6S)-3-(3-{N-[N-(Na-Acetyl-Nd-Formyl-Nd-hydroxy-l-Ornithyl)-l-Seryl]-N-(Hydroxy)Amino}Propyl)-6-[3-(N-Formyl-N-Hydroxyamino)Propyl]-2,5-Piperazinedione (M.W. 575.57) C22H37N7O11 [100157-28-6] Microbial Product

IFR-4190-v-20 °C

0.5 mg vial

Foroxymithine (Bulk)(3S,6S)-3-(3-{N-[N-(N a-Acetyl-N d-Formyl-N d-hydroxy-l-Ornithyl)-l-Seryl]-N-(Hydroxy)Amino}Propyl)-6-[3-(N-Formyl-N-Hydroxyamino)Propyl]-2,5-Piperazinedione (M.W. 575.57) C22H37N7O11 [100157-28-6] Microbial ProductInhibitor for ACE (Angiotensin I Converting Enzyme)H. Umezawa, T. Aoyagi, K. Ogawa, T. Obata, H. Iinuma, H. Naganawa, M. Hamada, and T. Takeuchi, J. Antibiotics, 38, 1813 (1985). (Original; Chem. Structure with IC50)

IFR-4190-20 °C

25 mg4190-v

OH

O

NH

O

NH

O

N

N

H O

OH

OH

NH

O

O

NH

N

O H

OH

NEW!


NAL

Order Hotline 1-800-777-4779 502-266-8787 155

ENZYME INHIBITO

RS AND SUBSTRATES

d-Aspartyl Endopeptidase InhibitorBz-Arg-His-d-Asp-CH2Cl

(Trifluoroacetate Form)[Bz-RHd-CMK](Benzoyl-l-arginyl-l-histidyl-d-aspart-1-yl) chloromethane (M.W. 563.01) C24H31N8O6Cl Synthetic Product Selective Inhibitor for D-Aspartyl EndopeptidaseT. Kinouchi, S. Ishiura, Y. Mabuchi, Y. Urakami-Manaka, H. Nishio, Y. Nishiuchi, M. Tsunemi, K. Takada, M. Watanabe, M. Ikeda, H. Matsui, S. Tomioka, H. Kawahara, T. Hamamoto, K. Suzuki, and Y. Kagawa, Biochem. Biophys. Res. Commun., 314, 730 (2004). • This compound is produced by Peptide Institute, Inc. under the license of Japan Science and Technology Agency.

ICL-3223-v-20 °C

5 mg vial

NHN

NH

O

NH

NH NH2

NH

ONH

O

OH

O

OCI

3223-v

Bestatin See Code IBS-4093-PI Ubenimex on page 153.BQ-123, BQ-610, and BQ-788 See pages 166-167 .CA-074 See Code IEC-4322-v on page 160.CA-074 Me See Code IEC-4323-v on page 160.

Calpain InhibitorsAc-Leu-Leu-Nle-H (aldehyde)

ALLN, MG 101Acetyl-l-leucyl-l-leucyl-l-norleucinal (M.W. 383.54) C20H37N3O4 Inhibitor for Calpain I and Proteasome

IAL-3671-PI-20 °C

5 mg

O

NH

O

NH

O

NH

O

H

3671-PI

T. Sasaki, M. Kishi, M. Saito, T. Tanaka, N. Higuchi, E. Kominami, N. Katunuma, and T. Murachi, J. Enzyme Inhib., 3, 195 (1990).

Ac-Leu-Leu-Met-H (aldehyde)ALLMAcetyl-l-leucyl-l-leucyl-l-methioninal (M.W. 401.57) C19H35N3O4S Inhibitor for Calpain II and Proteasome

T. Sasaki, M. Kishi, M. Saito, T. Tanaka, N. Higuchi, E. Kominami, N. Katunuma, and T. Murachi, J. Enzyme Inhib., 3, 195 (1990).

IAL-3678-PI-20 °C

5 mg

O

NH

O

NH

O

NH

S

H

O

3678-PI

E-64-c and E-64-d See page 161. .

Z-Leu-Leu-H (aldehyde)Benzyloxycarbonyl-l-leucyl-l-leucinal(M.W. 362.46) C20H30N2O4 Synthetic Product Inhibitor for Calpain*

IZL-3178-v-20 °C

5 mg vial

3178-v

O

O

NH

O

NH

O

H

Y. Saito, S. Tsubuki, H. Ito, and S. Kawashima, Neurosci. Lett., 120, 1 (1990). S. Tsubuki, Y. Saito, M. Tomioka, H. Ito, and S. Kawashima, J. Biochem., 119, 572 (1996). *This compound does not inhibit Proteasome at the level of 10-6 M concentration.

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

156 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTY

Caspase InhibitorsAc-Asp-Asn-Leu-Asp-H (aldehyde)

Acetyl-l-aspartyl-l-asparaginyl-l-leucyl-l-aspart-1-al (M.W. 501.49) C20H31N5O10 Synthetic Product Selective Inhibitor for Caspase-3 Designed by in silico Screening System

ICA-3221-v-20 °C

5 mg vial

O

NH

O

OH

O

NH

O

NH

O

O

NH

O

OHH

O

NH2

3221-v

A. Yoshimori, R. Takasawa, and S. Tanuma, BMC Pharmacol., 4, 7 (2004). A. Yoshimori, R. Takasawa, and S. Tanuma, Bio. Pharm. Bull., 27, 968 (2004). • This compound is produced by Peptide Institute, Inc. under the license of the Institute for Theoretical Medicine, Inc.

Ac-Asp-Gln-Thr-Asp-H (aldehyde)Acetyl-l-aspartyl-l-glutaminyl-l-threonyl-l-aspart-1-al (M.W. 503.46) C19H29N5O11 Synthetic Product Inhibitor for Caspase-7/3 (Deduced from the Cleavage Site of Focal Adhesion Kinase and Gelsolin)

ICA-3194-v-20 °C

5 mg vial

NH

OH

O

O

HO

O

NH

O

O

NHOH O

NH

NH2O

OH

3194-v

L.-P. Wen, J.A. Fahrni, S. Troie, J.-L. Guan, K. Orth, and G.D. Rosen, J. Biol. Chem., 272, 26056 (1997). S. Kothakota, T. Azuma, C. Reinhard, A. Klippel, J. Tang, K. Chu, T.J. McGarry, M.W. Kirschner, K. Koths, D.J. Kwiatkowski, and L.T. Williams, Science, 278, 294 (1997).

Ac-Asp-Glu-Val-Asp-H (aldehyde)Acetyl-l-aspartyl-l-glutamyl-l-valyl-l-aspart-1-al (M.W. 502.47) C20H30N4O11 [184179-08-6] Synthetic Product Inhibitor for Caspase-3/7/8D.W. Nicholson, A. Ali, N.A. Thornberry, J.P. Vaillancourt, C.K. Ding, M. Gallant, Y. Gareau, P.R. Griffin, M. Labelle, Y.A. Lazebnik, N.A. Munday, S.M. Raju, M.E. Smulson, T.-T. Yamin, V.L. Yu, and D.K. Miller, Nature, 376, 37 (1995).

IAP-3172-v-20 °C

5 mg vial

NH

OH

O

O

HO

NH

O

NH

O

OH

O

NH

O

OHO

3172-v

M. Enari, R.V. Talanian, W.W. Wong, and S. Nagata, Nature, 380, 723 (1996). N.A. Thornberry, T.A. Rano, E.P. Peterson, D.M. Rasper, T. Timkey, M. Garcia-Calvo, V.M. Houtzager, P.A. Nordstrom, S. Roy, J.P. Vaillancourt, K.T. Chapman, and D.W. Nicholson, J. Biol. Chem., 272, 17907 (1997).

Ac-Asp-Met-Gln-Asp-H (aldehyde)Acetyl-l-aspartyl-l-methionyl-l-glutaminyl-l-aspart-1-al (M.W. 533.55) C20H31N5O10S [259199-63-8] Synthetic Product Inhibitor for Caspase-3A. Takahashi, H. Hirata, S. Yonehara, Y. Imai, K.-K. Lee, R.W. Moyer, P.C. Turner, P.W. Mesner, T. Okazaki, H. Sawai, S. Kishi, K. Yamamoto, M. Okuma, and M. Sasada, Oncogene, 14, 2741 (1997).

ICA-3192-v-20 °C

5 mg vial

3192-v

NH

OH

O

O

HO

NH

O

NH

O

OH

O

NH

O

S

O NH2

H. Hirata, A. Takahashi, S. Kobayashi, S. Yonehara, H. Sawai, T. Okazaki, K. Yamamoto, and M. Sasada, J. Exp. Med., 187, 587 (1998).


NAL

Order Hotline 1-800-777-4779 502-266-8787 157

ENZYME INHIBITO

RS AND SUBSTRATES

Ac-Ile-Glu-Thr-Asp-H (aldehyde)Acetyl-l-isoleucyl-l-glutamyl-l-threonyl-l-aspart-1-al (M.W. 502.52) C21H34N4O10 [191338-86-0] Synthetic Product Inhibitor for Caspase-8/6 and Granzyme B (Deduced from the Cleavage Site of Procaspase-3)Z. Han, E.A. Hendrickson, T. A. Bremner, and J.H. Wyche, J. Biol. Chem., 272, 13432 (1997). M. Garcia-Calvo, E.P. Peterson, B. Leiting, R. Ruel, D.W. Nicholson, and N.A. Thornberry, J. Biol. Chem., 273, 32608 (1998).

ICA-3196-v-20 °C

3196-v

NH

OH

O

O

HO

NH

O

NH

O

NH

O

OH

OH

O

5 mg vial

Ac-Leu-Glu-His-Asp-H (aldehyde)(Trifluoroacetate Form) Acetyl-l-leucyl-l-glutamyl-l-histidyl-l-aspart-1-al (M.W. 538.55) C23H34N6O9 Synthetic Product Inhibitor for Caspase-9N.A. Thornberry, T.A. Rano, E.P. Peterson, D.M. Rasper, T. Timkey, M. Garcia-Calvo, V.M. Houtzager, P.A. Nordstrom, S. Roy, J.P. Vaillancourt, K.T. Chapman, and D.W. Nicholson, J. Biol. Chem., 272, 17907 (1997).

ICA-3199-v -20 °C

5 mg vial

NH

OH

O

O

HO

NH

O

NH

O

NH

O

OHO

NHN

3199-v

Ac-Trp-Glu-His-Asp-H (aldehyde)Acetyl-l-tryptophyl-l-glutamyl-l-histidyl-l-aspart-1-al (M.W. 611.60) C28H33N7O9 [189275-71-6] Synthetic Product Inhibitor for Caspase-1T.A. Rano, T. Timkey, E.P. Peterson, J. Rotonda, D.W. Nicholson, J.W. Becker, K.T. Chapman, and N.A. Thornberry, Chem. Biol., 4, 149 (1997). M. Garcia-Calvo, E.P. Peterson, B. Leiting, R. Ruel, D.W. Nicholson, and N.A. Thornberry, J. Biol. Chem., 273, 32608 (1998).

ICA-3187-v-20 °C

5 mg vial

NH

NH

OH

O

O

HO

NH

O

NH

O

NH

O

OHO

NHN

3187-v

Ac-Tyr-Val-Ala-Asp-CH2Cl(Acetyl-l-tyrosyl-l-valyl-l-alanyl-l-aspart-1-yl)chloromethane (M.W. 540.99) C24H33N4O8Cl [178603-78-6] Synthetic Product Inhibitor for CaspasesY.A. Lazebnik, S.H. Kaufmann, S. Desnoyers, G.G. Poirier, and W.C. Earnshaw, Nature, 371, 346 (1994). M. Enari, H. Hug, and S. Nagata, Nature, 375, 78 (1995).

ICL-3180-v -20 °C

5 mg vial

3180-v

O

NH

NH

ONH

O

OH

NH

O

O

OH

CI

O

C.E. Milligan, D. Prevette, H. Yaginuma, S. Homma, C. Cardwell, L.C. Fritz, K.J. Tomaselli, R.W. Oppenheim, and L.M. Schwartz, Neuron, 15, 385 (1995). E. Fujita, T. Mukasa, T. Tsukahara, K. Arahata, S. Omura, and T. Momoi, Biochem. Biophys. Res. Commun., 224, 74 (1996).

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

158 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYAc-Tyr-Val-Ala-Asp-H (aldehyde)

Acetyl-l-tyrosyl-l-valyl-l-alanyl-l-aspart-1-al (M.W. 492.52) C23H32N4O8 [143313-51-3] Synthetic Product Inhibitor for Caspase-1N.A. Thornberry, H.G. Bull, J.R. Calaycay, K.T. Chapman, A.D. Howard, M.J. Kostura, D.K. Miller, S.M. Molineaux, J.R. Weidner, J. Aunins, K.O. Elliston, J.M. Ayala, F.J. Casano, J. Chin, G.J.-F. Ding, L.A. Egger, E.P. Gaffney, G. Limjuco, O.C. Palyha, S.M. Raju, A.M. Rolando, J.P. Salley,

IAT-3165-v-20 °C

3165-vO

NH

NH

ONH

O

OH

NH

O

O

OH

H

O

5 mg vial

T.-T. Yamin, T.D. Lee, J.E. Shively, M. MacCross, R.A. Mumford, J.A. Schmidt, and M.J. Tocci, Nature, 356, 768 (1992). S.M. Molineaux, F.J. Casano, A.M. Rolando, E.P. Peterson, G. Limjuco, J. Chin, P.R. Griffin, J.R. Calaycay, G.J.-F. Ding, T.-T. Yamin, O.C. Palyha, S. Luell, D. Fletcher, D.K. Miller, A.D. Howard, N.A. Thornberry, and M.J. Kostura, Proc. Natl. Acad. Sci. USA, 90, 1809 (1993). M. Enari, R.V. Talanian, W.W. Wong, and S. Nagata, Nature, 380, 723 (1996). M. Garcia-Calvo, E.P. Peterson, B. Leiting, R. Ruel, D.W. Nicholson, and N.A. Thornberry, J. Biol. Chem., 273, 32608 (1998).

Ac-Tyr-Val-Lys-Asp-H (aldehyde)Acetyl-l-tyrosyl-l-valyl-l-lysyl-l-aspart-1-al (M.W. 549.62) C26H39N5O8 Synthetic Product Inhibitor for Caspase-1, Affinity Ligand for Caspase-1N.A. Thornberry, H.G. Bull, J.R. Calaycay, K.T. Chapman, A.D. Howard, M.J. Kostura, D.K. Miller, S.M. Molineaux, J.R. Weidner, J. Aunins, K.O. Elliston, J.M. Ayala, F.J. Casano, J. Chin, G.J.-F. Ding, L.A. Egger, E.P. Gaffney, G. Limjuco, O.C. Palyha, S.M. Raju, A.M. Rolando,

IAT-3166-v-20 °C

3166-v O

NH

NH

ONH

O

OH

NH

O

O

OH

H

NH2

O

5 mg vial

J.P. Salley, T.-T. Yamin, T.D. Lee, J.E. Shively, M. MacCross, R.A. Mumford, J.A. Schmidt, and M.J. Tocci, Nature, 356, 768 (1992).T.L. Graybill, R.E. Dolle, C.T. Helaszek, R.E. Miller, and M.A. Ator, Int. J. Pept. Protein Res., 44, 173 (1994).

Ac-Val-Asp-Val-Ala-Asp-H (aldehyde)Acetyl-l-valyl-l-aspartyl-l-valyl-l-alanyl-l-aspart-1-al (M.W. 543.57) C23H37N5O10 [194022-51-0] Synthetic Product Inhibitor for Caspase-2R.V. Talanian, C. Quinlan, S. Trautz, M.C. Hackett, J.A. Mankovich, D. Banach, T. Ghayur, K.D. Brady, and W.W. Wong, J. Biol. Chem., 272, 9677 (1997).

IVD-3204-v-20 °C

5 mg vial

3204-v

O

NH

NH

O

NH

NH

NH

O

O

H

O

O

OH

OH

O

O

Ac-Val-Glu-Ile-Asp-H (aldehyde)Acetyl-l-valyl-l-glutamyl-l-isoleucyl-l-aspart-1-al (M.W. 500.54) C22H36N4O9 Synthetic Product Inhibitor for Caspase-6 H. Hirata, A. Takahashi, S. Kobayashi, S. Yonehara, H. Sawai, T. Okazaki, K. Yamamoto, and M. Sasada, J. Exp. Med., 187, 587 (1998).

IVA-3182-v -20 °C

5 mg vial

3182-v

O

NH

NH

O

O

O OH

NH

OH

HO

NH

O

O

Biotinyl-Asp-Glu-Val-Asp-H (aldehyde)Biotinyl-l-aspartyl-l-glutamyl-l-valyl-l-aspart-1-al (M.W. 686.73) C28H42N6O12S [178603-73-1] Synthetic Product Inhibitor for Caspase-3/7/8D.W. Nicholson, A. Ali, N.A. Thornberry, J.P. Vaillancort, C.K. Ding, M. Gallant, Y. Gareau, P.R. Griffin, M. Labelle, Y.A. Lazebnik, N.A. Munday, S.M. Raju, M.E. Smulson,T.-T. Yamin, V.L. Yu, and D.K. Miller, Nature, 376, 37 (1995).

IBA-3173-v -20 °C

1 mg vial

O

NH

NH

S

O

NH

O

OH

O

NH

O OH

O

NH

O

NH

O

OHH

O

3173-v


NAL

Order Hotline 1-800-777-4779 502-266-8787 159

ENZYME INHIBITO

RS AND SUBSTRATES

Z-Asp-CH2-DCB(Benzyloxycarbonyl-l-aspart-1-yl)[(2,6-dichlorobenzoyl)oxy]methane(M.W. 454.26) C20H17NO7Cl2 [153088-73-4] Synthetic Product Inhibitor for Caspases

ICE-3174-v-20 °C

5 mg vial

O NH

O

O

O

O

O

OH

CI

CI

3174-v

R.E. Dolle, D. Hoyer, C.V.C. Prasad, S.J. Schmidt, C.T. Helaszek, R.E. Miller, and M.A. Ator, J. Med. Chem., 37, 563 (1994). T. Mashima, M. Naito, S. Kataoka, H. Kawai, and T. Tsuruo, Biochem. Biophys. Res. Commun., 209, 907 (1995).

Z-Glu-Lys(Biotinyl)-Asp-CH2-DMB[Benzyloxycarbonyl-l-glutamyl-(Ne-biotinyl-l-lysyl)-l-aspart-1-yl]-[(2,6-dimethylbenzoyl)oxy]methane (M.W. 897.00) C43H56N6O13S Synthetic Product Affinity Ligand for Caspases

L.M. Martins, T. Kottke, P.W. Mesner, G.S. Basi, S. Shinha, N. Frigon, Jr., E. Tatar, J.S. Tung, K. Bryant, A. Takahashi, P.A. Svingen, B.J. Madden, D.J. McCormick, W.C. Earnshaw, and S.H. Kaufmann, J. Biol. Chem., 272, 7421 (1997). L.M. Martins, P.W. Mesner, T.J. Kottke, G.S. Basi, S. Sinha, J.S. Tung, P.A. Svingen, B.J. Madden, A. Takahashi, D.J. McCormick, W.C. Earnshaw, and S. H. Kaufmann, Blood, 90, 4283 (1997).

ICA-3189-v -20 °C

1 mg vial

3189-v

O NH

NH

O

O

O OH

NH

O

O

O

OH

O

O

NH

O

S

N

NH

OH

Z-Val-Ala-Asp(OMe)-CH2F[Z-VAD-FMK]{Benzyloxycarbonyl-l-valyl-l-alanyl-[(2S)-2-amino-3-(methoxycarbonyl)propionyl]} fluoromethane (M.W. 467.49) C22H30N3O7F Synthetic Product Inhibitor for Caspases

ICA-3188-v-20 °C

1 mg vial

O NH

O

O

NH

NH

O

O

OF

OCH3

3188-v

E.A. Slee, H. Zhu, S.C. Chow, M. MacFarlane, D.W. Nicholson, and G.M. Cohen, Biochem. J., 315, 21 (1996). H. Zhu, H.O. Fearnhead, and G.M. Cohen, FEBS Lett., 374, 303 (1995).

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

160 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYCathepsin and Thiol Protease InhibitorsAntipain

(Hydrochloride Form)[(S)-1-Carboxy-2-Phenylethyl]- Carbamoyl-l-arginyl-l-valylargininal (M.W. 604.70) C27H44N10O6 [37691-11-5] Microbial Product

IAP-4062-v-20 °C

0.5 mg vial

NH

NH NH2

OH O

NH

O

NH

NH

NH NH2

O

NH

O

NH

O

H

4062-v

Antipain (Bulk)[(S)-1-Carboxy-2-phenylethyl]-carbamoyl-l-arginyl-l-valylargininal • monohydrochloride dihydrate (M.W. 604.70 • 36.46 • 36.03) C27H44N10O6 • HCI • 2H2O Microbial Product Inhibitor for Trypsin, u-PA, Papain, and Cathepsin A/B

IAP-4062-20 °C

25 mg100 mg

H. Suda, T. Aoyagi, M. Hamada, T. Takeuchi, and H. Umezawa, J. Antibiotics, 25, 263 (1972). (Original) S. Umezawa, K. Tatsuta, K. Fujimoto, T. Tsuchiya, H. Umezawa, and H. Naganawa, J. Antibiotics, 25, 267 (1972). (Original; Chem. Structure) J. Chau, J. Biol. Chem., 258, 4434 (1983). (Inhibitory Activity) • This compound is distributed through Peptide Institute, Inc. under the technical and scientific advices of the Microbial

Chemistry Research Foundation.

CA-074[(2 S, 3S)-3-Propylcarbamoyloxirane-2-carbonyl]-l-isoleucyl-l-proline methyl ester(M.W. 383.44) C18H29N3O6 [134448-10-5] Synthetic Product Inhibitor for Cathepsin BM. Murata, S. Miyashita, C. Yokoo, M. Tamai, K. Hanada, K. Hatayama, T. Towatari, T. Nikawa, and N. Katunuma, FEBS Lett., 280, 307 (1991).

IEC-4322-v -20 °C

5 mg vial

ONH

O

O

NH

O

N

OOH

4322-v

(Original; IC50) T. Towatari, T. Nikawa, M. Murata, C. Yokoo, M. Tamai, K. Hanada, and N. Katunuma, FEBS Lett., 280, 311 (1991). (Original; Pharmacol.) T. Inubushi, H. Kakegawa, Y. Kishino, and N. Katunuma, J. Biochem., 116, 282 (1994). (Biochem.)

CA-074 Me[(2 S, 3S)-3-Propylcarbamoyloxirane-2-carbonyl]-l-isoleucyl-l-proline methyl ester (M.W. 397.47) C19H31N3O6 [147859-80-1] Synthetic Product Proinhibitor for Intracellular Cathepsin B Membrane Permeable Analog of CA-074

IEC-4323-v-20 °C

5 mg vial

4323-v

ONH

O

O

NH

O

N

OO

D.J. Buttle, M. Murata, C.G. Knight, and A.J. Barrett, Arch. Biochem. Biophys., 299, 377 (1992). (Original) • This compound is distributed through Peptide Institute, Inc. under the license of Taisho Pharmaceutical Co., Ltd.

E-64[(2 S, 3S)-3-Carboxyoxiran-2-carbonyl]-l-leucine (4-guanidino-butyl)amide (M.W. 357.41) C15H27N5O5 • ½H2O [66701-25-5] Synthetic Product

IES-4096-v-20 °C

0.5 mg vial


NAL

Order Hotline 1-800-777-4779 502-266-8787 161

ENZYME INHIBITO

RS AND SUBSTRATES

E-64 (Bulk)[(2 S, 3S)-3-Carboxyoxiran-2-carbonyl]-l-leucine (4-guanidino-butyl)amide hemihydrate (M.W. 357.41 • 9.01) C15H27N5O5 • ½H2O [66701-25-5] Synthetic Product Inhibitor fof Thiol ProteasesK. Hanada, M. Tamai, M. Yamagishi, S. Ohmura, J. Sawada, and I. Tanaka, Agric. Biol. Chem., 42, 523 (1978). (Original) K. Hanada, M. Tamai, S. Ohmura, J. Sawada, T. Seki, and I. Tanaka, Agric. Biol. Chem., 42, 529 (1978). (Structure & Chem. Synthesis) Y. Shoji-Kasai, M. Senshu, S. Iwashita, and K. Imahori, Proc. Natl. Acad. Sci. USA, 85, 146 (1988). (Pharmacol.)

IES-4096-20 °C

25 mg100 mg

4096-v

OOH

O

O

NH

O

NH

NH

NH

NH2

E-64-c[(2 S, 3S)-3-Carboxyoxirane-2-carbonyl]-l-leucine (3-methyl-butyl)amide (M.W. 314.38) C15H26N2O5 [76684-89-4] Synthetic Product Inhibitor for Thiol Protease (Cathepsin B/H/L and Calpain)

IEC-4320-v-20 °C

5 mg vial

4320-v

OOH

O

O

NH

O

NH

S. Hashida, T. Towatari, E. Kominami, and N. Katunuma, J. Biochem, 88, 1805 (1980). M. Tamai, K. Hanada, T. Adachi, K. Oguma, K. Kashiwagi, S. Omura, and M. Ohzeki, J. Biochem, 90, 255 (1981). A.J. Barrett, A.A. Kembhavi, M.A. Brown, H. Kirschke, C.G. Knight, M. Tamai, and K. Hanada, Biochem. J., 201, 189 (1982). K. Suzuki, J. Biochem., 93, 1305 (1983).

E-64-d[(2 S, 3S)-3-Ethoxycarbonyloxirane-2-carbonyl]-l-leucine (3-methylbutyl)amide (M.W. 342.43) C17H30N2O5 [88321-09-9] Synthetic Product Inhibitor for Thiol Protease (Cathepsin B/H/L and Calpain) Membrane Permeable Analog of E-64-c

IED-4321-v-20 °C

5 mg vial

4321-v

O

O

O

NH

O

NH

O

M. Tamai, K. Matsumoto, S. Omura, I. Koyama, Y. Ozawa, and K. Hanada, J. Pharmacobio-Dyn., 9, 672 (1986). (Original) M. Tamai, C. Yokoo, M. Murata, K. Oguma, K. Sota, E. Sato, and Y. Kanaoka, Chem. Pharm. Bull., 35, 1098 (1987). (Chem. Synthesis & Biochem.)

Leupeptin(Sulfate Form)Acetyl-l-leucyl-l-leucyl-l-argininal (M.W. 426.55) C20H38N6O4 [55123-66-5] Microbial Product

ILP-4041-v-20 °C

0.5 mg vial4041-v

O

NH

O

NH

NH

O

NH

NH HN2

O

H

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

162 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYLeupeptin (Bulk)

Acetyl-l-leucyl-l-leucyl-l-argininal hemisulfate monohydrate (M.W. 426.55 • 49.04 • 18.02) C20H38N6O4 • ½H2O [103476-89-7] Microbial Product Inhibitor for Trypsin, Plasmin, Papain, and Cathepsin B

ILP-4041-20 °C

25 mg100 mg

1 g

S. Kondo, K. Kawamura, J. Iwanaga, M. Hamada, T. Aoyagi, K. Maeda, T. Takeuchi, and H. Umezawa, Chem. Pharm. Bull., 17, 1896 (1969). (Biological Activity) T. Aoyagi, T. Takeuchi, A. Matsuzaki, K. Kawamura, S. Kondo, M. Hamada, K. Maeda, and H. Umezawa, J. Antibiotics, 22, 283 (1969). (Original) T. Aoyagi, S. Miyata, M. Nanbo, F. Kojima, M. Matsuzaki, M. Ishizuka, T. Takeuchi, and H. Umezawa, J. Antibiotics, 22, 558 (1969). (Biological Activity) R.M. McConnell, J.L. York, D. Frizzell, and C. Ezell, J. Med. Chem., 36, 1084 (1993). (Inhibitory Activity) • This compound is distributed through Peptide Institute, Inc.under the technical and scientific advice of the Microbial Chemistry Research Foundation.

N-(4-Biphenylacetyl)-Cys(Me)-d-Arg-Phe-N-Phenylethylamide

(M.W. 735.96) C41H49N7O4SInhibitor for Cathepsin

IEC-3644-PI-20 °C

5 mg

S.F. Chowdhury, J. Sivaraman, J. Wang, G. Devanathan, P. Lachance, H. Qi, R. Ménard, J. Lefebvre, Y. Konishi, M. Cygler, T. Sulea, and E.O. Purisima, J. Med. Chem., 45, (2002).

Pepstatin A Purity: higher than 90% (HPLC)

Isovaleryl-l-valyl-l-valyl[(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl]-l-alanyl[(3S,4S)-4-Amino-3-hydroxy-6- methylheptanoic acid]

IPA-4397-v-20 °C

0.5 mg vial

4397-v

NH

NH

NH

NH

NH

OHO

O

O

OH O

O

OH O

• This compound is distributed through Peptide Institute, Inc. under the technical and scientific advice of the Institute of Microbial Chemistry Research Foundation.

Pepstatin A Purity: higher than 90% (HPLC)

IPA-4397 25 mg

Isovaleryl-l-valyl-l-valyl[(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl]-l-alanyl [(3S,4S)-4-Amino-3-hydroxy-6-methylheptanoic acid](M.W. 685.89) C34H63N5O9 [26305-03-3] Microbial Product Inhibitor for Pepsin, Cathepsin D/E and Renin H. Umezawa, T. Aoyagi, H. Morishima, M. Matsuzaki, M. Hamada, and T. Takeuchi, J. Antibiotics, 23, 259 (1970). (Original) T. Aoyagi, H. Morishima, R. Nishizawa, S. Kunimoto, T. Takeuchi, H. Umezawa, and H. Ikezawa, J. Antibiotics, 25, 689 (1972). (Biological Activity) • This compound is distributed through Peptide Institute, Inc. under the technical and scientific advice of the Institute of Microbial Chemistry Research Foundation.

Z-Leu-Leu-Leu-H (aldehyde) [MG-132]

Benzyloxycarbonyl-l-leucyl-l-leucyl-l-leucinal (M.W. 475.62) C26H41N3O5 [133407-82-6] Synthetic Product Inhibitor for Proteasome and Cathepsin K

IZL-3175-v-20 °C

5 mg vial

O

O

NH

O

NH

O

NHO

H

3175-v

Y. Saito, S. Tsubuki, H. Ito, and S. Kawashima, Neurosci. Lett., 120, 1 (1990). T.J. Jensen, M.A. Loo, S. Pind, D.B. Williams, A.L. Goldberg, and J.R. Riordan, Cell, 83, 129 (1995). B.J. Votta, M.A. Levy, A. Badger, J. Bradbeer, R.A. Dodds, I.E. James, S. Thompson, M.J.Bossard, T. Carr, J.R. Conner, T.A. Tomaszek, L. Szewczuk, F.H. Drake, D.F. Veber, and M. Gowen, J. Bone Miner. Res., 12, 1396 (1997) • This compound is distributed through Peptide Institute, Inc. under the license of Dr. H. Ito.


NAL

Order Hotline 1-800-777-4779 502-266-8787 163

ENZYME INHIBITO

RS AND SUBSTRATES

Chymotrypsin and Chymotrypsin-like InhibitorsAla-Ala-Phe-CH2Cl See Code IAA-3202-v on page 170

Aprotinin (Bulk)Arg-Pro-Asp-Phe-Cys-Leu-Glu-Pro-Pro-Tyr-Thr-Gly-Pro- Cys-Lys-Ala-Arg-Ile-Ile-Arg-Tyr-Phe-Tyr-Asn-Ala-Lys- Ala-Gly-Leu-Cys-Gln-Thr-Phe-Val-Tyr-Gly-Gly-Cys- Arg-Ala-Lys-Arg-Asn-Asn-Phe-Lys-Ser-Ala-Glu- Asp-Cys-Met-Arg-Thr-Cys-Gly-Gly-Ala

IAT-3830-PI-20 °C

25 mg

(Disulfide bonds between Cys5-Cys55, Cys14-Cys38, and Cys30-Cys51) (M.W. 6511.57) C284H432N84O79S7

I. Trautschold, E. Werle and G. Zickgraf-Rudel, Biochem. Pharm., 16, 59 (1967).

Chymostatin*A Mixture of Type A, B, and C

ICY-4063-v-20 °C

0.5 mg vial

[(S)-1-Carboxy-2-phenylethyl]carbamoyl-a-[2-iminohexahydro-4(S)- pyrimidyl]-(S)-glycyl-X-phenylalaninal X: l-leucyl (Type A), l-valyl (Type B), l-isoleucyl (Type C) [9076-44-2] Microbial Product

Chymostatin* (Bulk)A Mixture of Type A, B, and C[(S)-1-Carboxy-2-phenylethyl]carbamoyl-a-[2-iminohexahydro-4(S)-pyrimidyl]-(S)-glycyl-X-phenylalaninal

ICY-4063-20 °C

25 mg100 mg

X: l-leucyl (Type A), l-valyl (Type B), l-isoleucyl (Type C) [9076-44-2] Microbial Product Inhibitor for Chymotrypsin, Chymase, Papain, and Cathepsin B/G

H. Umezawa, T. Aoyagi, H. Morishima, S. Kunimoto, M. Matsuzaki, M. Hamada, and T. Takeuchi, J. Antibiotics, 23, 425 (1970). (Original) K. Tatsuta, N. Mikami, K. Fujimoto, S. Umezawa, H. Umezawa, and T. Aoyagi, J. Antibiotics, 26, 625 (1973). (Chem. Structure) R.L. Stein and A.M. Strimpler, Biochemistry, 26, 2611 (1987). (Inhibitory Activity) L.A. Johnson, K.E. Moon, and M. Eisenberg, Biochim. Biophys. Acta, 953, 269 (1988). (Inhibitory Activity) • This compound is distributed through Peptide Institute, Inc. under the technical and scientific advice of the Microbial Chemistry Research Foundation.

Coagulation Factors Inhibitors See IAP-4062-v and IAP-4062 Antipain on page 160; ILP-4041-v and ILP-4041 Leupeptin on pages 161-162.

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

164 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTY

Collagenase / MMP / Stromelysin Inhibitors .GalardinTM

Peptides International is now offering GalardinTM, an addition to other widely used enzyme inhibitors.1 Galardin or GM6001 is a potent, broad-spectrum matrix metal-loproteinase (MMP) inhibitor and is a member of the hydroxamate class of inhibitors. We are pleased to add galardin to complement our popular line of TAPI MMP inhibi-tors.21. J. Gordon, B.K. Kelly, and G.A. Miller, Nature. 195, 701 (1962).2. K. Darlak, R.B. Miller, M.S. Stack, A.F. Spatola, and R.D. Grey, J. Biol. Chem., 265, 5199 (1990).

GalardinTM GM6001, Ilomastat

N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-l-tryptophan methylamide(M.W. 388.47) C20H28N4O4Inhibitor for Collagenases and MMPsD. Grobelny, I. Poncz, and R.E. Galardy, Biochemistry, 31, 7152 (1992).

INH-3927-PI-20 °C

5 mg

Ac-SIMP-1Ac-S-CH2-(R)-CH(CH2CH(CH3)2)-CO-Phe-Ala-NH2(2R)-S-Acetyl-2-mercaptomethyl-4-methylpentanoyl-l-phenylalanyl-l-alanine amide (M.W. 421.56) C21H31N3O4S (Protected precursor) Collagenase Inhibitor

ISN-3821-PI-20 °C

5 mg

S NH

NH

NH2

O O

O

O

ISN-3821-PI Ac-SIMP-1

• Product produced under license from Research Corporation Technologies

SIMP-1(Free Thiol Form) HS-CH2-(R)-CH(CH2CH(CH3)2)-CO-Phe-Ala-NH2(2R)-2-mercaptomethyl-4-methypentanoyl-l-phenylalanyl-l-alanine amide (M.W. 379.53) C19H29N3O3S Collagenase Inhibitor

ISN-3825-PI-20 °C

5 mg

SH NH

NH

NH2

O

O

O

ISN-3825-PI SIMP-1

• Product produced under license from Research Corporation Technologies

Ac-SIMP-2(Protected Precursor) Ac-S-CH2-(R)-CH(CH2CH(CH3)2)-CO-Nal-Ala-NH2(2R)-S-Acetyl-2-mercaptomethyl-4-methylpentanoyl-l-b-(2-naphthyl)alanyl-l-alanine amide (M.W. 471.62) C25H33N3O4S Collagenase Inhibitor

ISN-3831-PI-20 °C

5 mg

S NH

NH

NH2

O O

O

O

ISN-3831-PI

• Product produced under license from Research Corporation Technologies.

SIMP-2(Free thiol form) HS-CH2-(R)-CH(CH2CH(CH3)2)-CO-Nal-Ala-NH2(2R)-2-mercaptomethyl-4-methylpentanoyl-l-b-(2-naphthyl)alanyl-l-alanine amide (M.W. 429.59) C23H31N3O3S Collagenase Inhibitor

ISN-3835-PI-20 °C

5 mg

SH NH

NH

NH2

O

O

O

ISN-3835-PI SIMP-2

• Product produced under license from Research Corporation Technologies.

NEW!


NAL

Order Hotline 1-800-777-4779 502-266-8787 165

ENZYME INHIBITO

RS AND SUBSTRATES

TAPI-OHONHCOCH2CH(CH2CH(CH3)2)CO-Nal-Ala-NH2 N-(R)-(2-(Hydroxyaminocarbonyl)methyl)-4-methylpentanoyl-l-3-(2'-naphthyl)alanyl-l-alanine amide (M.W. 456.53) C24H32N4O5 Inhibitor for Matrix Metalloproteases (MMP)

INH-3850-PI-20 °C

1 mg5 mg

OHNH

O

O

NH

NH

O

O

NH2

3850

K. Darlak, R.B. Miller, M.S. Stack, A.F. Spatola, and R.D. Grey, J. Biol. Chem., 265, 5199 (1990). A.F. Spatola, K. Darlak, S. Pegoraro, K. Nijhawan, M. Anzolin, L. Lankiewicz, and R.D. Gray, Peptides: Chemistry & Biology, J.A. Smith & J.E. Rivier (Eds.), ESCOM, Leiden, 1992, p. 820. K.M. Mohler, P.R. Sleath, J.N. Fitzner, D.P. Cerretti, M.Alderson, S.S Kerwar, D.S. Torrance, C. Otten-Evans, T. Greenstreet, K. Weerawarna, S.R. Kronheim, M. Petersen, M. Gerhart, C.J. Kozlosky, C.J. March, and R.A. Black, Nature, 370, 218 (1984).

TAPI-1HONHCOCH2CH(CH2CH(CH3)2)CO-Nal-Ala-NHCH2CH2NH2 N-(R)-(2-(Hydroxyaminocarbonyl)methyl)-4-methylpentanoyl-l-3-(2'-naphthyl)alanyl-l-alanine 2-aminoethyl amide (M.W. 499.60) C26H37N5O5 Inhibitor for Matrix Metalloproteases (MMP)

INH-3855-PI-20 °C

1 mg5 mg

OHNH

O

O

NH

NH

O

O

NH

NH2

3855

K. Darlak, R.B. Miller, M.S. Stack, A.F. Spatola, and R.D. Grey, J. Biol. Chem., 265, 5199 (1990). A.F. Spatola, K. Darlak, S. Pegoraro, K. Nijhawan, M. Anzolin, L. Lankiewicz, and R.D. Gray, Peptides: Chemistry & Biology, J.A. Smith & J.E. Rivier (Eds.), ESCOM, Leiden, 1992, p. 820. K.M. Mohler, P.R. Sleath, J.N. Fitzner, D.P. Cerretti, M.Alderson, S.S Kerwar, D.S. Torrance, C. Otten-Evans, T. Greenstreet, K. Weerawarna, S.R. Kronheim, M. Petersen, M. Gerhart, C.J. Kozlosky,C.J. March, and R.A. Black, Nature, 370, 218 (1984).

TAPI-2HONHCOCH2CH(CH2CH(CH3)2)CO-t-butyl-Gly-Ala-NHCH2CH2NH2 N-(R)-(2-(Hydroxyaminocarbonyl)methyl)-4-methylpentanoyl-l-t-butyl-glycyl-l-alanine 2-aminoethyl amide (M.W. 415.53) C19H37N5O5 Inhibitor for Metalloproteases (MMP)

INH-3852-PI-20 °C

1 mg5 mg

OHNH

O

O

NH

NH

O

O

NH

NH2

3852-v

J. Arribas, L. Coodly, P. Vollmer, T.K. Kishimoto, S. Rose-John, and J. Massagué, J. Biol. Chem., 271, 11376 (1996). N.M. Hooper, E.H. Karran, and A.J. Turner, Biochem. J., 321, 265 (1997).

Dipeptidyl Peptidase II (DPP II) InhibitorsH-Dab-Pip

(Trifluoroacetate Form) L-2,4-Diaminobutyrylpiperidinamide(M.W. 185.27) C9H19N3O Inhibitor for Dipeptidyl Peptidase II (DPP II)

IDP-3655-PI-20 °C

5 mg

N

ONH2

NH2

H-Dab-PipIDP-3655-PIDipeptidyl Peptidase II (DPP II) Inhibitor

K. Senten, P. Van der Veken, G. Bal, I. De Meester, A.-M. Lambier, S. Sharpé, B. Bauvois, A. Haemers, and K. Augustyns, Bioorg. Med. Chem. Lett. 12, 2825 (2002).

Diprotin AIle-Pro-Ile (M.W. 341.45) C17H31N3O4 [90614-48-5]

IDP-4132-v-20 °C

0.5 mg vial

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

166 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYDiprotin A (Bulk)

Ile-Pro-Ile • H2O Synthetic Product Inhibitor for Dipeptidyl-Aminopeptidase IV

IDP-4132-20 °C

25 mg100 mg

H. Umezawa, T. Aoyagi, K. Ogawa, H. Naganawa, M. Hamada, and T. Takeuchi, J. Antibiotics, 37, 422 (1984). (Original; IC50 & Chem. Structure) • This compound is distributed exclusively through Peptide Institute, Inc. under the license of the Microbial Chemistry Research Foundation.

E-64 See page 160.

Elastase InhibitorsCl-Ac-(OH)Leu-Ala-Gly-NH2

N-Chloroacetyl-N-hydroxy-l-leucyl-l-alanylglycine amide (M.W. 350.80) C13H23N4O5Cl Synthetic Product

ICL-4146-v-20 °C

0.5 mg vial

Cl-Ac-(OH)Leu-Ala-Gly-NH2 (Bulk)N-Chloroacetyl-N-hydroxy-l-leucyl-l-alanylglycine amideN. Nishino and J.C. Powers, J. Biol. Chem., 255, 3482 (1980). (Original)

ICL-4146-20 °C

25 mg100 mg

4146-v

CIO

NOH O

NH

O

NH

O

NH2

Elafin (Human) Ala-Gln-Glu-Pro-Val-Lys-Gly-Pro-Val-Ser-Thr-Lys-Pro-Gly-Ser-Cys-Pro-Ile-Ile-Leu-Ile-Arg-Cys-Ala-Met-Leu-Asn-Pro-Pro-Asn-Arg-Cys-Leu-Lys-Asp-Thr-Asp-Cys-Pro-Gly-Ile-Lys-Lys-Cys-Cys-Glu-Gly-Ser-Cys-Gly-Met-Ala-Cys-Phe-Val-Pro-Gln

PEL-4243-v-20 °C

20 mg vial

(Disulfide bonds between Cys16-Cys45, Cys23-Cys49, Cys32-Cys44 and Cys38-Cys53) (M.W. 5999.1) C254H416N72O75S10 Synthetic Product Elastase-Specific Inhibitor from Human Skin

O. Wiedow, J.-M. Schröder, H. Gregory, J.A. Young, and E. Christophers, J. Biol. Chem., 265, 14791 (1990). (Original) O. Wiedow, J.-M. Schröder, H. Gregory, J.A. Young, and E. Christophers, J. Biol. Chem., 266, 3356 (1991). (Correction of Sequence) M. Tsunemi, H. Kato, Y. Nishiuchi, S. Kumagaye, and S. Sakakibara, Biochem. Biophys. Res. Commun., 185, 967 (1992). (Chem. Synthesis & Biochem.) M. Tsunemi, Y. Matsuura, S. Sakakibara, and Y. Katsube, Biochemistry, 35, 11570 (1996). (Biochem; Crystal Structure of Elafin-Pancreatic Elastase)

ElastatinalMicrobial Product

IEL-4064-v-20 °C

0.5 mg vial

Elastatinal (Bulk)Microbial ProductInhibitor for Elastase

IEL-4064-20 °C

25 mg100 mg

H. Umezawa, T. Aoyagi, A. Okura, H. Morishima, T. Takeuchi, and Y. Okami, J. Antibiotics, 26, 787 (1973). (Original) • This compound is distributed exclusively through Peptide Institute, Inc. under the license of the Microbial Chemistry Research Foundation.

Endothelin A & B Receptors (Antagonists) BQ-123 Sodium Salt

cyclo (d-Trp-d-Asp-Pro-d-Val-Leu) (M.W. 610.72) C31H42N6O7

PED-3512-PI-20 °C

1 mg5 mg


NAL

Order Hotline 1-800-777-4779 502-266-8787 167

ENZYME INHIBITO

RS AND SUBSTRATES

BQ-610 Sodium SaltHomopiperidinyl-CO-Leu-d-Trp(CHO)-d-Trp-OH (M.W. 656.79) C36H44N6O6

K. Ishikawa, T. Fukami, T. Nagase, T. Mase, T. Hayama, K. Niiyama, K. Fujita, Y. Urakawa, U. Kumagai, T. Fukuroda, M. Ihara, and M. Yano. in C.H. Schneider, and A.N. Eberle (Eds.), Peptides, 1992, ESCOM, Leiden, 1993, p. 685.

PED-3610-PI-20 °C

1 mg 5 mg

N-CO-Leu-D-Trp(CHO)-D-Trp-OH

BQ-788 Sodium SaltN-cis-2,6-Dimethylpiperidinocarbonyl-l-g-Me-Leu-d-Trp(COOMe)-d-Nle (Sodium Salt)(M.W. 663.80) C34H50N5O7NaSoluble: 2 mg in 1 mL H2OT. Fukuroda, T. Fujikawa, S. Ozaki, K. Ishikawa, M. Yano, and M. Nishikibe, Biochem. Biophys Res. Commun., 199, 1461 (1994).

PED-3788-PI-20 °C

1 mg5 mg

N

N

NH

O

O

NH

NH

OONa

OO

O

3788

d-Glucaro-δ-Lactam See Code CAR-24004-v on page 225.

Gingipain InhibitorsKYT-1

(Hydrochloride Form)(3S)-N-[(1S)-5-Amino-1-(N,N-dimethylcarbamoyl)pentyl]-3-[(2S)-6-amino-2-[(benzyloxycarbonyl)amino]hexanoylamino]-6-guanidino-2-oxohexanamide (M.W. 619.76) C29H49N9O6 Synthetic Product Inhibitor for Arg-Gingipain

IRG-4395-v-20 °C

1 mg vial

O NH

ONH

O

ONH

O

NH

NH2 NH

NH2

NH2

N

O

4395-v

T. Kadowaki, A. Baba, N. Abe, R. Takii, M. Hashimoto, T. Tsukuba, S. Okazaki, Y. Suda, T. Asao, and K.Yamamoto,Mol. Pharmacol., 66, 1599 (2004). (Original)

KYT-36(Hydrochloride Form)(2S)-N-[(1S)-1-(4-Aminobutyl)-2-oxo-2-(N-benzylcarbamoyl)ethyl]-N'-(N-methylphenylamino)-2-[(benzyloxycarbonyl)amino]pentane-1,5-diamide (M.W. 630.73) C34H42N6O6 Synthetic Product Inhibitor for Lys-GingipainT. Kadowaki, A. Baba, N. Abe, R. Takii, M. Hashimoto, T. Tsukuba, S. Okazaki, Y. Suda, T. Asao, and K.Yamamoto, Mol. Pharmacol., 66, 1599 (2004). (Original)

IKG-4396-v-20 °C

1 mg vial

O NH

O

O NHN

NH

O

ONH

O

NH2

4396-v

Myr-Ser-Ile-Tyr-Arg-Arg-Gly-Ala-Arg-Arg-Trp-Arg-Lys-Leu See Code PKC-3403-v on page 222.MG-101 See Code IAL-3671-PI Ac-Leu-Leu-Nle-H on page 155.MG-115 See Code IAT-3170-v Z-Leu-Leu-Nva-H (aldehyde) on page 172.MG-132 See Code IZL-3175-v Z-Leu-Leu-Leu-H (aldehyde) on page 162.MMP Inhibitors See Collagenase Inhibitors on page 163-164 and TAPI-O, TAPI-1 and TAPI-2 on page 165..

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

168 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTY

Neutral Endopeptidase InhibitorsPhosphoramidon (Sodium Salt)

N-(a-Rhamnopyranosyloxyhydroxyphosphinyl)-l-leucyl-l-tryptophan (M.W. 543.50) C23H34N3O10P [36357-77-4] Microbial Product

IPO-4082-v-20 °C

0.5 mg vial

4082-v

NH

OH

ONH

ONH

POH

OO

O

OH OH

OH

CH3

Phosphoramidon (Bulk)N-(a-Rhamnopyranosyloxyhydroxyphosphinyl)--l-leucyl-l-tryptophan disodium salt dihydrate (M.W. 541.49 • 45.98 • 36.03) C23H32N3O10P [119942-99-3] Microbial Product

IPO-4082-20 °C

25 mg100 mg

Inhibitor for Thermolysin, Neutral Endopeptidase-24.11 (ANP Degradation Enzyme), and Endothelin converting Enzyme

H. Suda, T. Aoyagi, T. Takeuchi, and H. Umezawa, J. Antibiotics, 26, 621 (1973). (Original) S.L. Stephenson and A.J. Kenny, Biochem. J., 243, 183 (1987). (Pharmacol.) B.P. Roques and A. Beaumont, Trends Pharmacol. Sci., 11, 245 (1990). (Review) Y. Matsumura, K. Hisaki, M. Takaoka, and S. Morimoto, Eur. J. Pharmacol., 185, 103 (1990). (Pharmacol.) • This compound is distributed exclusively through Peptide Institute, Inc. under the license of the Microbial Chemistry Research Foundation.

Nojirimycin Bisulfite See Code CAR-24003-v on page 225Pepsin See Code IPA-4397-v and IPA-4397 on page 162 Pepstatin A See Code IPA-4397-v and IPA-4397 on page 162 PSI See Code IAT-3169-v Z-Ile-Glu(OtBu)-Ala-Leu-H (aldehyde) on page 172.Plasmin See Code ILP-4041 Leupeptin on page 161.

Propyl Endopeptidase InhibitorSUAM-14746

3-({4-[2-(E)-Styrylphenoxy]butanoyl}-L-4-hydroxyprolyl)-thiazolidine(M.W. 466.59) C26H30N2O4S Synthetic Product Inhibitor for Prolyl Endopeptidase

ISU-3214-v -20 °C

5 mg vial

O

N

O

OH

O

N S

3214-v

M.Saito, M. Hashimoto, N. Kawaguchi, H. Shibata, H. Fukami, T. Tanaka, and N. Higuchi, J. Enzyme Inhib., 5, 51 (1991) (Assay Method) • This compound is distributed under license of Suntory Ltd.

Protein Kinase InhibitorLys-Lys-Lys-Leu-Arg-Arg-Gln-Glu-Ala-Phe-Asp-Ala-Tyr[Lys3, Phe10, Try13]-Autocamtide-2-Related Inhibitory Peptide (AIP)

(M.W. 1652.9) C74H121N23O20 Synthetic Product Inhibitor for Calmodulin-Dependent Protein Kinase II

IKK-4374-v-20 °C

0.5 mg vial

A. Ishida and H. Fujisawa, J. Biol. Chem., 270, 2163 (1995). (AIP; Autocamtide-2-Related Inhibitory Peptide) A. Ishida, Y. Shigeri, Y. Tatsu, K. Uegaki, I. Kameshita, S. Okuno, T. Kitani, N. Yumoto, and H. Fujisawa, FEBS Lett., 427, 115 (1998). (Original) • This compound is distributed through Peptide Institute, Inc. under the license of the Agency of Industrial Science & Technology.


NAL

Order Hotline 1-800-777-4779 502-266-8787 169

ENZYME INHIBITO

RS AND SUBSTRATES

Renin See Code IPA-4397-v and IPA-4397 on page 162

Reverse Transcriptase InhibitorDoxorubicin-HCl

(M.W. 579.98) C27H29NO11 • HCl [25316-40-9]Inhibitor of Reverse Transcriptase and RNA Polymerase

IOX-3765-PI-20 °C

1 mg5 mg

β-Secretase InhibitorsLys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe

Sta(Statine): (3S,4S)-4-Amino-3-hydroxy-6-methylheptanoic acid(M.W. 1651.8) C73H118N16O27 Synthetic Product Inhibitor for β-Secretase

IBS-4378-v-20 °C

1 mg vial 4378-v

NH

OOH

S. Sinha, et al., Nature, 402, 537 (1999). (Original)

γ-Secretase Inhibitors(3,5-Difluorophenylacetyl)-Ala-Phg-OBut

(3,5-Difluorophenylacetyl)-l-alanyl-l-2-phenylglycine t-butyl ester (M.W. 432.46) C23H26N2O4F2 Synthetic Product Inhibitor for g-SecretaseH.F. Dovey, V. John, J.P. Anderson, L.Z. Chen, P. de Saint Andrieu, L.Y. Fang, S.B. Freedman, B. Folmer, E. Goldbach, E.J. Holsztynska, K.L. Hu, K.L. Johnson-Wood, S.L. Kennedy, D. Kholodenko, J.E. Knops,

IGS-3219-v-20 °C

5 mg vial

F

F

NH

NH

O

O

O

O

3219-v

L.H. Latimer, M. Lee, Z. Liao, I.M. Lieberburg, R.N. Motter, L.C. Mutter, J. Nietz, K.P. Quinn, K.L. Sacchi, P.A. Seubert, G.M. Shopp, E.D. Thorsett, J.S. Tung, J. Wu, S. Yang, C.T. Yin, D.B. Schenk, P.C. May, L.D. Altstiel, M.H. Bender, L.N. Boggs, T.C. Britton, J.C. Clemens, D.L. Czilli, D.K. Dieckman-McGinty, J.J. Droste, K.S. Fuson, B.D. Gitter, P.A. Hyslop, E.M. Johnstone, W.-Y. Li, S.P. Little, T.E. Mabry, F.D. Miller, B. Ni, J.S. Nissen, W.J. Porter, B.D. Potts, J.K. Reel, D. Stephenson, Y. Su, L.A. Shipley, C.A. Whitesitt, T. Yin, and J.E. Audia, J. Neurochem., 76, 173 (2001). (Original; Functional g-Secretase Inhibitor in Brain) A.Y. Kornilova, C. Das, and M.S. Wolfe, J. Biol. Chem., 278, 16470 (2003). (Comparison of in Cells and Cell-Free Activity)

(3,5-Difluorophenylacetyl)-Ala-Phg-OtBuN-[N-(3,5-Difluorophenacetyl)-l-alanyl)]-l-phenylglycine t-butyl ester (M.W. 432.47) C23H26N2O4F2 Inhibitor for g-Secretase

IGS-3641-PI-20 °C

10 mg

H.F. Dovey, V. John, J.P. Anderson, L.Z. Chen, P. de Saint. Andrieu, L.Y. Fang, S.B. Freedman, B. Folmer, E. Goldbach, E.J. Holsztynska, K.L. Hu, K.L. Johnson-Wood, S.L. Kennedy, D. Kholodenko, J.E. Knops, L.H. Latimer, M. Lee, Z. Liao, I.M. Lieberburg, R.N. Motter, L.C. Mutter, J. Nietz, K.P. Quinn, K.L. Sacchi, P.A. Seubert, G.M. Shopp, E.D. Thorsett, J.S. Tung, J. Wu, S. Yang, C.T. Yin, D.B. Schenk, P.C. May, L.D. Altstiel, M.H. Bender, L.N. Boggs, T.C. Britton, J.C. Clemens, D.L. Czilli, D.K. Dieckman-McGinty, J.J. Droste, K.S. Fuson, B.D. Gitter, P.A. Hyslop, E.M. Johnstone, W-Y. Li, S.P. Little, T.E. Mabry, F.D. Miller, B. Ni, J.S. Nissen, W.J. Porter, B.D. Potts, J.K. Reel, D. Stephenson, Y. Su, L.A. Shipley, C.A. Whitesitt, T. Yin, and J.E. Audia, J. Neurochem., 76, 173 (2001). (Original; Functional g-Secretase Inhibitor in Brain) A.Y. Kornilova, C. Das, and M.S. Wolfe, J. Biol. Chem., 278, 16470 (2003). (Comparison of in Cells and Cell-Free Activity)

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

170 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYL-685,458

[(2R,4R,5S)-2-Benzyl-5-(t-Butyloxycarbonylamino)-4-hydroxy-6-phenylhexanoyl]-l-leucyl-l-phenylalanine amide (M.W. 672.85) C39H52N4O6 Synthetic Product Inhibitor for g-Secretase

IGS-4394-v-20 °C

1 mg vial

NH

O NH

NH

NH2

O OO

OOH

4394-v

Y.-M. Li, M. Xu, M.-T. Lai, Q. Huang, J.L. Castro, J. DiMuzio-Mower, T. Harrison, C. Lellis, A. Nadin, J.G. Neduvelil, R.B. Register, M.K. Sardana, M.S. Shearman, A.L. Smith, X.-P. Shi, K.-C. Yin, J.A. Shafer, and S.J. Gardell, Nature, 405, 689 (2000). (Biochem.; g-Secretase Inhibitor) Y.-M. Li, M.-T. Lai, M. Xu, Q. Huang, J. DiMuzio-Mower, M.K. Sardana, X.-P. Shi, K.-C. Yin, J.A. Shafer, and S.J. Gardell, Proc. Natl. Acad. Sci. USA, 97, 6138 (2000). (Biochem; g-Secretase Inhibitor) M.S. Shearman, D. Beher, E.E. Clarke, H.D. Lewis, T. Harrison, P. Hunt, A. Nadin, A.L. Smith, G. Stevenson, and J.L. Castro, Biochemistry, 39, 8698 (2000). (Biochem; g-Secretase Inhibitor) G. Tian, C.D. Sobotka-Briner, J. Zysk, X. Liu, C. Birr, M.A. Sylvester, P.D. Edwards, C.D. Scott, and B.D. Greenberg, J. Biol. Chem., 277, 31499 (2002). (Biochem; Inhibition Mechanism)

Siastatin B See Code CAR-24002--v on page 225.SIMP Products See Collagenase Inhibitors on page 163-164.

Signal Peptide Peptidase Inhibitor(Z-Leu-Leu-NHCH2)2CO[(Z-LL)2 Ketone]

1,3-Bis[(benzyloxycarbonyl-l-leucyl-l-leucyl)amino]acetone (M.W. 809.00) C43H64N6O9 [313664-40-3] Synthetic Product Inhibitor for Signal Peptide Peptidase

IZL-3218-v-20 °C

5 mg vial

O

O

NH

NH

O

NH

O

O

NH

NH

NH

O

O

O

O

3218-v

A. Weihofen, M.K. Lemberg, H.L. Ploegh, M. Bogyo, and B. Martoglio, J. Biol. Chem., 275, 30951 (2000). (Original) A. Weihofen, K. Binns, M.K. Lemberg, K. Ashman, and B. Martoglio, Science, 296, 2215 (2002). (Signal Peptide Peptidase Inhibitor) A. Weihofen, M.K. Lemberg, E. Friedmann, H. Rueeger, A. Schmitz, P. Paganetti, G. Rovelli, and B. Martoglio, J. Biol. Chem., 278, 16528 (2003). (Signal Peptide Peptidase Inhibitory Activity)

Sodium Potassium ATPase Inhibitor-1 (Porcine) See Code PSP-4216-s on page 116.

Tripeptidyl Peptidase II InhibitorAla-Ala-Phe-CH2Cl

(l-alanyl-l-alanyl-l-phenylalanyl)chloromethane (M.W. 339.82) C16H22N3O3Cl [102129-66-8] Synthetic Product

IAA-3202-v-20 °C

5 mg vial

ONH

CINH

ONH2

O

3202-v

Inhibitor for Tripeptidyl Peptidase II (Component of Giant Protease with Some Proteasome Function), Chymotrypsin, and ChymaseR. Glas, M. Bogyo, J.S. McMaster, M. Gaczynska, and H.L. Ploegh, Nature, 392, 618 (1998). E. Geier, G. Pfeifer, M. Wilm, M. Lucchiari-Hartz, W. Baurmeister, K. Eichmann, and G. Niedermann, Science, 283, 978 (1999). L.A. Johnson, K.E. Moon, and M. Eisenberg, Biochem. Biophys. Acta, 953, 269 (1988)

Trypsin and Trypsin-like Protease Inhibitors See Code IAP-4062 Antipain on page 160, Code IAT-3830-PI Aprotinin on page 163, and Code ILP-4041 Leupeptin on page 161..


NAL

Order Hotline 1-800-777-4779 502-266-8787 171

ENZYME INHIBITO

RS AND SUBSTRATES

Ubiquitin Proteasome System Inhibitors Also see Code IAL-3678-PI Ac-Leu-Leu-Met-(aldehyde) on page 155, Code IAL-3671 Ac-Leu-Leu-Nle-H (aldehyde) [ALLM] on page 155, and Code IZL-3175-v Z-Leu-Leu-Leu-H (aldehyde) [MG-132] (for Proteasome) on page 162.

Epoxomicin(2R)-2-[Acetyl-(N-methyl-l-Isoleucyl)-l-isoleucyl-l-threonyl-l-Leucyl]-2-Methyloxirane(M.W. 554.72 ) C28H50N4O7 [134381-21-8] Synthetic Product Inhibitor for Proteasome

IEP-4381-v-20 °C

0.2 mg vial

4381-v

O

O

NO

NH

O

NH

OH

O

NH

O

L. Meng, R. Mohan, B.H.B. Kwok, M. Elofsson, N. Sin, and C.M. Crews, Proc. Natl. Acad. Sci. USA, 96, 10403 (1999). (Proteasome Inhibitor & Antiinflammatory Activity) N. Sin, K.B. Kim, M. Elofsson, L. Meng, H. Auth, B.H.B. Kwok, and C.M. Crews, Bioorg. Med. Chem. Lett., 9, 2283 (1999). (Proteasome Inhibitor) K.B. Kim, J. Myung, N. Sin, and C.M. Crews, Bioorg. Med. Chem. Lett., 9, 3335 (1999). (Proteasome Inhibitor) M. Groll, K.B. Kim, N. Kairies, R. Huber, and C.M. Crews, J. Am.Chem. Soc., 122, 1237 (2000). (Crystal Structure of Proteasome Complex)T. Aoyagi, T. Wada, H. Iinuma, K. Ogawa, F. Kojima, M. Nagai, H. Kuroda, A. Obayashi, and H. Umezawa, J. Appl. Biochem., 7, 388 (1985). (Pharmacol.) • This compound is distributed exclusively through Peptide Institute, Inc. under the license of the Microbial Chemistry Research Foundation.

LactacystinN-Acetyl-S-{(2R,3S,4R)-3-hydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxo-pyrolidine-2-carbonyl}-l-cysteine (M.W. 376.43) C15H24N2O7S [133343-34-7] Microbial Product Inhibitor for Proteasome

ILC-4368-v-20 °C

0.2 mg vial

4368-v

NH

OH

O

OH O

SNH

O

O OH

S. Omura, T. Fujimoto, K. Otoguro, K. Matsuzaki, R. Moriguchi, H. Tanaka, and Y. Sasaki, J. Antibiotics, 44, 113 (1991). (Original) S. Omura, K. Matsuzaki, T. Fujimoto, K. Kosuge, T. Furuya, S. Fujita, and A. Nakagawa, J. Antibiotics, 44, 117 (1991). (Original; Chem. Structure) G. Fenteany, R.F. Standaert, W.S. Lane, S. Choi, E.J. Corey, and S.L. Schreiber, Science, 268, 726 (1995). (Biochem.; Proteasome Inhibition) S. Imajoh-Ohmi, T. Kawaguchi, S. Sugiyama, K. Tanaka, S. Omura, and H. Kikuchi, Biochem. Biophys. Res. Commun., 217, 1070 (1995). (Biochem.; Apoptotic Effect) • This item is produced by Kyowa Medex Co., Ltd.

Ubiquitin AldehydeMet*-Gln-Ile-Phe-Val-Lys-Thr-Leu-Thr-Gly-Lys-Thr-Ile-Thr-Leu-Glu-Val-Glu-Pro-Ser-Asp-Thr-Ile-Glu-Asn-Val-Lys-Ala-Lys-Ile-Gln-Asp-Lys-Glu-Gly-Ile-Pro-Pro-Asp-Gln-Gln-Arg-Leu-Ile- Phe-Ala-Gly-Lys-Gln-Leu-Glu-Asp-Gly-Arg-Thr-Leu-Ser- Asp-Tyr-Asn-Ile-Gln-Lys-Glu-Ser-Thr-Leu-His-Leu-Val- Leu-Arg-Leu-Arg-Gly-Gly-H (aldehyde) * Met at position 1 is oxidized to Met(O). (M.W. 8564.70) C378H629N105O118S Semisynthetic ProductInhibitor for Deubiquitinating Enzyme

IUB-3207-v-20 °C

50 mg vial

J.R. Schaeffer and R.E. Cohen, Biochemistry, 35, 10886 (1996). F. Melandri, L. Grenier, L. Plamondon, W.P. Huskey, and R.L. Stein, Biochemistry, 35, 12893 (1996). S.H. Baek, K.S. Choi, Y.J. Yoo, J.M. Cho, R.T. Baker, K. Tanaka, and C.H. Chung, J. Biol. Chem., 272, 25560 (1997). L.C. Dang, F.D. Melandri, and R.L. Stein, Biochemistry, 37, 1868 (1998)

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

172 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYZ-Ile-Glu(OBut)-Ala-Leu-H (aldehyde) [PSI]

Benzyloxycarbonyl-l-isoleucyl-[(2S)2-amino-4- (t-Butyloxycarbonyl)butanoyl]-l-alanyl-l-leucinal (M.W. 618.76) C32H50N4O8 [158442-41-2] Synthetic Product Inhibitor for Proteasome

IAT-3169-v-20 °C

5 mg vial

O

O

NH

O

NH

O O

O

NH

O

NH

H

O

3169-v

M.E. Figueiredo-Pereira, K.A. Berg, and S. Wilk, J. Neurochem., 63, 1578 (1994). E.B.-M. Traenckner, S. Wilk, and P.A. Baeuerle, EMBO J., 13, 5433 (1994). M.E. Figueiredo-Pereira, W-E. Chen, H-M. Yuan, and S. Wilk, Arch. Biochem. Biophys., 317, 69 (1995).

Z-Leu-Leu-Nva-H (aldehyde)[MG-115]

Benzyloxycarbonyl-l-leucyl-l-leucyl-l-norvalinal (M.W. 461.59) C25H39N3O5 [133407-86-0] Synthetic Product Inhibitor for Proteasome

IAT-3170-v-20 °C

5 mg vial

3170-v

O

O

NH

O

NH

O

NH

O

H

Y. Saito, S. Tsubuki, H. Ito, and S. Kawashima, Neurosci. Lett., 120, 1 (1990). A. Vinitsky, C. Michaud, J.C. Powers, and M. Orlowski, Biochemistry, 31, 9421 (1992). K.L. Rock, C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A.L. Goldberg, Cell, 78, 761 (1994). V.J. Palombella, O.J. Rando, A.L. Goldberg, and T. Maniatis, Cell, 78, 773 (1994). • This compound is distributed through Peptide Institute, Inc. under the license of Dr. H. Ito.

u-PA Urokinase Inhibitor See Code IAP-4062 Antipain on page 160.


Order Hotline 1-800-777-4779 502-266-8787 173

ENZYME INHIBITO

RS AND SUBSTRATES

Inhibitors Actinonin

(Aminopeptidase M and Leucyl Aminopeptidase)

Amastatin (Aminopeptidases)

Arphamenine A (Aminopeptidase B)

Arphamenine B (Aminopeptidase B)

Collagenase Inhibitors (Collagen)

Diprotin A (Dipeptidyl Aminopeptidase IV)

Foroxymithine (Angiotensin I Converting Enzyme (ACE))

Leuhistin (Aminopeptidase M)

Phosphoramidon (Collagenase,Thermolysin and Enkephalinase (24.11))

Ubenimex (Bestatin) (Aminopeptidase B and Leucyl Aminopeptidase)

Others EDTA

a-Ketoamides

Divalent metal chelating reagents

8-Hydroxyisoquinolin

Captopril

Metalloproteases

Inhibitors Pepstatin A

(Renin, Cathepsin D)

Others Peptide Renin Inhibitors

Peptide HIV Inhibitors

Aspartyl Proteases

Inhibitors Antipain

(Cathepsin B)

Chymostatin (Cathepsin B and Papain)

E-64 (Thiol Proteases)

Leupeptin (Cathepsin B)

Others Peptidyl chloromethanes

Peptidyl aldehydes

Peptidyl diazomethanes

Cysteinyl Proteases

Inhibitors Aprotinin

(Kallikrein, Trypsin, Chymotrypsin and Plasmin)

Antipain (Trypsin)

Elastatinal (Elastase)

Chymostatin (Chymotrypsin)

Leupeptin (Trypsin, Plasmin)

Others Organophosphates

Peptidyl chloromethanes

Sulfonyl fluorides

Peptidyl aldehydes

Peptidyl borates

Seryl Proteases

Examples of Proteolytic Enzymes and Their Inhibitors

PRODUCT GRADE CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

174 Order Hotline 1-800-777-4779 502-266-8787

Enzyme Substrates & Related CompoundsADAM-17 SubstratesAbz-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Dap(Dnp)-NH2

SDP-3818-PI-20 °C

1 mg5 mg

(Acetate Form) 2-Aminobenzoyl-l-leucyl-l-alanyl-l-glutaminyl-l-alanyl-l-valyl-l-arginyl-l-Seryl-l-Seryl-l-Seryl-l-arginyl-[Ne (2,4-dinitrophenyl)-l-2,3-Diaminopropionyl] amide (M.W. 1444.54) C59H93N23O20 Fluorescence-Quenching Substrate for ADAM17 / TNF-a Converting EnzymeG. Jin, X. Huang, R. Black, M. Wolfson, C. Rauch, H. McGregor, G. Ellestad, R. Cowling, Anal. Biochem., 302, 269 (2002).

Dabcyl-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Edans

(Trifluoroacetate Form) (M.W. 1573.81) C70H104N22O18S [396716-14-6]TACE FRET Substrate IK.M.Mohler et al., Nature, 370, 218 (1994)A.J.H.Gearing et al., Nature, 370, 555 (1994)B.F.Becker et al., Biol. Chem., 383, 1821 (2002)

SFQ-3764-PI 1 mg5 mg

MOCAc-Lys-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2


A SMO-3226-v-20 °C

1 mg vial

(7-Methoxycoumarin-4-yl) acetyl-l-lysyl-l-prolyl-l-leucyl-glycyl-l-leucyl- [Nb-(2,4-dinitrophenyl)-l-2,3-diaminopropionyl]-l-alanyl-l-arginine amide (M.W. 1221.3) C55H80N16O16 Fluorescence-Quenching Substrate for Matrix Metalloproteinases and ADAM-17 / Tumor Necrosis Factor Converting Enzyme (TACE)U. Neumann, H. Kubota, K. Frei, V. Ganu, and D. Leppert, Anal. Biochem., 328, 166 (2004). A. Trifilieff, C. Walker, T. Keller, G. Kottirsch, and U. Neumann, Br. J. Pharmacol., 135, 1655 (2002). M.C. Riitano, H. Pfister, P. Engelhardt, U. Neumann, M. Reist, A. Zurbriggen, M. Stoffel, J. Peel, T. Jungi, P. Schawalder, and D.E. Spreng, Am. J. Vet. Res., 63, 1423 (2002).

MOCAc-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2

(Trifluoroacetate Form) (M.W. 1221.35) C55H80N16O16 Fluorescence-Quenching Substrate for MMPs, Cathepsin D and E, ADAM10, and ADAM17/TACE

SMO-3670-PI-20 °C

1 mg5 mg

U. Neumann , H. Kubota, K. Frei, V. Ganu, and D. Leppert, Anal. Biochem., 328, 166 (2004).

NEW! -20 °C

PRODUCT GRADE CODE QTYPEPTIDES INTERNATIO

NAL

Order Hotline 1-800-777-4779 502-266-8787 175

ENZYME INHIBITO

RS AND SUBSTRATES

ADAMTS-13 Substrates See page 209 for other FRETS Substrates.

FRETS-VWF73(Trifluoroacetate Form)

A SFR-3224-s-20 °C

0.1 mg vial

Asp-Arg-Glu-A2pr(Nma)-Ala-Pro-Asn- Leu-Val-Tyr-Met-Val-Thr-Gly- A2pr(Dnp)-Pro-Ala-Ser-Asp-Glu-Ile-Lys-Arg-Leu-Pro-Gly-Asp-Ile- Gln-Val-Val-Pro-Ile-Gly-Val-Gly-Pro-Asn-Ala-Asn-Val-Gln-Glu-Leu- Glu-Arg-Ile-Gly-Trp-Pro-Asn-Ala-Pro-Ile-Leu-Ile-Gln-Asp-Phe- Glu-Thr-Leu-Pro-Arg-Glu-Ala-Pro-Asp-Leu-Val-Leu-Gln-Arg A2pr(Nma): Nb-[2-(Methylamino)benzoyl]-2,3-diaminopropionic acid A2pr(Dnp): Nb-(2,4-dinitrophenyl)-2,3-diaminopropionic acid (M.W. 8314.30 ) C370H583N103O113S Purity: higher than 95% by HPLC Fluorescence-Quenching Substrate for ADAMTS-13K. Kokame, M. Matsumoto, Y. Fujimura, and T. Miyata, Blood, 103, 607 (2004). (VWF73 Sequence) K. Kokame, Y. Nobe, Y. Kokubo, A. Okayama, and T. Miyata, Br. J. Haematol., 129, 93 (2005). (FRETS-VWF73) • This compound is produced by Peptide Institute, Inc.under license of the National Cardiovascular Center in Japan

α-Amidating Enzyme SubstratesAc-Tyr-Val-Gly

Acetyl-l-tyrosyl-l-valyl-glycine (M.W. 379.41) C18H25N3O6 Substrate for a-Amidating Enzyme

AA SYG-3146 0.1 g1 g

Aminopeptidases SubstratesAla-MCA

(Tosylate Form)l-alanine 4-methylcoumaryl-7-amide(M.W. 246.26) C13H14N2O3 [77471-41-1] Substrate for Aminopeptidase.

AA MAM-3147-v-20 °C

5 mg vial

H. Umetsu, et al., Biosci. Biotechnol. Biochem., 68, 945 (2004).J.R. McDermott, et al., J. Neurochem., 45, 752 (1985)

Ala-pNAl-alanine p-nitroanilide(M.W. 209.20) C9H11N3O3 [1668-13-9]Substrate for Aminopeptidase

AA SAN-3068 0.1 g1 g5 g

G. Peleiderer, In, Proteolytic Enzymes, Methods in Enzymology, Vol. 19, (G.E. Perlmann and L. Lorand, Eds.), Academic Press, New York, 1970, pp. 514-521.

Leu-MCA(Tosylate Form) l-Leucine 4-methylcoumaryl-7-amide (M.W. 288.34) C16H20N2O3 Substrate for Aminopeptidase

AA MLM-3091-v-20 °C

5 mg vial

K. Saifuku, T. Sekine, T. Namihisa, T. Takahashi, and Y. Kanaoka, Clin. Chim. Acta, 84, 85 (1978).

-20 °C

-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

176 Order Hotline 1-800-777-4779 502-266-8787

Leu-NH2 • HCIl-Leucine amide monohydrochloride (M.W. 130.19 • 36.46) C6H14N2O • HCI [10466-61-2] Substrate for Aminopeptidase

AA SLN-3027 0.1 g1 g

F.H. Carpenter and J.M.Vahl, J. Biol. Chem., 248, 294 (1973). T. Sopanen and J. Mikola, Plant Physiol., 55, 809 (1975). H.F.M. Hermes, et al., Applied and Environm. Microbiol., 59, 4330 (1993).

Leu-pNAl-leucine p-nitroanilide (M.W. 251.28) C12H17N3O3 [4178-93-2] Substrate for Aminopeptidase

AA SLN-3014 0.1 g1 g5 g

G. Peleiderer, In, Proteolytic Enzymes, Methods in Enzymology, Vol. 19, (G.E. Perlmann and L. Lorand, Eds.), Academic Press, New York, 1970, pp. 514-521.

Lys-MCA(Hydrochloride Form) l-Lysine 4-methylcoumaryl-7-amide (M.W. 303.36) C16H21N3O3 Substrate for Aminopeptidase

A MKM-3132-v-20 °C

5 mg vial

H. Araki, et al, J. Biochem., 129, 279 (2001).

Met-Leu-pNA(Hydrochloride Salt) l-methionyl-l-leucine p-nitroanilide (M.W. 382.49 • 36.46) C17H26N4O4S • HClY. Wei and D. Pei, Anal. Biochem., 250, 29 (1997).

SML-3622-PI 5 mg25 mg

Met-MCA(Tosylate Form) l-Methionine 4-methylcoumaryl-7-amide (M.W. 306.38) C15H18N2O3S Substrate for Aminopeptidase

A MMM-3149-v-20 °C

5 mg vial

Phe-MCA(Tosylate Form) l-phenylalanine 4-methylcoumaryl-7-amide (M.W. 322.36) C19H18N2O3 [98516-72-4] Substrate for Aminopeptidase

AA MFM-3148-v-20 °C

5 mg vial

Y. Yanigisawa, et al., Biochem. Mol. Med.,59, 161 (1996).

Amyloid A4-Generating Enzyme SubstrateSuc-Ile-Ala-MCA

Succinyl-l-isoleucyl-l-alanine 4-methylcoumaryl-7-amide (M.W. 459.49) C23H29N3O7 [126103-95-5] Substrate for Amyloid A4-Generating Enzyme

A MIA-3158-v-20 °C

5 mg vial

S. Ishiura, T. Tsukahara, T. Tabira, T. Shimizu, K. Arahata, and H. Sugita, FEBS Lett., 260, 131 (1990). S. Ishiura, T. Nishikawa, T. Tsukahara, T. Momoi, H. Ito, K. Suzuki, and H. Sugita, Neurosci. Lett., 115, 329 (1990).

-20 °C

-20 °C


NAL

Order Hotline 1-800-777-4779 502-266-8787 177

ENZYME INHIBITO

RS AND SUBSTRATES

Z-Val-Lys-Met-MCA(Hydrochloride Form)

A MVM-3156-v-20 °C

5 mg vial

Benzyloxycarbonyl-l-valyl-l-lysyl-l-methionine 4-methylcoumaryl-7-amide (M.W. 667.82) C34H45N5O7S [141223-71-4] Substrate for Amyloid A4-Generating Enzyme and ProteasomeS. Ishiura, T. Nishikawa, T. Tsukahara, T. Momoi, H. Ito, K. Suzuki, and H. Sugita, Neurosci. Lett., 115, 329 (1990).

Angiotensin I Converting Enzyme I SubstratesAbz-Gly-Phe(NO2)-Pro-OH

(M.W. 483.48) C23H25N5O7 [67482-93-3]Substrate for ACE (Angiotensin-I Converting Enzyme)

SFQ-3937-PI -20 °C

5 mg25 mg

A. Carmel and A. Yaron, Eur. J. Biochem., 87, 265 (1978).

Bz-Gly-Ala-Pro[Hippuryl-alanyl-proline]

Benzoyl-glycyl-l-alanyl-l-proline (M.W. 347.37) C17H21N3O5 [73167-84-7]

AA SGP-3126 0.1 g1 g

Substrate for ACE (Angiotensin I Converting Enzyme)H.S Cheung, F.L. Wang, M.A. Ondetti, E.F. Sabo, and D. W. Cushman, J. Biol. Chem., 255, 401 ( 1980).

Bz-Gly-Gly-Gly[Hippuryl-glycyl-glycine]

Benzoylglycylglycylglycine (M.W. 293.28) C13H15N3O5 [31384-90-4]

AA SGG-3128 0.1 g1 g

Substrate for ACE (Angiotensin l Converting Enzyme)H.Y.T. Yang, E.G. Erdos, and Y. Levin, J. Pharmacol. Exp. Ther., 177, 291 (1971). T. Nakajima, G. Oshima, H.S.J. Yeh, R. Igic, and E.G. Erdos, Biochim. Biophys. Acta., 315, 430 (1973). G. Oshima, K. Nagasawa, and J. Kato, J. Biochem. (Tokyo), 80, 477 (1976).

Bz-Gly-His-Leu • H2O[Hippuryl-histidyl-leucine]

Benzoylglycyl-l-histidyl-l-leucine (M.W. 429.47 • 18.02) C21H27N5O5 • H2O [31373-65-6]

AA SGL-3064 0.1 g1 g

Substrate for ACE (Angiotensin I Converting Enzyme)D.W. Cushman and H.S. Cheung, Biochem. Pharmacol., 20, 1637 (1971).

Angiotensin I Converting Enzyme II SubstratesAbz-Gly-Phe-Ser-Pro-Tyr(NO2)-OH

(M.W. 733.74) C35H39N7O11Fluorescence-Quenching Substrate for ACE2 (TBC5180)

SFQ-3817-PI-20 °C

1 mg5 mg

Z.-H. Yan, K.-J. Ren, Y. Wang, S. Chen, T.A. Brock, and A. Rege, Anal. Biochem., 312, 141 (2003).

Abz-Ser-Pro-Tyr(NO2)-OH(M.W. 529.51) C24H27N5O9 Fluorescence-Quenching Substrate for ACE2 (TBC5182)

SFQ-3819-PI-20 °C

1 mg5 mg

Z.-H. Yan, K.-J. Ren, Y. Wang, S. Chen, T.A. Brock, and A. Rege, Anal. Biochem., 312, 141 (2003).

NEW!

-20 °C

-20 °C

-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

178 Order Hotline 1-800-777-4779 502-266-8787

ANP (Rat) Precursor Processing Enzyme SubstrateBoc-Ala-Gly-Pro-Arg-MCA

t-Butyloxycarbonyl-l-alanyl-glycyl-l-prolyl-l-arginine 4-methylcoumaryl-7-amide(M.W. 656.73) C31H44N8O8 [118850-78-5]

A MAR-3144-v-20 °C

5 mg vial

Substrate for ANP (Rat) Precursor Processing EnzymeT. Imada, R. Takayanagi, and T. Inagami, Biochem. Biophys. Res. Commun., 143, 587 (1987). T. Imada, R. Takayanagi, and T. Inagami, Biol. Chem. Hoppe-Seyler Suppl., 369, 113 (1988).

d-Aspartyl Endopeptidase SubstrateSuc-d-Asp-MCA

Succinyl-d-Aspartic acid a-(4-methylcoumaryl-7-amide) (M.W. 390.34) C18H18N2O8 Selective Substrate for d-Aspartyl Endopeptidase

AA MCA-3222-v-20 °C

5 mg vial

T. Kinouchi, S. Ishiura, Y. Mabuchi, Y. Urakami-Manaka, H. Nishio, Y. Nishiuchi, M. Tsunemi, K. Takada, M. Watanabe, M. Ikeda, H. Matsui, S. Tomioka, H. Kawahara, T. Hamamoto, K. Suzuki, and Y. Kagawa, Biochem. Biophys. Res. Commun., 314, 730 (2004).

dl-BAPA See Code SRN-3013 Benzoyl-dl-arginine p-Nitroanilide Hydrochloride on page 205.l-BAPA See Code SRN-3057 Benzoyl-l-arginine p-Nitroanilide Hydrochloride on page 183.Biotinyl-Asp-Glu-Val-Asp-H (aldehyde) See Code IBA-3173-v on page 158.

Boc-Glu(OBzl)-Gly-Arg-MCA(Hydrochloride Form)

A MEG-3115-v-20 °C

5 mg vial

t-Butyloxycarbonyl-[(2S)-2-amino-4-(benzyloxycarbonyl)butanoyl] glycyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 707.77) C35H45N7O9 [73554-94-6]S. Iwanaga, T. Morita, H. Kato, T. Harada, N. Adachi, T. Sugo, I. Maruyama, K. Takada, T. Kimura, and S. Sakakibara, KINlNS-II: Biochemistry, Pathophysiology, and Clinical Aspects, (S. Fujii, H. Moriya, and T. Suzuki, Eds.), Plenum Publishing Co., 1979, p. 147-163.

Bz-Ala-OMeBenzoyl-l-alanine methyl ester (M.W. 207.23) C11H13NO3 [7244-67-9]

AA SAM-3084 0.1 g1 g

Bz-Gly-Arg[Hippuryl-arginine]

Benzoyl-glycyl-l-arginine (M.W. 335.36) C15H21N5O4 [744-46-7]

AA SGR-3059 0.1 g1 g

Bz-Gly-Lys[Hippuryl-lysine]

Benzoylglycyl-l-lysine (M.W. 307.34) C15H21N3O4 [740-63-6]

AA SGK-3047 0.1 g1 g

-20 °C

-20 °C

-20 °C


NAL

Order Hotline 1-800-777-4779 502-266-8787 179

ENZYME INHIBITO

RS AND SUBSTRATES

Calpain SubstratesCalpain is a calcium-activated cysteine protease that participates in membrane remodeling, apoptosis, and signal transduction. Deregulation of calpain activity has been linked with cell death and tissue damage associated with Alzheimer’s Disease, myocardial infarction, stroke, and brain trauma.Current calpain substrates are not optimal, and it has been difficult to determine the best cleavage sequence due to the broad substrate specificity of calpains. However, Cuerrier, et al. was able to employ a unique approach in which they designed and digested a N-terminal acetylated degenerate library to determine substrate specificity at primed positions for µ-calpain.1 Based on these findings, a second partially degenerate library was made to determine specificity at unprimed positions. The resulting FRET substrate, H-Glu(Edans)-Pro-Leu-Phe-Ala-Glu-Arg-Lys(Dabcyl)-OH (SFQ-3914-PI) is more sensitive to hydrolysis in com-parison to other substrates, including the popular SLY-MCA. It should prove more sensitive in measuring µ-calpain activity.1. D. Cuerrier, T. Moldoveanu, P.L. Davies, J. Biol. Chem., 280, 40632 (2005).

Boc-Val-Leu-Lys-MCAt-Butyloxycarbonyl-l-valyl-l-leucyl-l-lysine 4-methylcoumaryl-7-amide (M.W. 615.76) C32H49N5O7 [73554-84-4] Substrate for Plasmin and Calpain

A MVL-3104-v-20 °C

5 mg vial

H. Kato, N. Adachi, Y. Ohno, S. Iwanaga, K. Takada, and S. Sakakibara, J. Biochem., 88, 183 (1980). T. Sasaki, T. Kikuchi, N. Yumoto, N. Yoshimura, and T. Murachi, J. Biol. Chem., 259, 12489 (1984).

H-Glu(Edans)-Pro-Leu-Phe-Ala-Glu-Arg-Lys(Dabcyl)-OH

(Acetate Form)(M.W. 1488.74) C72H97N17O16SFRET Substrate for Calpain 1

SFQ-3914-PI -20 °C

1 mg

Suc-Ala-Leu-Pro-Phe-pNASuccinyl-l-alanyl-l-leucyl-l-prolyl-l-phenylalanine p-nitroanilide (M.W. 666.72) C33H42N6O9

A SAF-3162-v-20 °C

10 mg vial

Substrate for PPlase (Peptidyl-prolyl cis-trans Isomerase)J.L. Kofron, P. Kuzmic, V. Kishore, E. Colon-Bonilla, and D.H. Rich, Biochemistry, 30, 6127 (1991).

Suc-Leu-Leu-Val-Tyr-MCASuccinyl-l-leucyl-l-leucyl-l-valyl-l-tyrosine 4-methylcoumaryl-7-amide (M.W. 763.88) C40H53N5O10 [94367-21-2]

A MLL-3120-v-20 °C

5 mg vial

Substrate for Chymotrypsin, Ingensin / Proteasome, and CalpainH. Sawada, H. Yokasawa, M. Hoshi, and S. Ishii, Experientia, 39, 377 (1983). T. Sasaki, T. Kikuchi, N. Yumoto, N. Yoshimura, and T. Murachi, J. Biol. Chem., 259, 12849 (1984). S. Ishiura, M. Sano, K. Kamakura, and H. Sugita, FEBS Lett., 189, 119 (1985). T. Tsukahara, S. Ishiura, and H. Sugita, Eur. J. Biochem., 177, 261, (1988).

NEW!


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

180 Order Hotline 1-800-777-4779 502-266-8787

Carboxypeptidase A SubstratesAc-Phe-Thiaphe-OH

N-Acetyl-l-phenylalanyl-l-3-thiaphenylalanineSTP-3621-PI

-20 °C

5 mg

Dipeptide Mimetic Substrate for Carboxypeptidase A (M.W. 372.45) C19H20N2O4SP. Shamamian, S. Marcus, E. Deutsch, T. Maldonado, A. Liu, J. Stewart, K. Eng, and C. Gilvarg, Presented at the Annual Meeting of the Society for Surgery of the Alimentary Tract, May 1998. K.S. Brown, W.D. Kingsbury, N.M. Hall, G.L. Dunn, and C. Gilvarg, Anal. Biochem., 161, 219 (1987). S.Y. Hwang, W.D. Kingsbury, N.M. Hall, D.R. Jakas, G.L. Dunn, and C. Gilvarg, Anal. Biochem., 154, 552 (1986).

Carnosine Synthase Substrate See Code OAH-3085 β-Ala-His on page 215. Caspase SubstratesAc-Asp-Asn-Leu-Asp-MCA[Ac-DNLD-MCA]

Acetyl-L-aspartyl-L-asparaginyl-L-leucyl-L-aspartic-acid a-(4-methylcoumaryl-7-amide) (M.W. 674.66) C30H38N6O12 Synthetic Product

A MCA-3220-v-20 °C

5 mg vial

Selective Substrate for Caspase-3 Designed by in silico Screening SystemA. Yoshimori, R. Takasawa, and S. Tanuma, Bio. Pharm. Bull., 27, 968 (2004). • This compound is produced by Peptide Institute, Inc. under the license of Institute for Theoretical Medicine, Inc.

Ac-Asp-Gln-Thr-Asp-MCA[Ac-DQTD-MCA]

Acetyl-l-aspartyl-l-glutaminyl-l-threonyl-l-aspartic acid a-(4-methylcoumaryl-7-amide) (M.W. 676.63) C29H36N6O13 Substrate for Caspase-7/3

A MCA-3193-v-20 °C

5 mg vial

(Deduced from the Cleavage Site of Focal Adhesion Kinase and Gelsolin)L.-P. Wen, et al., Science, 278, 294 (1997).

Ac-Asp-Glu-Val-Asp-MCA[Ac-DEVD-MCA]

Acetyl-l-aspartyl-l-glutamyl-l-valyl-l-aspartic acid a-(4-methylcoumaryl-7-amide) (M.W. 675.64) C30H37N5O13 [169332-61-0] Substrate for Caspase-3/7/8

A SAP-3171-v-20 °C

5 mg vial

D.W. Nicholson, et al., Nature, 376, 37 (1995). N.A. Thornberry, et al., J. Biol. Chem., 272, 17907 (1997).

Ac-Ile-Glu-Thr-Asp-MCA[Ac-IETD-MCA]

A MCA-3195-v-20 °C

5 mg vial

Acetyl-l-isoleucyl-l-glutamyl-l-threonyl-l-aspartic acid a-(4-methylcoumaryl-7-amide) (M.W. 675.68) C31H41N5O12 Substrate for Procaspase-3 Cleaving Enzyme (Caspase-8/6 and Granzyme-B) (Deduced from the Cleavage Site of Procaspase-3)N.A. Thornberry, et al., J. Biol. Chem., 272, 17907 (1997).


NAL

Order Hotline 1-800-777-4779 502-266-8787 181

ENZYME INHIBITO

RS AND SUBSTRATES

Ac-Leu-Glu-His-Asp-MCA[Ac-LEHD-MCA]

A MCA-3198-v-20 °C

5 mg vial

Acetyl-l-leucyl-l-glutamyl-l-histidyl-l-aspartic acid a- (4-methylcoumaryl-7-amide) (M.W. 711.72) C33H41N7O11 [292633-16-0] Substrate for Caspase-9

N.A. Thornberry, et al., J. Biol. Chem., 272, 17907 (1997).

Ac-Val-Asp-Val-Ala-Asp-MCA[Ac-VDVAD-MCA]

Acetyl-l-valyl-l-aspartyl-l-valyl-l-alanyl-l-aspartic acid a-(4-methylcoumaryl-7-amide) (M.W. 716.74) C33H44N6O12 Substrate for Caspase-2

A MCA-3203-v-20 °C

5 mg vial

R.V. Talanian, C. Quinlan, S. Trautz, M.C. Hackett, J.A. Mankovich, D. Banach, T. Ghayur, K.D. Brady, and W.W. Wong, J. Biol. Chem. 272, 9677 (1997).

Ac-Val-Glu-Ile-Asp-MCA[Ac-VEID-MCA]

Acetyl-l-valyl-l-glutamyl-l-isoleucyl-l-aspartic acid a-(4-methylcoumaryl-7-amide) (M.W. 673.71) C32H43N5O11 [219137-97-0] Substrate for Caspase-6

A MVA-3181-v-20 °C

5 mg vial

A. Takahashi, P.J. Goldschmidt-Clermont, E.S. Alnemri, T. Fernandes-Alnemri, K. Yoshizawa-Kumagaye, K. Nakajima, M. Sasada, G.G. Poirier, and W.C. Earnshaw, Exp. Cell Res., 231, 123 (1997). A. Takahashi, H. Hirata, S. Yonehara, Y. Imai, K.-K. Lee, R.W. Moyer, P.C. Turner, P.W. Mesner, T. Okazaki, H. Sawai, S. Kishi, K. Yamamoto, M. Okuma, and M. Sasada, Oncogene, 14, 2741 (1997).

Ac-Trp-Glu-His-Asp-MCA[Ac-WEHD-MCA]

Acetyl-l-tryptophyl-l-glutamyl-l-histidyl-l-aspartic acid a-(4-methylcoumaryl-7-amide) (M.W. 784.77) C38H40N8O11 [189275-74-9] Substrate for Caspase-1/

A MCA-3186-v-20 °C

5 mg vial

T.A. Rano, T. Timkey, E.P. Peterson, J. Rotonda, D.W. Nicholson, J.W. Becker, K.T. Chapman, and N.A. Thornberry, Chem. Biol., 4, 149 (1997). N.A. Thornberry, T.A. Rano, E.P. Peterson, D.M. Rasper, T. Timkey, M. Garcia-Calvo, V.M. Houtzager, P.A. Nordstrom, S. Roy, J.P. Vaillancourt, K.T. Chapman, and D.W. Nicholson, J. Biol. Chem., 272, 17907 (1997). J. Mikolajczyk, F.L. Scott, S. Krajewski, D.P. Sutherlin, and G.S. Salvesen, Biochemistry, 43, 10560 (2004).

Ac-Tyr-Val-Ala-Asp-MCA[Ac-YVAD-MCA]

A MAY-3161-v-20 °C

5 mg vial

Acetyl-l-tyrosyl-l-valyl-l-alanyl-l-aspartic acid a- (4-methylcoumaryl-7-amide) (M.W. 665.69) C33H39N5O10 [149231-65-2] Substrate for Caspase-1N.A. Thornberry, H.G. Bull, J.R. Calaycay, K.T. Chapman, A.D. Howard, M.J. Kostura, D.K. Miller, S.M. Molineaux, J.R. Weidner, J. Aunins, K.O. Elliston, J.M. Ayala, F.J. Casano, J. Chin, G.J.-F. Ding, L.A. Egger, E.P. Gaffney, G. Limjuco, O.C. Palyha, S.M. Raju, A.M. Rolando, J.P. Salley, T.T. Yamin, T.D. Lee, J.E. Shively, M. MacCross, R.A. Mumford, J.A. Schmidt, and M.J. Tocci, Nature, 356, 768 (1992).


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

182 Order Hotline 1-800-777-4779 502-266-8787

MOCAc-Asp-Glu-Val-Asp-Ala-Pro-Lys(Dnp)-NH2 [MOCAc-DEVDAPK(Dnp)-NH2]

A MOC-3184-v-20 °C

1 mg vial

(7-Methoxycoumarin-4-yl) acetyl-l-aspartyl-l-glutamyl-l-valyl-l-aspartyl-l- alanyl-l-prolyl-[Ne-(2,4-dinitrophenyl)-l-lysine] amide (M.W. 1154.1) C50H63N11O21 Fluorescence-Quenching Substrate for Caspase-3 M. Enari, R.V. Talanian, W.W. Wong, and S. Nagata, Nature, 380, 723, (1996).

MOCAc-Tyr-Val-Ala-Asp-Ala-Pro-Lys(Dnp)-NH2 [MOCAc-YVADAPK(Dnp)-NH2]

A MOC-3183-v-20 °C

1 mg vial

(7-Methoxycoumarin-4-yl) acetyl-l-tyrosyl-l-valyl-l-alanyl-l-aspartyl-l- alanyl-l-prolyl-Ne-(2,4-dinitrophenyl)-l-lysine amide (M.W. 1144.1) C53H65N11O18 Fluorescence-Quenching Substrate for Caspase-1 M. Enari, R.V. Talanian, W.W. Wong, and S. Nagata, Nature, 380, 723, (1996).

(Z-Asp-Glu-Val-Asp)2-Rh110(Z-DEVD)2-Rh110

(Trifluoroacetate Form)(M.W. 1515.48) C72H78N10O27Substrate for caspase 3 and caspase 7

SDR-3727-PI-20 °C

1 mg5 mg

P.D. Sanchez-Gonzalez et al. Toxicol. Lett, 203, 154 (2011).V. Gurtu et al, anal. Biochem, 251, 98 (1997).L.M. Martins et al, J. Biol. Chem. 272, 7421 (1997).

Cathepsin and Thiol Protease SubstratesAbz-Glu-Pro-Phe-Trp-Glu-Asp-Gln-EDDnp[Abz-EPFWEDQ-EDDnp]

(Ammonium Form)

SFR-3231-v-20 °C

1 mg vial

2-Aminobenzoyl-l-glutamyl-l-prolyl-l-phenylalanyl-l-tryptophyl-l-glutamyl- l-aspartyl-l-glutamine 2-(2,4-dinitrophenyl)aminoethyl-amide(M.W. 1277.25) C59H68N14O19Fluorescence-Quenching Substrate for Human Neutrophil Cathepsin GS. Attucci, et al., Biochem. J., 366, 965 (2002).B. Korkmaz, et al., Nat. Protoc., 3, 991(2008).

Arg-MCA(Hydrochloride Form)l-arginine 4-methylcoumaryl-7-amide (M.W. 331.37) C16H21N5O3 [65286-27-3]Substrate for Cathepsin H

AA MAR-3113-v -20 °C

5 mg vial

Y. Kanaoka, T. Takahashi, H. Nakayama, K. Takada, T. Kimura, and S. Sakakibara, Chem. Pharm. Bull., 25, 3126 (1977).

NEW!


NAL

Order Hotline 1-800-777-4779 502-266-8787 183

ENZYME INHIBITO

RS AND SUBSTRATES

Bz-l-Arg-pNA • HCI [l-BAPA]

AA SRN-3057 0.1 g5 g

Benzoyl-l-arginine p-nitroanilide monohydrochloride (M.W. 398.42 • 36.46) C19H22N6O4 • HCI [21653-40-7] Substrate for Trypsin-like Proteases and PapainK.A. Walsh, In, Proteolytic Enzymes, Methods in Enzymology, Vol. 19, (G.E. Perlmann and L. Lorand, Eds.), Academic Press, New York, 1970, pp. 41-63. R. Arnon, In, Proteolytic Enzymes, Methods in Enzymology, Vol. 19, (G.E. Perlmann and L. Lorand, Eds.), Academic Press, New York, 1970, pp. 226-244. G.A. Grant, A.Z. Eisen, and R.A. Bradshaw, In, Proteolytic Enzymes Part C, Methods in Enzymology, Vol. 80, (L. Lorand, ed.), Academic Press, New York, 1981, pp. 722-734.

Gly-Gly-Tyr-Arg • AcOH • 2H2OGlycyl-glycyl-l-tyrosyl-l-arginine

A OGG-3119 0.1 g1 g

(M.W. 451 • 60.05 • 36.03) C19H29N7O6 • CH3COOH • 2H2O [70195-20-9] Affinity Ligand for Papain M.O. Funk, Y. Nakagawa, J. Skochdopole, and E.T. Kaiser, Int. J. Peptide Protein Res., 13, 296 (1979).

MOCAc-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-d-Arg-NH2

A SMO-3200-v-20 °C

1 mg vial

(7-Methoxycoumarin-4-yl) acetyl-glycyl-l-lysyl-l-Proyl-l-isoleucyl-l-Leucyl-l-phenylalanyl-l-phenylalanyl-l-arginyl-l-leucyl-[Ne-(2,4-dinitrophenyl)-l-lysyl]-d-arginine amide (M.W. 1756.0) C85H122N22O19 Fluorescence-Quenching Substrate for Cathepsin D/EY. Yasuda, T. Kageyama, A. Akamine, M. Shibata, E. Kominami, Y. Uchiyama, and K. Yamamoto, J. Biochem., 125, 1137 (1999).

MOCAc-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 See Code SMO-3670-PI on page 174.

MOCAc-Gly-Ser-Pro-Ala-Phe-Leu-Ala-Lys(Dnp)-d-Arg-NH2 [KYS-1]


A SMO-3225-v-20 °C

1 mg vial

7-Methoxycoumarin-4-yl) acetyl-glycyl-l-seryl-l-prolyl-l-alanyl-l-phenylalanyl-l- leucyl-l-alanyl-[Ne-(2,4-dinitrophenyl)-l-lysyl]-d-arginine amide (M.W. 1327.4) C61H82N16O18 Fluorescence-Quenching Substrate for Cathepsin E K. Yamamoto, Japanese Patent Publication No.2003-246798. • This compound is produced by Peptide Institute, Inc. under the license of Kyushu TLO Co., Ltd.

Pyr-Phe-Leu-pNAl-Pyroglutamyl-l-phenylalanyl-l-leucine-p-nitroanilide (M.W. 509.55) C26H31N5O6 [85901-57-1] Substrate for Thiol Protease

AA SPL-3130 0.1 g1 g

l.Y. Filippova, E.N. Lysogorskaya, E.S. Oksenoit, G.N. Rudenskaya, and V.M. Stepanov, Anal. Biochem., 143, 293 (1984).

Z-Arg-Arg-MCA(Hydrochloride Form)

A MRR-3123-v-20 °C

5 mg vial

Benzyloxycarbonyl-l-arginyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 621.69) C30H39N9O6 [88937-61-5] Substrate for Cathepsin BA.J. Barrett and H. Kirschke, In, Proteolytic Enzymes Part C, Methods in Enzymology, Vol. 80, (L. Lorand, Ed.), Academic Press, New York, 1981, pp. 535.

-20 °C

-20 °C

-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

184 Order Hotline 1-800-777-4779 502-266-8787

Z-Gly-Pro-Arg-MCA(Hydrochloride Form)

AA MCA-3208-v-20 °C

5 mg vial

Benzyloxycarbonylglycyl-l-prolyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 619.67) C31H37N7O7 [201928-42-9] Substrate for Cathepsin K

K. Aibe, H. Yazawa, K. Abe, K. Teramura, M. Kumegawa, H. Kawashima, and K. Honda, Biol. Pharm. Bull., 19, 1026 (1996). F. Bühling, A. Gerber, C. Häckel, S. Krüger, T. Köhnlein, D. Brömme, D. Reinhold, S. Ansorge, and T. Welte, Am. J. Respir. Cell Mol. Biol., 20, 612 (1999).

Z-Glu-TyrBenzyloxycarbonyl-l-glutamyl-l-tyrosine (M.W. 444.43) C22H24N2O8 [988-75-0]

AA SEY-30184 °C

0.1 g1 g

Z-Leu-Arg-MCA(Hydrochloride Form)

AA MCA-3210-v-20 °C

5 mg vial

Benzyloxycarbonyl-l-leucyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 578.66) C30H38N6O6 Substrate for Cathepsin K/S/VD. Brömme, K. Okamoto, B.B. Wang, and S. Biroc, J. Biol. Chem., 271, 2126 (1996). D. Brömme, Z. Li, M. Barnes, and E. Mehler, Biochemistry, 38, 2377 (1999).

Z-Phe-Arg-MCA(Hydrochloride form)

AA MFR-3095-v-20 °C

5 mg vial

Benzyloxycarbonyl-l-phenylalanyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 612.68) C33H36N6O6 [65147-22-0] Substrate for Plasma Kallikrein, Cathespin B/L, and Arg-Gingipain

T. Morita, H. Kato, S. Iwanaga, K. Takada, T. Kimura, and S. Sakakibara, J. Biochem., 82, 1495 (1977). A.J. Barret, J. Biochem, 187, 909 (1980).

Z-Val-Val-Arg-MCA(Hydrochloride Form)

AA MCA-3211-v-20 °C

5 mg vial

Benzyloxycarbonyl-l-valyl-l-valyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 663.76) C34H45N7O7 Substrate for Cathepsin S/LD. Brömme, A. Steinert, S. Friebe, S. Fittkau, B. Wiederanders, and H. Kirschke, Biochem. J., 264, 475 (1989). H. Kirschke and B. Wiederanders, In, Proteolytic Enzymes: Serine and Cysteine Peptidases, Methods in Enzymology, Vol. 244, (A.J. Barret, Ed.), Academic Press, New York, 1994, pp. 500-511.


NAL

Order Hotline 1-800-777-4779 502-266-8787 185

ENZYME INHIBITO

RS AND SUBSTRATES

Cellular Prion Protein SubstrateCellular prion protein (PrPc) in normal brains is found at the cell membrane where it is cleaved by ADAM10 and TACE between His111 and Met112 to produce a secreted N-terminal (N1) fragment. A recent study developed an original FRETS substrate, Abz-Thr-Asn-Met-Lys-His-Met-Ala-Gly-Ala-Ala-Gln-EDDnp (SFQ-3916-PI), that comprises PrPc amino acid sequence 107-116 and contains the His111-Met112 cleav-age site.1 Hydrolytic cleavage was successfully measured when this new substrate was incubated with brain homogenates and intact cells, and activity was attenuated by TACE and ADAM10 inhibitors. Substrate hydrolysis was also attenuated in cells defi-cient in ADAM10 and TACE while cells overexpressing ADAM10 and TACE exhibited enhanced substrate hydrolysis. However, TACE and ADAM10 only partially inhibited Prpc in these studies. Therefore, this novel substrate should prove helpful in identify-ing additional enzymes involved in normal PrPc metabolism.1. M.A. Cissé, C. Gandreuil, J.-F. Hernandez, J. Martinez, F. Checler, and B. Vincent, Biochem. and Biophys. Res. Commun., 347, 254 (2006).

Abz-Thr-Asn-Met-Lys-His-Met-Ala-Gly-Ala-Ala-Gln-EDDnp

(M.W. 1486.66) C61H91N21O19S2Fluorescence-Quenching Substrate for Cellular Prion Protein (PrPc)

SFQ-3916-PI -20 °C

1 mg5 mg

Chymotrypsin and Chymotrypsin-like Protease SubstratesAc-Phe-OEt

Acetyl-l-phenylalanine ethyl ester (M.W. 235.28) C13H17NO3 [2361-96-8]

AA SFE-3006 0.1 g1 g 5 g

Ac-Trp-OEtAcetyl-l-tryptophan ethyl ester (M.W. 274.32) C15H18N2O3 [2382-80-1]

AA SWE-3034 0.1 g1 g

Ac-Tyr-NH2Acetyl-l-tyrosine amide (M.W. 222.24) C11H14N2O3 [1948-71-6]

A SYA-3009 0.1 g1 g

Ac-Tyr-OEt • H2OAcetyl-l-tyrosine ethyl ester monohydrate

AA SYE-3008 0.1 g1 g

(M.W. 251.28 • 18.02) C13H17NO4 • H2O [840-97-1]] Substrate for Chymotrypsin and C1s

P.E. Wilcox, In, Proteolytic Enzymes, Methods in Enzymology, Vol. 19, (G.E. Perlmann and L. Lorand, Eds), Academic Press, New York, 1970, pp. 64-108. R.B. Sim, In, Proteolytic Enzymes Part C, Methods in Enzymology, Vol. 80, (L. Lorand, Ed.), Academic Press, New York, 1981, pp. 26-42.

Bz-Tyr-pNABenzoyl-l-tyrosine p-nitroanilide (M.W. 405.40) C22H19N3O5 [6154-45-6] Substrate for Chymotrypsin

A SYN-3015 0.1 g1 g

G.A. Grant, A.Z. Eisen, and R.A. Bradshaw, In, Proteolytic Enzymes Part C, Methods in Enzymology, Vol. 80, (L. Lorand, Ed.), Academic Press, New York, 1981, pp. 722-734.

NEW!

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

186 Order Hotline 1-800-777-4779 502-266-8787

Bz-Tyr-OEtBenzoyl-l-tyrosine ethyl ester (M.W. 313.35) C18H19NO4 [3483-82-7] Substrate for Chymotrypsin

AA SYE-3010 0.1 g1 g

P.E. Wilcox, In, Proteolytic Enzymes, Methods in Enzymology, Vol. 19, (G.E. Perlmann and L. Lorand, Eds.), Academic Press, New York, 1970, pp. 64-108.

Glt-Ala-Ala-Phe-MCAGlutaryl-l-alanyl-l-alanyl-l-phenylalanine 4-meth-ylcoumaryl-7-amide (M.W. 578.61) C30H34N4O8 Substrate for Chymotrypsin

A MAF-3154-v-20 °C

5 mg vial

MeO-Suc-Arg-Pro-Tyr-MCA(Acetate Form) N-Methoxy-succinyl-l-arginyl-l-prolyl-l-tyrosine-4-methylcoumaryl-7-amide (M.W. 668.71) C35H43N7O9 Substrate for Chymotrypsin

SAP-3885-PI-20 °C

5 mg25 mg

B.P. Berdal, O. Olsvik, S. Myhre, and T. Omland, J. Clin. Microb., 16, 452 (1982).

MeO-Suc-Arg-Pro-Tyr-pNAN-Methoxy-succinyl-l-arginyl-l-prolyl-l-tyrosine-p-nitroanilide (M.W. 705.35) C31H40N8O9 Substrate for Chymotrypsin

SAP-3882-PI-20 °C

5 mg25 mg

B.P. Berdal, O. Olsvik, S. Myhre, and T. Omland, J. Clin. Microb., 16, 452 (1982).

Suc-Ala-Ala-Pro-Phe-MCASuccinyl-l-alanyl-l-alanyl-l-prolyl-l-phenylalanine 4-methylcoumaryl-7-amide (M.W. 661.70) C34H39N5O9 [88467-45-2] Substrate for Chymotrypsin

A MAA-3114-v-20 °C

5 mg vial

S. Sawada, H. Yokasawa, M. Hoshi and S. Ishii, Experientia, 39, 377 (1983).

Suc-Ala-Leu-Pro-Phe-pNA See Code MLL-3120-v on page 179.

Suc-Arg-Pro-Phe-His-Leu-Leu-Val-Tyr-MCA

A MRP-3110-v-20 °C

1 mg vial

Succinyl-l-arginyl-l-prolyl-l-phenylalanyl-l-histidyl-l-leucyl-l- leucyl-l-valyl-l-tyrosine 4-methylcoumaryl-7-amide (M.W. 1301.5) C66H88N14O14 [76524-84-0] Substrate for Renin and Proteinase AK. Murakami, T. Ohsawa, S. Hirose, K. Takada, and S. Sakakibara, Anal. Biochem., 110, 232 (1981). H. Yokosawa, H. Ito, S. Murata, and S. Ishii, Anal. Biochem., 134, 210 (1983).

Suc-lle-Ile-Trp-MCASuccinyl-l-isoleucyl-l-isoleucyl-l-tryptophan 4-methylcoumaryl-7-amide (M.W. 687.78) C37H45N5O8 [133525-12-9]

A MIW-3150-v-20 °C

5 mg vial

-20 °C


NAL

Order Hotline 1-800-777-4779 502-266-8787 187

ENZYME INHIBITO

RS AND SUBSTRATES

Coagulation Factor SubstratesBoc-Asp(OBzl)-Pro-Arg-MCA

t-Butyloxycarbonyl-[(2S)-2-amino-3-benzyloxycar-bonyl)propionyl]-l-prolyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 733.81) C37H47N7O9 [113866-00-5] Substrate for a-Thrombin

AA MDR-3139-v-20 °C

5 mg vial

S. Kawabata, T. Miura, T. Morita, H. Kato, K. Fujikawa, S. Iwanaga, K. Takada, T. Kimura, and S. Sakakibara, Eur. J. Biochem., 172, 17 (1988).

Boc-Gln-Gly-Arg-MCAt-Butyloxycarbonyl-l-glutaminyl-glycyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 616.67) C28H40N8O8 Substrate for Factor Xlla

A MQR-3136-v-20 °C

5 mg vial


Boc-Glu(OBzl)-Ala-Arg-MCA AA MER-3134-v-20 °C

5 mg vial t-Butyloxycarbonyl-[(2S)-2-amino-4-(benzyloxycarbonyl)

butanoyl]-l-alanyl-l-arginine4-methylcoumaryl-7-amide(M.W. 721.80) C36H47N7O9 [113866-16-3] Substrate for Factor XIaS. Kawabata, T. Miura, T. Morita, H. Kato, K. Fujikawa, S. Iwanaga, K. Takada, T. Kimura, and S. Sakakibara, Eur. J. Biochem., 172, 17 (1988).

Boc-lle-Glu-Gly-Arg-MCAt-Butyloxycarbonyl-l-isoleucyl-l-glutamylglycyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 730.81) C34H50N8O10 [65147-06-0] Substrate for Factor Xa

A MlE-3094-v-20 °C

5 mg vial

T. Morita, H. Kato, S. Iwanaga, K. Takada, T. Kimura, and S. Sakakibara, J. Biochem., 82, 1495 (1977).

Boc-Leu-Ser-Thr-Arg-MCAt-Butyloxycarbonyl-l-leucyl-l-seryl-l-threonyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 732.82) C34H52N8O10 [73554-93-5] Substrate for Activated Protein C

A MLS-3112-v-20 °C

5 mg vial

Y. Ohno, H. Kato, T. Morita, S. Iwanaga, K. Takada, S. Sakakibara, and J. Stenflo, J. Biochem., 90, 1387 (1981).

Boc-Leu-Ser-Thr-Arg-pNA • AcOH • H2O

A SLR-3125 25 mg100 mg

t-Butyloxycarbonyl-l-leucyl-l-Seryl-l-threonyl-l-arginine p-nitroanilide (M.W. 695.76 • 60.05 • 18.02) C30H49N9O10 • CH3COOH • H2O Substrate for Activated Protein C

Boc-Leu-Thr-Arg-MCAt-Butyloxycarbonyl-l-leucyl-l-threonyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 645.75) C31H47N7O8Substrate for Factor VIIa-Tf

A MLT-3106-v-20 °C

5 mg vial

Y. Shigematsu, T. Miyata, S. Higashi, T. Miki, J.E. Sadler, and S. Iwanaga, J. Biol. Chem., 267, 21329 (1992).

-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

188 Order Hotline 1-800-777-4779 502-266-8787

Boc-Val-Pro-Arg-MCAt-Butyloxycarbonyl-l-valyl-l-prolyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 627.73) C31H45N7O7 [65147-04-8] Substrate for a-Thrombin

AA MVP-3093-v-20 °C

5 mg vial

T. Morita, H. Kato, S. Iwanaga, K. Takada, T. Kimura, and S. Sakakibara, J. Biochem., 82, 1495 (1977). S. Kawabata, T. Morita, S. Iwanaga, and H. Igarashi, J. Biochem., 97, 1073 (1985).

Z-Pyr-Gly-Arg-MCA(Hydrochloride Form)

A MPR-3138-v-20 °C

5 mg vial

Benzyloxycarbonyl-l-pyroglutamyl-glycyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 633.65) C31H35N7O8 Substrate for Factor Xa


Collagenase / MMP / Stromelysin SubstratesAlso see Code SDP-3818-PI Abz-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Dap(Dnp)-NH2 on page 174 and Code SMO-3226-v MOCAc-Lys-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 on page 174.

Dnp-Gln-Gly-Ile-Ala-Gly-Gln-d-Arg2,4-dinitrophenyl-l-glutaminyl-glycyl-l-isoleucyl-l-alanyl-glycyl-l-glutaminyl-d-arginine (M.W. 894.89 ) C35H54N14O14

B SDQ-3088-v-20 °C

2.5 mg vial

Reference Substrate for Collagenase Assay with code SDP-3087-vY. Masui, T. Takemoto, S. Sakakibara, H. Hori, and Y. Nagai, Biochem. Med., 17, 215 (1977).

Dnp-Gly-Pro-Leu-Gly-Met-Arg-Gly-Leu-NH2(Trifluoroacetate Form) 2,4-dinitrophenyl-glycyl-l-prolyl-l-leucyl-glycyl-l-methionyl-l-arginyl-glycyl-leucine amide (M.W. 965.11) C40H64N14O12S Substrate for Collagenase 3 / MMP-13

SDP-3816-PI-20 °C

1 mg5 mg

S.J. Deng, D.M. Bickett, J.L. Mitchell, M.H. Lambert, R.K. Blackburn, H.L. Carter, III, J. Neugebauer, G. Pahel, M.P. Weiner, M.L. Moss, J. Biol. Chem., 275, 31422-31427 (2000).

Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala- Lys(NMa)-NH2

2,4-dinitrophenyl-l-prolyl-l-cyclohexylalanyl-glycyl-S-methyl-l-cysteinyl-l-histidyl-l-alanyl-Ne-methylanthranoyl-l-lysine amide (M.W. 1077.24) C49H68N14O12S Substrate for Collagenase

SDP-3815-PI-20 °C

2.5 mg5 mg

J. Berman, M. Green, E. Sugg, R. Anderegg, D.S. Millington, D.L. Norwood, J. McGeehan and J. Wiseman, J. Biol. Chem., 267, 1434 (1992).

Dnp-Pro-Gln-Gly2,4-dinitrophenyl-l-prolyl-l-glutaminyl-glycine (M.W. 466.40) C18H22N6O9 [65080-33-3]

AA SDP-3089 0.1 g1 g

Reference Compound to Measure Collagenase Activity with SDP-3087-v

Dnp-Pro-Leu-Gly2,4-dinitrophenyl-l-prolyl-l-leucylglycine (M.W. 451.43) C19H25N5O8

AA SDP-3082 0.1 g1 g

Reference Compound to Measure Collagenase Activity with SDP-3073-v

-20 °C

-20 °C


NAL

Order Hotline 1-800-777-4779 502-266-8787 189

ENZYME INHIBITO

RS AND SUBSTRATES

Dnp-Pro-Leu-Gly-Leu-Trp-Ala-d-Arg-NH22,4-dinitrophenyl-l-prolyl-l-leucylglycyl-l-leucyl-l-tryptophyl-l-alanyl-d-arginine amide (M.W. 977.10) C45H64N14O11 Substrate for Collagenase/Gelatinase

SDP-3820-PI-20 °C

2.5 mg5 mg

M.S. Stack and R.D. Gray, J. Biol. Chem., 264, 4277 (1989). K. Darlak, R.B. Miller, M.S. Stack, A.F. Spatola, and R.D. Gray, J. Biol. Chem., 265, 5199 (1990).

Dnp-Pro-Gln-Gly-Ile-Ala-Gly-Gln-d-Arg2,4-dinitrophenyl-l-prolyl-l-glutaminylglycyl-l-lsoleucyl-l-alanyl-glycyl-l-glutaminyl-d-arginine (M.W. 992.00) C40H61N15O15 [63014-08-4] Substrate for Animal Collagenase

B SDP-3087-v-20 °C

2.5 mg vial

Y. Masui, T. Takemoto, S. Sakakibara, H. Hori, and Y. Nagai, Biochem. Med., 17, 215 (1977).

Dnp-Pro-Leu-Gly-Ile-Ala-Gly-Arg-NH2 2,4-dinitrophenyl-l-prolyl-l-leucylglycyl-l-isoleucyl-l-alanyl-glycyl-l-arginine amide (M.W. 847.92) C36H57N13O11 Substrate for Animal Collagenase

A SDP-3073-v-20 °C

2.5 mg vial


MOCAc-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 See Code SMO-3670-PI on page 174.MOCAc-Lys-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 See Code SMO-3226-v on page 174

MOCAc-Pro-Cha-Gly-Nva-His-Ala-Dap(Dnp)-NH2.

SMO-3682-PI-20 °C

1 mg

(7-Methoxycoumarin-4-yl)acetyl-l-prolyl-l-cyclohexylalanyl-glycyl-l-norvalyl- l-histidinyl-l-alanyl-Nb-(2,4-dinitrophenyl)-l-2,3-diaminopropionic amide (M.W. 1100.16) C51H65N13O15 Fluorescence-Quenching Substrate for MMP 13J.L. Lauer-Fields, T. Broder, T. Sritharan, L. Chung, H. Nagase, and G.B. Fields, Biochemistry, 40, 5795 (2001)

MOCAc-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2

A MOC-3163-v-20 °C

1 mg vial

(7-Methoxycoumarin-4-yl) acetyl-l-prolyl-l-leucyl-glycyl-l-leucyl-[Nb- (2,4-dinitrophenyl)-l-2,3-diaminopropionyl]-l-alanyl-l-arginine amide (M.W. 1093.1) C49H68N14O15 [140430-53-1] Fluorescence-Quenching Substrate for Matrix MetalloproteinasesC.G. Knight, F. Willenbrock, and G. Murphy, FEBS Lett., 296, 263 (1992).

MOCAc-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2 [NFF-3]

B SMO-3168-v-20 °C

1 mg vial

(7-Methoxycoumarin-4-yl) acetyl-l-arginyl-l-prolyl-l-lysyl-l-prolyl-l-valyl-l-glutamyl-l- norvalyl-l-tryptophyl-l-arginyl-[Ne-(2,4-dinitrophenyl)-l-lysine] amide (M.W. 1675.8) C78H110N22O20 [158584-09-9] Fluorescence-Quenching Substrate for Matrix Metalloproteinase-3 (Stromelysin 1)H. Nagase, C.G. Fields, and G.B. Fields, J. Biol. Chem., 269, 20952 (1994). • This product is sold under license with the University of Minnesota.


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

190 Order Hotline 1-800-777-4779 502-266-8787

MOCAc-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met-Lys(Dnp)-NH2 [NFF-2]

B SMO-3167-v-20 °C

1 mg vial

(7-Methoxycoumarin-4-yl) acetyl-l-arginyl-l-prolyl-l-lysyl-l-prolyl-l-tyrosyl-l-alanyl-l-norvalyl-l- tryptophyl-l-methionyl-[Ne-(2,4-dinitrophenyl)-l-lysine] amide (M.W. 1656.9) C79H105N19O19S [158584-08-8] Fluorescence-Quenching Substrate for Matrix MetalloproteinasesH. Nagase, C.G. Fields, and G.B. Fields, J. Biol. Chem., 269, 20952 (1994). • This product is sold under license with the University of Minnesota.

Suc-Gly-Pro-Leu-Gly-Pro-MCASuccinyl-glycyl-l-prolyl-l-leucyl-glycyl-l-proline 4-methylcoumaryl-7-amide (M.W. 696.75) C34H44N6O10 [72698-36-3] Substrate for Collagenase-like Peptidase

A MGP-3108-v-20 °C

5 mg vial

K. Kojima, H. Kinoshita, T. Kato, T. Nagatsu, K. Takada, and S. Sakakibara, Anal. Biochem., 100, 43 (1979).

Z-Gly-Pro-Leu-Gly-Pro • H2O • AcOEtBenzyloxycarbonylglycyl-l-prolyl-l-leucyl-glycyl-l-proline • monohydrate mono (ethyl acetate)

AA SGP-3029 0.1 g1 g

(M.W. 573.64 • 18.02 • 88.11) C28H39N5O8 • H2O • CH3COOC2H5 [2646-61-9] Crystalline: Substrate for Bacterial CollagenaseY. Nagai, S. Sakakibara, H. Noda, and S. Akabori, Biochim. Biophys. Acta., 37, 567 (1960).

Z-Phe-Tyr-LeuBenzyloxycarbonyl-l-phenylalanyl-l-tyrosyl-l-leucine (M.W. 575.65) C32H37N3O7 Substrate for Metalloproteinase

AA SFL-3131 0.1 g1 g

Deformylase Substrates4-Methoxyphenylazoformyl-Phe [AAFP]

(Potassium Form) N-(4-Methoxyphenylazoformyl)-l-phenylalanine (M.W. 327.33) C17H17N3O4 [396717-86-5] Substrate for Carboxypeptidase A

B SAA-3197-v-20 °C

5 mg vial

W.L. Mock, Y. Liu, and D.J. Stanford, Anal. Biochem., 239, 218 (1996).

For-Met-Leu-pNAN-Formyl-l-methionyl-l-leucine p-nitroanilide (M.W. 410.50) C18H26N4O5SY. Wei and D. Pei, Anal. Biochem., 250, 29 (1997).

SFM-3624-PI-20 °C

5 mg25 mg

Dengue Fever Virus Protein SubstratesAbz-Lys-Lys-Gln-Arg-Ala-Gly-Val-Leu-Tyr(NO2)-NH2

Abz-KKQRAGVLY(NO2)-NH2(M.W. 1225.43) C55H88N18O14

SFQ-3958-PI -20 °C

1 mg5 mg

Substrate for for Dengue Virus Non-Structural Protein 3 (NS3) Serine ProteaseP. Niyomrattanakit, S. Yahorava, I. Mutule, F. Muturlis, R. Petrovska, P. Prusis, G. Katzenmeier, and J.E.S. Wikberg, Biochem. J., 397, 203-211 (2006).

NEW!

-20 °C

-20 °C


NAL

Order Hotline 1-800-777-4779 502-266-8787 191

ENZYME INHIBITO

RS AND SUBSTRATES

Benzoyl-Nle-Lys-Arg-Arg-MCA (M.W.. 833.01) C41H60N12O7Dengue Fever Virus Protein Substrate

MCA-3923-PI -20 °C

5 mg

J. Li, et al., J. Biol. Chem., 280, 28766 (2005).

Dengue Virus Non-Structural Protein 3 (NS3) Serine Protease SubstrateAbz-Arg-Arg-Arg-Arg-Ser-Ala-Gly-Tyr(NO2)-NH2

(M.W. 1184.30) C48H77N23O13Substrate for NS3 Serine Protease

SFQ-3957-PI -20 °C

1 mg5 mg

Dipeptidyl-Amino Peptidase SubstratesGly-Pro-MCA

(Tosylate Form) Glycyl-l-proline 4-methylcoumaryl-7-amide (M.W. 329.35) C17H19N3O4 [67341-42-8] Substrate for X-prolyl Dipeptidyl-Aminopeptidase

AA MGP-3090-v-20 °C

5 mg vial

T. Kato, T. Nagatsu, T. Kimura, and S. Sakakibara, Biochem. Med., 19, 351 (1978).

Gly-Pro-pNA • Tos [GPNT]

Glycyl-l-proline p-nitroanilide monotosylate

AA SGP-3074-v-20 °C

10 mg vial

(M.W. 292.29 • 172.20) C13H16N4O4 • C7H8O3S [65096-46-0] Substrate for X-prolyl Dipeptidyl-Aminopeptidase

T. Nagatsu, et al., Anal. Biochem., 74, 466 (1976). K. Fujita, M. Hirano, J. Ochiai, M.M. Funabashi, I. Nagatsu, T. Nagatsu and S. Sakakibara, Clin. Chim. Acta, 88, 15 (1978).

Lys-Ala-MCA(Tartarate Form) l-Lysyl-l-alanine 4-methylcoumaryl-7-amide (M.W. 374.43) C19H26N4O4 Substrate for Dipeptidyl-Aminopeptidase II

A MKA-3124-v-20 °C

5 mg vial

D. Mantle, M.F. Hardy, B. Lauffart, J.R. McDermott, A.I. Smith, and R.J.T. Pennington, Biochem. J., 211, 567 (1983).

Elastase SubstratesAbz-Ala-Pro-Glu-Glu-Ile-Met-Arg-Arg-Gln-EDDnp

[Abz-APEEIMRRQ-EDDnp](Trifluoroacetate Form)

SNE-3230-v-20 °C

1 mg vial

2-Aminobenzoyl-l-alanyl-l-prolyl-l-glutamyl-l-glutamyl-l-isoleucyl-l-methionyl-l-arginyl-l-arginyl-l-glutamine 2-(2,4-dinitrophenyl)aminoethylamide(M.W. 1456.59) C61H93N21O19SFluorescence-Quenching Substrate for Human Neutrophil ElastaseB. Korkmaz, S. Attucci, T. Moreau, E. Godat, L. Juliano, and F. Gauthier, Am. J. Respir. Cell Mol. Biol., 30, 801 (2004).B. Korkmaz, S. Attucci, M.A. Juliano, T. Kalupov, M.-L. Jourdan, L. Juliano, and F. Gauthier, Nat. Protoc., 3, 991 (2008).

Glt-Ala-Ala-Pro-Leu-pNA • H2OGlutaryl-l-alanyl-l-alanyl-l-prolyl-l-leucine-p-nitroanilide (M.W. 604.65 • 18.02) C28H40N6O9 • H2O Substrate for Pancreatic Elastase

AA SGL-3129 0.1 g1 g

E.G. Del Mar, C. Largman, J.W. Brodrick, M. Fassett, and M.C. Geokas, Biochemistry, 19, 468 (1980).

NEW!

NEW!

NEW!

-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

192 Order Hotline 1-800-777-4779 502-266-8787

Pyr-Pro-Val-pNAl-Pyroglutamyl-l-prolyl-l-valine p-nitroanilide (M.W. 445.47) C21H27N5O6 [83329-36-3]

SAP-3228-v-20 °C

5 mg vial

Selective Substrate for Human Granulocyte Elastase J.A. Kramps, Ch. van Twisk and A.C. van der Linden, Scand. J. Clin. Lab. Investig., 43, 427 (1983).L. Persson, J. Bergström, H. Ito, and A. Gustafsson, J. Periodontol., 72, 90 (2001).I. Groth and S. Alban, Planta Med., 74, 852 (2008).

Suc-Ala-Ala-Ala-MCASuccinyl-l-alanyl-l-alanyl-l-alanine 4-methylcou-maryl-7-amide (M.W. 488.49) C23H28N4O8 [73617-90-0] Substrate for Elastase

AA MAA-3133-v-20 °C

5 mg vial

R.A. Mumford, et. al., J. Biol. Chem., 255, 2227 (1980).

Suc-Ala-Ala-Ala-pNA [STANA]

Succinyl-l-alanyl-l-alanyl-l-alanine p-nitroanilide (M.W. 451.43) C19H25N5O8 [52299-14-6]

AA SAA-3071-v 5 mg vial

Suc-Ala-Ala-Ala-pNA (Bulk) [STANA]

Succinyl-l-alanyl-l-alanyl-l-alanine-p-Nitroanilide (M.W. 451.43) C19H25N5O8 [52299-14-6] Substrate for Elastase

AA SAA-3071 0.1 g

J. Bieth, B. Spiess, and C.G. Wermuth, Biochem. Med., 11, 350 (1974).

Suc(OMe)-Ala-Ala-Pro-Val-MCAN-Methoxysuccinyl-l-alanyl-l alanyl-l-prolyl-l-valine 4-methylcoumaryl-7-amide (M.W. 627.69) C31H41N5O9 [72252-90-5]

AA MAV-3153-v-20 °C

5 mg vial

Substrate for Human Leukocyte / Porcine Pancreatic ElastaseM.J. Castrillo, K. Nakajima, M. Zimmerman, and J.C. Powers, Anal. Biochem., 99, 53 (1979).

Suc-Ala-Ala-Pro-Abu-pNA(M.W. 562.58) C25H34N6O9 Substrate for Pancreatic Elastase

SAP-3667-PI-20 °C

5 mg25 mg

C.L. Largman, Biochemistry, 22, 3763 (1983). E.G. Del Mar, C. Largman, J.W. Brodick, M. Fassett, and M.C. Geokas, Biochemistry, 19, 468 (1980).

Suc-Ala-Ala-Pro-Gly-pNA(M.W. 534.53) C23H30N6O9 Substrate for Pancreatic Elastase

SAP-3666-PI-20 °C

5 mg25 mg


Suc-Ala-Ala-Pro-Trp-pNA (M.W. 663.69) C32H37N7O9 Substrate for Pancreatic Elastase

SAP-3668-PI-20 °C

5 mg25 mg


NEW!

-20 °C

-20 °C


NAL

Order Hotline 1-800-777-4779 502-266-8787 193

ENZYME INHIBITO

RS AND SUBSTRATES

Suc-Ala-Pro-Ala-MCASuccinyl-l-alanyl-l-prolyl-l-alanine 4-methylcou-maryl-7-amide (M.W. 514.53) C25H30N4O8 [88467-44-1] Substrate for Elastase

A MAP-3100-v-20 °C

5 mg vial

G. Oshima, K. Akashi, and M. Yamada, Arch. Biochem. Biophys, 233, 212 (1984).

Suc-Ala-Pro-Ala-pNASuccinyl-l-alanyl-l-prolyl-l-alanine p-nitroanilide (M.W. 477.47) C21H27N5O8 Substrate for Elastase

AA SAP-3118 0.1 g1 g

Furin and Carboxyl Side of Paired Basic Residue Cleaving Enzyme SubstratesBoc-Gln-Arg-Arg-MCA

t-Butyloxycarbonyl-l-glutaminyl-l-arginyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 715.80) C32H49N11O8 [109376-05-8]

A MQR-3122-v-20 °C

5 mg vial

Substrate for Carboxyl Side of Paired Basic Residue Cleaving EnzymeK. Mizuno, T. Nakamura, K. Takada, S. Sakakibara, and H. Matsuo, Biochem. Biophys. Res. Commun., 144, 807 (1987).

Pyr-Arg-Thr-Lys-Arg-MCAl-Pyroglutamyl-l-arginyl-l-threonyl-l-lysyl- l-arginine 4-methylcoumaryl-7-amide (M.W. 827.93) C37H57N13O9 [155575-02-3] Substrate for Furin

A MPR-3159-v-20 °C

5 mg vial

K. Hatsuzawa, M. Nagahama, S. Takahashi, K. Takada, K. Murakami, and K. Nakayama, J. Biol. Chem., 267, 16094 (1992).

Boc-Arg-Val-Arg-Arg-MCA A MRR-3155-v-20 °C

5 mg vialt-Butyloxycarbonyl-l-arginyl-l-valyl-l-arginyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 842.99) C38H62N14O8 Substrate for FurinK. Hatsuzawa, K. Murakami, and K. Nakayama, J. Biochem., 111, 296 (1992). K. Hatsuzawa, M. Nagahara, S. Takahashi, K. Takada, K. Murakami, and K. Nakayama, J. Biol. Chem., 267, 16094, (1992).

Boc-Gly-Arg-Arg-MCAt-Butyloxycarbonyl-glycyl-l-arginyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 644.72) C29H44N10O7 [113866-14-1]

A MGR-3142-v-20 °C

5 mg vial

Substrate for Carboxyl Side of Paired Basic Residue Cleaving EnzymeK. Mizuno, T. Nakamura, K. Takada, S. Sakakibara, and H. Matsuo, Biochem. Biophys. Res Commun., 144, 807 (1987).

Boc-Gly-Lys-Arg-MCAt-Butyloxycarbonyl-glycyl-l-lysyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 616.71) C29H44N8O7 [109358-48-7]

A MGK-3143-v-20 °C

5 mg vial


-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

194 Order Hotline 1-800-777-4779 502-266-8787

Boc-Leu-Arg-Arg-MCAt-Butyloxycarbonyl-l-leucyl-l-arginyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 700.83) C33H52N10O7

A MLR-3140-v-20 °C

5 mg vial

Substrate for Carboxyl Side of Paired Basic Residue Cleaving Enzyme and ProteasomeK. Mizuno, T. Nakamura, K. Takada, S. Sakakibara, and H. Matsuo, Biochem. Biophys. Res. Commun., 144, 807 (1987). M. Aki, N. Shimbara, M. Takashina, K. Akiyama, S. Kagawa, T. Tamura, N. Tanahashi, T. Yoshimura, K. Tanaka, and A. Ichihara, J. Biochem., 115, 257 (1994).

Boc-Leu-Lys-Arg-MCAt-Butyloxycarbonyl-l-leucyl-l-lysyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 672.82) C33H52N8O7 [109358-47-6]

A MLK-3141-v-20 °C

5 mg vial


GDP-l-Fuc Substrates See Code SGS-23004-s on page 229.

Gingipain SubstratesBoc-Phe-Ser-Arg-MCA

t-Butyloxycarbonyl-l-phenylalanyl-l-seryl-l-arginine 4-methylcoumaryl-7-amide (M.W. 665.74) C33H43N7O8 [73554-90-2]

AA MFS-3107-v-20 °C

5 mg vial

Substrate for Trypsin, Tryptase, 73K Protease, and Arg-GingipainS. Iwanaga, T. Morita, H. Kato, T. Harada, N. Adachi, T. Sugo, I. Maruyama, K. Takada, T. Kimura and S. Sakakibara, KININS-II: Biochemistry, Pathophysiology, and Clinical Aspects, (S. Fujii, H. Moriya and T. Suzuki, eds.), Plenum Publishing Co., 1979. pp. 147-163. M. Muramatsu, T. Itoh, M. Takei, and K. Endo, Biol. Chem. Hoppe-Seyler, 369, 617, (1988). A. Molla, T. Yamamoto, and H. Maeda, J. Biochem., 104, 616 (1988).

Z-His-Glu-Lys-MCA(Hydrochloride Form)

AA MCA-3215-v-20 °C

5 mg vial

Benzyloxycarbonyl-L-histidyl-L-glutamyl-L-lysine 4-methylcoumaryl-7-amide (M.W. 703.74) C35H41N7O9 Substrate for Lys-GingipainN. Abe, A. Baba, T. Kadowaki, K. Okamoto, S. Okazaki, T. Asao, and K. Yamamoto, J. Biochem., 128, 877 (2000).

Z-Phe-Arg-MCA See Code MFR-3095-v on page 184.

Glu-Glul-glutamyl-l-glutamic acid (M.W. 276.24) C10H16N2O7 [3929-61-1]

A OEE-3080 0.1 g1 g

Glu-pNA • H2Ol-Glutamic acid a-p-nitroanilide (M.W. 267.24 • 18.02) C11H13N3O5 • H2O

A SEN-3067 0.1 g1 g

Glu(Cys-Gly) [Glutathione; GSH]

g-l-glutamyl-l-cysteinylglycine (M.W. 307.32) C10H17N3O6S [70-18-8]

B OEG-3050 1 g5 g

25 g

Glutathione See Code OEG-3050 Glu(Cys-Gly) above.

-20 °C

-20 °C

-20 °C


NAL

Order Hotline 1-800-777-4779 502-266-8787 195

ENZYME INHIBITO

RS AND SUBSTRATES

Gly-GlyGlycylglycine (M.W. 132.12) C4H8N2O3 [556-50-3]

AA OGG-3028 5 g25 g

100 g

Gly-Gly-GlyGlycylglycylglycine (M.W. 189.17) C6H11N3O4 [556-33-2]

AA OGG-3061 1 g5 g

25 g

Gly-Gly-HisGlycylglycyl-l-histidine (M.W. 269.26) C10H15N5O4 [93404-95-6] Cu-Binding Peptide

A OGH-3076 0.1 g1 g

S. Lau, T.P.A. Kruch, and B. Sarkar, J. Biol. Chem., 249, 5878 (1974).

Gly-LeuGlycyl-l-leucine (M.W. 188.22) C8H16N2O3 [869-19-2]

AA OGL-3022 0.1 g1 g5 g

Gly-PheGlycyl-l-phenylalanine (M.W. 222.24) C11H14N2O3 [3321-03-7]

AA OGF-3053 0.1 g1 g

Gly-Phe-NH2 • AcOHGlycyl-l-phenylalanine amide (M.W. 221.26 • 60.05) C11H15N3O2 • CH3COOH [13467-26-0]

AA OGF-3023 0.1 g1 g

Gly-ProGlycyl-l-proline (M.W. 172.18) C7H12N2O3 [704-15-4]

AA OGP-3052 0.1 g1 g

GPNT See Code SGP-3074-v Glycyl-l-proline p-Nitroanilide • Tosylate on page 191.

γ-Glutamyl Trans-peptidase SubstrateGlu(pNA) • H2O

l-Glutamic acid g-p-nitroanilide (M.W. 267.24 • 18.02) C11H13N3O5 • H2O [122864-94-2] Substrate for g-Glutamyl Transpeptidase

A SEN-3066 0.1 g1 g5 g

Glycogen Synthase Kinase 3B Substrates[Ala353,357]-Presenilin 1 (349-361)

H-Gly-Pro-His-Arg-Ala-Thr-Pro-Glu-Ala-Arg-Ala-Ala-Val-OH (M.W. 1332.50) C56H93N21O17

SPR-3630-PI-20 °C

1 mg

Negative Control of Glycogen Synthase Kinase-3b SubstrateF. Kirschenbaum, S.-C. Hsu, B. Cordell, and J.V. McCarthy, J. Biol. Chem., 276, 7366-7375 (2000).

Presenilin 1 (349-361)H-Gly-Pro-His-Arg-Ser-Thr-Pro-Glu-Ser-Arg-Ala-Ala-Val-OH (M.W. 1364.49) C56H93N21O19

SPR-3629-PI-20 °C

1 mg

Glycogen Synthase Kinase-3b Substrate (GSK-3b Substrate)F. Kirschenbaum, S.-C. Hsu, B. Cordell, and J.V. McCarthy, J. Biol. Chem., 276, 7366-7375 (2000).

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

196 Order Hotline 1-800-777-4779 502-266-8787

Hepatitis C Protease SubstrateAc-Asp-Glu-Asp(Edans)-Glu-Glu-Abu-l-Lactoyl-Ser-Lys(Dabcyl)-NH2

(M.W. 1548.62) C68H89N15O25S [188530-20-3]FRET Substrate for Hepatitis C proteaseC. Lin, et al., J. Biol. Chem., 10, 1074 (2004).N. Kakiuchi, et al., J. Virol. Methods, 80, 77 (1999).Y. Liu, et al., Anal. Biochem., 267, 331 (1999).M. Taliani, et al., Anal. Biochem., 240, 60 (1996).

SFQ-3730-PI-20 °C

1 mg5 mg

Hepatocyte Growth Factor-Activator (HGF-A) SubstrateAc-Lys-Thr-Lys-Gln-Leu-Arg-MCA[Ac-KTKQLR-MCA]

Acetyl-l-lysyl-l-threonyl-l-lysyl-l-glutaminyl-l-leucyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 972.14) C45H73N13O11

AA MCA-3185-v-20 °C

5 mg vial

Substrate for Hepatocyte Growth Factor-Activator (HGF-A)K. Mizuno, Y. Tanoue, I. Okano, T. Harano, K. Takada, and T. Nakamura, Biochem. Biophys. Res. Commun., 198, 1161 (1994).

Hippuryl-alanyl-proline See Code SGP-3126 Bz-Gly-Ala-Pro on page 177.Hippuryl-arginine See Code SGR-3059 Benzoyl-glycyl-l-arginine on page 178.Hippuryl-glycyl-glycine See Code SGG-3128 Bz-Gly-Gly-Gly on page 177.Hippuryl-histidyl-leucine See Code SGL-3064 Benzoyl-glycyl-l-histidyl-l-leucine on page 177.Hippuryl-lysine See Code SGK-3047 Benzoyl-glycyl-l-lysine on page 178.

His-Leul-histidyl-l-leucine (M.W. 268.31) C12H20N4O3 [7763-65-7]

AA OHL-3065 0.1 g1 g

Histone Deacetylase SubstratesAc-Arg-Gly-Lys(Ac)-MCAAc-RGK(Ac)-MCA

(Trifluoroacetate Form) (M.W. 600.68) C28H40N8O7 [660846-97-9] Substrate for Histone Deacetylase D. Wegener, et al., Chem. Biol., 10, 61 (2003).

SRK-3728-PI -20 °C

1 mg5 mg

Ac-Arg-Gly-Lys-MCAAc-RGK-MCA

(Trifluoroacetate Form) (M.W. 558.64) C26H38N8O6 [660846-99-1] Substrate for Histone Deacetylase D. Wegener, et al., Chem. Biol., 10, 61 (2003).

SHD-3748-PI -20 °C

1 mg5 mg

Boc-Lys(TFA)-MCA(M.W. 499.49) C23H28F3N3O6 [97885-44-4] Substrate for Histone Deacetylase D. Riester, et al., Biochem. Biophys. Res. Commun., 324, 1116 (2004).A . Lahm, et al., Proc. Natl. Acad. Sci. U.S.A., 104, 17335 (2004).

SKT-3750-PI -20 °C

25 mg50 mg

100 mg

NEW!

NEW!

NEW!

NEW!

-20 °C


NAL

Order Hotline 1-800-777-4779 502-266-8787 197

ENZYME INHIBITO

RS AND SUBSTRATES

HIV-1 Protease SubstratesDabcyl-γ-Abu-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-Edans


SFQ-3763-PI-20 °C

1 mg5 mg

(M.W. 1532.75) C73H97N17O18S [127134-13-8]FRET Substrate for HIV ProteaseE.D.Matayoshi, et al., Science, 247, 954 (1990)M.W. Pennington, et al., Peptides 1992, Proceedings of the 22nd European Peptide Symposium, Interlaken, Switzerland, p. 936, (C.H.Schneider and A.N.Eberle, eds.) Escom, Leiden, (1993)U. Nillroth, et al., Antimicrob. Agents Chemother., 41, 2383 (1997)L.Bannwarth, et al., J. Med. Chem., 49, 4657 (2006)

Ser-Gln-Asn-Tyr-Pro-Ile-Val(M.W. 819.90) C37H57N9O12 Substrate for HIV-1 Protease

AA SSV-4236-v

-20 °C

5 mg vial

S. Billich, M.-T. Knoop, J. Hansen, P. Strop, J. Sedlacek, R. Mertz, and K. Moeliling, J. Biol. Chem., 263, 17905 (1988). P.L. Darke, R.F. Nutt, S.F. Brady, V.M. Garsky, T.M. Ciccarone, C.-T. Leu, P.K. Lumma, R.M. Freidinger, D.F. Veber, and I.S. Sigal, Biochem. Biophys. Res. Commun., 156, 297 (1988). P.L. Darke, et al., J. Biol. Chem., 264, 2307 (1989).

Horseshoe Crab Clotting Enzyme SubstrateBoc-Leu-Gly-Arg-MCA

(Hydrochloride Form) t-Butyloxycarbonyl-l-leucyl-glycyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 601.69) C29H43N7O7 [65147-09-3] Substrate for Horseshoe Crab Clotting Enzyme

AA MLG-3102-v-20 °C

5 mg vial

S. Iwanaga, T. Morita, T.Harada, S. Nakamura, M. Niwa, K. Takada, T. Kimura and S. Sakakibara, Haemostasis, 7, 183 (1978).

Human Rhino-virus-14 (HRV)3C Protease SubstrateSuc-Glu-Ala-Leu-Phe-Gln-pNA

Succinyl-l-glutamyl-l-alanyl-l-leucyl-l- phenylalanyl-l-Glutamine p-Nitroanilide (M.W. 826.87) C38H50N8O13 Substrate for 3C Human Rhinovirus-14 (HRV14)

SAP-3693-PI-20 °C

5 mg25 mg

Q. M. Wang, R.B. Johnson, G.A. Cox, E.C. Villarreal, and R.J. Loncharich, Anal. Biochem., 252, 238 (1997). Q.M. Wang, R.B. Johnson, L.N. Jungheim, J.D. Cohen, and E.C. Villarreal, Antimicrobial Agents and Chemot., 42, 916 (1998).

Kallikrein SubstratesPro-Phe-Arg-MCA

(Hydrochloride Form)A MPF-3096-v

-20 °C

5 mg vial

l-prolyl-l-phenylalanyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 575.66) C30H37N7O5 [115918-56-4]Substrate for Pancreatic / Urinary Kallikrein and ProteasomeT. Morita, H. Kato, S. Iwanaga, K. Takada, T. Kimura, and S. Sakakibara, J. Biochem., 82, 1495 (1977). V. Ustrell, G. Pratt, and M. Rechesteiner, Proc. Natl. Acad. Sci. USA, 92, 584 (1995).

Z-Phe-Arg-MCA See Code MFR-3095-v on page 184.

NEW!


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

198 Order Hotline 1-800-777-4779 502-266-8787

Human Kallikrein 6 SubstrateHuman kallikrein 6 (hK6) is greatly expressed in the central nervous system. It was shown to degrade myelin-associated proteins and is expressed in cells localized at sites of demyelination, suggesting hK6 plays a role in demyelinating diseases such as multiple sclerosis (MS).1,2 In addition, hK6 is attenuated in brain extracts of Alzheimer patients.3,4 Discovery of specific hK6 substrates would help to determine the functional role of this enzyme. Angelo et al. recently screened a number of potential FRETS-based hK6 substrates that were constructed based on a known hK1 substrate and found Abz-Ala-Phe-Arg-Phe-Ser-Gln-EEDnp (SFQ-3915-PI) to be the most potent (kcat = 11.6 s-1, Km = 0.3 µM).5 This substrate may help in studies focused on the biological role of hK6.1. Scarisbrick, et al., Brain, 125, 1283 (2002). 2. Blaber, et al., FASEB J., 18, 920 (2004). 3. Diamandis, et al., Clin. Biochem., 33, 579 (2000).

4. Ni, et al., Br. J. Cancer, 91, 725 (2004). 5. Angelo, et al., J. Biol. Chem., 281, 3116 (2006)

Abz-Ala-Phe-Arg-Phe-Ser-Gln-EDDnp (M.W. 1082.15) C50H63N15O13Substrate for Human Kallikrein 6 (hK6)

SFQ-3915-PI -20 °C

1 mg5 mg

Isopeptidase T Substrate See Code MLG-3176-v on page 206.

KYS-1 See Code SMO-3225-v on page 183.

Legumain SubstrateZ-Ala-Ala-Asn-MCA

Benzyloxycarbonyl-l-alanyl-l-alanyl-l-asparagine-4-methylcoumaryl-7-amide (M.W. 565.57) C28H31N5O8 [149697-16-5] Substrate for Legumain

A MCA-3209-v-20 °C

5 mg vial

A.A. Kembhavi, D.J. Buttle, C.G. Knight, and A.J. Barret, Arch. Biochem. Biophys., 303, 208 (1993). J.-M. Chen, et al., J. Biol. Chem., 272, 8090 (1997). B. Manoury, E.W. Hewitt, N. Morrice, P.M. Dando, A.J. Barret, and C. Watts, Nature, 396, 695 (1998). S.J. Choi, et al., J. Biol. Chem., 274, 27747 (1999). P.M. Dando, M. Fortunato, L. Smith, C.G. Knight, J.E. McKendrick, and A.J. Barret, Biochem. J., 339, 743 (1999).

Leu-Gly • ½ H2Ol-Leucylglycine (M.W. 188.22 • 9.01) C8H16N2O3 • ½ H2O [686-50-0]

AA OLG-3024 0.1 g1 g

Leu-Gly-Glyl-Leucylglycylglycine (M.W. 245.28) C10H19N3O4 [1187-50-4]

AA OLG-3025 0.1 g1 g

Lysine Hydroxylase SubstrateAla-Arg-Gly-Ile-Lys-Gly-Ile-Arg-Gly-Phe-Ser-Gly • 3AcOH • 5H2O[lysine Hydroxylase Substrate L-1]

AA SAG-4166-20 °C

25 mg

(M.W. 1218.4 • 180.16 • 90.08) C53H91N19O14 • 3CH3COOH • 5H2O Substrate for lysine Hydroxylase

K.I. Kivirikko, K. Shudo, S. Sakakibara, and D.J. Prockop, Biochemistry, 11, 122 (1972). (Original)

NEW!

-20 °C

-20 °C


NAL

Order Hotline 1-800-777-4779 502-266-8787 199

ENZYME INHIBITO

RS AND SUBSTRATES

Met-Metl-methionyl-l-methionine (M.W. 280.41) C10H20N2O3S2 [7349-78-2]

A OMM-3152 0.1 g1 g

MALTI SubstrateAc-Leu-Arg-Ser-Arg-MCA

Ac-LRSR-MCA(M.W. 729.84) C33H51N11O8Substrate for MALTI

MCA-3952-PI -20 °C

5 mg

P. Niyomrattanakit, S. Yahorava, I. Mutule, F. Muturlis, R. Petrovska, P. Prusis, G. Katzenmeier, and J.E.S. Wikberg, Biochem. J., 397, 203-211 (2006).

Reference Compound for MOCAc-type Fluorescence-Quenching SubstrateMOCAc-Pro-Leu-Gly AA MOC-3164-s

-20 °C

0.1 mg vial(7-Methoxycoumarin-4-yl) acetyl-l-prolyl-l-leucyl-glycine (M.W. 501.53) C25H31N3O8 [140430-56-4]Reference Compound for MOCAc-type Fluorescence-Quenching SubstrateC.G. Knight, F. Willenbrock, and G. Murphy, FEBS Lett., 296, 263 (1992).

Neprilysin SubstrateZ-Ala-Ala-Leu-pNA

Benzyloxycarbonyl-l-alanyl-l-alanyl-l-leucine p-nitroanilide (M.W. 527.57) C26H33N5O7 [61043-33-2]

AA SAP-3127 0.1 g1 g

Substrate for Subtilisin A and Serine Protease of Bacillus subtilis IFO3027 / NeprilysinV.M. Stepanov, et al., Biochem. Biophys. Res. Commun., 77, 298 (1977). Y. Shimizu, T. Nishino, and S. Murao, Agric. Biol. Chem., 47, 1775 (1983). Y. Takaki, et al., J. Biochem., 128, 897 (2000). N. Iwata, Y. Takaki, S. Fukami, S. Tsubuki, and T.C. Saido, J. Neurosci. Res., 70, 493 (2002).

Neutral Endopeptidase SubstratesZ-Gly-Gly-Leu-pNA

Benzyloxycarbonyl-glycylglycyl-l-leucine-p-nitroanilide(M.W. 499.52) C24H29N5O7 [53046-98-3] Substrate for Neutral Endopeptidase

AA SGL-3111 -20 °C

25 mg100 mg

1 g

M. Orlowski and S. Wilk, In, Peptides, Structure and Biological Functions, (E. Gross and J. Meienhofer, Eds.), Pierce Chemical Co., 1980, p. 925.

Abz-Ala-Gly-Leu-Ala-p-Nitro-Benzyl-Amide


SAG-3905-PI -20 °C

2-Aminobenzoyl-l-Alanyl-Glycyl-l-Leucyl-l-Alanyl-para-Nitro-Benzyl-Amide (M.W. 583.65) C28H37N7O7 Substrate for Thermolysin and Neutral Endopeptidase 24.11 (NEP)N. Nishino and J.C. Powers, J. Biol. Chem., 255, 3482 (1980). R.S. Rush, et al., Arch. Biochem. Biophys., 231, 390 (1984).D.I. Mundy and W.J. Strittmatter, Cell, 40, 645 (1985).

NEW!

-20 °C

-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

200 Order Hotline 1-800-777-4779 502-266-8787

Pepsin SubstrateMOCAc-Ala-Pro-Ala-Lys-Phe-Phe-Arg-Leu-Lys(Dnp)-NH2


A SMO-3216-v-20 °C

1 mg vial

(7-Methoxycoumarin-4-yl)Acetyl-l-alanyl-l-prolyl-l-alanyl-l-lysyl-l-phenylalanyl-l- phenylalanyl-l-arginyl-l-leucyl-[Ne-(2,4-dinitrophenyl)-l-lysine] amide (M.W. 1458.6) C71H95N17O17 Fluorescence-Quenching Substrate for Proteinase A / PepsinH. Kondo, Y. Shibano, T. Amachi, N. Cronin, K. Oda, and B.M. Dunn, J. Biochem., 124, 141 (1998). • This compound is distributed under the license of Suntory Limited.

Peptidoglutaminase SubstrateBoc-Gln-Pro

t-Butyloxycarbonyl-l-glutaminyl-l-proline (M.W. 343.38) C15H25N3O6 [2419-99-0] Substrate for Peptidoglutaminase

AA SQP-3151 0.1 g1 g

J.S. Hamada and W.E. Marshall, J. Food Sci., 53, 1132 (1988).

Reference Compound for Peptidyl-MCA SubstrateAMC

7-Amino-4-methyl-coumarin(M.W. 175.18) C10H9NO2 [26093-31-2]

AA MCA-3099-v-20 °C

5 mg vial

Reference Compound for Analysis with Peptidyl-MCA Substrates

Peptidyl Prolyl cis-trans Isomerase (PPlase) SubstrateSuc-Ala-Glu-Pro-Phe-pNASuc-AEPF-pNA

(Acetate Form) (M.W. 682.69) C32H38N6O11

SAP-3947-PI -20 °C

1 mg5 mg

Substrate for Peptidyl-prolyl Isomerase (PPIase) Pin1Z.J. Shen, S. Esnault, and J.S. Malter, Nat. Immunol., 6, 1280 (2005). S. Esnault, Z.J. Shen, E.Whitesel and J.S. Malter, J. Immunol., 177, 6999 (2006).

Suc-Ala-Leu-Pro-Phe-pNA See Code SAF-3162-v on page 179

Plasmin SubstrateBoc-Glu-Lys-Lys-MCA A MEK-3105-v

-20 °C

5 mg vial t-Butyloxycarbonyl-l-glutamyl-l-lysyl-l-lysine 4-methylcoumaryl-

7-amide (M.W. 660.76) C32H48N6O9 [73554-85-5] Substrate for PlasminH. Kato, N. Adachi, Y. Ohno, S. Iwanaga, K. Takada, and S. Sakakibara, J. Biochem., 88, 183 (1980).

Boc-Val-Leu-Lys-MCA See Code MVL-3104-v on page 179.

Prion Proteins See Celluar Prion Proteins on page 185.

NEW!

-20 °C


NAL

Order Hotline 1-800-777-4779 502-266-8787 201

ENZYME INHIBITO

RS AND SUBSTRATES

Prolyl Endopeptidase SubstrateSuc-Gly-Pro-MCA AA MGP-3109-v

-20 °C

5 mg vialSuccinyl-glycyl-l-proline 4-methylcoumaryl-7-amide (M.W. 429.42) C21H23N3O7 [80049-85-0]Substrate for Propyl Endopeptidase (Post-proline Cleaving Enzyme)T. Kato, T. Nakano, K. Kojima, T. Nagatsu, and S. Sakakibara, J. Neurochem., 35, 527 (1980).

Proteinase 3 SubstrateAbz-Val-Ala-Asp-Nva-Arg-Asp-Arg-Gln-EDDnp [Abz-VADnVRDRQ-EDDnp], nV = Nva


SNP-3232-v-20 °C

1 mg vial

2-Aminobenzoyl-l-valyl-l-alanyl-l-aspartyl-l-norvalyl-l-arginyl-l-aspartyl-l-arginyl-l-glutamine 2-(2,4-dinitrophenyl)aminoethyl-amide(M.W. 1285.3) C53H80N20O18Fluorescence-Quenching Substrate for Human Neutrophil Proteinase 3

B. Korkmaz, et al., J. Biol. Chem., 282, 1989 (2007).B. Korkmaz, et al., Nat. Protoc., 3, 991 (2008).

Proteinase A SubstratesMOCAc-Ala-Pro-Ala-Lys-Phe-Phe-Arg-Leu-Lys(Dnp)-NH2 See Code SMO-3216-v on page 200.Suc-Arg-Pro-Phe-His-Leu-Leu-Val-Tyr-MCA See Code MRP-3110-v on page 186

Protein Kinase SubstratePyr-Lys-Arg-Pro-Ser-Gln-Arg-Ser-Lys-Tyr-Leu

(M.W. 1373.6) C60H100N20O17 [136132-68-8] Substrate for Protein Kinase C

A SKL-4237-v-20 °C

5 mg vial

I. Yasuda, A. Kishimoto, S. Tanaka, M. Tominaga, A. Sakurai, and Y. Nishizuka, Biochem. Biophys. Res. Commun., 166, 1220 (1990).

Arg-Arg-Leu-lle-Glu-Asp-Ala-Glu-Tyr-Ala-Ala-Arg-Gly [RR-SRC]

(M.W. 1519.7) C64H106N22O21 [81156-93-6]Substrate for Tyrosine Protein-Kinase

AA

SRG-4184-v-20 °C

0.5 mg vial

J.E. Casnellie, M.L. Harrison, L.J. Pike, K.E. Hellström, and E.G. Krebs, Proc. Natl. Acad. Sci. USA, 79, 282 (1982).

H-Arg-Arg-Leu-Ile-Glu-Asp-Ala-Glu-Tyr-Ala-Ala-Arg-Gly-NH2

(Acetate Form) RRLIEDAEYAARG(M.W. 1518.71) C64H107N23O20 [81156-93-6]Substrate for Protein Tyrosine Kinase (PTK)

PTK-3956-PI -20 °C

1 mg5 mg

J.E. Casnellie, M.L. Harrison, L.J. Pike, K.E. Hellstrom, and E.G. Krebs, Proc. Natl. Acad. Sci. USA, 79, 282 (1982).S.E. Ramer, D.G. Winker, A. Carrera, T.M. Robets, and C.T. Walsh, Proc. Natl. Acad. Sci. USA, 88, 6254, (1991).H.S. Earp, K.S. Austin, G.Y. Gillespie, S.C. Buessow, A.A. Davies, and P.J. Parker, J. Biol. Chem., 260, 4351 (1985).

NEW!

NEW!


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

202 Order Hotline 1-800-777-4779 502-266-8787

Protein Phosphatase SubstrateH-Arg-Arg-Leu-Ile-Glu-Asp-Ala-Glu-Tyr(H2PO3)-Ala-Ala-Arg-Gly-NH2RRLIEDAE-pY-AARG

(Acetate Form) (M.W. 1598.69) C64H108N23O23P

PTP-3955-PI -20 °C

1 mg5 mg

Substrate for Protein Tyrosine Phosphatase (PTP)K.L. Lim, D.S.Y. Lai, M.B. Kalousek, Y. Wang, and C.J. Pallen, Eur. J. Biochem, 245, 693 (1997).V. Bhandari, K. Leong Lim, and C.J. Pallen, J. Biol. Chem., 273, 8691 (1998).J.J. Perez-Villar, et al., Molec. Cell. Biol., 19, 2903 (1999).

Pyro-glutamyl Peptidase SubstratesPyr-Ala

l-Pyroglutamyl-l-alanine (M.W. 200.19) C8H12N2O4 [21282-08-6] Substrate for Pyroglutamyl Peptidase

AA OVA-3079-20 °C

0.1 g1 g

R.F. Doolittle, In, Proteolytic Enzymes, Methods in Enzymology, Vol. 19, (G.E. Perlmann and L. Lorand, Eds.), Academic Press, New York, 1970, pp. 555-569.

Pyr-MCAl-Pyroglutamic acid 4-methylcoumaryl-7-amide (M.W. 286.28) C15H14N2O4 [66642-36-2] Substrate for Pyroglutamyl PeptidaseK. Fujiwara and D. Tsuru, J. Biochem., 83, 1145 (1978).

AA MPX-3101-v-20 °C

5 mg vial

Renin SubstratesAsp-Arg-Val-Tyr-lle-His-Pro-Phe-His-Leu-Val-Ile-His

(M.W. 1645.9) C79H116N22O17 [82048-97-3]Substrate for Renin

A SDH-4133-v-20 °C

0.5 mg vial

D.A. Tewksbury, R.A. Dart, and J. Travis, Biochem. Biophys. Res. Commun., 99, 1311 (1981).

Dabcyl-γ-Abu-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Edans

(Trifluoroacetate Form)(M.W. 1798.16) C90H120N22O16S [142988-22-5]FRET Substrate for Renin

SFQ-3731-PI-20 °C

1 mg5 mg

G.T. Wang, et al., Anal Biochem, 210, 351-9 (1993). N. Nakamura, et al., J Biochem (Tokyo), 109, 741-5 (1991). K. Murakami, et al., Anal Biochem, 110, 232-9 (1981).

Nma-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(Dnp)-D-Arg-D-Arg-NH2


SFQ-3229-v-20 °C

1 mg vial

[2-(Methylamino)benzoyl]-l-isoleucyl-l-histidyl-l-prolyl-l-phenylalanyl-l-histidyl-l-leucyl-l-valyl-l- isoleucyl-l-histidyl-l-threonyl-[Nε-(2,4-dinitrophenyl)-l-lysyl]-d-arginyl-d-arginine amide (M.W. 1952.20) C91H134N30O19 Synthetic Product Fluorescence-Quenching Substrate for Human Renin S. Takahashi, K. Hori, M. Shinbo, K. Hiwatashi, T. Gotoh, and S. Yamada, Biosci. Biotechnol. Biochem.,72, 3232 (2008).

Suc-Arg-Pro-Phe-His-Leu-Leu-Val-Tyr-MCA See Code MRP-3110-v on page 186.

NEW!

NEW!

NEW!


NAL

Order Hotline 1-800-777-4779 502-266-8787 203

ENZYME INHIBITO

RS AND SUBSTRATES

β-Secretase SubstratesMOCAc-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-Lys(Dnp)-Arg-Arg-NH2 [MOCAc-SEVNLDAEFRK(Dnp)RR-NH2]


B SMO-3212-v-20 °C

1 mg vial

(7-Methoxycoumarin-4-yl) acetyl-l-seryl-l-glutamyl-l-valyl-l-Asparaginyl-l-leucyl-l-aspartyl-l-alanyl-l-glutamyl-l-phenylalanyl-l-arginyl-[Ne-(2,4-dinitrophenyl)-l-lysyl]-l-arginyl-l-arginine amide (M.W. 2001.1) C86H125N27O29 Fluorescence-Quenching Substrate for b-SecretaseH. Koike, H. Seki, Z. Kouchi, M. Ito, T. Kinouchi, S. Tomioka, H. Sorimachi, T.C. Saido, K. Maruyama, K. Suzuki, and S. Ishiura, J. Biochem., 126, 235 (1999).

H-Arg-Glu(Edans)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(Dabcyl)-Arg-OH

(Trifluoroacetate Form) H-RE(Edans)-EVNLDAEFK(Dabcyl)R-OH(M.W. 2005.26) C91H129N25O25S

SFQ-3690-PI

1 mg

Fluorescence-Quenching Substrate for Memapsin 2 (b-Secretase)J. Ermolieff, J.A. Loy, G. Koelsch, and J. Tang, Biochemistry, 39, 12450 (2000). (substrate termed FS-1 this paper)

γ-Secretase SubstrateNma-Gly-Gly-Val-Val-Ile-Ala-Thr-Val-Lys(Dnp)-d-Arg-d-Arg-d-Arg-NH2


B SFQ-3217-v-20 °C

1 mg vial

[2-Methylamino)benzoylglycylglycyl-l-valyl-l-valyl-l-isoleucyl-l-alanyl-l-threonyl-l- valyl-[Ne-(2,4-dinitrophenyl)-l-lysyl]-d-arginyl-d-arginyl-d-arginine amide (M.W. 1609.8) C70H116N26O18 Fluorescence-Quenching Substrate for g-SecretaseM.R. Farmery, L.O. Tjernberg, S.E. Pursglove, A. Bergman, B. Winblad, and J. Näslund, J. Biol. Chem., 278, 24277 (2003). (Original)

Serum Peptidase SubstrateDnp-Leu-Gly-Ile-Ala-Gly-Arg-NH2

2,4-dinitrophenyl-l-leucyl-glycyl-l-isoleucyl-l-alanyl-glycyl-l-arginine amide (M.W. 750.80) C31H50N12O10 Substrate for Serum Peptidase

A SDL-3083-v-20 °C

2.5 mg vial


Site-1 Protease (S1P) SubstrateAc-Val-Phe-Arg-Ser-Leu-Lys-MCA

(Trifluoroacetate Form) Acetyl-l-valyl-l-phenyl-l-arginyl-l-seryl-l-leucyl-l-lysine 4-methylcoumaryl-7-amide(M.W. 948.14) C47H69N11O10Substrate for Site-1 Protease (S1P)

MCA-3679-PI-20 °C

1 mg5 mg

D. Cheng, P.J. Espenshade, C.A. Slaughter, J.C. Jaen, M.S. Brown, and J.L. Goldstein, J. Biol. Chem., 274, 22805 (1999).

-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

204 Order Hotline 1-800-777-4779 502-266-8787

Subtilisin A SubstrateZ-Ala-Ala-Leu-pNA See Code SAP-3127 on page 199.

Suc-Ala-Ala-pNASuccinyl-l-alanyl-l-alanine p-nitroanilide (M.W. 380.35) C16H20N4O7

AA SAA-3117 0.1 g1 g

Suc-Ala-pNASuccinyl-l-alanine p-nitroanilide (M.W. 309.27) C13H15N3O6

AA SAN-3116 0.1 g1 g

Trans-glutaminase SubstrateZ-Gln-Gly

Benzyloxycarbonyl-l-glutaminylglycine (M.W. 337.33) C15H19N3O6 [6610-42-0] Substrate for Transglutaminase

AA SZQ-3190 1 g5 g

J.E. Folk and P.W. Cole, J. Biol. Chem., 241, 5518 (1966). H. Ando, M. Adachi, K. Umeda, A. Matsuura, M. Nonaka, R. Uchio, H. Tanaka, and M. Motoki, Agric. Biol. Chem., 53, 2613 (1989).

Tripeptidyl Peptidase II SubstrateAla-Ala-Phe-MCA

(Hydrochloride Form)AA MCA-3201-v

-20 °C

5 mg vial

l-alanyl-l-alanyl-l-phenylalanine 4-methylcoumaryl-7-amide (M.W. 464.51) C25H28N4O5 [62037-41-6] Substrate for Tripeptidyl Peptidase II (Component of Giant Protease with Some Proteasome Function)R. Glas, M. Bogyo, J.S. McMaster, M. Gaczynska, and H. L. Ploegh, Nature, 392, 618 (1998). E. Geier, G. Pfeifer, M. Wilm, M. Lucchiari-Hartz, W. Baurmeister, K. Eichmann, and G. Niedermann, Science, 283, 978 (1999).

Trypsin and Trypsin-like Protease SubstratesAc-Arg-OMe • HCl

Acetyl-l-arginine methyl ester • monohydrochloride

B SRM-3078 1 g5 g

(M.W. 230.26 • 36.46) C9H18N4O3 • HCI [1784-05-0] Substrate for C1rR.B. Sim, In, Proteolytic Enzymes Part C, Methods in Enzymology, Vol. 80, (L. Lorand, ed.), Academic Press, New York, 1981, pp. 26-42.

Ac-Gly-Lys-OMe • AcOH [AGLME]

Acetyl-glycyl-l-lysine methyl ester

A SGK-3058 0.1 g1 g

(M.W. 259.30 • 60.05) C11H21N3O4 • CH3COOH [14752-92-2] Substrate for u-PA (Urokinase) and C1s

P.L. Walton, Biochim. Biophys. Acta., 132, 104 (1967). N. Miwa, Y. Obata, and A. Suzuki, Biochem. Biophys. Res. Commun., 112, 754 (1983). R.B. Sim, In, Proteolytic Enzymes Part C, Methods in Enzymology, Vol. 80, (L. Lorand, Ed.), Academic Press, New York, 1981, pp. 26-42.

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C


NAL

Order Hotline 1-800-777-4779 502-266-8787 205

ENZYME INHIBITO

RS AND SUBSTRATES

Boc-Gln-Ala-Arg-MCAt-Butyloxycarbonyl-l-glutaminyl-l-alanyl-l-arginine4-methylcoumaryl-7-amide (M.W. 630.69) C29H42N8O8 [113866-20-9] Substrate for Trypsin

A MQR-3135-v-20 °C

5 mg vial


Boc-Leu-Gly-Arg-MCA See Code MLG-3102-v on page 197.Boc-Phe-Ser-Arg-MCA See Code MFS-3107-v on page 194.

Bz-Arg-MCA(Hydrochloride form) Benzoyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 435.48) C23H25N5O4 [83701-04-6] Substrate for Trypsin

A MBR-3092-v-20 °C

5 mg vial

Y. Kanaoka, T. Takahashi, H. Nakayama, K. Takada, T. Kimura, and S. Sakakibara, Chem. Pharm. Bull., 25, 3126 (1977).

Bz-Arg-NH2 • HCl • H2OBenzoyl-l-arginine amide monohydrochloride monohydrate

AA SRA-3002 1 g5 g

(M.W. 277.32 • 36.46 • 18.02) C13H19N5O2 • HCI • H2O [4299-03-0] Substrate for TrypsinK.A. Walsh, In, Proteolytic Enzymes, Methods in Enzymology, Vol. 19, (G.E. Perlmann and L. Lorand, Eds.), Academic Press, New York, 1970, pp. 41-63.

Bz-Arg-OEt • HCl [BAEE]

Benzoyl-l-arginine ethyl ester monohydrochloride

A SRE-3001 1 g25 g

(M.W. 306.36 • 36.46) C15H22N4O3 • HCI [2645-08-1] Substrate for Trypsin K.A. Walsh, In, Proteolytic Enzymes, Methods in Enzymology, Vol. 19, (G.E. Perlmann and L. Lorand, Eds.), Academic Press, New York, 1970, pp. 41-63.

Bz-dl-Arg-pNA • HCl [dl-BAPA]

A SRN-3013 0.1 g5 g

Benzoyl-dl-arginine p-nitroanilide monohydrochloride (M.W. 398.42 • 36.46) C19H22N6O4 • HCl [911-77-3]Substrate for Trypsin-like ProteaseK.A. Thomas and R.A. Bradshaw, In, Proteolytic Enzymes Part C, Methods in Enzymology, Vol. 80, (L. Lorand, Ed.), Academic Press, New York, 1981, pp. 609-620. G.A. Grant, A.Z. Eisen, and R.A. Bradshaw, In, Proteolytic Enzymes Part C, Methods in Enzymology, Vol. 80, (L. Lorand, Ed.), Academic Press, New York, 1981, pp. 722-734.

Bz-L-Arg-pNA See Code SRN-3057 on page 183.

Tos-Arg-OMe • HCI[TAME] Tosyl-l-arginine methyl ester monohydrochloride

A STR-3003 5 g25 g

100 g(M.W. 342.41 • 36.46) C14H22N4O4S • HCI [1784-03-8] Substrate for TrypsinK.A. Walsh, In, Proteolytic Enzymes, Methods in Enzymology, Vol. 19, (G.E. Perlmann and L. Lorand, Eds.), Academic Press, New York, 1970, pp. 41-63.

-20 °C

-20 °C

-20 °C

-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

206 Order Hotline 1-800-777-4779 502-266-8787

Tos-Lys-OMe • HCITosyl-l-lysine methyl ester monohydrochloride (M.W. 314.40 • 36.46) C14H22N2O4S • HCI [5266-48-8] Substrate for Trypsin

A STK-3054 0.1 g1 g

F. Widmer and J.T. Johansen, Carlsberg Res. Commun., 44, 37 (1979). F. Widmer, K. Breddam, and J.T. Johansen, Proc. 16th European Peptide Symposium (K. Brunfeldt, Ed.), Scriptor, Copenhagen 1981, pp. 46-55.

Ubiquitin Proteasome System Substrates Ac-Arg-Leu-Arg-MCAAc-RLR-MCA

(Trifluoroacetate Form) (M.W. 642.76) C30H46N10O6 [929903-87-7]Fluorogenic Substrate; Subrate for 20S ProteasomeA.F. Kisselev, et al., J. Biol. Chem., 281 (2006).A.F. Kisselev and A.L.Goldberg, Meth. Enzy., 398 (2005).K.J. Rogders and R.T. Dean, Intl. J. Biochem.Cell.Biol., 35 (2003)

MCA-3729-PI -20 °C

1 mg5 mg

Ac-Gly-Pro-Leu-Asp-MCA[Ac-GPLD-MCA]

(Acetate Form)Substrate for Caspase-Like Site of Proteasomes(M.W. 599.65) C29H37N5O9

MCA-3649-PI-20 °C

5 mg

A. Kisselev, M. Garcia-Calvo, H.S. Overkleeft, E. Peterson, M.W. Pennington, H.L. Ploegh, N.A. Thornberry, and A.L.Goldberg, J. Biol. Chem., 278, 35869 (2003).

Ac-Nle-Pro-Nle-Asp-MCA(M.W. 655.75) C33H45N5O9

MCA-3650-PI-20 °C

5 mg

Substrate for Caspase-Like Site of ProteasomesA. Kisselev, M. Garcia-Calvo, H.S. Overkleeft, E. Peterson, M.W. Pennington, H.L. Ploegh, N.A. Thornberry, and A.L.Goldberg, J. Biol. Chem., 278, 35869 (2003).

Suc-Ala-Glu-MCASuccinyl-l-alanyl-l-glutamic acid a-4-methylcou-maryl-7-amide (M.W. 475.45) C22H25N3O9 Substrate for Ingensin / Proteasome.

A MAE-3160-v-20 °C

5 mg vial

S. Ishiura, T. Tsukahara, T. Tabira, and H. Sugita, FEBS Lett., 257, 388 (1980)

Z-Leu-Arg-Gly-Gly-MCABenzyloxycarbonyl-l-leucyl-l-arginyl-glycylglycine 4-methylcoumaryl-7-amide (M.W. 692.76) C34H44N8O8 [167688-68-2] Substrate for Isopeptidase T

A MLG-3176-v-20 °C

5 mg vial

R.L Stein, Z. Chen, and F. Melandri, Biochemistry, 34, 12616 (1995).

Z-Leu-Leu-Glu-MCABenzyloxycarbonyl-l-leucyl-l-leucyl-l-glutamic acid a-(4-methylcoumaryl-7-amide) (M.W. 664.75) C35H44N4O9 [348086-66-8] Substrate for Proteasome

A MLG-3179-v-20 °C

5 mg vial

NEW!

-20 °C


NAL

Order Hotline 1-800-777-4779 502-266-8787 207

ENZYME INHIBITO

RS AND SUBSTRATES

Z-Leu-Leu-Leu-MCABenzyloxycarbonyl-l-leucyl-l-leucyl-l-leucine 4-methylcoumaryl-7-amide (M.W. 648.79) C36H48N4O7 Substrate for Proteasome

A MLL-3177-v-20 °C

5 mg vial

S. Tsubuki, H. Kawasaki, Y. Saito, N. Miyashita, M. Inomata, and S. Kawashima, Biochem. Biophys. Res. Commun., 196, 1195 (1993).

Boc-Leu-Arg-Arg-MCA See Code MLR-3140-v on page 194.Pro-Phe-Arg-MCA See Code MPF-3096-v on page 197.Suc-Leu-Leu-Val-Tyr-MCA See Code MLL-3120-v on page 179.

u-PA (Urokinase) Substrates Also see SGK-3058 Ac-Gly-Lys-OMe • AcOH

Glt-Gly-Arg-MCAGlutarylglycyl-l-arginine 4-methylcoumaryl-7-amide (M.W. 502.52) C23H30N6O7 [65147-16-2] Substrate for u-PA (Urokinase)

A MGG-3097-v-20 °C

5 mg vial

T. Morita, H. Kato, S. Iwanaga, K. Takada, T. Kimura, and S. Sakakibara, J. Biochem., 82, 1495 (1977). S. Iwanaga, T. Morita, H. Kato, T. Harada, N. Adachi, T. Sugo, I. Maruyama, K. Takada, T. Kimura, and S. Sakakibara, In, KININS-II: Biochemistry, Pathophysiology, and Clinical Aspects, (S. Fujii, H. Moriya, and T. Suzuki, eds.), Plenum Publishing Co., 1979, pp. 147-163.

Pyr-Gly-Arg-MCAl-Pyroglutamyl-glycyl-l-arginine 4-methylcouma-ryl-7-amide (M.W. 499.52) C23H29N7O6 Substrate for t-PA and u-PA (Urokinase)

A MPR-3145-v-20 °C

5 mg vial

Vascular Processing Enzyme SubstratesAc-Glu-Ser-Glu-Asn-MCA[Ac-ESEN-MCA]

MCA-3227-v -20 °C

5 mg

Acetyl-l-glutamyl-l-seryl-l-glutamyl-l-asparagine α-(4-methylcoumaryl-7-amide)(M.W. 676.63) C29H36N6O13 Substrate for Vacuolar Processing Enzyme (VPE)M. Kuroyanagi, M. Nishimura, and I. Hara-Nishimura, Plant Cell Physiol., 43, 143 (2002).N. Hatsugai, M. Kuroyanagi, K. Yamada, T. Meshi, S. Tsuda, M. Kondo, M. Nishimura, and I. Hara-Nishimura, Science, 305, 855 (2004).M. Kuroyanagi, K. Yamada, N. Hatsugai, M. Kondo, M. Nishimura, and I. Hara-Nishimura, J. Biol. Chem., 280, 32914 (2005).

Z-Arg-OBzl(p-NO2) • HBrBenzyloxycarbonyl-l-arginine p-nitrobenzyl ester • Monohydrobromide (M.W. 443.45 • 80.91) C21H25N5O6 • HBr [96723-72-7]

A SRB-3157 0.1 g1 g

Z-Asp-CH2-DCB See Code ICE-3174-v on page 159.Z-Glu-Lys(bio)-Asp-aomk See Code ICA-3189-v on page 159. Z-Glu-Lys(Biotinyl)-Asp-CH2-DCB See Code ICA-3189-v on page 159.

Z-Gly-LeuBenzyloxycarbonylglycyl-l-leucine (M.W. 322.36) C16H22N2O5 [1421-69-8]

AA SGL-3019 0.1 g1 g

Z-Gly-Leu-NH2Benzyloxycarbonylglycyl-l-leucine amide (M.W. 321.37) C16H23N3O4 [7535-72-0]

AA SGL-3037 0.1 g1 g

NEW!

-20 °C

-20 °C

-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

208 Order Hotline 1-800-777-4779 502-266-8787

Z-Gly-PheBenzyloxycarbonylglycyl-l-phenylalanine (M.W. 356.37) C19H20N2O5 [1170-76-9]

AA SGF-30204 °C

0.1 g1 g

Z-Gly-Phe-NH2Benzyloxycarbonylglycyl-l-phenylalanine amide (M.W. 355.39) C19H21N3O4 [5513-69-9]

AA SGF-30214 °C

0.1 g1 g

Z-Gly-ProBenzyloxycarbonylglycyl-l-proline (M.W. 306.31) C15H18N2O5 [1160-54-9]

AA SGP-30554 °C

0.1 g1 g

Z-Gly-Pro-LeuBenzyloxycarbonylglycyl-l-prolyl-l-leucine (M.W. 419.47) C21H29N3O6 [2646-63-1]

AA SGL-30394 °C

0.1 g1 g

Z-Gly-Pro-Leu-GlyBenzyloxycarbonylglycyl-l-prolyl-l-leucyl-glycine (M.W. 476.52) C23H32N4O7

AA SGG-30404 °C

0.1 g1 g

Z-Ile-Glu(OtBu)-Ala-Leu-H (aldehyde) See Code IAT-3169-v on page 172.Z-Leu-Leu-H (aldehyde) See Code IZL-3178-v on page 155.Z-Leu-Leu-Leu-H (aldehyde) See Code IZL-3175-v on page 162.Z-Leu-Leu-Nva-H (aldehyde) See Code IAT-3170-v on page 172.

Z-Phe-TyrBenzyloxycarbonyl-l-phenylalanyl-l-tyrosine (M.W. 462.49) C26H26N2O6

AA SFY-30444 °C

0.1 g1 g

Z-Tyr-GluBenzyloxycarbonyl-l-tyrosyl-l-glutamic acid (M.W. 444.43) C22H24N2O8 [988-70-5]

AA SYE-30694 °C

0.1 g1 g

Z-Tyr-ONpBenzyloxycarbonyl-l-tyrosine p-nitrophenyl ester (M.W. 436.41) C23H20N2O7 [3556-56-7]

A-B SYN-3016-20 °C

0.1 g1 g


Order Hotline 1-800-777-4779 502-266-8787 209

ENZYME INHIBITO

RS AND SUBSTRATES

Design of FRETS-25XaaEach substrate (SFA-3701-v - SFV-3719-v) in the FRETS-25Xaa series contains a highly fluorescent 2-(N-methylamino)benzoyl (Nma) group linked to the side chain of the amino-terminal d-2,3-diamino proprionic acid (D-A2pr) residue, which is efficiently quenched by a 2,4-dinitrophenyl (Dnp) group linked to the e-amino function of Lys. Xaa represents a fixed position of each of the 19 natural amino acids excluding Cys (noted in product name, code SFA-3701-v - SFV-3719-v). A mixture of 5 amino acid residues (P, Y, K, I, and D) is at the Yaa position along with a mixture of 5 amino acid residues (F, A, V, E, and R) at the Zaa position for each fixed Xaa. This provides a peptide mixture of 25 combinations of each Xaa series resulting in a combinatorial library totaling 475 peptide substrates. Both Nma and Dnp groups are linked to the side chain of the individual residues, allowing for the determination of the cleavage site by a specific enzyme, through mass spectrometric analysis and Edman degradation as well.

PrincipleWhen an enzyme of interest cleaves any peptide bond between d-A2pr(Nma) and Lys(Dnp) in the substrate, the fluorescence at λex = 340 nm and λem = 440 nm increases in proportion to the release of the Nma fluorophore from the internal Dnp quencher.

Reagents1) Each substrate stock solutions: each FRETS-25Xaa (Code SFA-3701-v - Code SFV-3719-v) in 1.0 ml of

DMSO (1 mM, total of peptides)2) Reference compounds stock solution: a 1:1 mixture of two solutions of Code STD-3720-v and Code STD-

3721-v, each of which is reconstituted by dissolving peptides in 0.5 ml of DMSO at the concentration of 2 mM (1 mM, each reference compound)

3) Enzyme solution: an enzyme of interest in an appropriate buffer4) Buffer

Procedure for the deduction of the substrate specificity of an enzyme with unidentified cleavage specificityChoose the proper conditions for the measurement, such as substrate concentration and sensitivity setting, depending on the purpose of the experiment and the instrument available. Described here is one of the recommended procedures for determining the enzymatic cleavage site by the combination of the fluorometric analysis and liquid chromatography-mass spectrometry (LC-MS) analysis.

FRETS* - 25Xaa Series* FRETS: Fluorescence Resonance Energy Transfer Substrates

O

NH

NO2

NO2PheAlaValGluArg

ProTyrLysIleAsp

Xaa -Ala-Phe-Pro-Lys-D-Arg-D-ArgD-A2pr-Gly- - -

Zaa Yaa

Nma Dnp

FRETS 25

Fluorescence-Quenching Substrate Library All library products have the general structure:d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]-Gly-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg where A2pr(Nma) = Nb-[2-(N-Methylamino)benzoyl]-2,3-diaminopropionic acid (Lys(Dnp): Ne-(2,4-dinitrophenyl)lysine)All substrates are sold as trifluoroacetate form and contain 1 µmol of stated library.

Please refer to our complete product brochure for additional experimental details and protocol recommendations. Please contact our technical specialists or refer to our web site for additional information.

Frets (Peptide) Library

PEPT

IDES

INTE

RNAT

IONA

LEN

ZYM

E IN

HIBI

TORS

AND

SUB

STRA

TES

PEPT

IDES

INTE

RNAT

IONA

L

210 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LEN

ZYM

E IN

HIBI

TORS

AND

SUB

STRA

TES i) Primary screening: selection of the favored Xaa

• Substrate solution for primary screening (PS solution): Dilute 20 µl of each of the above substrate stock solution with 1980 µl of an appropriate buffer (10 µM)

• Reference compounds solution for primary screening (PR solution): Dilute 20 µl of the above reference compounds stock solution with 1980 µl of an appropriate buffer (10 µM)

1) Set a fluorescence spectrophotometer at λex = 340 nm and λem = 440 nm2) Mix one of the PS solution and the PR solution in ratios of 10/0, 9/1, 8/2, 5/5 and 0/103) Measure the fluorescence of the prepared solutions to obtain the calibration curve for the cleaved products4) Pipette 200 µl each of all PS solutions into the cells and incubate them in the fluorescence

spectrophotometer for 3 min (temperature equilibration)5) Measure the fluorescence of each solution (initial fluorescence blank)6) Add an appropriate volume of enzyme solution7) Record the increase of the fluorescence intensity8) Terminate the enzymatic reaction by using a proper inhibitor (leupeptin, E-64, pepstatin, EDTA and so on)

or changing the pH of the reaction medium (using TCA, AcOH, NaOH and so on)9) Choose the best Xaa-containing substrate for secondary screening

ii) Secondary screening: identification of the specificity of the enzyme (I)• Substrate solution for secondary screening (SS solution): Dilute 200 µl of the stock solution of the best Xaa-containing substrate chosen by the above primary screening with 1800 µl of an appropriate buffer (100 µM) • Reference compounds solution for secondary screening (SR solution): Dilute 200 µl of the above reference compounds stock solution with 1800 µl of an appropriate buffer (100 µM)

1) Set a fluorescence spectrophotometer at λex = 340 nm and λem = 440 nm2) Mix the SS solution and the SR solution in ratios of 100/0, 95/5, 90/10, 80/20, 50/50 and 0/1003) Measure the fluorescence of the prepared solutions to obtain the calibration curve for the cleaved products4) Pipette 200 µl of the SS solution into the cells and incubate them in the fluorescence spectrophotometer for

3 min (temperature equilibration)5) Measure the fluorescence of each solution (initial fluorescence blank)6) Add an appropriate volume of enzyme solution7) Record the increase of the fluorescence intensity8) Terminate the enzymatic reaction by using a proper inhibitor or changing the pH of the reaction medium upon

completion of the reaction at the points of 0%, 5%, 10% and 20% of the total9) Subject 100 µl aliquots to LC-MS

iii) LC-MS: identification of the specificity of the enzyme (2) • Analytical conditions column: ODS eluant: A) H2O containing 0.05% TFA, B) CH3CN containing 0.05% TFA gradient: 10% to 40% B) in A) over 50 min detection: UV at 220 nm and 400 nm or fluorescence

1) Inject 100 µl aliquots of each terminated solution at different stages of the reaction2) Measure the MW of the cleaved product(s) in the peak(s) with the absorbance at 220 nm but not with 400 nm

[identification of the N-terminal segment(s)]3) Deduce their structure from the attached list of the theoretical MW for the cleaved products *Comment 1: If the N-terminal segment has the identical retention time to the C-terminal segment or one of the starting uncleaved substrates, detection of the products by fluorescence is recommended. *Comment 2: In the accidental case where the two products with the same MW (ex. Zaa-Yaa=Phe-Asp and Val-Tyr, Glu-Asp and Phe-Pro) are generated from one of the substrates, their analyses should be carried out by MS-MS sequencing and/or by Edman degradation.


Order Hotline 1-800-777-4779 502-266-8787 211

ENZYME INHIBITO

RS AND SUBSTRATESUsefulness and limitation of FRETS-25Xaa series for screening of substrate specificities of proteases We have confirmed that FRETS-25Xaa series are effectively used for the assay of numerous proteases such as trypsin, chymotyrpsin, elastase, thrombin, papain, calpain, pepsin and thermolysin. However, they did not work well for the assay of caspase-3 and furin, probably because they have only three changeable sites (Zaa-Yaa-Xaa) in each substrate (deficiency of P4 site). This fact implies that FRETS-25Xaa might not be applicable to the assay of an enzyme with wide range interacting sites with substrate.

1. K. Takada, M. Tsunemi, Y. Nishiuchi, and T. Kimura, A Fluorescence Resonance Energy Transfer Substrate (FRETS) Library for Determining Protease Specificity. [Peptide Revolution: Genomic, Proteomics & Therapeutics] (Proceedings of the 18th American Peptide Symposium) 327 (2003).2. S. Tanskul, K. Oda, H. Oyama, N. Noparatnaraporn, M. Tsunemi, and K. Takada, Substrate specificity of alkaline serine proteinase isolated from photosynthetic bacterium, Rubrivivax gelatinosus KDDS1. Biochem. Biophys. Res. Commun., 309, 547 (2003).

PRODUCT CODE QTYFRETS (Peptide) Library

Please refer to instructions on page 209.

FRETS-25Ala(Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]-Ala-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFA-3701-v-20 °C

1 mmolvial

A2pr(Nma) : Nb-[2-(Methylamino)benzoyl]-2,3-diaminopropionic acid (Lys(Dnp): Nε-(2,4-dinitrophenyl)lysine) Fluorescence-Quenching Substrate Library

FRETS-25Arg(Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]-Arg-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFR-3702-v-20 °C

1 mmolvial

A2pr(Nma) : Nβ-[2-(Methylamino)benzoyl]-2,3-diaminopropionic acid (Lys(Dnp): Nε-(2,4-dinitrophenyl)lysine) Fluorescence-Quenching Substrate Library

FRETS-25Asn(Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]-Asn-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFN-3703-v-20 °C

1 mmolvial


FRETS-25Asp(Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]-Asp-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFD-3704-v-20 °C

1 mmolvial

A2pr(Nma) : Nb-[2-(Methylamino)benzoyl]-2,3-diaminopropionic acid (Lys(Dnp): Ne-(2,4-dinitrophenyl)lysine) Fluorescence-Quenching Substrate Library

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

212 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYFRETS-25Gln

(Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]-Gln-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFQ-3705-v-20 °C

1 mmolvial


FRETS-25Glu (Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- Glu-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFE-3706-v-20 °C

1 mmolvial


FRETS-25Gly (Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- Gly-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFG-3707-v-20 °C

1 mmolvial


FRETS-25His (Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- His-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFH-3708-v-20 °C

1 mmolvial


FRETS-25Ile (Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- Ile-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFI-3709-v-20 °C

1 mmolvial


FRETS-25Leu (Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- Leu-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFL-3710-v-20 °C

1 mmolvial


FRETS-25Lys(Trifluoroacetate Form)d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- Lys-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFK-3711-v-20 °C

1 mmolvial



NAL

Order Hotline 1-800-777-4779 502-266-8787 213

ENZYME INHIBITO

RS AND SUBSTRATES

FRETS-25Met (Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- Met-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFM-3712-v-20 °C

1 mmolvial


FRETS-25Phe (Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- Phe-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFF-3713-v-20 °C

1 mmolvial


FRETS-25Pro (Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- Pro-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFP-3714-v-20 °C

1 mmolvial


FRETS-25Ser(Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- Ser-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFS-3715-v-20 °C

1 mmolvial


FRETS-25Thr(Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- Thr-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFT-3716-v-20 °C

1 mmolvial


FRETS-25Trp(Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- Trp-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFW-3717-v-20 °C

1 mmolvial


FRETS-25Tyr(Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- Tyr-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFY-3718-v-20 °C

1 mmolvial


PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

214 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYFRETS-25Val

(Trifluoroacetate Form) d-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]- Val-Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg

SFV-3719-v-20 °C

1 mmolvial


FRETS-25-STD1d-A2pr(Nma)-Gly

STD-3720-v-20 °C

1 mmolvial

A2pr(Nma) : Ne-[2-(Methylamino)benzoyl]-2,3-diaminopropionic acid (M.W. 294.31) C13H18N4O4 Standard Compound 1 for Fluorescence-Quenching Substrate Library FRETS-25 Xaa Series

FRETS-25-STD2 (Trifluoroacetate Form) Ala-Phe-Pro-Lys(Dnp)-d-Arg-d-Arg- (Lys(Dnp): Ne-(2,4-dinitrophenyl)lysine) (M.W. 940.02) C41H61N15O11

STD-3721-v-20 °C

1 mmolvial

Standard Compound 2 for Fluorescence-Quenching Substrate Library FRETS-25 Xaa Series


NAL

Order Hotline 1-800-777-4779 502-266-8787 215

ENZYME INHIBITO

RS AND SUBSTRATES

Polypeptides(Pro-Pro-Gly)5 • H2O

(M.W. 1274.4) C60H87N15O16 Purity: higher than 97% by HPLC

OPG-4005-20 °C

25 mg100 mg

K. Kivirrikko, K. Suga, Y. Kishida, S. Sakakibara, and D.J. Prockop, Biochem. Biophys. Res. Commun., 45, 1591 (1971). (Chem. Synthesis and Biochem.)

(Pro-Pro-Gly)10 • H2O(M.W. 2530.8) C120H172N30O31 Purity: higher than 95% by HPLC

OPG-4006-20 °C

25 mg100 mg

S. Sakakibara, Y. Kishida, Y. Kikuchi, R. Sakai, and K. Kakiuchi, Bull. Chem. Soc. Japan, 41, 1273 (1968). (Chem. Synthesis)

(Pro-Hyp-Gly)5 • H2O(M.W. 1354.4) C60H87N15O21 Purity: higher than 96% by HPLC

OPG-4032-20 °C

25 mg

S. Sakakibara, K. Inouye, K. Shudo, Y. Kishida, Y. Kobayashi, and D.J. Prockop, Biochim. Biophys. Acta., 303, 198 (1973). (Chem. Synthesis)

(Pro-Hyp-Gly)10 • H2O(M.W. 2690.8) C120H172N30O41 Purity: higher than 90% by HPLC

OPG-4033-20 °C

25 mg

S. Sakakibara, K. Inouye, K. Shudo, Y. Kishida, Y. Kobayashi, and D.J. Prockop, Biochim. Biophys. Acta., 303, 198 (1973). (Chem. Synthesis)

Poly-l-Glutamic Acid Sodium SaltM.W. > 8000 cut off by dialysis, NCA polymerized product

OEE-3063 0.1 g1 g

Poly-l-lysine HydrobromideM.W. > 8000 cut off by dialysis, NCA polymerized product

OKK-3056 0.1 g1 g

Poly-l-lysine HydrochlorideM.W. > 8000 cut off by dialysis, NCA polymerized product [26124-78-7]

OKK-3075 0.1 g1 g

OligopeptidesDipeptidesb-Ala-His [Carnosine]

b-alanyl-l-Histidine (M.W. 226.23) C9H14N4O3 [305-84-0]

AA OAH-3085 1 g5 g

Glu-Glul-glutamyl-l-Glutamic Acid (M.W. 276.24) C10H16N2O7 [3929-61-1]

A OEE-3080 0.1 g1 g

Gly-GlyGlycyl-glycine (M.W. 132.12) C4H8N2O3 [556-50-3]

AA OGG-3028 5 g25 g

100 g

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

216 Order Hotline 1-800-777-4779 502-266-8787

Gly-LeuGlycyl-l-leucine (M.W. 188.23) C8H16N2O3 [869-19-2]

AA OGL-3022 0.1 g1 g5 g

Gly-PheGlycyl-l-phenylalanine (M.W. 222.24) C11H14N2O3 [3321-03-7]

AA OGF-3053 0.1 g1 g

Gly-Phe-NH2 • AcOHGlycyl-l-phenylalanine amide (M.W. 221.26 • 60.05) C11H15N3O2 • CH3COOH [13467-26-0]

AA OGF-3023 0.1 g1 g

Gly-ProGlycyl-l-proline (M.W. 172.18) C7H12N2O3 [704-15-4]

AA OGP-3052 0.1 g1 g

His-Leul-histidyl-l-leucine (M.W. 268.31) C12H20N4O3 [7763-65-7]

AA OHL-3065 0.1 g1 g

Leu-Gly • ½ H2Ol-leucyl-glycine (M.W. 188.22 • 9.01] C8H16N2O3 • ½ H2O [686-50-0]

AA OLG-3024 0.1 g1 g

cyclo (Leu-Gly) [Morphine Tolerance Peptide]

Cyclo (l-leucyl-l-glycine)

PMT-4070-20 °C

25 mg100 mg

R. Walter, R.F. Ritzmann, H.N. Bhargava, and L.B. Flexner, Proc. Natl. Acad. Sci. USA, 76, 518 (1979). (Original)I

Met-Metl-methionyl-l-Methionine (M.W. 280.41) C10H20N2O3S2 [7349-78-2]

A OMM-3152 0.1 g1 g

Pyr-Alal-Pyroglutamyl-l-alanine (M.W. 200.19) C8H12N2O4 [21282-08-6] Substrate for Pyroglutamyl Peptidase

AA OVA-3079 0.1 g1 g

R.F. Doolittle, In, Proteolytic Enzymes, Methods in Enzymology, Vol. 19, (G.E. Perlmann and L. Lorand, Eds.), Academic Press, New York, 1970, pp. 555-569.

TripeptidesGlu(Cys-Gly) [Glutathione,GSH]

g-l-glutamyl-l-Cysteinyl-glycine (M.W. 307.32) C10H17N3O6S [70-18-8]

B OEG-3050 1 g5 g

Gly-Gly-GlyGlycyl-glycyl-glycine (M.W. 189.17) C6H11N3O4 [556-33-2]

AA OGG-3061 1 g5 g

25 g

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C

-20 °C


NAL

Order Hotline 1-800-777-4779 502-266-8787 217

ENZYME INHIBITO

RS AND SUBSTRATES

Gly-Gly-HisGlycyl-glycyl-l-Histidine (M.W. 269.26) C10H15N5O4 [93404-95-06] Cu-Binding Peptide

A OGH-3076 0.1 g1 g

S. Lau, T.P.A Kruch, and B. Sarkar, J. Biol. Chem., 249, 5878 (1974).

Gly-His-Lys • AcOH • H2O [Liver-Cell Growth Factor]

l-glycyl-l-histidyl-l-lysine • AcOH • H2O

PLC-4022-20 °C

25 mg100 mg

L. Pickart, L. Thayer, and M.M. Thaler, Biochem. Biophys. Res. Commun., 54, 562 (1973). (Original)

Ile-Pro-Ile • H2O [Diprotin A]

l-isoleucyl-l-Propyl-l-Isoleucine • H2O

IDP-4132-20 °C

25 mg100 mg

(M.W. 341.45 . 18.02 ) C17H31N3O4 • H2O [90614-48-5] Inhibitor for Dipeptidyl Aminopeptidase IVH. Umezawa, T. Aoyagi, K. Ogawa, H. Naganawa, M. Hamada, and T. Takeuchi, J. Antibiotics, 37, 422 (1984). (Original; IC50 & Chem. Structure) • This compound is distributed through the Peptide Institute, Inc. under the license of Microbial Chemistry Research Foundation.

Leu-Gly-Glyl-leucyl-glycyl-glycine (M.W. 245.28) C10H19N3O4

AA OLG-3025 0.1 g1 g

Pro-Leu-Gly-NH2 • ½H2O [MSH-Release Inhibiting Factor; MIF]

l-prolyl-l-leucyl-glycine amide • ½H2O

PMI-4024-20 °C

25 mg100 mg

(M.W. 284.35 . 9.01) C13H24N4O3 . ½H2O [2002-44-0]

A. Vivas and M.E. Celis, J. Endocrinol., 78, 1 (1978). (Pharmacol.)

Pyr-His-Pro-NH2 • H2O TRH (Thyrotropin Releasing Hormone)

l-Pyroglutamyl-l-histidyl-l-proline amide (M.W. 362.39 • 18.02) C16H22N6O4 • 4H2O

AA PTR-4011-20 °C

25 g100 g

R. Burgus, T.F. Dunn, D. Desiderio, and R. Guillemin, C.R. Acad. Sci. Paris, 269, 1870 (1969) (Original; Ovine) J. Bøler, F. Enzman, K. Folkers, C.Y. Bowers, and A.V. Schally, Biochem. Biophys. Res. Commun., 37, 705 (1969). (Original; Porcine)

Thr-Val-Leu [Schizophrenia Related Peptide]

l-threonyl-l-valyl-l-Leuine (M.W. 331.41) C15H29N3O5

C.E. Frohman, Chem. Eng. News, 55, 35 (1977). (Original)

PSC-4061-20 °C

25 mg100 mg

TetrapeptidesArg-Gly-Asp-Ser • ½AcOH • 2H2O [Fibronectin Active Fragment (RGDS)]

l-arginyl-l-glycyl-l-aspartyl-l-Serine

PFA-4171-20 °C

25 mg100 mg

(M.W. 433.42 • 30.03 • 36.03 ) C15H27N7O8 • ½CH3COOH • 2H2OM.D. Piershbacher and E. Ruoslahti, Nature, 309, 30 (1984). (Original) D.M. Haverstick, J.F. Cowan, K.M. Yamada, and S.A. Santoro, Blood, 66, 946 (1985). (Pharmacol.)

-20 °C

-20 °C


PTID

ES IN

TERN

ATIO

NAL

ENZY

ME

INHI

BITO

RS A

ND S

UBST

RATE

S

218 Order Hotline 1-800-777-4779 502-266-8787

Gly-Gly-Tyr-Arg • AcOH • 2H2OGlycyl-glycyl-l-tyrosyl-l-arginine

OGG-3119 0.1 g1 g

(M.W. 451.48 • 60.05 • 36.03) C19H29N7O6 • CH3COOH • 2H2O Affinity Ligand for PapainM.O. Funk, Y. Nakagawa, J. Skochdopole, and E.T. Kaiser, Int. J. Peptide Protein Res., 13, 296, (1979).

Phe-Met-Arg-Phe-NH2 • 1½ AcOH • 2H2O [FMRF-amide]

l-Phenyl-l-methionyl-l-arginyl-l-phenylalanine amide 1½AcOH • 2H2O

PFM-4142 -20 °C

25 mg100 mg

(M.W. 598.76 • 90.08 • 36.03 ) C29H42N8O4S • 1½CH3COOH • 2H2O D.A. Price and M.J. Greenberg, Science, 197, 670 (1977). (Original)

Thr-Lys-Pro-Arg • 2AcOH • 4H2O [Tuftsin]

l-threonyl-l-lysyl-l-prolyl-l-arginine

PTF-4020-20 °C

25 mg100 mg

(M.W. 500.59 • 120.10 • 72.06 ) C21H40N8O6 • 2CH3COOH • 4H2O [72103-53-8] Phagocytosis-Stimulating PeptideK. Nishioka, A. Constantpoulos , P.S. Satoh, and V.A. Najjar, Biochem. Biophys. Res. Commun., 47, 172 (1972). (Original) K. Nishioka, P.S. Satoh, A. Constantpoulos, and V.A. Najjar, Biochim. Biophys. Acta, 310, 230 (1973). (Chem. Synthesis & Pharmacol.)

Trp-Met-Asp-Phe-NH2 • HCl • H2O [CCK-Tetrapeptide (30-33)]

PCK-4083-20 °C

25 mg100 mg

l-Trptophyl-l-methionyl-l-aspartyl-l-phenylalanine amide (M.W. 596.70 • 3646 • 18.02 ) C29H36N6O6S • HCI • H2O [5609-49-4]J.F. Rehfeld, L.I. Larsson, N.R. Goltermann, T.W. Schwarz, J.J. Holst, S.L. Jensen, and J.S. Morley, Nature, 284, 33 (1980). (Neural Pharmacol.)

-20 °C

Click Chemistry

CLICK ChemistryClick chemistry is the popular term that describes a class of efficient and selec-tive reactions that could be used to join molecules together rapidly and in high yield. The Huisgen 1,3-dipolar cycload-dition,1 in particular the Cu(I)-catalyzed variant, is applied by Meldal2 for the sol-id phase synthesis of peptidotriazoles, and by Sharpless3 for the creation of covalent links between diverse building blocks. Click chemistry has been used in peptide cyclization, DNA-peptide conjugation, fluores-cent dye labeling and surface immobilization of molecules. It has also been used in prob-ing enzyme activities in cell lysates4 or visualizing biomolecules in fixed cells.5,6 Recently, Bertozzi7 reported a unique copper-free version of click chemistry to create biomolecular probes for in vivo studies of live mice.

1. Huisgen, 1,3-Dipolar Cycloaddition Chemistry, Vol. 1, 1984, p. 1.2. Tornoe, et al., J Org Chem, 67:3057–3064 (2002).3. Rostovtsev, et al., Angew Chem Int Ed, 41:2596–2599 (2002).4. Speers, et al., J Am Chem Soc, 125:4686–4687 (2003).5. Beatty, et al., Angew Chem Int Ed, 45:7364–7367 (2006).6. Hsu, et al., Proc Natl Acad Sci USA, 104:2614–2619 (2007).7. Baskin, et al., Proc Natl Acad Sci USA, 104:16793–16797 (2007).

Building Blocks for CLICK ChemistryPeptides International offers a broad selection of reagents for click chemistry including azido building blocks, azido amino acids, azido-PEGs, and propargyl derivatives. Ap-plications of these reagents include novel drug design, ligations to modulate bimolecular function, targeted delivery, nanotechnology, radiotracer attachments, and others.Please contact us for bulk quantities or custom designed reagents for CLICK chemistry applications. We also offer cost effective custom chemistry services utilizing these in-novative reagents.

Protected Azido Acids Azido PEG reagents

R

OH

O

N3

NH

Prot

RO

ON3

X

Propargyl derivatives

R

R1

N N+ N-

R2

NN

N

R2

R1

+CuI


SPECIALTY PRODUCTS & TECHNO

LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 219

Click Chemistry Clickable-TAT Alkyne (49-57)5-hexynoyl-RKKRRQRRR-NH2

(Trifluoroacetate Form) 5-hexynoyl-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2 (M.W. 1432.76) C59H113N31O11 Modified HIV TAT Sequence 49-57 for Click ChemistryS. Brown and D. Graham, Tet Lett, 51, 5032 (2010).

TAT-3733-PI -20 °C

1 mg5 mg

Clickable-TAT Azide (49-57)5-azido-pentanoyl-RKKRRQRRR-NH2

(Trifluoroacetate Form) 5-azido-pentanoyl-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2 (M.W. 1463.78) C58H114N34O11 Modified HIV TAT Sequence 49-57 for Click ChemistryS. Brown and D. Graham, Tet Lett, 51, 5032 (2010)..

TAT-3734-PI -20 °C

1 mg5 mg

cyclo [Arg-Gly-Asp-d-Phe-Lys (PEG-PEG-Azide)] (Trifluoroacetate Form) (M.W. 920.0) C39H61N13O13Clickable RGD for Dendrimer Constructs

RGD-3759-PI-20 °C

1 mg5 mg

cyclo [Arg-Gly-Asp-d-Phe-Lys (Azide)] (Trifluoroacetate Form) (M.W. 629.68) C27H39N11O7 Clickable RGD for Dendrimer Constructs

RGD-3749-PI-20 °C

1 mg5 mg

8-Azido-3,6-Dioxaoctanoic AcidAzido-mini-PEGTM CHA salt (M.W. 189.17) C6H11N3O4 [88518-90-3]

Building Block for Click Chemistry

AXX-1905-PI4 °C

NH2

OO

O

OHN3

1 g5 g

5-Azido-Pentanoic Acidδ-Azidovaleric Acid

(M.W. 143.15) C5H9N3O2 [79583-98-5]Building Block for Click Chemistry

AXX-1906-PI4 °C

1 g5 g

6-Azido-Hexanoic Acidε-Azidocaproic Acid

(M.W. 157.17) C6H11N3O2 [79598-53-1]Building Block for Click ChemistryP. Wu, et al., Angew. Chem. Intl Ed. Engl., 43, 3928 (2004).C. Grandjean, et al., J. Org. Chem., 70, 7123 (2005).

AHA-1904-PI

4 °C

1 g5 g

CHA= Cyclohexylamine

PEPT

IDES

INTE

RNAT

IONA

LSP

ECIA

LTY

PRO

DUCT

S &

TECH

NOLO

GIE

S

220 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTY

NEW!

NEW!

NEW!

NEW!

NEW!

NEW!

NEW!

4 °C

Specialty Biologically Active Peptides

Derivatizable Cell Penetrating Peptides (CCPs)Cys-TAT (49-57)H-CRKKRRQRRR-NH2

(Trifluoroacetate Form) Cys-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2 (M.W. 1441.79) C56H112N32O11S Cys- Modified HIV TAT sequence 49-57 L. Santos-Cuevas, et al., Nucl Med Commun., 32, 303 (2011). P.A. Wender, et al., PNAS, 97, 13003 (2000). J. Park, et al., J. Gen. Virol., 83, 1173 (2002).

TAT-3735-PI-20 °C

1 mg5 mg

Cys(Npys)-TAT (49-57)C(Npys)RKKRKQRRR-NH2

(Trifluoroacetate Form) Cys(Npys)-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2 (M.W. 1594.93) C61H113N34O13S2 Cys- Activated TAT for Cargo Conjunction

TAT-3751-PI-20 °C

1 mg5 mg

J. Embury, et al., Diabetes, 50, 1706 (2001). H. Wang, et al., J. Clin. Invest., 109, 1463 (2002). Y.-Z. Lin, J. Biol. Chem., 270, 14255 (1995). D. Holzberg, et al., J. Biol. Chem., 278, 40213 (2003). E. Williams, et al., J. Biol. Chem., 272, 22349 (1997). L.A. Kueltzo and C.R. Middaugh, Expert Opinion on Investigational Drugs, 9, 2039 (2000).A. Mortlock, et al., Nucleic Acids Res., 31, e152 (2003). S.R. Schwarze, et al., Science. 285:1569-1572 (1999).F. Rabanal, et al., Tetrahedron Letters, 37(9):1347-1350 (1996).

Cys(Npys)-TAT (49-57), FAM-labeled(Trifluoroacetate Form) Cys(Npys)-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys(FAM)-NH2(M.W. 2082.42) C88H136N36O20S2 FAM Labeled, Cys-Activated TAT

TAT-3752-PI-20 °C

1 mg5 mg

Other Specialty Peptides and Miscellaneous Productscyclo [Arg-Gly-Asp-d-Phe-Lys (PEG-PEG-Azide)] See Code PCI-3759-PI on pages 21 and 220.

Doxorubicin-HCl(M.W. 579.98 • 36.46) C27H29NO11 • HCl [25316-40-9]Inhibitor of Reverse Transcriptase and RNA Polymerase

IOX-3765-PI-20 °C

1 mg5 mg

[13C18,15N3]-Hepcidin (Human) [[13C9,15N]Phe4,9, [15N]Gly12]-Hepcidin (Human)


PLP-3405-v -20 °C

20 μg vial

Asp-Thr-His-[13C9,15N]Phe-Pro-Ile-Cys-Ile-[13C9,15N]Phe-Cys-Cys- [15N]Gly-Cys-Cys-His-Arg-Ser-Lys-Cys-Gly-Met-Cys-Cys-Lys-Thr(Reported disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22)(M.W. 2810.2) C95

13C18H170N3115N3O31S9

Stable Isotope-Labeled Peptide for Mass Spectrometric Detection of Hepcidin (Human)N. Murao, M. Ishigai, H. Yasuno, Y. Shimonaka, and Y. Aso, Rapid Commun. Mass Spectrom., 21, 4033 (2007).T. Hosoki, K. Ikuta, Y. Shimonaka, Y. Sasaki, H. Yasuno, K. Sato, T. Ohtake, K. Sasaki, Y. Torimoto, K. Saito, and Y. Kohgo, Proteomics Clin. Appl., 3, 1256 (2009).

NEW!

NEW!

NEW!

NEW!

NEW!



LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 221

PRODUCT CODE QTY

4-[D10]Leu-Insulin (Human) [[2H10]LeuB6,B11,B15,B17]-Insulin (Human)


PLP-3404-s-20 °C

20 μgvial

A-chain:Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-AsnB-chain:Phe-Val-Asn-Gln-His-[2H10]Leu-Cys-Gly-Ser-His-[2H10]Leu-Val-Glu-Ala-[2H10]Leu-Tyr-[2H10]Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr(Disulfide bonds between CysA6-CysA11, CysA7-CysB7, and CysA20-CysB19)(M.W. 5847.8) C257H343D40N65O77S6Stable Isotope-Labeled Peptide Useful for Standardization of Insulin ImmunoassaysK. Van Uytfanghe, D. Rodríguez-Cabaleiro, D. Stöckl, and L.M. Thienpont, Rapid Commun. Mass Spectrom., 21, 819 (2007).D. Rodríguez-Cabaleiro, K. Van Uytfanghe, V. Stove, T. Fiers, and L.M. Thienpont, Clin. Chem., 53, 1462 (2007).3) W.G. Miller, L.M. Thienpont, K. Van Uytfanghe, P.M. Clark, P. Lindstedt, G. Nilsson, and M.W. Steffes,Clin. Chem., 55, 1011 (2009).

Myr-Ser-Ile-Tyr-Arg-Arg-Gly-Ala-Arg-Arg-Trp-Arg-Lys-Leu[Myristoyl-PKC ζ (113-125) TFA

PKC-3403-v -20 °C

1 mg

(Trifluoroacetate Form) Myristoyl-Ser-Ile-Tyr-Arg-Arg-Gly-Ala-Arg-Arg-Trp-Arg-Lys-Leu (M.W. 1928.40) C90H154N30O17 Myristoylated Cell Permeable PKCζ Pseudosubstrate Inhibitor C. Laudanna, D. Mochly-Rosen, T. Liron, G. Constantin, and E.C. Butcher, J. Biol. Chem., 273, 30306 (1998). (Pharmacol.)S. Lim, J.W. Choi, H.S. Kim, Y.-H. Kim, K. Yea, K. Heo, J.H. Kim, S.-H. Kim, M. Song, J.I. Kim, S.H. Ryu, and P.-G. Suh, Life Sci., 82, 733 (2008). (Biochem.)T. Hirose, D. Satoh, H. Kurihara, C. Kusaka, H. Hirose, K. Akimoto, T. Matsusaka, I. Ichikawa, T. Noda, and S. Ohno, PLoS ONE, 4, e4194 (2009). (Pharmacol. & Histochem.)P.V. Migues, O. Hardt, D.C. Wu, K. Gamache, T.C. Sacktor, Y.T. Wang, and K. Nader, Nat. Neurosci.,13, 630 (2010).(Pharmacol.)

NEW!

NEW!

PEPT

IDES

INTE

RNAT

IONA

LSP

ECIA

LTY

PRO

DUCT

S &

TECH

NOLO

GIE

S

222 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTY



LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 223

PRODUCT CODE QTYCarbohydrates2,3,4,6-Tetra-O-Acetyl-a-d-GlucopyranosylaFluoride

(M.W. 350.29) C14H19O9F Glycosyl Donor (Glycosyl Fluoride)

CAR-22001-20°C

AcOAcO

OAcO

FAcO

22001

1 g 5 g

2,3,4,6-Tetra-O-Acetyl-a-d-Galactopyranosyl Fluoride


CAR-22002-20°C

AcO

O

AcOAcO

F

OAc

22002

1 g5 g

2,3,4,6-Tetra-O-Acetyl-a-d-Mannopyranosyl Fluoride


CAR-22003-20°C

AcO

O

AcO

F

OAcAcO

1 g5 g

2-Deoxy-2-Phthalimido-3,4,6-Tri-O-Acetyl-a-d-Glucopyranosyl Fluoride

(M.W. 437.37) C20H20NO9F Glycosyl Donor (Glycosyl Fluoride)

CAR-22004-20°C

AcOO

AcO

F

OAc

Pht=N

22004

1 g5 g

2-Deoxy-2-Phthalimido-3,4,6-Tri-O-Acetyl-a-d-Galactopyranosyl Fluoride

(M.W. 437.37) C20H20NO9F Glycosyl Donor (Glycosyl Fluoride)

CAR-22005-20°C

AcO

O

AcO

F

OAc

Pht=N

1 g5 g

Methyla(Methyla5-Acetamido-4,7,8,9-Tetra-O-Acetyl-3,5-Dideoxy-2-Thio-d-Glycero-d-Galacto-2-Nonulopyranosid)onate

(M.W. 521.54) C21H31NO12S Glycosyl Donor (Thioglycoside)

CAR-22101-20°C

AcOAcO AcO

O SMe

COOMe

AcNH

OAc

22101

1 g5 g

PEPT

IDES

INTE

RNAT

IONA

LSP

ECIA

LTY

PRO

DUCT

S &

TECH

NOLO

GIE

S

224 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYPhenyltrifluoroacetimidate Glycosyl Donor

Synthetic Product (M.W. 795.92) C29H32N2O14Cl3F3 Glycosyl Donor (Phenyltrifluoroacetimidate)

CAR-22102 -20°C

5 mg1 g

K. Tanaka, T. Goi, and K. Fukase, Synlett, 2958 (2005). (Original; Synthesis) S. Tanaka, T. Goi, K. Tanaka, and K. Fukase, J. Carbohydr. Chem., 26, 369 (2007). (Synthesis)

Fmoc-Ser[Ac4Galβ(1- >3)Ac2GalNAcα(1- >O)]-OHO-β-2,3,4,6-Tetra-O-Acetyl-d-Galactopyranosyl-(1- >3)-O-a- 4,6- Di-O-Acetyl- 2- Acetamido-2-Deoxy-d-Galactopyranosyl- (1- >O)-9-Fluorenylmethoxycarbonyl-l-Serine Synthetic Product (M.W. 944.88) C44H52N2O21 Reagent for Mucin-Type O-Glycopeptide SynthesisT. Reipen and H. Kunz, Synthesis, 2487 (2003)

CAR-22103-20 °C

25 mg

Fmoc-Thr[Ac4Galβ(1- >3)Ac2GalNAca(1- >O)] -OH-O-β-2,3,4,6-Tetra-O-Acetyl-d-Galactopyranosyl-(1- >3)-O-a-4,6-Di-O-Acetyl-2-Acetamido-2-Deoxy-d-Galactopyranosyl- (1- >O)-9-Fluorenylmethoxycarbonyl-l-Threonine

Synthetic Product(M.W. 958.91) C45H54N2O21Reagent for Mucin-Type O-Glycopeptide SynthesisC. Brocke and H. Kunz, Synthesis, 525 (2004)

CAR-22104-20 °C

25 mg

5-Bromo-4-Chloroindol-3-yla5-Acetamido-3,5-Dideoxy-a-d-Glycero-d-Galacto-2-[X-Neu5Ac, X-Sialic Acid, X-NANA] Nonulopyranosidonic Acid

(Ammonium Form) (M.W. 537.74) C19H22N2O9BrCl Histochemical Substrate for Neuraminidase

CAR-23001-v-20°C

OH NH

OHOH

OHO O

AcNH

ClBr

COOH

23001-v

5 mgvial

2-NBDG2-[N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino]-2-Deoxy-d-Glucose(M.W. 342.26) C12H14N4O8 Reagent for Monitoring Glucose Uptake into Single, Living CellsK. Yoshioka, H. Takahashi, T. Homma, M. Saito, K.-B. Oh, Y. Nemoto, and H. Matsuoka, Biochim. Biophys. Acta, 1289, 5 (1996). (Original)K. Yamada, M. Nakata, N. Horimoto, M. Saito, H. Matsuoka, and N. Inagaki, J. Biol. Chem., 275, 22278 (2000). (Measurement of Glucose Uptake in Living Mammalian Cells) K. Yamada, M. Saito, H. Matsuoka, and N. Inagaki, Nature Protocols, 2, 753 (2007). (Chem. Synthesis & Protocols for Measurement)

CKG-23002-v-20 °C

OHOH

OOH

OH

NH

NNO

NO2

0.5 mgvial

J.V. Rocheleau, G.M. Walker, W.S. Head, O.P. McGuinness, and D.W. Piston, Proc. Natl. Acad. Sci. U.S.A., 101, 12899 (2004). (Monitoring of Glucose Uptake and NAD(P)H Response in Islet)

NEW!

NEW!

NEW!

NEW!



LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 225

PRODUCT CODE QTY2-NBDLG

2-[N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino]-2-Deoxy-l-Glucose (M.W. 342.26) C12H14N4O8 Control Substrate for 2-NBDG

CKG-23003-v-20 °C

0.5 mgvial

T. Yamamoto, Y. Nishiuchi, T. Teshima, H. Matsuoka, and K. Yamada, Tetrahedron Lett., 49, 6876 (2008). (Original) K. Yamada, M. Saito, H. Matsuoka, and N. Inagaki, Nature Protocols, 2, 753 (2007). (Protocols for Measurement) • This compound is distributed through Peptide Institute, Inc. under the license of Hirosaki University Graduate School of Medicine, Tokyo University of Agriculture and Technology, and the Peptide Institute, Inc.

UDP-β-l-Arabinofuranose UDP-β-L-Araf

(Triethylammonium Form)Uridine-5'-Diphospho- β-l-Arabinofuranose(M.W. 536.28) C14H22N2O16P2 Reagent for Research in Arabinofuranose Biogenesis in Plants

CKG-23005-s-20 °C

0.1 mgvial

T. Konishi, H. Ono, M. Ohnishi-Kameyama, S. Kaneko, and T. Ishii, Plant Physiol., 141,1098 (2006). (Substrate for Arabinofuranosyltransferase)T. Konishi, T. Takeda, Y. Miyazaki, M. Ohnishi-Kameyama, T. Hayashi, M.A. O'Neill, and T. Ishii, Glycobiol., 17, 345 (2007).(Use in Enzymatic Furanose-Pyranose Interconversion)Q. Zhang and H.-W. Liu, Bioorg. Med. Chem. Lett.,11, 145 (2001). (Chem. Synthesis)

O-(Acetamido-3,5-Dideoxy-d-Glycero-a-d-Galacto-2-Nonulopyranosylonic Acid)-(2→3)-O-β-d-Galactopyranosyl-(1→4)-O-β-d-Glucopyranosyl-(1→1)-2S,3R,4E)-2-N- (7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl) Aminooctanamido-4- Octadecene-1,3-diol [Gm3 Labelled by NBD]

(Ammonium Form) (M.W. 1219.3) C55H90N6O24 Fluorescence Labelled Ganglioside

CAR-24001-s-20°C

OH

NH

O

N

NO

NO2

OH

O

OOHO

OOH OHOH

O O

AcNH

OHOH

COOHOH

HN

OHOH

24001-S

0.1 mgvial

Glycosidase InhibitorsSiastatin B

(3S,4S,5R,6R)-6-(Acetylamino)-4,5-Dihydroxy-3-Piperidinecarboxylic AcidMicrobial Product (M.W. 218.21) C8H14N2O5 Inhibitor for Sialidase• This compound is distributed through Peptide Institute, Inc.

CAR-24002-v-20°C

OH

NH

CH3CONH

COOH

OH

24002-v

5 mgvial

under the technical and scientific advice of the Microbial Chemistry Research Foundation.

Nojirimycin Bisulfite5-amino-5-Deoxy-Glucopyranose BisulfiteMicrobial Product (M.W. 243.23) C6H13NO7S Inhibitor for β-Glucosidase (Apricot Emulsion)

CAR-24003-v-20°C

OH

OHOH

NHCH2OH

SO3H

24003-v

5 mgvial

d-Glucaro-d-Lactam(2S,3R,4S,5R)-3,4,5-Trihydroxy-6-Oxo-2-Piperidinecarboxylic Acid (Potassium Salt)Microbial Product (M.W. 191.14) C6H9NO6 Inhibitor for Bovine Liver β-Glucuronidase

CAR-24004-v-20°C

OH

OHOH

NH

O

HOOC

24004-v

5 mgvial

NEW!

NEW!

NEW!

NEW!

PEPT

IDES

INTE

RNAT

IONA

LSP

ECIA

LTY

PRO

DUCT

S &

TECH

NOLO

GIE

S

226 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYEndotoxins(Synthetic)Lipid A (E. coli)Compound 506, LA-15-PP

2-Deoxy-6-O-{2-deoxy-2-[(R)-3-(dodecanoyloxy) tetradecanoylamino]-3-O-[(R)-3-(tetradecanoyloxy) tetradecanoyl]-β-D-glucopyranosyl}-3-O-[(R)-3-hydroxytetradecanoyl]-2-[(R)-3- hydroxytetradecanoylamino]-a-D-glucopyranose 1,4'-diphosphate (M.W. 1798.4) C94H178N2O25P2 Synthetic Product Active Principle of EndotoxinM. Imoto, S. Kusumoto, T. Shiba, E.Th. Rietschel, C. Galanos, and O. Lüderitz, Tetrahedron Lett., 26, 907 (1985). (Original; Chem. Structure) M. Imoto, H. Yoshimura, T. Shimamoto, N. Sakaguchi, S. Kusumoto, and T. Shiba, Bull. Chem. Soc. Jpn., 60, 2205 (1987). (Chem. Synthesis)

CLP-24005-s-20°C

0.1 mgvial

Lipid IVaCompound 406, LA-14-PP, Precursor la

2-Deoxy-6-O-{2-deoxy-3-O-[(R)-3-hydroxytetradecanoyl]-2-[(R)-3-hydroxytetradecanoylamino]-β-D-glucopyranosyl}-3-O-[(R)-3- hydroxytetradecanoyl]-2-[(R)-3-hydroxytetradecanoyl-amino]-a- D-glucopyranose 1,4'-diphosphate (M.W. 1405.7) C68H130N2O23P2 Synthetic Product Biosynthetic Precursor of LipopolysaccharideM. Imoto, S. Kusumoto, T. Shiba, E.Th. Rietschel, C. Galanos, and O. Lüderitz, Tetrahedron Lett., 26, 907 (1985). (Original; Chem. Structure) M. Imoto, H. Yoshimura, M. Yamamoto, T. Shimamoto, S. Kusumoto, and T. Shiba,Bull. Chem. Soc. Jpn., 60, 2197 (1987). (Chem. Synthesis)

CLP-24006-s-20°C

OO

O

NH

HO

H2O3P OHO

O

NH

OPO3H2

O

O

O

O

O

O

O

O

O

OH

O

O

H2O3P O

O

OH

O

O

O

O

O

OOH

NHOPO

3H2

O

ONH

O

OH

O

O

O

O

O

24008

0.1 mgvial



LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 227

PRODUCT CODE QTYLipid A (Salmonella)

(Triethylammonium Form)2- Deoxy-6-O-[2-deoxy-2-[(R)-3-(dodecanoyloxy)tetradecanoylamino]-3-O-[(R)-3-(tetradecanoyloxy) tetradecanoyl]-β-d-glucopyranosyl]-3-O-[(R)-3-hydroxytetradecanoyl]-2-[(R)-3-(hexadecanoyloxy)tetradecanoylamino]-β-d-glucopyranose 1,4\’- diphosphate (M.W. 2036.80) C110H208N2O26P2 Synthetic ProductActive Principle of EndotoxinU. Seydel, B. Lindner, H.-W. Wollenweber, and E.T. Rietschel, Eur. J. Biochem., 145, 505 (1984). (Original; Chem. Structure) A.X. Tran, M.E. Lester, C.M. Stead, C.R.H. Raetz, D.J. Maskell, S.C. McGrath, R.J. Cotter, and M.S. Trent, J. Biol. Chem., 280, 28186 (2005). (Pharmacol.) Y. Shi, M.J. Cromie, F.-F. Hsu, J. Turk, and E.A. Groisman, Mol. Microbiol., 53, 229 (2004). (Pharmacol.) H.S. Gibbons, S. Lin, R.J. Cotter, and C.R.H. Raetz, J. Biol. Chem., 275, 32940 (2000). (Pharmacol.)

CLP-24008-s-20 °C

OO

O

NH

HO

H2O3P OHO

O

NH

OPO3H2

O

O

O

O

O

O

O

O

O

OH

O

O

H2O3P O

O

OH

O

O

O

O

O

OOH

NHOPO

3H2

O

ONH

O

OH

O

O

O

O

O

24008

0.1 mgvial

Antiproliferative FactorAntiproliferative factor (APF) (CAR-24007) is a low molecular weight, heat stable sialoglycopeptide that contains the transmembrane segment of Frizzled 8. It is made and secreted by bladder epithelial cells of patients with a condition known as interstitial cystitis (IC) which causes chronic pain due to ulcers, hemorrhaging, and thinning of the bladder epithelium.1,2 APF contributes to the pathology of IC by inhibiting bladder cell proliferation, and was also shown to regulate proliferation of bladder carcinoma cells.2,3 Recently, CKAP4/p63 was identified as a receptor for APF, but how its activity is mediated remains unknown.4

APF’s role as a negative regulator makes it a possible target for treatment of disease, and its unique presence in the urine of IC patients indicates it is a biomarker that may lead to a diagnostic tool for those suffering with IC. Chemists in the division of carbohydrate chemistry at the Peptide Institute achieved the total synthesis of this sialoglycopeptide, APF. In addition to other carbohydrate related products, APF is now available to aid in IC research.

1. S.K. Keay, Z. Szekely, T.P. Conrads, T. D. Veenstra, J.J. Barchi, Jr., C.-O. Zhang, K.R. Koch, and C.J. Michejda, Proc. Natl. Acad. Sci.U. S. A., 101, 11803 (2004). 2. S. Keay, M. Kleinberg, C.-O. Zhang, M.K. Hise, and J.W. Warren, J. Urol., 64, 2112 (2000). 3. S. Keay, C.-O. Zhang, M. Hise, A.L. Trifillis, J.R. Hebel, S.C. Jacobs, and J. R. Warren, J. Urol., 156, 2073 (1996). 4. T.P. Conrads, G.M. Tocci, B.L. Hood, C.-O. Zhang, L. Guo, K.R. Koch, C.J. Michejd, T.D. Veenstra, and S.K. Keay, J. Biol. Chem., 281, 7836 (2006).

See next page for product

NEW!

PEPT

IDES

INTE

RNAT

IONA

LSP

ECIA

LTY

PRO

DUCT

S &

TECH

NOLO

GIE

S

228 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTYAntiproliferative Factor Sialoglycopeptide APF Sialoglycopeptide Thr[Neu5Aca(2→3)Galβ(1→3)GalNAca(1→O)]541-Frizzled 8 (541-549)

(Ammonium Form)

CAR-24007-v-20°C

50 mg

O-(Acetamido-3,5-dideoxy-d-glycero-a-d-galacto-2-nonulopyranosylonic acid)-(2→3)-O-β-d-galactopyranosyl-(1→3)-O-a-2-acetamido-2-deoxy-d-galactopyranosyl-(1→O)- Thr-Val-Pro-Ala-Ala-Val-Val-Val-Ala (M.W. 1482.6) C63H107N11O29 Antiproliferative Factor from Interstitial Cystitis PatientsS.K. Keay, C.-O. Zhang, J. Shoenfelt, D.R. Eirkson, K. Whitmore, J.W. Warren, R. Marvel, and T. Chai, Urology, 57, 9 (2001). (Original) S. K. Keay, Z. Szekely, T..P. Conrads, T. D. Veenstra, J. J. Barchi, Jr., C.-O. Zhang, K.R. Koch, and C.J. and Michejda, Proc. Natl. Acad. Sci.U. S. A., 101, 11803 (2004). (Original; Structure & Pharmacol.) C.-O. Zhang, Z.-L. Li, and C.-Z. Kong, BioMed Central Urology, 5, 7 (2005). (Pharmacol.)

OHOH

O

OH

AcNH

OH

O

OH

COOH

AcNH OH OO

OH

OH

OH

O

N

O

NH2

O O

NH

O

NH

NH

O

NH

O

NH

O

NH

O

NH

O

O

OH

24007

Other Carbohydrate Related Products Adjuvant Peptide Code PAD-4031 on page 1. Phosphoramidon Code IPO-4082 on page 168.

NEW!



LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 229

PRODUCT CODE QTY GDP-l-Fuc: N-Acetyl-β-d-Glucosaminide α1-6Fucosyltransferase Substrate

GnGn-bi-Asn-PABASemisynthetic Product with Enzymatically Derived Bovine γ-Globulin Sugar Moiety

SGS-23004-s-20°C

0.1 mgvial

O-β-2-Acetamido-2-deoxy-d-glucopyranosyl-(1→2)-O-α-d-mannopyranosyl-(1→3)-[O-β-2-acetamido-2-deoxy-d-glucopyranosyl-(1→2)-O-α-d-mannopyranosyl-(1→6)]-O-β-d-mannopyranosyl-(1→4)-O-β-2-acetamido-2-deoxy-d-glucopyranosyl-(1→4)-N-β-2-acetamido-2-deoxy-d-glucopyranosyl-(1→4)-L-asparagine 4-(2-pyridylamino)butylamide(M.W. 1578.5) C63H103N9O37Semisynthetic Product Substrate for GDP-l-Fuc: N-Acetyl-β-d-Glucosaminide α1-6FucosyltransferaseN. Uozumi, T. Teshima, T. Yamamoto, A. Nishikawa, Y.-EGao, E. Miyoshi, C.-X. Gao, K. Noda, K.N. Islam, Y. Ihara,S. Fujii, T. Shiba, and N. Taniguchi, J. Biochem., 120, 385 (1996). (Original; Semisynthesis & Assay Method)K. Noda, E. Miyoshi, J. Gu, C.-X. Gao, S. Nakahara, T. Kitada, K. Honke, K. Suzuki, H. Yoshihara, K. Yoshikawa,K. Kawano, M. Tonetti, A. Kasahara, M. Hori, N. Hayashi, and N. Taniguchi, Cancer Res., 63, 6282 (2003).(GDP-l-fucose Levels in Human Hepatocellular Carcinoma)Y. Shimma, F. Saito, F. Oosawa, and Y. Jigami, Appl. Environ. Microbiol. 72, 7003 (2006).(Construction of a Library of Human Glycosyltransferases)K. Matsumoto, H. Yokote, T. Arao, M. Maegawa, K. Tanaka, Y. Fujita C. Shimizu, T. Hanafusa, Y. Fujiwara,and K. Nishio, Cancer Sci., 99, 1611 (2008). (Effect of Fucosylation on Epidermal Growth Factor Receptor Activity)

Maleimide activated-KLH

Maleimide activated-KLHMaleimide activated carrier protein for haptensMinimum of 400 moles of sulfhydryl reactive maleimide per mole of KHL

KLH-6000-PI-20°C

5 mg10 mg

Larger quantities are available, please inquire.

D.J. Betting, et al., J. Immunol., 181, 4131 (2008). P. Michon, et al., Infect. Immun., 68, 3164 (2000). G.L. Toller, et al., PNAS, 101, 15160 (2004). J.G. Joyce, et al., J. Biol. Chem., 277, 45811 (2002).

(See next page for article)

NEW!

NEW!

Activated KLH (Keyhole Limpet Hemocyanin) is a popular choice to use as a carrier protein for hap-tens in order to assist in the acti-vation of an immune response. Haptens or small peptides are of-ten limited by their size and can-not elicit an immune response by themselves. Activated KLH has a large molecular mass and high immunogenic properties that are ideal for immunogenic stimula-

tion. Small peptides containing free sulfhydryl groups can react with Maleimide groups of this carrier protein to form stable thioether bonds. Such carrier peptide conjugates can be used to stimulate antibodies for immunization.

• Convenient Vialing - Offered in single-use vials of 5 or 10 mg, Maleimide-Acti-vated mKLH is lyophilized and stabilized for easy application.

• Excellent Solubility - Our preparation of mariculture KLH is highly soluble, but if your research requires even greater hydrophilicity and solubility, a PEGylated form can be made available.

• Optimized Activation - Specifications require that each lot is activated with > 400 moles of sulfhydryl-reactive maleimide per mole of KLH, ensuring consis-tently high levels of conjugation.

• Sulfhydryl-reactive - Designed for conjugating cysteine-containing peptide an-tigens to enhance immunogenicity required for high-titer antibody production.

• Very Efficient Procedure - Complete the hapten-carrier conjugation reaction in two hours to yield sufficient immunogenicity for several injections and booster immunizations of host animals.

• High-Quality Carrier Protein - KLH is isolated from the mollusk Megathura crenulata (keyhole limpet); mKLH is a high-quality form of KLH that is harvested from limpets grown in mariculture.

• Highly Immunogenic - KLH has a high molecular mass (0.5 to 13 million dal-tons; aggregates of 350 and 390kDa subunits) and elicits a stronger immune response than BSA or ovalbumin.PE

PTID

ES IN

TERN

ATIO

NAL

SPEC

IALT

Y P

RODU

CTS

& TE

CHNO

LOG

IES

230 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTY

mini-PEG™ (8-amino-3,6-dioxaoctanoic acid, AEEA) is a hydrophilic bifunctional spacer used for peptide and peptide nucleic acid (PNA) synthesis.1,2 The popular solubilizing linker, mini-PEG™ is now available in a slightly longer version. These hydrophilic amino acids are widely used in both peptide and peptide nucleic acid (PNA) syntheses.Linkers, such as mini-PEG, can be used to minimize the adverse effects of bulky labeling reagents on hybridization properties of PNA oligomers or to enhance binding to lipid surfaces. Fmoc-mini-PEG™ (FXX-5521-PI) was recently used in tandem (X-AEEA-AEEA-Y) as a linker for a peptide oligonucleotide conjugate employed for the construction of peptide chips.3 In another application, Fmoc-mini-PEG was coupled to a glycopeptide antibiotic, vancomycin, for covalent attachment to titanium metal, which is reported to yield an implant device with reduced infections.4

In addition to Fmoc-mini-PEG, both Boc- and Fmoc-protected derivatives of 11-amino-3,6,9-trioxaundecanoic acid are now available as Boc-mini-PEG-3™ (BXX-5523-PI) and Fmoc-mini-PEG-3™ (FXX-5524-PI), where “3” designates 3 ethylene oxide units. The original Boc- and Fmoc- mini-PEG™ derivatives of 8-amino-3,6-dioxaoctanoic acid contain the shortest ether structure possible of poly(ethylene glycol)(PEG) with 2 ethylene oxide units. Please consider coupling more than one mini-PEG for additional spacer lengths. Please inquire for special bulk pricing.

1. A.M.P. Koskinen, T. Valo, S. Vihavainen, and J.M.L. Hakala, Bioorg. Med. Chem. Lett., 5, 573 (1995).2. J.W. Trauger, R.M. Kohli, C.T. Walsh, Biochemistry, 40, 7092 (2001).3. K. Ohtsuka, K. Uemura, T. Nojima, M. Waki, and S. Takenaka, Analyst, 131, 55 (2006).4. B. Jose, V. Antoci, A.R. Zeiger, E. Wickstrom, and N.J. Hickok, Chemistry & Biology, 12, 1041 (2005).

Boc-mini-PEG-3™

Boc-11-amino-3,6,9-Trioxaundecanoic Acid • DCHA

Boc-AEEEA tert-Butyloxycarbonyl-11-amino-3,6,9- Trioxaundecanoic Acid • Dicyclohexylamine (M.W. 307.35 • 181.32) C13H25NO7 • C12H23N

BXX-5523-PI4 °C

Boc-NHO

OO COOH

1 g5 g

Boc-mini-PEG™

Boc-8-amino-3,6-dioxaoctanoic acid • DCHABoc-AEEA tert-Butyloxycarbonyl-8-amino-3,6- Dioxaoctanoic Acid • Dicyclohexylamine (M.W. 263.29 • 181.3) C11H21NO6 • C12H23N

BXX-5519-PI4 °C

OO COOHBoc-NH

1 g5 g

Fmoc-mini-PEG-3™Fmoc-11-amino-3,6,9-Trioxaundecanoic Acid (Syrup)

Fmoc-AEEEA 9-Fluorenylmethoxycarbonyl-11- Amino-3,6,9-Trioxaundecanoic Acid (M.W. 429.47) C23H27NO7

FXX-5524-PI4 °C

OO

O COOHFmoc-NH

1 g5 g



LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 231

PRODUCT CODE QTY

Fmoc-mini-PEG™

Fmoc-8-amino-3,6-dioxaoctanoic acidFmoc-AEEA 9-Fluorenylmethoxycarbonyl-8-amino-3,6- Dioxaoctanoic Acid (M.W. 385.42) C21H23NO6

FXX-5521-PI4 °C

Fmoc-NHO

O COOH

1 g5 g

AEEA = [2-(2-amino-ethoxy)-ethoxy]-acetic acid AEEEA= {2-[2-(2-amino-ethoxy)-ethoxy]-ethoxy}-acetic acid

PEPT

IDES

INTE

RNAT

IONA

LSP

ECIA

LTY

PRO

DUCT

S &

TECH

NOLO

GIE

S

232 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTY

Specialty Resins

CLEAR-OXTM

Disulfide Peptides Made Simple.

The chemistry used to oxidize the free thiol (-SH) bonds to the corresponding disulfide (-S-S-) bond in a controlled

fashion remains a significant challenge in spite of many advances in peptide chemistry. Peptides International proudly introduces CLEAR-OXTM, a new polymer-supported oxidant, which combines the power of solid phase chemistry with the versatility of solution-phase reactions. CLEAR-OXTM is a highly effective polymer-supported reagent for the formation of disulfide-bonds.1,2 CLEAR resin is the polymer of choice due to its compatibility with both aqueous and organic environments. A lysine-preformed cyclic Ellman’s reagent [5,5’-dithiobis(2-nitrobenzoic acid) = DTNB] is covalently attached to a CLEAR polymeric support with a β-alanine spacer to yield CLEAR-OX.3,4 Since the mechanism is based on peptide capture, sensitive residues such as Tyr, Trp, and Met are not affected, leading to increased purity and yield.

These improved synthetic conditions allow for facile removal of the oxidant.

Single disulfide-bridged peptides with constrained amino acids have been successfully produced using CLEAR-OX with various ring sizes and lengths. Oxidations are performed at considerably higher concentrations than solution methods, thus leading to reduced solvent use for larger scale. Furthermore, oxidations are scalable with potential for recycling and automation using CLEAR-OX. Oxidations can be carried out immediately after cleavage with as low as two-fold excess of CLEAR-OX to obtain satisfactory yields. Most oxidations were complete within 1-2 hrs at an optimum pH < 7. Solubility problems of reduced peptides were overcome by the addition of organic solvents, such as acetonitrile, to the CLEAR-OX cyclization mixtures. While multiple bond formation is still under investigation, early reports indicate positive results.5 In CLEAR-OX mediated oxidations, product yields and purities were better than or comparable to existing oxidation methods. However, CLEAR-OX is a superior choice when sensitive residues are present and because the method is so easy to use.For additional information and references please visit: http://pepnet.com/CLEAR-OX.html.

References1. CLEAR resins are protected under US Patents 5,910,554 and 5,656,707.2. K. Darlak, D.W. Long, A. Czerwinski, M. Darlak, F. Valenzuela, A.F. Spatola, and G. Barany, J. Peptide Res., 63, 303-312 (2004).3. I. Annis, L. Chen, and G. Barany, J. Am. Chem. Soc., 120, 7226-7238 (1998).4. CLEAR-OXTM US Patent Application 11/165,609 (June 23, 2005).5. B.R. Green and G. Bulaj, Protein Peptide Lett., 13, 67-70 (2006)

PRODUCT CODE QTY

CLEAR-OXTM

Polymer-Supported Oxidant for Disulfide Bond FormationRCO-1260-PI

-20 °C

1 g5 g

Application NotesCLEAR-OXTM Resin ConditioningPrior to use, swell the appropriate amount of CLEAR-OXTM resin (substitution level 0.17-0.20 meq/g) (3 times excess for the quantity of the peptide) in dichloromethane (DCM) for at least 40 min, then wash with 2 x DCM, 3 x DMF, 3 x MeOH, 3 x deionized water, and finally with 3 x water-acetonitrile (1:1) that has been degassed and purged with nitrogen. Filter the resin and use directly as a slurry. Synthesize the linear, reduced peptide according to standard Fmoc/tBu solid-phase synthesis strategies. Cleave peptides from the resin with TFA: phenol: water: triisopropylsilane 88:5:5:2 v/v/v/v for 2 h at room temperature under inert atmosphere. Extract the peptide from the cleaved resin and precipitate from cold, diethyl ether. Dry the peptide in vacuo . Oxidize the crude peptide directly with the preconditioned CLEAR-OX, without further purification.(continued next page)



LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 233

NEW!

CLEAR-OXTM OxidationGeneral MethodDissolve the crude, dry peptide dithiol (20-25 mg) in degassed oxidation buffer. Adjust the solution pH to the desired value with either 50% acetic acid or 8 M ammonium hydroxide. Dilute the solution to the final concentration of 5-7 mg/ml and add to the pre-conditioned CLEAR-OX resin. Allow the reaction mixture to stir with gentle agitation (1-2 h) blanketed with inert gas. The start of oxidation can be noted as the color of the resin changes from yellow to deep orange. Reaction completion must be confirmed by Ellman’s test (please see G.L. Ellman, Arch. Biochem. Biophys., 82, 70–77 (1959)). If not complete after 2 hours, extend the reaction time accordingly. Once oxidation is complete, filter the reaction mixture and wash with the oxidation buffer, CH3CN : H2O (1 : 1, v/v). Combine filtrates, concentrate in vacuo to remove acetonitrile and lyophilize.

H-[Cys-Trp-Ala-Met-Ala-Cys]-Lys-NH2 Met- and Trp-Containing Peptide Oxidation at pH 4.6Immediately following cleavage from the resin and precipitate/drying step, dissolve 20 mg of dry, reduced peptide H-Cys-Trp-Ala-Met-Ala-Cys-Lys-NH2 in degassed 0.1 M ammonium acetate buffer/acetonitrile (1 : 1, v/v) at 6–7 mg/mL concentration level. Add the peptide solution to pre-swollen CLEAR-OX resin (0.2 meq/g; 3 x molar excess over the amount of peptide, 370 mg of CLEAR-OX). Stir the reaction mixture at 25 °C for 2 hours at pH 4.6. Adjust pH with 50% acetic acid. A color change of the resin from yellow to deep orange indicates oxidation has begun. Ell-man’s test should be used to confirm reaction completion (please see G.L. Ellman, Arch. Biochem. Biophys., 82, 70–77 (1959)). Once oxidation is complete, filter the reaction mixture and wash with a small amount of CH3CN : H2O (1 : 1, v/v). Concentrate the filtrate in vacuo to remove CH3CN then lyophilize. Analyze the final oxidized peptide by reverse-phase (RP)-HPLC and ES-MS to confirm identity. Molecular Weight [M + H]+ oxidized: 808.32 [M + H]+ reduced: 811.34 Crude purity of oxidized peptide by RP-HPLC 50%.

A color change of the resin from yellow to deep orange indicates oxidation has begun.

H-Asp-[Pen-Phe-d-Trp-Orn-Tyr-Cys]-Val-OHConstrained Penicillamine with Tyr- and Trp present. Oxidation at pH 6.8Immediately following cleavage from the resin and precipitate/drying step, dissolve 2.01 g of dry, re-duced peptide H-Asp-Pen-Phe-d-Trp-Orn-Tyr-Cys-Val-OH in 280 mL of degassed ammonium acetate buffer in acetonitrile NH4OAc-CH3CN (1: 1, v/v) at pH 6.8. Add the pre-conditioned CLEAR-OX resin (29.35 g; Sn = 0.19 meq/g) to the slurry in 60 mL of de-gassed 0.1 M NH4OAc-CH3CN (1: 1, v/v) to the peptide solution. Stir the reaction mixture at 25 °C for 1-2 hours at pH 6.8 A color change of the resin from yellow to deep orange indicates oxidation has begun. Ellman’s test should be used to confirm reaction completion (please see G.L. Ellman, Arch. Biochem. Biophys., 82, 70–77 (1959)). Once oxidation is complete, filter the reaction mixture and wash with the oxidation buffer, CH3CN : H2O (1 : 1, v/v) and water; total volume of the filtrate, 600 mL. Concentrate the filtrate in vacuo to remove CH3CN then lyophilize. Analyze the final oxidized peptide by reverse-phase (RP)-HPLC and ES-MS to confirm identity. Yield of the crude oxidized product 1.91 g, 95.6%. Purity by HPLC 63%; ESI-MS: calc. 1074.43, found 1075.44 [M + H]+.

PEPT

IDES

INTE

RNAT

IONA

LSP

ECIA

LTY

PRO

DUCT

S &

TECH

NOLO

GIE

S

234 Order Hotline 1-800-777-4779 502-266-8787

Publications That Reference CLEAR-OXTM

Title Authors Publication Information Article Highlights

Oxidative Folding of Hepcidin at Acidic pH

Ji. Zhang, S. Diamond, T. Arvedson, B.J. Sasu, L.P. Miranda

Biopolymers (Pep-tide Science), 2010, 2, pp 257-264

“Folding at pH 4.0 with CLEAR-OXTM also led to a high quality folding product but had the advantage of faster folding kinetics over the oxidation at pH 3.3. Importantly, we found that correctly folded epcidin could be obtained from directly folding of crude (unpurified) linear hepcidin using CLEAR-OXTM-assisted folding at pH < 5.5.

Utilization of CLEAR-OXTM, Polymer Sup-ported Oxidant for Disulfide Bridge For-mation in Peptides

A. Walewska, A. Lesner, A. Łęgowska, and K. Rolka

Poster, 29th European Peptide Symposium

“Two methods DMSO and CLEAR-OXTM resulted in high yield of properly folded peptide. However DMSO oxidation re-quires more time for clean up procedure than the of application of CLEAR-OXTM resin.”

Synthesis of Cysteine-Rich Peptides

K. Kádár, G. Panyi, and G.K. Tóth

Poster, 30th European Peptide Symposium

“The regioselectivity of the isolated isomer was verified with biological measurements. For the synthesis of Orexin A we optimized the folding conditions and, using a poly-mer-supported oxidant- the CLEAR-OXTM resin-, within two hours we could isolate the correctly folded isomer as the major reaction product.”

Oxidative Folding of Conotoxins in Immobi-lized Systems

B.R. Green and G. Bulaj Protein and Peptide Letters, January 2006, 13 (1) pp 67-70

“We tested two alternative oxidation strategies to produce conotoxins α-GI and µ-PIIIA. The peptides were either reversibly immobilized on a solid support and then oxidized, or the immobilized di-sulfide reagent (CLEAR-OXTM) was used to oxidize the peptides. Both strategies appeared more efficient at higher peptide concentrations, consistent with pseudo-dilution effects.”

Conantokin-Br from Conus brettinghami and Selectivity Deter-minants for the NR2D Subunit of the NMDA Receptor

V.D. Twede, R.W. Teichert, C.S. Walker, P. Gruszczynski, R. Kazmierkiewicz, G. Bulaj, and B.M. Olivera

Biochemistry, 2009, 48, pp 4063-4073 DOI:10.1021/bi802259a

“Conantokins were oxidized using either CLEAR-OX resin (Peptides International, Inc.), ...1:1 oxidized/reduced glutathione... For the CLEAR-OX reaction, 200 nmol of peptide per reaction was oxidized for 2h in a solution containing 20 mg of the acti-vated resin and 100 mM Tris HCI.”

Role of Hydroxypro-lines in the in Vitro Oxidative Folding and Biological Activity of Conotoxins

E. Lopez-Vera, A. Walewska, J.J. Skalicky, B.M. Olivera, and G. Bulaj

Biochemistry, 2008, 47 (6), pp 1741–1751

Folding of Conotoxins: Formation of the Na-tive Disulfide Bridges During Chemical Syn-thesis and Biosynthe-sis of Conus Peptides

G. Bulaj, and B.M. Olivera Antioxidants & Redox Signaling, January 2008, 10 (1) pp 141-156, doi:10.1089/ars.2007.1856.

For bulk quantities, please inquire



LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 235

Peptide AntiseraOur undiluted antisera are suitable for immunohistochemical use, for application to radioimmunoassay (RIA), or other non-isotopic immunoassay systems. These antisera are partially characterized by either of the following two methods: 1) (EIA) or 2) ELISA. These products are not controlled to the rigorous specifications of prediluted antisera, which are adjusted to optimum concentrations for RIA and other immunoassays. These antisera are sold for research and development purposes only. Each antiserum has been lyophilized from 0.001 M Phosphate Buffer (pH 7.0).

Storage and Stability:These Iyophilized antisera are stable for one month at room temperature. For long term storage, we recommend storing at -20 °C (freezer). After reconstitution with buffer, solu-tions may be kept at 4 °C for continuous use with a suitable preservative. For extended storage, the solutions should be frozen at -20 °C.

Adrenomedullin (Human) Antiserum(Rabbit)

NAD-14278-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Adrenomedullin (Human, 1-52) (Carrier-free) Reactivity: Adrenomedullin (Human, 1-52) + Adrenomedullin (Rat,1-50) + Adrenomedullin (Human, 1-25) - Adrenomedullin (Human, 22-52) + Sensitivity*: IC50 = 0.053 pmol/ml (Antiserum Dilution: x 10,000)

Adrenomedullin (Human) Antiserum Dilution Curve• This product is distributed under the license of Shionogi & Co., Ltd. Its use for any purpose other than research is strictly prohibited.

Adrenomedullin 2 (Human, 1-7) Antiserum(Rabbit)

NAD-14421-v-20 °C

50 µlvial

Adrenomeduillin 2 (Human) Specific Antiserum

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Adrenomedullin 2 (Human, 1-7)-TG (TG: Bovine Thyroglobulin) Reactivity: Adrenomedullin 2 (Human) + Adrenomedullin (Human) - Calcitonin (Human) - CGRP (Human) -

Adrenomedullin 2 Antiserum Dilution Curve

• This product is distributed under the license of Shionogi & Co., Ltd. Its use for any purpose other than research is strictly prohibited.

Abs

orba

nce

at 4

15 n

m

Antiserum

Serum Dilution

1

0.75

0.5

0.25

0

10000 100000

14278

Normal Serum

Adrenomedullin (Human) Antiserum Dilution Curve

Antiserum

Normal Serum

10000 100000

Serum Dilution

Abs

orba

nce

at 4

15 n

m

1.4

1.2

1.0

0.8

0.6

0.4

0.2

0.0

PEPT

IDES

INTE

RNAT

IONA

LSP

ECIA

LTY

PRO

DUCT

S &

TECH

NOLO

GIE

S

236 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTY

Amylin (Rat) Antiserum(Rabbit)

NAM-14220-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Amylin (Rat)-BSA (BSA: Bovine Serum Albumin) Cross-reactions were not observed at higher doses Specificity: Amylin (Rat) 100% (1-10 nmol/ml) against the following peptides: Amylin (Human) 60% CRF (Human) Calcitonin Gene Related Peptide (Human) 0% Oxytocin Calcitonin Gene Related Peptide (Rat) 0% Neuropeptide Y (Human) Calcitonin (Human) 0% Somatostatin Sensitivity*: IC50 = 0.80 pmol/ml (Antiserum Dilution: x 20,000) β-Endorphin (Human)

Antisera of Amyloid β-Protein Related PeptidesAmyloid β-Protein (Human, 1-40) Antiserum

(Rabbit) NAP-14307-v

-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Amyloid β-Protein (Human, 1-40) (Carrier-free) Cross-reactions were not observed at higher doses Specificity: Amyloid β-Protein (Human, 1-40) 100% (1-10 nmol/ml) against the following peptides: Amyloid β-Protein (Human, 1-25) 100% CRF (Human) Amyloid β-Protein (Human, 1-15 Amide) <1% BNP-32 (Human) Amyloid β-Protein (Human, 1-16) <1% Endothelin-1 (Human) Amyloid β-Protein (Human, 26-40) 0% Secretin (Human) Amyloid β-Protein (Human, 17-25) 0% Substance P Amyloid β-Protein (Human, 24-35) 0% Sensitivity*: IC50 = 0.60 pmol/ml (Antiserum Dilution: x 20,000)

β-Protein (Human, 1-16) AntiserumAmyloid β-Protein N-Terminal Specific Antiserum (Rabbit)

NAB-14359-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Amyloid β-Protein (Human, 1-16)-KLH (KLH: Keyhole Limpet Hemocyanin) Reactivity: Amyloid β-Protein (Human, 1-16) + Amyloid β-Protein (Human, 1-40) + Amyloid β-Protein (Human, 1-42) +

Amyloid β Protein (Human, 1-16) Antiserum Dilution Curve

* All sensitivity data are measured by enzyme immunoassay using β-d-galactosidase as a label.

Abs

orba

nce

at 4

15 n

m

Serum Dilution

1

0.75

0.5

0.25

0

10000 100000

14359

Antiserum

Normal Serum




LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 237

PRODUCT CODE QTY

Amyloid β-Protein (Human, 34-40) AntiserumAmyloid β-Protein (1-40) Specific Antiserum (Rabbit)

NAB-14356-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Amyloid β-Protein (Human, 34-40)-KLH (KLH: Keyhole Limpet Hemocyanin) Reactivity: Amyloid β-Protein (Human, 1-40) + Amyloid β-Protein (Human, 1-16) - Amyloid β-Protein (Human, 1-42) -

Amloid β Protein (Human, 34-40) Antiserum Dilution Curve


NAB-14357-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Amyloid β-Protein (Human, 37-42)-KLH (KLH: Keyhole Limpet Hemocyanin) Reactivity: Amyloid β-Protein (Human, 1-42) + Amyloid β-Protein (Human, 1-40) - Amyloid β-Protein (Human, 1-16) -



NAB-14414-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Amyloid β-Protein (Human, 37-43)-KLH (KLH: Keyhole Limpet Hemocyanin) Reactivity: Amyloid β-Protein (Human, 1-43) + Amyloid β-Protein (Human, 1-42) - Amyloid β-Protein (Human, 1-40) - Amyloid β-Protein (Human, 1-16) -


ANP (Human, 1-28) AntiserumA-Type (Atrial) Natriuretic Peptide (Human, 1-28) Antiserum (Rabbit)

NAF-14135-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: ANP (Human, 1-28)-TG (TG: Bovine Thyroglobulin) Cross-reactions were not observed at higher doses (1-10 nmol/ml) against the following peptides: Specificity: ANP (Human, 1-28) 100% ANP (Human, 7-28) 100% Oxytocin [Met(O)12]-ANP (Human,1-28) 150% [Arg8]-Vasopressin ANP (Rat, 1-28) 55% Somatostatin β-ANP (Human, 1-28 Dimer) 100% [Met5]-Enkephalin Sensitivity*: IC50 = 0.28 pmol/ml (Antiserum Dilution: x 10,000) β-Endorphin (Human)


Abs

orba

nce

at 4

15 n

m

Serum Dilution

1

0.75

0.5

0.25

0

10000 100000

14356

Antiserum

Normal Serum


Abs

orba

nce

at 4

15 n

m

Serum Dilution

1

0.75

0.5

0.25

0

10000 100000

14357

Antiserum

Normal Serum


Abs

orba

nce

at 4

15 n

m

Serum Dilution

1.8 1.6

1.4

1.2 1.0 0.8 0.6 0.4 0.2 0.0

10000 100000

Antiserum

Normal Serum

14414


PEPT

IDES

INTE

RNAT

IONA

LSP

ECIA

LTY

PRO

DUCT

S &

TECH

NOLO

GIE

S

238 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTY

BNP-26 (Porcine) AntiserumB-Type (Brain) Natriuretic Peptide (Porcine, 1-26) Antiserum (Rabbit)

NBN-14200-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: BNP-26 (Porcine)-TG (TG: Bovine Thyroglobulin) Cross-reactions were not observed at higher doses (1-10 nmol/ml) against the following peptides: Specificity: BNP-26 (Porcine) 100% BNP (Porcine, 20-26) <0.1% Oxytocin ANP (Human, 1-28) <0.1% Somatostatin ANP (Rat, 1-28) <0.1% [Met5]-Enkephalin Sensitivity*: IC50 = 5.5 pmol/ml (Antiserum Dilution: x 20,000) VIP CRF (Human)

Calcitonin (Human) Antiserum(Rabbit)

NCL-14051-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Cross-reactions were not observed at higher doses Immunogen: Calcitonin (Human)-TG (TG: Bovine Thyroglobulin) (1-10 nmol/ml) against the following peptides:Specificity: Calcitonin (Human) 100% CGRP (Human) Calcitonin (Human, 11-32) 100% Secretin (Human) Calcitonin (Rat) 100% Somatostatin Calcitonin (Salmon) 0% b-Endorphin (Human) Sensitivity*: IC50 = 3.0 pmol/ml (Antiserum Dilution: x 100,000) Neuropeptide Y (Porcine)

CCK-33 (Porcine) Antiserum(Rabbit)

NCK-14176-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Cross-reactions were not observed at higher doses Immunogen: CCK-33 (Porcine)-TG (TG: Bovine Thyroglobulin) (1-10 nmol/ml) against the following peptides:Specificity: CCK-33 (Porcine, Sulfated) 100% CRF (Human) CCK-33 (Human, Sulfated) 60% VIP Gastrin l <0.1% Neuropeptide Y (Human) CCK-8 (Sulfated Form) <0.1% b-Endorphin (Human) CCK-8 (Nonsulfated Form) <0.1% Somatostatin Peptide YY <0.1% Sensitivity*: IC50 = 0.3 pmol/ml (Antiserum Dilution: x 200,000)

CGRP (Human) AntiserumCalcitonin Gene Related Peptide (Human) Antiserum (Rabbit)

NCG-14160-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Cross-reactions were not observed at higher doses Immunogen: CGRP (Human)-TG (TG: Bovine Thyroglobulin) (1-10 nmol/ml) against the following peptides:Specificity: CGRP (Human) 100% [Met5]-Enkephalin CGRP II (Human) 20% Oxytocin CGRP (Rat) 10% Neuropeptide Y (Human) Sensitivity*: IC50 = 0.45 pmol/ml (Antiserum Dilution: x 20,000) β-Endorphin (Human) Somatostatin




LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 239

PRODUCT CODE QTY

CINC-1/gro (Rat) AntiserumCytokine-Induced Neutrophil Chemoattractant / Growth-Related Oncogene (Rat) Antiserum (Rabbit)

NIL-14233-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Cross-reactions were not observed at higher doses Immunogen: CINC/gro (Rat, 1-72) (Carrier-free) (1-10 nmol/ml) against the following peptides:Specificity: CINC/gro (Rat, 1-72) 100% Glucagon (Human) [Cys(Acm)9,11]-CINC/gro (Rat, 1-17) 0% Secretin (Human) CINC/gro (Rat, 11-34) 0% Gastrin I (Human) CINC/gro (Rat, 35-50) 0% CCK-8 (Sulfated Form) CINC/gro (Rat, 51-72) 0% Somatostatin Sensitivity*: IC50 = 0.19 pmol/ml (Antiserum Dilution: x 100,000)

CNP-22 (Human) AntiserumC-type Natriuretic Peptide-22 (Human) Antiserum (Rabbit)

NCT-14250-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Cross-reactions were not observed at higher doses Immunogen: CNP-22 (Human)-TG (TG: Bovine Thyrogloblin) (1-10 nmol/ml) against the following peptides:Specificity: CNP-22 (Human) 100% Secretin (Human) CNP-53 (Porcine, Rat) 100% CRF (Human) CNP-53 (Human) 100% Substance P ANP (Human, 1-28) 0% CGRP (Human) ANP (Rat, 1-28) 0% Endothelin-2 (Human) BNP-32 (Human) 0% BNP-45 (Human) 0% BNP-45 (Rat) 0% Sensitivity*: IC50 = 0.25 pmol/ml (Antiserum Dilution: x 10,000)

CRF (Human) AntiserumCorticotropin Releasing Factor (Human) Antiserum (Rabbit)

NCR-14136-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Cross-reactions were not observed at higher doses Immunogen: CRF (Human)-TG (TG: Bovine Thyroglobulin) (1-10 nmol/ml) against the following peptides:Specificity: CRF (Human) 100% Oxytocin CRF (Human, 31-42) 35% [Arg8]-Vasopressin CRF (Ovine) <0.1% [Met5]-Enkephalin CRF (Ovine, 31-42) <0.1% β-Endorphin (Human) Sensitivity*: IC50 = 5.2 pmol/ml (Antiserum Dilution: x 20,000) Somatostatin


PEPT

IDES

INTE

RNAT

IONA

LSP

ECIA

LTY

PRO

DUCT

S &

TECH

NOLO

GIE

S

240 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTY

β-Defensin-2 (Human) Antiserum(Rabbit)

NBD-14338-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: β-Defensin-2 (Human)-TG (TG: Bovine Thyroglobulin) Reactivity: β-Defensin-2 (Human) + β-Defensin-1 (Human) - a-Defensin-1 (Human) -

β-Defensin-2 (Human) Antiserum Dilution Curve

Elafin (Human) Antiserum(Rabbit)

NEL-14243-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Cross-reactions were not observed at higher doses Immunogen: Elafin (Human, 1-57) (Carrier-free) (1-10 nmol/ml) against the following peptides:Specificity: Elafin (Human) 100% Endothelin-1 (Human) Sensitivity*: IC50 = 0.40 pmol/ml (Antiserum Dilution: x 20,000) ANP (Human 1-28) CRF (Human) Substance P Neuropeptide Y (Human)

Endothelin AntiseraEndothelin-1 (Human) Antiserum

(Rabbit)NED-14198-v

-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Cross-reactions were not observed at higher doses Immunogen: Endothelin-1 (Human, 1-21)-TG (TG: Bovine Thyroglobulin) (1-10 nmol/ml) against the following peptides:Specificity: Endothelin 1 (Human) 100% Peptide YY Endothelin-2 (Human) 60% CGRP (Human) Endothelin 3 (Human) 40% Secretin (Human) Big Endothelin-1 (Human, 1-38) <1% β-Endorphin (Human) Big Endothelin-1 (Porcine, 1-39) <1% Somatostatin Sensitivity*: IC50 = 1.0 pmol/ml (Antiserum Dilution: x 20,000)

Big Endothelin-1 (Porcine, 22-39) Antiserum(Rabbit)

NED-14210-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Big Endothelin-1 (Porcine, 22-39)-BSA (BSA: Bovine Serum Albumin) Cross-reactions were not observed at higher doses (1-10 nmol/ml) against the following peptides:Specificity: Big Endothelin-1 (Porcine, 22-39) 100% Glucagon (Human) Big Endothelin-1 (Porcine, 1-39) 100% Secretin (Human) Big Endothelin-1 (Human, 1-38) 10% Gastrin I Big Endothelin-1 (Human, 18-38) 10% CCK-8 (Sulfated Form) Endothelin-1 (Human) 0% Somatostatin Endothelin-2 (Human) 0% Endothelin-3 (Human) 0% Sensitivity*: IC50 = 0.45 pmol/ml (Antiserum Dilution: x 30,000)


Abs

orba

nce

at 4

15 n

m

Serum Dilution

1

0.75 0.5 0.25 0

10000 100000

Antiserum

Normal Serum

14338

β-Defensin-2 (Human) Antiserum Dilution Curve



LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 241

PRODUCT CODE QTY

Big Endothelin-1 (Human, 22-38) Antiserum(Rabbit)

NED-14224-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Big Endothelin-1 (Human, 22-38)-BSA (BSA: Bovine Serum Albumin) Cross-reactions were not observed at higher doses (1-10 nmol/ml) against the following peptides:Specificity: Big Endothelin-1 (Human, 1-38) 100% Peptide YY Big Endothelin-1 (Human, 22-38) 50% CGRP (Human) Big Endothelin-2 (Human, 22-38) <0.1% Secretin (Human) Big Endothelin-3 (Human, 22-41 Amide) <0.1% b-Endorphin (Human) Endothelin-1 (Human) 0% Somatostatin Sensitivity*: IC50 = 2.5 pmol/ml (Antiserum Dilution: x 20,000)


NED-14225-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Big Endothelin-2 (Human, 22-38)-BSA (BSA: Bovine Serum Albumin) Cross-reactions were not observed at higher doses (1-10 nmol/ml) against the following peptides:Specificity: Big Endothelin-2 (Human, 1-38) 100% ANP (Human, 1-28) Big Endothelin-2 (Human, 22-38) 200% BNP-32 (Human) Big Endothelin-2 (Human, 1-37) 0% CNP-53 (Human) Big Endothelin-1 (Human, 1-38) 0% Substance P Big Endothelin-3 (Human, 1-41 Amide) 0% CRF (Human) Endothelin-1 (Human) 0% Endothelin-2 (Human) 0% Endothelin-3 (Human) 0% Sensitivity*: IC50 = 0.25 pmol/ml (Antiserum Dilution: x 40,000)


NED-14238-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Big Endothelin-2 (Human, 22-37)-BSA (BSA: Bovine Serum Albumin) Cross-reactions were not observed at higher doses (1-10 nmol/ml) against the following peptides:Specificity: Big Endothelin-2 (Human, 1-37) 100% Peptide YY Big Endothelin-2 (Human, 1-38) 0% CGRP (Human) Big Endothelin-2 (Human, 22-37) 400% Secretin (Human) Big Endothelin-1 (Human, 1-38) 0% b-Endorphin (Human) Big Endothelin-3 (Human, 1-41 Amide) 0% Somatostatin Endothelin-1 (Human) 0% Endothelin-2 (Human) 0% Endothelin-3 (Human) 0% Sensitivity*: IC50 = 1.8 pmol/ml (Antiserum Dilution: x 100,000)


PEPT

IDES

INTE

RNAT

IONA

LSP

ECIA

LTY

PRO

DUCT

S &

TECH

NOLO

GIE

S

242 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTY

Big Endothelin-3 (Human, 22-41 Amide) Antiserum

(Rabbit)

NED-14226-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Big Endothelin-3 (Human, 22-41 Amide)-BSA (BSA: Bovine Serum Albumin) Cross-reactions were not observed at higher doses (1-10 nmol/ml) against the following peptides:Specificity: Big Endothelin-3 (Human, 1-41 Amide) 100% Peptide YY Big Endothelin-3 (Human, 22-41 Amide) 35% CGRP (Human) Big Endothelin-3 (Rat, 1-41 Amide) 100% Secretin (Human) Big Endothelin-3 (Rat, 1-39) <0.1% b-Endorphin (Human) Big Endothelin-1 (Human, 1-38) 0% Somatostatin Big Endothelin-2 (Human, 1-37) 0% Endothelin-1 (Human) 0% Endothelin-2 (Human) 0% Endothelin-3 (Human) 0% Sensitivity*: IC50 = 0.45 pmol/ml (Antiserum Dilution: x 20,000)

Galanin (Rat) Antiserum(Rabbit)

NGA-14244-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Galanin (Rat)-BSA (BSA: Bovine Serum Albumin) Cross-reactions were not observed at higher doses (1-10 nmol/ml) against the following peptides:Specificity: Galanin (Rat) 100% Secretin (Human) Galanin (Rat, 1-16) 0% CRF (Human) Galanin (Human) 0% CGRP (Human) Sensitivity*: IC50 = 1.2 pmol/ml (Antiserum Dilution: x 30,000) ANP (Human, 1-28)

GRF (Human) AntiserumGrowth Hormone Releasing Factor (Human) Antiserum (Rabbit)

NGR-14127-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: GRF (Human)-KLH (KLH: Keyhole Limpet Hemocyanin) Cross-reactions were not observed at higher doses Specificity: GRF (Human) 100% (1-10 nmol/ml) against the following peptides: GRF (Porcine) 100% CRF (Human) GRF (Human, 30-44 Amide) 30% VIP GRF (Bovine) 5% Neuropeptide Y (Human) GRF (Ovine) 1% b-Endorphin (Human) GRF (Rat) <0.1% Somatostatin GRF (Human 1-29) <0.1% Sensitivity*: IC50 = 0.35 pmol/ml (Antiserum Dilution: x 20,000)




LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 243

PRODUCT CODE QTY

GRP (Human) AntiserumGastrin Releasing Peptide (Human) Antiserum (Rabbit)

NGR-14164-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: GRP (Human)-TG (TG: Bovine Thyroglobulin) Cross-reactions were not observed at higher doses Specificity: GRP (Human) 100% (1-10 nmol/ml) against the following peptides: GRP (Porcine) 75% Glucagon (Human) GRP (14-27) 55% Secretin (Human) Neuromedin C (GRP, 18-27) 10% Gastrin I (Human) Bombesin 10% Somatostatin Neuromedin B <0.1% CCK-8 (Sulfated Form) GRP (Human, 1-18) <0.1% Peptide YY <0.1% Sensitivity*: IC50 = 0.34 pmol/ml (Antiserum Dilution: x 10,000)

Lysenin Antiserum(Rabbit)

NLY-14802-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Lysenin (Carrier-free) Reactivity: Lysenin + For Immunohistochemistry: x 100 - 1,000 dilution

Abs

orba

nce

at 4

15 n

m

Serum Dilution

1

0.75 0.5

0.25

0

10000 100000

14802Antiserum

Normal Serum

Lysenin Antiserum Dilution Curve

Lysenin Antiserum Dilution Curve

Midkine (Human, 1-59) Antiserum(Rabbit)

NMK-14319-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Midkine (Human, 1-59)-TG (TG: Bovine Thyroglobulin) Reactivity: Midkine (Human) + Midkine (Human, 1-59) + Midkine (Human, 60-121) - Pleiotrophin (Human) -

Midkine (Human, 1-59) Antiserum Dilution Curve


Antiserum

Abs

orba

nce

at 4

15 n

m

1

0.75

0.5

0.25

0

10000 100000

14319

Serum Dilution

Normal Serum

Midkine (Human, 1-59) Antiserum Dilution Curve

PEPT

IDES

INTE

RNAT

IONA

LSP

ECIA

LTY

PRO

DUCT

S &

TECH

NOLO

GIE

S

244 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTY

NPY (Human) AntiserumNeuropeptide Y (Human) Antiserum (Rabbit)

NNP-14158-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: NPY (Human)-TG (TG: BovineThyroglobulin) Cross-reactions were not observed at higher doses NPY (Human) 100% (1-10 nmol/ml) against the following peptides: Specificity: NPY (Porcine) 100% Oxytocin NPY (Human, 1-9) <0.1% [Arg8]-Vasopressin NPY (Human, 24-36) <0.1% Somatostatin Pancreatic Polypeptide (Human) <0.1% ANP (Human, 1-28) Peptide YY <0.1% β-Endorphin (Human) Sensitivity*: IC50 = 3.0 pmol/ml (Antiserum Dilution: x 50,000)

Orexin-A (Human) Antiserum(Rabbit)

NOR-14346-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Orexin-A (Human)-BSA (BSA: Bovine Serum Albumin) Reactivity: Orexin-A (Human) + Orexin-B (Human) + Orexin-B (Rat) + GLP-1 (7-36 Amide) -

Orexin-A (Human) Antiserum Dilution Curve

Osteocalcin (Human, 38-49) Antiserum(Rabbit)

NOS-14276-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Osteocalcin (Human, 38-49)-BSA (BSA: Bovine Serum Albumin) Cross-reactions were not observed at higher doses (20-2000 pmol/ml): against the following peptides: Specificity: Gla17,21,24-Osteocalcin (Human, 1-49) 100% Endothelin-1 (Human) Glu17,Gla21,24-Osteocalcin (Human, 1-49) 100% ANP (Human, 1-28) Osteocalcin (Human, 38-49) 200% CRF (Human) Osteocalcin (Human, 1-13) 0% Substance P Sensitivity*: IC50 = 0.60 pmol/ml (Antiserum Dilution: x 50,000) Secretin (Human)

Proangiotensin-12 (Rat) Antibody(Rabbit)

NAN-14439-v-20 °C

50 µlvial

S. Nagata, J. Kato, K. Sasaki, N. Minamino, T. Eto, and K. Kitamura, Biochem. Biophys. Res. Commun., 350 ,1026 (2006).


Abs

orba

nce

at 4

15 n

m

Serum Dilution

1 0.75 0.5

0.25 0

10000 100000

14346

Antiserum

Normal Serum

Orexin-A (Human) Antiserum Dilution Curve

NEW!



LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 245

PRODUCT CODE QTY

[Pyr33]-Pancreastatin (Porcine, 33-49) Antiserum(Rabbit)

NPP-14186-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Cross-reactions were not observed at higher doses Immunogen: [Pyr33]-Pancreastatin (Porcine, 33-49)-TG (TG: Bovine Thyroglobulin) (1-10 nmol/ml) against the following peptides: Peptide YY Specificity: [Pyr33]-Pancreastatin (Porcine, 33-49) 100% CGRP (Human) Pancreastatin (Porcine, 1-49) 100% Somatostatin Chromogranin A (Human, 286-301 Amide) 100% Secretin (Human) Sensitivity*: IC50 = 0.27 pmol/ml (Antiserum Dilution: x 50,000) β-Endorphin (Human)

Salusin-β (Human) AntiserumSalusin-β (Human) Specific Antiserum (Rabbit)

NSL-14418-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Salusin-β (Human)-TG (TG: Bovine Thyroglobulin) Specificity: Salusin-β (Human) + Salusin-a (Human) - Salusin-β Antiserum Dilution Curve

Secretin (Porcine) Antiserum(Rabbit)

NSE-14112-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Cross-reactions were not observed at higher doses Immunogen: Secretin (Porcine)-TG (TG: Bovine Thyroglobulin) (1-10 nmol/ml) against the following peptides: Specificity: Secretin (Porcine) 100% GRP (Human) Secretin (Human) 100% Gastrin I (Human) Secretin (Chicken) 0% Neuropeptide Y (Porcine) Glucagon (Human) Sensitivity*: IC50 = 0.27 pmol/ml (Antiserum Dilution: x 50,000) Somatostatin

SPAI-1 (Porcine) AntiserumSodium Potassium ATPase Inhibitor-1 (Porcine) Antiserum (Na+,K+-ATPase Inhibitor-1 Antiserum) (Rabbit)

NSP-14216-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Cross-reactions were not observed at higher doses Immunogen: SPAI-1 (Porcine, 1-49)-BSA (100-200 nmol/ml) against the following peptides: (BSA: Bovine Serum Albumin) Calcitonin (Human) Specificity: SPAI-1 (Porcine, 1-49) 100% CRF (Human) SPAl-1 (Porcine, 1-14) 0% Endothelin-1 (Human) SPAI-1 (Porcine, 25-35) 0% BNP-26 (Porcine) Ouabain 0% Secretin (Human) Sensitivity*: IC50 = 0.14 pmol/ml (Antiserum Dilution: x 30,000)


PEPT

IDES

INTE

RNAT

IONA

LSP

ECIA

LTY

PRO

DUCT

S &

TECH

NOLO

GIE

S

246 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT CODE QTY

Urotensin II (Human) Antiserum(Rabbit)

NUT-14365-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Immunogen: Urotensin II (Human)-BSA (BSA: Bovine Serum Albumin) Reactivity: Urotensin II (Human) ++ Urotensin II (Rat) + Endothelin-1 - Somatostatin - ++: Positive Color Reaction +: Weakly Positive Color Reaction -: Negative Color Reaction in 60 min Urotensin II (Human) Antiserum Dilution Curve

VIP AntiserumVasoactive Intestinal Peptide Antiserum (Rabbit)

NVA-14110-v-20 °C

50 µlvial

Antiserum: lyophilized from 0.001 M Phosphate Buffer (pH 7.0) Cross-reactions were not observed at higher doses Immunogen: VIP-TG (TG: Bovine Thyroglobulin) (1-10 nmol/ml) against the following peptides: Specificity: VIP 100% CRF (Human) Secretin (Human) <0.1% Oxytocin Glucagon (Human) <0.1% Neuropeptide Y (Human) GRF (Human) <0.1% β-Endorphin (Human) Sensitivity*: IC50 = 1.2 pmol/ml (Antiserum Dilution: x 10,000) Somatostatin


Abs

orba

nce

at 4

15 n

m

Serum Dilution

1 0.75 0.5 0.25 0

10000 100000

14365

Antiserum

Normal Serum

Urotensin II (Human) Antiserum Dilution Curve



LOG

IES

Order Hotline 1-800-777-4779 502-266-8787 247

PRODUCT CODE QTY

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

248 Order Hotline 1-800-777-4779 502-266-8787

Amino AcidsClick Chemistry Amino AcidsBoc-Dab(N3)-OH • CHA

Boc-(S)-2-amino-4-azidobutanoic acid CHA salt(M.W. 343.4)[120042-08-2] OH

O

N3

NH

O

O

H2N

BLX-53111-PI4 °C

1 g5 g

25 g

Boc-d-Dab(N3)-OH • CHABoc-(R)-2-amino-4-azidobutanoic acid CHA salt(M.W. 343.4) OH

O

N3

NH

O

O

H2N

BDX-53115-PI4 °C

1 g5 g

25 g

Boc-Dap(N3)-OH • CHABoc-(S)-2-amino-3-azidopropanoic acid CHA salt(M.W. 329.4)

OH

O

NH

O

O

H2N

N3

BLX-53110-PI4 °C

1 g5 g

25 g

Boc-d-Dap(N3)-OH • CHABoc-(R)-2-amino-3-azidopropanoic acid CHA salt(M.W. 329.4)

OH

O

NH

O

O

H2N

N3

BDX-53114-PI4 °C

1 g5 g

25 g

Boc-Lys(N3)-OH • CHABoc-(S)-2-amino-6-azidohexanoic acid CHA salt(M.W. 371.5)[846549-33-5]

OH

O

NH

O

O

H2N

N3 BLK-53113-PI4 °C

1 g5 g

25 g

Boc-d-Lys(N3)-OH • CHABoc-(R)-2-amino-6-azidohexanoic acid CHA salt(M.W. 371.5)

OH

O

NH

O

O

H2N

N3 BDK-53117-PI4 °C

1 g5 g

25 g

Boc-Orn(N3)-OH • CHABoc-(S)-2-amino-5-azidopentanoic acid CHA salt(M.W. 357.4)

OH

O

NH

O

O

H2N

N3 BLO-53112-PI4 °C

1 g5 g

25 g

NEW!

NEW!

NEW!

NEW!

NEW!

NEW!


TOO

LS for PEPTIDE SYNTHESIS

Order Hotline 1-800-777-4779 502-266-8787 249

PRODUCT CODE QTYBoc-d-Orn(N3)-OH • CHA

Boc-(R)-2-amino-5-azidopentanoic acid CHA salt(M.W. 357.4) OH

O

NH

O

O

H2N

N3 BDO-53116-PI4 °C

1 g5 g

25 g

Fmoc-Azido-Lys-OHNα-9-Fluorenylmethoxycarbonyl-ε-Azido-l-Lysine(M.W. 394.43) C21H22N4O4 [159610-89-6]Building Block for Click ChemistryA. Le Chevalier Isaad, et al., J. Pept. Sci., 15, 451 (2009).P.E. Schneggenburger, et al., J. Pept. Sci., 16, 10 (2010).

FAK-1903-PI4 °C

OH

O

NH

O

O

N3 1 g5 g

Fmoc-d-Dab(N3)-OHFmoc-(R)-2-Amino-4-azidobutanoic acid (M.W. 366.4)

OH

O

N3

NH

O

O

FDX-53107-PI4 °C

1 g5 g

25 g

Fmoc-d-Dap(N3)-OHFmoc-(R)-2-Amino-3-Azidopropanoic Acid (M.W. 352.3)[1016163-79-3] OH

O

NH

O

ON3

FDX-53106-PI4 °C

1 g5 g

25 g

Fmoc-d-Lys(N3)-OHFmoc-(R)-2-Amino-6-Azidohexanoic Acid(M.W. 394.4)[1198791-53-5]

OH

O

NH

O

O

N3 FDK-53109-PI4 °C

1 g5 g

25 g

NEW!

NEW!

NEW!

NEW! NEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

250 Order Hotline 1-800-777-4779 502-266-8787

Fmoc-Orn(N3)-OHFmoc-(S)-2-Amino-5-azidopentanoic acid(M.W. 380.4)[1097192-04-5]

OH

O

NH

O

O

N3 FLO-53104-PI4 °C

1 g5 g

25 g

Fmoc-d-Orn(N3)-OHFmoc-(R)-2-Amino-5-Azidopentanoic Acid(M.W. 380.4)[1176270-25-9]

OH

O

NH

O

O

N3 FDO-53108-PI4 °C

1 g5 g

25 g

Fmoc-Dab(N3)-OHFmoc-(S)-2-Amino-4-azidobutanoic acid (M.W. 366.4)[942518-20-9]

OH

O

N3

NH

O

O

FLX-53103-PI4 °C

1 g5 g

25 g

Fmoc-Dap(N3)-OHFmoc-(S)-2-Amino-3-Azidopropanoic Acid (M.W. 352.3)[684270-46-0]

OH

O

NH

O

ON3

FLX-53102-PI4 °C

1 g5 g

25 g

l-Amino Acidsl-Alanine

(M.W. 89.09) C3H7NO2 [56-41-7]ALA-2701-PI 100 g

500 g

l-Arginine • HCI(M.W. 174.20 • 36.46) C6H14N4O2 • HCI[1119-34-2]

ALR-2702-PI 100 g500 g

l-Asparagine • H2O(M.W. 132.12 • 18.02) C4H8N2O3 • H2O [5794-13-18]

ALN-2703-PI 100 g500 g

l-Aspartic acid(M.W. 133.10) C4H7NO4 [56-84-8]

ALD-2704-PI 100 g500 g

l-Cysteine • HCI • H2O(M.W. 121.16 • 36.46 • 18.02)C3H7NO2S • HCI • H2O [7048-04-6]

ALC-2705-PI 100 g500 g

l-Cystine(M.W. 240.30) C6H12N2O4S2 [56-89-3]

ALC-2706-PI 100 g500 g

NEW!

NEW!

NEW!

NEW!

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C


TOO


Order Hotline 1-800-777-4779 502-266-8787 251

PRODUCT CODE QTYl-Glutamic Acid

(M.W. 147.13) C5H9NO4 [56-86-0]ALE-2708-PI 100 g

500 g

l-Glutamine(M.W. 146.15) C5H10N2O3 [56-85-9]

ALQ-2707-PI 100 g500 g

Glycine(M.W. 75.07) C2H5NO2 [56-40-6]

ALG-2709-PI 100 g500 g

l-Histidine • HCI • H2O(M.W. 155.16 • 36.46 • 18.02)C6H9N3O2 • HCI • H2O [5934-29-2]

ALH-2710-PI 100 g500 g

l-Hydroxyproline(M.W. 131.13) C5H9NO3 [51-35-4]

ALX-2711-PI 25 g100 g500 g

l-Isoleucine(M.W. 131.18) C6H13NO2 [73-32-5]

ALI-2712-PI 25 g100 g500 g

l-Leucine(M.W. 131.18) C6H13NO2 [61-90-5]

ALL-2713-PI 25 g100 g500 g

l-Lysine • HCI(M.W. 146.19 • 36.46) C6H14N2O2 • H2O [657-27-2]

ALK-2714-PI 100 g500 g

l-Methionine(M.W. 149.21) C5H11NO2S [63-68-3]

ALM-2715-PI 100 g500 g

l-Norleucine(M.W. 131.17) C6H13NO2 [327-57-1]

ALU-2728-PI 5 g25 g

l-Ornithine • HCI(M.W. 132.16 • 36.46) C5H12N2O2 • HCI [3184-13-2]

ALO-2716-PI 25 g100 g

l-Phenylalanine(M.W. 165.19) C9H11NO2 [63-91-2]

ALF-2717-PI 100 g500 g

l-Proline(M.W. 115.13) C5H9NO2 [147-85-3]

ALP-2718-PI 100 g500 g

l-Pyroglutamic Acid(l-Pyrrolidone carboxylic acid)(M.W. 129.12) C5H7NO3 [98-79-3]

ALU-2724-PI 25 g100 g

l-Serine(M.W. 105.09) C3H7NO3 [56-45-1]d-Ser Contamination: 0.5-1.5%

ALS-2719-PI 25 g100 g

l-Threonine(M.W. 119.12) C4H9NO3 [72-19-5]

ALT-2720-PI 100 g500 g4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

252 Order Hotline 1-800-777-4779 502-266-8787

l-Tryptophan(M.W. 204.23) C11H12N2O2 [73-22-3]

ALW-2721-PI 25 g100 g

l-Tyrosine(M.W. 181.19) C9H11NO3 [60-18-4]

ALY-2722-PI 100 g500 g

l-Valine(M.W. 117.15) C5H11NO2 [72-18-4]

ALV-2723-PI 100 g500 g

d-Amino Acidsd-Alanine

(M.W. 89.09) C3H7NO2 [338-69-2]ADA-2801-PI 5 g

25 g

d-Arginine(M.W. 174.20) C6H14N4O2 [157-06-2]

ADR-2802-PI 5 g25 g

d-Asparagine • H2O(M.W. 132.12 • 18.02) C4H8N2O3 • H2O [5794-24-1]

ADN-2815-PI 5 g25 g

d-Aspartic acid(M.W. 133.10) C4H7NO4 [1783-96-6]

ADD-2814-PI 5 g25 g

d-Cysteine • HCI • H2O(M.W. 121.16 • 36.46 • 18.02) C3H7NO2S • HCI • H2O [32443-99-5]

ADC-2817-PI 5 g25 g

d-Glutamic Acid(M.W. 147.13) C5H9NO4 [6893-26-1]

ADE-2804-PI 5 g25 g

d-Histidine(M.W. 155.16) C6H9N3O2 [351-50-8]

ADH-2805-PI 5 g25 g

d-Isoleucine(M.W. 131.17) C6H13NO2 [319-78-8]

ADI-2819-PI 1 g5 g

d-Leucine(M.W. 131.17) C6H13NO2 [328-38-1]

ADL-2806-PI 5 g25 g

d-Lysine • HCI(M.W. 146.19 • 36.46) C6H14N2O2 • HCI [7274-88-6]

ADK-2813-PI 5 g25 g

d-Methionine(M.W. 149.21) C5H11NO2S [348-67-4]

ADM-2807-PI 5 g25 g

d-Phenylalanine(M.W. 165.19) C9H11NO2 [673-06-3]

ADF-2808-PI 5 g25 g

d-Proline(M.W. 115.13) C5H9NO2 [344-25-2]

ADP-2816-PI 5 g25 g

d-Serine(M.W. 105.09) C3H7NO3 [312-84-5]

ADS-2818-PI 5 g25 g4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C


TOO


Order Hotline 1-800-777-4779 502-266-8787 253

PRODUCT CODE QTYd-Threonine

(M.W. 119.12) C4H9NO3 [632-20-2]ADT-2809-PI 5 g

25 g

d-Tryptophan(M.W. 204.23) C11H12N2O2 [153-94-6]

ADW-2810-PI 5 g25 g

d-Tyrosine(M.W. 181.19) C9H11NO3 [556-02-5]

ADY-2812-PI 5 g25 g

d-Valine(M.W. 117.15) C5H11NO2

ADV-2811-PI 5 g25 g

Amino Acid EstersArg(NO2)-OBzl • Tos

Ng-nitro-l-Arginine benzyl ester tosylate(M.W. 309.32 • 172.20) C13H19N5O4 • C7H8O3S [10342-07-1]

B EBR-20484 °C

5 g25 g

100 g

Asp(OBzl)-OBzl • Tosl-aspartic acid α, β-dibenzyl ester tosylateM.W. 313.35 • 172.20) C18H19NO4 • C7H8O3S [2886-33-1]

A EBD-20454 °C

5 g25 g

100 g

Glu(OBzl)-OBzl • Tosl-glutamic acid α,γ-dibenzyl ester tosylateM.W. 327.37 • 172.20) C19H21NO4 • C7H8O3S [2791-84-6]

A EBE-20464 °C

5 g25 g

100 g

Gly-OBzl • TosGlycine benzyl ester tosylate (M.W. 165.19 • 172.20) C9H11NO2 • C7H8O3S [1738-76-7]

A EBG-20474 °C

5 g25 g

100 g

Gly-OEt • HCIGlycine Ethyl ester hydrochloride (M.W. 103.12 • 36.46) C4H9NO2 • HCI [623-33-6]

EEG-2037-PI4 °C

5 g25 g

100 g

His-OMe • 2HCll-histidine methyl ester Dihydrochloride (M.W. 162.18 • 79.92) C7H11N3O2 • 2HCI [7389-87-9]

EMH-2038-PI4 °C

5 g25 g

100 g

Ile-OMe • HCIl-isoleucine methyl ester hydrochloride(M.W. 145.24 • 36.46) C7H15NO2 • HCI

A EMI-2039-PI4 °C

5 g25 g

100 g

Ile-OBzl • Tosl-isoleucine benzyl ester tosylate (M.W. 221.30 • 172.20) C13H19NO2 • C7H8O3S [16652-75-8]

A EBI-21114 °C

5 g25 g

100 g

Leu-OBzl • Tosl-Leucine benzyl ester tosylate(M.W. 221.30 • 172.20) C13H19NO2 • C7H8O3S [1738-77-8}

EBL-21124 °C

5 g25 g

100 g

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

254 Order Hotline 1-800-777-4779 502-266-8787

Leu-OEt • HCll-Leucine ethyl ester hydrochloride (M.W. 159.24 • 36.46) C8H17NO2 • HCI [2743-40-0]

EEL-2040-PI4 °C

5 g25 g

100 g

Met-OMe • HCIl-Methionine methyl ester hydrochloride (M.W. 163.24 • 36.46) C6H13NO2S • HCI [2491-18-1]

EMM-2036-PI4 °C

5 g25 g

100 g

Phe-OBzl • Tosl-phenylalanine benzyl ester tosylate(M.W. 255.31 • 172.20) C16H17NO2 • C7H8O3S [1738-78-9]

A EBF-21104 °C

5 g25 g

100 g

Phe-OEt • HCIl-phenylalanine ethyl ester hydrochloride (M.W. 193.24 • 36.46) C11H15NO2 • HCI [3182-93-2]

EEF-2041-PI4 °C

5 g25 g

100 g

Pro-OBzl • HCIl-proline benzyl Ester Hydrochloride (M.W. 205.25 • 36.45) C12H15NO2 • HCI [16652-71-4]

B EBP-20494 °C

5 g25 g

100 g

Ser-OMe • HCIl-serine methyl ester hydrochloride (M.W. 119.10 • 36.45) C4H9NO3 • HCI [5680-80-8]

EMS-2042-PI4 °C

5 g25 g

100 g

Tyr-OEt • HCIl-tyrosine ethyl ester hydrochlorideM.W. 209.24 • 36.44) C11H15NO3 • HCI [4089-07-0]

EEY-2043-PI4 °C

5 g25 g

100 g

Val-OMe • HCIl-Valine methyl ester hydrochloride(M.W. 131.14 • 36.46) C6H13NO2 • HCI [6306-52-1]

EMV-2044-PI4 °C

5 g25 g

100 g

Side Chain Derivatives of Amino AcidsArg(NO2)

Ng-nitro-l-Arginine(Nω-nitro-l-Arginine)

AA XNR-20054 °C

5 g25 g

100 gY. Kobayashi and K. Hattori, Jpn. J. Pharmacol., 52, 167 (1990).A. Gibson, S. Mirzazadeh, A.J. Hobbs, and P.K. Moore, Br. J. Pharmacol., 99, 602 (1990).

Arg(Tos)Ng-tosyl-l-arginine (M.W. 328.39) C13H20N4O4S [4353-32-6]

XTR-2101-PI4 °C

1 g5g

25 g

Asp(OBzl)l-aspartic acid β-benzyl ester (M.W. 223.20) C11H13NO4 [2177-63-1]

XBD-2093-PI4 °C

5 g25 g

100 g

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out


TOO


Order Hotline 1-800-777-4779 502-266-8787 255

PRODUCT CODE QTYGlu(OBzl)

l-glutamic acid γ-benzyl ester (M.W. 237.25) C12H15NO4 [1676-73-9]

A XBE-20034 °C

5 g25 g

100 g

Glu(OMe)l-glutamic acid γ-methyl ester (M.W. 161.16) C6H11NO4 [1499-55-4]

XME-2001-PI4 °C

5 g25 g

100 g

Lys(Z)Nε-Carbobenzoxy-l-lysine (M.W. 280.30) C14H20N2O4 [2212-75-1]

XZK-2006-PI4 °C

5 g25 g

100 g

Boc-Protected l-Amino AcidsBoc-Ala-OH

t-Butyloxycarbonyl-l-alanine (M.W. 189.21) C8H15NO4 [15761-38-3]

AA BLA-20514 °C

5 g25 g

100 g

Boc-β-Ala-OHt-Butyloxycarbonyl-β-alanine (M.W. 189.21) C8H15NO4 [3303-84-2]

AA BBA-21314 °C

5 g25 g

100 g

Boc-Arg(NO2)-OH*Nα-t-Butyloxycarbonyl-Ng-nitro-l-arginine (M.W. 319.32) C11H21N5O6 [2188-18-3]

AA-A BLR-20584 °C

5 g25 g

100 g

Boc-Arg(Tos)-OH*Nα-t-Butyloxycarbonyl-Ng-tosyl-l-arginine (M.W. 428.50) C18H28N4O5S [13836-37-8]

AA BLR-21254 °C

5 g25 g

100 g

Boc-Asn-OHt-Butyloxycarbonyl-l-asparagine (M.W. 232.23) C9H16N2O5 [7536-55-2]

AA-A BLN-20604 °C

5 g25 g

100 g

Boc-Asn-ONpt-Butyloxycarbonyl-l-asparagine-p-nitrophenyl ester (M.W. 353.33) C15H19N3O7 [4587-33-1]

B BLN-20774 °C

5 g25 g

100 g

Boc-Asp(OBzl)-OHt-Butyloxycarbonyl-l-aspartic acid β-benzyl ester (M.W. 323.34) C16H21NO6 [7536-58-5]

AA BLD-20594 °C

5 g25 g

100 g

Boc-Asp(OcHex)-OHt-Butyloxycarbonyl-l-aspartic acid β-cyclohexyl ester (M.W. 315.36) C15H25NO6 [73821-95-1]

AA BLD-21324 °C

5 g25 g

100 gJ.P. Tam, T.-W. Wong, M.W. Riemen, F.-S. Tjoeng, and R.B. Merrifield, Tetrahedron Lett., 42, 4033 (1979)

* These compounds typically co-crystallize with ¼ - 1 molecule of water and/or ethyl acetate per molecule of amino acid derivatives. The exact analytical data are provided to customers with each shipment.

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

256 Order Hotline 1-800-777-4779 502-266-8787

Boc-Cys(Acm)-OHt-Butyloxycarbonyl-S-acetamidomethyl-l-cysteine (M.W. 292.35) C11H20N2O5S [19746-37-3]

AA BLC-21214 °C

5 g25 g

100 gD.F. Veber, J.D. Milkowski, S.L. Varga, R.G. Denkewalter, and R. Hirschmann, J. Am. Chem. Soc., 94, 5456 (1972). B. Kamber, A. Hartmann, K. Eisler, B. Riniker, H. Rink, P. Sieber, and W. Rittel, Helv. Chim. Acta, 63, 899 (1980).

Boc-Cys(Bzl)-OHt-Butyloxycarbonyl-S-benzyl-l-cysteine (M.W. 311.40) C15H21NO4S [5068-28-0]

AA BLC-20614 °C

5 g25 g

100 g

Boc-Cys(tBu)-OHt-Butyloxycarbonyl-S-t-butyl-l-cysteine (M.W. 277.38) C12H23NO4S [56976-06-8]

AA BLC-21304 °C

5 g25 g

100 g

Boc-Cys(4-CH3Bzl)-OHt-Butyloxycarbonyl-S-4-methylbenzyl-l-cysteine (M.W. 325.42) C16H23NO4S [61925-77-7]

AA BLC-21294 °C

5 g25 g

100 gW.F. Heath, J.P. Tam, and R.B. Merrifield, Int. J. Pept. Protein Res., 28, 498 (1986)

Boc-Cys(MBzl)-OHt-Butyloxycarbonyl-S-p-methoxybenzyl-l-cysteine (M.W. 341.43) C16H23NO5S [18942-46-6]

AA BLC-20784 °C

5 g25 g

100 gM. Platen and E. Steckhan, Liebigs Ann. Chem., 9, 1563 (1984).

Boc-Gln-OHt-Butyloxycarbonyl-l-glutamine (M.W. 246.26) C10H18N2O5 [13726-85-7]

AA-A BLQ-20624 °C

5 g25 g

100 g

Boc-Gln-ONpt-Butyloxycarbonyl-l-glutamine p-nitrophenyl ester (M.W. 367.35) C16H21N3O7 [15387-45-8]

A-B BLQ-20794 °C

5 g25 g

100 g

Boc-Gln(Xan)-OHNα-t-Butyloxycarbonyl-Nγ-xanthenyl-l-glutamine (M.W. 426.47) C26H26N2O6 [55260-24-7]

BLQ-5349-PI4 °C

5 g25 g

Boc-Glu(OBzl)-OHt-Butyloxycarbonyl-l-glutamic acid γ-benzyl ester (M.W. 337.37) C17H23NO6 [13574-13-5]

AA BLE-21034 °C

5 g25 g

100 g

Boc-Glu(OcHex)-OHt-Butyloxycarbonyl-l-glutamic acid γ-cyclohexyl ester (M.W. 329.39) C16H27NO6 [73821-97-3]

AA BLE-21344 °C

5 g25 g

100 gJ.P. Tam, T.-W. Wong, M.W. Riemen, F.-S. Tjoeng, and R.B. Merrifield, Tetrahedron Lett., 42, 4033 (1979).

Boc-Gly-OHt-Butyloxycarbonyl-glycine (M.W. 175.18) C7H13NO4 [4530-20-5]

AA BLG-20544 °C

5 g25 g

100 g


TOO


Order Hotline 1-800-777-4779 502-266-8787 257

PRODUCT CODE QTYBoc-His(Bom)-OH

Nα-t-Butyloxycarbonyl-Nπ-benzyloxymethyl-l-histidine (M.W. 375.42) C19H25N3O5 [79950-65-5]

AA BLH-21384 °C

5 g25 g

100 gT. Brown, J.H. Jones, and J.D. Richards, J. Chem. Soc. Perkin Trans I, 1982, 1553.

Boc-His(Tos)-OHNα-t-Butyloxycarbonyl-Nτ-tosyl-l-histidine (M.W. 409.46) C18H23N3O6S [35899-43-5]

A BLH-2109-20 °C

5 g25 g

Boc-Hyp(Bzl)-OHt-Butyloxycarbonyl-O-benzyl-l-hydroxyproline (M.W. 321.37) C17H23NO5 [54631-81-1}

AA BLX-21164 °C

5 g25 g

Boc-Ile-OH • 1⁄2 H2Ot-Butyloxycarbonyl-l-isoleucine • hemihydrate (M.W. 231.29 • 9.01) C11H21NO4 • ½ H2O [13139-16-7]

AA BLI-20654 °C

5 g25 g

100 g

Boc-Leu-OH • H2Ot-Butyloxycarbonyl-l-leucine • monohydrate (M.W. 231.29 • 18.02) C11H21NO4 • H2O [13139-15-6]

AA BLL-20554 °C

5 g25 g

100 g

Boc-Lys(Boc)-OH • DCHANα,Nε,-di-t-butyloxycarbonyl-l-lysine • dicyclohexylamine salt (M.W. 346.43 • 181.32) C16H30N2O6 • C12 H23N [15098-69-8]

BLK-5328-PI4 °C

5 g25 g

Boc-Lys(Fmoc)-OHNα-t-Butyloxycarbonyl-Nε-9-fluorenylmethoxycarbonyl-l-lysine (M.W. 468.55) C26H32N2O6 [84624-27-1]

BLK-5364-PI4 °C

1 g5 g

25 g

Boc-Lys(Cl-Z)-OHNα-t-Butyloxycarbonyl-Nε-2-chlorobenzyloxycarbonyl-l-lysine (M.W. 414.88) C19H27N2O6Cl [54613-99-9]

AA BLK-21354 °C

5 g25 g

100 g

Boc-Lys(Z)-OHNα-t-Butyloxycarbonyl-Nε-benzyloxycarbonyl-l-lysine (M.W. 380.44) C19H28N2O6 [2389-45-9]

AA BLK-21084 °C

5 g25 g

100 g

Boc-Met-OHt-Butyloxycarbonyl-l-methionine (M.W. 249.33) C10H19NO4S [2488-15-5]

AA BLM-21044 °C

5 g25 g

100 g

Boc-Phe-OHt-Butyloxycarbonyl-l-phenylalanine (M.W. 265.30) C14H19NO4 [13734-34-4]

AA BLF-20684 °C

5 g25 g

100 g

Boc-Pro-OHt-Butyloxycarbonyl-l-proline (M.W. 215.25) C10H17NO4 [15761-39-4]

AA BLP-20564 °C

5 g25 g

100 g

PEPT

IDES

INTE

RNAT

IONA

LTO

OLS

for

PEP

TIDE

SYN

THES

IS

258 Order Hotline 1-800-777-4779 502-266-8787

PRODUCT GRADE CODE QTYBoc-Ser(Bzl)-OH

t-Butyloxycarbonyl-O-benzyl-l-serine (M.W. 295.33) C15H21NO5 [23680-31-1]

AA BLS-21024 °C

5 g25 g

100 g

Boc-Thr(Bzl)-OHt-Butyloxycarbonyl-O-benzyl-l-threonine (M.W. 309.36) C16H23NO5 [15260-10-3]

AA BLT-20704 °C

5 g25 g

100 g

Boc-Trp-OHNα-t-Butyloxycarbonyl-l-tryptophan (M.W. 304.34) C16H20N2O4 [13139-14-5]

A BLW-20574 °C

5 g25 g

100 g

Boc-Trp(CHO)-OHNα-t-Butyloxycarbonyl-Nin-formyl-l-tryptophan (M.W. 332.35) C17H20N2O5 [47355-10-2]

AA BLW-21154 °C

5 g25 g

100 gM. Ohno, S. Tsukamoto, S. Sato, and N. Izumiya, Bull. Chem. Soc. Jpn., 46, 3280 (1973).

Boc-Trp(Hoc)-OHNα-t-Butyloxycarbonyl-Nin-cyclohexyloxycarbonyl-l-tryptophan (M.W. 430.49) C23H30N2O6

A BLW-21394 °C

5 g

Y. Nishiuchi, H. Nishio, T. Inui, T. Kimura, and S. Sakakibara, Tetrahedron Lett., 37, 7529 (1996).

Boc-Tyr(Bzl)-OHt-Butyloxycarbonyl-O-benzyl-l-tyrosine (M.W. 371.43) C21H25NO5 [2130-96-3]

AA BLY-20714 °C

5 g25 g

100 g

Boc-Tyr(Br-Z)-OHt-Butyloxycarbonyl-O-2-bromobenzyloxycarbon-yl-l-tyrosine (M.W. 494.33) C22H24NO7Br [47689-67-8]

A BLY-21144 °C

5 g25 g

100 g

Boc-Tyr(Cl2-Bzl)-OHt-Butyloxycarbonyl-O-2,6-dichlorobenzyl-l-tyrosine (M.W. 440.32) C21H23NO5CI2 [40298-71-3]

AA BLY-21194 °C

5 g25 g

100 gD. Yamashiro and C.H. Li, J. Am. Chem. Soc., 95, 1310 (1980). Y. Kiso, M. Satomi, K. Ukawa, and T. Akita, J. Chem. Soc. Chem. Commun., 22, 1063 (1980).

Boc-Val-OHt-Butyloxycarbonyl-l-valine (M.W. 217.26) C10H19NO4 [13734-41-3]

AA BLV-21054 °C

5 g25 g

100 gBoc Amino Acids attached to Pam Resin are listed on page 287Boc Amino Acids attached to Merrifield Resin are listed on page 320

Boc-Protected d-Amino AcidsBoc-d-Ala-OH

t-Butyloxycarbonyl-d-alanine (M.W. 189.21) C8H15NO4 [7764-95-6]

AA BDA-26064 °C

1 g 5 g

25 g


TOO


Order Hotline 1-800-777-4779 502-266-8787 259

PRODUCT CODE QTYBoc-d-Arg(Tos)-OH*

Nα-t-Butyloxycarbonyl-Ng-tosyl-d-arginine (M.W. 428.50) C18H28N4O6S [61315-61-5]

AA BDR-26094 °C

1 g 5 g

Boc-d-Asn-OHt-Butyloxycarbonyl-d-asparagine (M.W. 232.23) C9H16N2O5 [75647-01-7]

AA-A BDN-26264 °C

1 g 5 g

25 g

Boc-d-Asn-ONpt-Butyloxycarbonyl-d-asparagine-p-nitrophenyl ester (M.W. 353.33) C19H19N3O7 [104199-82-8]

B BDN-2620-20 °C

1 g 5 g

Boc-d-Asn(Xan)-OHNα-t-Butyloxycarbonyl-Nβ-xanthenyl-d-asparagine (M.W. 412.45) C22H24N2O6

BDN-2651-PI-20 °C

1 g 5 g

Boc-d-Asp(OBzl)-OHt-Butyloxycarbonyl-d-aspartic acid β-benzyl ester (M.W. 323.35) C16H21NO6 [51186-58-4]

AA BDD-26164 °C

1 g 5 g

25 g

Boc-d-Asp(OcHex)-OHt-Butyloxycarbonyl-d-aspartic acid β-cyclohexyl ester (M.W. 315.37) C15H25NO6 [112898-18-7]

AA BDD-26174 °C

1 g 5 g

25 g

Boc-d-Asp-OFmt-Butyloxycarbonyl-d-aspartic acid-α-9-fluorenylmethyl ester (M.W. 411.46) C23H25NO6 [123417-19-6]

BDD-2618-PI4 °C

1 g 5 g

Boc-d-Ile-OH t-Butyloxycarbonyl-d-isoleucine (M.W. 231.29) C11H21NO4 [55721-65-8]

BDI-5318-PI4 °C

1 g 5 g

25 g

Boc-d-Lys(Fmoc)-OHNα-t-Butyloxycarbonyl-Nε-9-fluorenylmethoxycarbonyl-d-lysine (M.W. 468.55) C26H32N2O6 [115186-31-7]

BDX-5375-PI4 °C

1 g5 g

Boc-d-His(Tos)-OH • DCHANα-t-Butyloxycarbonyl-Nim-tosyl-d-histidine • dicyclohexylamine (M.W. 409.46 • 181.32) C18H23N3O6S • C12H23N

A BDH-26054 °C

1 g 5 g

25 g

Boc-d-Ile • ½ H2O t-Butyloxycarbonyl-d-isoleucine hemihydrate (M.W. 231.29 • 9.01) C13H21NO4 • ½H2O

AA BDI-26294 °C

1 g 5 g

Boc-d-Leu-OH • H2Ot-Butyloxycarbonyl-d-leucine • monohydrate (M.W. 231.29 • 18.02) C11H21NO4 • H2O [16937-99-8]

AA BDL-26034 °C

1 g 5 g

25 g

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

260 Order Hotline 1-800-777-4779 502-266-8787

Boc-d-Lys(Cl-Z)-OHNα-t-Butyloxycarbonyl-Nε-2-chloro-benzyloxycarbonyl-d-lysine (M.W. 414.88) C19H27N2O6Cl [57096-11-4]

AA BDK-26284 °C

1 g 5 g

25 g

Boc-d-Met-OHt-Butyloxycarbonyl-d-methionine (M.W. 249.33) C10H19NO4S [5241-66-7]

A BDM-26084 °C

1 g 5 g

25 g

Boc-d-Phe-OHt-Butyloxycarbonyl-d-phenylalanine (M.W. 265.30) C14H19NO4 [18942-49-9]

AA BDF-26044 °C

1 g 5 g

25 g

Boc-d-Phe(NO2)-OHt-Butyloxycarbonyl-p-nitro-d-phenylalanine (M.W. 310.31) C14H18N2O6 [61280-75-9]

BDF-5222-PI4 °C

1 g 5 g

Boc-d-Pro-OHt-Butyloxycarbonyl-d-proline (M.W. 215.25) C10H17NO4 [37784-17-1]

AA BDP-26104 °C

1 g 5 g

25 g

Boc-d-Ser(Bzl)-OHt-Butyloxycarbonyl-O-benzyl-d-serine (M.W. 295.33) C15H21NO5 [47173-80-8]

AA BDS-26274 °C

5 g25 g

Boc-d-Thr(Bzl)-OHt-Butyloxycarbonyl-O-benzyl-d-threonine (M.W. 309.36) C16H23NO5 [69355-99-3]

AA BDT-26244 °C

5 g25 g

Boc-d-Trp-OHNα-t-Butyloxycarbonyl-d-tryptophan (M.W. 304.34) C16H20N2O4 [5241-64-5]

A BDW-26024 °C

5 g25 g

Boc-d-Trp(CHO)-OHNα-t-Butyloxycarbonyl-Nin-formyl-d-tryptophan (M.W. 332.35) C17H20N2O5 [64905-10-8]

AA BDW-26144 °C

5 g25 g

Boc-d-Tyr(Br-Z)-OHt-Butyloxycarbonyl-O-2-bromobenzyloxycarbon-yl-d-tyrosine (M.W. 494.33) C22H24NO7Br [81189-61-9]

A BDY-26124 °C

5 g25 g

Boc-d-Tyr(Cl2-Bzl)-OHt-Butyloxycarbonyl-O-2,6-dichlorobenzyl-d-tyrosine (M.W. 440.32) C21H23NO5Cl2 [69541-62-4]

AA BDY-26224 °C

1 g 5 g

Boc-d-Val-OHt-Butyloxycarbonyl-d-valine (M.W. 217.27) C10H19NO4 [22838-58-0]

AA BDV-26194 °C

1 g 5 g

Unusual Boc-Amino AcidsBoc-Abu-OH

t-Butyloxycarbonyl-l-α-aminobutyric acid (M.W. 203.24) C9H17NO4 [34306-42-8]

BLX-5362-PI4 °C

1 g 5 g

25 g


TOO


Order Hotline 1-800-777-4779 502-266-8787 261

PRODUCT CODE QTYBoc-d-Abu-OH

t-Butyloxycarbonyl-d-α-aminobutyric acid (M.W. 203.24) C9H17NO4 [45121-22-0]

BDX-5365-PI4 °C

1 g 5 g

25 g

Boc-d-Abu-OH • DCHAt-Butyloxycarbonyl-d-α-aminobutyric acid • dicy-clohexylamine (M.W. 203.24 • 181.26) C9H17NO4 • C12H23N

BDX-5360-PI4 °C

5 g25 g

100 g

Boc-γ-Abu-OHt-Butyloxycarbonyl-γ-aminobutyric acid (M.W. 203.24) C9H17NO4 [57294-38-9]

BAB-5363-PI4 °C

5 g25 g

100 g

Boc-Abz-OHBoc-anthranilic acid Boc-2-aminobenzoic acid(M.W. 237.26) C12H15NO4 [68790-38-5]

ABZ-5014-PI4 °C

1 g5 g

Boc-ε-Aca-OHt-Butyloxycarbonyl-ε-aminocaproic acid (M.W. 231.29) C11H21NO4 [6404-29-1]

BAC-5352-PI4 °C

5 g25 g

Boc-p-Aminobenzoic AcidBoc-PABA (M.W. 237.26) C12H15NO4

BAB-5403-PI4 °C

1 g5 g

25 g

Boc-Asn(Xan)-OHNα-t-Butyloxycarbonyl-Nβ-xanthenyl-l-asparagine (M.W. 412.45) C22H24N2O6 [65420-40-8]

BLN-5351-PI4 °C

5 g25 g

Boc-Asp(OFm)-OH (Beta Ester)t-Butyloxycarbonyl-l-aspartic acid-β-9-fluorenylmethyl ester (M.W. 411.46) C23H25NO6

BLD-5662-PI4 °C

5 g25 g

Boc-Asp-OFm (Alpha Ester)t-Butyloxycarbonyl-l-aspartic acid-α-9-fluorenylmethyl ester (M.W. 411.46) C23H25NO6

BLD-5571-PI4 °C

5 g25 g

Boc-Aib-OHt-Butyloxycarbonyl-α-aminoisobutyric acid (t-Butyloxycarbonyl-α-methylalanine) (M.W. 203.20) C9H17NO4 [30992-29-1]

BLX-5340-PI4 °C

5 g25 g

Boc-5-Ava-OHt-Butyloxycarbonyl-5-aminovaleric acid (M.W. 217.27) C10H19NO4 [27219-07-4]

BLX-5366-PI4 °C

1 g 5 g

Boc-Cys(Npys)-OHt-Butyloxycarbonyl-S-(3-nitro-2-pyridylthio)-l-cysteine(M.W. 375.42) C13H17N3O6S2 [76880-29-0]

BCN-5000-PI4 °C

1 g5 g

Boc-Dab(Fmoc)-OHNα-t-Butyloxycarbonyl-Nγ-9-fluorenylmethoxycarbonyl-l-2,4-diaminobutyric acid (M.W. 440.50) C24H28N2O6 [17106-21-5]

BLX-5369-PI4 °C

1 g 5 g

NEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

262 Order Hotline 1-800-777-4779 502-266-8787

Boc-Dap-OHNα-t-Butyloxycarbonyl-l-2,3-diaminopropionic Acid (M.W. 204.23) C8H16N2O4 [73259-81-1]

BLX-5378-PI4 °C

1 g5 g

25 g

Boc-d-Dab(Fmoc)-OHNα-t-Butyloxycarbonyl-Nγ-9-fluorenylmethoxycarbonyl-d-2,4-diaminobutyric acid (M.W. 440.50) C24H28N2O6 [131570-57-5]

BDX-5357-PI4 °C

1 g 5 g

Boc-Dap(Fmoc)-OHNα-t-Butyloxycarbonyl-Nβ-9-fluorenylmethoxycarbonyl-l-2,3-diaminopropionic acid (M.W. 426.47) C23H26N2O6 [122235-70-5]

BLX-5359-PI4 °C

1 g 5 g

Boc-d-Dap(Fmoc)-OHNα-t-Butyloxycarbonyl-Nβ-9-fluorenylmethoxycarbonyl-d-2,3-diaminopropionic acid

BDX-5354-PI4 °C

1 g 5 g

Boc-Deg-OHt-Butyloxycarbonyl-diethylglycine (M.W. 231.29) C11H21NO4

BLX-5341-PI4 °C

1 g 5 g

25 g

Boc-Dhp-OHt-Butyloxycarbonyl-3,4-dehydro-l-proline (M.W. 197.23) C10H10NO4 [51154-06-4]

BLX-5324-PI4 °C

1 g

Boc-Dip-OHt-Butyloxycarbonyl-l-(3,3-diphenyl)alanine (M.W. 341.41) C20H23NO4 [138662-63-2]

BDF-5528-PI4 °C

1 g 5 g

Boc-d-Dip-OHt-Butyloxycarbonyl-d-(3,3-diphenyl)alanine (M.W. 341.41) C20H23NO4 [117027-46-0]

BDF-5530-PI4 °C

1 g5 g

Boc-Glu(OFm)-OH (Gamma Ester)t-Butyloxycarbonyl-l-glutamic Acid-γ-9-fluorenylmethyl ester (M.W. 425.49) C24H27NO6 [123417-18-5]

BLE-5683-PI4 °C

5 g25 g

Boc-Glu-OFm (Alpha Ester)t-Butyloxycarbonyl-l-glutamic Acid-α-9-fluorenylmethyl ester (M.W. 425.48) C24H27NO6

BLE-5591-PI4 °C

5 g25 g

Boc-Homo-Phe-OHt-Butyloxycarbonyl-l-homophenylalanine (M.W. 279.34) C15H21NO4 [100564-78-1]

BLF-5371-PI4 °C

1 g5 g

Boc-d-Homo-Phe-OHt-Butyloxycarbonyl-d-homophenylalanine (M.W. 279.34) C15H21NO4 [82732-07-8]

BDF-5373-PI4 °C

1 g5 g

Boc-Hydroxy-Tic-OHt-Butyloxycarbonyl-7-hydroxy-l-1,2,3,4-tetrahydroisoquinoline 3-carboxylic acid (M.W. 293.32) C15H19NO5

BLX-5345-PI4 °C

1 g


TOO


Order Hotline 1-800-777-4779 502-266-8787 263

PRODUCT CODE QTYBoc-d-Hydroxy-Tic-OH

t-Butyloxycarbonyl-7-hydroxy-d-1,2,3,4-tetrahydroisoquinoline 3-carboxylic acid (M.W. 293.32) C15H19NO5 [214630-00-9]

BDX-5343-PI4 °C

1 g

Boc-allo-Ile-OHt-Butyloxycarbonyl-allo-isoleucine (M.W. 231.29) C11H21NO4 [35264-07-4]

BLX-5342-PI4 °C

1 g5 g

Boc-d-lle-OH t-Butyloxycarbonyl-d-isoleucine (M.W. 231.29) C11H21NO4 [55721-65-8]

BDI-5318-PI4 °C

1 g5 g

Boc-mini-PEG™Boc-8-Amino-3,6-Dioxaoctanoic Acid • DCHA tert-butyloxycarbonyl-8-amino-3,6-dioxaoctanoic acid • dicyclo-hexylamine(M.W. 263.29 • 181.3) C11H21NO6 • C12 H23N Boc-AEEA

BXX-5519-PI4 °C

1 g5 g

Boc-mini-PEG-3™Boc-11-Amino-3,6,9-Trioxaundecanoic Acid • DCHA tert-butyloxycarbonyl-11-Amino-3,6,9-trioxaundecanoic acid • dicyclohexylamine (M.W. 307.35 • 181.32) C13H25NO7 • C12 H23N Boc-AEEEA

BXX-5523-PI4 °C

1 g5 g

Boc-Nal(2')-OHt-Butyloxycarbonyl-l-(2-naphthyl)alanine (M.W. 315.37) C18H21NO4 [58438-04-3]

BLX-5327-PI4 °C

1 g5 g

Boc-d-Nal(2')-OHt-Butyloxycarbonyl-d-(2-naphthyl)alanine (M.W. 315.37) C18H21NO4 [76985-10-9]

BDX-5319-PI4 °C

1 g5 g

Boc-Nal(1')-OHt-Butyloxycarbonyl-l-(1-naphthyl)alanine (M.W. 315.37) C18H21NO4 [55447-00-2]

BLX-5379-PI4 °C

1 g5 g

Boc-d-Nal(1')-OHt-Butyloxycarbonyl-d-(1-naphthyl)alanine (M.W. 315.37) C18H21NO4 [76932-48-4]

BDX-5381-PI4 °C

1 g5 g

Boc-Norleucine (syrup)t-Butyloxycarbonyl-l-norleucine (M.W. 231.29) C11H21NO4 [6404-28-0]

BLX-5325-PI4 °C

5 g25 g

Boc-Norvaline (syrup)t-Butyloxycarbonyl-l-norvaline (M.W. 217.27) C10H19NO4 [53308-95-5]

BLX-5320-PI4 °C

5 g25 g

Boc-Orn-OHt-Butyloxycarbonyl-l-ornithine (M.W. 232.28) C10H20N2O4 [21887-64-9]

BLO-5321-PI4 °C

1 g5 g

25 g

Boc-Orn(Cl-Z)-OHNα-t-Butyloxycarbonyl-Nδ-2-chlorobenzyloxycarbonyl-l-ornithine (M.W. 400.86) C18H25N2O6CI [118554-00-0]

BLO-5326-PI4 °C

5 g25 g

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

264 Order Hotline 1-800-777-4779 502-266-8787

Boc-Orn(Boc)-OHNα, Nδ,-di-t-Butyloxycarbonyl-l-ornithine (M.W. 332.40) C15H28N2O6 [57133-29-6]

BLO-5361-PI4 °C

1 g5 g

25 g

Boc-Orn(Fmoc)-OHNα-t-Butyloxycarbonyl-Nδ-9-fluorenylmethoxycarbonyl-l-ornithine (M.W. 454.53) C25H30N2O6 [150828-96-9]

BLX-5368-PI4 °C

1 g5 g

Boc-d-Orn(Fmoc)-OHNα-t-Butyloxycarbonyl-Nδ-9-fluorenylmethoxycarbonyl-d-ornithine (M.W. 454.53) C25H30N2O6

BDX-5355-PI4 °C

1 g5 g

Boc-3-Pal-OHt-Butyloxycarbonyl-l-(3-pyridyl)alanine (M.W. 266.30) C13H18N2O4 [117142-26-4]

BLX-5331-PI4 °C

1 g5 g

Boc-d-3-Pal-OHt-Butyloxycarbonyl-d-(3-pyridyl)alanine (M.W. 266.30) C13H18N2O4 [98266-33-2]

BDX-5339-PI4 °C

1 g5 g

Boc-4-Pal-OHt-Butyloxycarbonyl-l-(4-pyridyl)alanine (M.W. 266.30) C13H18N2O4 [37535-57-2]

BLX-5532-PI4 °C

1 g5 g

Boc-d-4-Pal-OHt-Butyloxycarbonyl-d-(4-pyridyl)alanine (M.W. 266.30) C13H18N2O4 [37535-58-3]

BDX-5533-PI4 °C

1 g5 g

Boc-Pen(Meb)-OH • DCHAt-Butyloxycarbonyl-S-p-methylbenzyl-l-penicillamine • Dicyclohexylamine (M.W. 353.48 • 181.32) C18H27NO4S • C12H23N [198474-61-2]

BLX-5221-PI4 °C

1 g5 g

Boc-d-Pen(Meb)-OH • DCHAt-Butyloxycarbonyl-S-d-methylbenzyl-d-penicillamine • Dicyclohexylamine (M.W. 353.48 • 181.32) C18H27NO4S • C12H23N [198470-36-9]

BDX-5220-PI4 °C

1 g5 g

25 g

Boc-Pen(Mob)-OH t-Butyloxycarbonyl-S-p-methoxybenzyl-l-penicillamine (M.W. 369.48) C18H27NO5S [120944-75-4]

BLX-5828-PI4 °C

1 g5 g

Boc-d-Pen(Mob)-OH t-Butyloxycarbonyl-S-p-methoxybenzyl-d-penicillamine (M.W. 369.48) C18H27NO5S [106306-57-4]

BDX-2615-PI4 °C

1 g5 g

Boc-Pentafluoro-Phe-OHt-Butyloxycarbonyl-pentafluoro-l-phenylalanine (M.W. 355.26) C14H14NO4F5 [34702-60-8]

BLF-5383-PI4 °C

1 g5 g

Boc-d-Pentafluoro-Phe-OHt-Butyloxycarbonyl-pentafluoro-d-phenylalanine (M.W. 355.26) C14H18NO4F5 [136207-26-6]

BDF-5385-PI4 °C

1 g5 g

Boc-p-Cl-Phe-OHt-Butyloxycarbonyl-p-chloro-l-phenylalanine (M.W. 299.76) C14H18NO4Cl [68090-88-0]

BLF-5315-PI4 °C

1 g5 g


NALTO

OLS for PEPTIDE SYNTHESIS

Order Hotline 1-800-777-4779 502-266-8787 265

Boc-p-Cl-d-Phe-OHt-Butyloxycarbonyl-p-chloro-d-phenylalanine (M.W. 299.76) C14H18NO4Cl [57292-44-1]

BDF-5316-PI4 °C

1 g5 g

Boc-p-F-Phe-OHt-Butyloxycarbonyl-p-fluoro-l-phenylalanine (M.W. 283.30) C14H18NO4F [41153-30-4]

BLF-5329-PI4 °C

1 g5 g

Boc-p-F-d-Phe-OHt-Butyloxycarbonyl-p-fluoro-d-phenylalanine (M.W. 283.30) C14H18NO4F [57292-45-2]

BDF-5335-PI4 °C

1 g5 g

Boc-Phe(NO2)-OHt-Butyloxycarbonyl-p-nitro-l-phenylalanine (M.W. 309.31) C14H18N2O6 [33305-77-0]

BLF-5333-PI4 °C

1 g5 g

Boc-Phe(NH2)-OHt-Butyloxycarbonyl-p-amino-l-phenylalanine (M.W. 280.33) C14H20N2O4 [55533-24-9]

BLF-5337-PI4 °C

1 g5 g

Boc-Phe(NH-Z)-OHNα-t-Butyloxycarbonyl-l-phenylalanine (p-amino-carbobenzoxy) (M.W. 414.46) C22H26N2O6

BLX-5230-PI4 °C

1 g5 g

Boc-Phg-OHt-Butyloxycarbonyl-l-phenylglycine (M.W. 251.28) C13H17NO4 [2900-27-8]

BFG-5323-PI4 °C

1 g5 g

Boc-d-Phg-OHt-Butyloxycarbonyl-d-phenylglycine (M.W. 251.28) C13H17NO4 [33125-05-2]

BDP-2600-PI4 °C

1 g5 g

Boc-Sar-OHt-Butyloxycarbonyl-sarcosine (M.W. 189.21) C8H15NO4 [13734-36-6]

AABSR-2120

4 °C

5 g25 g

100 g

Boc-2-Thienylalaninet-Butyloxycarbonyl-l-2-Thienylalanine (M.W. 271.34) C12H17NO4S [56675-37-7]

BBX-5387-PI4 °C

1 g5 g

Boc-d-2-Thienylalaninet-Butyloxycarbonyl-d-2-Thienylalanine (M.W. 271.34) C12H17NO4S [78452-55-8]

BDX-5389-PI4 °C

1 g5 g

Boc-Tic-OHt-Butyloxycarbonyl-l-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid (M.W. 277.32) C15H19NO4 [78879-20-6]

BLX-5347-PI4 °C

1 g5 g

Boc-d-Tic-OHt-Butyloxycarbonyl-d-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (M.W. 277.32) C15H19NO4 [115962-35-1]

BDX-5346-PI4 °C

1 g5 g

Boc-Tyr(Me)-OHt-Butyloxycarbonyl-O-methyl-l-tyrosine (t-Butyloxycarbonyl-p-methoxy-l-phenylalanine) (M.W. 295.34) C15H21NO5 [53267-93-9]

BLY-5332-PI4 °C

1 g5 g

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

266 Order Hotline 1-800-777-4779 502-266-8787

Boc-d-Tyr(Me)-OHt-Butyloxycarbonyl-O-methyl-d-tyrosine (t-Butyloxycarbonyl-p-methoxy-d-phenylalanine) (M.W. 295.34) C15H21NO5 [68856-96-2]

BDY-5336-PI4 °C

1 g5 g

Boc-Tyr(Et)-OHt-Butyloxycarbonyl-O-Ethyl-l-tyrosine (M.W. 309.40) C16H23NO5 [76757-91-0]

BLY-5334-PI4 °C

1 g5 g

Boc-d-Tyr(Et)-OHt-Butyloxycarbonyl-O-ethyl-d-tyrosine (M.W. 309.40) C16H23NO5 [76757-92-1]

BDY-5338-PI4 °C

1 g5 g

Boc-11-Aminoundecanoic Acid t-Butyloxycarbonyl-II-aminoundecanoic acid (M.W. 301.43) C16H31NO4

BAM-5454-PI4 °C

5 g25 g

Boc-N-Methyl Amino AcidsBoc-N-Me-Abz-OH

Boc-N-methyl-anthranilic acid(M.W. 251.28) C13H17NO4 [141871-02-5]

MBZ-5016-PI4 °C

1 g5 g

Boc-N-Me-Leu-OHt-Butyloxycarbonyl-N-methyl-l-leucine (M.W. 245.32) C12H23NO4 [53363-89-6]

BML-5313-PI4 °C

1 g5 g

Boc-N-Me-Phe-OHt-Butyloxycarbonyl-N-methyl-l-phenylalanine (M.W. 279.34) C15H21NO4 [37553-65-4]

BXF-5322-PI4 °C

1 g5 g

Boc-N-Me-Ser-OHt-Butyloxycarbonyl-N-methyl-l-serine (M.W. 219.24) C9H17NO5 [101772-29-6]

BMS-5310-PI4 °C

1 g5 g

Boc-N-Me-Tyr-OH • DCHAt-Butyloxycarbonyl-N-methyl-l-tyrosine • dicyclohexylamine (M.W. 295.34 •181.32) C15H21NO5 • C12H23N [95105-25-2]

BMY-5311-PI4 °C

1 g5 g

Boc-N-Me-Val-OHt-Butyloxycarbonyl-N-methyl-l-valine (M.W. 231.29) C11H21NO4 [45170-31-8]

BMV-5312-PI4 °C

1 g5 g

Boc-Amino Acid EstersBoc-Leu-OEt

t-Butyloxycarbonyl-l-leucine ethyl ester (M.W. 259.35)

BEL-5540-PI4 °C

1 g5 g

25 g

Boc-Phe-OEtt-Butyloxycarbonyl-l-phenylalanine ethyl ester

BEF-5841-PI4 °C

5 g25 g

100 g

NEW!


TOO


Order Hotline 1-800-777-4779 502-266-8787 267

PRODUCT CODE QTYFmoc-Protected l-Amino AcidsFmoc Protecting Group

We are pleased to offer a carefully selected list of stable, high purity fluorenylmethyloxycarbonyl (Fmoc) amino acid derivatives. The temporary, base labile, Fmoc protecting group is usually removed by 20% piperidine in dimethyl-formamide (DMF), and is ideal in applications involving orthogonal synthesis.

O NH

O

FMOC GroupFmoc-Ala-OH • H2O9-Fluorenylmethoxycarbonyl-l-alanine • H2O (M.W. 311.34 • 18.02) C18H17NO4 • H2O [35661-39-3]

FLA-1706-PI4 °C

5 g25 g

100 g

Fmoc-β-Ala-OH9-Fluorenylmethoxycarbonyl-β-alanine (M.W. 311.34) C18H17NO4 [35737-10-1]

FLX-1744-PI4 °C

1 g5 g

25 g

Fmoc-Arg-OH9-Fluorenylmethoxycarbonyl-l-arginine (M.W. 396.45) C21H24N4O4 [91000-69-0]

FLR-1708-PI4 °C

5 g25 g

Fmoc-Arg(Pbf)-OHNα-9-Fluorenylmethoxycarbonyl-Ng-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-l-arginine

FLR-1746-PI4 °C

5 g25 g

100 g

Fmoc-Arg(Pbf)-OHN-Fmoc-l-Arginine(Pbf)(M.W. 648.77) C21H23N5O6 [154445-77-9]

FLR-53012-PI4 °C

1 kg5 kg

Fmoc-Arg(Tos)-OHNα-9-Fluorenylmethoxycarbonyl-Ng-tosyl-l-arginine (M.W. 550.60) C28H30N4O6S [83792-47-6]

FLR-1710-PI4 °C

1 g5 g

Fmoc-Arg(Z)2-OH N-α-9-Fluorenylmethoxycarbonyl-N-γ-bis-carbobenzoxy-l-arginine (M.W. 664.72) C37H36N4O8 [207857-35-0]

FRC-1902-PI4 °C

1 g

Fmoc-Asn-OH9-Fluorenylmethoxycarbonyl-l-asparagine (M.W. 354.37) C19H18N2O5 [71989-16-7]

FLN-1704-PI4 °C

5 g25 g

100 g

Fmoc-Asn(Trt)-OHNα-9-Fluorenylmethoxycarbonyl-Nβ-trityl-l-asparagine (M.W. 596.69) C38H32N2O5 [132388-59-1]

FLN-1754-PI4 °C

5 g25 g

100 g

Fmoc-Asp(Edans)-OH(M.W. 603.66) C31H29N3O8S [182253-73-2]Building Blocks for FRETs

FDE-1900-PI4 °C

1 g

Fmoc-Asp(OBzl)-OH9-Fluorenylmethoxycarbonyl-l-aspartic acid β-benzyl ester (M.W. 445.46) C26H23NO6 [86060-83-5]

FLD-1712-PI4 °C

1 g5 g

25 g

NEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

268 Order Hotline 1-800-777-4779 502-266-8787

Fmoc-Asp(OtBu)-OH9-Fluorenylmethoxycarbonyl-l-aspartic acid β-t-butyl ester (M.W. 411.46) C23H25NO6 [129460-09-9]

FLD-1713-PI4 °C

5 g25 g

100 g

Fmoc-Cys(Acm)-OH9-Fluorenylmethoxycarbonyl-S-acetamidomethyl-l-cysteine (M.W. 414.48) C21H22N2O5S [86060-81-3]

FLC-1714-PI4 °C

5 g25 g

Fmoc-Cys(tBu)-OH9-Fluorenylmethoxycarbonyl-S-t-butyl-l-cysteine (M.W. 399.50) C22H25NO4S [67436-13-9]

FLC-1741-PI4 °C

5 g25 g

Fmoc-Cys(pMeOBzl)-OH9-Fluorenylmethoxycarbonyl-S-p-methoxybenzyl-l-cysteine (M.W. 463.51) C26H25NO5S [141892-41-3]

FLC-1717-PI4 °C

5 g25 g

Fmoc-Cys(Pam)2-OHFmoc-Cys((R,S)-2,3-di(palmitoyloxy)-propyl)-OH(M.W. 894.32) C53H83NO8S [210532-98-2]

FCP-5001-PI4 °C

1 g5 g

Fmoc-Cys(Trt)-OH9-Fluorenylmethoxycarbonyl-S-trityl-l-cysteine (M.W. 585.71) C37H31NO4S [103213-32-7]

FLC-1718-PI4 °C

5 g25 g

100 g

Fmoc-Cys(Xan)-OH9-Fluorenylmethoxycarbonyl-S-xanthenyl-l-cysteine (M.W. 523.61) C31H25NO5S

FLC-5358-PI4 °C

5 g25 g

Fmoc-Cys(Xan)-OPfp9-Fluorenylmethoxycarbonyl-S-xanthenyl-l-cysteine pentafluo-rophenyl ester (M.W. 689.66) C37H24NO5SF5

FLC-5374-PI4 °C

1 g5 g

Fmoc-Dap(Octanoyl)-OHN-α-9-Fluorenylmethoxycarbonyl-N-β-octanoyl-l-2,3-diaminopropionic acid (M.W. 452.56) C26H32N2O5Building Blocks for FRETs

FDO-1909-PI4 °C

1 g

Fmoc-Glu(OtBu)-OH 9-Fluorenylmethoxycarbonyl-l-glutamic Acid γ-t-butyl ester (M.W. 425.49) C24H27NO6

FLE-1720-PI4 °C

5 g25 g

100 g

Fmoc-Gln-OH9-Fluorenylmethoxycarbonyl-l-glutamine (M.W. 368.39) C20H20N2O5 [71989-20-3]

FLQ-1721-PI4 °C

5 g25 g

100 g

Fmoc-Gln(Trt)-OHNα-9-Fluorenylmethoxycarbonyl-Nγ-trityl-l-glutamine (M.W. 610.72) C39H34N2O5 [132327-80-1]

FLQ-1755-PI4 °C

5 g25 g

100 g

NEW!

NEW!


TOO


Order Hotline 1-800-777-4779 502-266-8787 269

PRODUCT CODE QTYFmoc-His(Bzl)-OH

Nα-Fluorenylmethoxycarbonyl-Nim-benzyl-l-histidine (M.W. 467.53) C28H25N3O4

FLH-1742-PI4 °C

1 g5 g

25 g

Fmoc-His(Fmoc)-OHNα,Nim-di-9-Fluorenylmethoxycarbonyl-l-histidine (M.W. 599.65) C36H29N3O6 [98929-98-7]

FLH-1702-PI4 °C

1 g5 g

25 g

Fmoc-His(Trt)-OHNα-9-Fluorenylmethoxycarbonyl-Nim-trityl-l-histidine (M.W. 619.73) C40H33N3O4 [128545-09-5]

FLH-1740-PI4 °C

5 g25 g

100 g

Fmoc-Ile-OH9-Fluorenylmethoxycarbonyl-l-isoleucine (M.W. 353.42) C21H23NO4 [71989-23-6]

FLI-1724-PI4 °C

5 g25 g

100 g

Fmoc-Leu-OH9-Fluorenylmethoxycarbonyl-l-leucine (M.W. 353.42) C21H23NO4 [35661-60-0]

FLL-1725-PI4 °C

5 g25 g

100 g

Fmoc-Lys(Boc)-OHNα-9-Fluorenylmethoxycarbonyl-Nε-t-butyloxycarbonyl-l-lysine (M.W. 468.55) C26H32N2O6 [71989-26-9]

FLK-1726-PI4 °C

5 g25 g

100 g

Fmoc-Lys-(Dabcyl)-OHN-alpha-9-Fluorenylmethoxycarbonyl-N-ε-(4,4-dimethylazobenzene-4’carbonyl)-L-lysine (M.W. 619.73) C36H37N5O5 [146998-27-8]

FKD-1908-PI4 °C

1 g

Fmoc-Lys(Fmoc)-OHNα,Nε-di-9-Fluorenylmethoxycarbonyl-l-lysine (M.W. 590.68) C36H34N2O6 [78081-87-5]

FLK-1750-PI4 °C

1 g5 g

25 g

Fmoc-Lys(ivDde)-OH(M.W. 574.72) C34H42N2O6 [204777-78-6]

FLK-1759-PI4 °C

1 g5 g

Fmoc-Lys(Z)-OHNα-Fluorenylmethoxycarbonyl-Nε-benzyloxycarbonyl-l-lysine (M.W. 502.57) C29H30N2O6 [86060-82-4]

FLK-1727-PI4 °C

1 g5 g

25 g

Fmoc-Met-OH9-Fluorenylmethoxycarbonyl-l-methionine (M.W. 371.46) C20H21NO4S [71989-28-1]

FLM-1703-PI4 °C

5 g25 g

100 g

Fmoc-Phe-OH9-Fluorenylmethoxycarbonyl-l-phenylalanine (M.W. 387.44) C24H21NO4 [35661-40-6]

FLF-1730-PI4 °C

5 g25 g

100 g

NEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

270 Order Hotline 1-800-777-4779 502-266-8787

Fmoc-Pro-OH9-Fluorenylmethoxycarbonyl-l-proline (M.W. 337.38) C20H19NO4 [71989-31-6]

FLP-1731-PI4 °C

5 g25 g

100 g

Fmoc-Ser(Bzl)-OHNα-9-Fluorenylmethoxycarbonyl-O-benzyl-l-serine (M.W. 417.46) C25H23NO5 [83792-48-7]

FLS-1732-PI4 °C

1 g5 g

25 g

Fmoc-Ser(tBu)-OHNα-9-Fluorenylmethoxycarbonyl-O-t-butyl-l-serine (M.W. 383.45) C22H25NO5 [71989-33-8]

FLS-1733-PI4 °C

5 g25 g

100 g

Fmoc-Ser(Trt)-OHNα-9-Fluorenylmethoxycarbonyl-O-trityl-l-serine (M.W. 569.66) C37H31NO5 [111061-56-4]

FLS-1756-PI4 °C

5 g25 g

Fmoc-Thr(Bzl)-OH9-Fluorenylmethoxycarbonyl-O-benzyl-l-threonine (M.W. 431.49) C26H25NO5 [47872-75-0]

FLT-1734-PI4 °C

1 g5 g

25 g

Fmoc-Thr(tBu)-OH9-Fluorenylmethoxycarbonyl-O-t-butyl-l-threonine (M.W. 397.48) C23H27NO5 [71989-35-0]

FLT-1700-PI4 °C

5 g25 g

100 g

Fmoc-Thr(Trt)-OHNα-9-Fluorenylmethoxycarbonyl-O-trityl-l-Threorine (M.W. 583.69) C38H33NO5 [133180-01-5]

FLT-1768-PI4 °C

1 g5 g

25 g

Fmoc-Trp-OHNα-9-Fluorenylmethoxycarbonyl-l-tryptophan (M.W. 426.48) C26H22N2O4 [35737-15-6]

FLW-1735-PI4 °C

5 g25 g

100 g

Fmoc-Trp(Boc)-OHNα-9-Fluorenylmethoxycarbonyl-Nin-t-butyloxycarbonyl-l-tryptophan (M.W. 526.59) C31H30N2O6 [143824-78-6]

FLW-1769-PI4 °C

5 g25 g

100 g

Fmoc-Tyr(Bzl)-OH9-Fluorenylmethoxycarbonyl-O-benzyl-l-tyrosine (M.W. 493.56) C31H27NO5 [71989-40-7]

FLY-1736-PI4 °C

1 g5 g

25 g

Fmoc-Tyr(tBu)-OH9-Fluorenylmethoxycarbonyl-O-t-butyl-l-tyrosine (M.W. 459.55) C28H29NO5 [71989-38-3]

FLY-1737-PI4 °C

5 g25 g

100 g

Fmoc-Tyr(Cl2-Bzl)-OHNα-9-Fluorenylmethoxycarbonyl-O-2,6-dichlorobenzyl-l-tyrosine (M.W. 562.45) C31H25NO5Cl2 [112402-12-7]

FLY-1738-PI4 °C

1 g5 g

25 g


TOO


Order Hotline 1-800-777-4779 502-266-8787 271

PRODUCT CODE QTYFmoc-Val-OH

9-Fluorenylmethoxycarbonyl-l-valine (M.W. 339.39) C20H21NO4 [68858-20-8]

FLV-1739-PI4 °C

5 g25 g

100 gFmoc Amino Acids attached to CLEAR Resins are listed on page 299, Rink-Amide MBHA Resins on page 292, and Wang Resins on page 289.

Fmoc-Protected d-Amino AcidsFmoc-d-Gln(Trt)-OH

Nα-9-Fluorenylmethoxycarbonyl-Nγ-trityl-d-glutamine (M.W. 610.72) C39H34N2O5 [200623-62-7]

FDQ-1809-PI4 °C

1 g5 g

Fmoc-d-Glu(OtBu)-OH9-Fluorenylmethoxycarbonyl-d-glutamic acid γ-t-butyl ester (M.W. 425.49) C24H27NO6 [104091-08-9]

FDE-1810-PI4 °C

1 g5 g

Fmoc-d-His(Trt)-OHNα-9-Fluorenylmethoxycarbonyl-Nim-trityl-d-histidine (M.W. 619.73) C40H33N3O4 [135610-90-1]

FDH-1812-PI4 °C

1 g5 g

Fmoc-d-lle-OH9-Fluorenylmethoxycarbonyl-d-isoleucine (M.W. 353.42) C21H23NO4 [143688-83-9]

FDI-1856-PI4 °C

1 g5 g

Fmoc-d-Leu-OH9-Fluorenylmethoxycarbonyl-d-leucine (M.W. 353.42) C21H23NO4 [14360-54-2]

FDL-1814-PI4 °C

1 g5 g

Fmoc-d-Lys(Boc)-OHNα-9-Fluorenylmethoxycarbonyl-Nε-t-butyloxycarbonyl-d-lysine (M.W. 468.55) C26H32N2O6 [92122-45-7]

FDK-1815-PI4 °C

1 g5 g

Fmoc-d-Lys(Mtt)-OHNα-9-Fluorenylmethoxycarbonyl-Nε-4-methyltrityl-d-lysine (M.W. 624.79) C41H40N2O4

FDK-1898-PI4 °C

1 g5 g

Fmoc-d-Met-OH9-Fluorenylmethoxycarbonyl-d-Methionine (M.W. 371.45) C20H21NO4S [112883-40-6]

FDM-1816-PI4 °C

1 g5 g

Fmoc-d-Orn(Boc)-OHNα-9-Fluorenylmethoxycarbonyl-Nδ-t-butyloxycarbonyl-d-ornithine (M.W. 454.52) C25H30N2O6 [118476-89-4]

FDX-1818-PI4 °C

1 g5 g

Fmoc-d-Phe-OH9-Fluorenylmethoxycarbonyl-d-phenylalanine (M.W. 387.44) C24H21NO4 [86123-10-6]

FDF-1830-PI4 °C

1 g5 g

Fmoc-d-Pro-OH9-Fluorenylmethoxycarbonyl-d-proline (M.W. 337.38) C20H19NO4 [101555-62-8]

FDP-1826-PI4 °C

1 g5 g

Fmoc-d-Ser(tBu)-OH9-Fluorenylmethoxycarbonyl-O-t-butyl-d-serine (M.W. 383.45) C22H25NO5 [128107-47-1]

FDS-1831-PI4 °C

1 g5 g

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

272 Order Hotline 1-800-777-4779 502-266-8787

Fmoc-d-Ser(Trt)-OH9-Fluorenylmethoxycarbonyl-O-trityl-d-serine (M.W. 569.66) C37H31NO5

FDS-1869-PI4 °C

1 g5 g

Fmoc-d-Thr(tBu)-OH9-Fluorenylmethoxycarbonyl-O-t-butyl-d-threonine (M.W. 397.48) C23H27NO5 [138797-71-4]

FDT-1828-PI4 °C

1 g5 g

Fmoc-d-Trp-OHNα-9-Fluorenylmethoxycarbonyl-d-tryptophan (M.W. 426.47) C26H22N2O4 [86123-11-7]

FDW-1832-PI4 °C

1 g5 g

Fmoc-d-Trp(Boc)-OHNα-Fluorenylmethoxycarbonyl-Nin-t-butyloxycarbonyl-d-tryptophan(M.W. 526.59) C31H30N2O6 [163619-04-3]

FDW-1829-PI4 °C

1 g5 g

Fmoc-d-Tyr(tBu)-OH9-Fluorenylmethoxycarbonyl-O-t-butyl-d-tyrosine (M.W. 459.55) C28H29NO5 [118488-18-9]

FDY-1833-PI4 °C

1 g5 g

Fmoc-d-Val-OH9-Fluorenylmethoxycarbonyl-d-valine (M.W. 339.39) C20H21NO4 [84624-17-9]

FDV-1834-PI4 °C

1 g5 g

Unusual Fmoc-Amino AcidsFmoc-Abu-OH

9-Fluorenylmethoxycarbonyl-l-α-aminobutyric acid (M.W. 325.13 • 18.01) C19H19NO4 • H2O [135112-27-5]

FLX-1753-PI4 °C

1 g5 g

25 g

Fmoc-d-Abu-OH9-Fluorenylmethoxycarbonyl-d-α-aminobutyric acid (M.W. 325.13 • 18.01) C19H19NO4 • H2O [170642-27-0]

FDX-1860-PI4 °C

1 g5 g

25 g

Fmoc-γ-Abu-OH9-Fluorenylmethoxycarbonyl-γ-aminobutyric acid (M.W. 325.37) C19H19NO4 [116821-47-7]

FAB-1773-PI4 °C

5 g25 g

Fmoc-ε-Aca-OH9-Fluorenylmethoxycarbonyl-ε-aminocaproic acid 9-Fluorenylmethoxycarbonyl-6-Aminohexanoic Acid (M.W. 353.42) C21H23NO4 [88574-06-5]

FLX-1775-PI4 °C

1 g5 g

25 g

Fmoc-Adp-OHN-α-9-Fluorenylmethoxycarbonyl-3-amino-2,2-Dimethyl-Propionic Acid(M.W. 339.39) C20H21NO4

FAP-1907-PI4 °C

1 g5 g

Fmoc-Aib-OH9-Fluorenylmethoxycarbonyl-α-aminoisobutyric acid (M.W. 325.37) C19H19NO4 [94744-50-0]

FLX-1749-PI4 °C

1 g5 g

25 g

NEW!


TOO


Order Hotline 1-800-777-4779 502-266-8787 273

PRODUCT CODE QTYFmoc-Ala-Cys(Trt)-OH

9-Fluorenylmethoxycarbonyl-l-Alanyl-S-Trityl-Cysteine(M.W. 656.79) C40H36N2O5SComponent of Cysteinyl Prolyl Ester (CPE) Autoactivation UnitT. Kawakami and S. Aimoto, Chem. Lett., 36, 76 (2007).T. Kawakami and S. Aimoto, Tetrahedron Lett., 48, 1903 (2007).T. Kawakami and S. Aimoto, Tetrahedron, 65, 3871 (2009).

FCP-23504 °C

1 g

• This compound is produced by Peptide Institute, Inc. under the license of Osaka University and Osaka Foundation

Fmoc-11-Aminoundecanoic Acid9-Fluorenylmethoxycarbonyl-11-aminoundecanoic acid (M.W. 423.56) C26H33NO4 [88574-07-6]

FAA-1707-PI4 °C

1 g5 g

Fmoc-5-Ava-OH9-Fluorenylmethoxycarbonyl-5-aminovaleric acid (M.W. 339.39) C20H21NO4 [123622-48-0]

FLX-5518-PI4 °C

1 g5 g

Fmoc-Asp-OAll (Alpha Ester)9-Fluorenylmethoxycarbonyl-l-aspartic acid-α-Allyl ester (M.W. 395.42) C22H21NO6 [146982-24-3]

FLD-5536-PI4 °C

1 g5 g

Fmoc-Cha-OH9-Fluorenylmethoxycarbonyl-β-cyclohexyl-l-alanine (M.W. 393.49) C24H27NO4 [135673-97-1]

FLX-5545-PI4 °C

1 g5 g

Fmoc-d-Cha-OH9-Fluorenylmethoxycarbonyl-β-cyclohexyl-d-alanine (M.W. 393.50) C24H27NO4 [144701-25-7]

FDX-1879-PI4 °C

1 g5 g

Fmoc-Cpg-OHN-α-9-Fluorenylmethoxycarbonyl-Cyclopentyl-l-Glycine(M.W. 365.43) C22H23NO4 [220497-61-0]

FPG-1901-PI4 °C

1 g5 g

Fmoc-hCys(Trt)-OHFmoc-hCys(Trt)-OH

N-α-(9-Fluorenylmethyloxy-carbonyl)-S-trityl-l-homocysteine(M.W. 599.76) C38H33NO4S [167015-23-8] Fmoc Unusual Amino Acid

S. Lindman, et al., Bioorg. Med. Chem., 9, 763 (2001)J. Liang and K. Burgess, Tetrahedron, 58, 8743 (2002)S. Lindman, et al., Bioorg. Med. Chem., 11, 2974 (2003)A. Saporito, et al., Biopolymers, 83, 508 (2006)

FCT-5004-PI-20 °C

1 g5 g

Fmoc-Dab(Boc)-OHNα-9-Fluorenylmethoxycarbonyl-Nγ-t-butyloxycarbonyl-l-2,4-diaminobutyric acid (M.W. 440.50) C24H28N2O6 [125238-99-5]

FLX-5522-PI4 °C

1 g5 g

Fmoc-d-Dab(Boc)-OHNα-9-Fluorenylmethoxycarbonyl-Nγ-t-butyloxycarbonyl-d-2,4-diaminobutyric acid (M.W. 440.50) C24H28N2O6 [114360-56-4]

FDX-5541-PI4 °C

1 g5 g

NEW!

NEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

274 Order Hotline 1-800-777-4779 502-266-8787

Fmoc-Dap(Boc)-OHNα-9-Fluorenylmethoxycarbonyl-Nβ-t-butyloxycarbonyl-l-2,3-diaminopropionic acid (M.W. 426.47) C23H26N2O6 [162558-25-0]

FLX-5526-PI4 °C

1 g5 g

Fmoc-d-Dap(Boc)-OHNα-9-Fluorenylmethoxycarbonyl-Nβ-t-butyloxycarbonyl-d-2,3-diaminopropionic acid (M.W. 426.47) C23H26N2O6 [198544-42-2]

FDX-5525-PI4 °C

1 g5 g

Fmoc-Dap(Dnp)-OHFmoc-Dpa-OH (M.W. 492.45) C24H20N4O8 [140430-54-2]Building Block for FRET Substrates

FDD-5019-PI4 °C

1 g5 g

Fmoc-Deg-OH9-Fluorenylmethoxycarbonyl-diethylglycine (M.W. 353.42) C21H23NO4

FLX-1799-PI4 °C

1 g5 g

Fmoc-3,5-Diiodo-l-Tyr-OHNα-9-Fluorenylmethoxycarbonyl-3,5-diiodo-L-tyrosine(M.W. 655.23) C24H19I2NO5 [103213-31-6]

FDY-5009-PI4 °C

1 g5 g

Fmoc-3,3-Dip-OH9-Fluorenylmethoxycarbonyl-l-3,3-diphenylalanine (M.W. 463.54) C30H25NO4

FLX-5529-PI4 °C

1 g5 g

Fmoc-d-3,3-Dip-OH9-Fluorenylmethoxycarbonyl-d-3,3-diphenylalanine (M.W. 463.54) C30H25NO4

FDX-5531-PI4 °C

1 g5 g

Fmoc-Glu-OAll (Alpha Ester)9-Fluorenylmethoxycarbonyl-l-glutamic acid-α-allyl ester (M.W. 409.44) C23H23NO6

FLE-5538-PI4 °C

1 g5 g

Fmoc-Glu(OBzl)-OH9-Fluorenylmethoxycarbonyl-l-glutamic Acid γ-benzyl ester (M.W. 459.50) C27H25NO6 [123639-61-2]

FLE-1719-PI 1 g5 g

25 g

Fmoc-Gly-Cys(Trt)-OH9-Fluorenylmethoxycarbonyl-Glycyl-S-Trityl-Cysteine(M.W. 642.76) C39H34N2O5SComponent of Cysteinyl Prolyl Ester (CPE) Autoactivation UnitT. Kawakami and S. Aimoto, Chem. Lett., 36, 76 (2007).T. Kawakami and S. Aimoto, Tetrahedron Lett., 48, 1903 (2007).T. Kawakami and S. Aimoto, Tetrahedron, 65, 3871 (2009).

FCP-23514 °C

1 g


Fmoc-Har(Pbf)-OHNα-(9-Fluorenylmethyloxy-carbonyl)-Nγ-(2,2,4,6,7-Pentamethyldihydrobenzofuran-5-Sulfonyl)-l-Homoarginine (M.W. 662.81) C35H42N4O7S [15445-77-9]

FHP-5005-PI4 °C

1 g5 g

Fmoc-Hyp(tBu)-OH9-Fluorenylmethoxycarbonyl-O-t-butyl-l-hydroxyproline (M.W. 409.49) C24H27NO5 [122996-47-8]

FLX-1771-PI4 °C

1 g5 g

NEW!

NEW!

NEW!


TOO


Order Hotline 1-800-777-4779 502-266-8787 275

PRODUCT CODE QTYFmoc-allo-Ile-OH

9-Fluorenylmethoxycarbonyl-l-allo-isoleucine (M.W. 353.42)

FLI-1757-PI4 °C

1 g5 g

Fmoc-3,Iodo-l-Tyr-OHFmoc-3-iodo-Tyr-OH; Fmoc-3-iodo-l-tyrosine(M.W. 529.34) C24H20I2NO5 [134486-00-3]

FDY-5043-PI4 °C

1 g5 g

Fmoc-Leu-Cys(Trt)-OH9-Fluorenylmethoxycarbonyl-l-Leucyl-S-Trityl-Cysteine(M.W. 698.87) C43H42N2O5SComponent of Cysteinyl Prolyl Ester (CPE) Autoactivation UnitT. Kawakami and S. Aimoto, Chem. Lett., 36, 76 (2007).T. Kawakami and S. Aimoto, Tetrahedron Lett., 48, 1903 (2007).T. Kawakami and S. Aimoto, Tetrahedron, 65, 3871 (2009).

FCP-23524 °C

1 g


Fmoc-Lys(Mtt)-OHNα-9-Fluorenylmethoxycarbonyl-Nε-4-methyltrityl-l-lysine (M.W. 624.79) C41H40N2O4 [167393-62-6]

FLK-1798-PI4 °C

1 g5 g

25 g

Fmoc-Lys(Dnp)-OHN-α-(9-Fluorenylmethylcarbonyl)-N-ε-(2,4-Dinitrophenyl)-l-Lysine (M.W. 534.53) C27H26N4O8 [148083-64-1] Building Block for FRET Substrates

FKD-5018-PI4 °C

1 g5 g

Fmoc-mini-PEGTM

Fmoc-8-Amino-3,6-Dioxaoctanoic Acid9-Fluorenylmethoxycarbonyl-8-amino-3,6-dioxaoctanoic acid (M.W. 385.42) C21H23NO6 Fmoc-AEEA

FXX-5521-PI4 °C

1 g5 g

Fmoc-mini-PEG-3TM

Fmoc-11-Amino-3,6,9-Trioxaundecanoic Acid (Syrup)9-Fluorenylmethoxycarbonyl-8-amino-3,6,9-trioxaundecanoic acid (M.W. 429.47) C23H27NO7 Fmoc-AEEEA

FXX-5524-PI4 °C

1 g5 g

Fmoc-Nal(2')-OH9-Fluorenylmethoxycarbonyl-l-(2-naphthyl)alanine (M.W. 437.50) C28H23NO4 [112883-43-9]

FLX-1758-PI4 °C

1 g5 g

Fmoc-d-Nal(2')-OH9-Fluorenylmethoxycarbonyl-d-(2-naphthyl)alanine (M.W. 437.50) C28H23NO4 [138774-94-4]

FDX-1859-PI4 °C

1 g5 g

Fmoc-Nal(1')-OH9-Fluorenylmethoxycarbonyl-l-(1-Naphthyl)alanine (M.W. 437.50) C28H23NO4 [96402-49-2]

FLX-1778-PI4 °C

1 g5 g

Fmoc-d-Nal(1')-OH9-Fluorenylmethoxycarbonyl-d-(1-naphthyl)alanine (M.W. 437.50) C28H23NO4

FDX-1780-PI4 °C

1 g5 g

NEW!

NEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

276 Order Hotline 1-800-777-4779 502-266-8787

Fmoc-Nle-OH9-Fluorenylmethoxycarbonyl-l-norleucine (M.W. 353.42) C21H23NO6 [77284-32-3]

FLU-1728-PI4 °C

1 g5 g

25 g

Fmoc-Nva-OH9-Fluorenylmethoxycarbonyl-l-norvaline (M.W. 339.39) C20H21NO4 [135112-28-6]

FLX-1785-PI4 °C

5 g25 g

Fmoc-Orn(Boc)-OHNα-9-Fluorenylmethoxycarbonyl-Nδ-t-butyloxycarbonyl-l-ornithine (M.W. 454.52) C25H30N2O6 [109425-55-0]

FLO-1729-PI4 °C

1 g5 g

25 g

Fmoc-d-Orn(Boc)-OHNα-9-Fluorenylmethoxycarbonyl-Nδ-t-butyloxycarbonyl-d-ornithine (M.W. 454.52) C25H30N2O6 [118476-89-4]

FDX-1818-PI4 °C

1 g5 g

Fmoc-Orn(Fmoc)-OHNα,Nδ-di-9-Fluorenylmethoxycarbonyl-l-ornithine (M.W. 576.65) C35H32N2O6

FLO-1788-PI4 °C

1 g5 g

25 g

Fmoc-Orn(Mtt)-OHNα-9-Fluorenylmethoxycarbonyl-Nδ-4-methyltrityl-l-ornithine (M.W. 610.76) C40H38N2O4

FLO-1747-PI4 °C

1 g5 g

Fmoc-d-Orn(Mtt)-OHNα-9-Fluorenylmethoxycarbonyl-Nδ-4-methyl-trityl-d-ornithine (M.W. 610.79) C40H36N2O4

FDO-1897-PI4 °C

1 g5 g

Fmoc-3-Pal-OH9-Fluorenylmethoxycarbonyl-l-(3-pyridyl)alanine (M.W. 388.42) C23H20N2O4 [175453-07-3]

FLX-1766-PI4 °C

1 g

Fmoc-d-3-Pal-OH9-Fluorenylmethoxycarbonyl-d-(3-pyridyl)alanine (M.W. 388.42) C23H20N2O4 [142994-45-4]

FDX-1772-PI4 °C

1 g

Fmoc-4-Pal-OH9-Fluorenylmethoxycarbonyl-l-(4-pyridyl)alanine (M.W. 388.43) C23H20N2O4 [169555-95-7]

FLX-5534-PI4 °C

1 g5 g

Fmoc-d-4-Pal-OH9-Fluorenylmethoxycarbonyl-d-(4-pyridyl)alanine (M.W. 388.43) C23H20N2O4 [20528-30-9]

FDX-5535-PI4 °C

1 g5 g

Fmoc-Ppa(Bzl)-OHFmoc-4-phosphono-Phe(Bzl)-OH

FPZ-5006-PI4 °C

1 g5 g

Nα-9-Fluorenylmethyloxycarbonyl-4-phosphono-O-benzyl-l-phenyalanine(M.W. 557.55) C31H28NO7P[943148-45-6]

C.Thurieau, et al., Helv. Chim. Acta, 77, 679 (1994)C.J.Stankovic, et al., Bioorg. Med. Chem. Lett., 7, 1909 (1997)S.S.Chauhan, et al., Tetrahedron Lett., 48, 4051 (2007)

NEW!


TOO


Order Hotline 1-800-777-4779 502-266-8787 277

PRODUCT CODE QTYFmoc-Pen(Meb)-OH

9-Fluorenylmethoxycarbonyl-S-p-methylbenzyl-l-penicillamine (M.W. 475.64) C28H29NO4S

FLX-1760-PI4 °C

1 g5 g

Fmoc-d-Pen(Acm)-OH9-Fluorenylmethoxycarbonyl-S-acetamidomethyl-d-penicillamine (M.W. 442.54) C23H26N2O5S [201531-77-3]

FDX-1827-PI4 °C

1 g5 g

Fmoc-d-Pen(Meb)-OH9-Fluorenylmethoxycarbonyl-S-p-methylbenzyl-d-penicillamine (M.W. 475.64) C28H29NO4S

FDX-1861-PI4 °C

1 g5 g

Fmoc-Pen(Acm)-OH9-Fluorenylmethoxycarbonyl-S-acetamidomethyl-l-penicillamine (M.W. 442.54) C23H26N2O5S [201531-76-2]

FLX-1711-PI4 °C

1 g5 g

Fmoc-Phe-OH (ring-D5)N-(9-Fluorenylmethoxycarbonyl)-L-phenylalanine-2,3,4,5,6-D5(M.W. 392.48) C24H26D5NO4

FFD-5007-PI4 °C

1 g5 g

Fmoc-p-F-Phe-OH9-Fluorenylmethoxycarbonyl-p-Fluoro-l-phenylalanine (M.W. 405.40) C24H20NO4F [169243-86-1]

FLF-1770-PI4 °C

1 g5 g

Fmoc-d-p-F-Phe-OH9-Fluorenylmethoxycarbonyl-p-fluoro-d-phenylalanine (M.W. 405.40) C24H20NO4F [177966-64-2]

FDF-1774-PI4 °C

1 g5 g

Fmoc-p-Cl-Phe-OH9-Fluorenylmethoxycarbonyl-l-p-chloro-l-phenylalanine (M.W. 421.88) C24H20NO4Cl [175453-08-4]

FLF-1762-PI4 °C

1 g5 g

Fmoc-d-p-Cl-Phe-OH9-Fluorenylmethoxycarbonyl-p-Chloro-d-phenylalanine (M.W. 421.88) C24H20NO4Cl [142994-19-2]

FDF-1863-PI4 °C

1 g5 g

Fmoc-Phe(NO2)-OH9-Fluorenylmethoxycarbonyl-p-nitro-l-phenylalanine (M.W. 432.40) C24H20N2O6 [95753-55-2]

FLF-1781-PI4 °C

1 g5 g

Fmoc-d-Phe(NO2)-OH9-Fluorenylmethoxycarbonyl-p-nitro-d-phenylalanine (M.W. 432.40) C24H20N2O6 [177966-63-1]

FDF-1783-PI4 °C

1 g5 g

Fmoc-Phg-OH9-Fluorenylmethoxycarbonyl-l-phenylglycine (M.W. 373.40) C23H19NO4 [102410-65-1]

FFG-1789-PI4 °C

1 g5 g

Fmoc-d-Phg-OH9-Fluorenylmethoxycarbonyl-d-phenylglycine (M.W. 373.41) C23H19NO4 [111524-95-9]

FDX-1862-PI4 °C

1 g5 g

Fmoc-Pra-OH9-Fluorenylmethoxycarbonyl-propargyl-l-glycine (S)-2-(Fmoc-amino)-4-pentynoic acid (M.W. 335.36) C20H17NO4

R.A. Turner, et al., Org. Lett., 9, 5011 (2007)L. Garcia, et al., Org. Biomol. Chem., 7, 5020 (2009)A. Le Chevalier Isaad, et al., J. Pept. Sci., 15, 451 (2009)

PRA-5010-PI4 °C

1 g5 gNEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

278 Order Hotline 1-800-777-4779 502-266-8787

Fmoc-Tic-OH9-Fluorenylmethoxycarbonyl-l-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (M.W. 399.40) C25H21NO4 [136030-33-6]

FLX-1767-PI4 °C

1 g5 g

Fmoc-d-Tic-OH9-Fluorenylmethoxycarbonyl-d-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (M.W. 399.40) C25H21NO4 [130309-33-0]

FDX-1846-PI4 °C

1 g5 g

Fmoc-N-Methyl Amino AcidsFmoc-N-Me-Ala-OH

9-Fluorenylmethoxycarbonyl-N-methyl-l-alanine (M.W. 325.37) C19H19NO4 [84000-07-7]

FMA-1791-PI4 °C

1 g5 g

Fmoc-N-Me-d-Ala-OH9-Fluorenylmethoxycarbonyl-N-methyl-d-alanine (M.W. 325.37) C19H19NO4 [138774-92-2]

FMA-1790-PI4 °C

1 g5 g

Fmoc-N-Me-Asp(OBzl)-OH9-Fluorenylmethoxycarbonyl-N-Methyl-l-aspartic acid β-benzyl ester (M.W. 459.50) C27H25NO6

FMD-1792-PI4 °C

1 g5 g

Fmoc-N-Me-d-Asp(OBzl)-OH9-Fluorenylmethoxycarbonyl-N-Methyl-d-aspartic acid β-benzyl ester (M.W. 459.50) C27H25NO6

FMD-1890-PI4 °C

1 g5 g

Fmoc-N-Me-Glu(OBzl)-OH9-Fluorenylmethoxycarbonyl-N-Methyl-l-glutamic acid γ-benzyl ester (M.W. 473.53) C28H27NO7

FME-1782-PI4 °C

1 g5 g

Fmoc-Sar-OH Fmoc-N-Me-Gly-OH

9-Fluorenylmethoxycarbonyl-sarcosine 9-Fluorenylmethoxycarbonyl-N-methyl-glycine (M.W. 311.34) C18H17NO4 [77128-70-2]

FLX-1751-PI4 °C

5 g25 g

Fmoc-N-Me-Ile-OH 9-Fluorenylmethoxycarbonyl-N-methyl-l-isoleucine (M.W. 367.45) C22H25NO4 [138775-22-1]

FMI-1793-PI4 °C

1 g5 g

Fmoc-N-Me-Leu-OH9-Fluorenylmethoxycarbonyl-N-methyl-l-leucine (M.W. 367.40) C22H25NO4 [103478-62-2]

FML-1794-PI4 °C

1 g5 g

Fmoc-N-Me-d-Leu-OH9-Fluorenylmethoxycarbonyl-N-methyl-d-leucine (M.W. 367.40) C22H25NO4 [103478-63-3]

FML-1784-PI 1 g5 g

Fmoc-N-Me-Phe-OH9-Fluorenylmethoxycarbonyl-N-methyl-l-phenylalanine (M.W. 401.47) C25H23NO4 [77128-73-5]

FMF-1795-PI 1 g5 g

Fmoc-N-Me-d-Phe-OH9-Fluorenylmethoxycarbonyl-N-methyl-d-phenylalanine (M.W. 401.47) C25H23NO4 [138775-05-0]

FMF-1896-PI 1 g5 g

4 °C4 °C

4 °C4 °C

4 °C4 °C


TOO


Order Hotline 1-800-777-4779 502-266-8787 279

PRODUCT CODE QTYFmoc-N-Me-Val-OH

9-Fluorenylmethoxycarbonyl-N-methyl-l-valine (M.W. 353.40) C21H23NO4 [84000-11-3]

FMV-1796-PI 1 g5 g

Fmoc-N-Me-d-Val-OH9-Fluorenylmethoxycarbonyl-N-methyl-d-valine (M.W. 353.40) C21H23NO4 [103478-58-6]

FMV-1787-PI 1 g5 g

Z-Protected l-Amino AcidsZ-Ala-OH

Benzyloxycarbonyl-l-alanine (M.W. 223.20) C11H13NO4 [1142-20-7]

ZLA-2007-PI4 °C

5 g25 g

100 g

Z-Arg-OHBenzyloxycarbonyl-l-arginine (M.W. 308.30) C14H20N4O4 [1234-35-1]

ZLR-2008-PI4 °C

5 g25 g

100 g

Z-Arg(NO2)-OHNα-benzyloxycarbonyl-Ng-nitro-l-arginine (M.W. 353.30) C14H19N5O6 [2304-98-5]

ZLR-2009-PI4 °C

5 g25 g

100 g

Z-Asn-OH Benzyloxycarbonyl-l-asparagine (M.W. 266.30) C12H14N2O5 [2304-96-3]

ZLN-2010-PI4 °C

5 g25 g

100 g

Z-Asp-OHBenzyloxycarbonyl-l-aspartic acid (M.W. 267.20) C12H13NO6 [1152-61-0]

ZLD-2011-PI4 °C

5 g25 g

100 g

Z-Cys(Bzl)-OHBenzyloxycarbonyl-S-benzyl-l-cysteine (M.W. 345.40) C18H19NO4S [3257-18-9]

ZLC-2014-PI4 °C

5 g25 g

100 g

Z-Gln-OHBenzyloxycarbonyl-l-glutamine (M.W. 280.30) C13H16N2O5 [2650-64-8]

ZLQ-2017-PI4 °C

5 g25 g

100 g

Z-Glu-OHBenzyloxycarbonyl-l-glutamic acid (M.W. 281.26) C13H15NO6 [1155-62-0]

ZLE-2015-PI4 °C

5 g25 g

100 g

Z-Gly-OHBenzyloxycarbonyl-glycine (M.W. 209.20) C10H11NO4 [1138-80-3]

ZLG-2018-PI4 °C

5 g25 g

100 g

Z-Ile-OHBenzyloxycarbonyl-l-isoleucine (Syrup) (M.W. 265.40) C14H19NO4 [3160-59-6]

ZLI-2028-PI4 °C

5 g25 g

100 g

4 °C4 °C

4 °C4 °C

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

280 Order Hotline 1-800-777-4779 502-266-8787

Z-Leu-OH Benzyloxycarbonyl-l-leucine (Syrup) (M.W. 265.30) C14H19NO4 [2018-66-8]

ZLL-2029-PI4 °C

5 g25 g

100 g

Z-Lys(Z)-OHNα,Nε-di-benzyloxycarbonyl-l-lysine (M.W. 414.50) C22H26N2O6 [405-39-0]

ZLK-2019-PI4 °C

5 g25 g

100 g

Z-Met-OHBenzyloxycarbonyl-l-methionine (M.W. 283.40) C13H17NO4S [1152-62-1]

ZLM-2020-PI4 °C

5 g25 g

100 g

Z-Phe-OHBenzyloxycarbonyl-l-phenylalanine (M.W. 299.30) C17H17NO4 [1161-13-3]

ZLF-2021-PI4 °C

5 g25 g

100 g

Z-Pro-OHBenzyloxycarbonyl-l-proline (M.W. 249.27) C13H15NO4 [1148-11-4]

ZLP-2022-PI4 °C

5 g25 g

100 g

Z-Pyr-OHBenzyloxycarbonyl-l-pyroglutamic acid (N-benzyloxycarbonyl-l-pyrrolidone carboxylic acid) (M.W. 263.20) C13H13NO5 [32159-21-0]

ZLU-21174 °C

5 g25 g

100 g

Z-d-Pyr-OHBenzyloxycarbonyl-d-pyroglutamic acid (N-benzyloxycarbonyl-d-pyrrolidone carboxylic acid) (M.W. 263.20) C13H13NO5 [78339-57-8]

ZDU-26134 °C

1 g5 g

25 g

Z-Ser-OHBenzyloxycarbonyl-l-serine (M.W. 239.20) C11H13NO5 [1145-80-8]

ZLS-2023-PI4 °C

5 g25 g

100 gZ-Thr-OH

Benzyloxycarbonyl-l-threonine (M.W. 253.30) C12H15NO5 [19728-63-3]

ZLT-2024-PI4 °C

5 g25 g

Z-Trp-OHBenzyloxycarbonyl-l-tryptophan (M.W. 338.40) C19H18N2O4 [7432-21-5]

ZLW-2025-PI4 °C

5 g25 g

Z-Tyr-OHBenzyloxycarbonyl-l-tyrosine (M.W. 315.30) C17H17NO5 [1164-16-5]

ZLY-2026-PI4 °C

5 g25 g

Z-Val-OHBenzyloxycarbonyl-l-valine (M.W. 251.28) C13H17NO4 [1149-26-4]

ZLV-2027-PI4 °C

5 g25 g


TOO


Order Hotline 1-800-777-4779 502-266-8787 281

PRODUCT CODE QTYUnusual Amino AcidsDiethylglycine (Deg)

(M.W. 131.18) C6H13NO2 [2566-29-2]ALX-5041-PI

4 °C

1 g5 g

Palmitoyl-Cys((RS)-2,3-di(palmitoyloxy)-propyl)-OH Pam3-Cys-OH

(M.W. 910.49) C54H103NO7S [87420-41-5]

PAC-5002-PI4 °C

1 g5 g

K.-H.Wiesmueller et al., Hoppe-Seyler’s Z. Physiol. Chem., 364, 593 (1983)G.Jung et al., Angew. Chem. Int. Ed. Engl., 24, 872 (1985)K.-H.Wiesmueller et al., Vaccine, 7, 29 (1989)W.Zeng et al., J. Pept. Sci., 2, 66 (1996)W.Zeng et al., J. Immunol., 169, 4905 (2002)D.C.Jackson et al., Proc. Natl. Acad. Sci. USA, 101, 15440 (2004)S.J.Keding and S.J.Danishefsky, Proc. Natl. Acad. Sci. USA, 101, 11937 (2004)

Fmoc-Ala-OH (2,3,3,3,-D4)N-(9-Fluorenylmethoxycarbonyl)-l-alanine-2,3,3,3-D4(M.W. 315.37) C18H13D4NO4 [225101-69-9]

FAD-5008-PI4 °C

1 g5 g

cis-4-Hydroxy-l-proline(M.W. 131.13) C5H9NO3 [618-27-9]

ALX-5330-PI 1 g5 g

l-Pen(M.W. 149.21) C5H11NO2S [1113-41-3]

AXL-5021-PI 1 g5 g

d-Pen(M.W. 149.21) C5H11NO2S [52-67-5]

AXP-5020-PI 5 g25 g

l-Pen(p-Me-Bzl)l-penicillamine (S-p-methylbenzyl-l-penicillamine)(M.W. 253.20) C13H19NO2S

XLM-5121-PI 1 g5 g

d-Pen(p-Me-Bzl)d-penicillamine (S-p-methylbenzyl-d-penicillamine)(M.W. 253.20) C13H19NO2S

XDM-5120-PI4 °C

1 g5 g

l-Ticl-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid(M.W. 177.20) C10H11NO2 [74163-81-8]

ALX-5029-PI 1 g5 g

d-Ticd-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid(M.W. 177.20) C10H11NO2 [103733-65-9]

ADX-5028-PI 1 g5 g

Hydroxy-Tic7-Hydroxy-l-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid(M.W. 193.20) C10H11NO3

ALX-5027-PI 1 g

d-Hydroxy-Tic7-Hydroxy-d-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acidM.W. 193.20) C10H11NO3 [152286-30-1]

ADX-5026-PI 1 g

NEW!

NEW!

4 °C

4 °C

4 °C

4 °C

4 °C

4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

282 Order Hotline 1-800-777-4779 502-266-8787

ResinsUnsubstituted Resins for Solid Phase Synthesis Aminomethylated Polystyrene Resin • HCl

Divinylbenzene 1%, 100-200 mesh NH2: 0.3-0.8 meq/g

RAM-1440-PI 5 g25 g

Aminomethylated Polystyrene Resin • HCl

Divinylbenzene 1%, 200-400 mesh

(smaller beads)

RAM-1049-PI 5 g25 g

Aminomethylated Polystyrene Resin • HCI


RAM-1051-PI 5 g25 g

Benzhydrylamine Resin • HCl (BHA) Divinylbenzene 1%, 100-200 mesh NH2: 0.3-1.0 meq/g

RBH-1046-PI 5 g25 g

Benzhydrylamine Resin • HCl (BHA) Divinylbenzene 1%, 200-400 mesh NH2: 0.3-1.0 meq/g

HFRCONH2

RBH-1048-PI 5 g25 g

Benzhydrylamine Resin • HCI (BHA)Divinylbenzene 2%, 100-200 mesh NH2: 0.3-1.5 meq/g

RBH-1028 5 g25 g

Chloromethylated Polystyrene Resin Divinylbenzene 1%, 100-200 mesh Cl: 0.3-1.5 meq/g

RCM-1034-PI

Chloromethylated Polystyrene Resin Divinylbenzene 2%, 200-400 mesh Cl: 1.0 meq/g

RCM-1017-PI 25 g 100 g

Chloromethylated Polystyrene Resin p-substituted, Divinylbenzene 1%, 100-200 mesh Cl: 0.7-1.1 meq/g

RCM-1052-PI

Chloromethylated Polystyrene Resin p-substituted, Divinylbenzene 1%, 200-400 mesh Cl: 0.7-1.1 meq/g

RCM-1054-PI 25 g 100 g

HMBA-MBHA ResinHydroxymethylbenzoyl-MBHA Resin Divinylbenzene 1%, 200-400 mesh For preparation of various C-modified peptides

NH3/MeOH NH2NH2/

DMF NaOH (aq) MeOH/Et3N

NaBH4/EtOH

RHM-1079-PI 1 g5 g

RCONH2 RCONHNH2

RCO2H RCOOCH3 RCH2OH

Cleavage ReagentCleavage Product

4 °C

4 °C

4 °C

4 °C

4 °C

4 °C

4 °C

4 °C

4 °C

4 °C

4 °C


TOO


Order Hotline 1-800-777-4779 502-266-8787 283

PRODUCT CODE QTYHMPB-MBHA Resin

4-(4-hydroxymethyl-3-methoxyphenoxy)- butyryl-MBHA Resin Divinylbenzene 1%, 200-400 mesh For preparation of protected peptide fragments, acid sensitive resin (cleavage =1%TFA)

1% TFA/CH2Cl2(smaller beads)

RHM-1077-PI 1 g5 g

RCO2H

Hydroxymethyl Polystyrene ResinHO-CH2-Phenyl-Polymer Divinylbenzene 1%, 100-200 mesh For the preparation of peptide acids

HF RFR-1069-PI 5 g25 gNaBH4

RCO2HROH

Hydroxymethyl Polystyrene ResinDivinylbenzene 2%, 200-400 mesh

RFR-1072-PI 5 g25 g

p-Methyl-Benzhydrylamine Resin • HCl (MBHA)


RMB-1045-PI 5 g25 g

p-Methyl-Benzhydrylamine Resin • HCI (MBHA)

Divinylbenzene 2%,100-200 meshNH2: 0.3-1.5 meq/g

RMB-1039 5 g25 g

p-Methyl-Benzhydrylamine Resin • HCI (MBHA)

Divinylbenzene 1%, 200-400 meshNH2: 0.3-1.5 meq/g

HF RMB-2100-PI 5 g25 g

100 gRCONH2

(Please be sure to specify the preferred milliequivalents/gram when ordering)

Rink-Amide-AM Resin Nle internal reference 4-(2’,4’-Dimethoxyphenyl-Fmoc-Aminomethyl) Phenoxyacetylnorleucyl Aminomethyl Resin Divinylbenzene 1%, 200-400 mesh NH2: 0.3-0.6 meq/g For the preparation of peptide amides

TFA RHM-1073-PI4 °C

5 g25 gRCONH2

Rink-Amide-MBHA Resin4-(2’,4’-Dimethoxyphenyl-Fmoc-Aminomethyl) Phenoxyacetyl-MBHA Resin Divinylbenzene 1%, 100-200 meshNH2: 0.3-0.6 meq/gFor the preparation of peptide amides

TFA RFR-1063-PI4 °C

5 g25 gRCONH2

Rink-Amide-MBHA ResinDivinylbenzene 1%, 200-400 mesh NH2: 0.3-0.6 meq/gFor the preparation of peptide amides

TFA RFR-1067-PI4 °C

5 g25 gRCONH2

Wang Resinp-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

TFA NaBH4

RWN-1399-PI4 °C

5 g25 g

RCO2H ROH


4 °C

4 °C

4 °C

4 °C

4 °C

4 °C

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

284 Order Hotline 1-800-777-4779 502-266-8787

Wang Resinp-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 200-400 mesh

TFA NaBH4

RWN-1398-PI4 °C

5 g25 g

RCO2H ROH

Chlorotrityl Resins (For preparation of acids, alcohols, thiols, or amines) Caution: Extremely moisture sensitive. Keep dry and tightly closed. Always warm to room temperature before opening

2-Chlorotrityl Chloride ResinDivinylbenzene 1%, 100-200 mesh Extremely acid sensitive resin, for preparation of peptide fragments (Cleavage: AcOH/TFE/CH2Cl2)

RCT-1056-PI4 °C

5 g25 g

2-Chlorotrityl Chloride ResinDivinylbenzene 1%, 200-400 mesh Extremely acid sensitive resin, for preparation of peptide fragments (Cleavage: AcOH/TFE/CH2Cl2)

0.5%TFA/DCM

AcOH/TFE/DCM TFA

TFMSA TFA

RCT-1083-PI4 °C

ClCl R

5 g25 g

RCO2H RSH RNH2

Chlorotrityl Polystyrene Macrobead Particle size: (500-560 μm) 0.6-1.0 meq/g

RTH-9937-PI4 °C

5 g

H-γ-Abu-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHX-11048-PI4 °C

1 g5 g

H-e-Aca-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHX-11049-PI4 °C

1 g5 g

H-e-Aca-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHX-1059-PI4 °C

1 g5 g

H-Ala-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHA-11050-PI4 °C

1 g5 g

H-Ala-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHA-1081-PI4 °C

1 g5 g

H-β-Ala-2-ClTrt-Resin Divinylbenzene 1%, 100-200 mesh

RHX-11055-PI4 °C

1 g5 g

H-β-Ala-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHX-1078-PI4 °C

1 g5 g

H-d-Ala-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHA-11077-PI4 °C

1 g5 g

H-Arg(Pbf)-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHX-11051-PI4 °C

1 g5 g

NEW!



TOO


Order Hotline 1-800-777-4779 502-266-8787 285

PRODUCT CODE QTYH-Arg(Pbf)-2-ClTrt-Resin

Divinylbenzene 1%, 200-400 meshRHR-1082-PI

4 °C

1 g5 g

H-Asn(Trt)-2-ClTrt-Resin Divinylbenzene 1%, 100-200 mesh

RHN-11053-PI4 °C

1 g5 g

H-Asn(Trt)-2-ClTrt-Resin Divinylbenzene 1%, 200-400 mesh

RHN-1062-PI4 °C

1 g5 g

H-Asn-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHN-1080-PI4 °C

1 g5 g

H-Asp(OtBu)-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHD-11054-PI4 °C

1 g5 g

H-Asp(OtBu)-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHD-1086-PI4 °C

H-Cys(Trt)-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHC-11056-PI4 °C

1 g5 g

H-Cys(Trt)-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHC-1090-PI4 °C

1 g5 g

H-Gln(Trt)-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHQ-11058-PI4 °C

1 g5 g

H-Gln(Trt)-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHQ-1064-PI4 °C

1 g5 g

H-Gln-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHQ-1092-PI4 °C

1 g5 g

H-Glu(OtBu)-2-ClTrt-Resin Divinylbenzene 1%, 100-200 mesh

RHE-11059-PI4 °C

1 g5 g

H-Glu(OtBu)-2-ClTrt-Resin Divinylbenzene 1%, 200-400 mesh

RHE-1093-PI4 °C

1 g5 g

H-Gly-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHG-11060-PI4 °C

1 g5 g

H-Gly-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHG-1085-PI4 °C

1 g5 g

H-His(Trt)-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHH-11061-PI4 °C

1 g5 g

H-His(Trt)-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHH-1087-PI4 °C

1 g5 g

H-Ile-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHI-11062-PI4 °C

1 g5 g

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

286 Order Hotline 1-800-777-4779 502-266-8787

H-Ile-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHI-1088-PI4 °C

1 g5 g

H-Leu-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHL-11063-PI4 °C

1 g5 g

H-Leu-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHL-1094-PI4 °C

1 g5 g

H-Lys(Boc)-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHK-11064-PI4 °C

1 g5 g

H-Lys(Boc)-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHK-1091-PI4 °C

1 g5 g

H-mini-PEGTM-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHM-11074-PI4 °C

1 g5 g

H-Met-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHM-11065-PI4 °C

1 g5 g

H-Met-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHM-1074-PI4 °C

1 g5 g

H-Nle-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHX-11040-PI4 °C

1 g5 g

H-Phe-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHF-11066-PI4 °C

1 g5 g

H-Phe-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHF-1095-PI4 °C

1 g5 g

H-Pro-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh Excellent resin for synthesis of peptides containingC-terminal Pro without DKP formation.

RHP-11067-PI4 °C

1 g5 g

H-Pro-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh Excellent resin for synthesis of peptides containingC-terminal Pro without DKP formation.

RHP-1089-PI4 °C

1 g5 g

H-Ser(tBu)-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHS-11068-PI4 °C

1 g5 g

H-Ser(tBu)-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHS-1096-PI4 °C

1 g5 g

H-Thr(tBu)-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHT-11069-PI4 °C

1 g5 g

H-Thr(tBu)-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHT-1097-PI4 °C

1 g5 g


TOO


Order Hotline 1-800-777-4779 502-266-8787 287

PRODUCT CODE QTYH-Trp(Boc)-2-ClTrt-Resin

Divinylbenzene 1%, 100-200 meshRHW-11070-PI

4 °C

1 g5 g

H-Trp(Boc)-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHW-1099-PI4 °C

1 g5 g

H-Trp-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHW-11071-PI4 °C

1 g5 g

H-Trp-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHW-1098-PI4 °C

1 g5 g

H-Tyr(tBu)-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHY-11072-PI4 °C

1 g5 g

H-Tyr(tBu)-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHY-1075-PI4 °C

1 g5 g

H-Val-2-ClTrt-ResinDivinylbenzene 1%, 100-200 mesh

RHV-11073-PI4 °C

1 g5 g

H-Val-2-ClTrt-ResinDivinylbenzene 1%, 200-400 mesh

RHV-1076-PI4 °C

1 g5 g

Boc-Amino Acid-Pam ResinsBoc-Amino Acid-Pam Resins are supplied with substitution levels for each lot. Boc-D-amino acids and resins are available upon request. Boc-Amino Acid-Pam Resins: Divinylbenzene 1%, 100-200 and 200-400 mesh.

Unsubstituted Resin

BOC amino acid pam resins

OH CH2 CH2 C

ONH CH2 P

Boc-γ-Abu-Pam Resint-Butyloxycarbonyl-γ-Aminobutyric Acid Pam ResinDivinylbenzene 1%, 200-400 mesh

RPX-1410-PI4 °C

1 g5 g

Boc-Ala-Pam Resint-Butyloxycarbonyl-l-Alanine-Pam ResinDivinylbenzene 1%, 200-400 mesh

RPA-1451-PI4 °C

1 g5 g

Boc-β-Ala-Pam Resint-Butyloxycarbonyl-β-Alanine-Pam Resin(0.4-0.7 meq/g) Divinylbenzene 1%, 200-400 mesh

RPB-1431-PI4 °C

[Higher Substitution]

1 g5 g

Boc-β-Ala-Pam Resint-Butyloxycarbonyl-β-Alanine-Pam Resin (0.1-0.3 meq/g) Divinylbenzene 1%, 200-400 mesh

RPB-1421-PI 4 °C

[Lower Substitution]

1 g5 g

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

288 Order Hotline 1-800-777-4779 502-266-8787

Boc-Arg(Tos)-Pam ResinNα-t-Butyloxycarbonyl-Nγ-Tosyl-l-Arginine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPR-1425-PI4 °C

1 g5 g

Boc-Asn-Pam Resint-Butyloxycarbonyl-l-Asparagine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPN-1460-PI4 °C

1 g5 g

Boc-Asp(OBzl)-Pam Resint-Butyloxycarbonyl-l-Aspartic Acid β-Benzyl Ester-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPD-1430-PI4 °C

1 g5 g

Boc-Asp(OcHex)-Pam Resint-Butyloxycarbonyl-β-Cyclohexyl-l-Aspartic Acid-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPD-1432-PI4 °C

1 g5 g

Boc-Cys(4-CH3-Bzl)-Pam Resint-Butyloxycarbonyl-S-p-Methylbenzyl-l-Cysteine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPC-1429-PI4 °C

1 g5 g

Boc-Glu(OBzl)-Pam Resint-Butyloxycarbonyl-l-Glutamic Acid γ−Benzyl Ester-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPE-1436-PI4 °C

1 g5 g

Boc-Glu(OcHex)-Pam Resint-Butyloxycarbonyl-γ-Cyclohexyl Ester-l-Glutamic Acid-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPE-1434-PI4 °C

1 g5 g

Boc-Gln-Pam Resint-Butyloxycarbonyl-l-Glutamine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPQ-1462-PI4 °C

1 g5 g

Boc-Gly-Pam Resint-Butyloxycarbonyl-Glycine-Pam Resin Divinylbenzene 1%, 100-200 mesh

RPG-1459-PI4 °C

1 g5 g

Boc-Gly-Pam Resint-Butyloxycarbonyl-Glycine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPG-1454-PI4 °C

1 g5 g

Boc-lle-Pam Resint-Butyloxycarbonyl-l-lsoleucine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPI-1465-PI4 °C

1 g5 g

Boc-Leu-Pam Resin t-Butyloxycarbonyl-Leucine-Pam Resin Divinylbenzene 1%, 100-200 mesh

RPL-1457-PI4 °C

1 g5 g

Boc-Leu-Pam Resint-Butyloxycarbonyl-l-Leucine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPL-1455-PI4 °C

1 g5 g

Boc-Lys(Cl-Z)-Pam ResinNα-t-Butyloxycarbonyl-Nε-2-Chloro-Benzyloxycarbonyl-l-Lysine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPK-1435-PI 4 °C

1 g5 g

Boc-Met(O)-Pam Resint-Butyloxycarbonyl-l-Methionine-S-Sulfoxide-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPM-1404-PI4 °C

1 g5 g

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out


TOO


Order Hotline 1-800-777-4779 502-266-8787 289

PRODUCT CODE QTYBoc-Phe-Pam Resin

t-Butyloxycarbonyl-l-Phenylalanine-Pam Resin Divinylbenzene 1%, 100-200 mesh

RPF-1471-PI4 °C

1 g5 g

Boc-Phe-Pam Resint-Butyloxycarbonyl-l-Phenylalanine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPF-1468-PI4 °C

1 g5 g

Boc-Pro-Pam Resint-Butyloxycarbonyl-l-Proline-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPP-1456-PI4 °C

1 g5 g

Boc-Ser(Bzl)-Pam Resint-Butyloxycarbonyl-O-Benzyl-l-Serine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPS-1402-PI4 °C

1 g5 g

Boc-Thr(Bzl)-Pam Resint-Butyloxycarbonyl-O-Benzyl-l-Threonine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPT-1470-PI4 °C

1 g5 g

Boc-Trp(CHO)-Pam Resin Nα-t-Butyloxycarbonyl-Nin-Formyl-l-Tryptophan-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPW-1415-PI4 °C

1 g5 g

Boc-Tyr(Br-Z)-Pam Resin t-Butyloxycarbonyl-O-2-Bromobenzyloxycarbonyl-l-Tyrosine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPY-1414-PI4 °C

1 g5 g

Boc-Tyr(Cl2-Bzl)-Pam Resin t-Butyloxycarbonyl-O-2,6-Dichlorobenzyl-l-Tyrosine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPY-1419-PI4 °C

1 g5 g

Boc-Val-Pam Resin t-Butyloxycarbonyl-l-Valine-Pam Resin Divinylbenzene 1%, 200-400 mesh

RPV-1405-PI4 °C

1 g5 g

CLEAR-OXTM are found in the Specialty Products and Services Section on page 232.

Fmoc-Amino Acid-Wang Resinsp-Alkoxybenzyl Alcohol Resin Fmoc-amino acid resins are supplied with their exact substitution levels. Fmoc-d-amino acids, or unusual Fmoc amino acids attached to the Wang resin are available upon request..

Unsubstituted Resin OH CH2 O CH2 P

Fmoc Amino Wang ResinFmoc-Ala-Wang Resin9-Fluorenylmethoxycarbonyl- l-Alanine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFA-1306-PI4 °C

1 g5 g

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

290 Order Hotline 1-800-777-4779 502-266-8787

Fmoc-β-Ala-Wang Resin9-Fluorenylmethoxycarbonyl-β-Alanine- p-Alkoxybenzyl Alcohol Resin (0.4-0.7 meq/g) Divinylbenzene 1%, 100-200 mesh

RFX-1344-PI4 °C

[Higher Substitution]

1 g5 g

Fmoc-β-Ala-Wang Resin9-Fluorenylmethoxycarbonyl-β-Alanine- p-Alkoxybenzyl Alcohol Resin (0.1-0.2 meq/g) Divinylbenzene 1%, 100-200 mesh

RFX-1345-PI4 °C

[Lower Substitution]

1 g5 g

Fmoc-Asn(Trt)-Wang ResinNα-9-Fluorenylmethoxycarbonyl-Nβ-Trityl- l-Asparagine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFN-1354-PI4 °C

1 g5 g

Fmoc-Asp(OtBu)-Wang Resin9-Fluorenylmethoxycarbonyl-l-Aspartic Acid- β-t-Butyl Ester-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFD-1313-PI4 °C

1 g5 g

Fmoc-Cys(tBu)-Wang Resin9-Fluorenylmethoxycarbonyl- S-t-Butyl-l-Cysteine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFC-1341-PI4 °C

1 g5 g

Fmoc-Cys(Trt)-Wang Resin 9-Fluorenylmethoxycarbonyl-S-Trityl- l-Cysteine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFC-1318-PI4 °C

1 g5 g

Fmoc-Cys(Xan)-Wang Resin 9-Fluorenylmethoxycarbonyl-S-Xanthyl-l-Cysteine- p-Alkoxyben-zyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFC-1319-PI4 °C

1 g5 g

Fmoc-Glu(OtBu)-Wang Resin9-Fluorenylmethoxycarbonyl-l-Glutamic Acid- γ-t-Butyl Ester-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFE-1320-PI4 °C

1 g5 g

Fmoc-d-Glu(OtBu)-Wang ResinDivinylbenzene 1%, 100-200 mesh

RFE-1358-PI4 °C

1 g5 g

Fmoc-Gln(Trt)-Wang Resin Nα-9-Fluorenylmethoxycarbonyl-Nγ-Trityl-l-Glutamine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFQ-1355-PI4 °C

1 g5 g

Fmoc-Gly-Wang Resin9-Fluorenylmethoxycarbonyl-Glycine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFG-1301-PI4 °C

1 g5 g

NEW!


TOO


Order Hotline 1-800-777-4779 502-266-8787 291

PRODUCT CODE QTYFmoc-His(Trt)-Wang Resin

Nα-9-Fluorenylmethoxycarbonyl-Nim-Trityl-l-Histidine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFH-1340-PI4 °C

1 g5 g

Fmoc-lle-Wang ResinNim-9-Fluorenylmethoxycarbonyl-l-lsoleucine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFI-1324-PI4 °C

1 g5 g

Fmoc-Leu-Wang Resin 9-Fluorenylmethoxycarbonyl-l-Leucine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFL-1325-PI4 °C

1 g5 g

Fmoc-Lys(Boc)-Wang Resin9-Fluorenylmethoxycarbonyl-Nε-t-Butyloxycarbonyl-l-Lysine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFK-1326-PI4 °C

1 g5 g

Fmoc-Met-Wang Resin9-Fluorenylmethoxycarbonyl-l-Methionine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFM-1303-PI4 °C

1 g5 g

Fmoc-Phe-Wang Resin9-Fluorenylmethoxycarbonyl-l-Phenylalanine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFF-1330-PI4 °C

1 g5 g

Fmoc-Pro-Wang Resin9-Fluorenylmethoxycarbonyl-l-Proline-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFP-1331-PI4 °C

1 g5 g

Fmoc-Ser(tBu)-Wang Resin9-Fluorenylmethoxycarbonyl-O-t-Butyl-l-Serine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFS-1333-PI4 °C

1 g5 g

Fmoc-Thr(tBu)-Wang Resin9-Fluorenylmethoxycarbonyl-O-t-Butyl-l-Threonine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFT-1300-PI4 °C

1 g5 g

Fmoc-Trp(Boc)-Wang ResinNα-9-Fluorenylmethoxycarbonyl-Nin -t-Butyloxycarbonyl-l-Tryptophan-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFW-1342-PI4 °C

1 g5 g

Fmoc-Trp-Wang Resin 9-Fluorenylmethoxycarbonyl-l-Tryptophan-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFW-1335-PI4 °C

1 g5 g

Fmoc-Tyr(tBu)-Wang Resin9-Fluorenylmethoxycarbonyl-O-t-Butyl-l-Tyrosine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFY-1337-PI4 °C

1 g5 g

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

292 Order Hotline 1-800-777-4779 502-266-8787

Fmoc-Val-Wang Resin9-Fluorenylmethoxycarbonyl-l-Valine-p-Alkoxybenzyl Alcohol Resin Divinylbenzene 1%, 100-200 mesh

RFV-1339-PI4 °C

1 g5 g

Fmoc-Amino Acid-Rink-Amide MBHA ResinsSubstitution range 0.2 meq/g - 0.6 meq/g

Fmoc-Ala-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFA-10010-PI4 °C

1 g5 g

Fmoc-β-Ala-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFX-10011-PI4 °C

1 g5 g

Fmoc-Arg(Pbf)-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFR-10012-PI4 °C

1 g5 g

Fmoc-Asn(Trt)-Rink-Amide MBHA Resin Divinylbenzene 1%, 100-200 mesh

RFN-10013-PI4 °C

1 g5 g

Fmoc-Asp(OtBu)-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFD-10014-PI4 °C

1 g5 g

Fmoc-Cys(Trt)-Rink-Amide MBHA Resin Divinylbenzene 1%, 100-200 mesh

RFC-10015-PI4 °C

1 g5 g

Fmoc-Gln(Trt)-Rink-Amide MBHA Resin Divinylbenzene 1%, 100-200 mesh

RFQ-10019-PI4 °C

1 g5 g

Fmoc-Glu(OtBu)-Rink-Amide MBHA Resin Divinylbenzene 1%, 100-200 mesh

RFE-10020-PI4 °C

1 g5 g

Fmoc-Gly-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFG-10021-PI4 °C

1 g5 g

Fmoc-His(Trt)-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFH-10022-PI4 °C

1 g5 g

Fmoc-Ile-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFI-10023-PI4 °C

1 g5 g

Fmoc-Leu-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFL-10024-PI4 °C

1 g5 g

Fmoc-Lys(Boc)-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFK-10025-PI4 °C

1 g5 g

Fmoc-Met-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFM-10026-PI4 °C

1 g5 g

Fmoc-Phe-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFF-10027-PI4 °C

1 g5 g

Fmoc-Pro-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFP-10029-PI4 °C

1 g5 g


TOO


Order Hotline 1-800-777-4779 502-266-8787 293

PRODUCT CODE QTYFmoc-Ser(tBu)-Rink-Amide MBHA Resin

Divinylbenzene 1%, 100-200 meshRFS-10030-PI

4 °C

1 g5 g

Fmoc-Thr(tBu)-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFT-10031-PI4 °C

1 g5 g

Fmoc-Trp-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFW-10032-PI4 °C

1 g5 g

Fmoc-Trp(Boc)-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFW-10033-PI4 °C

1 g5 g

Fmoc-Tyr(tBu)-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFY-10034-PI4 °C

1 g5 g

Fmoc-Val-Rink-Amide MBHA ResinDivinylbenzene 1%, 100-200 mesh

RFV-10035-PI4 °C

1 g5 g

PEPT

IDES

INTE

RNAT

IONA

LTO

OLS

for

PEP

TIDE

SYN

THES

IS

294 Order Hotline 1-800-777-4779 502-266-8787

TentaGel Resins from Rapp Polymere, GermanyTentaGel is a gelatinous resin, an important support for solid phase synthesis. TentaGel resins are constructed with a backbone of low crosslinked polystyrene grafted with polyoxyethylene (polyethylene glycol) as shown below. The typical chain length of POE (n) is approximately 68 ethylene oxide units or an average MW of 3000. This long chain creates a spacer that effec-tively separates the reactive site (X) from the crosslinked backbone matrix.

What is the difference between TentaGel R and TentaGel S? TentaGel S is the base resin; it is available in a variety of functional groups and in 90 μm or 130 μm sizes. TentaGel R is specially modified with an optimized ratio of PEG attached to the polystyrene core. This results in improved swelling properties and its structure helps overcome peptide aggregation problems. For this reason TentaGel R (“Research” grade) is often used for the synthesis of long or dif-ficult peptide sequences. TentaGel R is a softer gel than TentaGel S. While it can be used in continuous flow synthesizers, a lower flow rate (10-15 mL/min) is recommended. Both resins are appropriate for Fmoc-chemistry.This polystyrene-based support with polyoxyethylene arms is an excellent resin for preparation of peptide organic libraries on a solid support. The highly uniform beads and compatible oxy-ethylene spacer make this support quite useful for testing mixtures directly on the solid support. The water compatibility permits use in numerous biological applications. Resins are available in two bead sizes (90 and 130 microns).Please inquire for additional products of Rapp Polymere.

Table: TentaGel Characteristics vs. Bead Size

Resin SubstitutionFunctional Group Beads/g

Capacity/ Bead [nmol]

(for Polystyrene, = 1 mmol/g)

Capacity/ Bead [nmol]

(for TentaGel S = 0.28 mmol/g)

TentaGel S ResinNH2 90 μm

-O-CH2-CH2-NH2 2.86 x 106 0.4 0.1

TentaGel S ResinNH2 130 μm

-O-CH2-CH2-NH2 782,770 1.3 0.35

Please note: The above resin choices have been especially selected for combinatorial chemistry or solid phase organic synthesis applications.


TOO


Order Hotline 1-800-777-4779 502-266-8787 295

PRODUCT CODE QTY

TentaGel S - Base ResinsThe typical capacity range for our TentaGel base resins is 0.2-0.3 meq/g. The TentaGel S base resins are available with several different derivative choices. Please inquire for further information.

TentaGel S Br Resin(90 μm) -O-CH2-CH2-Br

RTS-9901-PI4 °C

1 g5 g25g

TentaGel S NH2 Resin(90 μm) -O-CH2-CH2-NH2

RTS-9902-PI4 °C

1 g5 g25g

TentaGel S COOH Resin

(90 μm)-NH-CO-CH2-CH2-COOH

RTS-9903-PI4 °C

1 g5 g25g

TentaGel S SH Resin(90 μm) -CH2-CH2-SH

RTS-9904-PI4 °C

1 g5 g25g

TentaGel S SH Resin(130 μm) -CH2-CH2-SH

RTS-9905-PI4 °C

1 g5 g25g

TentaGel HL (High Load) Resins TentaGel HL (High Load) (mean particle size 75 μm: capacity 0.4-0.6 meq/g)

TentaGel HL-OH Resin-O-CH2-CH2-OH

RTH-9330-PI4 °C

1 g5 g

TentaGel HL-Br Resin-O-CH2-CH2-Br

RTH-9331-PI4 °C

1 g5 g

TentaGel HL-NH2 Resin -O-CH2-CH2-NH2 RTH-9332-PI

4 °C

1 g5 g

TentaGel HL-COOH Resin -NH-CO-CH2-CH2-COOH

RTH-9333-PI4 °C

1 g5 g

TentaGel HL-SH Resin-CH2-CH2-SH

RTH-9334-PI4 °C

1 g5 g

TentaGel HL (High Load) (mean particle size 110 μm: capacity 0.4-0.6 meq/g)

TentaGel HL-OH Resin-O-CH2-CH2-OH

RTH-9335-PI4 °C

1 g5 g

TentaGel HL-BR Resin-O-CH2-CH2-Br

RTH-9336-PI 4 °C

1 g5 g

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

296 Order Hotline 1-800-777-4779 502-266-8787

TentaGel NH2 Resin-O-CH2-CH2-NH2

RTH-9337-PI4 °C

1 g5 g

TentaGel HL-COOH Resin -NH-CO-CH2-CH2-COOH

RTH-9338-PI4 °C

1 g5 g

TentaGel HL-SH Resin-CH2-CH2-SH

RTH-9339-PI4 °C

1 g5 g

TentaGel HL (High Load) with Handles mean particle size 75 μm: capacity 0.3-0.4 meq/g

TentaGel HL PHB Resin RTH-9340-PI4 °C

1 g5 g

TentaGel HL HMBA Resin RTH-9341-PI4 °C

1 g5 g

TentaGel HL RAM Resin RTH-9342-PI4 °C

1 g5 g

TentaGel MacrobeadsThese resins are designed for single bead synthesis and single bead analysis. (mean particle size 280-320 μm: capacity 0.2-0.3 meq/g)

TentaGel Macrobead-OH Resin -O-CH2-CH2-OH

TMB-9343-PI4 °C

1 g5 g

TentaGel Macrobead-Br Resin -O-CH2-CH2-Br

TMB-9344-PI4 °C

1 g5 g

TentaGel Macrobead-NH2 Resin -O-CH2-CH2-NH2

TMB-9345-PI4 °C

1 g5 g

TentaGel Macrobead-COOH Resin -NH-CO-CH2-CH2-COOH

TMB-9346-PI4 °C

1 g5 g

TentaGel Macrobead-SH Resin -CH2-CH2-SH

TMB-9347-PI4 °C

1 g5 g

TentaGel Macrobead Resins with HandlesParticle size 280-320 μm; capacity: 0.2-0.3 meq/g. Additional particle sizes available, please inquire.

TentaGel Macrobead PHB Resin

TMB-9348-PI4 °C

1 g5 g

TentaGel Macrobead HMBA Resin

TMB-9349-PI4 °C

1 g5 g

TentaGel Macrobead RAM Resin

TMB-9350-PI4 °C

1 g5 g


TOO


Order Hotline 1-800-777-4779 502-266-8787 297

PRODUCT CODE QTYTentaGels MicrosphereTentaGel Microsphere NH2 Resin

Particle size 30 μm mono-sized; capacity: 0.2-0.3 meq/g.

-O-CH2-CH2-NH2

RTM-9401-PI4 °C

5 g

TentaGel S NH2 ResinParticle size 130 μm; capacity: 0.2-0.35 meq/g This resin is used in combi-natorial chemistry.

-O-CH2-CH2-NH2

RTS-9932-PI 4 °C

1 g5 g

25 g

TentaGel R NH2 ResinParticle size 90 μm; capacity: 0.18-0.22 meq/g This resin is specially designed for difficult and long sequences.

RTS-9992-PI4 °C

1 g5 g

25 g

Peptide Synthesis - for preparation of peptide acidsTentaGel S PHB Resin

Particle size 90 μm; capacity: 0.2-0.3 meq/g O CH2 OHTentaGel

TentaGel S PHB Resin RTS-9913-PI

RTS-9913-PI4 °C

1 g5 g

25 g

TentaGel R PHB ResinParticle size 90 μm; capacity: 0.18-0.23 meq/gThis resin is specially designed for difficult and long sequences.

RTS-9993-PI4 °C

1 g5 g

25 g

Peptide Synthesis-for preparation of peptide amidesTentaGel S RAM Resin

(Rink-type) (90 μm) 0.2-0.27 meq/gRTS-9923-PI

4 °C

1 g5 g

25 g

TentaGel R RAM Resin(Rink-type) (90 μm) 0.18-0.22 meq/g This resin is specially designed for difficult and long sequences.

RTS-9995-PI4 °C

1 g5 g

25 gCH2 O CHC

O NH fmo

OMe

Fmoc

OMe

tentagel r ram resin

Immunization & AntibodiesTentaGel PAP Resin

(90 μm) 0.2-0.25 meq/g Using this resin, cleavage yields the POE-peptide

PS POE-CH2-CH2-NH2 RTS-9002-PI4 °C

1 g5 g

25 gconjugates. Even less soluble peptides may be completely solubilized with this linker.

Cleavage point

ww

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

298 Order Hotline 1-800-777-4779 502-266-8787

TentaGel B Resins (Bifunctional)TentaGel B Particle size 90 μm; capacity: 0.2-0.3 meq/g

INSIDE OUTSIDETentaGel B NH2 / Boc Resin

(90 μm)NH2 Boc

RTS-9321-PI 4 °C

5 g

TentaGel B Boc / NH2 Resin(90 μm)

Boc NH2

RTS-9312-PI4 °C

5 g

TentaGel B Resin Particle size 130 μm; Capacity: 0.2-0.3 meq/g

TentaGel B NH2 / Boc Resin

(130 μm)NH2 Boc

RTS-9311-PI4 °C

5 g

TentaGel B Boc / NH2 Resin(130 μm)

Boc NH2

RTS-9912-PI4 °C

5 g

*TentaGel B resins represent a line of bifunctional resins that are useful for orthogonal synthesis.References

E. Bayer, W. Rapp, In, Peptide Chemistry 1987, Ed. T. Shiba and S.Sakakibara, Protein Research Foundation, Osaka 1988, 263. W. Bessler, et al., J. Immunol. 135, 1900-1905 (1985). W. Rapp, et al., Innovations and Perspectives in Solid Phase Synthesis, R. Epton, Ed., SPCC(UK) Ltd., Birmingham, 1991.Please inquire for additional products of Rapp Polymere.

MAPS (Multiple Antigen Peptide Systems) ResinsIn 1988, James P. Tam introduced the Multiple Antigenic Peptides (MAPs) concept to enhance antibody generation against a synthetic peptide multiplet and to avoid the need for conjugation to carrier protein.* Since then, researchers have found even more uses for these branched lysine cores to generate peptide tetramers, octamers or other novel species. Orthogonally branched analogs (RBL-1433-PI and RBL-1428-PI) are especially useful for preparing sequences with multiple epitopes.*J.P. Tam, Proc. Natl. Acad. Sci. USA, 85, 5409-5413 (1988).

Base MAP CoresFmoc-β-Ala-Wang Resin


RFX-1345-PI4 °C

1 g5 g

Boc-β-Ala-Pam Resint-Butyloxycarbonyl-β-Alanine-Pam Resin Divinylbenzene 1%, 200-400 mesh NH2: 0.1-0.3 meq/g

RPB-1421-PI 4 °C

1 g5 g

25 g

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out


TOO


Order Hotline 1-800-777-4779 502-266-8787 299

PRODUCT CODE QTY4 Branch MAP CoresFmoc4-Lys2-Lys-β-Ala-CLEAR Acid Resin

100-200 meshCFM-1214-PI

4 °C

1 g

Fmoc4-Lys2-Lys-β-Ala-Wang ResinDivinylbenzene 1%, 100-200 mesh NH2: 0.2-0.6 meq/g

RFX-1390-PI4 °C

1 g5 g

(Boc-Lys(Fmoc))2-Lys-β-Ala-Pam ResinDivinylbenzene 1%, 200-400 mesh NH2: 0.2-0.6 meq/g

RBL-1433-PI4 °C

1 g5 g

Boc4-Lys2-Lys-β-Ala-Pam ResinDivinylbenzene 1%, 200-400 mesh NH2: 0.2-0.6 meq/g

RBL-1437-PI4 °C

1 g5 g

Boc4-Lys2-Lys-Cys(Acm)-β-Ala-Pam ResinDivinylbenzene 1%, 200-400 mesh NH2: 0.2-0.6 meq/g

RBL-1443-PI4 °C

1 g5 g

8 Branch MAP CoresFmoc8-Lys4-Lys2-Lys-β-Ala-CLEAR Acid Resin

100-200 meshCFM-1218-PI

4 °C

1 g

Fmoc8-Lys4-Lys2-Lys-β-Ala-Wang ResinDivinylbenzene 1%, 100-200 mesh NH2: 0.4-0.8 meq/g

RFX-1395-PI4 °C

1 g5 g

Boc8-Lys4-Lys2-Lys-β-Ala-Pam ResinDivinylbenzene 1%, 200-400 mesh NH2: 0.4-0.8 meq/g

RBL-1439-PI4 °C

1 g5 g

(Boc-Lys(Fmoc))4-Lys2-Lys-β-Ala-Pam ResinDivinylbenzene 1%, 200-400 mesh NH2: 0.4-0.8 meq/g

RBL-1428-PI4 °C

1 g5 g

Boc8-Lys4-Lys2-Lys-Cys(Acm)-β-Ala-Pam ResinDivinylbenzene 1%, 200-400 mesh NH2: 0.4-0.8 meq/g

RBL-1441-PI4 °C

1 g5 g

Resins for Protein LigationS-Trityl-β-Mercaptopropionyl-AM Resin

Divinylbenzene 1%, 100-200 meshRAM-1055-PI

4 °C

5 g25 g

S-Trityl-β-Mercaptopropionyl-Leu-Pam ResinDivinylbenzene 1%, 100-200 mesh

RPL-1458-PI4 °C

1 g5 g

S-Trityl-β-Mercaptopropionyl-p-Methyl-Benzhydrylamine Resin

Divinylbenzene 1%, 100-200 mesh

RMB-1058-PI4 °C

5 g25 g

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

300 Order Hotline 1-800-777-4779 502-266-8787

ReagentsCondensation Reagents, Additives, Linkers, and Other Reagents for Peptide SynthesisBiotin-ONpBiotin 4-Nitrophenyl Ester

(M.W. 365.41) C16H19N3O5S [33755-53-2]

D. Baumeister, Intl J of Peptide Res and Ther, 11,139 (2005).D.F. Winkler and P.L. McGeer, Proteomics, 8, 961 (2008).

BDN-6004-PI-20°C

1 g5 g

Biotin-OSud-Biotin-N-hydroxysuccinimide Ester (M.W. 341.39) C14H19N3O5S [35013-72-0]

D.F. Winkler and P.L. McGeer, Proteomics, 8, 961 (2008).

BOS-6003-PI-20°C

1 g5 g

BOP Reagent Benzotriazol-1-yl-oxy-tris (dimeth-ylamino) phosphonium hexafluo-rophosphate (M.W. 442.29) C12H22N6OF6P2 [56602-33-6]

NN

N

O

P

BOP KBP-1060-PI

+ PF6-

KBP-1060-PI 5 g25 g

100 g

DCCD Dicyclohexylcarbodiimide (M.W. 206.33) C13H22N2 [538-75-0] Crystalline MassJ.C. Sheehan and G.P. Hess, J. Amer Chem. Soc., 77, 1065 (1955).

N NC

DCCD KDC-1001-PI

KDC-1001 4 °C

100 g500 g

DCCD Dicyclohexylcarbodiimide (M.W. 206.33) C13H22N2 [538-75-0] Redistilled for Solid Phase Synthesis

KDC-1023 4 °C

100 g500 g

J.C. Sheehan and G.P. Hess, J. Amer. Chem. Soc., 77, 1065 (1955). R.S. Hodges and R.B. Merrifield, Int. J. Pept. Protein Res., 6, 397 (1974).

DOTA(tBu)3-OH 4,7,10-tricarboxymethyl-tert-butyl ester 1,4,7,10-tetraazacyclodo-decane-1-acetate DOTA-tris(tBu)ester (M.W. 572 • 75) C28H52N4O8 [137076-54-1]Protected DOTA for Peptides and Antibody Labelling

M. Ginj, Tetrahedron Letters, 46(16), 2821 (2005). I. Dijkgraaf, Organic & Biomolecular Chemistry, 5(6), 935 (2007). S. Roosenburg, Bioconjugate Chemistry, 21(4), 663 (2010).

DTB-5003-PI4 °C

1 g5 g

NEW!

NEW!

NEW!

4 °C

4 °C

4 °C

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out


TOO


Order Hotline 1-800-777-4779 502-266-8787 301

PRODUCT CODE QTYEDDNP

N-(2,4-Dintrophenyl)-ethylenediamine (M.W. 226.19) C8H10N4O4 [28767-75-1]

EDP-5012-PI4 °C

1 g5 g

EEDQ N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (M.W. 247.29) C14H17NO3 [16357-59-8]

KEE-10244 °C

25 g100 g

B. Belleau and G. Malek, J. Am. Chem. Soc., 90, 1651 (1968). H. Yajima and H. Kawatani, Chem. Pharm. Bull., 19, 1905 (1971).

Fmoc-OSu 9-Fluorenylmethoxycarbonyl-N-succinimide ester M.W. 337.33) C19H15NO5 [82911-69-1]A. Paquet, Can. J. Chem., 60, 976 (1982).

NO O

O

O

O

Fmoc-OSu KFS-1042-PI

KFS-1042-PI 5 g25 g

100 g

HBTU Reagent N-HBTU 1-[bis(Dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate 3-oxide (M.W. 379.25) C11H16N5OPF6 [94790-37-1]

NN

N

O

NN

PF6-

HBTU KHB-1065-PI

+

+ -

KHB-1065-PI4 °C

5 g25 g

100 g

HCTU Reagent1H-Benzotriazolium-1-[bis(dimethylamino)methylene]-5-chloro-hexafluorophosphate-(1-),3-oxide (M.W. 413.69) C11H15N5OClPF6 [330645-87-9] Coupling Reagent Cl N

NN

O

NN

PF6-

HCTU KHC-1018-PI

+

+ -

KHC-1018-PI4 °C

5 g25 g

100 g

6-Cl-HOBt Reagent1-Hydroxy-6-chlorobenzotriazole (M.W. 169.57) C6H4N3OCI [2619-18-96] Efficient reagent to suppress racemization and to enhance coupling in peptide synthesis

Cl NN

N

OH

6-Cl--HOBt, KHC-1009-PI

KCH-1009-PI 4 °C

25 g100 g

HOBt Anhydrous 1-Hydroxybenzotriazole anhy-drous (M.W. 135.13) C6H5N3O [2592-95-2] N

NN

OH

HOBt, KBT-1029-PI

KBT-1029-PI4 °C

25 g100 g

NEW!

4 °C4 °C

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

bobbrousseau

Cross-Out

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

302 Order Hotline 1-800-777-4779 502-266-8787

HOSu N-Hydroxysuccinimide (M.W. 115.09) C4H5NO3 [6066-82-6]G.W. Anderson, J.E. Zimmerman, and F.M. Callahan, J. Amer. Chem. Soc., 86, 1839 (1964)

N

O

O

OH

N-HOSU, KSU-1011-PI

KSU-1011 RT

25 g100 g

Marfey’s Reagent N-(2,4-Dinitro-5-fluorophenyl)-l-alaninamide

P. Marfey, Carlsberg Res. Commun., 49, 591 (1984).

KMF-3870-PI 4 ÁC

25 mg100 mg500 mg

Nefken’s Reagent N-Carboethoxy phthalimide (M.W. 219.19) C11H9NO4 [22509-74-6]G.H.L. Nefkens, Nature, 185, 309 (1960).

KNF-1033 4 °C

25 g100 g500 g

Pam Ester 4-(Bromomethyl)phenylacetic acid phenacyl ester (M.W. 347.22) A useful intermediate for synthe-sis of Pam resins

CH2BrCH2

O O

OC CCH2

KPE-1068-PI 4 °C

1 g5 g

25 g

TBTU Reagent 1-[bis(Dimethylamino)Methylene]-1H-benzotriazolium tetrafluorobo-rate 3-oxide (M.W. 321.13) C11H16N5OBF4 [125700-67-6] N

NN

O

NN

+

+ BF4-

TBTU KTB-1066-PI

-

KTB-1066-PI 4 °C

25 g100 g500 g

TCTU Reagent1-H-Benzotriazolium-1-[bis(dimethylamino)methylene]-5-chloro-tetrafluoroborate-(1-), 3-oxide (M.W. 355.57) C11H15BClF4N5O[330641-16-2] Cl N

NN

O

NN

+

+

BF4-

TCTU KTC-1010-PI

-

KTC-1010-PI4 °C

25 g100 g


TOO


Order Hotline 1-800-777-4779 502-266-8787 303

PRODUCT CODE QTYUDP-β-L-Arabinofuranose Uridine-5’-diphospho-β-L-arabinofuranose

(Triethylammonium Form) (M.W. 536.28) C14H22N2O16P2 Synthetic Product

CKG-23005-s-20 °C

0.1 mgvial

Reagent for Research in Arabinofuranose Biogenesis in Plants T. Konishi, H. Ono, M. Ohnishi-Kameyama, S. Kaneko, and T. Ishii, Plant Physiol., 141, 1098 (2006). (Substrate for Arabinofuranosyltransferase) T. Konishi, T. Takeda, Y. Miyazaki, M. Ohnishi-Kameyama, T. Hayashi, M.A. O'Neill, and T. Ishii, Glycobiol., 17, 345 (2007). (Use in Enzymatic Furanose-Pyranose Interconversion) Q. Zhang and H.-W. Liu, Bioorg. Med. Chem. Lett., 11, 145 (2001). (Chem. Synthesis)

WSCD • HCl Water-Soluble Carbodiimide hydrochloride

NN

NC

WSCD.HCl KWS-1030-PI

•HCl

KWS-10304 °C

5 g25 g

Boc-Amino Acid-Pam Linker ReagentsBoc-Glu(OBzl)-Pam Acid

4-(t-Butyloxycarbonyl-(g-benzyl)-glutamyloxymethyl]-phenylacetic acid Useful Reagent for Pam Resin Preparation (M.W. 485.54) C16H21NO8

BEP-5482-PI4 °C

1 g5 g

Boc-Gly-Pam Acid4-(t-Butyloxycarbonyl-glycyloxymethyl)-phenylacetic acid (M.W. 323.35) C16H21NO6 Useful Reagent for Pam Resin Preparation

BGP-5484-PI4 °C

1 g5 g

Boc-Leu-Pam Acid4-(t-Butyloxycarbonyl-Leucyloxymethyl)-phenylacetic acid (M.W. 379.46) C20H29NO6 Useful Reagent for Pam Resin Preparation

BLP-5487-PI4 °C

1 g5 g

Boc-Val-Pam Acid4-(t-Butyloxycarbonyl-valyloxymethyl)-phenylacetic acid (M.W. 365.43) C19H27NO6 Useful Reagent for Pam Resin Preparation

BVP-5499-PI4 °C

1 g5 g

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

304 Order Hotline 1-800-777-4779 502-266-8787

COMU (1-[1-(Cyano-2-ethoxy-2-Oxoethylideneaminooxy)-Dimethylamino-Morpholino]-Uronium Hexafluorophosphate) allows for the use of one equivalent of base during the coupling protocol, thus contributing to the reduction of potential racemization in the growing peptide chain without impairing the reaction rate or the overall yield of the coupling process. Additionally, COMU is highly soluble in DMF and NMP, safe, and non-allergenic, which makes it a compelling reagent alternative.

COMU Reagent1-[1-(Cyano-2-ethoxy-2-Oxoethylideneaminooxy)-dimethylamino-Morpholino]-Uronium hexafluorophosphate (M.W. 428.27) C12H19N4O4PF6 [1075198-30-9] Coupling Reagent COMU allows for the use of one equivalent of base during the coupling protocol, thus contributing to the reduction of potential racemization in the growing peptide chain without impairing the reaction rate or the overall yield of the coupling process.A. El-Faham and F.Albericio, J. Org. Chem., 73, 2731 (2008). A.El-Faham, et al., Poster P10103-039 presented at the 30th EPS, Helsinki, 2008).

KCM-1015-PI4 °C

5 g25 g

100 g

C2H5OOC

N

CN

O

N+

N

OPF6-

K?CM-1015-PI

Protein Ligation Synthesis ReagentsAc-S-Mpa-OPfp

Acetyl-S-β-mercaptopropionic acid pentafluorophenyl ester(M.W. 300.21) C10H5O3SF5

ASX-5049-PI4 ÁC

1 g5 g

S-Acm-β-Mercaptopropionic AcidS-acetamidomethyl-β-mercaptopropionic acid(M.W. 177.22) C6H11NO3S [52574-08-0]

SAM-5510-PI4 °C

1 g5 g

Maleimidopropionic Acid(M.W. 169.14) C7H7NO4 [7423-55-4]

MPA-5011-PI 1 g5 g

S-p-Me-Bzl-β-Mercaptopropionic AcidS-p-methylbenzyl-β-mercaptopropionic acid(M.W. 210.29) C11H14O2S [78981-22-3]

AXP-5030-PI 5 g25 g

S-trityl-β-Mercaptopropionic Acid(M.W. 348.47) C22H20O2S [27144-18-9]

ASX-5047-PI 1 g5 g

S-trityl-Mercaptoacetic Acid(M.W. 334.44) C21H18O2S [68-11-1]

ASX-5048-PI 1 g5 g

S-Acm-PmpS-acetamidomethyl-β-mercapto-β, β-Cyclopentamethylenepropionic acid(M.W. 245.34) C11H19NO3S

ASX-5045-PI 4 ÁC

1 g5 g

S-p-Me-Bzl-Pmpβ-(S-4-methylbenzylmercapto)-β, β-Cyclopentamethylenepropionic acid(M.W. 278.40) C16H22SO2

ASX-5042-PI 1 g5 g

NEW!

4 °C

4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C

4 °C4 °C


TOO


Order Hotline 1-800-777-4779 502-266-8787 305

PRODUCT CODE QTYPyClocK®

HCTU and TCTU, based on Cl-HOBt, are good alternatives to HBTU/TBTU. The presence of the Cl atom results in a better leaving group since it is more acidic than HOBt (pKa: 3.35 for Cl-HOBt and 4.60 for HOBt); therefore the active esters are more reactive than OBt esters.1 PI proudly introduces a new coupling reagent, PyClocK, the phosphonium salt of Cl-HOBt. PyClocK® has been reported to be faster than PyBOP® in activating hindered amino acids such as Fmoc-Aib-OH; and in some cases its reactivity was close to the most active reagent, PyAOP®. PyClocK® can not react with the free amine function and therefore does not terminate the growing peptide as the aminium salts do, through the formation of guanidine derivatives. Thus, PyClocK is especially useful for slow coupling reactions and could be used in excess to assure complete activation of the carboxylic function. 1. O. Marder. F. Albericio, Chimica Oggi, 21, 6 (2003).PyClocK® is a proprietary product of Luxembourg Industries Ltd. PyBOP® is a registered trademaek of Merck Biosciences AG. PyAOP® is a registered trademaek of Applied BioSystems.

Synthesis on Hindered Derivatives of Leu-EnkephalinalinamidePyClocK® PyBOP® PyAOP®

H-Tyr-Aib-Aib-Phe-Leu-NH2 97.24 85.11 99.47

Impurity: H-Tyr-Aib-Phe-Leu-NH2

2.76 14.89 0.53

Stability: PyBOP® > PyClocK® > PyAOP®

Reactivity: PyAOP® > PyClocK® > PyBOP®

PyClocK®

6-Chloro-benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (M.W. 554.85) C18H27N6OF6ClP2 Coupling Reagent for Peptide Synthesis

KPC-1016-PI 5 g25 g

N

NN

OCl

N

N

PF6 -

N

+P

PyClocK KPC-1016-PI

NEW! 4 °C4 °C

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

306 Order Hotline 1-800-777-4779 502-266-8787

dPEG®

dPEG® Biotinylation Reagents• Very water soluble, hydrophilic and eliminates non-specific binding.• Non-antigenic and non-immunogenic spacer arm• The dPEG® pegylation spacer and its properties eliminates aggregation and precipitation when labeling antibodies and other biological materials, and will also significantly increase S/N in analytical applications as well.

Reference:Greg T. Hermanson, Bioconjugate Techniques, 2nd Ed, Academic Press, Inc., San Diego, CA, (2008).

Protocol:See Hermanson pg. 728 for a typical protocol for a antibody or protein biotinylation using an in situ activated form of DPG-5706-PI. Generally customers use this when they have their favorite way of activating the acid, as opposed to using our dPEG®

12 pegylation spacer containing biotin reagent. The reagent can be pre-dissolved in an organic solvent or can be directly dissolved in your reaction medium based on its inherent water solubility.

NHS-dPEG®4 Biotin

Chain length from amide to terminal carbonyl is 19.2 Angstroms and 16 atoms spacer Ideal spacer length for binding streptavidin conjugates (M.W. 588.67) Amine reactive biotinylation reagent with a dPEG® pegylation spacer arm; activate in situ

• The dPEG® pegylation spacer and its properties eliminate aggregation and precipitation when labeling antibodies and other biological materials, and will also significantly increase S/N in analytical applications as well.

DPG-5701-PI4 °C

50 mg1 g

OO

O

S

NH

ONH

NH

O

OO

ON

O

O

10200

NHS-dPEG®12 Biotin

47.6 Angstrom and 40 atoms spacer (M.W. 941.09) Amine reactive biotinylation reagent with a dPEG® pegylation spacer arm; activate in situ

DPG-5703-PI4 °C

50 mg1 g

HN

S

N

O

OO

OO

OO

ONH

OO

OO

O

ONHO O

OO

10198

NEW!

NEW!


TOO


Order Hotline 1-800-777-4779 502-266-8787 307

PRODUCT CODE QTYNHS-dPEG®

4 Biotinidase-Resistant BiotinAmine reactive biotinylation pegylation reagent with a dPEG®

4 spacer(M.W. 673.78)Amine Reactive Biotinylation ReagentD. Scott Wilbur, et al., Bioconjugate Chemistry, 17(6), 1514-1522 (2006).

DPG-5702-PI4 °C

50 mg 500 mg

1 g

NH

NH

OO

OO O

N

O

O OO

O

S

NH

NH

O

10202

• Amine reactive biotinylation pegylation reagent with a dPEG® spacer, the perfect length for most applications.• Biotindase resistant - vital especially for in vivo work or clinical analysis.• This reagent gives the spacer length with the pegylation arm for optimal biotin binding with streptavidin conjugates; chain length from amide to terminal carbonyl is 19.2 Angstroms. • Designed to be the same length as the LC-LC spacer, which is ideal for the streptavidin binding pocket.• Eliminates non-specific binding issues, things like aggregation and precipitation when labeling antibodies and other biological materials (a problem with conventional biotinylation reagents).

Fmoc-Amido-(dPEG®4 Biotin) Acid

Spacer properties: 18.1 Angstrom and 17 atoms spacer (M.W. 827.98)

DPG-5704-PI4 °C

50 mg 100 mg

1 g

O

NH

O

N

O

OHO

O

O O

O NH

OS

NH NH

O

10602

Biotinylation reagent in peptide synthesis, with built-in pegylation spacer arm for optimal Streptavidin binding

• An N-Fmoc protected hydrophilic, non-immunogenic biotinylation pegylation reagent for peptide synthesis.• Useful for incorporating the powerful dPEG®

4-biotin directly into the peptide synthesis, without having to label a side chain or label the N-terminus.• Incorporation of the dPEG®

4 spacer with the biotin will increase water solubility and reduce or eliminate aggregation, while having the length in the spacer to optimize the interaction with the avidin conjugate of your choice.

NEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

308 Order Hotline 1-800-777-4779 502-266-8787

dPEG® Biotin Acid• Imparted physical properties are the biotin same as the dPEG®

X NHS esters (DPG-5701-PI, DPG-5703-PI); the labeled compound becomes very hydrophilic because of the dPEG® pegylation spacer, making the biotin very available for streptavidin binding in the capture/binding step.• The DPG-5705-PI pegylation spacer is the same length as DPG-5701-PI and DPG-5703-PI, respectively, and its length is optimal for rapid and tight avidin/SA binding properties.• Very water soluble, hydrophilic and eliminates non-specific binding.• DPG-5703-PI has a longer 47.6 Angstrom spacer: the longer pegylation arm gives ready accessibility to the biotin by the streptavidin/avidin conjugate binding; also where the amine of the biotinylation site may be buried, the longer arm is ideal for giving accessibility to the binding conjugates.• Non-antigenic and non-immunogenic spacer arm.• The dPEG® pegylation spacer and its properties eliminates aggregation and precipitation when labeling antibodies and other biological materials, and will also significantly increase S/N in analytical applications as well.

dPEG®4 Biotin Acid

Chain length from amide to terminal carbonyl is 19.2 Angstroms and 16 atoms spacer(M.W. 491.60)

DPG-5705-PI4 °C

50 mg1 g

SOHN

H

OO

OO

ONH

NH

O O

10199dPEG®12 Biotin Acid

47.6 Angstrom and 40 atoms spacer (M.W. 844.02) Amine Reactive Biotinylation Reagent; Activate in situ

DPG-5706-PI4 °C

50 mg1 g

NH

O

S

NH

NH

O

OO

OO

OO

OO

OO

OO OH

O

10197NHS-Biotin(M.W. 341.38) Amine Reactive Label with Aliphatic SpacerGreg T. Hermanson, Bioconjugate Techniques, 2nd Ed, Academic Press, Inc., San Diego, CA, (2008).

• Efficient label for certain peptides and nucleic acids.• Permeates cell membranes..

DPG-5707-PI4 °C

100 mg1 g

N

NHNH

S

O

O

O O

O

10205NHS-LC-Biotin8.8 Angstrom spacer (M.W. 454.54)Amine Reactive Label with Extended Aliphatic Spacer

Greg T. Hermanson, Bioconjugate Techniques, 2nd Ed, Academic Press, Inc., San Diego, CA, (2008).

DPG-5708-PI 4 °C

50 mg1 g

N

NH

NH

S

O

NH

O

O

OO

O

10206•Contains extended spacer arm to enhance binding with streptavidin.•Requires use of DMF, but is more soluble than NHS-biotin.• 8.8 Angstrom hydrophilic spacer arm (non-dPEG®).

NEW!

NEW!

NEW!

NEW!


TOO


Order Hotline 1-800-777-4779 502-266-8787 309

PRODUCT CODE QTYCarbonyl / Carboxyl Reactive Reagents

• A carboxy protected dPEG®x amino acid pegylation reagent• dPEG® pegylation spacer and modifier with a reactive amine and a t-butyl protected carboxylic acid.• dPEG® pegylation spacer is extremely hydrophilic, will enhance the water solubility of a compound in which it is incorporated and reduce non-specific binding where applicable. The spacer is also non- immunogenic. The ester is both water soluble, as well as in common used organic solvents of moder- ate prolarity.• t-Butyl group: – Is easily removed with TFA (25% TFA in CH2Cl2, ice bath/0° C, takes about 5 h). – Provides a potentially powerful purification handle due to its hydrophobicity. Subsequently it is removed to perform additional chemistry. This applies best when using normal phase (e.g., silica gel) chromatography. – Neutralizes the zwitterion of the amino acid for better reactivity at the amine. – Reacts with carboxylic acids and other carbonyls.

Amino-dPEG®2 t-Butyl Ester

10.9 Angstroms and 10 atoms spacer (nitrogen to carbonyl carbon)(M.W. 233.30)Carboxy-Protected dPEG®

2 Amino Acid

DPG-5709-PI4 °C

100 mg500 mg

1 g

NH2

OO O

O

10264Amino-dPEG®4 t-Butyl Ester


4 Amino Acid

DPG-5711-PI4 °C

100 mg500 mg

1 g

NH2

OO

OO O

O

10221

Amino-dPEG®4 Methyl Ester Kit


4 Amino Acid Methyl protected dPEG® amino acid: dPEG® pegylation spacer andmodifiercontainingareactiveamine

DPG-5712-PI4 °C

100 mg500 mg

1 g

NH2

OO

OO

O

OCH3

10330

Note: The amino-dPEG® methyl esters are not stable upon prolonged storage. There are kits developed in order to make these valuable pegylation compounds available in a pure form in situ.

Each kit contains three component parts: a) 1 eq. of amino-dPEG® acid; b) 1.5 eq. of p-toluene sulfonic acid; c) sufficient dry methanol for the package size.• Methyl group is removed with mild base once the amine is reacted.• dPEG® pegylation spacer is hydrophilic, highly water soluble and non-immunogenic. The ester is water soluble, as well as being soluble in a variety of organic solvents especially methylene chloride.• Contrasting the t-butyl group, the methyl group can be easily removed with base, either KOH or with a carbonate base, e.g., potassium carbonate in aqueous methanol. This can be done in an aqueous or combination aqueous organic solvent system. The specific conditions are going to be dictated by the stability of the system into which the methyl ester is being introduced.• Methyl group can also, like the t-Butyl group provide a potential purification handle due to its hydrophobicity. Subsequently it is removed to perform additional chemistry. This applies best when using normal phase (e.g., silica gel) chromatography. The methyl group neutralizes the zwitterion of the amino acid for better reactivity at the amine.

NEW!

NEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

310 Order Hotline 1-800-777-4779 502-266-8787

Amino-dPEG® Acids• Soluble and non-immunogenic.• Zwitterionic, extremely water soluble, and soluble in methylene chloride.• Unprotected amino acid for those who prefer the potential simplicity of not having to remove one more protecting group. Pegylation reagent reacts selectively as the amine with NHS and other active esters in the presence of a 3º amine, e.g., TEA.• The dPEG® amino acids can also be used in situ to make the methyl ester, which is generally not stable for extended periods of storage (see DPG-5712-PI for kit and protocol).• Spacer will minimize or eliminate aggregation problems with its incorporation into peptides and related compounds.

Application: Surface and particle modification with terminal carboxyl functionality.• GREAT for coating beads in order to reduce non-specific binding problems.• Reacts like common amino acids. The amine can be reacted selectively in the presence of an appropriate base with an activated ester.• Can be reacted in solvents as non-polar as methylene chloride.

Amino-dPEG®4 Acid

18.0 Angstrom and 16 atoms spacer(M.W. 265.30)Unprotected amino acid

DPG-5710-PI4 °C

100 mg500 mg

1 gNH2

OO

OO OH

O

10244

Amino-dPEG®8 Acid

32.2 Angstroms and 28 atoms spacer (nitrogen to carbonyl carbon)(M.W. 441.51) Unprotected dPEG®

8 Amino Acid

DPG-5713-PI4 °C

100 mg1 g

OH

O

OO

OO

OO

OO

NH2

10277

Amino-dPEG®12 Acid

46.5 Angstroms and 40 atoms spacer (M.W. 617.72) Unprotected dPEG®

12 Amino Acid

DPG-5715-PI4 °C

100 mg1 g

OO

OO

OO

OO

OO

ONH2 O

OOH

10287

Amino-dPEG®24 Acid

89 Angstroms and 76 atoms spacer (M.W. 1146.35) Unprotected amino acid

DPG-5717-PI4 °C

100 mg1 g

OO

OO

OOHO

OO

OO

OO

OO

OO

O

OOOOOOOONH2

10317

NEW!

NEW!

NEW!

NEW!


TOO


Order Hotline 1-800-777-4779 502-266-8787 311

PRODUCT CODE QTYAmino-dPEG® t-Butyl Esters

• A carboxy protected dPEG®x amino acid pegylation reagent.

• dPEG® pegylation spacer and modifier with a reactive amine and a t-butyl protected carboxylic acid.• dPEG® pegylation spacer is extremely hydrophilic, will enhance the water solubility of a compound in which it is incorporated and reduce non-specific binding where applicable. The spacer is also non- immunogenic. The ester is both water soluble, as well as in common used organic solvents of moder- ate prolarity.• t-Butyl group: – Is easily removed with TFA (25% TFA in CH2Cl2, ice bath/0° C, takes about 5 h). – Provides a potentially powerful purification handle due to its hydrophobicity. Subsequently it is removed to perform additional chemistry. This applies best when using normal phase (e.g., silica gel) chromatography. – Neutralizes the zwitterion of the amino acid for better reactivity at the amine. – Reacts with carboxylic acids and other carbonyls.

Amino-dPEG®8 t-Butyl Ester


8 Amino Acid

DPG-5714-PI4 °C

100 mg500 mg

1 g

OOO

OO

OO

OO

NH2

O

10271Amino-dPEG®

12 t-Butyl Ester46.5 Angstroms and 40 atoms spacer (nitrogen to carbonyl carbon)(M.W. 673.83)Carboxy-Protected dPEG®

12 Amino Acid

DPG-5716-PI4 °C

100 mg500 mg

1 g

OOO

OO

OO

OO

OO

OO

NH2

O

10281Amino-dPEG®24 t-Butyl Ester

89 Angstroms and 76 atoms spacer (nitrogen to carbonyl carbon) (M.W. 1202.46)

DPG-5718-PI4 °C

100 mg1 g

A carboxy protected dPEG®x amino acid pegylation reagent, dPEG® pegylation spacer and modifier with a reactive amine and a t-butyl protected carboxylic acid

OOO

OO

O

OO

OO

OO

OOO

OO

OO

NH2 OO

OO

OO

O

10311

NEW!

NEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

312 Order Hotline 1-800-777-4779 502-266-8787

Methoxy Terminated Amine Reactive Reagents• Makes discrete MW pegylation modification possible with our unique range of m-dPEG® pegylation NHS esters.• m-dPEG® pegylation produces compounds with increased water solubility and reduced aggregation, also reduces immunogenicity and potentially even toxicity.• Can be used in conjunction with amino protected amino dPEG® acids for the pegylation of surfaces for produce hydrophilic and reactive surfaces with no non-specific binding issues.• Allows for low MW discrete pegylation of small molecule drugs and other related compounds for increased water solubility and reduced aggregation, or of surfaces to reduce non-specific binding; may even be useful for “dusting” enzymes and other proteins to increase chemical stability.• Amine reactive.• Produces stable amide bond.

m-dPEGTM 2-NHS Ester(MW = 245)

Methoxy-dPEGTM-N-hydroxysuccinimide (MW=245) 8.5 Angstroms and 8 atoms spacer(M.W. 245.23) Can be used in conjunction with amino protected amino dPEG® acids for the pegylation of surfaces for produce hydrophilic and reactive surfaces with no non-specific binding issues

DPG-5719-PI4 °C

100 mg500 mg

1 g

CH3OO O

NO

O

O

10327m-dPEG®4-NHS Ester (MW = 333)

Methoxy-dPEGTM-N-hydroxysuccinimide (MW=333)15.6 Angstroms and 14 atoms spacer(M.W. 333.33)

DPG-5720-PI4 °C

100 mg500 mg

1 g N

OO

O

O

OO

O

H3CO

10211

m-dPEG®8-NHS Ester(MW = 509)

Methoxy-dPEGTM-N-hydroxysuccinimide (MW=509) 29.8 Angstroms and 26 atoms spacer (M.W. 509.54)Amine Reactive Makes discrete MW pegylation modification possible with a unique range of m-dPEG® pegylation NHS esters

DPG-5723-PI4 °C

100 mg

NOO

OO

OO

OO

CH3OO

O

O

10260

m-dPEG®12-NHS Ester (MW = 685)

Methoxy-dPEGTM-N-hydroxysuccinimide (MW=685) 44.0 Angstroms and 38 atoms spacer(M.W. 685.75)Amine Reactive

DPG-5725-PI4 °C

100 mg

ON

OO

OO

OO

OO

OO

OO

OO

10262

CH3O

m-dPEGTM16-NHS Ester(MW = 862)

Methoxy-dPEGTM-N-hydroxysuccinimide (MW=862) 57.9 Angstroms and 50 atoms spacer (M.W. 861.97)Amine Reactive

DPG-5726-PI4 °C

100 mg 1 g

OO

OO

OO

OO

OO

OO

OO

OO O

O

N

O

O

10322

NEW!

NEW!

NEW!

NEW!

NEW!

1 g

1 g


TOO


Order Hotline 1-800-777-4779 502-266-8787 313

PRODUCT CODE QTYm-dPEG®

24-NHS Ester (MW = 1214)Methoxy-dPEGTM-N-hydroxysuccinimide (MW=1214) 86.2 Angstroms and 74 atoms spacer (M.W. 1214.39)

DPG-5727-PI4 °C

100 mg500 mg

1 gAmine ReactiveMakes discrete MW pegylation modification possible with a unique range of m-dPEG® pegylation NHS esters

OO

OCH3O

OO

OO O

OO

OO

O OO O

OO

OO

OO

OO O

OO

N

O

10304

m-dPEGTM -Acids

• Acid form of the corresponding m-dPEG® NHS esters• Can activate the acid in situ using standard activation methods, e.g., with EDC and NHS in methylene chloride• Pegylation spacer is water soluble, non-immunogenic and non-toxic, so can be used to modulate the properties of the m-dPEG® pegylation modified compounds.

m-dPEGTM4 -Acid (MW = 236)

Methoxy-dPEGTM (MW=236) 15.6 Angstroms and 14 atoms spacer (M.W. 236.26) Acid form of NHS Ester, DPG-5720-PI

DPG-5721-PI4 °C

100 mg1 g

OO

O OH

OH3CO

10234m-dPEG®2 -Acid (MW = 148)

8.5 Angstroms and 8 atoms spacer (M.W. 148.16) Acid form of NHS Ester, DPG-5719-PI

DPG-5722-PI4 °C

100 mg500 mg

1 g

CH3O O OH

O

10326m-dPEG®8-Acid (MW = 412)

29.8 Angstroms and 26 atoms spacer (M.W. 412.47) Acid form of NHS Ester, DPG-5723-PI

DPG-5724-PI4 °C

100 mg1 g

CH3OO

OO

OO

OO OH

O

10324m-dPEG®24 acid (MW = 1117)

Methoxy-dPEGTM-N-hydroxysuccinimide (MW=1117) 86.2 Angstroms and 74 atoms spacer(M.W. 1117.31) Acid form of NHS Ester, DPG-5727-PI

DPG-5728-PI4 °C

100 mg500 mg

1 g

NEW!

NEW!

NEW!

NEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

314 Order Hotline 1-800-777-4779 502-266-8787

NHS-dPEG®4-(m-dPEG®

12)3 Ester(M.W. 2420.80)Amine reactive, activated ester, a dPEGTM

4 based tribranched pegylation reagent

DPG-5729-PI4 °C

100 mg1 g

O

O

NH

OO

OON

H

O OO

ONH

O

O

NH

O

OO

OO

OO

OO

OO

OCH3O

OO

OO

OO

OO

OO

OCH3O

NH

OO

OO

OO

OO

OO

OCH3O

O

NO

O

10401

•Single compound; made synthetically from 99.5% pure tetraethylene glycol.• Imparts significant and surprising water solubility, and the modifier itself is non-immunogenic and non-toxic.• Potentially very useful as a drug modifier with high hydrodynamic volume.• Produces compounds with reduced aggregation, or surfaces with reduced non-specific binding.• Produces stable amide bond.

Carboxyl-dPEG®4-(m-dPEG®

12)3 Ester(M.W. 2323.73)Amine reactive pegylation reagent with a tribranched dPEG®

4 branch; activate carboxylic acid in situ

DPG-5730-PI4 °C

100 mg1 g

OH

O

NH

OO

OON

H

O OO

ONH

O

O

NH

O

OO

OO

OO

OO

OO

OCH3O

OO

OO

OO

OO

OO

OCH3O

NH

OO

OO

OO

OO

OO

OCH3O

O

10402

• Single compound; made synthetically from 99.5% pure tetraethylene glycol.• Imparts significant and surprising water solubility, and the modifier itself is non-immunogenic and non-toxic.• Potentially very useful as a drug modifier with high hydrodynamic volume.• Produces compounds with reduced aggregation, or surfaces with reduced non-specific binding.• Produces stable amide bond.• Activate in situ with EDC/NHS.

Methoxy Terminated Carbonyl / Carboxyl Reactive Reagents• Carbonyl/carboxyl reactive dPEG®; this unique pegylation reagent reacts with

acids, active esters and aldehydes.• Each is a single compound; made from 99.5% pure tetraethylene glycol.• In modification reactions: Pegylation arm imparts significant and surprising water

solubility, and the modifier itself is non-immunogenic and non-toxic, so can decrease these properties in the modified application.

• For surface applications: m-dPEG® amine pegylation reagent will react on surfaces to significantly reduce or eliminate non-specific interactions and create a monolayer surface structure. Can be used in conjunction with the amino dPEG® acids or amino dPEG® esters to protect the surface as well as to impart functionality back to a carboxylated surface.

Reference: Greg T. Hermanson, Bioconjugate Techniques, 2nd Ed, Elsevier Inc., Burlington, MA 01803, April, 2008 (ISBN-13: 978-0-12-370501-3; ISBN-10: 0-12-370501-0). Specifically, see pp. 726-729, Chapter 18, on discrete PEG compounds for pegylation applications.

NEW!


TOO


Order Hotline 1-800-777-4779 502-266-8787 315

PRODUCT CODE QTYm-dPEG®

4 Amine15.5 Angstroms and 14 atoms spacer(M.W. 207.27)Carbonyl/carboxyl reactive dPEG®; this unique pegylation reagent reacts with acids, active esters and aldehydes.

DPG-5731-PI4 °C

100 mg500 mg

1 g

NH2

OO

OCH3O

10175

m-dPEG®8 Amine

29.7 Angstroms and 26 atoms spacer(M.W. 383.48)

DPG-5732-PI4 °C

100 mg1 g

Carbonyl/carboxyl reactive dPEG®; this unique pegylation reagent reacts with acids, active esters and aldehydes.

OCH3O O

OO

OO

ONH2

10278m-dPEG®12 Amine

43.9 Angstroms and 38 atoms spacer(M.W. 559.69) Carbonyl/carboxyl reactive dPEG®; this unique pegylation reagent reacts with acids, active esters and aldehydes.

DPG-5733-PI4 °C

100 mg1 g

OO

OO

OO

CH3OO

OO

OO

NH2

10288m-dPEG®24 Amine

86.1 Angstroms and 74 atoms spacer(M.W. 1088.32) Carbonyl/carboxyl reactive dPEG®; this unique pegylation reagent reacts with acids, active esters and aldehydes

DPG-5734-PI4 °C

100 mg1 g

OO

OO

NH2OO

OO

OO

OO

CH3O OO

OO

OOO

OO

OO

10318Surface Reactive and Thiophilic Reagents

• Thiol is reactive with metal surfaces, other thiols, disulfides, maleimides, vinyl sulfones,and haloacet- amides and incorporates the pegylation spacer into all of these various functionality.• dPEG® pegylation spacer is hydrophilic, highly water soluble, and non-immunogenic.

Thiol-dPEG®4 Acid

18.3 Angstroms and 16 atoms spacer (M.W. 282.35) Bifunctional thiol acids with dPEG® pegylation spacer

DPG-5735-PI4 °C

100 mg 1 g

SHO

OO

O OH

O10247

Thiol-dPEG®8 Acid

32.5 Angstroms and 28 atoms spacer (M.W. 458.57) Bifunctional thiol acids with dPEG® pegylation spacer• Incorporates the dPEG® carboxylic acid.• Once functionalized, the carboxylic acid moiety can be activated for further reaction, e.g. with EDC/NHS.• Potentially activatable carboxylic acid moiety.

DPG-5737-PI4 °C

100 mg500 mg

1 g

SHO

OO

OO

OO

O OH

O

10183

NEW!

NEW!

NEW!

NEW!

NEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

316 Order Hotline 1-800-777-4779 502-266-8787

Thiol-dPEG®4 t-Butyl Ester

(M.W. 338.46) Thiol and protected acid bifunctional reagent with unique dPEG® spacer t-Butyl group is easily removed with TFA (25% TFA in CH2Cl2, ice bath/0° C, about 5 h) and provides a potentially powerful purification handle.

DPG-5736-PI4 °C

100 mg500 mg

1 g

SHO

OO

O O

O

10248

Hydroxy-dPEG®4 t-Butyl Ester

18.0 Angstroms and 16 atoms spacer (M.W. 322.39)Surface Modification Reagent with Free Alcohol

DPG-5738-PI4 °C

1 g

OO

OO OOH

O

10223

Miscellaneous ReagentsO-Benzyl-dPEG®

4 Acid18 Angstroms and 16 atoms spacer(M.W. 356.41)Amine reactive Carboxylic Acid dPEG® pegylation modifier/spacer; with Protected Hydroxyl

M. Bodanszky and A. Bodanszky, The Practice of Peptide Synthesis, pp. 129-134, 2nd Ed., Springer-Verlag, Berlin Heidelberg, (1994). This reference contains specific protocols.P.J. Kocienski, Protecting Groups, pp. 46-49, Georg Thieme Verlag, Stuttgart, (1994).

DPG-5739-PI4 °C

100 mg500 mg

1 g

OO

OO

O OH

O

10233Heterobifunctional dPEG® CrosslinkersOur dPEG® pegylation version of the popular SATA reagent, providing a method for converting the amino group to a thiol with the incorporation of the pegylation unit• Adds the properties of dPEG®, including added pegylation spacer distance, a spacer that is highly hydrophilic, non-antigenic, non-immunogenic and non-toxic• Greater accessibility of reaction/modification site, i.e., spacer distance makes the amine, now thiol, much more accessible, e.g., a maleimide, vinyl sulfone or a α-haloketo functionalize reaction partner.

MAL-dPEG®4-AcidMol. Wt.: 416.42; single compound 17.5 Angstromsand 16 atomsspacerPegylation Crosslinker Reagent with Amine and Sulfhydryl / Thiol Reactivity

• Activate the carboxyl in situ with EDC/NHS or other activation chemistry of the carboxylic acid

DPG-5763-PI4 °C

100 mg 1 g

NH

OO

OO OH

OO

N

O

O

10338

NEW!

NEW!

NEW!

NEW!


TOO


Order Hotline 1-800-777-4779 502-266-8787 317

PRODUCT CODE QTYS-Acetyl-dPEG®

4 Acid (dPEG®4 SATA Acid)

18.3 Angstroms and 16 atoms spacer (M.W. 324.39)

DPG-5741-PI4 °C

100 mg500 mg

1 g

SO

OO

O OH

O O

10180

S-Acetyl-dPEG®8 Acid (dPEG®

8 SATA Acid) 32.5 Angstroms and 28 atoms spacer(M.W. 500.60)• This acid form needs to be activated in sita to some form of active ester.

DPG-5742-PI4 °C

100 mg500 mg

1 g

SO

OO

OO

O

OO

O OH

O

10182

S-Acetyl-dPEG®4 NHS Ester (dPEG®

4 SATA)18.3 Angstroms and 16 atoms spacer (M.W. 421.46)

DPG-5740-PI4 °C

100 mg500 mg

1 g

SO

OO

O O

OON

O

O

10181S-Acetyl-dPEG®

8 NHS Ester (dPEGTM8 SATA)


DPG-5743-PI4 °C

100 mg1 g

SO

OO

OO

OO

O ON

O OO

10184

O

Mono-N-t-Boc-Amido-dPEG®

• Convenient mono-protected dPEG diamine for pegylation -- selectively react just one end, then subsequently deprotect with TFA to make other amine available for reaction• Hydrophilic, non-immunogenic dPEG® pegylyation spacer• Water soluble with pegylation spacer

Mono-N-t-Boc-Amido-dPEG®3 Amine

15 Angstroms and 16.9 atoms spacer(M.W. 320.43)

DPG-5744-PI4 °C

500 mg 1g

O

O

NH

OO

O NH2

10225

Mono-N-t-Boc-Amido-dPEG®11 Amine


DPG-5745-PI4 °C

100 mg1 g

OO

OO

OO

NH

NH2OO

OO

O

O

O

10172

Mono-t-Boc-1,6-Diaminohexane42.8 Angstroms and 37 atoms spacer (M.W. 216.32)

DPG-5746-PI4 °C

1 g

NH

ONH2

10176

O

NEW!

NEW!

NEW!

NEW!

NEW!

NEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

318 Order Hotline 1-800-777-4779 502-266-8787

Mono-N-Cbz-Amido-dPEG®3 Amine

16.9 Angstroms and 15 atoms spacer (M.W. 354.44)Introduces a 15 atom and 16.9 Angstrom hydrophilic, non-immunogenic dPEG® pegylation spacer

DPG-5747-PI4 °C

500 g1 g

O NH

OO

O NH2

O

10269dPEG® Peptide Synthesis Reagents with SpacersFmoc-Based Solid Phase SynthesisFmoc-Amido-dPEG®

2 Acid10.9 Angstroms and 10 atoms spacer (M.W. 399.44) Peptide pegylation reagent, Fmoc protected dPEG® amino acids

DPG-5748-PI4 °C

1 g5 g

O NH

OO OH

O O

10243Fmoc-Amido-dPEG®

4 Acid18.1 Angstroms and 17 atoms spacer (M.W. 487.54)

DPG-5749-PI4 °C

100 mg500 g

1 g OHO

OO

ONH

O

OO

10213

Fmoc-Amido-dPEG®6 Acid

25.1 Angstroms and 22 atoms spacer (M.W. 575.65) N-Fmoc protected hydrophilic, non-immunogenic spacer

DPG-5750-PI4 °C

100 mg500 g

1 g

O NH

O

OO

OO

OO OH

O

10063

Fmoc-Amido-dPEG®8 Acid

32.2 Angstroms and 28 atoms spacer (M.W. 663.75) N-Fmoc protected hydrophilic, non-immunogenic spacer

DPG-5751-PI4 °C

100 mg1 g

OH

O

OO

OO

OO

OO

NH

O

O

10273Fmoc-Amido-dPEG®12 Acid

46.5 Angstroms and 40 atoms spacer (M.W. 839.96)N-Fmoc protected hydrophilic, non-immunogenic spacer

DPG-5752-PI4 °C

100 mg1 g

OO

OO

OO

NH

O OH

O

OO

OO

OO

O

10283

NEW!

NEW!

NEW!

NEW!

NEW! NEW!

NEW!


TOO


Order Hotline 1-800-777-4779 502-266-8787 319

PRODUCT CODE QTYFmoc-Amido-dPEG®

24 Acid89 Angstroms and 76 atoms spacer (M.W. 1368.59) N-Fmoc protected hydrophilic, non-immunogenic spacer Peptide pegylation reagent, Fmoc protected dPEG® amino acids, Useful for incorporating all of the properties of a dPEG®, either as a spacer in or terminating group of the peptide sequence

DPG-5753-PI4 °C

100 mg1 g

OO

OO

OO

OO

OO

NH

O OO

OO

OO

OO

O

O

OO

OO

O OH

O

10313

Cbz-Based Solid Phase SynthesisCbz-Amido-dPEG®

4 Acid19.2 Angstroms and 17 atoms spacer (M.W. 399.44)N-Cbz protected hydrophilic, non-immunogenic spacer

DPG-5754-PI4 °C

100 mg1 g

O NH

OO

OO OH

OO

10268Cbz-Amido-dPEG®

6 Acid25.1 Angstroms and 22 atoms spacer (M.W. 487.54) N-Cbz protected hydrophilic, non-immunogenic spacer

DPG-5755-PI4 °C

100 mg1 g

O NH

OO

OO

OO

O OH

O

10066Cbz-Amido-dPEG®8 Acid

32.2 Angstroms and 28 atoms spacer (M.W. 575.65)N-Cbz Protected Hydrophilic, Non-Immunogenic Spacer

DPG-5756-PI4 °C

100 mg1 g

OHOO

OO

OO

OO

NH

O

OO

10276

Cbz-Amido-dPEG®12 Acid

46.5 Angstroms and 40 atoms spacer (M.W. 751.86) N-Cbz Protected Hydrophilic, Non-Immunogenic Spacer

DPG-5757-PI4 °C

100 mg1 g

O

O NH

OO

OO

OO OHO

OO

OO

OO

10286

Cbz-Amido-dPEG®24 Acid

88.5 Angstroms and 76 atoms spacer (M.W. 1280.49) N-CBZ protected dPEG® amino acid pegylation reagents for peptide synthesis

DPG-5758-PI4 °C

100 mg1 g

OH

O

OO

O

OO

OO

OO

OO

OO

OO

O

OO

OO

OO

OO

NH

O

O

10316

NEW!

NEW!

NEW!

NEW!

NEW!

NEW!

PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

320 Order Hotline 1-800-777-4779 502-266-8787

Merrifield Boc-Based Solid Phase Synthesist-Boc-Amido-dPEG®

4 Acid19.2 Angstroms and 17 atoms spacer(M.W. 365.42)N-t-Boc Protected Hydrophilic, Non-Immunogenic Spacer• N-t-boc protected dPEG® amino acid pegylation reagents for peptide synthesis.

DPG-5759-PI4 °C

100 mg500 g

1 gO N

H

OO

OO

O OH

O

10220Thiol Modifiers• Useful pegylation reagents for incorporating the sulfhydryl moiety into a peptide, that contains the dPEG® pegylation unit.• Potentially a significant alternative to cysteine for incorporating the sulfydryl into peptides. • Bulk pricing available, please inquire.

Trityl-S-dPEG®4 Acid

18.3 Angstroms and 16 atoms spacer(M.W. 524.67)• Pegylation reagent incorporates a dPEG® chain of 16 atoms and 18.3 Å in length.• Trityl is removed using 25-50% TFA with 5% TIS (triisopropyl silane).

DPG-5760-PI4 °C

100 mg500 g

1 g

SO

OO

O OH

O

10300

Methoxytrityl-S-dPEG®4 Acid

18.3 Angstroms and 16 atoms spacer (M.W. 554.70)

DPG-5761-PI4 °C

100 mg500 g

1 g

OCH3

SO

OO

O

O

OH

10301

Methoxytrityl-S-dPEG®8 Acid


DPG-5762-PI4 °C

100 mg500 g

1 gOH

O

OO

OO

OOS

OO

CH3O

10166Hydroxyl ModifiersO-Benzyl-dPEG®

4 Acid18 Angstroms and 16 atoms spacer(M.W. 356.41)M. Bodanszky and A. Bodanszky, The Practice of Peptide Synthesis, pp. 129-134, 2nd Ed., 1994, Springer-Verlag, Berlin Heidelberg. This reference contains specific protocols.P.J. Kocienski, Protecting Groups, pp. 46-49, 1994, Georg Thieme Verlag, Stuttgart.

DPG-5739-PI4 °C

100 mg500 g

1 g

OO

OO

O OH

O

10233

NEW!

NEW!

NEW!

NEW!

NEW!


TOO


Order Hotline 1-800-777-4779 502-266-8787 321

PRODUCT CODE QTYLaboratory EquipmentTubing and ConnectorsTeflon Tubing 1 ⁄8” (10 feet)

The 1⁄8” diameter Teflon tubing is ideal for connecting a semi-automated synthesis assembly. Use this tubing with the avail-able Teflon connectors (STC•22900-PI) to connect ¼” glass tubing of a reaction vessel. Typically, solid phase assemblies connect to valves, stopcocks, aspirators, pumps, nitrogen tanks, and reagent bottles through a variety of configurations. Purchase this tubing in ample lengths and let your imagination and creativity be your guide.

STB-21018-PI 10 feet

Teflon Connectors(for attaching ¼” tubing to 1 ⁄8” Teflon tubing) (Two required for each reaction vessel)

STC-22900-PI 1 each

Teflon Connectors (for attaching ¼” glass tubing to ¼” Teflon tubing) (Two required for each reaction vessel)

STC-22902-PI 1 each

Specialty GlasswareManual Reaction Vessel

This glass reaction vessel features an inert Teflon lined screw cap, a Teflon stopcock and a coarse glass frit. The vessel can be matched to many 180° shakers, and its large diameter opening allows easy access for the addition of reagents, resins, and solvents.

5 mL Manual Reaction Vessel SHG-20205-PI 1 each






Manual Reaction Vessels with BafflesFor better mixing action with larger vessel sizes

200 mL Manual Reaction Vessel with Baffles SHG-20295-PI 1 each




PRODUCT CODE QTYPE

PTID

ES IN

TERN

ATIO

NAL

TOO

LS f

or P

EPTI

DE S

YNTH

ESIS

322 Order Hotline 1-800-777-4779 502-266-8787

Manual Reaction Vessels with JacketSame design as SHG-20215-PI listed above but comes with an external water jacket and ribbed entry port. This vessel is perfect for solid phase reactions where precise temperature control, above or below room temperature, is important.

15 mL Manual Reaction Vessel with Jacket SHG-22215-PI 1 each




Manual Reaction Vessels with 3-way Teflon Stopcock with Two ¼” Outlets15 mL Manual Reaction Vessel with 3-way Teflon Stopcock

SHG-22315-PI 1 each

30 mL Manual Reaction Vessel with 3-way Teflon Stopcock

SHG-22330-PI 1 each


SHG-22360-PI 1 each


SHG-22390-PI 1 each

30 mL Manual Reaction Vessel with 24/40 Vacuum Adapter Joint

SHG-22630-PI 1 each


SHG-22660-PI 1 each


SHG-22690-PI 1 each


SHG-22695-PI 1 each

15 mL Amber Manual Reaction Vessel SHG-21115-PI 1 each




600 mL and Larger Septum (Teflon-coated Silicone Rubber)

SEP-22845-PI 1 each

Replacement Screw Caps and SeptaTo order the screw caps for Manual Reaction Vessel & Manual Reaction Vessel with Jacket, please use the codes given below:

Screw Cap for 5, 10, and 15 mL Manual Reaction Vessels

CAP-22201-PI 1 each

Screw Cap for 30 mL - 400 mL Manual Reaction Vessels

CAP-22203-PI 1 each


TOO


Order Hotline 1-800-777-4779 502-266-8787 323

PRODUCT CODE QTYScrew Cap for 600 mL and Larger Manual Reaction Vessels

CAP-22205-PI 1 each

Screw Cap for PS-3 Reaction Vessel (package of 3 each)

SHG-20003-PI 1 package of 3

Extra Septa (Teflon-coated Silicone Rubber)Septum for the cap on 10 and 15 mL Manual Reaction Vessels

SEP-22825-PI 1 each

Septum for the cap on 30 mL - 400 mL Manual Reaction Vessels

SEP-22832-PI 1 each

Replacement Screw Cap (open) plus Septum for:Open Screw Cap (10 and 15 mL) with Teflon-coated Septum

CAP-22225-PI 1 each

Open Screw Cap (30 mL and larger) with Teflon-coated Septum

CAP-22232-PI 1 each

Tubing and ConnectorsTeflon Tubing 1 ⁄8” (10 feet)

The 1⁄8” diameter Teflon tubing is ideal for connecting a semi-automated synthesis assembly. Use this tubing with the avail-able Teflon connectors (STC•22900-PI)to connect ¼” glass tubing of a reaction vessel. Typically, solid phase assemblies connect to valves, stopcocks, aspirators, pumps, nitrogen tanks, and reagent bottles through a variety of configurations. Purchase this tubing in ample lengths and let your imagination and creativity be your guide.

STB-21018-PI 10 feet

Teflon Connectors (for attaching ¼” tubing to 1 ⁄8” Teflon tubing) (Two required for each reaction vessel)These connectors can be used to attach glass tubing to glass tubing or to Teflon and other rigid plastic tubing. A simple turning action ensures a secure fit between the connector and glass or plastic or other rigid rod.

STC-22900-PI 1 each

Teflon Connectors (for attaching ¼” glass tubing to ¼” Teflon tubing) (Two required for each reaction vessel)

STC-22902-PI 1 each

General Laboratory GlasswareEvaporator Trap 200 mL (Splash Guard Adapter)

This is an especially well-made, thick walled glass evaporator trap (also known as a “splash-guard”). Its standard 24/40 joints and optimal size makes it a popular choice for any laboratory.

SHG-20200-PI 1 each

HF Apparatus and Parts Parts are still available for the HF appartatus by special order. Please inquire with Peptides International Customer Service Representatives for more information..

PEPT

IDES

INTE

RNAT

IONA

LTO

OLS

for

PEP

TIDE

SYN

THES

IS

324 Order Hotline 1-800-777-4779 502-266-8787

Code Page Number Code Page Number Code Page Number Code Page NumberPEPTIDES INTERNATIO

NALINDEX by PRO

DucT cODE Num

bER

Order Hotline 1-800-777-4779 502-266-8787 325

KDC-1001 ............... 300KBL-1002-PI ............. 26KBL-1006-PI ............. 26KCH-1009-PI .......... 301KTC-1010-PI ........... 302KSU-1011 ................ 302KCM-1015-PI .......... 304KPC-1016-PI ........... 305RCM-1017-PI .......... 282KHC-1018-PI .......... 301KDC-1023 ............... 300KEE-1024 ................ 301RBH-1028 ............... 282KBT-1029-PI ........... 301KWS-1030............... 303KNF-1033 ................ 302RCM-1034-PI .......... 282RMB-1039 ............... 283KFS-1042-PI ........... 301RMB-1045-PI .......... 283RBH-1046-PI .......... 282RBH-1048-PI .......... 282RAM-1049-PI .......... 282RAM-1051-PI .......... 282RCM-1052-PI .......... 282RCM-1054-PI .......... 282RAM-1055-PI .......... 299RCT-1056-PI ........... 284RMB-1058-PI .......... 299RHX-1059-PI .......... 284KBP-1060-PI ........... 300RHN-1062-PI .......... 285RFR-1063-PI ........... 283RHQ-1064-PI .......... 285KHB-1065-PI ........... 301KTB-1066-PI ........... 302RFR-1067-PI ........... 283KPE-1068-PI ........... 302RFR-1069-PI ........... 283RFR-1072-PI ........... 283RHM-1073-PI .......... 283RHM-1074-PI .......... 286RHY-1075-PI ........... 287RHV-1076-PI ........... 287RHM-1077-PI .......... 283RHX-1078-PI .......... 284RHM-1079-PI .......... 282RHN-1080-PI .......... 285RHA-1081-PI .......... 284RHR-1082-PI .......... 285RCT-1083-PI ........... 284RHG-1085-PI .......... 285RHD-1086-PI .......... 285RHH-1087-PI .......... 285RHP-1089-PI .......... 286RHC-1090-PI .......... 285

RHK-1091-PI .......... 286RHQ-1092-PI .......... 285RHE-1093-PI .......... 285RHL-1094-PI ........... 286RHF-1095-PI ........... 286RHS-1096-PI .......... 286RHT-1097-PI ........... 286RHW-1098-PI ......... 287RHW-1099-PI ......... 287CFM-1214-PI .......... 299CFM-1218-PI .......... 299RCO-1260-PI .......... 233CBL-1291-PI ............. 13RFT-1300-PI ........... 291RFG-1301-PI .......... 290RFM-1303-PI .......... 291RFA-1306-PI ........... 289RFD-1313-PI ........... 290RFC-1318-PI ........... 290RFC-1319-PI ........... 290RFE-1320-PI ........... 290RFI-1324-PI ............ 291RFL-1325-PI ........... 291RFK-1326-PI ........... 291RFF-1330-PI ........... 291RFP-1331-PI ........... 291RFS-1333-PI ........... 291RFW-1335-PI .......... 291RFY-1337-PI ........... 291RFV-1339-PI ........... 292RFH-1340-PI ........... 291RFC-1341-PI ........... 290RFW-1342-PI .......... 291RFX-1344-PI ........... 290RFX-1345-PI ..290, 298RFN-1354-PI ........... 290RFQ-1355-PI .......... 290RFX-1390-PI ........... 299RFX-1395-PI ........... 299RWN-1398-PI ......... 284RWN-1399-PI ......... 283RPS-1402-PI ........... 289RPM-1404-PI .......... 288RPV-1405-PI ........... 289RPX-1410-PI ........... 287RPY-1414-PI ........... 289RPW-1415-PI .......... 289RPY-1419-PI ........... 289RPB-1421-PI ..287, 298RPR-1425-PI .......... 288RBL-1428-PI ........... 299RPC-1429-PI .......... 288RPD-1430-PI .......... 288RPB-1431-PI ........... 287RPD-1432-PI .......... 288RBL-1433-PI ........... 299

RPE-1434-PI ........... 288RPK-1435-PI ........... 288RPE-1436-PI ........... 288RBL-1437-PI ........... 299RBL-1439-PI ........... 299RAM-1440-PI .......... 282RBL-1441-PI ........... 299RBL-1443-PI ........... 299RPA-1451-PI ........... 287RPG-1454-PI .......... 288RPL-1455-PI ........... 288RPP-1456-PI ........... 289RPL-1457-PI ........... 288RPL-1458-PI ........... 299RPG-1459-PI .......... 288RPN-1460-PI .......... 288RPQ-1462-PI .......... 288RPI-1465-PI ............ 288RPF-1468-PI ........... 289RPT-1470-PI ........... 289RPF-1471-PI ........... 289FLT-1700-PI ............ 270FLG-1701-PI ........... 269FLH-1702-PI ........... 269FLM-1703-PI ........... 269FLN-1704-PI ........... 267FLA-1706-PI............ 267FAA-1707-PI ........... 273FLR-1708-PI ........... 267FLR-1710-PI ........... 267FLX-1711-PI ............ 277FLD-1712-PI ........... 267FLD-1713-PI ........... 268FLC-1714-PI ........... 268FLC-1717-PI ........... 268FLC-1718-PI ........... 268FLE-1719-PI............ 274FLE-1720-PI............ 268FLQ-1721-PI ........... 268FLI-1724-PI ............. 269FLL-1725-PI ............ 269FLK-1726-PI............ 269FLK-1727-PI............ 269FLU-1728-PI ........... 276FLO-1729-PI ........... 276FLF-1730-PI ............ 269FLP-1731-PI............ 270FLS-1732-PI............ 270FLS-1733-PI............ 270FLT-1734-PI ............ 270FLW-1735-PI ........... 270FLY-1736-PI ............ 270FLY-1737-PI ............ 270FLY-1738-PI ............ 270FLV-1739-PI ............ 271FLH-1740-PI ........... 269

FLC-1741-PI ........... 268FLH-1742-PI ........... 269FLX-1744-PI............ 267FLR-1746-PI ........... 267FLO-1747-PI ........... 276FLX-1749-PI ...272, 273FLK-1750-PI............ 269FLX-1751-PI............ 278FLX-1753-PI............ 272FLN-1754-PI ........... 267FLQ-1755-PI ........... 268FLS-1756-PI............ 270FLI-1757-PI ............. 275FLX-1758-PI............ 275FLX-1759-PI............ 269FLX-1760-PI............ 277FLF-1762-PI ............ 277FLX-1766-PI............ 276FLX-1767-PI............ 278FLT-1768-PI ............ 270FLW-1769-PI ........... 270FLF-1770-PI ............ 277FLX-1771-PI............ 274FDX-1772-PI ........... 276FAB-1773-PI ........... 272FDF-1774-PI ........... 277FLX-1775-PI............ 272FLX-1778-PI............ 275FDX-1780-PI ........... 275FLF-1781-PI ............ 277FME-1782-PI .......... 278FDF-1783-PI ........... 277FML-1784-PI ........... 278FLX-1785-PI............ 276FMV-1787-PI ........... 279FLO-1788-PI ........... 276FFG-1789-PI ........... 277FMA-1790-PI .......... 278FMA-1791-PI .......... 278FMD-1792-PI .......... 278FMI-1793-PI ............ 278FML-1794-PI ........... 278FMF-1795-PI ........... 278FMV-1796-PI ........... 279FLK-1798-PI............ 275FLX-1799-PI............ 274FDQ-1809-PI .......... 271FDE-1810-PI ........... 271FDH-1812-PI ........... 271FDL-1814-PI ........... 271FDK-1815-PI ........... 271FDM-1816-PI .......... 271FDX-1818-PI ..271, 276FDP-1826-PI ........... 271FDX-1827-PI ........... 277FDT-1828-PI ........... 272

Code Page Number Code Page Number Code Page Number Code Page NumberPE

PTID

ES IN

TERN

ATIO

NAL

INDE

X by

PRO

DucT

cO

DE N

umbE

R

326 Order Hotline 1-800-777-4779 502-266-8787

FDW-1829-PI .......... 272FDF-1830-PI ........... 271FDS-1831-PI ........... 271FDW-1832-PI .......... 272FDY-1833-PI ........... 272FDV-1834-PI ........... 272FDX-1846-PI ........... 278FDI-1856-PI ............ 271FDX-1859-PI ........... 275FDX-1860-PI ........... 272FDX-1861-PI ........... 277FDX-1862-PI ........... 277FDF-1863-PI ........... 277FDS-1869-PI ........... 272FDX-1879-PI ........... 273FMD-1890-PI .......... 278FMF-1896-PI ........... 278FDO-1897-PI .......... 276FDK-1898-PI ........... 271FDE-1900-PI ........... 267FPG-1901-PI ........... 273FRC-1902-PI ........... 267FAK-1903-PI ........... 249AHA-1904-PI ........... 220AXX-1905-PI ........... 220AXX-1906-PI ........... 220FAP-1907-PI ........... 272FKD-1908-PI ........... 269FDO-1909-PI .......... 268XME-2001-PI .......... 255XBE-2003 ................ 255XNR-2005 ............... 254XZK-2006-PI ........... 255ZLA-2007-PI............ 279ZLR-2008-PI ........... 279ZLR-2009-PI ........... 279ZLN-2010-PI ........... 279ZLD-2011-PI............ 279ZLC-2014-PI ........... 279ZLE-2015-PI............ 279ZLQ-2017-PI ........... 279ZLG-2018-PI ........... 279ZLK-2019-PI............ 280ZLM-2020-PI ........... 280ZLF-2021-PI ............ 280ZLP-2022-PI............ 280ZLS-2023-PI............ 280ZLT-2024-PI ............ 280ZLW-2025-PI ........... 280ZLY-2026-PI ............ 280ZLV-2027-PI ............ 280ZLI-2028-PI ............. 279ZLL-2029-PI ............ 280EMM-2036-PI .......... 254EEG-2037-PI .......... 253EMH-2038-PI .......... 253

EMI-2039-PI ............ 253EEL-2040-PI ........... 254EEF-2041-PI ........... 254EMS-2042-PI .......... 254EEY-2043-PI ........... 254EMV-2044-PI .......... 254EBD-2045 ............... 253EBE-2046 ................ 253EBG-2047 ............... 253EBR-2048 ............... 253EBP-2049 ................ 254BLA-2051 ................ 255BLG-2054 ................ 256BLL-2055 ................ 257BLP-2056 ................ 257BLW-2057 ............... 258BLR-2058 ................ 255BLD-2059 ................ 255BLN-2060 ................ 255BLC-2061 ................ 256BLQ-2062 ................ 256BLI-2065 ................. 257BLF-2068 ................ 257BLT-2070 ................. 258BLY-2071 ................. 258BLN-2077 ................ 255BLC-2078 ................ 256BLQ-2079 ................ 256XBD-2093-PI ........... 254RMB-2100-PI .......... 283XTR-2101-PI ........... 254BLS-2102 ................ 258BLE-2103 ................ 256BLM-2104 ............... 257BLV-2105 ................ 258BLK-2108 ................ 257BLH-2109 ................ 257EBF-2110 ................ 254EBI-2111 ................. 253EBL-2112 ................ 253BLY-2114 ................. 258BLW-2115 ............... 258BLX-2116 ................ 257ZLU-2117 ................ 280BLY-2119 ................. 258BSR-2120 ............... 265BLC-2121 ................ 256BLR-2125 ................ 255BLC-2129 ................ 256BLC-2130 ................ 256BBA-2131 ................ 255BLD-2132 ................ 255BLE-2134 ................ 256BLK-2135 ................ 257BLH-2138 ................ 257BLW-2139 ............... 258

FCP-2351 ................ 274FCP-2352 ................ 275BDP-2600-PI ........... 265BDW-2602 .............. 260BDL-2603 ................ 259BDF-2604 ................ 260BDH-2605 ............... 259BDA-2606 ............... 258BDM-2608 ............... 260BDR-2609 ............... 259BDP-2610 ............... 260BDY-2612 ................ 260ZDU-2613 ............... 280BDW-2614 .............. 260BDX-2615-PI ........... 264BDD-2616 ............... 259BDD-2617 ............... 259BDD-2618-PI .......... 259BDV-2619 ................ 260BDN-2620 ............... 259BDY-2622 ................ 260BDT-2624 ................ 260BDN-2626 ............... 259BDS-2627 ............... 260BDK-2628 ............... 260BDI-2629 ................. 259BDN-2651-PI .......... 259ALA-2701-PI ........... 250ALR-2702-PI ........... 250ALN-2703-PI ........... 250ALD-2704-PI ........... 250ALC-2705-PI ........... 250ALC-2706-PI ........... 250ALQ-2707-PI ........... 251ALE-2708-PI ........... 251ALG-2709-PI ........... 251ALH-2710-PI ........... 251ALX-2711-PI............ 251ALI-2712-PI ............. 251ALL-2713-PI ............ 251ALK-2714-PI ........... 251ALM-2715-PI ........... 251ALO-2716-PI ........... 251ALF-2717-PI............ 251ALP-2718-PI ........... 251ALS-2719-PI ........... 251ALT-2720-PI ............ 251ALW-2721-PI ........... 252ALY-2722-PI ............ 252ALV-2723-PI ............ 252ALU-2724-PI ........... 251ALU-2728-PI ........... 251ADA-2801-PI ........... 252ADR-2802-PI .......... 252ADE-2804-PI ........... 252ADH-2805-PI .......... 252

ADL-2806-PI ........... 252ADM-2807-PI .......... 252ADF-2808-PI ........... 252ADT-2809-PI ........... 253ADW-2810-PI .......... 253ADV-2811-PI ........... 253ADY-2812-PI ........... 253ADK-2813-PI ........... 252ADD-2814-PI .......... 252ADN-2815-PI .......... 252ADP-2816-PI ........... 252ADC-2817-PI .......... 252ADS-2818-PI ........... 252ADI-2819-PI ............ 252SRE-3001 ............... 205SRA-3002 ............... 205STR-3003 ................ 205SFE-3006 ................ 185SYE-3008 ................ 185SYA-3009 ................ 185SYE-3010 ................ 186SRN-3013 ............... 205SLN-3014 ................ 176SYN-3015 ............... 185SYN-3016 ............... 208SEY-3018 ................ 184SGL-3019 ................ 207SGF-3020 ............... 208SGF-3021 ............... 208OGL-3022 .......195, 216OGF-3023 .......195, 216OLG-3024 .......198, 216OLG-3025 .......198, 216SLN-3027 ................ 176OGG-3028 ......195, 216SGP-3029 ............... 190SWE-3034............... 185SGL-3037 ................ 207SGL-3039 ................ 208SGG-3040 ............... 208SFY-3044 ................ 208SGK-3047 ............... 178OEG-3050 .......194, 216OGP-3052 .......195, 216OGF-3053 .......195, 216STK-3054 ................ 206SGP-3055 ............... 208OKK-3056 ............... 215SRN-3057 ............... 183SGK-3058 ............... 204SGR-3059 ............... 178OGG-3061 ......195, 216OEE-3063 ............... 215SGL-3064 ................ 177OHL-3065 .......195, 216SEN-3066 ............... 195


NALINDEX by PRO

DucT cODE Num

bER

Order Hotline 1-800-777-4779 502-266-8787 327

SEN-3067 ............... 194SAN-3068 ............... 175SYE-3069 ................ 208SAA-3071 ................ 192SAA-3071-v............. 192SDP-3073-v ............ 189SGP-3074-v ............ 191OKK-3075 ............... 215OGH-3076.......195, 217SRM-3078 ............... 204OVA-3079 .......202, 216 OEE-3080 .......194, 215SDP-3082 ............... 188SDL-3083-v ............. 203SAM-3084 ............... 178OAH-3085 ............... 215SDP-3087-v ............ 189SDQ-3088-v ............ 188SDP-3089 ............... 188MGP-3090-v ........... 191MLM-3091-v ............ 175MBR-3092-v ............ 205MVP-3093-v ............ 188MlE-3094-v .............. 187MFR-3095-v ............ 184MPF-3096-v ............ 197MGG-3097-v ........... 207MCA-3099-v ............ 200MAP-3100-v ............ 193MPX-3101-v ............ 202MLG-3102-v ............ 197MVL-3104-v ............ 179MEK-3105-v ............ 200MLT-3106-v ............. 187MFS-3107-v ............ 194MGP-3108-v ........... 190MGP-3109-v ........... 201MRP-3110-v ............ 186SGL-3111 ................ 199MLS-3112-v............. 187MAR-3113-v ............ 182MAA-3114-v ............ 186MEG-3115-v ............ 178SAN-3116 ................ 204SAA-3117 ................ 204SAP-3118 ................ 193OGG-3119.......183, 218MLL-3120-v ............. 179MQR-3122-v ........... 193MRR-3123-v ........... 183MKA-3124-v ............ 191SLR-3125 ................ 187SGP-3126 ............... 177SAP-3127 ................ 199SGG-3128 ............... 177SGL-3129 ................ 191

SPL-3130 ................ 183SFL-3131 ................ 190MKM-3132-v ........... 176MAA-3133-v ............ 192MER-3134-v ............ 187MQR-3135-v ........... 205MQR-3136-v ........... 187MPR-3138-v ............ 188MDR-3139-v ........... 187MLR-3140-v ............ 194MLK-3141-v ............ 194MGR-3142-v ........... 193MGK-3143-v ........... 193MAR-3144-v ............ 178MPR-3145-v ............ 207SYG-3146 ............... 175MAM-3147-v ........... 175MFM-3148-v ........... 176MMM-3149-v ........... 176MIW-3150-v ............ 186SQP-3151 ............... 200OMM-3152 .............. 216OMM-3152 .............. 216MAV-3153-v ............ 192MAF-3154-v ............ 186MRR-3155-v ........... 193MVM-3156-v ........... 177SRB-3157 ............... 207MIA-3158-v ............. 176MPR-3159-v ............ 193MAE-3160-v ............ 206MAY-3161-v............. 181SAF-3162-v ....179, 186MOC-3163-v ........... 189MOC-3164-s ........... 199IAT-3165-v ............... 158IAT-3166-v ............... 158SMO-3167-v ........... 190SMO-3168-v ........... 189IAT-3169-v ............... 172IAT-3170-v ............... 172SAP-3171-v............. 180IAP-3172-v .............. 156IBA-3173-v .............. 158ICE-3174-v .............. 159IZL-3175-v ............... 162MLG-3176-v ............ 206MLL-3177-v ............. 207IZL-3178-v ............... 155MLG-3179-v ............ 206ICL-3180-v .............. 157MVA-3181-v ............ 181IVA-3182-v .............. 158MOC-3183-v ........... 182MOC-3184-v ........... 182MCA-3185-v ............ 196

MCA-3186-v ............ 181ICA-3187-v .............. 157ICA-3188-v .............. 159ICA-3189-v .............. 159SZQ-3190 ............... 204ICA-3192-v .............. 156MCA-3193-v ............ 180ICA-3194-v .............. 156MCA-3195-v ............ 180ICA-3196-v .............. 157SAA-3197-v............. 190MCA-3198-v ............ 181ICA-3199-v .............. 157SMO-3200-v ........... 183MCA-3201-v ............ 204IAA-3202-v .....163, 170MCA-3203-v ............ 181IVD-3204-v .............. 158IUB-3207-v .............. 171MCA-3208-v ............ 184MCA-3209-v ............ 198MCA-3210-v ............ 184MCA-3211-v ... 184, 211SMO-3212-v ........... 203ISU-3214-v .............. 168MCA-3215-v ............ 194SMO-3216-v ........... 200SFQ-3217-v ............ 203IZL-3218-v ............... 170IGS-3219-v .............. 169MCA-3220-v ...180, 182ICA-3221-v .............. 156MCA-3222-v ............ 178ICL-3223-v .............. 155SFR-3224-s............. 175SMO-3225-v ........... 183SMO-3226-v .................174, 188, 189MCA-3227-v ............ 207SAP-3228-v............. 192SFQ-3229-v ............ 202SNE-3230-v ............ 191SFR-3231-v............. 182SNP-3232-v ............ 201PAG-3402-s ............ 123PKC-3403-v ............ 222PLP-3404-s ............. 222PLP-3405-v ............. 221PED-3512-PI ........... 166PED-3512-PI ............. 56PLP-3602-PI ............. 60PED-3610-PI ........... 167PED-3610-PI ............. 56PAB-3615-PI ............. 12PCA-3618-PI ............. 23STP-3621-PI ........... 180

SML-3622-PI ........... 176SFM-3624-PI .......... 190PGH-3625-PI ............ 66PGH-3626-PI ............ 66PGH-3627-PI ............ 66PGH-3628-PI ............ 66SPR-3629-PI ........... 195SPR-3630-PI ........... 195PAB-3631-PI ............. 12PAB-3632-PI ............. 12POV-3636-PI ............. 97PAB-3637-PI ............. 11PUT-3639-PI ........... 143PUT-3640-PI ........... 143IGS-3641-PI ............ 169PHR-3642-PI ............ 12PDL-3643-PI ............. 39IEC-3644-PI ............ 162PGH-3645-PI ............ 66PGH-3646-PI ............ 66PGH-3647-PI ............ 66PGH-3648-PI ............ 67MCA-3649-PI .......... 206MCA-3650-PI .......... 206PCI-3651-PI .......22, 25PGH-3652-PI .......... 119PGH-3653-PI ............ 65PGH-3654-PI ............ 65IDP-3655-PI ............ 165PGH-3656-PI ............ 66PMB-3657-PI ............ 59PMB-3658-PI ............ 59POV-3659-PI ............. 97PMG-3660-PI ............ 60PCI-3661-PI .............. 21PCI-3662-PI .............. 23PAR-3663-PI ........... 110PAR-3664-PI ........... 110PAR-3665-PI ........... 110SAP-3666-PI ........... 192SAP-3667-PI ........... 192SAP-3668-PI ........... 192PMC-3669-PI ............ 82SMO-3670-PI .......... 174IAL-3671-PI ............. 155PAR-3672-PI ........... 112PAR-3673-PI ........... 112PAR-3674-PI ........... 112PAR-3675-PI ........... 113PAR-3676-PI ........... 110PAR-3677-PI ........... 110IAL-3678-PI ............. 155MCA-3679-PI .......... 203PGH-3680-PI ............ 67PGH-3681-PI ............ 67SMO-3682-PI .......... 189


PTID

ES IN

TERN

ATIO

NAL

INDE

X by

PRO

DucT

cO

DE N

umbE

R

328 Order Hotline 1-800-777-4779 502-266-8787

PMC-3683-PI ............ 82PMC-3684-PI ............ 82PMC-3685-PI ............ 82PCI-3686-PI .............. 20PCI-3687-PI .............. 20PCI-3688-PI .............. 23PAR-3689-PI ............111SFQ-3690-PI ........... 203PAR-3691-PI ........... 112SAP-3693-PI ........... 197PGH-3694-PI ............ 66PAR-3695-PI ........... 110PCI-3696-PI .............. 21PCI-3697-PI .............. 22PNM-3698-PI ............ 90PCI-3699-PI .............. 22SFA-3701-v ............. 211SFR-3702-v............. 211SFN-3703-v............. 211SFD-3704-v............. 211SFQ-3705-v ............ 212SFE-3706-v ............. 212SFG-3707-v ............ 212SFH-3708-v............. 212SFI-3709-v .............. 212SFL-3710-v ............. 212SFL-3710-v ............. 213SFK-3711-v ............. 212SFM-3712-v ............ 213SFF-3713-v ............. 213SFP-3714-v ............. 213SFS-3715-v ............. 213SFT-3716-v ............. 213SFW-3717-v ............ 213SFY-3718-v ............. 213SFV-3719-v ............. 214STD-3720-v............. 214STD-3721-v............. 214PGL-3722-PI ............. 68PGL-3723-PI ............. 68PCP-3724-PI ............. 32PCP-3725-PI ............. 32PYY-3726-PI ........... 103SDR-3727-PI .......... 182SRK-3728-PI ........... 196MCA-3729-PI .......... 206SFQ-3730-PI ........... 196SFQ-3731-PI ........... 202TAT-3733-PI ............ 220TAT-3734-PI ............ 220TAT-3735-PI ............ 221RGD-3736-PI ............ 22SRC-3737-PI .......... 117PFB-3742-PI ............. 61PAR-3743-PI ............111ENT-3744-PI ........... 129

PLP-3745-PI ............. 73SHK-3746-PI ........... 140PSI-3747-PI ............ 117SHD-3748-PI .......... 196RGD-3749-PI ............ 21RGD-3749-PI .......... 220SKT-3750-PI ........... 196TAT-3751-PI ............ 221TAT-3752-PI ............ 221PTH-3753-PI ............. 99IAP-3754-PI ............ 154ANP-3755-PI ............. 17END-3756-PI ............ 52PVA-3757-PI ........... 143FAP-3758-PI ............. 26PCI-3759-PI .............. 21PCI-3759-PI ............ 220ECT-3760-PI ........... 129RGD-3761-PI ............ 25RGD-3762-PI ............ 25SFQ-3763-PI ........... 197SFQ-3764-PI ........... 174IOX-3765-PI ............ 169IOX-3765-PI ............ 221RGD-3766-PI ............ 24BIV-3767-PI ............... 26PLP-3768-PI ............. 74PLP-3769-PI ............. 73PED-3788-PI .....56, 167SDP-3815-PI ........... 188SDP-3816-PI ........... 188SFQ-3817-PI ........... 174SFQ-3817-PI ........... 177SDP-3818-PI ........... 174SFQ-3819-PI ........... 177SDP-3820-PI ........... 189ISN-3821-PI ............ 164ISN-3825-PI ............ 164IAT-3830-PI ............. 163ISN-3831-PI ............ 164ISN-3835-PI ............ 164INH-3850-PI ............ 165INH-3852-PI ............ 165INH-3855-PI ............ 165PAC-3860-PI ............... 1KMF-3870-PI .......... 302PMC-3881-PI ............ 81SAP-3882-PI ........... 186PCI-3883-PI .............. 21SAP-3885-PI ........... 186PMC-3886-PI ............ 82PMC-3887-PI ............ 83PAR-3888-PI ............111PAR-3889-PI ............111PGH-3890-PI ............ 95PGH-3891-PI ............ 95

PGH-3892-PI ............ 95PGH-3893-PI ............ 95PCI-3899-PI .............. 23PHN-3901-PI ............ 37PGH-3902-PI ............ 70SAG-3905-PI .......... 199PAR-3906-PI .. 108, 110PFA-3907-PI ............. 26PGH-3908-PI ............ 71PCI-3909-PI .............. 26PCI-3910-PI .............. 26PGH-3911-PI ............ 70PCI-3912-PI .............. 23PAR-3913-PI ........... 110SFQ-3914-PI ........... 179SFQ-3915-PI ........... 198SFQ-3916-PI ........... 185PCI-3917-PI .............. 23PCI-3919-PI .............. 21PAR-3920-PI ............111PAN-3921-PI ............. 13PCP-3922-PI ............. 83MCA-3923-PI .......... 191PFA-3924-PI ............. 24PAR-3925-PI ........... 109PAR-3926-PI ........... 109INH-3927-PI ............ 164PUT-3928-PI ........... 143PCI-3929-PI .............. 25PCI-3930-PI .............. 25PAR-3931-PI ........... 108PAR-3932-PI ........... 112PAR-3933-PI ........... 112PAR-3934-PI ........... 109PAR-3935-PI ........... 109PAR-3936-PI ........... 108SFQ-3937-PI ........... 177PAR-3938-PI ............111PAR-3939-PI ........... 112PAR-3940-PI ............111PAR-3941-PI ........... 109PAR-3942-PI ........... 108PAR-3943-PI ........... 109PAR-3944-PI ........... 108PAR-3945-PI ........... 109SAP-3947-PI ........... 200PAN-3948-PI ............. 15PAN-3949-PI ............. 13PAR-3951-PI ........... 110PCI-3953-PI .............. 24PCI-3954-PI .............. 21PTP-3955-PI ........... 202PTK-3956-PI ........... 201SFQ-3957-PI ........... 191SFQ-3958-PI ........... 190PCI-3959-PI .............. 22

PCI-3960-PI .............. 20PVS-3961-PI ............. 61PMG-3962-PI ............ 60PCI-3964-PI .............. 36PCI-3965-PI .............. 26PLP-3966-PI ............. 61PLP-3967-PI ............. 60PMG-3968-PI ............ 60PLP-3970-PI ............. 60PVP-3971-PI ............. 61PMB-3972-PI ............ 59PMB-3973-PI ............ 59PMB-3974-PI ............ 60PCI-3975-PI .............xxxPTG-3976-PI ............. 58PCI-3978-PI .............xxxPCI-3979-PI .............xxxPAN-4001 .................. 13PAN-4001-v ............... 13PBK-4002 .................. 27PBK-4002-v............... 27PEL-4003 .................. 50PEL-4003-v ............... 50PGR-4004 ................. 63OPG-4005 ............... 215OPG-4006 ............... 215PAN-4007 .................. 13PAN-4007-v ............... 13PBK-4008 .................. 30PBK-4008-v............... 30IAB-4009 ................. 153IAB-4009-v ........28, 153IAC-4010 ................. 154IAC-4010-v ........28, 154PTR-4011 ........122, 217PTR-4011-v ............. 121PBK-4012 .................. 30PBK-4012-v............... 30PLR-4013 .................. 80PLR-4013-v ............... 79PSP-4014 ................ 119PSP-4014-v............. 119PAN-4016 .................. 15PAN-4016-v ............... 15PTF-4020 ........141, 218PTF-4020-v ....122, 141PLC-4022 ................ 217PLC-4022 .................. 78PSI-4023 ................. 117PSI-4023-v .............. 116PMI-4024 ..........82, 217POX-4025-v .............. 98PVP-4026-v............. 144PVP-4027-v............. 144PAN-4028 .................. 14PAN-4028-v ............... 14


NALINDEX by PRO

DucT cODE Num

bER

Order Hotline 1-800-777-4779 502-266-8787 329

PNT-4029 .................. 93PNT-4029-v ............... 93PPY-4030 ................ 104PPY-4030-v ............. 103PAD-4031 .................... 1PAD-4031-v ................. 1OPG-4032 ............... 215OPG-4033 ............... 215PAN-4034 .................. 16PAN-4034-v ............... 16PAN-4035 .................. 15PAN-4035-v ............... 15PAN-4036 .................. 14PAN-4036-v ............... 14PAN-4037 .................. 16PAN-4037-v ............... 16PSI-4038-v .............. 117ILP-4041 ................. 162ILP-4041-v .....161, 163PEK-4042 .................. 57PEK-4042-v............... 57PEK-4043 .................. 57PEK-4043-v............... 56PCL-4051-s ............... 32PCL-4051-v ............... 32PDS-4054 ................. 48PDS-4054-v .............. 48PEN-4055-v .............. 51PBK-4056-v............... 31PMR-4057-v .............. 82PST-4058 ................ 116PST-4058-v ............. 116PSP-4059-v............. 120PEN-4060-v .............. 52PSC-4061 ............... 115PSC-4061 ............... 217IAP-4062 ................. 160IAP-4062-v ......160, 163ICY-4063 ................. 163ICY-4063-v .............. 163IEL-4064 ................. 166IEL-4064-v .............. 166PBK-4065 .................. 29PBK-4065-v............... 29PCT-4066 .................. 35PCT-4066-v ............... 35PBK-4067 .................. 28PBK-4067-v............... 28PTH-4068-s............... 99PTH-4068-v............... 99PAN-4069 .................. 14PAN-4069-v ............... 14PMI-4070 ................ 216PMT-4070 ................. 85PAN-4071 .................. 16PAN-4071-v ............... 16

PBK-4075-v............... 30PMF-4076-v .............. 80PEK-4078-v............... 33PEK-4079 .................. 33PEK-4079-v............... 33PDY-4080-v ............... 49IPO-4082 ................. 168IPO-4082-v .............. 168PCK-4083 .........35, 218PCK-4083-v .............. 35POX-4084-v .............. 98PVP-4085-v............. 144PBM-4086 ................. 27PBM-4086-v .............. 27PCK-4087-v .............. 35PlN-4088-s ........76, 222PlN-4088-v ................ 76PEN-4089-v .............. 52PEN-4090-v .............. 87PEN-4091-v .............. 87PVI-4092 ................. 145IBS-4093-PI ...153, 154PTH-4094-v............. 100IAM-4095 ................ 152IAM-4095-v ............. 152IES-4096 ................. 161IES-4096-v .............. 160IBK-4097 ...........29, 154IBK-4097-v ........29, 154PGL-4098-s............... 67PCK-4100-v .............. 35PSI-4101-v .............. 117PAN-4102 .................. 16PAN-4102-v ............... 15PTH-4106-v............. 100PMS-4107 ................. 80PMS-4107-v .............. 80PDY-4108-v ............... 49PAC-4109-v ................. 1PVA-4110-s ............. 143PVA-4110-v ............. 143PCR-4111-s............... 37PCR-4111-v............... 37PSE-4112-v ............. 116PSP-4113 ................ 120PSP-4113-v ............. 120PSP-4114-v ............. 120PEK-4115 .................. 57PEK-4115-v ............... 57PEK-4116 .................. 57PEK-4116-v ............... 57PEK-4117-v ............... 58PEK-4118-v ............... 57PBM-4119-v .............. 26PTH-4124-v............. 100PCN-4126-v ............ 125

PGR-4127-s .............. 70PGR-4127-v .............. 70PTH-4129-v............. 101PBK-4130 .................. 30PBK-4130-v............... 29IDP-4132 .........166, 217IDP-4132-v .............. 165SDH-4133-v ............ 202PTH-4134-v............... 99PAF-4135-s ............... 17PAF-4135-v ............... 17PCR-4136-s .............. 37PCR-4136-v .............. 37PAF-4137-v ............... 18PAF-4138-v .........17, 18PAF-4139-v ............... 18PCN-4140-v ............ 126PCR-4141-s .............. 37PFM-4142 .........85, 218PFM-4142-v .............. 85PGR-4143-v .............. 63PBC-4144 ................. 78PAF-4145-v ............... 17ICL-4146 ................. 166ICL-4146-v .............. 166PML-4147-v .............. 85IAR-4148 ................. 152IAR-4148-v .............. 152IAR-4149 ................. 152IAR-4149-v .............. 152PAF-4151-s ............... 18PAF-4151-v ............... 19PNM-4152 ................. 88PNM-4152-v .............. 88PNM-4153 ................. 89PNM-4153-v .............. 89PNK-4154 ................. 88PNK-4154-v .............. 87IEB-4155 ................. 153IAC-4157-PI ............ 152PNP-4158-s .............. 92PNP-4158-v .............. 92PAF-4159-v ............... 19PCG-4160-s .............. 34PCG-4160-v .............. 34PCN-4161-v ............ 127PNP-4162-s .............. 92PNP-4162-v .............. 92PCG-4163-s .............. 34PCG-4163-v .............. 34PGR-4164-v .............. 64PSE-4165-v............. 116SAG-4166 ............... 198PDE-4167 ................... 1PAF-4168-s ............... 18PTH-4169-v............. 100

PTH-4170-v............. 100PFA-4171 ..........25, 217PFA-4171-v ............... 25PSP-4172 ................ 119PSP-4172-v............. 119PSP-4173 ................ 120PSP-4173-v............. 120PBK-4175-v............... 30PCK-4176-s .............. 36PPM-4177-v ............ 102PGR-4178-s .............. 64PGR-4178-v .............. 64PTH-4179-v............. 101PTH-4180-v............. 101PTH-4181-v............. 101PGR-4183-s .............. 63SRG-4184-v ............ 201PTH-4185-v............. 101PPP-4186-v............... 98PPT-4188 ................ 103PPT-4188-v ............. 102PFA-4189 .................. 25PFA-4189-v ............... 25IFR-4190 ................. 154IFR-4190-v .............. 154PBK-4191-v............... 30PVP-4192-v............. 144PBK-4193-v............... 29PLP-4194 .................. 78PLP-4194-v ............... 78PNT-4195-s ............. 135PMG-4196-v ............. 80PED-4198-s .............. 52PED-4198-v .............. 52PED-4199-s .............. 53PED-4199-v .............. 53PBN-4200-v .............. 31PCK-4201-s .............. 36PBK-4202 .................. 28PBK-4202-v............... 28PVP-4203-v............. 144PTH-4205-v............. 102PSF-4206-s ............. 139PED-4207-s .............. 54PED-4207-v .............. 54PED-4208-s .............. 54PED-4208-v .............. 54PED-4209-s .............. 53PED-4211-s............... 56PBN-4212-v .............. 31PBN-4213-v .............. 31PCR-4214-v .............. 98PTH-4215-v............. 102PSP-4216-s............. 116PCN-4217-v ............ 126PBN-4218-s .............. 32


PTID

ES IN

TERN

ATIO

NAL

INDE

X by

PRO

DucT

cO

DE N

umbE

R

330 Order Hotline 1-800-777-4779 502-266-8787

PAM-4219-v ................ 9PAM-4220-v ................ 9PPA-4221-v ............. 104PED-4222-s .............. 55PED-4223-s .............. 55PCB-4227-s ............ 124PCN-4228-v ............ 126PCT-4229-v ............... 38PBN-4230-v .............. 31PPA-4231-v ............. 104PCG-4232-v .............. 34PIL-4233-v ................ 36PIB-4235-s .............. 131SSV-4236-v ............. 197SKL-4237-v ............. 201PCT-4240-s ............... 39PCT-4241-s ............... 38PEL-4243-v ............. 166PEL-4243-v ........49, 50PGA-4244-v .............. 63PGA-4245-v .............. 62PSF-4246-s ............. 139PAG-4247-s ................ 5ILH-4249-v .............. 153PCT-4251-v ............... 39PED-4253-s .............. 55PCL-4255-s ............. 124PAG-4256-s ............ 122PAP-4257-v ............... 19PMC-4258-v .............. 81PKL-4259-s ............. 132PSC-4260-s ............ 140POS-4261-s .............. 97POS-4262-s .............. 97PCN-4263-v ............ 127PCO-4264-v ............ 125PCO-4265-v ............ 125PED-4266-s .............. 54PED-4267-s .............. 55PDC-4269-s .............. 40PHS-4270-s .............. 75PDF-4271-s............... 40PGN-4274-s .............. 71PGN-4275-s .............. 71PAD-4278-s ................. 2PXN-4279-v ............ 145PGP-4280-v .............. 68PAD-4281-s ................. 2PCN-4282-v ............ 124PCN-4283-s ............ 128PCN-4283-v ............ 128PCN-4284-v ............ 128PED-4285-v .............. 56PPA-4286-v ............. 104PSK-4287-s............. 140PJP-4288-v ............... 76

PCN-4289-v ............ 127PAR-4290-s ............. 133PAM-4291-v ................ 4PAM-4292-v ................ 4PKB-4293 .................. 28PKB-4293-v............... 27PAG-4294-s ............ 123PUG-4295-s .............. 72PAN-4296-v ............... 16PMK-4298-v .............. 84PMK-4299-s .............. 84PPL-4300-s ............. 136PAD-4302-v ................. 2PBK-4303 .................. 29PBK-4303-v............... 29ICA-4304 ................... 23ICA-4304-v ................ 22IPF-4305-v .............. 105PAM-4307-v ................ 9PAM-4309-v .............. 11PCC-4310-s ............ 123PCN-4311-v ............ 126PTT-4313-s ............. 141PNP-4314-s .............. 93PNP-4315-s .............. 93PNP-4317 ................. 88PNP-4317-v .............. 88PNO-4318-v .............. 94IEC-4320-v .............. 161IED-4321-v .............. 161IEC-4322-v .............. 160IEC-4323-v .............. 160PTH-4324-v............... 99PAD-4325-v ................. 2PUC-4327-s ............ 118PUC-4328-s ............ 118PCN-4329-v .............. 38PDN-4330-s ............ 128PAN-4331 .................. 14PAN-4331-v ............... 14PAN-4332 .................. 15PAN-4332-v ............... 15PGX-4333 ................. 51PGX-4333-v .............. 51PLP-4334 .................. 51PLP-4334-v ............... 51PTN-4335-v............. 106PNO-4336-v .............. 94PDF-4337-s............... 45PDF-4338-s............... 46PAM-4339-v ................ 4PMT-4340-s ............ 134PMT-4341-s ............ 133IPH-4342-v .............. 153PIM-4343-s ............. 132PGL-4344-v............... 67

PEX-4345-v............... 58POR-4346-s .............. 96POR-4347-s .............. 96POR-4348-s .............. 96PAM-4349-v .............. 10PCA-4350-s .............. 33PCA-4351-s .............. 33PPR-4352-v ............ 106PPR-4353-v ............ 107PUG-4354-s .............. 71PNO-4355-v .............. 94PAB-4358-v ............... 12PAB-4359-v ............... 10PED-4360-s .............. 53PAP-4361-v ............... 20PAP-4362-s ............... 19PCB-4363-s ............ 140PTK-4364-s ............. 141PUT-4365-v ............. 142PAR-4366-s ................. 7PAB-4367-v ............... 11ILC-4368-v .............. 171PMC-4369-v .............. 81PAB-4370-v ............... 10PUT-4371-v ............. 142PGH-4372-s .............. 64PGH-4373-s .............. 65IKK-4374-v .............. 168PKT-4375-s ............. 132PGL-4376-v............... 69PNM-4377-v .............. 90IBS-4378-v .............. 169PAB-4379-v ............... 10PRF-4380-s............. 114IEP-4381-v .............. 171PDF-4382-s............... 46PUC-4383-s ............ 119PHN-4384-v .......37, 75PHN-4385-v .............. 75PST-4387-s ............. 118PST-4388-s ............. 118PMT-4389-v .............. 77PGL-4391-s............... 63PLP-4392-s ............... 74PCB-4393-s ............ 129IGS-4394-v .............. 170IRG-4395-v ............. 167IKG-4396-v .............. 167IPA-4397 ................. 162IPA-4397 ................. 179IPA-4397-v .............. 162PYY-4400-v ............. 103PNP-4403-v .............. 91PNP-4404-v .............. 92PLP-4405-s ............... 75PDF-4406-s............... 47

PUT-4408-v ............. 142PTX-4409-s ............. 137PMT-4410-s ............ 134PND-4411-v .............. 50PND-4412-v .............. 50PAB-4413-s ............... 11PDF-4415-s............... 44PDF-4416-s............... 42PSL-4417-s ............. 115PSL-4418-s ............. 115PRF-4419-s............. 113PAB-4420-s ............... 11PAD-4421-s ................. 3PAD-4422-s ................. 3PMT-4424-s ............ 134PNP-4425-v .............. 91PNM-4426-s .............. 89PNM-4427-s .............. 89PDF-4428-s............... 41PDF-4431-s............... 43PDF-4432-s .................. .........105, 130, 138, 142PGX-4433-s ...................................130, 138, 142PLP-4434-s ............... 73PTX-4435-s ............. 138PGH-4436-s .............. 65PGH-4436-s .............. 71PGH-4437-s .............. 65PAN-4439-v ............... 17PCN-4440-v ............ 127PNR-4441-s .............. 86PNR-4442-s .............. 87PNR-4443-s .............. 87PNR-4444-s .............. 87PLL-4445-s ............... 79PMT-4446-v .............. 78PMT-4447-s .............. 78PAL-4449-s ................. 7PTX-4450-s ............. 137PNS-4452-v .............. 90PKS-4453-v............... 78PDL-4454-s ............... 48PLL-4455-s ............. 131PAP-4456-s ................. 5PPT-4457-v ............. 139PDF-4458-s............... 45PNP-4459-v .............. 91PPT-4460-v ............. 102PRF-4461-v............. 115PRF-4462-v............. 115PUG-4463-s .............. 72TNN-4464-v ............ 121PLP-4467-v ............... 73AMP-4468-s ................ 8 AGP-4469-s ................ 6


NALINDEX by PRO

DucT cODE Num

bER

Order Hotline 1-800-777-4779 502-266-8787 331

BCN-5000-PI .......... 261FCP-5001-PI ........... 268PAC-5002-PI ........... 281DTB-5003-PI ........... 300FCT-5004-PI ........... 273FHP-5005-PI ........... 274FPZ-5006-PI ........... 276FFD-5007-PI ........... 277FAD-5008-PI ........... 281FDY-5009-PI ........... 274PRA-5010-PI ........... 277MPA-5011-PI ........... 304EDP-5012-PI ........... 301MBZ-5016-PI .......... 266FKD-5018-PI ........... 275FDD-5019-PI ........... 274AXP-5020-PI ........... 281AXL-5021-PI ........... 281ADX-5026-PI ........... 281ALX-5027-PI ........... 281ADX-5028-PI ........... 281ALX-5029-PI ........... 281AXP-5030-PI ........... 304ALX-5041-PI ........... 280ASX-5042-PI ........... 304FDY-5043-PI ........... 275ASX-5045-PI ........... 281ASX-5045-PI ........... 304ASX-5047-PI ........... 304ASX-5048-PI ........... 304ASX-5049-PI ........... 304XDM-5120-PI .......... 281XLM-5121-PI ........... 281BDX-5220-PI ........... 264BLX-5221-PI ........... 264BDF-5222-PI ........... 260BLX-5230-PI ........... 265BMS-5310-PI .......... 266BMY-5311-PI ........... 266BMV-5312-PI .......... 266BML-5313-PI ........... 266BLF-5315-PI............ 264BDF-5316-PI ........... 265BDI-5318-PI ...259, 263BDX-5319-PI ........... 263BLX-5320-PI ........... 263BLO-5321-PI ........... 263BXF-5322-PI ........... 266BFG-5323-PI ........... 265BLX-5324-PI ........... 262BLX-5325-PI ........... 263BLO-5326-PI ........... 263BLX-5327-PI ........... 263BLK-5328-PI ........... 257BLF-5329-PI............ 265ALX-5330-PI ........... 281

BLX-5331-PI ........... 264BLY-5332-PI ............ 265BLF-5333-PI............ 265BLY-5334-PI ............ 266BDF-5335-PI ........... 265BDY-5336-PI ........... 266BLF-5337-PI............ 265BDY-5338-PI ........... 266BDX-5339-PI ........... 264BLX-5340-PI ........... 261BLX-5341-PI ........... 262BLX-5342-PI ........... 263BDX-5343-PI ........... 263BLX-5345-PI ........... 262BDX-5346-PI ........... 265BLX-5347-PI ........... 265BLQ-5349-PI ........... 256BLN-5351-PI ........... 261BAC-5352-PI ........... 261BDX-5354-PI ........... 262BDX-5355-PI ........... 264BDX-5357-PI ........... 262FLC-5358-PI ........... 268BLX-5359-PI ........... 262BDX-5360-PI ........... 261BLO-5361-PI ........... 264BLX-5362-PI ........... 260BAB-5363-PI ........... 261BLK-5364-PI ........... 257BDX-5365-PI ........... 261BLX-5366-PI ........... 261BLX-5368-PI ........... 264BLX-5369-PI ........... 261BLF-5371-PI............ 262BDF-5373-PI ........... 262FLC-5374-PI ........... 268BDX-5375-PI ........... 259BLX-5378-PI ........... 262BLX-5379-PI ........... 263BDX-5381-PI ........... 263BLF-5383-PI............ 264BDF-5385-PI ........... 264BBX-5387-PI ........... 265BDX-5389-PI ........... 265BAB-5403-PI ........... 261BAM-5454-PI .......... 266BEP-5482-PI ........... 303BGP-5484-PI .......... 303BLP-5487-PI ........... 303BVP-5499-PI ........... 303SAM-5510-PI .......... 281SAM-5510-PI .......... 304FLX-5518-PI............ 273BXX-5519-PI ........... 231BXX-5519-PI ........... 263FXX-5521-PI ........... 232

FXX-5521-PI ........... 275FLX-5522-PI............ 273BXX-5523-PI ........... 231BXX-5523-PI ........... 263FXX-5524-PI ........... 231FXX-5524-PI ........... 275FDX-5525-PI ........... 274FLX-5526-PI............ 274BDF-5528-PI ........... 262FLX-5529-PI............ 274BDF-5530-PI ........... 262FDX-5531-PI ........... 274BLX-5532-PI ........... 264BDX-5533-PI ........... 264FLX-5534-PI............ 276FDX-5535-PI ........... 276FLD-5536-PI ........... 273FLE-5538-PI............ 274BEL-5540-PI ........... 266FDX-5541-PI ........... 273FLX-5545-PI............ 273BLD-5571-PI ........... 261BLE-5591-PI ........... 262BLD-5662-PI ........... 261BLE-5683-PI ........... 262DPG-5701-PI .......... 306DPG-5702-PI .......... 307DPG-5703-PI .......... 306DPG-5704-PI .......... 307DPG-5705-PI .......... 308DPG-5706-PI .......... 308DPG-5707-PI .......... 308DPG-5708-PI .......... 308DPG-5709-PI .......... 309DPG-5710-PI .......... 310DPG-5711-PI .......... 309DPG-5712-PI .......... 309DPG-5713-PI .......... 310DPG-5714-PI .......... 311DPG-5715-PI .......... 310DPG-5716-PI .......... 311DPG-5717-PI .......... 310DPG-5718-PI .......... 311DPG-5719-PI .......... 312DPG-5720-PI .......... 312DPG-5721-PI .......... 313DPG-5722-PI .......... 313DPG-5723-PI .......... 312DPG-5724-PI .......... 313DPG-5725-PI .......... 312DPG-5726-PI .......... 312DPG-5727-PI .......... 313DPG-5728-PI .......... 313DPG-5729-PI .......... 314DPG-5730-PI .......... 314DPG-5731-PI .......... 315

DPG-5732-PI .......... 315DPG-5733-PI .......... 315DPG-5734-PI .......... 315DPG-5735-PI .......... 315DPG-5736-PI .......... 316DPG-5737-PI .......... 315DPG-5738-PI .......... 316DPG-5739-PI .......... 316DPG-5740-PI .......... 317DPG-5741-PI .......... 317DPG-5742-PI .......... 317DPG-5743-PI .......... 317DPG-5744-PI .......... 317DPG-5745-PI .......... 317DPG-5746-PI .......... 317DPG-5747-PI .......... 318DPG-5748-PI .......... 318DPG-5749-PI .......... 318DPG-5750-PI .......... 318DPG-5751-PI .......... 318DPG-5752-PI .......... 318DPG-5753-PI .......... 319DPG-5754-PI .......... 319DPG-5755-PI .......... 319DPG-5756-PI .......... 319DPG-5757-PI .......... 319DPG-5758-PI .......... 319DPG-5759-PI .......... 320DPG-5760-PI .......... 320DPG-5761-PI .......... 320DPG-5762-PI .......... 320DPG-5763-PI .......... 316BLX-5828-PI ........... 264BEF-5841-PI ........... 266KLH-6000-PI ........... 229BDN-6004-PI .......... 300RTS-9002-PI ........... 297RTS-9311-PI ........... 298RTS-9312-PI ........... 298RTS-9321-PI ........... 298RTH-9330-PI ........... 295RTH-9331-PI ........... 295RTH-9332-PI ........... 295RTH-9333-PI ........... 295RTH-9334-PI ........... 295RTH-9335-PI ........... 295RTH-9336-PI ........... 295RTH-9336-PI ........... 296RTH-9337-PI ........... 296RTH-9338-PI ........... 296RTH-9339-PI ........... 296RTH-9340-PI ........... 296RTH-9341-PI ........... 296RTH-9342-PI ........... 296TMB-9343-PI .......... 296TMB-9344-PI .......... 296


PTID

ES IN

TERN

ATIO

NAL

INDE

X by

PRO

DucT

cO

DE N

umbE

R

332 Order Hotline 1-800-777-4779 502-266-8787

TMB-9345-PI .......... 296TMB-9346-PI .......... 296TMB-9347-PI .......... 296TMB-9348-PI .......... 296TMB-9349-PI .......... 296TMB-9350-PI .......... 296RTM-9401-PI .......... 297RTS-9901-PI ........... 295RTS-9902-PI ........... 295RTS-9903-PI ........... 295RTS-9904-PI ........... 295RTS-9905-PI ........... 295RTS-9912-PI ........... 298RTS-9913-PI ........... 297RTS-9923-PI ........... 297RTS-9932-PI ........... 297RTH-9937-PI ........... 284RTS-9992-PI ........... 297RTS-9993-PI ........... 297RTS-9995-PI ........... 297RFA-10010-PI ......... 292RFX-10011-PI ......... 292RFR-10012-PI ......... 292RFN-10013-PI ......... 292RFD-10014-PI ......... 292RFC-10015-PI ......... 292RFQ-10019-PI ........ 292RFE-10020-PI ......... 292RFG-10021-PI ........ 292RFH-10022-PI ......... 292RFI-10023-PI .......... 292RFL-10024-PI ......... 292RFK-10025-PI ......... 292RFM-10026-PI ........ 292RFF-10027-PI ......... 292RFP-10029-PI ......... 292RFS-10030-PI ......... 293RFT-10031-PI ......... 293RFW-10032-PI ........ 293RFW-10033-PI ........ 293RFY-10034-PI ......... 293RFV-10035-PI ......... 293RHX-11040-PI ......... 286RHX-11048-PI ......... 284RHX-11049-PI ......... 284RHA-11050-PI ......... 284RHX-11051-PI ......... 284RHN-11053-PI ........ 285RHD-11054-PI ........ 285RHX-11055-PI ......... 284RHC-11056-PI ........ 285RHQ-11058-PI ........ 285RHE-11059-PI ......... 285RHG-11060-PI ........ 285RHH-11061-PI ........ 285RHI-11062-PI .285, 286

RHK-11064-PI ......... 286RHM-11065-PI ........ 286RHF-11066-PI ......... 286RHP-11067-PI ......... 286RHS-11068-PI ......... 286RHT-11069-PI ......... 286RHW-11070-PI ........ 287RHW-11071-PI ........ 287RHY-11072-PI ......... 287RHV-11073-PI ......... 287RHM-11074-PI ........ 286RHX-11074-PI ........... 17NCL-14051-v .......... 239NVA-14110-v ........... 247NSE-14112-v .......... 246NGR-14127-v .......... 243NAF-14135-v .......... 238NCR-14136-v .......... 240NNP-14158-v .......... 245NCG-14160-v .......... 239NGR-14164-v .......... 244NCK-14176-v .......... 239NPP-14186-v .......... 246NED-14198-v .......... 241NBN-14200-v .......... 239NED-14210-v .......... 241NSP-14216-v .......... 246NAM-14220-v .......... 237NED-14224-v .......... 242NED-14225-v .......... 242NED-14226-v .......... 243NIL-14233-v ............ 240NED-14238-v .......... 242NEL-14243-v ........... 241NGA-14244-v .......... 243NCT-14250-v .......... 240NOS-14276-v .......... 245NAD-14278-v .......... 236NAP-14307-v .......... 237NMK-14319-v .......... 244NBD-14338-v .......... 241NOR-14346-v .......... 245NAB-14356-v .......... 238NAB-14357-v .......... 238NAB-14359-v .......... 237NUT-14365-v .......... 247NAB-14414-v .......... 238NSL-14418-v ........... 246NAD-14421-v .......... 236NAN-14439-v .......... 245NLY-14802-v ........... 244SHG-20003-PI ....... 323SHG-20200-PI ........ 323SHG-20205-PI ........ 321SHG-20210-PI ........ 321SHG-20215-PI ........ 321

SHG-20230-PI ........ 321SHG-20260-PI ........ 321SHG-20290-PI ........ 321SHG-20295-PI ........ 321SHG-20300-PI ........ 321SHG-20400-PI ........ 321SHG-20600-PI ........ 321STB-21018-PI .321, 323SHG-21115-PI ......... 322SHG-21130-PI ........ 322SHG-21160-PI ........ 322SHG-21190-PI ........ 322CAR-22001 ............. 223CAR-22002 ............. 223CAR-22003 ............. 223CAR-22004 ............. 223CAR-22005 ............. 223CAR-22101 ............. 223CAR-22102 ............. 224CAR-22103 ............. 224CAR-22104 ............. 224CAP-22201-PI ......... 322CAP-22203-PI ......... 322CAP-22205-PI ......... 323SHG-22215-PI ........ 322CAP-22225-PI ......... 323SHG-22230-PI ........ 322CAP-22232-PI ......... 323SHG-22260-PI ........ 322SHG-22290-PI ........ 322SHG-22315-PI ........ 322SHG-22330-PI ........ 322SHG-22360-PI ........ 322SHG-22390-PI ........ 322SHG-22630-PI ........ 322SHG-22660-PI ........ 322SHG-22690-PI ........ 322SHG-22695-PI ........ 322SEP-22825-PI ......... 323SEP-22832-PI ......... 323SEP-22845-PI ......... 322STC-22900-PI .321, 323STC-22902-PI .321, 323CAR-23001-v .......... 224CKG-23002-v .......... 224CKG-23003-v .......... 225SGS-23004-s .......... 229CKG-23005-s .......... 225CKG-23005-s .......... 303CAR-24001-s .......... 225CAR-24002-v .......... 225CAR-24003-v .......... 225CAR-24004-v .225, 229CLP-24005-s ........... 226CLP-24005-s ........... 229CLP-24006-s ........... 226

CAR-24007-v .......... 228CLP-24008-s ........... 227FLR-53012-PI ......... 267FLX-53102-PI ......... 250FLX-53103-PI ......... 250FLO-53104-PI ......... 250FDX-53106-PI ......... 249FDX-53107-PI ......... 249FDO-53108-PI ........ 250FDK-53109-PI ......... 249BLX-53110-PI ......... 248BLX-53111-PI .......... 248BLO-53112-PI ......... 248BLK-53113-PI ......... 248BDX-53114-PI ......... 248BDX-53115-PI ......... 248BDO-53116-PI ........ 249BDK-53117-PI ......... 248

Name Page Number Name Page Number

Symbols and Numbers(This section includes product names that start with Greek characters, brackets, numbers, etc.)

a-Conotoxin GI .......................................................... 125a-Conotoxin ImI ......................................................... 126a-Conotoxin MI .......................................................... 126a-Conotoxin SI .......................................................... 126α-Conotoxin SIIIA ....................................................... 127a-Defensin-1 (Human) ................................................ 40a-Defensin-3 (Human) ................................................ 42α-Defensin-4 (Human) ................................................. 43a-Defensin-5 (Human) ................................................ 44α-Defensin-6 (Human) ................................................. 45a-Endorphin................................................................. 51a-Mating Factor ........................................................... 80a-MSH ......................................................................... 82a-Neo-Endorphin (Porcine) ........................................ 87a-Amidating Enzyme Substrate ................................ 175β-Defensin-2 (Human) ................................................. 41β-Defensin-2 (Human) Antiserum ............................. 241β-Protein (Human, 1-16) Antiserum .......................... 237β-Secretase Substrates ............................................. 203γ-Glutamyl Trans-peptidase Substrate ..................... 195γ-Secretase Substrate ............................................... 203ω-Agatoxin IVA........................................................... 122ω-Agatoxin TK ........................................................... 123ω-Agatoxins ............................................................... 122ω-Conotoxin GVIA ..................................................... 127ω-Conotoxin MVIIA .................................................... 127ω-Conotoxin MVIIC ................................................... 128ω-Conotoxin MVIIC ................................................... 128ω-Conotoxin SVIB ..................................................... 128(1- >O)-9-Fluorenylmethoxycarbonyl-l-Threonine ... 224(3,5-Difluorophenylacetyl)-Ala-Phg-OtBu ................. 169(3,5-Difluorophenylacetyl)-Ala-Phg-OtBu ................. 169(Boc-Lys(Fmoc))2-Lys-b-Ala-Pam Resin .................. 299(Boc-Lys(Fmoc))4-Lys2-Lys-b-Ala-Pam Resin .......... 299(Pro-Hyp-Gly)10 • 20 H2O ........................................... 215(Pro-Hyp-Gly)5 • 10 H2O ............................................ 215(Pro-Pro-Gly)10 • 9 H2O .............................................. 215(Pro-Pro-Gly)10 • H2O ................................................. 215(Pro-Pro-Gly)5 • 4 H2O ............................................... 215(Pro-Pro-Gly)5 • H2O .................................................. 215(Z-Asp-Glu-Val-Asp)2-Rh110 ..................................... 182(Z-Leu-Leu-NHCH2)2CO ............................................ 170[13C18,15N3]-Hepcidin (Human) .................................... 221[Arg8]-Vasotocin ......................................................... 144[Asn1, Val5]-Angiotensin II (Bulk) ................................ 14[Asn1, Val5]-Angiotensin II ............................................ 14[Asu1,6,Arg8]-Vasopressin.......................................... 144[Asu1,6,Arg8]-Vasotocin .............................................. 144[Asu1,6]-Oxytocin........................................................... 98[D-Ala2, D-Leu5]-Enkephalin ........................................ 57[D-Ala2, D-Leu5]-Enkephalin (Bulk) ............................. 57[D-Ala2, Met5]-Enkephalin ........................................... 57

[D-Ala2, Met5]-Enkephalin (Bulk) ................................ 57[D-Ala2, Met5]-Enkephalinamide ................................. 58[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P ................119[D-Arg1,D-Pro2,D-Trp7,9,Leu11]-Substance P (Bulk) .....................................................................................119[D-Arg1,D-Trp7,9,Leu11]-Substance P .......................... 120[D-Arg1,D-Trp7,9,Leu11]-Substance P (Bulk) ................ 120[D-Pro2,D-Trp7,9]-Substance P ................................... 120[D-Pro2,D-Trp7,9]-Substance P (Bulk) ........................ 120[D-Pro4,D-Trp7,9]-Substance P (4-11) ....................... 120[D-Trp8]-Somatostatin1 ................................................ 17[Dap3]-Ghrelin (Human, Rat, 1-5) ................................ 67[Dap3]-Ghrelin (Rat) ..................................................... 67[Glu1]-Fibrinopeptide B ................................................ 61[Gly14]-Humanin ........................................................... 75[Gm3 Labelled by NBD] ............................................. 225[Hyp3]-Bradykinin (Human) .......................................... 29[Leu31,Pro34]-NPY (Porcine) ..................................... 93[Met(O)12]-ANP (Human, 1-28) .................................... 17[Met(O)12]-ANP (Human, 1-28) .................................... 17[N-Me-Asp1]-Angiotensin II .......................................... 13[Nle4, D-Phe7]-b-MSH-Amide ....................................... 82[Nle8,18,Tyr34]-Parathyroid Hormone (Human, 1-34 Amide) ........................................................................ 101[Nle8,18,Tyr34]-Parathyroid Hormone (Human, 3-34 Amide) ........................................................................ 101[Pmp1,Tyr(Me)2]-Arg8-Vasopressin ............................ 144[Pyr1]-Apelin-13 (Human, Bovine) ............................... 20[Pyr3]-Amyloid b-Protein (Human, 3-42) ......................11[Pyr33]-Pancreastatin (Porcine, 33-49) ........................ 98[Pyr33]-Pancreastatin (Porcine, 33-49) Antiserum ..... 246[Sar1, Ala8]-Angiotensin II ............................................. 15[Sar1, Ala8]-Angiotensin II (Bulk) ................................. 15[Sar1, Ile8]-Angiotensin II .............................................. 15[Sar1, Ile8]-Angiotensin II (Bulk) .................................. 15[Sar1, Thr8]-Angiotensin II ............................................ 15[Sar1, Thr8]-Angiotensin II (Bulk) ................................ 16[Sar1, Val5, Ala8]-Angiotensin II .................................... 16[Sar1, Val5, Ala8]-Angiotensin II (Bulk) ........................ 16[Sar1]-Angiotensin II ..................................................... 15[Thi5,8, D-Phe7]-Bradykinin ............................................ 30[Trp3, Arg5]-Ghrelin (1-5) .............................................. 70[Tyr0]-C-Peptide (Human) ........................................... 32[Tyr1]-Somatostatin .....................................................117[Tyr34]-Parathyroid Hormone (Bovine, 1-34 Amide) .. 101[Tyr34]-Parathyroid Hormone (Bovine, 7-34 Amide) .. 101[Tyr8]-Bradykinin ........................................................... 30[Tyr8]-Substance P ..................................................... 120[Val5]-Angiotensin I (Bovine) (Bulk) ............................ 14[Val5]-Angiotensin I (Bovine) ........................................ 14[Val5]-Angiotensin II ...................................................... 16[Val5]-Angiotensin II (Bulk) .......................................... 1610 mL Manual Reaction Vessel ................................. 32115 mL Amber Manual Reaction Vessel ..................... 32215 mL Manual Reaction Vessel ................................. 321


INDEX by PRODucT cO

DE NAME

Order Hotline 1-800-777-4779 502-266-8787 333


15 mL Manual Reaction Vessel with 3-way Teflon Stopcock .................................................................... 32215 mL Manual Reaction Vessel with Jacket ............. 3222-Chlorotrityl Chloride Resin ..................................... 2842-Deoxy-2-Phthalimido-3,4,6-Tri-O-Acetyl-a-D-Galacto pyranosyl Fluoride ..................................................... 2232-Deoxy-2-Phthalimido-3,4,6-Tri-O-Acetyl-a-D-Galacto-pyranosyl Fluoride ..................................................... 2232-Deoxy-2-Phthalimido-3,4,6-Tri-O-Acetyl-a-D-Glucopy-ranosyl Fluoride ......................................................... 2232-Deoxy-2-Phthalimido-3,4,6-Tri-O-Acetyl-a-D-Glucopy-ranosyl Fluoride ......................................................... 2232-Furoyl-Leu-Ile-Gly-Arg-Leu-Orn-NH2 ......................1102-Furoyl-Orn-Leu-Arg-Gly-Ile-Leu-NH2 ......................1102-NBDG ..................................................................... 2242-NBDLG ................................................................... 2252,3,4,6-Tetra-O-Acetyl-a-D-Galactopyranosyl Fluoride .. .................................................................................... 223200 mL Manual Reaction Vessel with Baffles ........... 3213-Mercaptopropionyl-Phe-Cha-Cha-Arg-Lys-Pro-Asn-Asp-Lys-NH2 ...............................................................11030 mL Amber Manual Reaction Vessel ..................... 32230 mL Manual Reaction Vessel ................................. 32130 mL Manual Reaction Vessel with 24/40 Vacuum Adapter Joint .............................................................. 32230 mL Manual Reaction Vessel with 3-way Teflon Stopcock .................................................................... 322300 mL Manual Reaction Vessel with Baffles ........... 3214 Branch MAP Cores ................................................. 2994-[D10]Leu-Insulin (Human) ........................................ 2224-Methoxyphenylazoformyl-Phe ............................... 190400 mL Manual Reaction Vessel with Baffles ........... 32143-52) ........................................................................... 7845-54) ........................................................................... 775 mL Manual Reaction Vessel .................................. 3215 mL Manual Reaction Vessel ................................... 3215-Azido-Pentanoic Acid ............................................. 2205-Bromo-4-Chloroindol-3-yl 5-Acetamido-3,5-Dideoxy-a-D-Glycero-D-Galacto-2-Nonulopyranosidonic Acid [X-Neu5Ac, X-Sialic Acid, X-NANA] .......................... 2245-Bromo-4-Chloroindol-3-yl5-Acetamido-3,5-Dideoxy-a-D-Glycero-D-Galacto-2-[X-Neu5Ac, X-Sialic Acid, X-NANA] Nonulopyranosidonic Acid ......................... 2246-Azido-Hexanoic Acid .............................................. 2206-Cl-HOBt Reagent ................................................... 30160 mL Amber Manual Reaction Vessel ..................... 32260 mL Manual Reaction Vessel ................................ 32160 mL Manual Reaction Vessel with 3-way Teflon Stopcock .................................................................... 32260 mL Manual Reaction Vessel with Jacket ............. 322600 mL and Larger Septum (Teflon-coated Silicone Rubber) ...................................................................... 322600 mL and Larger Septum (Teflon-coated Silicone Rubber) ...................................................................... 322600 mL Manual Reaction Vessel with Baffles ........... 3218 Branch MAP Cores ................................................. 299

8-Azido-3,6-Dioxaoctanoic Acid ................................ 22090 mL Amber Manual Reaction Vessel ..................... 32290 mL Manual Reaction Vessel ................................ 32190 mL Manual Reaction Vessel with 3-way Teflon Stopcock .................................................................... 32290 mL Manual Reaction Vessel with Jacket ............. 322

AA-Type (Atrial) Natriuretic Peptides (ANP) and Related Peptides ....................................................................... 17ABZ-5014-PI .............................................................. 261Abz-Ala-Gly-Leu-Ala-p-Nitro-Benzyl-Amide ............. 199Abz-Ala-Phe-Arg-Phe-Ser-Gln-EDDnp ..................... 198Abz-Ala-Pro-Glu-Glu-Ile-Met-Arg-Arg-Gln-EDDnp ... 191Abz-Arg-Arg-Arg-Arg-Ser-Ala-Gly-Tyr(NO2)-NH2 ..... 191Abz-Gly-Phe-Ser-Pro-Tyr(NO2)-OH .......................... 174Abz-Gly-Phe-Ser-Pro-Tyr(NO2)-OH .......................... 177Abz-Gly-Phe(NO2)-Pro-OH ....................................... 177Abz-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Dap(Dnp)-NH2 ............................................................ 174Abz-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Dap(Dnp)-NH2 ............................................................ 174Abz-Ser-Pro-Tyr(NO2)-OH ......................................... 177Abz-Thr-Asn-Met-Lys-His-Met-Ala-Gly-Ala-Ala-Gln-EDDnp........................................................................ 185Ac-Arg-[Cys-Met-Ava-Arg-Val-Tyr-Ava-Cys]-NH2 ...... 81Ac-Arg-Gly-Lys-MCA ................................................. 196Ac-Arg-Gly-Lys(Ac)-MCA .......................................... 196Ac-Arg-Leu-Arg-MCA ................................................ 206Ac-Arg-OMe • HCl ..................................................... 204Ac-Asp-Asn-Leu-Asp-H (aldehyde) .......................... 156Ac-Asp-Asn-Leu-Asp-MCA........................................ 180Ac-Asp-Gln-Thr-Asp-H (aldehyde) ............................ 156Ac-Asp-Gln-Thr-Asp-MCA ......................................... 180Ac-Asp-Glu ..................................................................... 1Ac-Asp-Glu • H2O (Bulk) ............................................... 1Ac-Asp-Glu-Asp(Edans)-Glu-Glu-Abu-l-Lactoyl-Ser-Lys(Dabcyl)-NH2 ........................................................ 196Ac-Asp-Glu-Val-Asp-H (aldehyde) ............................ 156Ac-Asp-Glu-Val-Asp-MCA ......................................... 180Ac-Asp-Met-Gln-Asp-H (aldehyde) ........................... 156Ac-D-Arg-[Cys-Met-Leu-Asn-Arg-Val-Tyr-Arg-Pro-Cys]-NH2 ............................................................................... 82Ac-Glu-Ser-Glu-Asn-MCA ......................................... 207Ac-Gly-D-Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-(Gly)4-Ser-D-Arg-(Leu)6-D-Arg-NH2 ........................................ 24Ac-Gly-Lys-OMe • AcOH .......................................... 204Ac-Gly-Pro-Leu-Asp-MCA ......................................... 206Ac-His-D-Phe(p-Iodo)-Arg-Trp-NH2 ............................. 82Ac-Ile-Glu-Thr-Asp-H (aldehyde) .............................. 157Ac-Ile-Glu-Thr-Asp-MCA ........................................... 180Ac-Leu-Arg-Ser-Arg-MCA ......................................... 199Ac-Leu-Glu-His-Asp-H (aldehyde) ............................ 157Ac-Leu-Glu-His-Asp-MCA ......................................... 181Ac-Leu-Leu-Met-H (aldehyde)................................... 155Ac-Leu-Leu-Nle-H (aldehyde) ................................... 155

PEPT

IDES

INTE

RNAT

IONA

LIN

DEX

by P

RODu

cT N

AME

334 Order Hotline 1-800-777-4779 502-266-8787


Ac-Leu-Pro-N-Me-Phe-Phe-Asp-NH2 ..........................11Ac-Leu-Pro-Phe-Phe-Asp-NH2 .................................... 12Ac-Lys-N-Me-Leu-Val-N-Me-Phe-Phe-NH2 ................ 12Ac-Lys-Thr-Lys-Gln-Leu-Arg-MCA ............................ 196Ac-Nle-cyclo [Asp-His-D-Phe-Arg-Trp-Lys]-NH2 .......... 82Ac-Nle-Pro-Nle-Asp-MCA .......................................... 206Ac-Phe-OEt ................................................................ 185Ac-Phe-Thiaphe-OH .................................................. 180Ac-S-Mpa-OPfp ......................................................... 304Ac-SIMP-1 .................................................................. 164Ac-SIMP-2 .................................................................. 164Ac-SIMP-2 .................................................................. 164Ac-Trp-Glu-His-Asp-H (aldehyde) ............................. 157Ac-Trp-Glu-His-Asp-MCA .......................................... 181Ac-Trp-OEt1 ................................................................. 85Ac-Tyr-NH2 ................................................................. 185Ac-Tyr-OEt • H2O ....................................................... 185Ac-Tyr-Val-Ala-Asp-CH2Cl ......................................... 157Ac-Tyr-Val-Ala-Asp-H (aldehyde) .............................. 158Ac-Tyr-Val-Ala-Asp-MCA ........................................... 181Ac-Tyr-Val-Gly ............................................................ 175Ac-Tyr-Val-Lys-Asp-H (aldehyde) .............................. 158Ac-Tyr-Val-Nle-Gly-His-D-Phe-Arg-Trp-Asp-Arg-Phe-Gly-NH2 ........................................................................ 82Ac-Val-Asp-Val-Ala-Asp-H (aldehyde) ...................... 158Ac-Val-Asp-Val-Ala-Asp-MCA ................................... 181Ac-Val-Glu-Ile-Asp-H (aldehyde) ............................... 158Ac-Val-Glu-Ile-Asp-MCA ............................................ 181Ac-Val-Phe-Arg-Ser-Leu-Lys-MCA ........................... 203Acetyl-Myelin Basic Protein (Human, Rat, 1-11) ........ 59Acetyl-Myelin Basic Protein (Mouse, 1-11) ................. 59ACTH (Human, 1-24) .................................................... 1Actinonin .................................................................... 152ACV (Delta-(l-Alpha aminoadipyl)-l-Cysteinyl-Bis-D-Valine) ............................................................................ 1ADAM-17 Substrates ................................................. 174ADAMTS-13 Substrates ............................................ 175Adjuvant Peptide ........................................................... 1Adjuvant Peptide (Bulk) ............................................... 1Adjuvant Peptide .................................................... 1, 5, 7Adrenocorticotropic Hormone (ACTH) .......................... 1Adrenomedullin (Human, 1-25) ..................................... 2Adrenomedullin (Human, 22-52) ................................... 2Adrenomedullin (Human) Antiserum ......................... 236Adrenomedullin (Human) .............................................. 2Adrenomedullin (Rat) ..................................................... 2Adrenomedullin 2 (Human, 1-7) Antiserum .............. 236Adrenomedullin 2 (Human) ........................................... 3Adrenomedullin 2 (Rat).................................................. 3Adrenomedullins and Related Peptides........................ 2Adropin (Human, 34-76 ) ............................................... 5Agelenin ......................................................................... 5Agouti-Related Protein ..................................6, 7, 8, 121Agouti-Related Protein (Human, 86-132) ..................... 7Ala-Ala-Phe-CH2Cl .................................................... 170Ala-Ala-Phe-MCA ...................................................... 204

Ala-Arg-Gly-Ile-Lys-Gly-Ile-Arg-Gly-Phe-Ser-Gly • 3AcOH • 5H2O ........................................................... 198Ala-MCA ..................................................................... 175Ala-pNA ...................................................................... 175Alarin (Human) ............................................................... 7Amastatin ................................................................... 152Amastatin (Bulk) ....................................................... 152AMC ........................................................................... 200Amino Acid Esters...................................................... 253Amino Acids ............................................................... 248Amino-dPEG® Acids .................................................. 310Amino-dPEG® t-Butyl Esters ......................................311Amino-dPEG®12 Acid ................................................ 310Amino-dPEG®12 t-Butyl Ester ....................................311Amino-dPEG®2 t-Butyl Ester ..................................... 309Amino-dPEG®24 Acid ................................................ 310Amino-dPEG®24 t-Butyl Ester ....................................311Amino-dPEG®4 Acid .................................................. 310Amino-dPEG®4 Methyl Ester Kit ............................... 309Amino-dPEG®4 t-Butyl Ester ..................................... 309Amino-dPEG®8 Acid .................................................. 310Amino-dPEG®8 t-Butyl Ester ......................................311Aminomethylated Polystyrene Resin • HCI ............. 282Aminomethylated Polystyrene Resin • HCl .............. 282Aminomethylated Polystyrene Resin • HCl .............. 282Aminomethylated Polystyrene Resin • HCl ............... 282Aminopeptidase ......................................................... 152Aminopeptidases Substrates .................................... 175Amphipathic Peptide Antibiotic .................................... 12Amylin (Human) ............................................................. 9Amylin (Rat) ................................................................... 9Amylin (Rat) Antiserum .............................................. 237Amylins ........................................................................... 9Amyloid-Protein (Human, 37-42) Antiserum ............. 238Amyloid-Protein (Human, 37-43) Antiserum ............. 238Amyloid A4-Generating Enzyme Substrate .............. 176Amyloid b-Protein (40-1) ..............................................11Amyloid b-Protein (42-1) ..............................................11Amyloid b-Protein (Human, 1-16) ............................... 10Amyloid b-Protein (Human, 1-40) ................................. 9Amyloid b-Protein (Human, 1-40) [HCI Form] ........... 10Amyloid b-Protein (Human, 1-40) Antiserum............ 237Amyloid b-Protein (Human, 1-42) ............................... 10Amyloid b-Protein (Human, 1-43) ............................... 10Amyloid b-Protein (Human, 25-35) ..............................11Amyloid b-Protein (Human, 34-40) Antiserum ......... 238Amyloid b-Protein Related Peptides ............................. 9Angiotensin (Human, 1-7) ........................................... 15Angiotensin (Human, 1-7) (Bulk) ................................ 15Angiotensin and Related Peptides .............................. 13Angiotensin I (Human) (Bulk) ..................................... 13Angiotensin I (Human) (0.5 mg vial) ........................... 13Angiotensin I Converting Enzyme I Substrates ........ 177Angiotensin I Converting Enzyme II Substrates ....... 177Angiotensin I Converting Enzyme Inhibitors .....152, 153Angiotensin II (Human) (Bulk) .................................... 13


INDEX by PRODucT cO

DE NAME

Order Hotline 1-800-777-4779 502-266-8787 335


Angiotensin II (Human) (0.5 mg vial) .......................... 13Angiotensin III (Human) (Bulk) ................................... 14Angiotensin III (Human) (Bulk) ................................... 14Angiotensin III (Human) ............................................... 14Angiotensin IV (Human) .............................................. 14Angiotensin IV (Human) (Bulk) ................................... 14ANP (Human, 1-28) Antiserum.................................. 238ANP (Human, 1-28) ..................................................... 17ANP (Human, 1-28) ..................................................... 17ANP (Human, 5-27) ..................................................... 18ANP (Human, 5-28) ..................................................... 18ANP (Human, 7-28) .................................................... 18ANP (Rat, 1-28) ........................................................... 18ANP (Rat, 3-28) .......................................................... 19ANP (Rat) Precursor Processing Enzyme Substrate 178Antagonists to the Endothelin A & B Receptors........ 166Antipain ...................................................................... 160Antipain (Bulk) ........................................................... 160Antiproliferative Factor ............................................... 227Antiproliferative Factor Sialoglycopeptide ................. 228Antisera of Amyloid -Protein Related Peptides ......... 237Apamin ........................................................................ 19Apelin-36 (Human) ...................................................... 19Apelins ......................................................................... 19Aprotinin (Bulk) ......................................................... 163Arg-Arg-Leu-lle-Glu-Asp-Ala-Glu-Tyr-Ala-Ala-Arg-Gly ... .................................................................................... 201Arg-Gly-Asp RGD Peptides ......................................... 20Arg-Gly-Asp (RGD) for Cell Adhesion of Biomaterials 24Arg-Gly-Asp-Ser • AcOH • 2H2O ............................... 217Arg-MCA .................................................................... 182Arg(NO2)..................................................................... 254Arg(NO2)-OBzl • Tos .................................................. 253Arg(Tos) ...................................................................... 254Arphamenine A (Bulk) ............................................... 152Arphamenine B .......................................................... 152Arphamenine B (Bulk) .............................................. 152Asp-Arg-Val-Tyr-lle-His-Pro-Phe-His-Leu-Val-Ile-His .................................................................................... 202Asp(OBzl) ................................................................... 254Asp(OBzl)-OBzl • Tos2 ................................................ 53

Bb-Ala-His .................................................................... 215b-ANP (Human) ........................................................... 18b-Casomorphin-5 (Bovine) .......................................... 33b-Casomorphin-5 (Bovine) (Bulk) .............................. 33b-Casomorphin-7 (Bovine) .......................................... 33b-Casomorphins .......................................................... 33b-Defensin-1 (Human) ................................................ 45b-Defensin-2 (Human) ................................................ 46b-Defensin-3 (Human) ................................................ 46b-Defensin-4 (Human) ................................................ 47b-Endorphin (Equine) .................................................. 52b-Endorphin (Human) ................................................. 52b-Neo-Endorphin (Porcine) ......................................... 87

b-Sheet Breaker Peptide iAb5 .................................... 12b-Sheet Breaker Peptide iAb5 (Bulk)......................... 12B-Type (Brain) Natriuretic Peptides (BNP) ................. 31BAM-12P ...................................................................... 26Base MAP Cores ....................................................... 298Benzhydrylamine Resin • HCI (BHA) ........................ 282Benzhydrylamine Resin • HCl (BHA) ....................... 282Benzhydrylamine Resin • HCl (BHA) ........................ 282Benzoyl-Nle-Lys-Arg-Arg-MCA ................................. 191Big Endothelin-1 (Human, 1-38).................................. 54Big Endothelin-1 (Human, 22-38) Antiserum ............ 242Big Endothelin-1 (Porcine, 1-39) ................................. 54Big Endothelin-1 (Porcine, 1-39) ................................. 54Big Endothelin-1 (Porcine, 22-39) Antiserum ........... 241Big Endothelin-1 (Rat, 1-39) ........................................ 54Big Endothelin-2 (Human, 22-37) Antiserum ............ 242Big Endothelin-2 (Human, 22-38) Antiserum ............ 242Big Endothelin-3 (Human, 22-41 Amide) Antiserum . 243Big Endothelin-3 (Rat, 1-41 Amide) ............................ 55Big Gastrin (Human) .................................................... 63Big-Endothelin-1 (Human, 1-38) ................................. 54Big-Endothelin-2 (Human, 1-37) ................................. 55Big-Endothelin-2 (Human, 1-38) ................................. 55Big-Endothelin-3 (Human, 1-41 Amide) ...................... 55Biotin-Onp .................................................................. 300Biotin-Osu .................................................................. 300Biotinyl--Agatoxin IVA ................................................ 123Biotinyl-Asp-Glu-Val-Asp-H (aldehyde) ..................... 158Bis-ACV.......................................................................... 1BNP-26 (Porcine) Antiserum ..................................... 239BNP-26 (Porcine) ........................................................ 31BNP-32 (Human) ........................................................ 31BNP-32 (Rat) .............................................................. 31BNP-45 (Rat) .............................................................. 32Boc--Abu-OH ............................................................. 261Boc--Aca-OH ............................................................. 261Boc--Ala-Pam Resin .................................................. 287Boc-11-Aminoundecanoic Acid ................................ 266Boc-2-Thienylalanine ................................................. 265Boc-3-Pal-OH ............................................................ 264Boc-4-Pal-OH ............................................................ 264Boc-5-Ava-OH ........................................................... 261Boc-Abu-OH .............................................................. 260Boc-Abz-OH ............................................................... 261Boc-Aib-OH ................................................................ 261Boc-Ala-Gly-Pro-Arg-MCA ........................................ 178Boc-Ala-OH ................................................................ 255Boc-Ala-Pam Resin .................................................. 287Boc-allo-Ile-OH .......................................................... 263Boc-Amino Acid Esters .............................................. 266Boc-Amino Acid-Pam Linker Reagents .................... 303Boc-Amino Acid-Pam Resins .................................... 287Boc-Arg-Val-Arg-Arg-MCA......................................... 193Boc-Arg(NO2)-OH ...................................................... 255Boc-Arg(Tos)-OH ....................................................... 255Boc-Arg(Tos)-Pam Resin .......................................... 288

PEPT

IDES

INTE

RNAT

IONA

LIN

DEX

by P

RODu

cT N

AME

336 Order Hotline 1-800-777-4779 502-266-8787


Boc-Asn-OH ............................................................... 255Boc-Asn-ONp ............................................................. 255Boc-Asn-Pam Resin .................................................. 288Boc-Asn(Xan)-OH ...................................................... 261Boc-Asp-OFm (Alpha Ester) ..................................... 261Boc-Asp(OBzl)-OH .................................................... 255Boc-Asp(OBzl)-Pam Resin ........................................ 288Boc-Asp(OBzl)-Pro-Arg-MCA .................................... 187Boc-Asp(OcHex)-OH ................................................. 255Boc-Asp(OcHex)-Pam Resin ................................... 288Boc-Asp(OFm)-OH (Beta Ester) ............................... 261Boc-b-Ala-OH ............................................................ 255Boc-b-Ala-Pam Resin .............................................. 287Boc-b-Ala-Pam Resin .............................................. 298Boc-Cys(4-CH3-Bzl)-Pam Resin .............................. 288Boc-Cys(4-CH3Bzl)-OH ............................................. 256Boc-Cys(Acm)-OH ..................................................... 256Boc-Cys(Bzl)-OH ....................................................... 256Boc-Cys(MBzl)-OH .................................................... 256Boc-Cys(Npys)-OH .................................................... 261Boc-Cys(tBu)-OH ....................................................... 256Boc-D-2-Thienylalanine .............................................. 265Boc-D-3-Pal-OH ......................................................... 264Boc-D-4-Pal-OH ......................................................... 264Boc-D-Abu-OH ........................................................... 261Boc-D-Abu-OH • DCHA .............................................. 261Boc-D-Ala-OH ............................................................. 258Boc-D-Arg(Tos)-OH .................................................... 259Boc-D-Asn-OH ............................................................ 259Boc-D-Asn-ONp.......................................................... 259Boc-D-Asn(Xan)-OH................................................... 259Boc-D-Asp-OFm ......................................................... 259Boc-D-Asp(OBzl)-OH ................................................. 259Boc-D-Asp(OcHex)-OH .............................................. 259Boc-D-Dab(Fmoc)-OH ............................................... 262Boc-D-Dab(N3)-OH • CHA ......................................... 248Boc-D-Dap(Fmoc)-OH ............................................... 262Boc-D-Dap(N3)-OH • CHA ......................................... 248Boc-D-Dip-OH ............................................................ 262Boc-D-His(Tos)-OH • DCHA ....................................... 259Boc-D-Homo-Phe-OH ................................................ 262Boc-D-Hydroxy-Tic-OH .............................................. 263Boc-D-Ile • H2O ......................................................... 259Boc-D-Ile-OH .............................................................. 259Boc-D-Leu-OH • H2O .................................................. 259Boc-D-lle-OH ............................................................. 263Boc-D-Lys(Cl-Z)-OH ................................................... 260Boc-D-Lys(Fmoc)-OH ................................................. 259Boc-D-Lys(N3)-OH • CHA .......................................... 248Boc-D-Met-OH ............................................................ 260Boc-D-Nal(1’)-OH ....................................................... 263Boc-D-Nal(2’)-OH ....................................................... 263Boc-D-Orn(Fmoc)-OH ................................................ 264Boc-D-Orn(N3)-OH • CHA .......................................... 249Boc-D-Pen(Meb)-OH • DCHA .................................... 264Boc-D-Pen(Mob)-OH .................................................. 264

Boc-D-Pentafluoro-Phe-OH ....................................... 264Boc-D-Phe-OH ........................................................... 260Boc-D-Phe(NO2)-OH .................................................. 260Boc-D-Phg-OH ........................................................... 265Boc-D-Pro-OH ............................................................ 260Boc-D-Ser(Bzl)-OH ..................................................... 260Boc-D-Thr(Bzl)-OH ..................................................... 260Boc-D-Tic-OH ............................................................. 265Boc-D-Trp-OH ............................................................. 260Boc-D-Trp(CHO)-OH .................................................. 260Boc-D-Tyr(Br-Z)-OH ................................................... 260Boc-D-Tyr(Cl2-Bzl)-OH............................................... 260Boc-D-Tyr(Et)-OH ....................................................... 266Boc-D-Tyr(Me)-OH ..................................................... 266Boc-D-Val-OH ............................................................. 260Boc-Dab(Fmoc)-OH .................................................. 261Boc-Dab(N3)-OH • CHA ............................................ 248Boc-Dap-OH .............................................................. 262Boc-Dap(Fmoc)-OH .................................................. 262Boc-Dap(N3)-OH • CHA ............................................ 248Boc-Deg-OH .............................................................. 262Boc-Dhp-OH .............................................................. 262Boc-Dip-OH................................................................ 262Boc-g-Abu-Pam Resin ............................................... 287Boc-Gln-Ala-Arg-MCA ............................................... 205Boc-Gln-Arg-Arg-MCA ............................................... 193Boc-Gln-Gly-Arg-MCA ............................................... 187Boc-Gln-OH ............................................................... 256Boc-Gln-ONp ............................................................. 256Boc-Gln-Pam Resin .................................................. 288Boc-Gln-Pro ............................................................... 200Boc-Gln(Xan)-OH ...................................................... 256Boc-Glu-Lys-Lys-MCA ............................................... 200Boc-Glu-OFm (Alpha Ester) ...................................... 262Boc-Glu(OBzl)-Ala-Arg-MCA ..................................... 187Boc-Glu(OBzl)-Gly-Arg-MCA..................................... 178Boc-Glu(OBzl)-OH ..................................................... 256 Boc-Glu(OBzl)-Pam Resin ....................................... 288Boc-Glu(OcHex)-OH ................................................. 256Boc-Glu(OcHex)-Pam Resin ..................................... 288Boc-Glu(OFm)-OH (Gamma Ester) .......................... 262Boc-Gly-Arg-Arg-MCA ............................................... 193Boc-Gly-Lys-Arg-MCA ............................................... 193Boc-Gly-OH25 ............................................................... 6Boc-Gly-Pam Acid ..................................................... 303Boc-Gly-Pam Resin .................................................. 288Boc-Gly-Pam Resin .................................................. 288Boc-His(Bom)-OH ...................................................... 257Boc-His(Tos)-OH........................................................ 257Boc-Homo-Phe-OH ................................................... 262Boc-Hydroxy-Tic-OH ................................................. 262Boc-Hyp(Bzl)-OH ......................................................... 57Boc-Ile-OH • 1⁄2 H2O ................................................. 257Boc-Leu-Arg-Arg-MCA .............................................. 194Boc-Leu-Gly-Arg-MCA ............................................... 197Boc-Leu-Lys-Arg-MCA............................................... 194


INDEX by PRODucT cO

DE NAME

Order Hotline 1-800-777-4779 502-266-8787 337


Boc-Leu-OEt .............................................................. 266Boc-Leu-OH • H2O ..................................................... 257Boc-Leu-Pam Acid ..................................................... 303Boc-Leu-Pam Resin ................................................. 288Boc-Leu-Pam Resin .................................................. 288Boc-Leu-Ser-Thr-Arg-MCA ........................................ 187Boc-Leu-Ser-Thr-Arg-pNA • cOH • H2O .................... 187Boc-Leu-Thr-Arg-MCA ............................................... 187Boc-lle-Glu-Gly-Arg-MCA .......................................... 187Boc-lle-Pam Resin .................................................... 288Boc-Lys(Boc)-OH • DCHA ......................................... 257Boc-Lys(Cl-Z)-OH ...................................................... 257Boc-Lys(Cl-Z)-Pam Resin ........................................ 288Boc-Lys(Fmoc)-OH .................................................... 257Boc-Lys(N3)-OH • CHA ............................................. 248Boc-Lys(TFA)-MCA .................................................... 196Boc-Lys(Z)-OH ........................................................... 257Boc-Met-OH ............................................................... 257Boc-Met(O)-Pam Resin ............................................ 288Boc-mini-PEG-3™ ..................................................... 231Boc-mini-PEG-3™ ..................................................... 263Boc-mini-PEG™ ................................................231, 263Boc-N-Me-Leu-OH..................................................... 266Boc-N-Me-Phe-OH .................................................... 266Boc-N-Me-Ser-OH ..................................................... 266Boc-N-Me-Tyr-OH • DCHA ........................................ 266Boc-N-Me-Val-OH ...................................................... 266Boc-N-Methyl Amino Acids ........................................ 266Boc-Nal(1’)-OH .......................................................... 263Boc-Nal(2’)-OH .......................................................... 263Boc-Norleucine (syrup) .............................................. 263Boc-Norvaline (syrup) ................................................ 263Boc-Orn-OH ............................................................... 263Boc-Orn(Boc)-OH ...................................................... 264Boc-Orn(Cl-Z)-OH ..................................................... 263Boc-Orn(Fmoc)-OH ................................................... 264Boc-Orn(N3)-OH • CHA .............................................. 248Boc-p-Aminobenzoic Acid ......................................... 261Boc-p-Cl-D-Phe-OH ................................................... 265Boc-p-Cl-Phe-OH ...................................................... 264Boc-p-F-D-Phe-OH ..................................................... 265Boc-p-F-Phe-OH ........................................................ 265Boc-Pen(Meb)-OH • DCHA ....................................... 264Boc-Pen(Mob)-OH .................................................... 264Boc-Pentafluoro-Phe-OH .......................................... 264Boc-Phe-OEt .............................................................. 266Boc-Phe-OH .............................................................. 257Boc-Phe-Pam Resin ................................................. 289Boc-Phe-Ser-Arg-MCA .............................................. 194Boc-Phe(NH-Z)-OH ................................................... 265Boc-Phe(NH2)-OH ..................................................... 265Boc-Phe(NO2)-OH ..................................................... 265Boc-Phg-OH .............................................................. 265Boc-Pro-OH ............................................................... 257Boc-Pro-Pam Resin .................................................. 289Boc-Protected D-Amino Acids .................................... 258

Boc-Protected l-Amino Acids ..................................... 255Boc-Sar-OH ............................................................... 265Boc-Ser(Bzl)-OH ........................................................ 258Boc-Ser(Bzl)-Pam Resin .......................................... 289Boc-Thr(Bzl)-OH ........................................................ 258Boc-Thr(Bzl)-Pam Resin ........................................... 289Boc-Tic-OH ................................................................ 265Boc-Trp-OH ................................................................ 258Boc-Trp(CHO)-OH ..................................................... 258Boc-Trp(CHO)-Pam Resin ........................................ 289Boc-Trp(Hoc)-OH ....................................................... 258Boc-Tyr(Br-Z)-OH ...................................................... 258Boc-Tyr(Br-Z)-Pam Resin .......................................... 289Boc-Tyr(Bzl)-OH ........................................................ 258Boc-Tyr(Cl2-Bzl)-OH .................................................. 258Boc-Tyr(Cl2-Bzl)-Pam Resin ...................................... 289Boc-Tyr(Et)-OH .......................................................... 266Boc-Tyr(Me)-OH ........................................................ 265Boc-Val-Leu-Lys-MCA ............................................... 179Boc-Val-OH ................................................................ 258Boc-Val-Pam Acid ...................................................... 303Boc-Val-Pam Resin ................................................... 289Boc-Val-Pro-Arg-MCA................................................ 188Boc4-Lys2-Lys-b-Ala-Pam Resin ............................... 299Boc4-Lys2-Lys-Cys(Acm)-b-Ala-Pam Resin .............. 299Boc8-Lys4-Lys2-Lys-b-Ala-Pam Resin ...................... 299Boc8-Lys4-Lys2-Lys-Cys(Acm)-b-Ala-Pam Resin ...... 299Bombesin ..................................................................... 27Bombesin (Bulk) ......................................................... 27BOP Reagent ............................................................ 300Bovine Adrenal Medulla Dodecapeptide (BAM-12P) . 26BQ-123 ................................................................ 56, 166BQ-610 .................................................................56, 167BQ-788 .................................................................56, 167Bradykinin and Related Peptides ................................ 27Bradykinin-Potentiator B .............................................. 28Bradykinin-Potentiator B ........................................... 153Bradykinin-Potentiator B (Bulk) ................................ 153Bradykinin-Potentiator C.............................................. 28Bradykinin-Potentiator C........................................... 154Bradykinin-Potentiator C (Bulk) ................................ 154Bradykinin .................................................................... 27Bradykinin (Bulk) ......................................................... 27Bz-Ala-OMe ............................................................... 178Bz-Arg-His-D-Asp-CH2Cl (Trifluoroacetate Form) ..... 155Bz-Arg-MCA ............................................................... 205Bz-Arg-NH2 • HCl • H2O ............................................. 205Bz-Arg-OEt • HCl ....................................................... 205Bz-dl-Arg-pNA • HCl .................................................. 205Bz-Gly-Ala-Pro ........................................................... 177Bz-Gly-Arg ................................................................. 178Bz-Gly-Gly-Gly ........................................................... 177Bz-Gly-His-Leu • H2O ................................................ 177Bz-Gly-Lys .................................................................. 178Bz-l-Arg-pNA • HCI .................................................... 183Bz-Tyr-OEt ................................................................. 186

PEPT

IDES

INTE

RNAT

IONA

LIN

DEX

by P

RODu

cT N

AME

338 Order Hotline 1-800-777-4779 502-266-8787


Bz-Tyr-pNA ................................................................. 185

CC Peptide ..................................................................... 32C-Peptide (Human) ...................................................... 32C-Type Natriuretic Peptide (CNP) ............................... 38CA-074 ....................................................................... 160CA-074 Me ................................................................. 160Calcicludine (CaC) .................................................... 123Calciseptine ............................................................... 124Calcitonin ..................................................................... 32Calcitonin (Human) ...................................................... 32Calcitonin (Human) Antiserum .................................. 239Calmodulin-Dependent Protein Kinase II.................. 168Calpain Inhibitors ....................................................... 155Calpain Substrates .................................................... 179Carbonyl / Carboxyl Reactive Reagents ................... 309Carboxyl-dPEG®4-(m-dPEG®12)3 Ester ................... 314Carboxypeptidase A Substrates ................................ 180Carnosine Synthase Substrate ................................. 180CART (Human, 55-102) .............................................. 33CART (Rat, 55-102) ..................................................... 33CART Peptides ............................................................ 33Caspase Inhibitors ..................................................... 156Caspase Substrates .................................................. 180Cathepsin and Thiol Protease Substrates ................ 182Cathepsin Inhibitors ................................................... 160Cbz-Amido-dPEG®12 Acid ........................................ 319Cbz-Amido-dPEG®24 Acid ........................................ 319Cbz-Amido-dPEG®4 Acid .......................................... 319Cbz-Amido-dPEG®6 Acid .......................................... 319Cbz-Amido-dPEG®8 Acid .......................................... 319Cbz-Based Solid Phase Synthesis ........................... 319CCK-33 (Human) ........................................................ 36CCK-33 (Porcine) Antiserum ..................................... 239CCK-33 (Porcine) ........................................................ 36CCK-Octapeptide (26-33) (Non-Sulfated Form) ........ 35CCK-Octapeptide (26-33) (Sulfated Form) ................ 35CCK-Tetrapeptide (30-33) .......................................... 35CCK-Tetrapeptide (30-33) (Bulk)................................ 35CD36 Binding Peptide ................................................. 36Cell Pepnetrating Peptides (CCP) ............................ 221Cellular Prion Protein Substrates .............................. 185CGP 4211 .................................................................. 216CGRP ........................................................................... 34CGRP (Human, 8-37) ................................................. 34CGRP (Human) Antiserum ........................................ 239CGRP (Human) .......................................................... 34CGRP (Rat) ................................................................. 34CGRP (Rat) ................................................................. 34Charybdotoxin ............................................................ 124Charybdotoxin (ChTX) .............................................. 124Chemotactic Peptide ................................................... 35Chemotactic Peptide (Bulk) ........................................ 35Chemotactic Peptide ................................................... 35Chloromethylated Polystyrene Resin ....................... 282

Chloromethylated Polystyrene Resin ....................... 282Chloromethylated Polystyrene Resin ....................... 282Chlorotoxin ................................................................. 124Chlorotrityl Polystyrene Macrobead ......................... 284Chlorotrityl Resins ...................................................... 284Cholecystokinin (CCK) Related Peptides ................... 35Chromogranin A (Human, 286-301 Amide) ................ 98Chymostatin ............................................................... 163Chymostatin (Bulk) ................................................... 163Chymotrypsin and Chymotrypsin-like Inhibitors ....... 163Chymotrypsin and Chymotrypsin-like Protease Sub-strates ........................................................................ 185CINC-1/gro ................................................................... 36CINC-1/gro (Rat) .......................................................... 36CINC-1/gro (Rat) Antiserum ...................................... 240cis-4-Hydroxy-l-Proline .............................................. 281Cl-Ac-(OH)Leu-Ala-Gly-NH2 ..................................... 166Cl-Ac-(OH)Leu-Ala-Gly-NH2 (Bulk) .......................... 166CLEAR-OXTM ............................................................. 232CLEAR-OXTM Oxidation ............................................. 234CLEAR-OXTM Resin Conditioning ............................. 233CLICK Chemistry ....................................................... 219Click Chemistry Amino Acids ..................................... 248Clickable-TAT Alkyne (49-57) .................................... 220Clickable-TAT Azide (49-57) ...................................... 220CNP-22 (Human) ......................................................... 38CNP-22 (Human) Antiserum ..................................... 240CNP-53 (Human) ......................................................... 38CNP-53 (Porcine, Rat)................................................. 39Coagulation Factor Substrates .................................. 187Colivelin ........................................................................ 37Collagenase / MMP / Stromelysin Substrates .......... 188Collagenase Inhibitors .......................................163, 164COMU ........................................................................ 304COMU Reagent ......................................................... 304Conantokin G ............................................................ 125Conantokin T ............................................................. 125Conantokins ............................................................... 125Condensation Reagents, Additives, Linkers, and Other Reagents for Peptide Synthesis ................................ 300Conotoxins ................................................................. 125Corticotropin-Releasing Factor / Hormones (CRF/CRH) ...................................................................................... 37Cortistatin ..................................................................... 38Cortistatin (Rat) ............................................................ 38CRF (Human, Rat) ....................................................... 37CRF (Human) Antiserum ........................................... 240CRF (Ovine) ................................................................. 37cyclo (Arg-Ala-Asp-D-Phe-Cys) ................................... 20cyclo (Arg-Ala-Asp-D-Phe-Lys(Ac-SCH2CO)) ............. 22cyclo (Arg-Ala-Asp-D-Phe-Lys) .................................... 21cyclo (Arg-Ala-Asp-D-Phe-Val) .................................... 23cyclo (Arg-Ala-Asp-D-Tyr-Cys) ..................................... 23cyclo (Arg-Gly-Asp-D-Phe-Cys) ................................... 20cyclo (Arg-Gly-Asp-D-Phe-Glu) .................................... 20cyclo (Arg-Gly-Asp-D-Phe-Lys(Biotin-PEG-PEG)) ...... 22


INDEX by PRODucT cO

DE NAME

Order Hotline 1-800-777-4779 502-266-8787 339


cyclo (Arg-Gly-Asp-D-Phe-Lys) .................................... 21cyclo (Arg-Gly-Asp-D-Phe-Lys) .................................... 21cyclo (Arg-Gly-Asp-D-Phe-Val) .................................... 22cyclo (Arg-Gly-Asp-D-Phe-Val) • AcOH • 2H2O (Bulk) .... ...................................................................................... 23cyclo (Arg-Gly-Asp-D-Tyr-Cys) .................................... 23cyclo (Arg-Gly-Asp-D-Tyr-Glu) ..................................... 23cyclo (Arg-Gly-Asp-D-Tyr-Lys) ..................................... 23cyclo (Arg-Gly-Glu-D-Phe-Lys) .................................... 24cyclo (Leu-Gly) ........................................................... 216cyclo [Arg-Ala-Asp-D-Phe-Lys(PEG-PEG)] ................. 21cyclo [Arg-Gly-Asp-D-Phe-Lys (PEG-PEG-Azide)] ..... 21cyclo [Arg-Gly-Asp-D-Phe-Lys (PEG-PEG-Azide)] ... 220cyclo [Arg-Gly-Asp-D-Phe-Lys(Ac-SCH2CO)] ............ 22cyclo [Arg-Gly-Asp-D-Phe-Lys(PEG-PEG)] ................. 21cyclo [CO-(CH2)2-CO-D-Nal(2’)-Arg-Trp-Lys]-NH2 ...... 83Cys-TAT (49-57) ......................................................... 221Cys(Npys)-TAT (49-57) .............................................. 221Cys(Npys)-TAT (49-57), FAM-labeled ....................... 221

DD-, l-Peptide with Antitumor Activity ............................. 39D-Alanine .................................................................... 252D-Amino Acids ............................................................ 252D-Arginine ................................................................... 252D-Arginyl-[Hyp3, Thi5,8, D-Phe7]-Bradykinin ............... 28D-Arginyl-[Hyp3, Thi5,8, D-Phe7]-Bradykinin (Bulk) ... 28D-Arginyl-[Hyp3,Thi5,D-Tic7,Oic8]-Bradykinin ............ 27D-Arginyl-[Hyp3,Thi5,D-Tic7,Oic8]-Bradykinin (Bulk) . 28D-Asparagine • H2O .................................................... 252D-Aspartic Acid ........................................................... 252D-Aspartyl Endopeptidase Substrate......................... 178D-Cysteine • HCI • H2O .............................................. 252D-Glucaro-d-Lactam ................................................... 225D-Glutamic Acid .......................................................... 252D-Histidine .................................................................. 252D-Hydroxy-Tic ............................................................. 281D-Isoleucine ................................................................ 252D-Leu7 ........................................................................ 121D-Leucine ................................................................... 252D-Lysine • HCI ............................................................ 252D-Methionine .............................................................. 252D-Pen .......................................................................... 281D-Pen(p-Me-Bzl) ......................................................... 281D-Phenylalanine ......................................................... 252D-Proline ..................................................................... 252D-Serine ...................................................................... 252D-Threonine ................................................................ 253D-Tic ............................................................................ 281D-Tryptophan .............................................................. 253D-Tyrosine .................................................................. 253D-Valine ...................................................................... 253Dabcyl--Abu-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Edans ......................................................................... 202Dabcyl--Abu-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-Edans ..... .................................................................................... 197

Dabcyl-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Edans ......................................................................... 174DCCD ........................................................................ 300Decorsin ....................................................................... 40Defensin Peptides........................................................ 40Deformylase Substrates ............................................ 190Delta Sleep-Inducing Peptide (DSIP).......................... 48Delta Sleep-Inducing Peptide (DSIP) (Bulk) ............. 48Dendrotoxin I .............................................................. 128Dengue Fever Virus Protein Substrates ...........190, 191Dermcidin- 1L (Human) ............................................... 48Dermcidin- 1L / DCD.................................................... 48Des 1-10 Obestatin (Human) ...................................... 95Des 1-10 Obestatin (Rat, Mouse) .............................. 95Des-Acyl Ghrelin (Human) .......................................... 71Des-Acyl Ghrelin (Human) .......................................... 65Des-Acyl Ghrelin (Rat) ................................................. 65Des-Arg10-Kallidin ....................................................... 29Des-Arg10-Kallidin (Bulk) ........................................... 29Des-Arg9-[Leu8]-Bradykinin ........................................ 29Des-Arg9-[Leu8]-Bradykinin (Bulk) ............................ 29Des-Arg9-Bradykinin (Bulk) ........................................ 28Des-Arg9-Bradykinin ................................................... 28Des-Asp1-[Ile8]-Angiotensin II..................................... 16Des-Asp1-[Ile8]-Angiotensin II (Bulk) ......................... 16Des-n-Octanoyl-[Ser3]-Ghrelin (Human, 1-14) ............ 66Des-n-Octanoyl-[Ser3]-Ghrelin (Human, 1-18) ............ 66Des-n-Octanoyl-[Ser3]-Ghrelin (Human, Rat, 1-10) ... 66Des-n-Octanoyl-[Ser3]-Ghrelin (Human, Rat, 1-5) ...... 67Des-n-Octanoyl-[Ser3]-Ghrelin (Human) ..................... 65Des-n-Octanoyl-[Ser3]-Ghrelin (Rat) ........................... 65Des-Pro2-Bradykinin .................................................... 29Des-Pro2-Bradykinin .................................................. 154Des-Pro2-Bradykinin (Bulk) ....................................... 154Des-Pro2-Bradykinin (Bulk) ........................................ 29Diethylglycine (Deg)................................................... 281Dipeptides .................................................................. 215Dipeptidyl Peptidase II (DPP II) .........................155, 165Dipeptidyl-Peptidase Substrates ............................... 191Diprotin A .................................................................... 165Diprotin A (Bulk) ........................................................ 166Dnp-Gln-Gly-Ile-Ala-Gly-Gln-D-Arg ........................... 188Dnp-Gly-Pro-Leu-Gly-Met-Arg-Gly-Leu-NH2 ............ 188Dnp-Leu-Gly-Ile-Ala-Gly-Arg-NH2 ............................. 203Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMa)-NH2 . 188Dnp-Pro-Gln-Gly ........................................................ 188Dnp-Pro-Gln-Gly-Ile-Ala-Gly-Gln-D-Arg .................... 189Dnp-Pro-Leu-Gly........................................................ 188Dnp-Pro-Leu-Gly-Ile-Ala-Gly-Arg-NH2 ...................... 189Dnp-Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NH2 ................. 189DOTA(tBu)3-OH......................................................... 300Doxorubicin-HCl ......................................................... 169Doxorubicin-HCl ......................................................... 221dPEG® Biotin Acid ...................................................... 308dPEG® Biotinylation Reagents .................................. 306dPEG® Peptide Synthesis Reagents with Spacers .. 318

PEPT

IDES

INTE

RNAT

IONA

LIN

DEX

by P

RODu

cT N

AME

340 Order Hotline 1-800-777-4779 502-266-8787


dPEG®12 Biotin Acid .................................................. 308dPEG®4 Biotin Acid .................................................... 308Dynorphin A (Human, 1-13) ......................................... 49Dynorphin A (Human) .................................................. 49Dynorphins ................................................................... 49

EE-64 ............................................................................ 160E-64 (Bulk) ................................................................ 161E-64-c ......................................................................... 161E-64-d ........................................................................ 161Ebelactone A (Bulk) .................................................. 153Echistatin .................................................................... 129EDDNP....................................................................... 301EEDQ ........................................................................ 301Elafin ...................................................................... 49, 50Elafin (Human) ........................................................... 166Elafin (Human) Antiserum ......................................... 241Elastase Inhibitors ..................................................... 166Elastase Substrates ................................................... 191Elastatinal ................................................................... 166Elastatinal (Bulk) ....................................................... 166Eledoisin Related Peptide ........................................... 50Eledoisin Related Peptide (Bulk) ................................ 50Eledoisin Related Peptide ........................................... 50Endokinin C (Human) .................................................. 50Endokinin D (Human) .................................................. 50Endokinins ................................................................... 50Endomorphin-1 ............................................................ 51Endomorphin-2 ............................................................ 51Endomorphins .............................................................. 51Endorphins ................................................................... 51Endothelin Antisera .................................................... 241Endothelin Inhibitors .................................................... 56Endothelin-1 (1-31) (Human) ...................................... 53Endothelin-1 (Human) Antiserum .............................. 241Endothelin-1 (Human) ................................................. 52Endothelin-2 (Human) ................................................. 53Endothelin-3 (Human) ................................................. 53Endothelins .................................................................. 52Enkephalins ................................................................. 56Enterotoxin ................................................................. 129Enterotoxin STp .................................................129, 140Enzyme Inhibitors ...................................................... 152Enzyme Substrates & Related Compounds ............. 174Epoxomicin ................................................................ 171Evaporator Trap 200 mL (Splash Guard Adapter) .... 323Examples of Proteolytic Enzymes and Their Inhibitors ... .................................................................................... 173Exendin ........................................................................ 58Exendin (5-39) ............................................................. 58Experimental Autoimmune Encephalomyelitis Products . ...................................................................................... 59Extra Septa (Teflon-coated Silicone Rubber) ........... 323

FFibronectin Active Fragment (GRGDS) ..................... 25Fibronectin Active Fragment (GRGDS) (Bulk) .......... 25Fibronectin Active Fragment (RGDS) ........................ 25Fibronectin Active Fragment (RGDS) (Bulk) .............. 25Fibronectin Adhesion-Promoting Peptide ................... 26Fmoc-γ-Abu-OH ........................................................ 272Fmoc-ε-Aca-OH ......................................................... 272Fmoc-11-Aminoundecanoic Acid .............................. 273Fmoc-3-Pal-OH.......................................................... 276Fmoc-3,3-Dip-OH ...................................................... 274Fmoc-3,5-Diiodo-l-Tyr-OH ........................................ 274Fmoc-3,Iodo-l-Tyr-OH ............................................... 275Fmoc-4-Pal-OH.......................................................... 276Fmoc-5-Ava-OH......................................................... 273Fmoc-Abu-OH............................................................ 272Fmoc-ADP-OH .......................................................... 272Fmoc-Aib-OH ............................................................. 272Fmoc-Ala-Cys(Trt)-OH .............................................. 273Fmoc-Ala-OH (2,3,3,3,-D4) ....................................... 281Fmoc-Ala-OH • H2O ................................................... 267Fmoc-Ala-Rink-Amide MBHA Resin ......................... 292Fmoc-Ala-Wang Resin .............................................. 289Fmoc-allo-Ile-OH ....................................................... 275Fmoc-Amido-(dPEG®4 Biotin) Acid ........................... 307Fmoc-Amido-dPEG®12 Acid ..................................... 318Fmoc-Amido-dPEG®2 Acid ........................................ 318Fmoc-Amido-dPEG®24 Acid ..................................... 319Fmoc-Amido-dPEG®4 Acid ........................................ 318Fmoc-Amido-dPEG®6 Acid ........................................ 318Fmoc-Amido-dPEG®8 Acid ........................................ 318Fmoc-Amino Acid-Rink-Amide MBHA Resins .......... 292Fmoc-Amino Acid-Wang Resins ............................... 289Fmoc-Arg-OH ............................................................ 267Fmoc-Arg(Pbf)-OH .................................................... 267Fmoc-Arg(Pbf)-OH .................................................... 267Fmoc-Arg(Pbf)-Rink-Amide MBHA Resin ................. 292Fmoc-Arg(Tos)-OH .................................................... 267Fmoc-Asn-OH ............................................................ 267Fmoc-Asn(Trt)-OH ..................................................... 267Fmoc-Asn(Trt)-Rink-Amide MBHA Resin ................. 292Fmoc-Asn(Trt)-Wang Resin ...................................... 290Fmoc-Asp-OAll (Alpha Ester) .................................... 273Fmoc-Asp(OBzl)-OH ................................................. 267Fmoc-Asp(OtBu)-OH ................................................. 268Fmoc-Asp(OtBu)-Rink-Amide MBHA Resin ............ 292Fmoc-Asp(OtBu)-Wang Resin .................................. 290Fmoc-Azido-Lys-OH .................................................. 249Fmoc-b-Ala-OH ......................................................... 267Fmoc-b-Ala-Rink-Amide MBHA Resin .................... 292Fmoc-b-Ala-Wang Resin .......................................... 290Fmoc-b-Ala-Wang Resin ........................................... 298Fmoc-Based Solid Phase Synthesis ......................... 318Fmoc-Cha-OH ........................................................... 273Fmoc-Cpg-OH ........................................................... 273Fmoc-Cys(Acm)-OH .................................................. 268


INDEX by PRODucT cO

DE NAME

Order Hotline 1-800-777-4779 502-266-8787 341


Fmoc-Cys(Pam)2-OH................................................ 268Fmoc-Cys(pMeOBzl)-OH .......................................... 268Fmoc-Cys(tBu)-OH .................................................... 268Fmoc-Cys(tBu)-Wang Resin .................................... 290Fmoc-Cys(Trt)-OH ..................................................... 268Fmoc-Cys(Trt)-Rink-Amide MBHA Resin ................. 292Fmoc-Cys(Trt)-Wang Resin ...................................... 290Fmoc-Cys(Xan)-OH ................................................... 268Fmoc-Cys(Xan)-OPfp ................................................ 268Fmoc-Cys(Xan)-Wang Resin .................................... 290Fmoc-D-3-Pal-OH ...................................................... 276Fmoc-D-3,3-Dip-OH ................................................... 274Fmoc-D-4-Pal-OH ...................................................... 276Fmoc-D-Abu-OH ........................................................ 272Fmoc-D-Cha-OH ........................................................ 273Fmoc-D-Dab(Boc)-OH ............................................... 273Fmoc-D-Dab(N3)-OH .................................................. 249Fmoc-D-Dap(Boc)-OH ............................................... 274Fmoc-D-Dap(N3)-OH ................................................. 249Fmoc-D-Gln(Trt)-OH................................................... 271Fmoc-D-Glu(OtBu)-OH .............................................. 271Fmoc-D-His(Trt)-OH ................................................... 271Fmoc-D-Leu-OH ......................................................... 271Fmoc-D-lle-OH ........................................................... 271Fmoc-D-Lys(Boc)-OH ................................................. 271Fmoc-D-Lys(Mtt)-OH .................................................. 271Fmoc-D-Lys(N3)-OH ................................................... 249Fmoc-D-Met-OH ......................................................... 271Fmoc-D-Nal(1’)-OH .................................................... 275Fmoc-D-Nal(2’)-OH .................................................... 275Fmoc-D-Orn(Boc)-OH ........................................271, 276Fmoc-D-Orn(Mtt)-OH ................................................. 276Fmoc-D-Orn(N3)-OH .................................................. 250Fmoc-D-p-Cl-Phe-OH ................................................ 277Fmoc-D-p-F-Phe-OH .................................................. 277Fmoc-D-Pen(Acm)-OH............................................... 277Fmoc-D-Pen(Meb)-OH ............................................... 277Fmoc-D-Phe-OH ........................................................ 271Fmoc-D-Phe(NO2)-OH ............................................... 277Fmoc-D-Phg-OH ........................................................ 277Fmoc-D-Pro-OH ......................................................... 271Fmoc-D-Ser(tBu)-OH ................................................. 271Fmoc-D-Ser(Trt)-OH................................................... 272Fmoc-D-Thr(tBu)-OH.................................................. 272Fmoc-D-Tic-OH .......................................................... 278Fmoc-D-Trp-OH .......................................................... 272Fmoc-D-Trp(Boc)-OH ................................................. 272Fmoc-D-Tyr(tBu)-OH .................................................. 272Fmoc-D-Val-OH .......................................................... 272Fmoc-Dab(Boc)-OH .................................................. 273Fmoc-Dab(N3)-OH ..................................................... 250Fmoc-Dap(Boc)-OH .................................................. 274Fmoc-Dap(Dnp)-OH .................................................. 274Fmoc-Dap(N3)-OH .................................................... 250Fmoc-Deg-OH ........................................................... 274Fmoc-Gln-OH ............................................................ 268

Fmoc-Gln(Trt)-OH ...................................................... 268Fmoc-Gln(Trt)-Rink-Amide MBHA Resin .................. 292Fmoc-Gln(Trt)-Wang Resin ....................................... 290Fmoc-Glu-OAll (Alpha Ester) .................................... 274Fmoc-Glu(OBzl)-OH .................................................. 274Fmoc-Glu(OtBu)-OH ................................................ 268Fmoc-Glu(OtBu)-Rink-Amide MBHA Resin .............. 292Fmoc-Glu(OtBu)-Wang Resin .................................. 290Fmoc-Gly-Cys(Trt)-OH .............................................. 274Fmoc-Gly-Rink-Amide MBHA Resin ........................ 292Fmoc-Gly-Wang Resin ............................................. 290Fmoc-Har(Pbf)-OH .................................................... 274Fmoc-hCys(Trt)-OH ................................................... 273Fmoc-His(Bzl)-OH ..................................................... 269Fmoc-His(Fmoc)-OH ................................................. 269Fmoc-His(Trt)-OH ...................................................... 269Fmoc-His(Trt)-Rink-Amide MBHA Resin ................. 292Fmoc-His(Trt)-Wang Resin........................................ 291Fmoc-Hyp(tBu)-OH.................................................... 274Fmoc-Ile-OH .............................................................. 269Fmoc-Ile-Rink-Amide MBHA Resin ........................... 292Fmoc-Leu-Cys(Trt)-OH.............................................. 275Fmoc-Leu-OH2 ............................................................. 69Fmoc-Leu-Rink-Amide MBHA Resin ........................ 292Fmoc-Leu-Wang Resin ............................................. 291Fmoc-lle-Wang Resin ............................................... 291Fmoc-Lys(Boc)-OH .................................................... 269Fmoc-Lys(Boc)-Rink-Amide MBHA Resin ............... 292Fmoc-Lys(Boc)-Wang Resin .................................... 291Fmoc-Lys(Dnp)-OH ................................................... 275Fmoc-Lys(Fmoc)-OH ................................................. 269Fmoc-Lys(ivDde)-OH ................................................. 269Fmoc-Lys(Mtt)-OH ..................................................... 275Fmoc-Lys(Z)-OH ........................................................ 269Fmoc-Met-OH ............................................................ 269Fmoc-Met-Rink-Amide MBHA Resin ....................... 292Fmoc-Met-Wang Resin ............................................ 291Fmoc-mini-PEGTM-3 ................................................... 275Fmoc-mini-PEG™-3 .................................................. 231Fmoc-mini-PEGTM ...................................................... 275Fmoc-mini-PEG™ ..................................................... 232Fmoc-N-Me-Ala-OH .................................................. 278Fmoc-N-Me-Asp(OBzl)-OH ....................................... 278Fmoc-N-Me-D-Ala-OH ............................................... 278Fmoc-N-Me-D-Asp(OBzl)-OH .................................... 278Fmoc-N-Me-D-Leu-OH............................................... 278Fmoc-N-Me-D-Phe-OH .............................................. 278Fmoc-N-Me-D-Val-OH ................................................ 279Fmoc-N-Me-Glu(OBzl)-OH ........................................ 278Fmoc-N-Me-Ile-OH .................................................... 278Fmoc-N-Me-Leu-OH .................................................. 278Fmoc-N-Me-Phe-OH ................................................. 278Fmoc-N-Me-Val-OH ................................................... 279Fmoc-N-Methyl Amino Acids ..................................... 278Fmoc-Nal(1’)-OH ....................................................... 275Fmoc-Nal(2’)-OH ....................................................... 275

PEPT

IDES

INTE

RNAT

IONA

LIN

DEX

by P

RODu

cT N

AME

342 Order Hotline 1-800-777-4779 502-266-8787


Fmoc-Nle-OH ............................................................. 276Fmoc-Nva-OH............................................................ 276Fmoc-Orn(Boc)-OH ................................................... 276Fmoc-Orn(Fmoc)-OH ................................................ 276Fmoc-Orn(Mtt)-OH .................................................... 276Fmoc-Orn(N3)-OH ..................................................... 250Fmoc-OSu ................................................................. 301Fmoc-p-Cl-Phe-OH.................................................... 277Fmoc-p-F-Phe-OH ..................................................... 277Fmoc-Pen(Acm)-OH .................................................. 277Fmoc-Pen(Meb)-OH .................................................. 277Fmoc-Phe-OH............................................................ 269Fmoc-Phe-OH (ring-D5) ............................................ 277Fmoc-Phe-Rink-Amide MBHA Resin ....................... 292Fmoc-Phe-Wang Resin ............................................ 291Fmoc-Phe(NO2)-OH .................................................. 277Fmoc-Phg-OH............................................................ 277Fmoc-Ppa(Bzl)-OH .................................................... 276Fmoc-Pra-OH ............................................................ 277Fmoc-Pro-OH ............................................................ 270Fmoc-Pro-Rink-Amide MBHA Resin ........................ 292Fmoc-Pro-Wang Resin .............................................. 291Fmoc-Protected D-Amino Acids ................................. 271Fmoc-Protected l-Amino Acids .................................. 267Fmoc-Sar-OH ............................................................ 278Fmoc-Ser(Bzl)-OH ..................................................... 270Fmoc-Ser(tBu)-OH .................................................... 270Fmoc-Ser(tBu)-Rink-Amide MBHA Resin ................ 293Fmoc-Ser(tBu)-Wang Resin ..................................... 291Fmoc-Ser(Trt)-OH ...................................................... 270Fmoc-Ser[Ac4Gal(1- >3)Ac2GalNAc(1- >O)]-OH ...... 224Fmoc-Thr(Bzl)-OH ..................................................... 270Fmoc-Thr(tBu)-OH ..................................................... 270Fmoc-Thr(tBu)-Rink-Amide MBHA Resin ................ 293Fmoc-Thr(tBu)-Wang Resin ...................................... 291Fmoc-Thr(Trt)-OH ...................................................... 270Fmoc-Thr[Ac4Gal(1- >3)Ac2GalNAc(1- >O)] -OH-O--2,3,4,6-Tetra-O-Acetyl-D-Galactopyranosyl-(1- >3)-O--4,6-Di-O-Acetyl-2-Acetamido-2-Deoxy-D-Galactopy-ranosyl- ...................................................................... 224Fmoc-Tic-OH ............................................................. 278Fmoc-Trp-OH ............................................................. 270Fmoc-Trp-Rink-Amide MBHA Resin ........................ 293Fmoc-Trp-Wang Resin .............................................. 291Fmoc-Trp(Boc)-OH .................................................... 270Fmoc-Trp(Boc)-Rink-Amide MBHA Resin ............... 293Fmoc-Trp(Boc)-Wang Resin .................................... 291Fmoc-Tyr(Bzl)-OH ..................................................... 270Fmoc-Tyr(Cl2-Bzl)-OH ............................................... 270Fmoc-Tyr(tBu)-OH ..................................................... 270Fmoc-Tyr(tBu)-Rink-Amide MBHA Resin ................ 293Fmoc-Tyr(tBu)-Wang Resin ...................................... 291Fmoc-Val-OH ............................................................. 271Fmoc-Val-Rink-Amide MBHA Resin ........................ 293Fmoc-Val-Wang Resin .............................................. 292Fmoc4-Lys2-Lys-b-Ala-CLEAR Acid Resin ................ 299

Fmoc4-Lys2-Lys-b-Ala-Wang Resin .......................... 299Fmoc8-Lys4-Lys2-Lys-b-Ala-CLEAR Acid Resin ....... 299Fmoc8-Lys4-Lys2-Lys-b-Ala-Wang Resin .................. 299FMRF-Amide .............................................................. 85FMRF-Amide (Bulk) .................................................... 85For-Met-Leu-pNA ....................................................... 190Foroxymithine ........................................................... 154Foroxymithine (Bulk) ................................................. 154FRETS (Peptide) Library ............................................211FRETS Peptide Library ............................................. 209FRETS-25-STD1 ....................................................... 214FRETS-25-STD2 ....................................................... 214FRETS-25Ala ..............................................................211FRETS-25Arg .............................................................211FRETS-25Asn.............................................................211FRETS-25Asp.............................................................211FRETS-25Gln ............................................................ 212FRETS-25Glu ............................................................ 212FRETS-25Gly ............................................................ 212FRETS-25Gly ............................................................ 212FRETS-25His ............................................................. 212FRETS-25Ile .............................................................. 212FRETS-25Leu ....................................................212, 213FRETS-25Lys ............................................................ 212FRETS-25Met ............................................................ 213FRETS-25Phe ........................................................... 213FRETS-25Pro ............................................................ 213FRETS-25Pro ............................................................ 213FRETS-25Ser ............................................................ 213FRETS-25Thr ............................................................ 213FRETS-25Trp............................................................. 213FRETS-25Tyr ............................................................. 213FRETS-25Val ............................................................. 214FRETS-25Val ............................................................. 214FRETS-25Xaa (Design of) ........................................ 209FRETS-VWF73 .......................................................... 175Furin and Carboxyl Side of Paired Basic Residue Cleaving Enzyme Substrates .................................... 193

Gg-Endorphin ................................................................. 52Galactosyl-cyclo (Arg-Gly-Asp-D-Phe-Lys) ................. 22Galanin (Human) ......................................................... 62Galanin (Rat) ................................................................ 63Galanin (Rat) Antiserum ............................................ 243Galanin-like Peptide (Human, 1-60) ............................ 63Galanins and Related Peptides................................... 62GalardinTM .................................................................. 164Gastrin I (Human) ........................................................ 63Gastrin Related Peptide (Bulk) ................................... 63Gastrins and Related Peptides ................................... 63GDP-l-Fuc: N-Acetyl--D-Glucosaminide 1-6Fucosyl-transferase Substrate ................................................ 229General Laboratory Glassware ................................. 323GH-RH) and Growth Hormone Related Peptides ...... 70Ghrelin (Human, 1-14) ................................................ 66


INDEX by PRODucT cO

DE NAME

Order Hotline 1-800-777-4779 502-266-8787 343


Ghrelin (Human, 1-18) ................................................ 66Ghrelin (Human, Rat, 1-10) ........................................ 66Ghrelin (Human, Rat, 1-5) .......................................... 66Ghrelin (Human) ......................................................... 64Ghrelin (Rat) ................................................................ 65Ghrelin and Des Ghrelin Peptides (full length) ........... 64Gingipain Substrates ................................................. 194GIP (Human) ................................................................ 64Gla17,21,24-Osteocalcin (Human) ................................... 97Glt-Ala-Ala-Phe-MCA................................................. 186Glt-Ala-Ala-Pro-Leu-pNA • H2O ................................. 191Glt-Gly-Arg-MCA ........................................................ 207Glu-Glu ....................................................................... 215Glu-pNA • H2O ........................................................... 194Glu(Cys-Gly) .............................................................. 194Glu(Cys-Gly) ............................................................. 216Glu(OBzl) ................................................................... 255Glu(OBzl)-OBzl • Tos ................................................. 253Glu(OMe) ................................................................... 255Glu(pNA) • H2O .......................................................... 195Glu17,Gla21,24-Osteocalcin (Human) ............................. 97Glucagon ...................................................................... 67Glucagon (Human) ..................................................... 67Glucagon-like Peptide 1 (Human ................................ 68Glucagon-like Peptide 1 (Human, 7-36 Amide) .......... 67Glucagon-like Peptide 1 (Human, 7-37) ..................... 68Glucagon-like Peptide 2 (Human) .............................. 69Glucagon-Like Peptides .............................................. 67Gly-Gly ....................................................................... 215Gly-Gly-Gly ................................................................ 216Gly-Gly-His ................................................................. 217Gly-Gly-Tyr-Arg • AcOH • 2 H2O ................................ 218Gly-Gly-Tyr-Arg • AcOH • 2H2O ................................. 183Gly-His-Lys • AcOH • H2O ......................................... 217Gly-Leu ....................................................................... 216Gly-OBzl • Tos ............................................................ 253Gly-OEt • HCI ............................................................. 253Gly-Phe ...................................................................... 216Gly-Phe-NH2 • AcOH ................................................. 216Gly-Pro ....................................................................... 216Gly-Pro-MCA .............................................................. 191Gly-Pro-pNA • Tos ...................................................... 191Glycine ....................................................................... 251Glycogen Synthase Kinase 3B Substrates ............... 195Glycosidase Inhibitors ............................................... 225GRF (Human) .............................................................. 70GRF (Human) Antiserum ........................................... 243Growth Hormone Releasing Factor (GRF) ................. 70GRP (Human) ............................................................. 64GRP (Human) Antiserum........................................... 244GsMTx-4 .................................................................... 129Guangxitoxin .............................................................. 130Guangxitoxin-1E ........................................................ 130Guanylin (Human) ....................................................... 71Guanylin (Rat, Mouse)................................................. 71Guanylins and Uroguanylins ....................................... 71

HH-AEEEA-Glu[cyclo (Arg-Gly-Asp-D-Tyr-Lys)]2 ........... 24H-Ala-2-ClTrt-Resin .................................................. 284H-Ala-Phe(para-Fluoro)-Arg-Cha-Cit-Tyr-NH2 .......... 108H-Ala-Phe(para-Fluoro)-Arg-Cha-homoArg-Tyr-NH2 112H-Ala-Tyr-Pro-Gly-Lys-Phe-NH2 .................................112H-Ala-Tyr-Pro-Gly-Lys-Phe-OH ..................................112H-Arg-Ala-Asp-Ser-Lys-OH ......................................... 25H-Arg-Arg-Leu-Ile-Glu-Asp-Ala-Glu-Tyr-Ala-Ala-Arg-Gly-NH2 ...................................................................... 201H-Arg-Glu(Edans)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(Dabcyl)-Arg-OH ................................................. 203H-Arg-Gly-Asp-Ser-Lys-OH ......................................... 25H-Arg-Gly-Tyr-Val-Tyr-Gln-Gly-Leu-OH ...................... 61H-Arg-Leu-Leu-Phe-Thr-NH2 ......................................110H-Arg(Pbf)-2-ClTrt-Resin ...................................284, 285H-Asn-2-ClTrt-Resin ................................................. 285H-Asn(Trt)-2-ClTrt-Resin ........................................... 285H-Asp-[Pen-Phe-D-Trp-Orn-Tyr-Cys]-Val-OH ........... 234H-Asp-[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-OH ............... 143H-Asp(OtBu)-2-ClTrt-Resin ....................................... 285H-b-Ala-2-ClTrt-Resin................................................ 284H-Cys(Trt)-2-ClTrt-Resin .......................................... 285H-Dab-Pip .................................................................. 165H-e-Aca-2-ClTrt-Resin ............................................... 284H-g-Abu-2-ClTrt-Resin ............................................... 284H-Gln-2-ClTrt-Resin ................................................... 285H-Gln(Trt)-2-ClTrt-Resin ............................................ 285H-Gln(Trt)-2-ClTrt-Resin ............................................ 285H-Glu-Gly-Val-Asn-Asp-Asn-Glu-Glu-Gly-Phe-Phe-Ser-Ala-Arg-OH .................................................................. 61H-Glu(OtBu)-2-ClTrt-Resin ........................................ 285H-Glu[cyclo (Arg-Ala-Asp-D-Phe-Lys)]2 ......................xxxH-Glu[cyclo (Arg-Gly-Asp-D-Phe-Lys)] .......................... 2H-Glu[cyclo (Arg-Gly-Asp-D-Tyr-Lys)]........................ 223H-Glu{Glu[cyclo (Arg-Ala-Asp-D-Phe-Lys)]2}2 .............xxx H-Glu{Glu[cyclo (Arg-Gly-Asp-D-Phe-Lys)]2}2 ............xxx H-Gly-2-ClTrt-Resin .................................................... 85H-Gly-2-ClTrt-Resin ................................................... 285H-Gly-Arg-Ala-Asp-Ser-Pro-OH .................................. 26H-Gly-Asp-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-OH ............... 36H-Gly-Gly-Gly-Gly-Arg-Gly-Asp-Ser-Pro-OH.............. 26H-Gly-Tyr-Pro-Gly-Gln-Val-NH2 ..................................112H-Gly-Tyr-Pro-Gly-Lys-Phe-NH2 ................................112H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 ............................ 66H-His-D-Trp-D-Lys-Trp-D-Phe-Lys-NH2 ........................ 66H-His(Trt)-2-ClTrt-Resin ............................................ 285H-Ile-2-ClTrt-Resin .............................................285, 286H-KL-D-Leu-RLL-D-Lys-D-Lys-l-D-Leu-RL-D-Leu-LK-NH2 ...................................................................................... 39H-Leu-2-ClTrt-Resin .................................................. 286H-Leu-Ser-Ile-Gly-Arg-Leu-NH2 .................................110H-Leu-Ser-Ile-Gly-Lys-Val-NH2 ...................................111H-Lys-Val-Pro-Arg-Asn-Gln-Asp-Trp-Leu-OH ............. 83H-Lys(Boc)-2-ClTrt-Resin ......................................... 286H-Met-2-ClTrt-Resin .................................................. 286

PEPT

IDES

INTE

RNAT

IONA

LIN

DEX

by P

RODu

cT N

AME

344 Order Hotline 1-800-777-4779 502-266-8787


H-mini-PEGTM-2-ClTrt-Resin...................................... 286H-Nle-2-ClTrt-Resin .................................................. 286H-Phe-2-ClTrt-Resin ................................................. 286H-Phe-Leu-Leu-Arg-Asn-OH ..................................... 108H-Phe-Ser-Leu-Leu-Arg-Tyr-NH2 ...............................111H-Phe-Thr-Leu-Leu-Arg-Asn-Pro- ............................. 109H-Pro-2-ClTrt-Resin .................................................. 286H-Ser-Leu-Ile-Gly-Arg-Leu-NH2 ................................110H-Ser-Leu-Ile-Gly-Arg-Leu-OH ..................................111H-Ser-Leu-Ile-Gly-Arg-NH2 .........................................111H-Ser-Leu-Ile-Gly-Lys-Val-NH2 ...................................111H-Ser-Leu-Ile-Gly-Lys-Val-OH ....................................111H-Ser-Phe-Asn-Gly-Gly-Pro-NH2 ...............................112H-Ser-Phe-Leu-Leu-Arg-Asn-NH2 ..............................110H-Ser-Phe-Leu-Leu-Arg-Asn-OH .............................. 109H-Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe-NH2 .............................................................. 109H-Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe-OH ............................................................... 109H-Ser-Phe-Leu-Leu-Arg-Asn-Pro-OH ....................... 109H-Ser-Phe-Leu-Leu-Arg-NH2 .................................... 108H-Ser-Phe-Leu-Leu-Arg-OH ..................................... 108H-Ser-Phe-Leu-Leu-Cit-OH ....................................... 109H-Ser(tBu)-2-ClTrt-Resin .......................................... 286H-Thr-Phe-Arg-Gly-Ala-Pro-NH2 ................................111H-Thr-Phe-Leu-Leu-Arg-Asn-.................................... 109H-Thr-Phe-Leu-Leu-Arg-NH2 ......................................110H-Thr(tBu)-2-ClTrt-Resin ........................................... 286H-Tic-[Pen-Phe-D-Trp-Orn-Try-Cys]-Val-OH ............. 143H-Trp-2-ClTrt-Resin .................................................. 287H-Trp(Boc)-2-ClTrt-Resin ......................................... 287H-Tyr-Ala-Pro-Gly-Lys-Phe-NH2 .................................112H-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 ................. 90H-Tyr(tBu)-2-ClTrt-Resin .......................................... 287H-Val-2-ClTrt-Resin ................................................... 287HBTU Reagent ......................................................... 301HCTU Reagent .......................................................... 301Hepatitis C Protease Substrate ................................. 196Hepatocyte Growth Factor-Activator (HGF-A) Substrate .................................................................................... 196Hepcidin ....................................................................... 73Hepcidin 1 (Mouse) .........................................58, 73, 74Hepcidin/LEAP-1 (Human) .......................................... 74Hepcidin (Rat) (50 µg vial) .......................................... 73Hepcidin (Rat) (Bulk) ................................................... 73Heterobifunctional dPEG® Crosslinkers .................... 316HF Apparatus and Parts ............................................ 323His-Leu ....................................................................... 216His-OMe • 2HCl ......................................................... 253Histatin ......................................................................... 75Histatin 5 (Human) ....................................................... 75Histone Deacetylase Substrates ............................... 196HIV-1 Protease Substrates ........................................ 197HMBA-MBHA Resin ................................................. 282HMPB-MBHA Resin ................................................. 283HOBt Anhydrous ....................................................... 301

Horseshoe Crab Clotting Enzyme Substrate ............ 197HOSu ........................................................................ 302Human Kallikrein 6 Substrate .................................... 198Human Rhino-virus-14 (HRV)3C Protease Substrate ..... .................................................................................... 197Humanin ....................................................................... 75Huwentoxin- IV .......................................................... 131Hydroxy-dPEG®4 t-Butyl Ester .................................. 316Hydroxy-Tic ................................................................ 281Hydroxyl Modifiers ..................................................... 320Hydroxymethyl Polystyrene Resin 283Hydroxymethyl Polystyrene Resin^tRFR-1069-PI .... 283

IIberiotoxin ................................................................... 131Ile-OBzl • Tos ............................................................. 253Ile-OMe • HCI ............................................................. 253Ile-Pro-Ile • H2O.......................................................... 217Immunization & Antibodies ........................................ 297Imperatoxin A ............................................................. 132Insulin ........................................................................... 76Insulin (Human) .......................................................... 76Insulin (Human) .......................................................... 76Insulin (Human) ........................................................ 222Isoleucyl-Seryl-Bradykinin ........................................... 29Isoleucyl-Seryl-Bradykinin (Bulk) .............................. 30Isopeptidase T Substrate ........................................... 198

JJoining Peptide (Rat) ................................................... 76Joining Peptides .................................................... 76, 77

KKaliotoxin (1-37) ......................................................... 132Kaliotoxin (1-37) ......................................................... 132Kallikrein Substrates .................................................. 197Kisspeptin-10 (Human) / Metastin (Human ................ 77Kisspeptin-10 (Rat) / Metastin (Rat ............................. 78Kisspeptin-52 (Human) / Metastin (Human ................ 78Kisspeptin-54 (Human) / Metastin (Human ................ 78KKALLALALHHLAHLALHLALALKKA ........................ 12Kurtoxin ..................................................................... 132KYS-1 ......................................................................... 198KYT ............................................................167, 168, 169KYT-1 ......................................................................... 167KYT-36 ....................................................................... 167

LL-685,458 ................................................................... 170l-Alanine ..................................................................... 250l-Amino Acids............................................................. 250l-Arginine • HCI .......................................................... 250l-Asparagine • H2O .................................................... 250l-Aspartic Acid ............................................................ 250l-Cysteine • HCI • H2O ............................................... 250l-Cystine ..................................................................... 250


INDEX by PRODucT cO

DE NAME

Order Hotline 1-800-777-4779 502-266-8787 345


l-Glutamic Acid .......................................................... 251l-Glutamine ................................................................ 251l-Histidine • HCI • H2O ............................................... 251l-Hydroxyproline ........................................................ 251l-Leucine .................................................................... 251l-lsoleucine................................................................. 251l-Lysine • HCI ............................................................. 251l-Methionine ............................................................... 251l-Norleucine ............................................................... 251l-Ornithine • HCI ........................................................ 251l-Pen .......................................................................... 281l-Pen(p-Me-Bzl) ......................................................... 281l-Phenylalanine .......................................................... 251l-Proline ..................................................................... 251l-Pyroglutamic Acid.................................................... 251l-Serine ...................................................................... 251l-Threonine ................................................................ 251l-Tic ............................................................................ 281l-Tryptophan .............................................................. 252l-Tyrosine ................................................................... 252l-Valine ....................................................................... 252Laboratory Equipment ............................................... 321Lactacystin ................................................................. 171Laminin ......................................................................... 78Laminin Pentapeptide YIGSR-NH2 ............................ 78Laminin Pentapeptide YIGSR-NH2 (Bulk) .................. 78Legumain Substrates................................................. 198Leu-Gly • H2O ........................................................... 198Leu-Gly-Gly ........................................................198, 217Leu-MCA .................................................................... 175Leu-NH2 • HCI ............................................................ 176Leu-OBzl • Tos ........................................................... 253Leu-OEt • HCl ............................................................ 254Leu-pNA ..................................................................... 176Leu-Pro-Leu-Arg-Phe-NH2 • 2AcOH • 2H2O ............... 78Leucine-Enkephalin ..................................................... 56Leucine-Enkephalin (Bulk) ......................................... 57Leucine-Enkephalin (Sulfated Form) .......................... 57Leuhistin ..................................................................... 153Leupeptin ................................................................... 162Leupeptin (Bulk) ........................................................ 162LH-RH (Human) ........................................................... 79LH-RH (Human) (Bulk) ............................................... 80Lipid A (E. coli) ........................................................... 229Lipid A (E. coli) ........................................................... 226Lipid A (Salmonella) ................................................... 227Lipid IVa ..................................................................... 226List of Muscarinic Toxins ............................................ 133Liver-Cell Growth Factor (Bulk) .................................. 78Liver-Cell Growth Factor.............................................. 78Liver-Expressed Antimicrobial Peptide 2 (Human) ..... 75LL-37 (Human) ............................................................. 79Luteinizing Hormone-Releasing Hormone (LH-RH) ... 79Lys-Ala-MCA .............................................................. 191Lys-Lys-Lys-Leu-Arg-Arg-Gln-Glu-Ala-Phe-Asp-Ala-Tyr . .................................................................................... 168

Lys-MCA ..................................................................... 176Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe ............................................................................. 169Lys(Z) ......................................................................... 255Lysenin Antiserum ..................................................... 244Lysine Hydroxylase Substrate ................................... 198Lysyl-[Hyp3]-Bradykinin (Human) ............................... 30Lysyl-Bradykinin ........................................................... 30Lysyl-Bradykinin (Bulk) .............................................. 30

Mm-Conotoxin GIIIB ..................................................... 126m-Conotoxin GS ........................................................ 127m-dPEG® acid (MW = 1117) ...................................... 313m-dPEG®12 Amine .................................................... 315m-dPEG®2 -Acid (MW = 148) .................................... 313m-dPEG®24 Amine .................................................... 315m-dPEG®24-NHS Ester (MW = 1214) ...................... 313m-dPEG®4 Amine ...................................................... 315m-dPEG®4-NHS Ester (MW = 333) .......................... 312m-dPEG®8 Amine ...................................................... 315m-dPEG®8-NHS Ester(MW = 509) ........................... 312m-dPEGTM -Acids..................................................... 313m-dPEGTM 2-NHS Ester(MW = 245) ...................... 312m-dPEGTM16-NHS Ester(MW = 862) ..................... 312m-dPEGTM4 -Acid (MW = 236) ................................ 313Magainin...............................................................80, 180MAL-dPEG®4-Acid..................................................... 316Maleimide activated-KLH .......................................... 229Maleimidopropionic Acid ............................................ 304MALTI Substrate ........................................................ 199Manual Reaction Vessel ............................................ 321Manual Reaction Vessels with 3-way Teflon Stopcock with Two Outlets........................................................ 322Manual Reaction Vessels with Baffles ...................... 321Manual Reaction Vessels with Jacket ....................... 322MAPS (Multiple Antigen Peptide Systems) Resins .. 298Marfey’s Reagent ...................................................... 178Margatoxin (MgTX) .................................................... 133Mast Cell Degranulating Peptide (MCD) ..................... 81Mastoparan .................................................................. 80Mastoparan (Bulk) ...................................................... 80Mastoparan .................................................................. 80MCD-Peptide ............................................................... 81Melanin-Concentrating Hormone (Human) ................ 81Melanin-Concentrating Hormone and Related Peptides . ................................................................................ 79, 81Melanocyte Stimulating Hormone (MSH) and Related Peptides ....................................................................... 82MeO-Suc-Arg-Pro-Tyr-MCA ...................................... 186MeO-Suc-Arg-Pro-Tyr-pNA ....................................... 186Merrifield Boc-Based Solid Phase Synthesis ........... 320Met-Leu-pNA .............................................................. 176Met-MCA .................................................................... 176Met-Met ...................................................................... 216Met-OMe • HCI .......................................................... 254

PEPT

IDES

INTE

RNAT

IONA

LIN

DEX

by P

RODu

cT N

AME

346 Order Hotline 1-800-777-4779 502-266-8787


Methionine-Enkephalin ................................................ 57Methionine-Enkephalin (Bulk) .................................... 57Methionyl-Lysyl-Bradykinin (Human, Bovine) ............. 30Methionyl-Lysyl-Bradykinin (Human, Bovine) (Bulk) 30Methoxy Terminated Amine Reactive Reagents....... 312Methoxy Terminated Carbonyl / Carboxyl Reactive Reagents .................................................................... 314Methoxytrityl-S-dPEG®4 Acid .................................... 320Methoxytrityl-S-dPEG®8 Acid .................................... 320Methyl (Methyl 5-Acetamido-4,7,8,9-Tetra-O-Acetyl-3,5-Dideoxy-2-Thio-D-Glycero-D-Galacto-2-Nonulopyrano-sid)onate .................................................................... 223MHC-class I-restricted epitope in hgp100 ................... 83Midkine (Human, 1-59) Antiserum ............................ 244Midkine (Human, 60-121) ............................................ 84Midkine (Human) ......................................................... 84Midkines ....................................................................... 84mini-PEG™ ................................................................ 231Miscellaneous dPEG Reagents ................................ 316MOCAc-Ala-Pro-Ala-Lys-Phe-Phe-Arg-Leu-Lys(Dnp)-NH2 ............................................................................. 200MOCAc-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met-Lys(Dnp)-NH2 ............................................................. 190MOCAc-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2 ............................................................. 189MOCAc-Asp-Glu-Val-Asp-Ala-Pro-Lys(Dnp)-NH2 .... 182MOCAc-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 ................................................... 183MOCAc-Gly-Ser-Pro-Ala-Phe-Leu-Ala-Lys(Dnp)-D-Arg-NH2 ............................................................................ 183MOCAc-Lys-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 .. ............................................................................174, 188MOCAc-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 .. .................................................................................... 174MOCAc-Pro-Cha-Gly-Nva-His-Ala-Dap(Dnp)-NH2 .. 189MOCAc-Pro-Leu-Gly ................................................. 199MOCAc-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 .. 189MOCAc-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-Lys(Dnp)-Arg-Arg-NH2 ............................................... 203MOCAc-type Fluorescence-Quenching Substrate ... 199MOCAc-Tyr-Val-Ala-Asp-Ala-Pro-Lys(Dnp)-NH2 ...... 182MOG (40-54) ................................................................ 60MOG (92-106) .............................................................. 60MOG (Rat, Mouse, 35-55) ........................................... 60Molluscan Cardioexcitatory Neuropeptide .................. 85Mono-N-Cbz-Amido-dPEG®3 Amine ........................ 318Mono-N-t-Boc-Amido-dPEG® .................................... 317Mono-N-t-Boc-Amido-dPEG®11 Amine ..................... 317Mono-N-t-Boc-Amido-dPEG®3 Amine ...................... 317Mono-t-Boc-1,6-Diaminohexane ............................... 317Morphine Tolerance Peptide (Bulk) ............................ 85Morphine Tolerance Peptide........................................ 85Motilin ........................................................................... 85Motilin (Human, Porcine) ............................................. 85Mouse) ......................................................................... 96MSH-Release Inhibiting Factor (Bulk)........................ 82

Muscarinic Toxin 1 ..................................................... 133Muscarinic Toxin 3 ..................................................... 134Muscarinic Toxin 7 ..................................................... 134Muscarinic Toxins ...................................................... 133Myelin Basic Protein (1-20) ......................................... 59Myelin Basic Protein (111-129) .................................... 60Myelin Basic Protein (87-99) ....................................... 59Myelin PLP (139-151) .................................................. 60Myelin PLP (178-191) .................................................. 60Myelin PLP (180-199) .................................................. 61Myelin PLP (57–70) ..................................................... 60Myr-Ser-Ile-Tyr-Arg-Arg-Gly-Ala-Arg-Arg-Trp-Arg-Lys-Leu ............................................................................. 222

NN-(4-Biphenylacetyl)-Cys(Me)-D-Arg-Phe-N-Phenyle-thylamide .................................................................... 162Nefken’s Reagent ..................................................... 302Neo-Endorphins ........................................................... 87Neprilysin Substrate................................................... 199Neuroendocrine Regulatory Peptide-1 (Human) ........ 86Neuroendocrine Regulatory Peptide-1 (Rat) .............. 87Neuroendocrine Regulatory Peptide-2 (Human) ........ 87Neuroendocrine Regulatory Peptide-2 (Rat) .............. 87Neuroendocrine Regulatory Peptides ......................... 86Neurokinin A ................................................................. 87Neurokinin A (Bulk) ..................................................... 88Neurokinin B ............................................................... 88Neurokinin B (Bulk) ..................................................... 88Neurokinin B (Neuromedin K) ..................................... 88Neurokinins .................................................................. 87Neuromedin B .............................................................. 88Neuromedin B (Bulk) ................................................. 88Neuromedin C .............................................................. 88Neuromedin C (Bulk) ................................................. 89Neuromedin C .............................................................. 89Neuromedin S (Human) .............................................. 89Neuromedin S (Rat) ..................................................... 89Neuromedin U (Rat) ................................................... 90Neuromedins ...................................................88, 90, 91Neuronostatin-13 (Human) .......................................... 90Neuropeptide B-29 (Rat) (Non-Brominated Form) ..... 91Neuropeptide S (Human) ............................................ 91Neuropeptide W-30 (Human) ...................................... 91Neuropeptide W-30 (Rat) ............................................ 92Neuropeptide Y (NPY) and Related Peptides ............ 92Neurotensin .................................................................. 93Neurotensin (Bulk) ..................................................... 93Neurotensin .................................................................. 93Neurotoxin NSTX-3 ................................................... 135Neutral Endopeptidase Inhibitors .............................. 168Neutral Endopeptidase Substrates ........................... 199NHS-Biotin ................................................................. 308NHS-dPEG®12 Biotin ................................................ 306NHS-dPEG®4 Biotin................................................... 306NHS-dPEG®4 Biotinidase-Resistant Biotin ............... 307


INDEX by PRODucT cO

DE NAME

Order Hotline 1-800-777-4779 502-266-8787 347


NHS-dPEG®4-(m-dPEG®12)3 Ester ......................... 314NHS-LC-Biotin ........................................................... 308Nma-Gly-Gly-Val-Val-Ile-Ala-Thr-Val-Lys(Dnp)-D-Arg-D-Arg-D-Arg-NH2 ............................................................ 203Nma-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(Dnp)-D-Arg-D-Arg-NH2 ......................................................... 202Nociceptin (Human) ..................................................... 94Nocistatin (Bovine) ....................................................... 94Nocistatin (Human) ...................................................... 94Nocistatins.................................................................... 94Nojirimycin Bisulfite .................................................... 225NPY (Human, Rat) ....................................................... 92NPY (Human, Rat) ....................................................... 92NPY (Human) Antiserum ........................................... 245NPY (Porcine, 13-36) .................................................. 93NPY (Porcine, Bovine) ................................................. 92

OO-(Acetamido-3,5-Dideoxy-D-Glycero-a-D-Galacto-2-Nonulopyranosylonic Acid)-(23)-O-b-D-Galactopy-ranosyl-(14)-O-b-D-Glucopyranosyl-(11)-2S,3R,4E)-2-N-o-BAL ........................................................................... 26o-BAL-CLEAR Resin ................................................... 13O-Benzyl-dPEG®4 Acid ............................................. 316Obestatin (Human) ...................................................... 95Obestatin (Rat, Mouse) .............................................. 95Obestatin and Related Analogs................................... 95Oligopeptides ............................................................. 215Open Screw Cap (10 and 15 mL) with Teflon-coated Septum ....................................................................... 323Open Screw Cap (30 mL and larger) with Teflon-coated Septum ....................................................................... 323Orexin-A (Human) ........................................................ 96Orexin-A (Human) Antiserum .................................... 245Orexin-B (Human) ....................................................... 96Orexin-B (Rat ............................................................... 96Orexins ......................................................................... 96Osteocalcin (Human, 38-49) Antiserum .................... 245Osteocalcins ................................................................ 97OVA Peptide (257-264)................................................ 97OVA Peptide (323-339)................................................ 97OVA Peptide Fragment ................................................ 97Oxytocin ....................................................................... 98Oxytocins ..................................................................... 98

Pp-BAL ........................................................................... 26p-Methyl-Benzhydrylamine Resin • HCI (MBHA) ..... 283p-Methyl-Benzhydrylamine Resin • HCl (MBHA) .... 283PACAP (Human, 6-38) .............................................. 104PACAP27 (Human, 1-27 Amide) ............................... 104PACAP38 (Human).................................................... 104Palmitoyl-Cys((RS)-2,3-di(palmitoyloxy)-propyl)-OH 281Pam Ester ................................................................. 302PAMP (Human) .............................................................. 4PAMP (Rat) .................................................................... 4

PAMP-12 (Human) ........................................................ 4Pancreastatins ............................................................. 98PAR Peptides (see Protease-Activated Receptor Peptides)Parathyroid Hormone (Human, 1-31 Amide) .............. 99Parathyroid Hormone (Human, 1-34) ......................... 99Parathyroid Hormone (Human, 1-34) ......................... 99Parathyroid Hormone (Human, 1-44) ....................... 100Parathyroid Hormone (Human, 1-84) ......................... 99Parathyroid Hormone (Human, 13-34) ..................... 100Parathyroid Hormone (Human, 39-68) ..................... 100Parathyroid Hormone (Human, 39-84) ..................... 100Parathyroid Hormone (Human, 69-84) ..................... 100Parathyroid Hormone (PTH) and Related Peptides ... 99Pepsin Substrate ....................................................... 200Pepstatin A (Purity Higher than 90% by HPLC) ....... 162Pepstatin A (Purity Higher than 90% by HPLC) ........ 162Pepstatin A (Purity Higher than 90% by HPLC) ........ 179Peptide 234 ................................................................ 102Peptide Histidine-Methionine (PHM) ......................... 102Peptide Synthesis - for preparation of peptide acids 297Peptide T .................................................................... 102Peptide T (Bulk) ........................................................ 103Peptide T .................................................................... 102Peptide YY ................................................................. 103Peptide YY (Dog, Mouse, Porcine, Rat, 3-36) .......... 103Peptide YY (Human, 3-36) ........................................ 103Peptidoglutaminase Substrate .................................. 200Peptidyl Prolyl cis-trans Isomerase (PPlase) ............ 200Peptidyl-MCA Substrate ............................................ 200Phe-MCA .................................................................... 176Phe-Met-Arg-Phe-NH2 • 1 AcOH • 2H2O................... 218Phe-OBzl • Tos ........................................................... 254Phe-OEt • HCI ............................................................ 254Phebestin .................................................................. 153PHM-27(Human) ....................................................... 102Phosphoramidon (Bulk) ............................................ 168Phosphoramidon .................................(Sodium Salt)168Physalaemin .............................................................. 103Physalaemin (Bulk) ................................................... 104Physalaemin .............................................................. 103Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) ..................................................................... 104Plasmin Substrate...................................................... 200Platelet Factor-4 (Human, 58-70)105Platelet Factor-4 Related Peptide ............................. 105Plectasin ..................................................................... 105Pleiotrophin ................................................................ 106Pleiotrophin (Human) ................................................. 106PLTX-II ....................................................................... 136Poly-l-Glutamic Acid Sodium Salt ............................. 215Poly-l-Lysine Hydrobromide ...................................... 215Poly-l-Lysine Hydrochloride ...................................... 215Polypeptides .............................................................. 215Presenilin 1 (349-361) ............................................... 195Prion Proteins See Celluar Prion Proteins on page . 200

PEPT

IDES

INTE

RNAT

IONA

LIN

DEX

by P

RODu

cT N

AME

348 Order Hotline 1-800-777-4779 502-266-8787


Pro-Asn-Asp-Lys-NH2 ................................................ 109Pro-Leu-Gly-NH2 • H2O .............................................. 217Pro-OBzl • HCI ........................................................... 254Pro-Phe-Arg-MCA ...................................................... 197Proangiotensin-12 (Rat) Antisera .............................. 245Prolactin-Releasing Peptide (Human) ...................... 106Prolactin-Releasing Peptide (Rat) ............................. 107Prolactin-Releasing Peptides .................................... 106Prolyl Endo-peptidase Substrate............................... 201Protease-Activated Receptor (PAR) Peptides .......... 108Protease-Activated Receptor 1 (PAR1) ....................... 18Protease-Activated Receptor 2 (PAR2) ......................110Protease-Activated Receptor 3 (PAR3) ......................111Protease-Activated Receptor 4 (PAR4) ......................112Protein Kinase C Substrate ....................................... 201Protein Ligation Synthesis Reagents ........................ 304Protein Tyrosine Phosphotase Substrate ................. 202Proteinase 3 Substrate .............................................. 201Proteinase A Substrates ............................................ 201ProTx-I ....................................................................... 137ProTx-I and ProTx-II .................................................. 136ProTx-II ...................................................................... 137Psalmotoxin ............................................................... 138Psalmotoxin 1 ............................................................ 138PTH-rP(Human, 1-34 Amide) .................................... 102PTH-rP(Human, 7-34 Amide) .................................... 102Purotoxin-1 ................................................................. 139PyClocK® .................................................................... 305Pyr-Ala ....................................................................... 216Pyr-Arg-Thr-Lys-Arg-MCA ......................................... 193Pyr-Gly-Arg-MCA ....................................................... 207Pyr-His-Pro-NH2 • H2O .............................................. 217Pyr-Lys-Arg-Pro-Ser-Gln-Arg-Ser-Lys-Tyr-Leu ......... 201Pyr-MCA ..................................................................... 202Pyr-Phe-Leu-pNA ...................................................... 183Pyr-Pro-Val-pNA ........................................................ 192Pyro-glutamyl Peptidase Substrates ......................... 202Pyroglutamylated RFamide Peptide ..........................113Pyroglutamylated RFamide Peptide (Human) ...........113

RReagents .................................................................... 300Renin Substrates ....................................................... 202Replacement Screw Cap (open) plus Septum ......... 323Replacement Screw Cap for PS-3 ............................ 323Replacement Screw Caps and Septa ....................... 322Resins for Protein Ligation ........................................ 299Reverse Transcriptase Inhibitor ................................ 169RF Amide Related Peptides .......................................114RFamide-Related Peptide-1 (Human) .......................114RFamide-Related Peptide-3 (Human) .......................115RFamide-Related Peptide-3 (Rat) .............................115RFamide-Related Peptide-3 (RFRP-3) ......................114Rink-Amide-AM Resin ............................................... 283Rink-Amide-MBHA Resin RFR-1063-PIRink-Amide-MBHA Resin .......................................... 283

SS-Acetyl-dPEG®4 Acid (dPEG®4 SATA Acid) ............ 317S-Acetyl-dPEG®4 NHS Ester (dPEG®4 SATA) ......... 317S-Acetyl-dPEG®8 Acid (dPEG®8 SATA Acid) ............ 317S-Acetyl-dPEG®8 NHS Ester (dPEGTM8 SATA) ..... 317S-Acm--Mercaptopropionic Acid ............................... 304S-Acm-b-Mercaptopropionic Acid ............................. 281S-Acm-Pmp ............................................................... 281S-Acm-Pmp ............................................................... 304S-p-Me-Bzl-b-Mercaptopropionic Acid ...................... 304S-p-Me-Bzl-Pmp ........................................................ 304S-Trityl--Mercaptopropionyl-AM Resin ...................... 299S-Trityl--Mercaptopropionyl-Leu-Pam Resin ............ 299S-Trityl--Mercaptopropionyl-p-Methyl-Benzhydrylamine Resin .......................................................................... 299S-Trityl-b-Mercaptopropionic Acid ............................. 304S-Trityl-Mercaptoacetic Acid ...................................... 304Salusin- (Human) Antiserum ..................................... 246Salusin-a (Human) ......................................................115Salusin-b (Human) ......................................................115Salusins .......................................................................115Sarafotoxin S6b ......................................................... 139Sarafotoxin S6c ......................................................... 139Sarafotoxins ............................................................... 139Schizophrenia Related Peptide (Bulk) ......................115Schizophrenia Related Peptide ..........................115, 117Screw Cap for 30 mL - 400 mL Manual Reaction Vessels ....................................................................... 322Screw Cap for 5, 10, and 15 mL Manual Reaction Vessels ....................................................................... 322Screw Cap for 600 mL and Larger Manual Reaction Vessels ....................................................................... 323Screw Cap for PS-3 Reaction Vessel ....................... 323Scyllatoxin .................................................................. 140Secretin .......................................................................116Secretin (Human)........................................................116Secretin (Porcine) ......................................................116Secretin (Porcine) Antiserum..................................... 246Septum for the cap on 10 and 15 mL Manual Reaction Vessels ....................................................................... 323Septum for the cap on 30 mL - 400 mL Manual Reac-tion Vessels ............................................................... 323Ser-Gln-Asn-Tyr-Pro-Ile-Val ...................................... 197Ser-OMe • HCI ........................................................... 254Serum Peptidase Substrate ...................................... 203Serum Thymic Factor .................................................116Serum Thymic Factor (Bulk)......................................116Serum Thymic Factor .................................................116Siastatin B .................................................................. 225Side Chain Derivatives of Amino Acids ..................... 254Signal Peptide Peptidase Inhibitor ............................ 170SIMP-1 ....................................................................... 164SIMP-2 ....................................................................... 164Site-1 Protease (S1P) Substrate ............................... 203SNX-482 .................................................................... 140Sodium Potassium ATPase Inhibitor-1 (SPAI-1) ........116


INDEX by PRODucT cO

DE NAME

Order Hotline 1-800-777-4779 502-266-8787 349


Somatostatin ...............................................................116Somatostatin (Bulk) .................................................. 117Somatostatin (SRIF) and Related Peptides ...............116SPAI-1 (Porcine) .........................................................116SPAI-1 (Porcine) Antiserum ....................................... 246Specialty Glassware .................................................. 321Src Homology 2 Domain Ligand (Biotinylated) ..........117Stichodactyla Toxin (ShK).......................................... 140Stresscopin (Human) ..................................................118Stresscopin-Related Peptide (Human) .....................118Stresscopins / Urocortin and Related Peptides .........118SUAM-14746 ............................................................ 168Substance P ................................................................119Substance P (Bulk) ....................................................119Substance P and Related Peptides ...........................119Subtilisin A Substrate ................................................. 204Suc-[Glu9, Ala11,15]-Endothelin-1 (8-21) ................... 56Suc-Ala-Ala-Ala-MCA ................................................ 192Suc-Ala-Ala-Ala-pNA ................................................. 192Suc-Ala-Ala-Ala-pNA (Bulk)...................................... 192Suc-Ala-Ala-pNA ........................................................ 204Suc-Ala-Ala-Pro-Abu-pNA ......................................... 192Suc-Ala-Ala-Pro-Gly-pNA .......................................... 192Suc-Ala-Ala-Pro-Phe-MCA ........................................ 186Suc-Ala-Glu-MCA ...................................................... 206Suc-Ala-Glu-Pro-Phe-pNA ........................................ 200Suc-Ala-Leu-Pro-Phe-pNA ........................................ 200Suc-Ala-pNA .............................................................. 204Suc-Ala-Pro-Ala-MCA ................................................ 193Suc-Ala-Pro-Ala-pNA ................................................. 193Suc-Arg-Pro-Phe-His-Leu-Leu-Val-Tyr-MCA ............ 186Suc-D-Asp-MCA ......................................................... 178Suc-Glu-Ala-Leu-Phe-Gln-pNA ................................. 197Suc-Gly-Pro-Leu-Gly-Pro-MCA ................................. 190Suc-Gly-Pro-MCA ...................................................... 201Suc-Ile-Ala-MCA ........................................................ 176Suc-Leu-Leu-Val-Tyr-MCA ........................................ 179Suc-lle-Ile-Trp-MCA ................................................... 186Suc(OMe)-Ala-Ala-Pro-Val-MCA ............................... 192Surface Reactive and Thiophilic Reagents ............... 315

Tt-Boc-Amido-dPEG®4 Acid ........................................ 320TAPI-1 ........................................................................ 165TAPI-2 ........................................................................ 165TAPI-O ....................................................................... 165TBTU Reagent .......................................................... 302TCTU Reagent........................................................... 302Teflon Connectors ..............................................321, 323Teflon Connectors (for attaching glass tubing to Teflon tubing) ....................................................................... 323Teflon Tubing 1⁄8 (10 feet) .................................321, 323TentaGel B ................................................................. 298TentaGel B Boc / NH2 Resin ..................................... 298TentaGel B NH2 / Boc Resin ...................................... 298TentaGel B Particle size 90 m ................................... 298

TentaGel B Resin Particle size 130 m; Capacity: 0.2-0.3 meq/g ......................................................................... 298TentaGel B Resins (Bifunctional) .............................. 298TentaGel HL (High Load) Resins .............................. 295TentaGel HL HMBA Resin ......................................... 296TentaGel HL PHB Resin ............................................ 296TentaGel HL RAM Resin ........................................... 296TentaGel HL-Br Resin .......................................295, 296TentaGel HL-COOH Resin ................................295, 296TentaGel HL-NH2 Resin ............................................ 295TentaGel HL-OH Resin ............................................. 295TentaGel HL-OH Resin .............................................. 295TentaGel HL-SH Resin .............................................. 295TentaGel Macrobead HMBA Resin .......................... 296TentaGel Macrobead PHB Resin .............................. 296TentaGel Macrobead RAM Resin ............................. 296TentaGel Macrobead Resins with Handles............... 296TentaGel Macrobead-Br Resin ................................. 296TentaGel Macrobead-COOH Resin .......................... 296TentaGel Macrobead-NH2 Resin .............................. 296TentaGel Macrobead-OH Resin ............................... 296TentaGel Macrobead-OH Resin ................................ 296TentaGel Macrobead-SH Resin ................................ 296TentaGel Macrobeads ............................................... 296TentaGel Microsphere NH2 Resin ............................. 297TentaGel PAP Resin .................................................. 297TentaGel R NH2 Resin ............................................... 297TentaGel R PHB Resin .............................................. 297TentaGel R RAM Resin ............................................. 297TentaGel Resins from Rapp Polymere, Germany .... 294TentaGel S - Base Resins ......................................... 295TentaGel S Br Resin .................................................. 295TentaGel S COOH Resin ......................................... 295TentaGel S COOH Resin .......................................... 295TentaGel S NH2 Resin .......................................295, 297TentaGel S PHB Resin .............................................. 297TentaGel S RAM Resin ............................................. 297TentaGel S SH Resin ................................................ 295TentaGels Microsphere ............................................. 297Tertiapin ...................................................................... 141Tetrapeptides ............................................................. 217Thiol Modifiers............................................................ 320Thiol-dPEG®4 Acid ..................................................... 315Thiol-dPEG®4 t-Butyl Ester ........................................ 316Thiol-dPEG®8 Acid ..................................................... 315Thr-Lys-Pro-Arg • 2AcOH • 4H2O .............................. 218Thr-Val-Leu ................................................................ 217Thyrotropin Releasing Hormone (TRH) .................... 121Tityustoxin Ka ............................................................ 141TMRIA-K4 .................................................................. 122Tos-Arg-OMe • HCI .................................................... 205Tos-Lys-OMe • HCI .................................................... 206Toxins ......................................................................... 122trans-Cinnamoyl-Tyr-Pro-Gly-Lys-Phe-NH2 ...............113Trans-glutaminase Substrate .................................... 204TRH ............................................................................ 121

PEPT

IDES

INTE

RNAT

IONA

LIN

DEX

by P

RODu

cT N

AME

350 Order Hotline 1-800-777-4779 502-266-8787


TRH (Bulk) ................................................................ 122Tripeptides ................................................................. 216Tripeptidyl Peptidase II Substrate .....................170, 204Trityl-S-dPEG®4 Acid ................................................. 320Trp-Met-Asp-Phe-NH2 • HCl • H2O ............................ 218Trypsin and Trypsin-like Protease Substrates .......... 204Tubing and Connectors .....................................321, 323Tuftsin (Bulk) ............................................................. 141Tuftsin ......................................................................... 141Tyr-OEt • HCI ............................................................. 254Tyr34]-Parathyroid Hormone (Human....................... 101Tyrosyl-BNP-32 (Human) ........................................... 31Tyrosyl-Bradykinin ...................................................... 31Tyrosyl-CNP-22 (Human) ............................................ 39Tyrosyl-CRF (Human ................................................... 37

Uu-PA (Urokinase) Substrates ..................................... 207Ubenimex (Bestatin) (Bulk) ...................................... 153Ubiquitin Proteasome System Inhibitors ................... 171Ubiquitin Proteasome System Substrates, (Enzymes in the) ........................................................ 206Ubiquitin-H (aldehyde), Semisynthetic Product ........ 171uc-Ala-Ala-Pro-Trp-pNA ............................................ 192UDP--l-Arabinofuranose ........................................... 225UDP--l-Arabinofuranose ........................................... 303Unsubstituted Resins for Solid Phase Synthesis ..... 282Unusual Amino Acids ................................................. 281Unusual Boc-Amino Acids ......................................... 260Unusual Fmoc-Amino Acids ...................................... 272Urantide™ .................................................................. 143Urocortin (Human) ......................................................118Urocortin (Rat) ............................................................118Urocortin II (Mouse) ....................................................119Uroguanylin (Human) .................................................. 72Uroguanylin (Rat) ......................................................... 71Uroguanylin Isomer B (Human) .................................. 72Urotensin II (Human) ................................................. 142Urotensin II (Human) Antiserum ................................ 247Urotensin II (Rat)........................................................ 142Urotensin II and Related Peptides ............................ 142Urotensin II-Related Peptide (Human, Rat, Mouse) . 142

VVal-OMe • HCI ........................................................... 254Vascular Processing Enzyme Substrates ................. 207Vasoactive Intestinal Peptide (VIP) ........................... 143Vasopressin ............................................................... 144Vasotocin .................................................................... 144VIC (Mouse) ................................................................. 56VIP (Human, Porcine) ................................................ 143VIP (Human, Porcine) ................................................ 143VIP Antiserum ............................................................ 247Viral Protein 2 (70-86) .................................................. 61Virus Replication Inhibiting Peptide (Bulk) ............... 145Virus Replication Inhibiting Peptide ........................... 145

VP2 (70-86) .................................................................. 61

WWang Resin .......................................................283, 284WSCD • HCl .............................................................. 303

XXenin .......................................................................... 145Xenin 25 (Human) ..................................................... 145

ZZ-Ala-Ala-Asn-MCA ................................................... 198Z-Ala-Ala-Leu-pNA .................................................... 199Z-Ala-OH .................................................................... 279Z-Arg-Arg-MCA .......................................................... 183Z-Arg-OBzl(p-NO2) • HBr ........................................... 207Z-Arg-OH ................................................................... 279Z-Arg(NO2)-OH .......................................................... 279Z-Asn-OH ................................................................... 279Z-Asp-CH2-DCB ......................................................... 159Z-Asp-OH ................................................................... 279Z-Cys(Bzl)-OH ........................................................... 279Z-D-Pyr-OH ................................................................. 280Z-Gln-Gly.................................................................... 204Z-Gln-OH ................................................................... 279Z-Glu-Lys(Biotinyl)-Asp-CH2-DMB ............................ 159Z-Glu-OH2 ................................................................... 79Z-Glu-Tyr .................................................................... 184Z-Gly-Gly-Leu-pNA .................................................... 199Z-Gly-Leu ................................................................... 207Z-Gly-Leu-NH2 ........................................................... 207Z-Gly-OH .................................................................... 279Z-Gly-Phe ................................................................... 208Z-Gly-Phe-NH2 ........................................................... 208Z-Gly-Pro.................................................................... 208Z-Gly-Pro-Arg-MCA ................................................... 184Z-Gly-Pro-Leu ............................................................ 208Z-Gly-Pro-Leu-Gly ..................................................... 208Z-Gly-Pro-Leu-Gly-Pro • H2O • AcOEt ...................... 190Z-His-Glu-Lys-MCA.................................................... 194Z-Ile-Glu(OtBu)-Ala-Leu-H (aldehyde) ...................... 172Z-Ile-OH ..................................................................... 279Z-Leu-Arg-Gly-Gly-MCA ............................................ 206Z-Leu-Arg-MCA.......................................................... 184Z-Leu-Leu-Glu-MCA .................................................. 206Z-Leu-Leu-H (aldehyde)1 ............................................ 55Z-Leu-Leu-Leu-H (aldehyde) ..................................... 162Z-Leu-Leu-Leu-MCA .................................................. 207Z-Leu-Leu-Nva-H (aldehyde) .................................... 172Z-Leu-OH .................................................................. 280Z-Lys(Z)-OH ............................................................... 280Z-Met-OH ................................................................... 280Z-Phe-Arg-MCA ......................................................... 184Z-Phe-OH ................................................................... 280Z-Phe-Tyr ................................................................... 208Z-Phe-Tyr-Leu ............................................................ 190


INDEX by PRODucT cO

DE NAME

Order Hotline 1-800-777-4779 502-266-8787 351

Name Page Number

Z-Pro-OH ................................................................... 280Z-Protected l-Amino Acids ......................................... 279Z-Pyr-Gly-Arg-MCA ................................................... 188Z-Pyr-OH .................................................................... 280Z-Ser-OH ................................................................... 280Z-Trp-OH .................................................................... 280Z-Tyr-Glu .................................................................... 208Z-Tyr-OH .................................................................... 280Z-Tyr-ONp .................................................................. 208Z-Val-Ala-Asp(OMe)-CH2F ........................................ 159Z-Val-Lys-Met-MCA ................................................... 177Z-Val-OH .................................................................... 280Z-Val-Val-Arg-MCA .................................................... 226

PEPT

IDES

INTE

RNAT

IONA

LIN

DEX

by P

RODu

cT N

AME

352 Order Hotline 1-800-777-4779 502-266-8787

Peptides International, Inc.11621 Electron DriveLouisville, KY 40299 USAPhone: +1-502-266-8787 Phone: +1-800-777-4779 Fax: +1- 502-267-1329Email: [email protected]: PEPNET.

CATALOG PRODUCTSIncluding:• RGD Platform• ProTx-II & Other Toxins• Biologically Active Peptides• Substrates & Inhibitors• dPEGs and Linkers

CUSTOM CHEMISTRY SERVICESMade in USA• Design Consultation• Chemistry Development• Process Scale-up• Pilot-Scale Synthesis• Click Chemistry• Solution & Solid Phase• SubstratesbyDesignTM

EXCELLENCE COMPOUNDED• High Purity, Quality and Value• Strict Confidentiality• Friendly Service• Proactive Project Management

Documents

Leading by Excellence Since 1983 - LuBioScience | Company · PDF fileDear Customers: Throughout its many years of service, the team at Peptides International has maintained a commitment